bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
Retinoblastoma is a Protein, Oct-1 is a Protein, interleukin-8 is a Protein, retinoblastoma is a Protein, IFN - gamma is a Protein, Rb is a Protein, IFN - gamma is a Protein, Rb is a Protein, Rb is a Protein, Oct-1 is a Protein, Rb is a Protein, Rb is a Protein, Oct-1 is a Protein, Oct-1 is a Protein, interleukin 8 is a Protein, promoter is a Entity, Oct-1 is a Protein, Rb is a Protein, interleukin 8 is a Protein	215_task1	Sentence: Retinoblastoma protein expression leads to reduced Oct-1 DNA binding activity and enhances interleukin-8 expression. Tumor cell lines with a defective retinoblastoma gene are unable to transcribe the HLA class II genes in response to IFN-gamma treatment, and reconstitution of functional Rb rescues IFN-gamma-induced class II gene expression. However, the molecular mechanism of Rb rescue of the class II genes is unknown. We have examined the effect of Rb expression on the activation of the promoter for HLA-DRA, the prototype class II gene. Oct-1, a POU domain transcription factor, was identified as a repressor of HLA-DRA promoter activity in the Rb-defective cells. Rb expression led to phosphorylation of Oct-1, thus relieving its repressive effect. Oct-1 has also been shown to repress interleukin 8 promoter activity. Consistent with reduced levels of Oct-1 DNA binding activity in the Rb-transformed cell lines, interleukin 8 expression is higher in these cell lines. Instructions: please typing these entity words according to sentence: Retinoblastoma, Oct-1, interleukin-8, retinoblastoma, IFN - gamma, Rb, IFN - gamma, Rb, Rb, Oct-1, Rb, Rb, Oct-1, Oct-1, interleukin 8, promoter, Oct-1, Rb, interleukin 8 Options: Entity, Protein	[ "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	Retinoblastoma protein expression leads to reduced Oct-1 DNA binding activity and enhances interleukin-8 expression. Tumor cell lines with a defective retinoblastoma gene are unable to transcribe the HLA class II genes in response to IFN-gamma treatment, and reconstitution of functional Rb rescues IFN-gamma-induced class II gene expression. However, the molecular mechanism of Rb rescue of the class II genes is unknown. We have examined the effect of Rb expression on the activation of the promoter for HLA-DRA, the prototype class II gene. Oct-1, a POU domain transcription factor, was identified as a repressor of HLA-DRA promoter activity in the Rb-defective cells. Rb expression led to phosphorylation of Oct-1, thus relieving its repressive effect. Oct-1 has also been shown to repress interleukin 8 promoter activity. Consistent with reduced levels of Oct-1 DNA binding activity in the Rb-transformed cell lines, interleukin 8 expression is higher in these cell lines.	[ "Retinoblastoma", "protein", "expression", "leads", "to", "reduced", "Oct-1", "DNA", "binding", "activity", "and", "enhances", "interleukin-8", "expression", ".", "\n", "Tumor", "cell", "lines", "with", "a", "defective", "retinoblastoma", "gene", "are", "unable", "to", "transcribe", "the", "HLA", "class", "II", "genes", "in", "response", "to", "IFN", "-", "gamma", "treatment", ",", "and", "reconstitution", "of", "functional", "Rb", "rescues", "IFN", "-", "gamma", "-", "induced", "class", "II", "gene", "expression", ".", "However", ",", "the", "molecular", "mechanism", "of", "Rb", "rescue", "of", "the", "class", "II", "genes", "is", "unknown", ".", "We", "have", "examined", "the", "effect", "of", "Rb", "expression", "on", "the", "activation", "of", "the", "promoter", "for", "HLA", "-", "DRA", ",", "the", "prototype", "class", "II", "gene", ".", "Oct-1", ",", "a", "POU", "domain", "transcription", "factor", ",", "was", "identified", "as", "a", "repressor", "of", "HLA", "-", "DRA", "promoter", "activity", "in", "the", "Rb", "-", "defective", "cells", ".", "Rb", "expression", "led", "to", "phosphorylation", "of", "Oct-1", ",", "thus", "relieving", "its", "repressive", "effect", ".", "Oct-1", "has", "also", "been", "shown", "to", "repress", "interleukin", "8", "promoter", "activity", ".", "Consistent", "with", "reduced", "levels", "of", "Oct-1", "DNA", "binding", "activity", "in", "the", "Rb", "-", "transformed", "cell", "lines", ",", "interleukin", "8", "expression", "is", "higher", "in", "these", "cell", "lines", "." ]	[ "Protein", "Entity" ]
Retinoblastoma, Oct-1, interleukin-8, retinoblastoma, IFN - gamma, Rb, IFN - gamma, Rb, Rb, Oct-1, Rb, Rb, Oct-1, Oct-1, interleukin 8, promoter, Oct-1, Rb, interleukin 8	215_task2	Sentence: Retinoblastoma protein expression leads to reduced Oct-1 DNA binding activity and enhances interleukin-8 expression. Tumor cell lines with a defective retinoblastoma gene are unable to transcribe the HLA class II genes in response to IFN-gamma treatment, and reconstitution of functional Rb rescues IFN-gamma-induced class II gene expression. However, the molecular mechanism of Rb rescue of the class II genes is unknown. We have examined the effect of Rb expression on the activation of the promoter for HLA-DRA, the prototype class II gene. Oct-1, a POU domain transcription factor, was identified as a repressor of HLA-DRA promoter activity in the Rb-defective cells. Rb expression led to phosphorylation of Oct-1, thus relieving its repressive effect. Oct-1 has also been shown to repress interleukin 8 promoter activity. Consistent with reduced levels of Oct-1 DNA binding activity in the Rb-transformed cell lines, interleukin 8 expression is higher in these cell lines. Instructions: please extract entity words from the input sentence	[ "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	Retinoblastoma protein expression leads to reduced Oct-1 DNA binding activity and enhances interleukin-8 expression. Tumor cell lines with a defective retinoblastoma gene are unable to transcribe the HLA class II genes in response to IFN-gamma treatment, and reconstitution of functional Rb rescues IFN-gamma-induced class II gene expression. However, the molecular mechanism of Rb rescue of the class II genes is unknown. We have examined the effect of Rb expression on the activation of the promoter for HLA-DRA, the prototype class II gene. Oct-1, a POU domain transcription factor, was identified as a repressor of HLA-DRA promoter activity in the Rb-defective cells. Rb expression led to phosphorylation of Oct-1, thus relieving its repressive effect. Oct-1 has also been shown to repress interleukin 8 promoter activity. Consistent with reduced levels of Oct-1 DNA binding activity in the Rb-transformed cell lines, interleukin 8 expression is higher in these cell lines.	[ "Retinoblastoma", "protein", "expression", "leads", "to", "reduced", "Oct-1", "DNA", "binding", "activity", "and", "enhances", "interleukin-8", "expression", ".", "\n", "Tumor", "cell", "lines", "with", "a", "defective", "retinoblastoma", "gene", "are", "unable", "to", "transcribe", "the", "HLA", "class", "II", "genes", "in", "response", "to", "IFN", "-", "gamma", "treatment", ",", "and", "reconstitution", "of", "functional", "Rb", "rescues", "IFN", "-", "gamma", "-", "induced", "class", "II", "gene", "expression", ".", "However", ",", "the", "molecular", "mechanism", "of", "Rb", "rescue", "of", "the", "class", "II", "genes", "is", "unknown", ".", "We", "have", "examined", "the", "effect", "of", "Rb", "expression", "on", "the", "activation", "of", "the", "promoter", "for", "HLA", "-", "DRA", ",", "the", "prototype", "class", "II", "gene", ".", "Oct-1", ",", "a", "POU", "domain", "transcription", "factor", ",", "was", "identified", "as", "a", "repressor", "of", "HLA", "-", "DRA", "promoter", "activity", "in", "the", "Rb", "-", "defective", "cells", ".", "Rb", "expression", "led", "to", "phosphorylation", "of", "Oct-1", ",", "thus", "relieving", "its", "repressive", "effect", ".", "Oct-1", "has", "also", "been", "shown", "to", "repress", "interleukin", "8", "promoter", "activity", ".", "Consistent", "with", "reduced", "levels", "of", "Oct-1", "DNA", "binding", "activity", "in", "the", "Rb", "-", "transformed", "cell", "lines", ",", "interleukin", "8", "expression", "is", "higher", "in", "these", "cell", "lines", "." ]	[ "Protein", "Entity" ]
Serumkinetik is an umlsterm, hirnspezifischen is an umlsterm, Markers is an umlsterm, Protein is an umlsterm, angeborener is an umlsterm, Methodik is an umlsterm, Haemoglobin - Saettigung is an umlsterm, USA is an umlsterm, Protein is an umlsterm, Radioimmunassays is an umlsterm, Schweden is an umlsterm, Protein is an umlsterm, Kindern is an umlsterm, Komplikationen is an umlsterm, Standardabweichungen is an umlsterm, Kinder is an umlsterm, Bypasszeit is an umlsterm, Temperatur is an umlsterm, Protein is an umlsterm, Haemoglobin - Saettigung is an umlsterm, Reperfusion is an umlsterm, Protein is an umlsterm, Membranschaedigung is an umlsterm, Blut - Hirnschranke is an umlsterm, Proteins is an umlsterm, Hypothermie is an umlsterm	IntensiveMedizin.00370617.ger.abstr_task0	Sentence: Fragestellung : Das Ziel diese prospektiven Studie war , die Serumkinetik des hirnspezifischen Markers Protein S-100, eines Gliazell- und Astrozytenproteins , in Beziehung zur kontinuierlich registrierten zerebralen Oxygenierung vor und nach Korrekturoperationen angeborener Herzfehler zu evaluieren . Methodik : Die regionale zerebrale Haemoglobin-Saettigung wurde mit Hilfe der Nahinfrarotspektroskopie ( INVOS 3100A , Somanetics , USA ) bestimmt und das Protein S-100 mittels eines doppelseitigen Radioimmunassays analysiert ( Sangtec 100 IRMA , Bromma , Schweden ) . Ergebnisse : Das Protein S-100 war bei allen Kindern ohne nachweisbare neurologische Komplikationen nach Ende der extrakorporalen Zirkulation um 2 Standardabweichungen des praeoperativen Ausgangswertes erhoeht gefunden ( p 0,0001 ) . Die maximalen Serum-S-100-Konzentrationen korrelierten signifikant mit dem Alter ( r=-0,75, p 0,0001 ) und Gewicht ( r=-0,72, p=0,005) der Kinder , der Bypasszeit ( r=0,44, p=0,005) und der minimalen rektalen Temperatur ( r=-0,67, p=0,004) waehrend der extrakorporalen Zirkulation . Ein statistischer Zusammenhang fand sich zwischen dem postoperativen Serumspiegel des Protein S-100 und dem Abfall der regionalen zerebralen Haemoglobin-Saettigung waehrend der Reperfusion ( r=-0,37, p=0,02) und am Ende der extrakorporalen Zirkulation ( r=-0,42, p=0,008). Schlussfolgerung : Die Astrogliazellen scheinen auf die extrakorporale Zirkulation mit einer Expression des Protein S-100 zu reagieren . Eine Membranschaedigung im endothelialastrozytaeren Zellkomplex der Blut-Hirnschranke koennte die Freisetzung des Proteins in die Blutstrombahn erklaeren . Beeinflussende Faktoren scheinen geringes Alter , Laenge der extrakorporalen Zirkulation , Grad der Hypothermie und moegliche Reduktion der postoperativen zerebralen Oxygenierung zu sein . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fragestellung : Das Ziel diese prospektiven Studie war , die Serumkinetik des hirnspezifischen Markers Protein S-100, eines Gliazell- und Astrozytenproteins , in Beziehung zur kontinuierlich registrierten zerebralen Oxygenierung vor und nach Korrekturoperationen angeborener Herzfehler zu evaluieren . Methodik : Die regionale zerebrale Haemoglobin-Saettigung wurde mit Hilfe der Nahinfrarotspektroskopie ( INVOS 3100A , Somanetics , USA ) bestimmt und das Protein S-100 mittels eines doppelseitigen Radioimmunassays analysiert ( Sangtec 100 IRMA , Bromma , Schweden ) . Ergebnisse : Das Protein S-100 war bei allen Kindern ohne nachweisbare neurologische Komplikationen nach Ende der extrakorporalen Zirkulation um 2 Standardabweichungen des praeoperativen Ausgangswertes erhoeht gefunden ( p 0,0001 ) . Die maximalen Serum-S-100-Konzentrationen korrelierten signifikant mit dem Alter ( r=-0,75, p 0,0001 ) und Gewicht ( r=-0,72, p=0,005) der Kinder , der Bypasszeit ( r=0,44, p=0,005) und der minimalen rektalen Temperatur ( r=-0,67, p=0,004) waehrend der extrakorporalen Zirkulation . Ein statistischer Zusammenhang fand sich zwischen dem postoperativen Serumspiegel des Protein S-100 und dem Abfall der regionalen zerebralen Haemoglobin-Saettigung waehrend der Reperfusion ( r=-0,37, p=0,02) und am Ende der extrakorporalen Zirkulation ( r=-0,42, p=0,008). Schlussfolgerung : Die Astrogliazellen scheinen auf die extrakorporale Zirkulation mit einer Expression des Protein S-100 zu reagieren . Eine Membranschaedigung im endothelialastrozytaeren Zellkomplex der Blut-Hirnschranke koennte die Freisetzung des Proteins in die Blutstrombahn erklaeren . Beeinflussende Faktoren scheinen geringes Alter , Laenge der extrakorporalen Zirkulation , Grad der Hypothermie und moegliche Reduktion der postoperativen zerebralen Oxygenierung zu sein .	[ "Fragestellung", ":", "Das", "Ziel", "diese", "prospektiven", "Studie", "war", ",", "die", "Serumkinetik", "des", "hirnspezifischen", "Markers", "Protein", "S-100", ",", "eines", "Gliazell-", "und", "Astrozytenproteins", ",", "in", "Beziehung", "zur", "kontinuierlich", "registrierten", "zerebralen", "Oxygenierung", "vor", "und", "nach", "Korrekturoperationen", "angeborener", "Herzfehler", "zu", "evaluieren", ".", "Methodik", ":", "Die", "regionale", "zerebrale", "Haemoglobin", "-", "Saettigung", "wurde", "mit", "Hilfe", "der", "Nahinfrarotspektroskopie", "(", "INVOS", "3100A", ",", "Somanetics", ",", "USA", ")", "bestimmt", "und", "das", "Protein", "S-100", "mittels", "eines", "doppelseitigen", "Radioimmunassays", "analysiert", "(", "Sangtec", "100", "IRMA", ",", "Bromma", ",", "Schweden", ")", ".", "Ergebnisse", ":", "Das", "Protein", "S-100", "war", "bei", "allen", "Kindern", "ohne", "nachweisbare", "neurologische", "Komplikationen", "nach", "Ende", "der", "extrakorporalen", "Zirkulation", "um", "2", "Standardabweichungen", "des", "praeoperativen", "Ausgangswertes", "erhoeht", "gefunden", "(", "p", "0,0001", ")", ".", "Die", "maximalen", "Serum", "-", "S-100-Konzentrationen", "korrelierten", "signifikant", "mit", "dem", "Alter", "(", "r=-0,75", ",", "p", "0,0001", ")", "und", "Gewicht", "(", "r=-0,72", ",", "p=0,005", ")", "der", "Kinder", ",", "der", "Bypasszeit", "(", "r=0,44", ",", "p=0,005", ")", "und", "der", "minimalen", "rektalen", "Temperatur", "(", "r=-0,67", ",", "p=0,004", ")", "waehrend", "der", "extrakorporalen", "Zirkulation", ".", "Ein", "statistischer", "Zusammenhang", "fand", "sich", "zwischen", "dem", "postoperativen", "Serumspiegel", "des", "Protein", "S-100", "und", "dem", "Abfall", "der", "regionalen", "zerebralen", "Haemoglobin", "-", "Saettigung", "waehrend", "der", "Reperfusion", "(", "r=-0,37", ",", "p=0,02", ")", "und", "am", "Ende", "der", "extrakorporalen", "Zirkulation", "(", "r=-0,42", ",", "p=0,008", ")", ".", "Schlussfolgerung", ":", "Die", "Astrogliazellen", "scheinen", "auf", "die", "extrakorporale", "Zirkulation", "mit", "einer", "Expression", "des", "Protein", "S-100", "zu", "reagieren", ".", "Eine", "Membranschaedigung", "im", "endothelialastrozytaeren", "Zellkomplex", "der", "Blut", "-", "Hirnschranke", "koennte", "die", "Freisetzung", "des", "Proteins", "in", "die", "Blutstrombahn", "erklaeren", ".", "Beeinflussende", "Faktoren", "scheinen", "geringes", "Alter", ",", "Laenge", "der", "extrakorporalen", "Zirkulation", ",", "Grad", "der", "Hypothermie", "und", "moegliche", "Reduktion", "der", "postoperativen", "zerebralen", "Oxygenierung", "zu", "sein", "." ]	[ "umlsterm" ]
Serumkinetik is an umlsterm, hirnspezifischen is an umlsterm, Markers is an umlsterm, Protein is an umlsterm, angeborener is an umlsterm, Methodik is an umlsterm, Haemoglobin - Saettigung is an umlsterm, USA is an umlsterm, Protein is an umlsterm, Radioimmunassays is an umlsterm, Schweden is an umlsterm, Protein is an umlsterm, Kindern is an umlsterm, Komplikationen is an umlsterm, Standardabweichungen is an umlsterm, Kinder is an umlsterm, Bypasszeit is an umlsterm, Temperatur is an umlsterm, Protein is an umlsterm, Haemoglobin - Saettigung is an umlsterm, Reperfusion is an umlsterm, Protein is an umlsterm, Membranschaedigung is an umlsterm, Blut - Hirnschranke is an umlsterm, Proteins is an umlsterm, Hypothermie is an umlsterm	IntensiveMedizin.00370617.ger.abstr_task1	Sentence: Fragestellung : Das Ziel diese prospektiven Studie war , die Serumkinetik des hirnspezifischen Markers Protein S-100, eines Gliazell- und Astrozytenproteins , in Beziehung zur kontinuierlich registrierten zerebralen Oxygenierung vor und nach Korrekturoperationen angeborener Herzfehler zu evaluieren . Methodik : Die regionale zerebrale Haemoglobin-Saettigung wurde mit Hilfe der Nahinfrarotspektroskopie ( INVOS 3100A , Somanetics , USA ) bestimmt und das Protein S-100 mittels eines doppelseitigen Radioimmunassays analysiert ( Sangtec 100 IRMA , Bromma , Schweden ) . Ergebnisse : Das Protein S-100 war bei allen Kindern ohne nachweisbare neurologische Komplikationen nach Ende der extrakorporalen Zirkulation um 2 Standardabweichungen des praeoperativen Ausgangswertes erhoeht gefunden ( p 0,0001 ) . Die maximalen Serum-S-100-Konzentrationen korrelierten signifikant mit dem Alter ( r=-0,75, p 0,0001 ) und Gewicht ( r=-0,72, p=0,005) der Kinder , der Bypasszeit ( r=0,44, p=0,005) und der minimalen rektalen Temperatur ( r=-0,67, p=0,004) waehrend der extrakorporalen Zirkulation . Ein statistischer Zusammenhang fand sich zwischen dem postoperativen Serumspiegel des Protein S-100 und dem Abfall der regionalen zerebralen Haemoglobin-Saettigung waehrend der Reperfusion ( r=-0,37, p=0,02) und am Ende der extrakorporalen Zirkulation ( r=-0,42, p=0,008). Schlussfolgerung : Die Astrogliazellen scheinen auf die extrakorporale Zirkulation mit einer Expression des Protein S-100 zu reagieren . Eine Membranschaedigung im endothelialastrozytaeren Zellkomplex der Blut-Hirnschranke koennte die Freisetzung des Proteins in die Blutstrombahn erklaeren . Beeinflussende Faktoren scheinen geringes Alter , Laenge der extrakorporalen Zirkulation , Grad der Hypothermie und moegliche Reduktion der postoperativen zerebralen Oxygenierung zu sein . Instructions: please typing these entity words according to sentence: Serumkinetik, hirnspezifischen, Markers, Protein, angeborener, Methodik, Haemoglobin - Saettigung, USA, Protein, Radioimmunassays, Schweden, Protein, Kindern, Komplikationen, Standardabweichungen, Kinder, Bypasszeit, Temperatur, Protein, Haemoglobin - Saettigung, Reperfusion, Protein, Membranschaedigung, Blut - Hirnschranke, Proteins, Hypothermie Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fragestellung : Das Ziel diese prospektiven Studie war , die Serumkinetik des hirnspezifischen Markers Protein S-100, eines Gliazell- und Astrozytenproteins , in Beziehung zur kontinuierlich registrierten zerebralen Oxygenierung vor und nach Korrekturoperationen angeborener Herzfehler zu evaluieren . Methodik : Die regionale zerebrale Haemoglobin-Saettigung wurde mit Hilfe der Nahinfrarotspektroskopie ( INVOS 3100A , Somanetics , USA ) bestimmt und das Protein S-100 mittels eines doppelseitigen Radioimmunassays analysiert ( Sangtec 100 IRMA , Bromma , Schweden ) . Ergebnisse : Das Protein S-100 war bei allen Kindern ohne nachweisbare neurologische Komplikationen nach Ende der extrakorporalen Zirkulation um 2 Standardabweichungen des praeoperativen Ausgangswertes erhoeht gefunden ( p 0,0001 ) . Die maximalen Serum-S-100-Konzentrationen korrelierten signifikant mit dem Alter ( r=-0,75, p 0,0001 ) und Gewicht ( r=-0,72, p=0,005) der Kinder , der Bypasszeit ( r=0,44, p=0,005) und der minimalen rektalen Temperatur ( r=-0,67, p=0,004) waehrend der extrakorporalen Zirkulation . Ein statistischer Zusammenhang fand sich zwischen dem postoperativen Serumspiegel des Protein S-100 und dem Abfall der regionalen zerebralen Haemoglobin-Saettigung waehrend der Reperfusion ( r=-0,37, p=0,02) und am Ende der extrakorporalen Zirkulation ( r=-0,42, p=0,008). Schlussfolgerung : Die Astrogliazellen scheinen auf die extrakorporale Zirkulation mit einer Expression des Protein S-100 zu reagieren . Eine Membranschaedigung im endothelialastrozytaeren Zellkomplex der Blut-Hirnschranke koennte die Freisetzung des Proteins in die Blutstrombahn erklaeren . Beeinflussende Faktoren scheinen geringes Alter , Laenge der extrakorporalen Zirkulation , Grad der Hypothermie und moegliche Reduktion der postoperativen zerebralen Oxygenierung zu sein .	[ "Fragestellung", ":", "Das", "Ziel", "diese", "prospektiven", "Studie", "war", ",", "die", "Serumkinetik", "des", "hirnspezifischen", "Markers", "Protein", "S-100", ",", "eines", "Gliazell-", "und", "Astrozytenproteins", ",", "in", "Beziehung", "zur", "kontinuierlich", "registrierten", "zerebralen", "Oxygenierung", "vor", "und", "nach", "Korrekturoperationen", "angeborener", "Herzfehler", "zu", "evaluieren", ".", "Methodik", ":", "Die", "regionale", "zerebrale", "Haemoglobin", "-", "Saettigung", "wurde", "mit", "Hilfe", "der", "Nahinfrarotspektroskopie", "(", "INVOS", "3100A", ",", "Somanetics", ",", "USA", ")", "bestimmt", "und", "das", "Protein", "S-100", "mittels", "eines", "doppelseitigen", "Radioimmunassays", "analysiert", "(", "Sangtec", "100", "IRMA", ",", "Bromma", ",", "Schweden", ")", ".", "Ergebnisse", ":", "Das", "Protein", "S-100", "war", "bei", "allen", "Kindern", "ohne", "nachweisbare", "neurologische", "Komplikationen", "nach", "Ende", "der", "extrakorporalen", "Zirkulation", "um", "2", "Standardabweichungen", "des", "praeoperativen", "Ausgangswertes", "erhoeht", "gefunden", "(", "p", "0,0001", ")", ".", "Die", "maximalen", "Serum", "-", "S-100-Konzentrationen", "korrelierten", "signifikant", "mit", "dem", "Alter", "(", "r=-0,75", ",", "p", "0,0001", ")", "und", "Gewicht", "(", "r=-0,72", ",", "p=0,005", ")", "der", "Kinder", ",", "der", "Bypasszeit", "(", "r=0,44", ",", "p=0,005", ")", "und", "der", "minimalen", "rektalen", "Temperatur", "(", "r=-0,67", ",", "p=0,004", ")", "waehrend", "der", "extrakorporalen", "Zirkulation", ".", "Ein", "statistischer", "Zusammenhang", "fand", "sich", "zwischen", "dem", "postoperativen", "Serumspiegel", "des", "Protein", "S-100", "und", "dem", "Abfall", "der", "regionalen", "zerebralen", "Haemoglobin", "-", "Saettigung", "waehrend", "der", "Reperfusion", "(", "r=-0,37", ",", "p=0,02", ")", "und", "am", "Ende", "der", "extrakorporalen", "Zirkulation", "(", "r=-0,42", ",", "p=0,008", ")", ".", "Schlussfolgerung", ":", "Die", "Astrogliazellen", "scheinen", "auf", "die", "extrakorporale", "Zirkulation", "mit", "einer", "Expression", "des", "Protein", "S-100", "zu", "reagieren", ".", "Eine", "Membranschaedigung", "im", "endothelialastrozytaeren", "Zellkomplex", "der", "Blut", "-", "Hirnschranke", "koennte", "die", "Freisetzung", "des", "Proteins", "in", "die", "Blutstrombahn", "erklaeren", ".", "Beeinflussende", "Faktoren", "scheinen", "geringes", "Alter", ",", "Laenge", "der", "extrakorporalen", "Zirkulation", ",", "Grad", "der", "Hypothermie", "und", "moegliche", "Reduktion", "der", "postoperativen", "zerebralen", "Oxygenierung", "zu", "sein", "." ]	[ "umlsterm" ]
Serumkinetik, hirnspezifischen, Markers, Protein, angeborener, Methodik, Haemoglobin - Saettigung, USA, Protein, Radioimmunassays, Schweden, Protein, Kindern, Komplikationen, Standardabweichungen, Kinder, Bypasszeit, Temperatur, Protein, Haemoglobin - Saettigung, Reperfusion, Protein, Membranschaedigung, Blut - Hirnschranke, Proteins, Hypothermie	IntensiveMedizin.00370617.ger.abstr_task2	Sentence: Fragestellung : Das Ziel diese prospektiven Studie war , die Serumkinetik des hirnspezifischen Markers Protein S-100, eines Gliazell- und Astrozytenproteins , in Beziehung zur kontinuierlich registrierten zerebralen Oxygenierung vor und nach Korrekturoperationen angeborener Herzfehler zu evaluieren . Methodik : Die regionale zerebrale Haemoglobin-Saettigung wurde mit Hilfe der Nahinfrarotspektroskopie ( INVOS 3100A , Somanetics , USA ) bestimmt und das Protein S-100 mittels eines doppelseitigen Radioimmunassays analysiert ( Sangtec 100 IRMA , Bromma , Schweden ) . Ergebnisse : Das Protein S-100 war bei allen Kindern ohne nachweisbare neurologische Komplikationen nach Ende der extrakorporalen Zirkulation um 2 Standardabweichungen des praeoperativen Ausgangswertes erhoeht gefunden ( p 0,0001 ) . Die maximalen Serum-S-100-Konzentrationen korrelierten signifikant mit dem Alter ( r=-0,75, p 0,0001 ) und Gewicht ( r=-0,72, p=0,005) der Kinder , der Bypasszeit ( r=0,44, p=0,005) und der minimalen rektalen Temperatur ( r=-0,67, p=0,004) waehrend der extrakorporalen Zirkulation . Ein statistischer Zusammenhang fand sich zwischen dem postoperativen Serumspiegel des Protein S-100 und dem Abfall der regionalen zerebralen Haemoglobin-Saettigung waehrend der Reperfusion ( r=-0,37, p=0,02) und am Ende der extrakorporalen Zirkulation ( r=-0,42, p=0,008). Schlussfolgerung : Die Astrogliazellen scheinen auf die extrakorporale Zirkulation mit einer Expression des Protein S-100 zu reagieren . Eine Membranschaedigung im endothelialastrozytaeren Zellkomplex der Blut-Hirnschranke koennte die Freisetzung des Proteins in die Blutstrombahn erklaeren . Beeinflussende Faktoren scheinen geringes Alter , Laenge der extrakorporalen Zirkulation , Grad der Hypothermie und moegliche Reduktion der postoperativen zerebralen Oxygenierung zu sein . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fragestellung : Das Ziel diese prospektiven Studie war , die Serumkinetik des hirnspezifischen Markers Protein S-100, eines Gliazell- und Astrozytenproteins , in Beziehung zur kontinuierlich registrierten zerebralen Oxygenierung vor und nach Korrekturoperationen angeborener Herzfehler zu evaluieren . Methodik : Die regionale zerebrale Haemoglobin-Saettigung wurde mit Hilfe der Nahinfrarotspektroskopie ( INVOS 3100A , Somanetics , USA ) bestimmt und das Protein S-100 mittels eines doppelseitigen Radioimmunassays analysiert ( Sangtec 100 IRMA , Bromma , Schweden ) . Ergebnisse : Das Protein S-100 war bei allen Kindern ohne nachweisbare neurologische Komplikationen nach Ende der extrakorporalen Zirkulation um 2 Standardabweichungen des praeoperativen Ausgangswertes erhoeht gefunden ( p 0,0001 ) . Die maximalen Serum-S-100-Konzentrationen korrelierten signifikant mit dem Alter ( r=-0,75, p 0,0001 ) und Gewicht ( r=-0,72, p=0,005) der Kinder , der Bypasszeit ( r=0,44, p=0,005) und der minimalen rektalen Temperatur ( r=-0,67, p=0,004) waehrend der extrakorporalen Zirkulation . Ein statistischer Zusammenhang fand sich zwischen dem postoperativen Serumspiegel des Protein S-100 und dem Abfall der regionalen zerebralen Haemoglobin-Saettigung waehrend der Reperfusion ( r=-0,37, p=0,02) und am Ende der extrakorporalen Zirkulation ( r=-0,42, p=0,008). Schlussfolgerung : Die Astrogliazellen scheinen auf die extrakorporale Zirkulation mit einer Expression des Protein S-100 zu reagieren . Eine Membranschaedigung im endothelialastrozytaeren Zellkomplex der Blut-Hirnschranke koennte die Freisetzung des Proteins in die Blutstrombahn erklaeren . Beeinflussende Faktoren scheinen geringes Alter , Laenge der extrakorporalen Zirkulation , Grad der Hypothermie und moegliche Reduktion der postoperativen zerebralen Oxygenierung zu sein .	[ "Fragestellung", ":", "Das", "Ziel", "diese", "prospektiven", "Studie", "war", ",", "die", "Serumkinetik", "des", "hirnspezifischen", "Markers", "Protein", "S-100", ",", "eines", "Gliazell-", "und", "Astrozytenproteins", ",", "in", "Beziehung", "zur", "kontinuierlich", "registrierten", "zerebralen", "Oxygenierung", "vor", "und", "nach", "Korrekturoperationen", "angeborener", "Herzfehler", "zu", "evaluieren", ".", "Methodik", ":", "Die", "regionale", "zerebrale", "Haemoglobin", "-", "Saettigung", "wurde", "mit", "Hilfe", "der", "Nahinfrarotspektroskopie", "(", "INVOS", "3100A", ",", "Somanetics", ",", "USA", ")", "bestimmt", "und", "das", "Protein", "S-100", "mittels", "eines", "doppelseitigen", "Radioimmunassays", "analysiert", "(", "Sangtec", "100", "IRMA", ",", "Bromma", ",", "Schweden", ")", ".", "Ergebnisse", ":", "Das", "Protein", "S-100", "war", "bei", "allen", "Kindern", "ohne", "nachweisbare", "neurologische", "Komplikationen", "nach", "Ende", "der", "extrakorporalen", "Zirkulation", "um", "2", "Standardabweichungen", "des", "praeoperativen", "Ausgangswertes", "erhoeht", "gefunden", "(", "p", "0,0001", ")", ".", "Die", "maximalen", "Serum", "-", "S-100-Konzentrationen", "korrelierten", "signifikant", "mit", "dem", "Alter", "(", "r=-0,75", ",", "p", "0,0001", ")", "und", "Gewicht", "(", "r=-0,72", ",", "p=0,005", ")", "der", "Kinder", ",", "der", "Bypasszeit", "(", "r=0,44", ",", "p=0,005", ")", "und", "der", "minimalen", "rektalen", "Temperatur", "(", "r=-0,67", ",", "p=0,004", ")", "waehrend", "der", "extrakorporalen", "Zirkulation", ".", "Ein", "statistischer", "Zusammenhang", "fand", "sich", "zwischen", "dem", "postoperativen", "Serumspiegel", "des", "Protein", "S-100", "und", "dem", "Abfall", "der", "regionalen", "zerebralen", "Haemoglobin", "-", "Saettigung", "waehrend", "der", "Reperfusion", "(", "r=-0,37", ",", "p=0,02", ")", "und", "am", "Ende", "der", "extrakorporalen", "Zirkulation", "(", "r=-0,42", ",", "p=0,008", ")", ".", "Schlussfolgerung", ":", "Die", "Astrogliazellen", "scheinen", "auf", "die", "extrakorporale", "Zirkulation", "mit", "einer", "Expression", "des", "Protein", "S-100", "zu", "reagieren", ".", "Eine", "Membranschaedigung", "im", "endothelialastrozytaeren", "Zellkomplex", "der", "Blut", "-", "Hirnschranke", "koennte", "die", "Freisetzung", "des", "Proteins", "in", "die", "Blutstrombahn", "erklaeren", ".", "Beeinflussende", "Faktoren", "scheinen", "geringes", "Alter", ",", "Laenge", "der", "extrakorporalen", "Zirkulation", ",", "Grad", "der", "Hypothermie", "und", "moegliche", "Reduktion", "der", "postoperativen", "zerebralen", "Oxygenierung", "zu", "sein", "." ]	[ "umlsterm" ]
GSK-3 is a protein, Axin is a protein-family, GSK-3 is a protein, beta - catenin is a protein-family, APC is a protein	1.0alpha7.train.1041_task0	Sentence: GSK-3 functions as part of a multiprotein complex in which Axin directly binds GSK-3, beta-catenin, and APC ( Hart et al. 1998 ; Ikeda et al. 1998 Itoh ; et al. 1998 ; Nakamura et al. 1998 ; Sakanaka et al. 1998 ; Yamamoto et al. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-family, protein	[ "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "B-protein", "O", "O", "B-protein-family", "I-protein-family", "I-protein-family", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	GSK-3 functions as part of a multiprotein complex in which Axin directly binds GSK-3, beta-catenin, and APC ( Hart et al. 1998 ; Ikeda et al. 1998 Itoh ; et al. 1998 ; Nakamura et al. 1998 ; Sakanaka et al. 1998 ; Yamamoto et al.	[ "GSK-3", "functions", "as", "part", "of", "a", "multiprotein", "complex", "in", "which", " ", "Axin", "directly", "binds", " ", "GSK-3", ",", " ", "beta", "-", "catenin", ",", "and", " ", "APC", "(", "Hart", "et", "al", ".", "1998", " ", ";", " ", "Ikeda", " ", "et", "al", ".", "1998", "Itoh", " ", ";", " ", "et", "al", ".", "1998", " ", ";", " ", "Nakamura", "et", "al", ".", "1998", " ", ";", " ", "Sakanaka", "et", "al", ".", "1998", " ", ";", " ", "Yamamoto", "et", "al", "." ]	[ "protein-family", "protein" ]
GSK-3 is a protein, Axin is a protein-family, GSK-3 is a protein, beta - catenin is a protein-family, APC is a protein	1.0alpha7.train.1041_task1	Sentence: GSK-3 functions as part of a multiprotein complex in which Axin directly binds GSK-3, beta-catenin, and APC ( Hart et al. 1998 ; Ikeda et al. 1998 Itoh ; et al. 1998 ; Nakamura et al. 1998 ; Sakanaka et al. 1998 ; Yamamoto et al. Instructions: please typing these entity words according to sentence: GSK-3, Axin, GSK-3, beta - catenin, APC Options: protein-family, protein	[ "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "B-protein", "O", "O", "B-protein-family", "I-protein-family", "I-protein-family", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	GSK-3 functions as part of a multiprotein complex in which Axin directly binds GSK-3, beta-catenin, and APC ( Hart et al. 1998 ; Ikeda et al. 1998 Itoh ; et al. 1998 ; Nakamura et al. 1998 ; Sakanaka et al. 1998 ; Yamamoto et al.	[ "GSK-3", "functions", "as", "part", "of", "a", "multiprotein", "complex", "in", "which", " ", "Axin", "directly", "binds", " ", "GSK-3", ",", " ", "beta", "-", "catenin", ",", "and", " ", "APC", "(", "Hart", "et", "al", ".", "1998", " ", ";", " ", "Ikeda", " ", "et", "al", ".", "1998", "Itoh", " ", ";", " ", "et", "al", ".", "1998", " ", ";", " ", "Nakamura", "et", "al", ".", "1998", " ", ";", " ", "Sakanaka", "et", "al", ".", "1998", " ", ";", " ", "Yamamoto", "et", "al", "." ]	[ "protein-family", "protein" ]
GSK-3, Axin, GSK-3, beta - catenin, APC	1.0alpha7.train.1041_task2	Sentence: GSK-3 functions as part of a multiprotein complex in which Axin directly binds GSK-3, beta-catenin, and APC ( Hart et al. 1998 ; Ikeda et al. 1998 Itoh ; et al. 1998 ; Nakamura et al. 1998 ; Sakanaka et al. 1998 ; Yamamoto et al. Instructions: please extract entity words from the input sentence	[ "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "B-protein", "O", "O", "B-protein-family", "I-protein-family", "I-protein-family", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	GSK-3 functions as part of a multiprotein complex in which Axin directly binds GSK-3, beta-catenin, and APC ( Hart et al. 1998 ; Ikeda et al. 1998 Itoh ; et al. 1998 ; Nakamura et al. 1998 ; Sakanaka et al. 1998 ; Yamamoto et al.	[ "GSK-3", "functions", "as", "part", "of", "a", "multiprotein", "complex", "in", "which", " ", "Axin", "directly", "binds", " ", "GSK-3", ",", " ", "beta", "-", "catenin", ",", "and", " ", "APC", "(", "Hart", "et", "al", ".", "1998", " ", ";", " ", "Ikeda", " ", "et", "al", ".", "1998", "Itoh", " ", ";", " ", "et", "al", ".", "1998", " ", ";", " ", "Nakamura", "et", "al", ".", "1998", " ", ";", " ", "Sakanaka", "et", "al", ".", "1998", " ", ";", " ", "Yamamoto", "et", "al", "." ]	[ "protein-family", "protein" ]
Pentraxin-3 is a Intervention_Pharmacological, chronic heart failure : is a Participant_Condition, Pentraxin-3 ( PTX3 ) is a Intervention_Pharmacological, statin is a Intervention_Pharmacological, 1457 patients is a Participant_Sample-size, Controlled Rosuvastatin Multinational Trial in HF ( CORONA is a Participant_Condition, 1233 patients is a Participant_Sample-size, baseline PTX3 levels is a Intervention_Pharmacological, PTX3 concentration is a Outcome_Physical, Baseline elevated PTX3 is a Intervention_Pharmacological, risk of all - cause mortality is a Outcome_Mortality, cardiovascular mortality is a Outcome_Mortality, hospitalization for worsening HF is a Outcome_Physical, fatal events is a Outcome_Mortality, hsCRP levels is a Outcome_Physical, PTX3 . is a Outcome_Physical, patients with chronic HF is a Participant_Condition	55694_task0	Sentence: Pentraxin-3 in chronic heart failure : the CORONA and GISSI-HF trials . AIMS Pentraxin-3 ( PTX3 ) is a component of the humoral arm of innate immunity which can regulate inflammatory processes . Since the role of inflammation in the progression of chronic heart failure ( HF ) is debated , we investigated the prognostic value of PTX3 and the effect of a statin in two large populations of patients with HF . METHODS AND RESULTS Plasma levels of PTX3 were measured at randomization and after 3 months in 1457 patients enrolled in the Controlled Rosuvastatin Multinational Trial in HF ( CORONA ) and 1233 patients enrolled in the GISSI-Heart Failure trial ( GISSI-HF ) . The relationships between baseline PTX3 levels or their changes over time and mortality were evaluated with multivariable Cox proportional hazard models including clinical factors , high sensitivity C-reactive protein ( hsCRP ) , and N-terminal pro brain natriuretic peptide ( NT-proBNP ) . PTX3 concentration [ median ( Q1-Q3 ) = 5.34 ( 3.55-7.64 ) ng/mL , n = 2690 ] was higher in females , in older patients , and those with lower body mass index . Baseline elevated PTX3 was associated with a higher risk of all-cause mortality [ 759 events , hazard ratio ( HR ) for 1 SD increase 1.20 , 95 % confidence interval ( CI ) 1.12-1.30 , P < 0.0001 ] , cardiovascular mortality ( 587 events , HR 1.27 , 95 % CI 1.17-1.38 , P < 0.0001 ) , or hospitalization for worsening HF ( 720 events , HR 1.21 , 95 % CI 1.12-1.30 , P < 0.0001 ) , and marginally improved discrimination . Three-month changes in PTX3 were associated with fatal events after adjustment for hsCRP or NT-proBNP . Rosuvastatin lowered hsCRP levels but significantly raised PTX3 . CONCLUSION In two independent clinical trials that enrolled patients with chronic HF , PTX3 was consistently associated with outcomes . The opposite effects of a statin on hsCRP and PTX3 call for further investigation . TRIAL REGISTRATION NCT00336336 ( GISSI-HF ) , NCT00206310 ( CORONA ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size	[ "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Pentraxin-3 in chronic heart failure : the CORONA and GISSI-HF trials . AIMS Pentraxin-3 ( PTX3 ) is a component of the humoral arm of innate immunity which can regulate inflammatory processes . Since the role of inflammation in the progression of chronic heart failure ( HF ) is debated , we investigated the prognostic value of PTX3 and the effect of a statin in two large populations of patients with HF . METHODS AND RESULTS Plasma levels of PTX3 were measured at randomization and after 3 months in 1457 patients enrolled in the Controlled Rosuvastatin Multinational Trial in HF ( CORONA ) and 1233 patients enrolled in the GISSI-Heart Failure trial ( GISSI-HF ) . The relationships between baseline PTX3 levels or their changes over time and mortality were evaluated with multivariable Cox proportional hazard models including clinical factors , high sensitivity C-reactive protein ( hsCRP ) , and N-terminal pro brain natriuretic peptide ( NT-proBNP ) . PTX3 concentration [ median ( Q1-Q3 ) = 5.34 ( 3.55-7.64 ) ng/mL , n = 2690 ] was higher in females , in older patients , and those with lower body mass index . Baseline elevated PTX3 was associated with a higher risk of all-cause mortality [ 759 events , hazard ratio ( HR ) for 1 SD increase 1.20 , 95 % confidence interval ( CI ) 1.12-1.30 , P < 0.0001 ] , cardiovascular mortality ( 587 events , HR 1.27 , 95 % CI 1.17-1.38 , P < 0.0001 ) , or hospitalization for worsening HF ( 720 events , HR 1.21 , 95 % CI 1.12-1.30 , P < 0.0001 ) , and marginally improved discrimination . Three-month changes in PTX3 were associated with fatal events after adjustment for hsCRP or NT-proBNP . Rosuvastatin lowered hsCRP levels but significantly raised PTX3 . CONCLUSION In two independent clinical trials that enrolled patients with chronic HF , PTX3 was consistently associated with outcomes . The opposite effects of a statin on hsCRP and PTX3 call for further investigation . TRIAL REGISTRATION NCT00336336 ( GISSI-HF ) , NCT00206310 ( CORONA ) .	[ "Pentraxin-3", "in", "chronic", "heart", "failure", ":", "the", "CORONA", "and", "GISSI", "-", "HF", "trials", ".", "AIMS", "Pentraxin-3", "(", "PTX3", ")", "is", "a", "component", "of", "the", "humoral", "arm", "of", "innate", "immunity", "which", "can", "regulate", "inflammatory", "processes", ".", "Since", "the", "role", "of", "inflammation", "in", "the", "progression", "of", "chronic", "heart", "failure", "(", "HF", ")", "is", "debated", ",", "we", "investigated", "the", "prognostic", "value", "of", "PTX3", "and", "the", "effect", "of", "a", "statin", "in", "two", "large", "populations", "of", "patients", "with", "HF", ".", "METHODS", "AND", "RESULTS", "Plasma", "levels", "of", "PTX3", "were", "measured", "at", "randomization", "and", "after", "3", "months", "in", "1457", "patients", "enrolled", "in", "the", "Controlled", "Rosuvastatin", "Multinational", "Trial", "in", "HF", "(", "CORONA", ")", "and", "1233", "patients", "enrolled", "in", "the", "GISSI", "-", "Heart", "Failure", "trial", "(", "GISSI", "-", "HF", ")", ".", "The", "relationships", "between", "baseline", "PTX3", "levels", "or", "their", "changes", "over", "time", "and", "mortality", "were", "evaluated", "with", "multivariable", "Cox", "proportional", "hazard", "models", "including", "clinical", "factors", ",", "high", "sensitivity", "C", "-", "reactive", "protein", "(", "hsCRP", ")", ",", "and", "N", "-", "terminal", "pro", "brain", "natriuretic", "peptide", "(", "NT", "-", "proBNP", ")", ".", "PTX3", "concentration", "[", "median", "(", "Q1-Q3", ")", "=", "5.34", "(", "3.55", "-", "7.64", ")", "ng", "/", "mL", ",", "n", "=", "2690", "]", "was", "higher", "in", "females", ",", "in", "older", "patients", ",", "and", "those", "with", "lower", "body", "mass", "index", ".", "Baseline", "elevated", "PTX3", "was", "associated", "with", "a", "higher", "risk", "of", "all", "-", "cause", "mortality", "[", "759", "events", ",", "hazard", "ratio", "(", "HR", ")", "for", "1", "SD", "increase", "1.20", ",", "95", "%", "confidence", "interval", "(", "CI", ")", "1.12", "-", "1.30", ",", "P", "<", "0.0001", "]", ",", "cardiovascular", "mortality", "(", "587", "events", ",", "HR", "1.27", ",", "95", "%", "CI", "1.17", "-", "1.38", ",", "P", "<", "0.0001", ")", ",", "or", "hospitalization", "for", "worsening", "HF", "(", "720", "events", ",", "HR", "1.21", ",", "95", "%", "CI", "1.12", "-", "1.30", ",", "P", "<", "0.0001", ")", ",", "and", "marginally", "improved", "discrimination", ".", "Three", "-", "month", "changes", "in", "PTX3", "were", "associated", "with", "fatal", "events", "after", "adjustment", "for", "hsCRP", "or", "NT", "-", "proBNP", ".", "Rosuvastatin", "lowered", "hsCRP", "levels", "but", "significantly", "raised", "PTX3", ".", "CONCLUSION", "In", "two", "independent", "clinical", "trials", "that", "enrolled", "patients", "with", "chronic", "HF", ",", "PTX3", "was", "consistently", "associated", "with", "outcomes", ".", "The", "opposite", "effects", "of", "a", "statin", "on", "hsCRP", "and", "PTX3", "call", "for", "further", "investigation", ".", "TRIAL", "REGISTRATION", "NCT00336336", "(", "GISSI", "-", "HF", ")", ",", "NCT00206310", "(", "CORONA", ")", "." ]	[ "Participant_Condition", "Outcome_Physical", "Outcome_Mortality", "Intervention_Pharmacological", "Participant_Sample-size" ]
Pentraxin-3 is a Intervention_Pharmacological, chronic heart failure : is a Participant_Condition, Pentraxin-3 ( PTX3 ) is a Intervention_Pharmacological, statin is a Intervention_Pharmacological, 1457 patients is a Participant_Sample-size, Controlled Rosuvastatin Multinational Trial in HF ( CORONA is a Participant_Condition, 1233 patients is a Participant_Sample-size, baseline PTX3 levels is a Intervention_Pharmacological, PTX3 concentration is a Outcome_Physical, Baseline elevated PTX3 is a Intervention_Pharmacological, risk of all - cause mortality is a Outcome_Mortality, cardiovascular mortality is a Outcome_Mortality, hospitalization for worsening HF is a Outcome_Physical, fatal events is a Outcome_Mortality, hsCRP levels is a Outcome_Physical, PTX3 . is a Outcome_Physical, patients with chronic HF is a Participant_Condition	55694_task1	Sentence: Pentraxin-3 in chronic heart failure : the CORONA and GISSI-HF trials . AIMS Pentraxin-3 ( PTX3 ) is a component of the humoral arm of innate immunity which can regulate inflammatory processes . Since the role of inflammation in the progression of chronic heart failure ( HF ) is debated , we investigated the prognostic value of PTX3 and the effect of a statin in two large populations of patients with HF . METHODS AND RESULTS Plasma levels of PTX3 were measured at randomization and after 3 months in 1457 patients enrolled in the Controlled Rosuvastatin Multinational Trial in HF ( CORONA ) and 1233 patients enrolled in the GISSI-Heart Failure trial ( GISSI-HF ) . The relationships between baseline PTX3 levels or their changes over time and mortality were evaluated with multivariable Cox proportional hazard models including clinical factors , high sensitivity C-reactive protein ( hsCRP ) , and N-terminal pro brain natriuretic peptide ( NT-proBNP ) . PTX3 concentration [ median ( Q1-Q3 ) = 5.34 ( 3.55-7.64 ) ng/mL , n = 2690 ] was higher in females , in older patients , and those with lower body mass index . Baseline elevated PTX3 was associated with a higher risk of all-cause mortality [ 759 events , hazard ratio ( HR ) for 1 SD increase 1.20 , 95 % confidence interval ( CI ) 1.12-1.30 , P < 0.0001 ] , cardiovascular mortality ( 587 events , HR 1.27 , 95 % CI 1.17-1.38 , P < 0.0001 ) , or hospitalization for worsening HF ( 720 events , HR 1.21 , 95 % CI 1.12-1.30 , P < 0.0001 ) , and marginally improved discrimination . Three-month changes in PTX3 were associated with fatal events after adjustment for hsCRP or NT-proBNP . Rosuvastatin lowered hsCRP levels but significantly raised PTX3 . CONCLUSION In two independent clinical trials that enrolled patients with chronic HF , PTX3 was consistently associated with outcomes . The opposite effects of a statin on hsCRP and PTX3 call for further investigation . TRIAL REGISTRATION NCT00336336 ( GISSI-HF ) , NCT00206310 ( CORONA ) . Instructions: please typing these entity words according to sentence: Pentraxin-3, chronic heart failure :, Pentraxin-3 ( PTX3 ), statin, 1457 patients, Controlled Rosuvastatin Multinational Trial in HF ( CORONA, 1233 patients, baseline PTX3 levels, PTX3 concentration, Baseline elevated PTX3, risk of all - cause mortality, cardiovascular mortality, hospitalization for worsening HF, fatal events, hsCRP levels, PTX3 ., patients with chronic HF Options: Intervention_Pharmacological, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size	[ "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Pentraxin-3 in chronic heart failure : the CORONA and GISSI-HF trials . AIMS Pentraxin-3 ( PTX3 ) is a component of the humoral arm of innate immunity which can regulate inflammatory processes . Since the role of inflammation in the progression of chronic heart failure ( HF ) is debated , we investigated the prognostic value of PTX3 and the effect of a statin in two large populations of patients with HF . METHODS AND RESULTS Plasma levels of PTX3 were measured at randomization and after 3 months in 1457 patients enrolled in the Controlled Rosuvastatin Multinational Trial in HF ( CORONA ) and 1233 patients enrolled in the GISSI-Heart Failure trial ( GISSI-HF ) . The relationships between baseline PTX3 levels or their changes over time and mortality were evaluated with multivariable Cox proportional hazard models including clinical factors , high sensitivity C-reactive protein ( hsCRP ) , and N-terminal pro brain natriuretic peptide ( NT-proBNP ) . PTX3 concentration [ median ( Q1-Q3 ) = 5.34 ( 3.55-7.64 ) ng/mL , n = 2690 ] was higher in females , in older patients , and those with lower body mass index . Baseline elevated PTX3 was associated with a higher risk of all-cause mortality [ 759 events , hazard ratio ( HR ) for 1 SD increase 1.20 , 95 % confidence interval ( CI ) 1.12-1.30 , P < 0.0001 ] , cardiovascular mortality ( 587 events , HR 1.27 , 95 % CI 1.17-1.38 , P < 0.0001 ) , or hospitalization for worsening HF ( 720 events , HR 1.21 , 95 % CI 1.12-1.30 , P < 0.0001 ) , and marginally improved discrimination . Three-month changes in PTX3 were associated with fatal events after adjustment for hsCRP or NT-proBNP . Rosuvastatin lowered hsCRP levels but significantly raised PTX3 . CONCLUSION In two independent clinical trials that enrolled patients with chronic HF , PTX3 was consistently associated with outcomes . The opposite effects of a statin on hsCRP and PTX3 call for further investigation . TRIAL REGISTRATION NCT00336336 ( GISSI-HF ) , NCT00206310 ( CORONA ) .	[ "Pentraxin-3", "in", "chronic", "heart", "failure", ":", "the", "CORONA", "and", "GISSI", "-", "HF", "trials", ".", "AIMS", "Pentraxin-3", "(", "PTX3", ")", "is", "a", "component", "of", "the", "humoral", "arm", "of", "innate", "immunity", "which", "can", "regulate", "inflammatory", "processes", ".", "Since", "the", "role", "of", "inflammation", "in", "the", "progression", "of", "chronic", "heart", "failure", "(", "HF", ")", "is", "debated", ",", "we", "investigated", "the", "prognostic", "value", "of", "PTX3", "and", "the", "effect", "of", "a", "statin", "in", "two", "large", "populations", "of", "patients", "with", "HF", ".", "METHODS", "AND", "RESULTS", "Plasma", "levels", "of", "PTX3", "were", "measured", "at", "randomization", "and", "after", "3", "months", "in", "1457", "patients", "enrolled", "in", "the", "Controlled", "Rosuvastatin", "Multinational", "Trial", "in", "HF", "(", "CORONA", ")", "and", "1233", "patients", "enrolled", "in", "the", "GISSI", "-", "Heart", "Failure", "trial", "(", "GISSI", "-", "HF", ")", ".", "The", "relationships", "between", "baseline", "PTX3", "levels", "or", "their", "changes", "over", "time", "and", "mortality", "were", "evaluated", "with", "multivariable", "Cox", "proportional", "hazard", "models", "including", "clinical", "factors", ",", "high", "sensitivity", "C", "-", "reactive", "protein", "(", "hsCRP", ")", ",", "and", "N", "-", "terminal", "pro", "brain", "natriuretic", "peptide", "(", "NT", "-", "proBNP", ")", ".", "PTX3", "concentration", "[", "median", "(", "Q1-Q3", ")", "=", "5.34", "(", "3.55", "-", "7.64", ")", "ng", "/", "mL", ",", "n", "=", "2690", "]", "was", "higher", "in", "females", ",", "in", "older", "patients", ",", "and", "those", "with", "lower", "body", "mass", "index", ".", "Baseline", "elevated", "PTX3", "was", "associated", "with", "a", "higher", "risk", "of", "all", "-", "cause", "mortality", "[", "759", "events", ",", "hazard", "ratio", "(", "HR", ")", "for", "1", "SD", "increase", "1.20", ",", "95", "%", "confidence", "interval", "(", "CI", ")", "1.12", "-", "1.30", ",", "P", "<", "0.0001", "]", ",", "cardiovascular", "mortality", "(", "587", "events", ",", "HR", "1.27", ",", "95", "%", "CI", "1.17", "-", "1.38", ",", "P", "<", "0.0001", ")", ",", "or", "hospitalization", "for", "worsening", "HF", "(", "720", "events", ",", "HR", "1.21", ",", "95", "%", "CI", "1.12", "-", "1.30", ",", "P", "<", "0.0001", ")", ",", "and", "marginally", "improved", "discrimination", ".", "Three", "-", "month", "changes", "in", "PTX3", "were", "associated", "with", "fatal", "events", "after", "adjustment", "for", "hsCRP", "or", "NT", "-", "proBNP", ".", "Rosuvastatin", "lowered", "hsCRP", "levels", "but", "significantly", "raised", "PTX3", ".", "CONCLUSION", "In", "two", "independent", "clinical", "trials", "that", "enrolled", "patients", "with", "chronic", "HF", ",", "PTX3", "was", "consistently", "associated", "with", "outcomes", ".", "The", "opposite", "effects", "of", "a", "statin", "on", "hsCRP", "and", "PTX3", "call", "for", "further", "investigation", ".", "TRIAL", "REGISTRATION", "NCT00336336", "(", "GISSI", "-", "HF", ")", ",", "NCT00206310", "(", "CORONA", ")", "." ]	[ "Participant_Condition", "Outcome_Physical", "Outcome_Mortality", "Intervention_Pharmacological", "Participant_Sample-size" ]
Pentraxin-3, chronic heart failure :, Pentraxin-3 ( PTX3 ), statin, 1457 patients, Controlled Rosuvastatin Multinational Trial in HF ( CORONA, 1233 patients, baseline PTX3 levels, PTX3 concentration, Baseline elevated PTX3, risk of all - cause mortality, cardiovascular mortality, hospitalization for worsening HF, fatal events, hsCRP levels, PTX3 ., patients with chronic HF	55694_task2	Sentence: Pentraxin-3 in chronic heart failure : the CORONA and GISSI-HF trials . AIMS Pentraxin-3 ( PTX3 ) is a component of the humoral arm of innate immunity which can regulate inflammatory processes . Since the role of inflammation in the progression of chronic heart failure ( HF ) is debated , we investigated the prognostic value of PTX3 and the effect of a statin in two large populations of patients with HF . METHODS AND RESULTS Plasma levels of PTX3 were measured at randomization and after 3 months in 1457 patients enrolled in the Controlled Rosuvastatin Multinational Trial in HF ( CORONA ) and 1233 patients enrolled in the GISSI-Heart Failure trial ( GISSI-HF ) . The relationships between baseline PTX3 levels or their changes over time and mortality were evaluated with multivariable Cox proportional hazard models including clinical factors , high sensitivity C-reactive protein ( hsCRP ) , and N-terminal pro brain natriuretic peptide ( NT-proBNP ) . PTX3 concentration [ median ( Q1-Q3 ) = 5.34 ( 3.55-7.64 ) ng/mL , n = 2690 ] was higher in females , in older patients , and those with lower body mass index . Baseline elevated PTX3 was associated with a higher risk of all-cause mortality [ 759 events , hazard ratio ( HR ) for 1 SD increase 1.20 , 95 % confidence interval ( CI ) 1.12-1.30 , P < 0.0001 ] , cardiovascular mortality ( 587 events , HR 1.27 , 95 % CI 1.17-1.38 , P < 0.0001 ) , or hospitalization for worsening HF ( 720 events , HR 1.21 , 95 % CI 1.12-1.30 , P < 0.0001 ) , and marginally improved discrimination . Three-month changes in PTX3 were associated with fatal events after adjustment for hsCRP or NT-proBNP . Rosuvastatin lowered hsCRP levels but significantly raised PTX3 . CONCLUSION In two independent clinical trials that enrolled patients with chronic HF , PTX3 was consistently associated with outcomes . The opposite effects of a statin on hsCRP and PTX3 call for further investigation . TRIAL REGISTRATION NCT00336336 ( GISSI-HF ) , NCT00206310 ( CORONA ) . Instructions: please extract entity words from the input sentence	[ "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Pentraxin-3 in chronic heart failure : the CORONA and GISSI-HF trials . AIMS Pentraxin-3 ( PTX3 ) is a component of the humoral arm of innate immunity which can regulate inflammatory processes . Since the role of inflammation in the progression of chronic heart failure ( HF ) is debated , we investigated the prognostic value of PTX3 and the effect of a statin in two large populations of patients with HF . METHODS AND RESULTS Plasma levels of PTX3 were measured at randomization and after 3 months in 1457 patients enrolled in the Controlled Rosuvastatin Multinational Trial in HF ( CORONA ) and 1233 patients enrolled in the GISSI-Heart Failure trial ( GISSI-HF ) . The relationships between baseline PTX3 levels or their changes over time and mortality were evaluated with multivariable Cox proportional hazard models including clinical factors , high sensitivity C-reactive protein ( hsCRP ) , and N-terminal pro brain natriuretic peptide ( NT-proBNP ) . PTX3 concentration [ median ( Q1-Q3 ) = 5.34 ( 3.55-7.64 ) ng/mL , n = 2690 ] was higher in females , in older patients , and those with lower body mass index . Baseline elevated PTX3 was associated with a higher risk of all-cause mortality [ 759 events , hazard ratio ( HR ) for 1 SD increase 1.20 , 95 % confidence interval ( CI ) 1.12-1.30 , P < 0.0001 ] , cardiovascular mortality ( 587 events , HR 1.27 , 95 % CI 1.17-1.38 , P < 0.0001 ) , or hospitalization for worsening HF ( 720 events , HR 1.21 , 95 % CI 1.12-1.30 , P < 0.0001 ) , and marginally improved discrimination . Three-month changes in PTX3 were associated with fatal events after adjustment for hsCRP or NT-proBNP . Rosuvastatin lowered hsCRP levels but significantly raised PTX3 . CONCLUSION In two independent clinical trials that enrolled patients with chronic HF , PTX3 was consistently associated with outcomes . The opposite effects of a statin on hsCRP and PTX3 call for further investigation . TRIAL REGISTRATION NCT00336336 ( GISSI-HF ) , NCT00206310 ( CORONA ) .	[ "Pentraxin-3", "in", "chronic", "heart", "failure", ":", "the", "CORONA", "and", "GISSI", "-", "HF", "trials", ".", "AIMS", "Pentraxin-3", "(", "PTX3", ")", "is", "a", "component", "of", "the", "humoral", "arm", "of", "innate", "immunity", "which", "can", "regulate", "inflammatory", "processes", ".", "Since", "the", "role", "of", "inflammation", "in", "the", "progression", "of", "chronic", "heart", "failure", "(", "HF", ")", "is", "debated", ",", "we", "investigated", "the", "prognostic", "value", "of", "PTX3", "and", "the", "effect", "of", "a", "statin", "in", "two", "large", "populations", "of", "patients", "with", "HF", ".", "METHODS", "AND", "RESULTS", "Plasma", "levels", "of", "PTX3", "were", "measured", "at", "randomization", "and", "after", "3", "months", "in", "1457", "patients", "enrolled", "in", "the", "Controlled", "Rosuvastatin", "Multinational", "Trial", "in", "HF", "(", "CORONA", ")", "and", "1233", "patients", "enrolled", "in", "the", "GISSI", "-", "Heart", "Failure", "trial", "(", "GISSI", "-", "HF", ")", ".", "The", "relationships", "between", "baseline", "PTX3", "levels", "or", "their", "changes", "over", "time", "and", "mortality", "were", "evaluated", "with", "multivariable", "Cox", "proportional", "hazard", "models", "including", "clinical", "factors", ",", "high", "sensitivity", "C", "-", "reactive", "protein", "(", "hsCRP", ")", ",", "and", "N", "-", "terminal", "pro", "brain", "natriuretic", "peptide", "(", "NT", "-", "proBNP", ")", ".", "PTX3", "concentration", "[", "median", "(", "Q1-Q3", ")", "=", "5.34", "(", "3.55", "-", "7.64", ")", "ng", "/", "mL", ",", "n", "=", "2690", "]", "was", "higher", "in", "females", ",", "in", "older", "patients", ",", "and", "those", "with", "lower", "body", "mass", "index", ".", "Baseline", "elevated", "PTX3", "was", "associated", "with", "a", "higher", "risk", "of", "all", "-", "cause", "mortality", "[", "759", "events", ",", "hazard", "ratio", "(", "HR", ")", "for", "1", "SD", "increase", "1.20", ",", "95", "%", "confidence", "interval", "(", "CI", ")", "1.12", "-", "1.30", ",", "P", "<", "0.0001", "]", ",", "cardiovascular", "mortality", "(", "587", "events", ",", "HR", "1.27", ",", "95", "%", "CI", "1.17", "-", "1.38", ",", "P", "<", "0.0001", ")", ",", "or", "hospitalization", "for", "worsening", "HF", "(", "720", "events", ",", "HR", "1.21", ",", "95", "%", "CI", "1.12", "-", "1.30", ",", "P", "<", "0.0001", ")", ",", "and", "marginally", "improved", "discrimination", ".", "Three", "-", "month", "changes", "in", "PTX3", "were", "associated", "with", "fatal", "events", "after", "adjustment", "for", "hsCRP", "or", "NT", "-", "proBNP", ".", "Rosuvastatin", "lowered", "hsCRP", "levels", "but", "significantly", "raised", "PTX3", ".", "CONCLUSION", "In", "two", "independent", "clinical", "trials", "that", "enrolled", "patients", "with", "chronic", "HF", ",", "PTX3", "was", "consistently", "associated", "with", "outcomes", ".", "The", "opposite", "effects", "of", "a", "statin", "on", "hsCRP", "and", "PTX3", "call", "for", "further", "investigation", ".", "TRIAL", "REGISTRATION", "NCT00336336", "(", "GISSI", "-", "HF", ")", ",", "NCT00206310", "(", "CORONA", ")", "." ]	[ "Participant_Condition", "Outcome_Physical", "Outcome_Mortality", "Intervention_Pharmacological", "Participant_Sample-size" ]
Entzugsbehandlung is an umlsterm, Alkoholkranker is an umlsterm, Therapie is an umlsterm, Suchtberater is an umlsterm, Therapie- is an umlsterm, Alkoholpatienten is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Therapieziel is an umlsterm, Patienten is an umlsterm, alkoholrueckfaellig is an umlsterm, Patienten is an umlsterm, Zeit is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, alkoholrueckfaellig is an umlsterm, Alkoholkranke is an umlsterm, Therapieschritten is an umlsterm, Leben is an umlsterm	DerNervenarzt.70680574.ger.abstr_task0	Sentence: Die stationaere psychiatrische Entzugsbehandlung Alkoholkranker ist - neben der Therapie durch niedergelassene Nervenaerzte und Suchtberater - ein Bindeglied zwischen medizinisch ausgerichteter Entgiftung und psychosozial orientierter Entwoehnung . Ein wesentliches Ziel der integrierten Entgiftungs- und Motivationsbehandlung ist die Foerderung von Therapie- und Abstinenzbereitschaft . Von 529 Alkoholpatienten , die sich einer solchen 2- bis 3-woechigen stationaeren Behandlung unterzogen , wurden 469 89% ) ( nach 8 Monaten katamnestisch erfasst . 242 Patienten ( 52% der Katamnese- bzw. 46% der Ausgangsstichprobe ) hatten das primaere Therapieziel erreicht und eine Entwoehnungsbehandlung angetreten . Hiervon wurden 54 Patienten nur in der Wartezeit zwischen Entgiftung und Entwoehnung nach ihren Angaben alkoholrueckfaellig , lebten aber danach ( waehrend und nach der Entwoehnung ) abstinent . 60 dieser 242 Patienten ( 25% ) wurden indes in der Zeit nach der Entwoehnung bis zur Katamnese ( im Mittel 4 Monate ) rueckfaellig . 227 Patienten begannen nach der Entgiftungs- und Motivationstherapie keine weitere Entwoehnungsbehandlung . Von diesen Patienten wurden 113 50% ) ( innerhalb des achtmonatigen Katamnesezeitraumes alkoholrueckfaellig . Obwohl es sich bei dieser Untersuchung nicht um eine kontrollierte Studie handelt , weisen die Ergebnisse und die klinischen Erfahrungen daraufhin , dass sich im Rahmen eines integrierten stationaeren Entgiftungs- und Motivationskonzeptes auf spezialisierten Stationen zahlreiche akut aufgenommene Alkoholkranke zu weiteren suchtspezifischen Therapieschritten motivieren lassen , die die Chance auf ein dauerhaftes abstinentes Leben deutlich erhoehen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Die stationaere psychiatrische Entzugsbehandlung Alkoholkranker ist - neben der Therapie durch niedergelassene Nervenaerzte und Suchtberater - ein Bindeglied zwischen medizinisch ausgerichteter Entgiftung und psychosozial orientierter Entwoehnung . Ein wesentliches Ziel der integrierten Entgiftungs- und Motivationsbehandlung ist die Foerderung von Therapie- und Abstinenzbereitschaft . Von 529 Alkoholpatienten , die sich einer solchen 2- bis 3-woechigen stationaeren Behandlung unterzogen , wurden 469 89% ) ( nach 8 Monaten katamnestisch erfasst . 242 Patienten ( 52% der Katamnese- bzw. 46% der Ausgangsstichprobe ) hatten das primaere Therapieziel erreicht und eine Entwoehnungsbehandlung angetreten . Hiervon wurden 54 Patienten nur in der Wartezeit zwischen Entgiftung und Entwoehnung nach ihren Angaben alkoholrueckfaellig , lebten aber danach ( waehrend und nach der Entwoehnung ) abstinent . 60 dieser 242 Patienten ( 25% ) wurden indes in der Zeit nach der Entwoehnung bis zur Katamnese ( im Mittel 4 Monate ) rueckfaellig . 227 Patienten begannen nach der Entgiftungs- und Motivationstherapie keine weitere Entwoehnungsbehandlung . Von diesen Patienten wurden 113 50% ) ( innerhalb des achtmonatigen Katamnesezeitraumes alkoholrueckfaellig . Obwohl es sich bei dieser Untersuchung nicht um eine kontrollierte Studie handelt , weisen die Ergebnisse und die klinischen Erfahrungen daraufhin , dass sich im Rahmen eines integrierten stationaeren Entgiftungs- und Motivationskonzeptes auf spezialisierten Stationen zahlreiche akut aufgenommene Alkoholkranke zu weiteren suchtspezifischen Therapieschritten motivieren lassen , die die Chance auf ein dauerhaftes abstinentes Leben deutlich erhoehen .	[ "Die", "stationaere", "psychiatrische", "Entzugsbehandlung", "Alkoholkranker", "ist", "-", "neben", "der", "Therapie", "durch", "niedergelassene", "Nervenaerzte", "und", "Suchtberater", "-", "ein", "Bindeglied", "zwischen", "medizinisch", "ausgerichteter", "Entgiftung", "und", "psychosozial", "orientierter", "Entwoehnung", ".", "Ein", "wesentliches", "Ziel", "der", "integrierten", "Entgiftungs-", "und", "Motivationsbehandlung", "ist", "die", "Foerderung", "von", "Therapie-", "und", "Abstinenzbereitschaft", ".", "Von", "529", "Alkoholpatienten", ",", "die", "sich", "einer", "solchen", "2-", "bis", "3-woechigen", "stationaeren", "Behandlung", "unterzogen", ",", "wurden", "469", "89", "%", ")", "(", "nach", "8", "Monaten", "katamnestisch", "erfasst", ".", "242", "Patienten", "(", "52", "%", "der", "Katamnese-", "bzw", ".", "46", "%", "der", "Ausgangsstichprobe", ")", "hatten", "das", "primaere", "Therapieziel", "erreicht", "und", "eine", "Entwoehnungsbehandlung", "angetreten", ".", "Hiervon", "wurden", "54", "Patienten", "nur", "in", "der", "Wartezeit", "zwischen", "Entgiftung", "und", "Entwoehnung", "nach", "ihren", "Angaben", "alkoholrueckfaellig", ",", "lebten", "aber", "danach", "(", "waehrend", "und", "nach", "der", "Entwoehnung", ")", "abstinent", ".", "60", "dieser", "242", "Patienten", "(", "25", "%", ")", "wurden", "indes", "in", "der", "Zeit", "nach", "der", "Entwoehnung", "bis", "zur", "Katamnese", "(", "im", "Mittel", "4", "Monate", ")", "rueckfaellig", ".", "227", "Patienten", "begannen", "nach", "der", "Entgiftungs-", "und", "Motivationstherapie", "keine", "weitere", "Entwoehnungsbehandlung", ".", "Von", "diesen", "Patienten", "wurden", "113", "50", "%", ")", "(", "innerhalb", "des", "achtmonatigen", "Katamnesezeitraumes", "alkoholrueckfaellig", ".", "Obwohl", "es", "sich", "bei", "dieser", "Untersuchung", "nicht", "um", "eine", "kontrollierte", "Studie", "handelt", ",", "weisen", "die", "Ergebnisse", "und", "die", "klinischen", "Erfahrungen", "daraufhin", ",", "dass", "sich", "im", "Rahmen", "eines", "integrierten", "stationaeren", "Entgiftungs-", "und", "Motivationskonzeptes", "auf", "spezialisierten", "Stationen", "zahlreiche", "akut", "aufgenommene", "Alkoholkranke", "zu", "weiteren", "suchtspezifischen", "Therapieschritten", "motivieren", "lassen", ",", "die", "die", "Chance", "auf", "ein", "dauerhaftes", "abstinentes", "Leben", "deutlich", "erhoehen", "." ]	[ "umlsterm" ]
Entzugsbehandlung is an umlsterm, Alkoholkranker is an umlsterm, Therapie is an umlsterm, Suchtberater is an umlsterm, Therapie- is an umlsterm, Alkoholpatienten is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Therapieziel is an umlsterm, Patienten is an umlsterm, alkoholrueckfaellig is an umlsterm, Patienten is an umlsterm, Zeit is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, alkoholrueckfaellig is an umlsterm, Alkoholkranke is an umlsterm, Therapieschritten is an umlsterm, Leben is an umlsterm	DerNervenarzt.70680574.ger.abstr_task1	Sentence: Die stationaere psychiatrische Entzugsbehandlung Alkoholkranker ist - neben der Therapie durch niedergelassene Nervenaerzte und Suchtberater - ein Bindeglied zwischen medizinisch ausgerichteter Entgiftung und psychosozial orientierter Entwoehnung . Ein wesentliches Ziel der integrierten Entgiftungs- und Motivationsbehandlung ist die Foerderung von Therapie- und Abstinenzbereitschaft . Von 529 Alkoholpatienten , die sich einer solchen 2- bis 3-woechigen stationaeren Behandlung unterzogen , wurden 469 89% ) ( nach 8 Monaten katamnestisch erfasst . 242 Patienten ( 52% der Katamnese- bzw. 46% der Ausgangsstichprobe ) hatten das primaere Therapieziel erreicht und eine Entwoehnungsbehandlung angetreten . Hiervon wurden 54 Patienten nur in der Wartezeit zwischen Entgiftung und Entwoehnung nach ihren Angaben alkoholrueckfaellig , lebten aber danach ( waehrend und nach der Entwoehnung ) abstinent . 60 dieser 242 Patienten ( 25% ) wurden indes in der Zeit nach der Entwoehnung bis zur Katamnese ( im Mittel 4 Monate ) rueckfaellig . 227 Patienten begannen nach der Entgiftungs- und Motivationstherapie keine weitere Entwoehnungsbehandlung . Von diesen Patienten wurden 113 50% ) ( innerhalb des achtmonatigen Katamnesezeitraumes alkoholrueckfaellig . Obwohl es sich bei dieser Untersuchung nicht um eine kontrollierte Studie handelt , weisen die Ergebnisse und die klinischen Erfahrungen daraufhin , dass sich im Rahmen eines integrierten stationaeren Entgiftungs- und Motivationskonzeptes auf spezialisierten Stationen zahlreiche akut aufgenommene Alkoholkranke zu weiteren suchtspezifischen Therapieschritten motivieren lassen , die die Chance auf ein dauerhaftes abstinentes Leben deutlich erhoehen . Instructions: please typing these entity words according to sentence: Entzugsbehandlung, Alkoholkranker, Therapie, Suchtberater, Therapie-, Alkoholpatienten, Behandlung, Patienten, Therapieziel, Patienten, alkoholrueckfaellig, Patienten, Zeit, Patienten, Patienten, alkoholrueckfaellig, Alkoholkranke, Therapieschritten, Leben Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Die stationaere psychiatrische Entzugsbehandlung Alkoholkranker ist - neben der Therapie durch niedergelassene Nervenaerzte und Suchtberater - ein Bindeglied zwischen medizinisch ausgerichteter Entgiftung und psychosozial orientierter Entwoehnung . Ein wesentliches Ziel der integrierten Entgiftungs- und Motivationsbehandlung ist die Foerderung von Therapie- und Abstinenzbereitschaft . Von 529 Alkoholpatienten , die sich einer solchen 2- bis 3-woechigen stationaeren Behandlung unterzogen , wurden 469 89% ) ( nach 8 Monaten katamnestisch erfasst . 242 Patienten ( 52% der Katamnese- bzw. 46% der Ausgangsstichprobe ) hatten das primaere Therapieziel erreicht und eine Entwoehnungsbehandlung angetreten . Hiervon wurden 54 Patienten nur in der Wartezeit zwischen Entgiftung und Entwoehnung nach ihren Angaben alkoholrueckfaellig , lebten aber danach ( waehrend und nach der Entwoehnung ) abstinent . 60 dieser 242 Patienten ( 25% ) wurden indes in der Zeit nach der Entwoehnung bis zur Katamnese ( im Mittel 4 Monate ) rueckfaellig . 227 Patienten begannen nach der Entgiftungs- und Motivationstherapie keine weitere Entwoehnungsbehandlung . Von diesen Patienten wurden 113 50% ) ( innerhalb des achtmonatigen Katamnesezeitraumes alkoholrueckfaellig . Obwohl es sich bei dieser Untersuchung nicht um eine kontrollierte Studie handelt , weisen die Ergebnisse und die klinischen Erfahrungen daraufhin , dass sich im Rahmen eines integrierten stationaeren Entgiftungs- und Motivationskonzeptes auf spezialisierten Stationen zahlreiche akut aufgenommene Alkoholkranke zu weiteren suchtspezifischen Therapieschritten motivieren lassen , die die Chance auf ein dauerhaftes abstinentes Leben deutlich erhoehen .	[ "Die", "stationaere", "psychiatrische", "Entzugsbehandlung", "Alkoholkranker", "ist", "-", "neben", "der", "Therapie", "durch", "niedergelassene", "Nervenaerzte", "und", "Suchtberater", "-", "ein", "Bindeglied", "zwischen", "medizinisch", "ausgerichteter", "Entgiftung", "und", "psychosozial", "orientierter", "Entwoehnung", ".", "Ein", "wesentliches", "Ziel", "der", "integrierten", "Entgiftungs-", "und", "Motivationsbehandlung", "ist", "die", "Foerderung", "von", "Therapie-", "und", "Abstinenzbereitschaft", ".", "Von", "529", "Alkoholpatienten", ",", "die", "sich", "einer", "solchen", "2-", "bis", "3-woechigen", "stationaeren", "Behandlung", "unterzogen", ",", "wurden", "469", "89", "%", ")", "(", "nach", "8", "Monaten", "katamnestisch", "erfasst", ".", "242", "Patienten", "(", "52", "%", "der", "Katamnese-", "bzw", ".", "46", "%", "der", "Ausgangsstichprobe", ")", "hatten", "das", "primaere", "Therapieziel", "erreicht", "und", "eine", "Entwoehnungsbehandlung", "angetreten", ".", "Hiervon", "wurden", "54", "Patienten", "nur", "in", "der", "Wartezeit", "zwischen", "Entgiftung", "und", "Entwoehnung", "nach", "ihren", "Angaben", "alkoholrueckfaellig", ",", "lebten", "aber", "danach", "(", "waehrend", "und", "nach", "der", "Entwoehnung", ")", "abstinent", ".", "60", "dieser", "242", "Patienten", "(", "25", "%", ")", "wurden", "indes", "in", "der", "Zeit", "nach", "der", "Entwoehnung", "bis", "zur", "Katamnese", "(", "im", "Mittel", "4", "Monate", ")", "rueckfaellig", ".", "227", "Patienten", "begannen", "nach", "der", "Entgiftungs-", "und", "Motivationstherapie", "keine", "weitere", "Entwoehnungsbehandlung", ".", "Von", "diesen", "Patienten", "wurden", "113", "50", "%", ")", "(", "innerhalb", "des", "achtmonatigen", "Katamnesezeitraumes", "alkoholrueckfaellig", ".", "Obwohl", "es", "sich", "bei", "dieser", "Untersuchung", "nicht", "um", "eine", "kontrollierte", "Studie", "handelt", ",", "weisen", "die", "Ergebnisse", "und", "die", "klinischen", "Erfahrungen", "daraufhin", ",", "dass", "sich", "im", "Rahmen", "eines", "integrierten", "stationaeren", "Entgiftungs-", "und", "Motivationskonzeptes", "auf", "spezialisierten", "Stationen", "zahlreiche", "akut", "aufgenommene", "Alkoholkranke", "zu", "weiteren", "suchtspezifischen", "Therapieschritten", "motivieren", "lassen", ",", "die", "die", "Chance", "auf", "ein", "dauerhaftes", "abstinentes", "Leben", "deutlich", "erhoehen", "." ]	[ "umlsterm" ]
Entzugsbehandlung, Alkoholkranker, Therapie, Suchtberater, Therapie-, Alkoholpatienten, Behandlung, Patienten, Therapieziel, Patienten, alkoholrueckfaellig, Patienten, Zeit, Patienten, Patienten, alkoholrueckfaellig, Alkoholkranke, Therapieschritten, Leben	DerNervenarzt.70680574.ger.abstr_task2	Sentence: Die stationaere psychiatrische Entzugsbehandlung Alkoholkranker ist - neben der Therapie durch niedergelassene Nervenaerzte und Suchtberater - ein Bindeglied zwischen medizinisch ausgerichteter Entgiftung und psychosozial orientierter Entwoehnung . Ein wesentliches Ziel der integrierten Entgiftungs- und Motivationsbehandlung ist die Foerderung von Therapie- und Abstinenzbereitschaft . Von 529 Alkoholpatienten , die sich einer solchen 2- bis 3-woechigen stationaeren Behandlung unterzogen , wurden 469 89% ) ( nach 8 Monaten katamnestisch erfasst . 242 Patienten ( 52% der Katamnese- bzw. 46% der Ausgangsstichprobe ) hatten das primaere Therapieziel erreicht und eine Entwoehnungsbehandlung angetreten . Hiervon wurden 54 Patienten nur in der Wartezeit zwischen Entgiftung und Entwoehnung nach ihren Angaben alkoholrueckfaellig , lebten aber danach ( waehrend und nach der Entwoehnung ) abstinent . 60 dieser 242 Patienten ( 25% ) wurden indes in der Zeit nach der Entwoehnung bis zur Katamnese ( im Mittel 4 Monate ) rueckfaellig . 227 Patienten begannen nach der Entgiftungs- und Motivationstherapie keine weitere Entwoehnungsbehandlung . Von diesen Patienten wurden 113 50% ) ( innerhalb des achtmonatigen Katamnesezeitraumes alkoholrueckfaellig . Obwohl es sich bei dieser Untersuchung nicht um eine kontrollierte Studie handelt , weisen die Ergebnisse und die klinischen Erfahrungen daraufhin , dass sich im Rahmen eines integrierten stationaeren Entgiftungs- und Motivationskonzeptes auf spezialisierten Stationen zahlreiche akut aufgenommene Alkoholkranke zu weiteren suchtspezifischen Therapieschritten motivieren lassen , die die Chance auf ein dauerhaftes abstinentes Leben deutlich erhoehen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Die stationaere psychiatrische Entzugsbehandlung Alkoholkranker ist - neben der Therapie durch niedergelassene Nervenaerzte und Suchtberater - ein Bindeglied zwischen medizinisch ausgerichteter Entgiftung und psychosozial orientierter Entwoehnung . Ein wesentliches Ziel der integrierten Entgiftungs- und Motivationsbehandlung ist die Foerderung von Therapie- und Abstinenzbereitschaft . Von 529 Alkoholpatienten , die sich einer solchen 2- bis 3-woechigen stationaeren Behandlung unterzogen , wurden 469 89% ) ( nach 8 Monaten katamnestisch erfasst . 242 Patienten ( 52% der Katamnese- bzw. 46% der Ausgangsstichprobe ) hatten das primaere Therapieziel erreicht und eine Entwoehnungsbehandlung angetreten . Hiervon wurden 54 Patienten nur in der Wartezeit zwischen Entgiftung und Entwoehnung nach ihren Angaben alkoholrueckfaellig , lebten aber danach ( waehrend und nach der Entwoehnung ) abstinent . 60 dieser 242 Patienten ( 25% ) wurden indes in der Zeit nach der Entwoehnung bis zur Katamnese ( im Mittel 4 Monate ) rueckfaellig . 227 Patienten begannen nach der Entgiftungs- und Motivationstherapie keine weitere Entwoehnungsbehandlung . Von diesen Patienten wurden 113 50% ) ( innerhalb des achtmonatigen Katamnesezeitraumes alkoholrueckfaellig . Obwohl es sich bei dieser Untersuchung nicht um eine kontrollierte Studie handelt , weisen die Ergebnisse und die klinischen Erfahrungen daraufhin , dass sich im Rahmen eines integrierten stationaeren Entgiftungs- und Motivationskonzeptes auf spezialisierten Stationen zahlreiche akut aufgenommene Alkoholkranke zu weiteren suchtspezifischen Therapieschritten motivieren lassen , die die Chance auf ein dauerhaftes abstinentes Leben deutlich erhoehen .	[ "Die", "stationaere", "psychiatrische", "Entzugsbehandlung", "Alkoholkranker", "ist", "-", "neben", "der", "Therapie", "durch", "niedergelassene", "Nervenaerzte", "und", "Suchtberater", "-", "ein", "Bindeglied", "zwischen", "medizinisch", "ausgerichteter", "Entgiftung", "und", "psychosozial", "orientierter", "Entwoehnung", ".", "Ein", "wesentliches", "Ziel", "der", "integrierten", "Entgiftungs-", "und", "Motivationsbehandlung", "ist", "die", "Foerderung", "von", "Therapie-", "und", "Abstinenzbereitschaft", ".", "Von", "529", "Alkoholpatienten", ",", "die", "sich", "einer", "solchen", "2-", "bis", "3-woechigen", "stationaeren", "Behandlung", "unterzogen", ",", "wurden", "469", "89", "%", ")", "(", "nach", "8", "Monaten", "katamnestisch", "erfasst", ".", "242", "Patienten", "(", "52", "%", "der", "Katamnese-", "bzw", ".", "46", "%", "der", "Ausgangsstichprobe", ")", "hatten", "das", "primaere", "Therapieziel", "erreicht", "und", "eine", "Entwoehnungsbehandlung", "angetreten", ".", "Hiervon", "wurden", "54", "Patienten", "nur", "in", "der", "Wartezeit", "zwischen", "Entgiftung", "und", "Entwoehnung", "nach", "ihren", "Angaben", "alkoholrueckfaellig", ",", "lebten", "aber", "danach", "(", "waehrend", "und", "nach", "der", "Entwoehnung", ")", "abstinent", ".", "60", "dieser", "242", "Patienten", "(", "25", "%", ")", "wurden", "indes", "in", "der", "Zeit", "nach", "der", "Entwoehnung", "bis", "zur", "Katamnese", "(", "im", "Mittel", "4", "Monate", ")", "rueckfaellig", ".", "227", "Patienten", "begannen", "nach", "der", "Entgiftungs-", "und", "Motivationstherapie", "keine", "weitere", "Entwoehnungsbehandlung", ".", "Von", "diesen", "Patienten", "wurden", "113", "50", "%", ")", "(", "innerhalb", "des", "achtmonatigen", "Katamnesezeitraumes", "alkoholrueckfaellig", ".", "Obwohl", "es", "sich", "bei", "dieser", "Untersuchung", "nicht", "um", "eine", "kontrollierte", "Studie", "handelt", ",", "weisen", "die", "Ergebnisse", "und", "die", "klinischen", "Erfahrungen", "daraufhin", ",", "dass", "sich", "im", "Rahmen", "eines", "integrierten", "stationaeren", "Entgiftungs-", "und", "Motivationskonzeptes", "auf", "spezialisierten", "Stationen", "zahlreiche", "akut", "aufgenommene", "Alkoholkranke", "zu", "weiteren", "suchtspezifischen", "Therapieschritten", "motivieren", "lassen", ",", "die", "die", "Chance", "auf", "ein", "dauerhaftes", "abstinentes", "Leben", "deutlich", "erhoehen", "." ]	[ "umlsterm" ]
erythromycin is a Intervention_Pharmacological, gentamicin is a Intervention_Pharmacological, abomasal emptying rate is a Outcome_Other, gastric emptying is a Outcome_Physical, rate of abomasal emptying is a Outcome_Physical, control is a Intervention_Control, low - dose gentamicin is a Intervention_Pharmacological, high - dose gentamicin is a Intervention_Pharmacological, Abomasal emptying rate is a Outcome_Physical, acetaminophen and glucose absorption is a Outcome_Physical, plasma acetaminophen concentration is a Outcome_Physical, time of actual C ( max ) ( actual T ( max ) ) is a Outcome_Physical, model T ( max ) is a Outcome_Physical, time to actual T ( max ) is a Outcome_Physical	34609_task0	Sentence: Effect of erythromycin and gentamicin on abomasal emptying rate in suckling calves . BACKGROUND Commonly used dosage protocols for antimicrobial agents may alter the rate of gastric emptying . HYPOTHESIS Parenteral administration of erythromycin increases and gentamicin decreases the rate of abomasal emptying . ANIMALS Five male Holstein-Friesian calves ( 8-15 days of age ) . METHODS Calves received each of the following 4 IM treatments in random order : control , 2 mL of 0.9 % NaCl ; erythromycin , 8.8 mg/kg ; low-dose gentamicin , 4.4 mg/kg ; high-dose gentamicin , 6.6 mg/kg . Abomasal emptying rate was assessed by acetaminophen and glucose absorption . Calves were fed 2 L of cow 's milk containing acetaminophen ( 50 mg/kg body weight ) 30 minutes after each treatment was administered , and jugular venous blood samples were obtained periodically after suckling . The maximum observed plasma acetaminophen concentration ( actual C ( max ) ) and time of actual C ( max ) ( actual T ( max ) ) were determined , and pharmacokinetic modeling was used to calculate model C ( max ) and model T ( max ) . RESULTS Erythromycin increased abomasal emptying rate , as indicated by a shorter time to actual T ( max ) and model T ( max ) ( P < .05 ) . Abomasal emptying rate after injection of low-dose gentamicin was similar to that of control . Administration of high-dose gentamicin resulted in a longer time to actual T ( max ) ( P= .021 ) but did not change model T ( max ) ( P= .62 ) . CONCLUSIONS AND CLINICAL RELEVANCE IM injection of erythromycin increased abomasal emptying rate in dairy calves , whereas low-dose and high-dose gentamicin did not alter the rate of abomasal emptying as measured by acetaminophen kinetics and glucose absorption . The clinical relevance of these findings remains to be determined . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Intervention_Control	[ "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effect of erythromycin and gentamicin on abomasal emptying rate in suckling calves . BACKGROUND Commonly used dosage protocols for antimicrobial agents may alter the rate of gastric emptying . HYPOTHESIS Parenteral administration of erythromycin increases and gentamicin decreases the rate of abomasal emptying . ANIMALS Five male Holstein-Friesian calves ( 8-15 days of age ) . METHODS Calves received each of the following 4 IM treatments in random order : control , 2 mL of 0.9 % NaCl ; erythromycin , 8.8 mg/kg ; low-dose gentamicin , 4.4 mg/kg ; high-dose gentamicin , 6.6 mg/kg . Abomasal emptying rate was assessed by acetaminophen and glucose absorption . Calves were fed 2 L of cow 's milk containing acetaminophen ( 50 mg/kg body weight ) 30 minutes after each treatment was administered , and jugular venous blood samples were obtained periodically after suckling . The maximum observed plasma acetaminophen concentration ( actual C ( max ) ) and time of actual C ( max ) ( actual T ( max ) ) were determined , and pharmacokinetic modeling was used to calculate model C ( max ) and model T ( max ) . RESULTS Erythromycin increased abomasal emptying rate , as indicated by a shorter time to actual T ( max ) and model T ( max ) ( P < .05 ) . Abomasal emptying rate after injection of low-dose gentamicin was similar to that of control . Administration of high-dose gentamicin resulted in a longer time to actual T ( max ) ( P= .021 ) but did not change model T ( max ) ( P= .62 ) . CONCLUSIONS AND CLINICAL RELEVANCE IM injection of erythromycin increased abomasal emptying rate in dairy calves , whereas low-dose and high-dose gentamicin did not alter the rate of abomasal emptying as measured by acetaminophen kinetics and glucose absorption . The clinical relevance of these findings remains to be determined .	[ "Effect", "of", "erythromycin", "and", "gentamicin", "on", "abomasal", "emptying", "rate", "in", "suckling", "calves", ".", "BACKGROUND", "Commonly", "used", "dosage", "protocols", "for", "antimicrobial", "agents", "may", "alter", "the", "rate", "of", "gastric", "emptying", ".", "HYPOTHESIS", "Parenteral", "administration", "of", "erythromycin", "increases", "and", "gentamicin", "decreases", "the", "rate", "of", "abomasal", "emptying", ".", "ANIMALS", "Five", "male", "Holstein", "-", "Friesian", "calves", "(", "8", "-", "15", "days", "of", "age", ")", ".", "METHODS", "Calves", "received", "each", "of", "the", "following", "4", "IM", "treatments", "in", "random", "order", ":", "control", ",", "2", "mL", "of", "0.9", "%", "NaCl", ";", "erythromycin", ",", "8.8", "mg", "/", "kg", ";", "low", "-", "dose", "gentamicin", ",", "4.4", "mg", "/", "kg", ";", "high", "-", "dose", "gentamicin", ",", "6.6", "mg", "/", "kg", ".", "Abomasal", "emptying", "rate", "was", "assessed", "by", "acetaminophen", "and", "glucose", "absorption", ".", "Calves", "were", "fed", "2", "L", "of", "cow", "'", "s", "milk", "containing", "acetaminophen", "(", "50", "mg", "/", "kg", "body", "weight", ")", "30", "minutes", "after", "each", "treatment", "was", "administered", ",", "and", "jugular", "venous", "blood", "samples", "were", "obtained", "periodically", "after", "suckling", ".", "The", "maximum", "observed", "plasma", "acetaminophen", "concentration", "(", "actual", "C", "(", "max", ")", ")", "and", "time", "of", "actual", "C", "(", "max", ")", "(", "actual", "T", "(", "max", ")", ")", "were", "determined", ",", "and", "pharmacokinetic", "modeling", "was", "used", "to", "calculate", "model", "C", "(", "max", ")", "and", "model", "T", "(", "max", ")", ".", "RESULTS", "Erythromycin", "increased", "abomasal", "emptying", "rate", ",", "as", "indicated", "by", "a", "shorter", "time", "to", "actual", "T", "(", "max", ")", "and", "model", "T", "(", "max", ")", "(", "P", "<", ".05", ")", ".", "Abomasal", "emptying", "rate", "after", "injection", "of", "low", "-", "dose", "gentamicin", "was", "similar", "to", "that", "of", "control", ".", "Administration", "of", "high", "-", "dose", "gentamicin", "resulted", "in", "a", "longer", "time", "to", "actual", "T", "(", "max", ")", "(", "P=", ".021", ")", "but", "did", "not", "change", "model", "T", "(", "max", ")", "(", "P=", ".62", ")", ".", "CONCLUSIONS", "AND", "CLINICAL", "RELEVANCE", "IM", "injection", "of", "erythromycin", "increased", "abomasal", "emptying", "rate", "in", "dairy", "calves", ",", "whereas", "low", "-", "dose", "and", "high", "-", "dose", "gentamicin", "did", "not", "alter", "the", "rate", "of", "abomasal", "emptying", "as", "measured", "by", "acetaminophen", "kinetics", "and", "glucose", "absorption", ".", "The", "clinical", "relevance", "of", "these", "findings", "remains", "to", "be", "determined", "." ]	[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control" ]
erythromycin is a Intervention_Pharmacological, gentamicin is a Intervention_Pharmacological, abomasal emptying rate is a Outcome_Other, gastric emptying is a Outcome_Physical, rate of abomasal emptying is a Outcome_Physical, control is a Intervention_Control, low - dose gentamicin is a Intervention_Pharmacological, high - dose gentamicin is a Intervention_Pharmacological, Abomasal emptying rate is a Outcome_Physical, acetaminophen and glucose absorption is a Outcome_Physical, plasma acetaminophen concentration is a Outcome_Physical, time of actual C ( max ) ( actual T ( max ) ) is a Outcome_Physical, model T ( max ) is a Outcome_Physical, time to actual T ( max ) is a Outcome_Physical	34609_task1	Sentence: Effect of erythromycin and gentamicin on abomasal emptying rate in suckling calves . BACKGROUND Commonly used dosage protocols for antimicrobial agents may alter the rate of gastric emptying . HYPOTHESIS Parenteral administration of erythromycin increases and gentamicin decreases the rate of abomasal emptying . ANIMALS Five male Holstein-Friesian calves ( 8-15 days of age ) . METHODS Calves received each of the following 4 IM treatments in random order : control , 2 mL of 0.9 % NaCl ; erythromycin , 8.8 mg/kg ; low-dose gentamicin , 4.4 mg/kg ; high-dose gentamicin , 6.6 mg/kg . Abomasal emptying rate was assessed by acetaminophen and glucose absorption . Calves were fed 2 L of cow 's milk containing acetaminophen ( 50 mg/kg body weight ) 30 minutes after each treatment was administered , and jugular venous blood samples were obtained periodically after suckling . The maximum observed plasma acetaminophen concentration ( actual C ( max ) ) and time of actual C ( max ) ( actual T ( max ) ) were determined , and pharmacokinetic modeling was used to calculate model C ( max ) and model T ( max ) . RESULTS Erythromycin increased abomasal emptying rate , as indicated by a shorter time to actual T ( max ) and model T ( max ) ( P < .05 ) . Abomasal emptying rate after injection of low-dose gentamicin was similar to that of control . Administration of high-dose gentamicin resulted in a longer time to actual T ( max ) ( P= .021 ) but did not change model T ( max ) ( P= .62 ) . CONCLUSIONS AND CLINICAL RELEVANCE IM injection of erythromycin increased abomasal emptying rate in dairy calves , whereas low-dose and high-dose gentamicin did not alter the rate of abomasal emptying as measured by acetaminophen kinetics and glucose absorption . The clinical relevance of these findings remains to be determined . Instructions: please typing these entity words according to sentence: erythromycin, gentamicin, abomasal emptying rate, gastric emptying, rate of abomasal emptying, control, low - dose gentamicin, high - dose gentamicin, Abomasal emptying rate, acetaminophen and glucose absorption, plasma acetaminophen concentration, time of actual C ( max ) ( actual T ( max ) ), model T ( max ), time to actual T ( max ) Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Intervention_Control	[ "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effect of erythromycin and gentamicin on abomasal emptying rate in suckling calves . BACKGROUND Commonly used dosage protocols for antimicrobial agents may alter the rate of gastric emptying . HYPOTHESIS Parenteral administration of erythromycin increases and gentamicin decreases the rate of abomasal emptying . ANIMALS Five male Holstein-Friesian calves ( 8-15 days of age ) . METHODS Calves received each of the following 4 IM treatments in random order : control , 2 mL of 0.9 % NaCl ; erythromycin , 8.8 mg/kg ; low-dose gentamicin , 4.4 mg/kg ; high-dose gentamicin , 6.6 mg/kg . Abomasal emptying rate was assessed by acetaminophen and glucose absorption . Calves were fed 2 L of cow 's milk containing acetaminophen ( 50 mg/kg body weight ) 30 minutes after each treatment was administered , and jugular venous blood samples were obtained periodically after suckling . The maximum observed plasma acetaminophen concentration ( actual C ( max ) ) and time of actual C ( max ) ( actual T ( max ) ) were determined , and pharmacokinetic modeling was used to calculate model C ( max ) and model T ( max ) . RESULTS Erythromycin increased abomasal emptying rate , as indicated by a shorter time to actual T ( max ) and model T ( max ) ( P < .05 ) . Abomasal emptying rate after injection of low-dose gentamicin was similar to that of control . Administration of high-dose gentamicin resulted in a longer time to actual T ( max ) ( P= .021 ) but did not change model T ( max ) ( P= .62 ) . CONCLUSIONS AND CLINICAL RELEVANCE IM injection of erythromycin increased abomasal emptying rate in dairy calves , whereas low-dose and high-dose gentamicin did not alter the rate of abomasal emptying as measured by acetaminophen kinetics and glucose absorption . The clinical relevance of these findings remains to be determined .	[ "Effect", "of", "erythromycin", "and", "gentamicin", "on", "abomasal", "emptying", "rate", "in", "suckling", "calves", ".", "BACKGROUND", "Commonly", "used", "dosage", "protocols", "for", "antimicrobial", "agents", "may", "alter", "the", "rate", "of", "gastric", "emptying", ".", "HYPOTHESIS", "Parenteral", "administration", "of", "erythromycin", "increases", "and", "gentamicin", "decreases", "the", "rate", "of", "abomasal", "emptying", ".", "ANIMALS", "Five", "male", "Holstein", "-", "Friesian", "calves", "(", "8", "-", "15", "days", "of", "age", ")", ".", "METHODS", "Calves", "received", "each", "of", "the", "following", "4", "IM", "treatments", "in", "random", "order", ":", "control", ",", "2", "mL", "of", "0.9", "%", "NaCl", ";", "erythromycin", ",", "8.8", "mg", "/", "kg", ";", "low", "-", "dose", "gentamicin", ",", "4.4", "mg", "/", "kg", ";", "high", "-", "dose", "gentamicin", ",", "6.6", "mg", "/", "kg", ".", "Abomasal", "emptying", "rate", "was", "assessed", "by", "acetaminophen", "and", "glucose", "absorption", ".", "Calves", "were", "fed", "2", "L", "of", "cow", "'", "s", "milk", "containing", "acetaminophen", "(", "50", "mg", "/", "kg", "body", "weight", ")", "30", "minutes", "after", "each", "treatment", "was", "administered", ",", "and", "jugular", "venous", "blood", "samples", "were", "obtained", "periodically", "after", "suckling", ".", "The", "maximum", "observed", "plasma", "acetaminophen", "concentration", "(", "actual", "C", "(", "max", ")", ")", "and", "time", "of", "actual", "C", "(", "max", ")", "(", "actual", "T", "(", "max", ")", ")", "were", "determined", ",", "and", "pharmacokinetic", "modeling", "was", "used", "to", "calculate", "model", "C", "(", "max", ")", "and", "model", "T", "(", "max", ")", ".", "RESULTS", "Erythromycin", "increased", "abomasal", "emptying", "rate", ",", "as", "indicated", "by", "a", "shorter", "time", "to", "actual", "T", "(", "max", ")", "and", "model", "T", "(", "max", ")", "(", "P", "<", ".05", ")", ".", "Abomasal", "emptying", "rate", "after", "injection", "of", "low", "-", "dose", "gentamicin", "was", "similar", "to", "that", "of", "control", ".", "Administration", "of", "high", "-", "dose", "gentamicin", "resulted", "in", "a", "longer", "time", "to", "actual", "T", "(", "max", ")", "(", "P=", ".021", ")", "but", "did", "not", "change", "model", "T", "(", "max", ")", "(", "P=", ".62", ")", ".", "CONCLUSIONS", "AND", "CLINICAL", "RELEVANCE", "IM", "injection", "of", "erythromycin", "increased", "abomasal", "emptying", "rate", "in", "dairy", "calves", ",", "whereas", "low", "-", "dose", "and", "high", "-", "dose", "gentamicin", "did", "not", "alter", "the", "rate", "of", "abomasal", "emptying", "as", "measured", "by", "acetaminophen", "kinetics", "and", "glucose", "absorption", ".", "The", "clinical", "relevance", "of", "these", "findings", "remains", "to", "be", "determined", "." ]	[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control" ]
erythromycin, gentamicin, abomasal emptying rate, gastric emptying, rate of abomasal emptying, control, low - dose gentamicin, high - dose gentamicin, Abomasal emptying rate, acetaminophen and glucose absorption, plasma acetaminophen concentration, time of actual C ( max ) ( actual T ( max ) ), model T ( max ), time to actual T ( max )	34609_task2	Sentence: Effect of erythromycin and gentamicin on abomasal emptying rate in suckling calves . BACKGROUND Commonly used dosage protocols for antimicrobial agents may alter the rate of gastric emptying . HYPOTHESIS Parenteral administration of erythromycin increases and gentamicin decreases the rate of abomasal emptying . ANIMALS Five male Holstein-Friesian calves ( 8-15 days of age ) . METHODS Calves received each of the following 4 IM treatments in random order : control , 2 mL of 0.9 % NaCl ; erythromycin , 8.8 mg/kg ; low-dose gentamicin , 4.4 mg/kg ; high-dose gentamicin , 6.6 mg/kg . Abomasal emptying rate was assessed by acetaminophen and glucose absorption . Calves were fed 2 L of cow 's milk containing acetaminophen ( 50 mg/kg body weight ) 30 minutes after each treatment was administered , and jugular venous blood samples were obtained periodically after suckling . The maximum observed plasma acetaminophen concentration ( actual C ( max ) ) and time of actual C ( max ) ( actual T ( max ) ) were determined , and pharmacokinetic modeling was used to calculate model C ( max ) and model T ( max ) . RESULTS Erythromycin increased abomasal emptying rate , as indicated by a shorter time to actual T ( max ) and model T ( max ) ( P < .05 ) . Abomasal emptying rate after injection of low-dose gentamicin was similar to that of control . Administration of high-dose gentamicin resulted in a longer time to actual T ( max ) ( P= .021 ) but did not change model T ( max ) ( P= .62 ) . CONCLUSIONS AND CLINICAL RELEVANCE IM injection of erythromycin increased abomasal emptying rate in dairy calves , whereas low-dose and high-dose gentamicin did not alter the rate of abomasal emptying as measured by acetaminophen kinetics and glucose absorption . The clinical relevance of these findings remains to be determined . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effect of erythromycin and gentamicin on abomasal emptying rate in suckling calves . BACKGROUND Commonly used dosage protocols for antimicrobial agents may alter the rate of gastric emptying . HYPOTHESIS Parenteral administration of erythromycin increases and gentamicin decreases the rate of abomasal emptying . ANIMALS Five male Holstein-Friesian calves ( 8-15 days of age ) . METHODS Calves received each of the following 4 IM treatments in random order : control , 2 mL of 0.9 % NaCl ; erythromycin , 8.8 mg/kg ; low-dose gentamicin , 4.4 mg/kg ; high-dose gentamicin , 6.6 mg/kg . Abomasal emptying rate was assessed by acetaminophen and glucose absorption . Calves were fed 2 L of cow 's milk containing acetaminophen ( 50 mg/kg body weight ) 30 minutes after each treatment was administered , and jugular venous blood samples were obtained periodically after suckling . The maximum observed plasma acetaminophen concentration ( actual C ( max ) ) and time of actual C ( max ) ( actual T ( max ) ) were determined , and pharmacokinetic modeling was used to calculate model C ( max ) and model T ( max ) . RESULTS Erythromycin increased abomasal emptying rate , as indicated by a shorter time to actual T ( max ) and model T ( max ) ( P < .05 ) . Abomasal emptying rate after injection of low-dose gentamicin was similar to that of control . Administration of high-dose gentamicin resulted in a longer time to actual T ( max ) ( P= .021 ) but did not change model T ( max ) ( P= .62 ) . CONCLUSIONS AND CLINICAL RELEVANCE IM injection of erythromycin increased abomasal emptying rate in dairy calves , whereas low-dose and high-dose gentamicin did not alter the rate of abomasal emptying as measured by acetaminophen kinetics and glucose absorption . The clinical relevance of these findings remains to be determined .	[ "Effect", "of", "erythromycin", "and", "gentamicin", "on", "abomasal", "emptying", "rate", "in", "suckling", "calves", ".", "BACKGROUND", "Commonly", "used", "dosage", "protocols", "for", "antimicrobial", "agents", "may", "alter", "the", "rate", "of", "gastric", "emptying", ".", "HYPOTHESIS", "Parenteral", "administration", "of", "erythromycin", "increases", "and", "gentamicin", "decreases", "the", "rate", "of", "abomasal", "emptying", ".", "ANIMALS", "Five", "male", "Holstein", "-", "Friesian", "calves", "(", "8", "-", "15", "days", "of", "age", ")", ".", "METHODS", "Calves", "received", "each", "of", "the", "following", "4", "IM", "treatments", "in", "random", "order", ":", "control", ",", "2", "mL", "of", "0.9", "%", "NaCl", ";", "erythromycin", ",", "8.8", "mg", "/", "kg", ";", "low", "-", "dose", "gentamicin", ",", "4.4", "mg", "/", "kg", ";", "high", "-", "dose", "gentamicin", ",", "6.6", "mg", "/", "kg", ".", "Abomasal", "emptying", "rate", "was", "assessed", "by", "acetaminophen", "and", "glucose", "absorption", ".", "Calves", "were", "fed", "2", "L", "of", "cow", "'", "s", "milk", "containing", "acetaminophen", "(", "50", "mg", "/", "kg", "body", "weight", ")", "30", "minutes", "after", "each", "treatment", "was", "administered", ",", "and", "jugular", "venous", "blood", "samples", "were", "obtained", "periodically", "after", "suckling", ".", "The", "maximum", "observed", "plasma", "acetaminophen", "concentration", "(", "actual", "C", "(", "max", ")", ")", "and", "time", "of", "actual", "C", "(", "max", ")", "(", "actual", "T", "(", "max", ")", ")", "were", "determined", ",", "and", "pharmacokinetic", "modeling", "was", "used", "to", "calculate", "model", "C", "(", "max", ")", "and", "model", "T", "(", "max", ")", ".", "RESULTS", "Erythromycin", "increased", "abomasal", "emptying", "rate", ",", "as", "indicated", "by", "a", "shorter", "time", "to", "actual", "T", "(", "max", ")", "and", "model", "T", "(", "max", ")", "(", "P", "<", ".05", ")", ".", "Abomasal", "emptying", "rate", "after", "injection", "of", "low", "-", "dose", "gentamicin", "was", "similar", "to", "that", "of", "control", ".", "Administration", "of", "high", "-", "dose", "gentamicin", "resulted", "in", "a", "longer", "time", "to", "actual", "T", "(", "max", ")", "(", "P=", ".021", ")", "but", "did", "not", "change", "model", "T", "(", "max", ")", "(", "P=", ".62", ")", ".", "CONCLUSIONS", "AND", "CLINICAL", "RELEVANCE", "IM", "injection", "of", "erythromycin", "increased", "abomasal", "emptying", "rate", "in", "dairy", "calves", ",", "whereas", "low", "-", "dose", "and", "high", "-", "dose", "gentamicin", "did", "not", "alter", "the", "rate", "of", "abomasal", "emptying", "as", "measured", "by", "acetaminophen", "kinetics", "and", "glucose", "absorption", ".", "The", "clinical", "relevance", "of", "these", "findings", "remains", "to", "be", "determined", "." ]	[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control" ]
cell is a Cell	PMC-2959883-sec-06_task0	Sentence: Data collection: CrystalClear (Rigaku/MSC, 2005 >); cell refinement: CrystalClear; data reduction: CrystalClear; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 >); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 >); molecular graphics: ORTEPII (Johnson, 1976 >); software used to prepare material for publication: SHELXL97. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cell	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Data collection: CrystalClear (Rigaku/MSC, 2005 >); cell refinement: CrystalClear; data reduction: CrystalClear; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 >); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 >); molecular graphics: ORTEPII (Johnson, 1976 >); software used to prepare material for publication: SHELXL97.	[ "Data", "collection", ":", "CrystalClear", "(", "Rigaku", "/", "MSC", ",", "2005", ">", ")", ";", "cell", "refinement", ":", "CrystalClear", ";", "data", "reduction", ":", "CrystalClear", ";", "program(s", ")", "used", "to", "solve", "structure", ":", "SHELXS97", "(", "Sheldrick", ",", "2008", ">", ")", ";", "program(s", ")", "used", "to", "refine", "structure", ":", "SHELXL97", "(", "Sheldrick", ",", "2008", ">", ")", ";", "molecular", "graphics", ":", "ORTEPII", "(", "Johnson", ",", "1976", ">", ")", ";", "software", "used", "to", "prepare", "material", "for", "publication", ":", "SHELXL97", ".", "\n" ]	[ "Cell" ]
cell is a Cell	PMC-2959883-sec-06_task1	Sentence: Data collection: CrystalClear (Rigaku/MSC, 2005 >); cell refinement: CrystalClear; data reduction: CrystalClear; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 >); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 >); molecular graphics: ORTEPII (Johnson, 1976 >); software used to prepare material for publication: SHELXL97. Instructions: please typing these entity words according to sentence: cell Options: Cell	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Data collection: CrystalClear (Rigaku/MSC, 2005 >); cell refinement: CrystalClear; data reduction: CrystalClear; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 >); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 >); molecular graphics: ORTEPII (Johnson, 1976 >); software used to prepare material for publication: SHELXL97.	[ "Data", "collection", ":", "CrystalClear", "(", "Rigaku", "/", "MSC", ",", "2005", ">", ")", ";", "cell", "refinement", ":", "CrystalClear", ";", "data", "reduction", ":", "CrystalClear", ";", "program(s", ")", "used", "to", "solve", "structure", ":", "SHELXS97", "(", "Sheldrick", ",", "2008", ">", ")", ";", "program(s", ")", "used", "to", "refine", "structure", ":", "SHELXL97", "(", "Sheldrick", ",", "2008", ">", ")", ";", "molecular", "graphics", ":", "ORTEPII", "(", "Johnson", ",", "1976", ">", ")", ";", "software", "used", "to", "prepare", "material", "for", "publication", ":", "SHELXL97", ".", "\n" ]	[ "Cell" ]
cell	PMC-2959883-sec-06_task2	Sentence: Data collection: CrystalClear (Rigaku/MSC, 2005 >); cell refinement: CrystalClear; data reduction: CrystalClear; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 >); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 >); molecular graphics: ORTEPII (Johnson, 1976 >); software used to prepare material for publication: SHELXL97. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Data collection: CrystalClear (Rigaku/MSC, 2005 >); cell refinement: CrystalClear; data reduction: CrystalClear; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 >); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 >); molecular graphics: ORTEPII (Johnson, 1976 >); software used to prepare material for publication: SHELXL97.	[ "Data", "collection", ":", "CrystalClear", "(", "Rigaku", "/", "MSC", ",", "2005", ">", ")", ";", "cell", "refinement", ":", "CrystalClear", ";", "data", "reduction", ":", "CrystalClear", ";", "program(s", ")", "used", "to", "solve", "structure", ":", "SHELXS97", "(", "Sheldrick", ",", "2008", ">", ")", ";", "program(s", ")", "used", "to", "refine", "structure", ":", "SHELXL97", "(", "Sheldrick", ",", "2008", ">", ")", ";", "molecular", "graphics", ":", "ORTEPII", "(", "Johnson", ",", "1976", ">", ")", ";", "software", "used", "to", "prepare", "material", "for", "publication", ":", "SHELXL97", ".", "\n" ]	[ "Cell" ]
Lidocain is an umlsterm, Tocainid is an umlsterm, Tinnitus aurium is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Lidocain is an umlsterm, medikamentoese Therapie is an umlsterm, Tocainid is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Therapie is an umlsterm, Tocainid is an umlsterm, Patienten is an umlsterm, Therapie is an umlsterm, Tocainid is an umlsterm, Patienten is an umlsterm, Medikament is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Tinnitus aurium is an umlsterm, Lidocain is an umlsterm, Tocainid is an umlsterm	HNO.70450069.ger.abstr_task0	Sentence: Um die Wirksamkeit von Lidocain und Tocainid auf Tinnitus aurium zu ueberpruefen , untersuchten wir retrospektiv von 1993 bis Mai 1995 77 Patienten . Waehrend des stationaeren Aufenthalts erhielten die Patienten eine Testdosis Lidocain i.v. und bei positivem Ansprechen auf die Testdosis eine sich anschliessende medikamentoese Therapie mit Tocainid , einem oral verabreichbaren Strukturanalogon des Lidocains . Die tinnitussupprimierende Wirkung wurde entsprechend den subjektiven Angaben und anhand einer visuellen Analogskala klassifiziert . Unsere Ergebnisse zeigen , dass von 77 Patienten nur 19 Patienten eine Tinnitussuppression unterschiedlicher Auspraegung angaben . Von ihnen waehlten 14 Patienten eine weiterfuehrende Therapie mit Tocainid ( 3x400 mg/Tag ) ; 5 Patienten lehnten die Therapie wegen moeglicher Nebenwirkungen ab ; 3 Monate nach der Verordnung von Tocainid hatten 10 Patienten das Medikament wegen Nebenwirkungen und 3 Patienten wegen mangelnder Wirkung abgesetzt . Wir schaetzen die therapeutische Erfolgsquote fuer die Behandlung des Tinnitus aurium mit Lidocain bedeutend geringer ein als dies im Schrifttum der Fall ist . Das oral anwendbare Stukturanalogon Tocainid kommt wegen der hohen Rate an Nebenwirkungen und nicht ausreichender Tinnitussuppression allenfalls in besonderen Einzelfaellen als Behandlungsmoeglichkeit in Frage . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Um die Wirksamkeit von Lidocain und Tocainid auf Tinnitus aurium zu ueberpruefen , untersuchten wir retrospektiv von 1993 bis Mai 1995 77 Patienten . Waehrend des stationaeren Aufenthalts erhielten die Patienten eine Testdosis Lidocain i.v. und bei positivem Ansprechen auf die Testdosis eine sich anschliessende medikamentoese Therapie mit Tocainid , einem oral verabreichbaren Strukturanalogon des Lidocains . Die tinnitussupprimierende Wirkung wurde entsprechend den subjektiven Angaben und anhand einer visuellen Analogskala klassifiziert . Unsere Ergebnisse zeigen , dass von 77 Patienten nur 19 Patienten eine Tinnitussuppression unterschiedlicher Auspraegung angaben . Von ihnen waehlten 14 Patienten eine weiterfuehrende Therapie mit Tocainid ( 3x400 mg/Tag ) ; 5 Patienten lehnten die Therapie wegen moeglicher Nebenwirkungen ab ; 3 Monate nach der Verordnung von Tocainid hatten 10 Patienten das Medikament wegen Nebenwirkungen und 3 Patienten wegen mangelnder Wirkung abgesetzt . Wir schaetzen die therapeutische Erfolgsquote fuer die Behandlung des Tinnitus aurium mit Lidocain bedeutend geringer ein als dies im Schrifttum der Fall ist . Das oral anwendbare Stukturanalogon Tocainid kommt wegen der hohen Rate an Nebenwirkungen und nicht ausreichender Tinnitussuppression allenfalls in besonderen Einzelfaellen als Behandlungsmoeglichkeit in Frage .	[ "Um", "die", "Wirksamkeit", "von", "Lidocain", "und", "Tocainid", "auf", "Tinnitus", "aurium", "zu", "ueberpruefen", ",", "untersuchten", "wir", "retrospektiv", "von", "1993", "bis", "Mai", "1995", "77", "Patienten", ".", "Waehrend", "des", "stationaeren", "Aufenthalts", "erhielten", "die", "Patienten", "eine", "Testdosis", "Lidocain", "i.v", ".", "und", "bei", "positivem", "Ansprechen", "auf", "die", "Testdosis", "eine", "sich", "anschliessende", "medikamentoese", "Therapie", "mit", "Tocainid", ",", "einem", "oral", "verabreichbaren", "Strukturanalogon", "des", "Lidocains", ".", "Die", "tinnitussupprimierende", "Wirkung", "wurde", "entsprechend", "den", "subjektiven", "Angaben", "und", "anhand", "einer", "visuellen", "Analogskala", "klassifiziert", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "von", "77", "Patienten", "nur", "19", "Patienten", "eine", "Tinnitussuppression", "unterschiedlicher", "Auspraegung", "angaben", ".", "Von", "ihnen", "waehlten", "14", "Patienten", "eine", "weiterfuehrende", "Therapie", "mit", "Tocainid", "(", "3x400", "mg", "/", "Tag", ")", ";", "5", "Patienten", "lehnten", "die", "Therapie", "wegen", "moeglicher", "Nebenwirkungen", "ab", ";", "3", "Monate", "nach", "der", "Verordnung", "von", "Tocainid", "hatten", "10", "Patienten", "das", "Medikament", "wegen", "Nebenwirkungen", "und", "3", "Patienten", "wegen", "mangelnder", "Wirkung", "abgesetzt", ".", "Wir", "schaetzen", "die", "therapeutische", "Erfolgsquote", "fuer", "die", "Behandlung", "des", "Tinnitus", "aurium", "mit", "Lidocain", "bedeutend", "geringer", "ein", "als", "dies", "im", "Schrifttum", "der", "Fall", "ist", ".", "Das", "oral", "anwendbare", "Stukturanalogon", "Tocainid", "kommt", "wegen", "der", "hohen", "Rate", "an", "Nebenwirkungen", "und", "nicht", "ausreichender", "Tinnitussuppression", "allenfalls", "in", "besonderen", "Einzelfaellen", "als", "Behandlungsmoeglichkeit", "in", "Frage", "." ]	[ "umlsterm" ]
Lidocain is an umlsterm, Tocainid is an umlsterm, Tinnitus aurium is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Lidocain is an umlsterm, medikamentoese Therapie is an umlsterm, Tocainid is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Therapie is an umlsterm, Tocainid is an umlsterm, Patienten is an umlsterm, Therapie is an umlsterm, Tocainid is an umlsterm, Patienten is an umlsterm, Medikament is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Tinnitus aurium is an umlsterm, Lidocain is an umlsterm, Tocainid is an umlsterm	HNO.70450069.ger.abstr_task1	Sentence: Um die Wirksamkeit von Lidocain und Tocainid auf Tinnitus aurium zu ueberpruefen , untersuchten wir retrospektiv von 1993 bis Mai 1995 77 Patienten . Waehrend des stationaeren Aufenthalts erhielten die Patienten eine Testdosis Lidocain i.v. und bei positivem Ansprechen auf die Testdosis eine sich anschliessende medikamentoese Therapie mit Tocainid , einem oral verabreichbaren Strukturanalogon des Lidocains . Die tinnitussupprimierende Wirkung wurde entsprechend den subjektiven Angaben und anhand einer visuellen Analogskala klassifiziert . Unsere Ergebnisse zeigen , dass von 77 Patienten nur 19 Patienten eine Tinnitussuppression unterschiedlicher Auspraegung angaben . Von ihnen waehlten 14 Patienten eine weiterfuehrende Therapie mit Tocainid ( 3x400 mg/Tag ) ; 5 Patienten lehnten die Therapie wegen moeglicher Nebenwirkungen ab ; 3 Monate nach der Verordnung von Tocainid hatten 10 Patienten das Medikament wegen Nebenwirkungen und 3 Patienten wegen mangelnder Wirkung abgesetzt . Wir schaetzen die therapeutische Erfolgsquote fuer die Behandlung des Tinnitus aurium mit Lidocain bedeutend geringer ein als dies im Schrifttum der Fall ist . Das oral anwendbare Stukturanalogon Tocainid kommt wegen der hohen Rate an Nebenwirkungen und nicht ausreichender Tinnitussuppression allenfalls in besonderen Einzelfaellen als Behandlungsmoeglichkeit in Frage . Instructions: please typing these entity words according to sentence: Lidocain, Tocainid, Tinnitus aurium, Patienten, Patienten, Lidocain, medikamentoese Therapie, Tocainid, Patienten, Patienten, Patienten, Therapie, Tocainid, Patienten, Therapie, Tocainid, Patienten, Medikament, Patienten, Behandlung, Tinnitus aurium, Lidocain, Tocainid Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Um die Wirksamkeit von Lidocain und Tocainid auf Tinnitus aurium zu ueberpruefen , untersuchten wir retrospektiv von 1993 bis Mai 1995 77 Patienten . Waehrend des stationaeren Aufenthalts erhielten die Patienten eine Testdosis Lidocain i.v. und bei positivem Ansprechen auf die Testdosis eine sich anschliessende medikamentoese Therapie mit Tocainid , einem oral verabreichbaren Strukturanalogon des Lidocains . Die tinnitussupprimierende Wirkung wurde entsprechend den subjektiven Angaben und anhand einer visuellen Analogskala klassifiziert . Unsere Ergebnisse zeigen , dass von 77 Patienten nur 19 Patienten eine Tinnitussuppression unterschiedlicher Auspraegung angaben . Von ihnen waehlten 14 Patienten eine weiterfuehrende Therapie mit Tocainid ( 3x400 mg/Tag ) ; 5 Patienten lehnten die Therapie wegen moeglicher Nebenwirkungen ab ; 3 Monate nach der Verordnung von Tocainid hatten 10 Patienten das Medikament wegen Nebenwirkungen und 3 Patienten wegen mangelnder Wirkung abgesetzt . Wir schaetzen die therapeutische Erfolgsquote fuer die Behandlung des Tinnitus aurium mit Lidocain bedeutend geringer ein als dies im Schrifttum der Fall ist . Das oral anwendbare Stukturanalogon Tocainid kommt wegen der hohen Rate an Nebenwirkungen und nicht ausreichender Tinnitussuppression allenfalls in besonderen Einzelfaellen als Behandlungsmoeglichkeit in Frage .	[ "Um", "die", "Wirksamkeit", "von", "Lidocain", "und", "Tocainid", "auf", "Tinnitus", "aurium", "zu", "ueberpruefen", ",", "untersuchten", "wir", "retrospektiv", "von", "1993", "bis", "Mai", "1995", "77", "Patienten", ".", "Waehrend", "des", "stationaeren", "Aufenthalts", "erhielten", "die", "Patienten", "eine", "Testdosis", "Lidocain", "i.v", ".", "und", "bei", "positivem", "Ansprechen", "auf", "die", "Testdosis", "eine", "sich", "anschliessende", "medikamentoese", "Therapie", "mit", "Tocainid", ",", "einem", "oral", "verabreichbaren", "Strukturanalogon", "des", "Lidocains", ".", "Die", "tinnitussupprimierende", "Wirkung", "wurde", "entsprechend", "den", "subjektiven", "Angaben", "und", "anhand", "einer", "visuellen", "Analogskala", "klassifiziert", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "von", "77", "Patienten", "nur", "19", "Patienten", "eine", "Tinnitussuppression", "unterschiedlicher", "Auspraegung", "angaben", ".", "Von", "ihnen", "waehlten", "14", "Patienten", "eine", "weiterfuehrende", "Therapie", "mit", "Tocainid", "(", "3x400", "mg", "/", "Tag", ")", ";", "5", "Patienten", "lehnten", "die", "Therapie", "wegen", "moeglicher", "Nebenwirkungen", "ab", ";", "3", "Monate", "nach", "der", "Verordnung", "von", "Tocainid", "hatten", "10", "Patienten", "das", "Medikament", "wegen", "Nebenwirkungen", "und", "3", "Patienten", "wegen", "mangelnder", "Wirkung", "abgesetzt", ".", "Wir", "schaetzen", "die", "therapeutische", "Erfolgsquote", "fuer", "die", "Behandlung", "des", "Tinnitus", "aurium", "mit", "Lidocain", "bedeutend", "geringer", "ein", "als", "dies", "im", "Schrifttum", "der", "Fall", "ist", ".", "Das", "oral", "anwendbare", "Stukturanalogon", "Tocainid", "kommt", "wegen", "der", "hohen", "Rate", "an", "Nebenwirkungen", "und", "nicht", "ausreichender", "Tinnitussuppression", "allenfalls", "in", "besonderen", "Einzelfaellen", "als", "Behandlungsmoeglichkeit", "in", "Frage", "." ]	[ "umlsterm" ]
Lidocain, Tocainid, Tinnitus aurium, Patienten, Patienten, Lidocain, medikamentoese Therapie, Tocainid, Patienten, Patienten, Patienten, Therapie, Tocainid, Patienten, Therapie, Tocainid, Patienten, Medikament, Patienten, Behandlung, Tinnitus aurium, Lidocain, Tocainid	HNO.70450069.ger.abstr_task2	Sentence: Um die Wirksamkeit von Lidocain und Tocainid auf Tinnitus aurium zu ueberpruefen , untersuchten wir retrospektiv von 1993 bis Mai 1995 77 Patienten . Waehrend des stationaeren Aufenthalts erhielten die Patienten eine Testdosis Lidocain i.v. und bei positivem Ansprechen auf die Testdosis eine sich anschliessende medikamentoese Therapie mit Tocainid , einem oral verabreichbaren Strukturanalogon des Lidocains . Die tinnitussupprimierende Wirkung wurde entsprechend den subjektiven Angaben und anhand einer visuellen Analogskala klassifiziert . Unsere Ergebnisse zeigen , dass von 77 Patienten nur 19 Patienten eine Tinnitussuppression unterschiedlicher Auspraegung angaben . Von ihnen waehlten 14 Patienten eine weiterfuehrende Therapie mit Tocainid ( 3x400 mg/Tag ) ; 5 Patienten lehnten die Therapie wegen moeglicher Nebenwirkungen ab ; 3 Monate nach der Verordnung von Tocainid hatten 10 Patienten das Medikament wegen Nebenwirkungen und 3 Patienten wegen mangelnder Wirkung abgesetzt . Wir schaetzen die therapeutische Erfolgsquote fuer die Behandlung des Tinnitus aurium mit Lidocain bedeutend geringer ein als dies im Schrifttum der Fall ist . Das oral anwendbare Stukturanalogon Tocainid kommt wegen der hohen Rate an Nebenwirkungen und nicht ausreichender Tinnitussuppression allenfalls in besonderen Einzelfaellen als Behandlungsmoeglichkeit in Frage . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Um die Wirksamkeit von Lidocain und Tocainid auf Tinnitus aurium zu ueberpruefen , untersuchten wir retrospektiv von 1993 bis Mai 1995 77 Patienten . Waehrend des stationaeren Aufenthalts erhielten die Patienten eine Testdosis Lidocain i.v. und bei positivem Ansprechen auf die Testdosis eine sich anschliessende medikamentoese Therapie mit Tocainid , einem oral verabreichbaren Strukturanalogon des Lidocains . Die tinnitussupprimierende Wirkung wurde entsprechend den subjektiven Angaben und anhand einer visuellen Analogskala klassifiziert . Unsere Ergebnisse zeigen , dass von 77 Patienten nur 19 Patienten eine Tinnitussuppression unterschiedlicher Auspraegung angaben . Von ihnen waehlten 14 Patienten eine weiterfuehrende Therapie mit Tocainid ( 3x400 mg/Tag ) ; 5 Patienten lehnten die Therapie wegen moeglicher Nebenwirkungen ab ; 3 Monate nach der Verordnung von Tocainid hatten 10 Patienten das Medikament wegen Nebenwirkungen und 3 Patienten wegen mangelnder Wirkung abgesetzt . Wir schaetzen die therapeutische Erfolgsquote fuer die Behandlung des Tinnitus aurium mit Lidocain bedeutend geringer ein als dies im Schrifttum der Fall ist . Das oral anwendbare Stukturanalogon Tocainid kommt wegen der hohen Rate an Nebenwirkungen und nicht ausreichender Tinnitussuppression allenfalls in besonderen Einzelfaellen als Behandlungsmoeglichkeit in Frage .	[ "Um", "die", "Wirksamkeit", "von", "Lidocain", "und", "Tocainid", "auf", "Tinnitus", "aurium", "zu", "ueberpruefen", ",", "untersuchten", "wir", "retrospektiv", "von", "1993", "bis", "Mai", "1995", "77", "Patienten", ".", "Waehrend", "des", "stationaeren", "Aufenthalts", "erhielten", "die", "Patienten", "eine", "Testdosis", "Lidocain", "i.v", ".", "und", "bei", "positivem", "Ansprechen", "auf", "die", "Testdosis", "eine", "sich", "anschliessende", "medikamentoese", "Therapie", "mit", "Tocainid", ",", "einem", "oral", "verabreichbaren", "Strukturanalogon", "des", "Lidocains", ".", "Die", "tinnitussupprimierende", "Wirkung", "wurde", "entsprechend", "den", "subjektiven", "Angaben", "und", "anhand", "einer", "visuellen", "Analogskala", "klassifiziert", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "von", "77", "Patienten", "nur", "19", "Patienten", "eine", "Tinnitussuppression", "unterschiedlicher", "Auspraegung", "angaben", ".", "Von", "ihnen", "waehlten", "14", "Patienten", "eine", "weiterfuehrende", "Therapie", "mit", "Tocainid", "(", "3x400", "mg", "/", "Tag", ")", ";", "5", "Patienten", "lehnten", "die", "Therapie", "wegen", "moeglicher", "Nebenwirkungen", "ab", ";", "3", "Monate", "nach", "der", "Verordnung", "von", "Tocainid", "hatten", "10", "Patienten", "das", "Medikament", "wegen", "Nebenwirkungen", "und", "3", "Patienten", "wegen", "mangelnder", "Wirkung", "abgesetzt", ".", "Wir", "schaetzen", "die", "therapeutische", "Erfolgsquote", "fuer", "die", "Behandlung", "des", "Tinnitus", "aurium", "mit", "Lidocain", "bedeutend", "geringer", "ein", "als", "dies", "im", "Schrifttum", "der", "Fall", "ist", ".", "Das", "oral", "anwendbare", "Stukturanalogon", "Tocainid", "kommt", "wegen", "der", "hohen", "Rate", "an", "Nebenwirkungen", "und", "nicht", "ausreichender", "Tinnitussuppression", "allenfalls", "in", "besonderen", "Einzelfaellen", "als", "Behandlungsmoeglichkeit", "in", "Frage", "." ]	[ "umlsterm" ]
Three hundred forty - one Tanzanian preschool children is a participant, levamisole is an intervention, placebo is an intervention	1157_task0	Sentence: Three hundred forty-one Tanzanian preschool children were randomly assigned to levamisole or placebo treatment given at three-month intervals . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: intervention, participant	[ "B-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "O", "O", "O", "O", "B-intervention", "O", "B-intervention", "O", "O", "O", "O", "O", "O", "O", "O" ]	Three hundred forty-one Tanzanian preschool children were randomly assigned to levamisole or placebo treatment given at three-month intervals .	[ "Three", "hundred", "forty", "-", "one", "Tanzanian", "preschool", "children", "were", "randomly", "assigned", "to", "levamisole", "or", "placebo", "treatment", "given", "at", "three", "-", "month", "intervals", "." ]	[ "participant", "intervention" ]
Three hundred forty - one Tanzanian preschool children is a participant, levamisole is an intervention, placebo is an intervention	1157_task1	Sentence: Three hundred forty-one Tanzanian preschool children were randomly assigned to levamisole or placebo treatment given at three-month intervals . Instructions: please typing these entity words according to sentence: Three hundred forty - one Tanzanian preschool children, levamisole, placebo Options: intervention, participant	[ "B-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "O", "O", "O", "O", "B-intervention", "O", "B-intervention", "O", "O", "O", "O", "O", "O", "O", "O" ]	Three hundred forty-one Tanzanian preschool children were randomly assigned to levamisole or placebo treatment given at three-month intervals .	[ "Three", "hundred", "forty", "-", "one", "Tanzanian", "preschool", "children", "were", "randomly", "assigned", "to", "levamisole", "or", "placebo", "treatment", "given", "at", "three", "-", "month", "intervals", "." ]	[ "participant", "intervention" ]
Three hundred forty - one Tanzanian preschool children, levamisole, placebo	1157_task2	Sentence: Three hundred forty-one Tanzanian preschool children were randomly assigned to levamisole or placebo treatment given at three-month intervals . Instructions: please extract entity words from the input sentence	[ "B-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "O", "O", "O", "O", "B-intervention", "O", "B-intervention", "O", "O", "O", "O", "O", "O", "O", "O" ]	Three hundred forty-one Tanzanian preschool children were randomly assigned to levamisole or placebo treatment given at three-month intervals .	[ "Three", "hundred", "forty", "-", "one", "Tanzanian", "preschool", "children", "were", "randomly", "assigned", "to", "levamisole", "or", "placebo", "treatment", "given", "at", "three", "-", "month", "intervals", "." ]	[ "participant", "intervention" ]
Neoplasien is an umlsterm, Verhalten is an umlsterm, Wachstumspotential is an umlsterm, Trauma is an umlsterm, Selbst is an umlsterm, Rezidivraten is an umlsterm, Wachstumspotentials is an umlsterm, Therapieempfehlung is an umlsterm, Klassifikation is an umlsterm	DerChirurg.00710894.ger.abstr_task0	Sentence: Zusammenfassung . Desmoidtumore ( DTs ) sind seltene nicht-metastasierende Neoplasien , , die sowohl sporadisch als auch im Zusammenhang mit einer familiaeren adenomatoesen Polyposis ( FAP ) vorkommen . DTs weisen ein unvorhersehbares biologisches Verhalten auf , wobei etwa 10 % ein aeusserst aggressives Wachstumspotential demonstrieren und andere sich spontan zurueckbilden . Das chirurgische Trauma triggert das Desmoidwachstum und ist bei FAP-Patienten durch die indizierte prophylaktische Colektomie unvermeidbar . Therapeutische Strategien werden weiterhin kontrovers diskutiert . Die chirurgische Resektion eines Desmoidtumors sollte nur dann als Option diskutiert werden , wenn ein Sicherheitsabstand von mindestens 2 cm gewaehrleistet ist . Selbst bei R0-Resektionen sind die Rezidivraten sehr hoch . Debulking-Operationen fuehren unweigerlich zu einer Steigerung des aggressiven Wachstumspotentials . Die meisten Aspekte bei Desmoiden bleiben widerspruechlich und reflektieren das Fehlen einer systematischen Aufarbeitung der Erkrankung . Ein erster Loesungsschritt aus diesem Dilemma in Richtung standardisierte Therapieempfehlung koennte die Etablierung der vorgeschlagenen klinischen Klassifikation darstellen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Zusammenfassung . Desmoidtumore ( DTs ) sind seltene nicht-metastasierende Neoplasien , , die sowohl sporadisch als auch im Zusammenhang mit einer familiaeren adenomatoesen Polyposis ( FAP ) vorkommen . DTs weisen ein unvorhersehbares biologisches Verhalten auf , wobei etwa 10 % ein aeusserst aggressives Wachstumspotential demonstrieren und andere sich spontan zurueckbilden . Das chirurgische Trauma triggert das Desmoidwachstum und ist bei FAP-Patienten durch die indizierte prophylaktische Colektomie unvermeidbar . Therapeutische Strategien werden weiterhin kontrovers diskutiert . Die chirurgische Resektion eines Desmoidtumors sollte nur dann als Option diskutiert werden , wenn ein Sicherheitsabstand von mindestens 2 cm gewaehrleistet ist . Selbst bei R0-Resektionen sind die Rezidivraten sehr hoch . Debulking-Operationen fuehren unweigerlich zu einer Steigerung des aggressiven Wachstumspotentials . Die meisten Aspekte bei Desmoiden bleiben widerspruechlich und reflektieren das Fehlen einer systematischen Aufarbeitung der Erkrankung . Ein erster Loesungsschritt aus diesem Dilemma in Richtung standardisierte Therapieempfehlung koennte die Etablierung der vorgeschlagenen klinischen Klassifikation darstellen .	[ "Zusammenfassung", ".", "Desmoidtumore", "(", "DTs", ")", "sind", "seltene", "nicht", "-", "metastasierende", "Neoplasien", ",", ",", "die", "sowohl", "sporadisch", "als", "auch", "im", "Zusammenhang", "mit", "einer", "familiaeren", "adenomatoesen", "Polyposis", "(", "FAP", ")", "vorkommen", ".", "DTs", "weisen", "ein", "unvorhersehbares", "biologisches", "Verhalten", "auf", ",", "wobei", "etwa", "10", "%", "ein", "aeusserst", "aggressives", "Wachstumspotential", "demonstrieren", "und", "andere", "sich", "spontan", "zurueckbilden", ".", "Das", "chirurgische", "Trauma", "triggert", "das", "Desmoidwachstum", "und", "ist", "bei", "FAP", "-", "Patienten", "durch", "die", "indizierte", "prophylaktische", "Colektomie", "unvermeidbar", ".", "Therapeutische", "Strategien", "werden", "weiterhin", "kontrovers", "diskutiert", ".", "Die", "chirurgische", "Resektion", "eines", "Desmoidtumors", "sollte", "nur", "dann", "als", "Option", "diskutiert", "werden", ",", "wenn", "ein", "Sicherheitsabstand", "von", "mindestens", "2", "cm", "gewaehrleistet", "ist", ".", "Selbst", "bei", "R0-Resektionen", "sind", "die", "Rezidivraten", "sehr", "hoch", ".", "Debulking", "-", "Operationen", "fuehren", "unweigerlich", "zu", "einer", "Steigerung", "des", "aggressiven", "Wachstumspotentials", ".", "Die", "meisten", "Aspekte", "bei", "Desmoiden", "bleiben", "widerspruechlich", "und", "reflektieren", "das", "Fehlen", "einer", "systematischen", "Aufarbeitung", "der", "Erkrankung", ".", "Ein", "erster", "Loesungsschritt", "aus", "diesem", "Dilemma", "in", "Richtung", "standardisierte", "Therapieempfehlung", "koennte", "die", "Etablierung", "der", "vorgeschlagenen", "klinischen", "Klassifikation", "darstellen", "." ]	[ "umlsterm" ]
Neoplasien is an umlsterm, Verhalten is an umlsterm, Wachstumspotential is an umlsterm, Trauma is an umlsterm, Selbst is an umlsterm, Rezidivraten is an umlsterm, Wachstumspotentials is an umlsterm, Therapieempfehlung is an umlsterm, Klassifikation is an umlsterm	DerChirurg.00710894.ger.abstr_task1	Sentence: Zusammenfassung . Desmoidtumore ( DTs ) sind seltene nicht-metastasierende Neoplasien , , die sowohl sporadisch als auch im Zusammenhang mit einer familiaeren adenomatoesen Polyposis ( FAP ) vorkommen . DTs weisen ein unvorhersehbares biologisches Verhalten auf , wobei etwa 10 % ein aeusserst aggressives Wachstumspotential demonstrieren und andere sich spontan zurueckbilden . Das chirurgische Trauma triggert das Desmoidwachstum und ist bei FAP-Patienten durch die indizierte prophylaktische Colektomie unvermeidbar . Therapeutische Strategien werden weiterhin kontrovers diskutiert . Die chirurgische Resektion eines Desmoidtumors sollte nur dann als Option diskutiert werden , wenn ein Sicherheitsabstand von mindestens 2 cm gewaehrleistet ist . Selbst bei R0-Resektionen sind die Rezidivraten sehr hoch . Debulking-Operationen fuehren unweigerlich zu einer Steigerung des aggressiven Wachstumspotentials . Die meisten Aspekte bei Desmoiden bleiben widerspruechlich und reflektieren das Fehlen einer systematischen Aufarbeitung der Erkrankung . Ein erster Loesungsschritt aus diesem Dilemma in Richtung standardisierte Therapieempfehlung koennte die Etablierung der vorgeschlagenen klinischen Klassifikation darstellen . Instructions: please typing these entity words according to sentence: Neoplasien, Verhalten, Wachstumspotential, Trauma, Selbst, Rezidivraten, Wachstumspotentials, Therapieempfehlung, Klassifikation Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Zusammenfassung . Desmoidtumore ( DTs ) sind seltene nicht-metastasierende Neoplasien , , die sowohl sporadisch als auch im Zusammenhang mit einer familiaeren adenomatoesen Polyposis ( FAP ) vorkommen . DTs weisen ein unvorhersehbares biologisches Verhalten auf , wobei etwa 10 % ein aeusserst aggressives Wachstumspotential demonstrieren und andere sich spontan zurueckbilden . Das chirurgische Trauma triggert das Desmoidwachstum und ist bei FAP-Patienten durch die indizierte prophylaktische Colektomie unvermeidbar . Therapeutische Strategien werden weiterhin kontrovers diskutiert . Die chirurgische Resektion eines Desmoidtumors sollte nur dann als Option diskutiert werden , wenn ein Sicherheitsabstand von mindestens 2 cm gewaehrleistet ist . Selbst bei R0-Resektionen sind die Rezidivraten sehr hoch . Debulking-Operationen fuehren unweigerlich zu einer Steigerung des aggressiven Wachstumspotentials . Die meisten Aspekte bei Desmoiden bleiben widerspruechlich und reflektieren das Fehlen einer systematischen Aufarbeitung der Erkrankung . Ein erster Loesungsschritt aus diesem Dilemma in Richtung standardisierte Therapieempfehlung koennte die Etablierung der vorgeschlagenen klinischen Klassifikation darstellen .	[ "Zusammenfassung", ".", "Desmoidtumore", "(", "DTs", ")", "sind", "seltene", "nicht", "-", "metastasierende", "Neoplasien", ",", ",", "die", "sowohl", "sporadisch", "als", "auch", "im", "Zusammenhang", "mit", "einer", "familiaeren", "adenomatoesen", "Polyposis", "(", "FAP", ")", "vorkommen", ".", "DTs", "weisen", "ein", "unvorhersehbares", "biologisches", "Verhalten", "auf", ",", "wobei", "etwa", "10", "%", "ein", "aeusserst", "aggressives", "Wachstumspotential", "demonstrieren", "und", "andere", "sich", "spontan", "zurueckbilden", ".", "Das", "chirurgische", "Trauma", "triggert", "das", "Desmoidwachstum", "und", "ist", "bei", "FAP", "-", "Patienten", "durch", "die", "indizierte", "prophylaktische", "Colektomie", "unvermeidbar", ".", "Therapeutische", "Strategien", "werden", "weiterhin", "kontrovers", "diskutiert", ".", "Die", "chirurgische", "Resektion", "eines", "Desmoidtumors", "sollte", "nur", "dann", "als", "Option", "diskutiert", "werden", ",", "wenn", "ein", "Sicherheitsabstand", "von", "mindestens", "2", "cm", "gewaehrleistet", "ist", ".", "Selbst", "bei", "R0-Resektionen", "sind", "die", "Rezidivraten", "sehr", "hoch", ".", "Debulking", "-", "Operationen", "fuehren", "unweigerlich", "zu", "einer", "Steigerung", "des", "aggressiven", "Wachstumspotentials", ".", "Die", "meisten", "Aspekte", "bei", "Desmoiden", "bleiben", "widerspruechlich", "und", "reflektieren", "das", "Fehlen", "einer", "systematischen", "Aufarbeitung", "der", "Erkrankung", ".", "Ein", "erster", "Loesungsschritt", "aus", "diesem", "Dilemma", "in", "Richtung", "standardisierte", "Therapieempfehlung", "koennte", "die", "Etablierung", "der", "vorgeschlagenen", "klinischen", "Klassifikation", "darstellen", "." ]	[ "umlsterm" ]
Neoplasien, Verhalten, Wachstumspotential, Trauma, Selbst, Rezidivraten, Wachstumspotentials, Therapieempfehlung, Klassifikation	DerChirurg.00710894.ger.abstr_task2	Sentence: Zusammenfassung . Desmoidtumore ( DTs ) sind seltene nicht-metastasierende Neoplasien , , die sowohl sporadisch als auch im Zusammenhang mit einer familiaeren adenomatoesen Polyposis ( FAP ) vorkommen . DTs weisen ein unvorhersehbares biologisches Verhalten auf , wobei etwa 10 % ein aeusserst aggressives Wachstumspotential demonstrieren und andere sich spontan zurueckbilden . Das chirurgische Trauma triggert das Desmoidwachstum und ist bei FAP-Patienten durch die indizierte prophylaktische Colektomie unvermeidbar . Therapeutische Strategien werden weiterhin kontrovers diskutiert . Die chirurgische Resektion eines Desmoidtumors sollte nur dann als Option diskutiert werden , wenn ein Sicherheitsabstand von mindestens 2 cm gewaehrleistet ist . Selbst bei R0-Resektionen sind die Rezidivraten sehr hoch . Debulking-Operationen fuehren unweigerlich zu einer Steigerung des aggressiven Wachstumspotentials . Die meisten Aspekte bei Desmoiden bleiben widerspruechlich und reflektieren das Fehlen einer systematischen Aufarbeitung der Erkrankung . Ein erster Loesungsschritt aus diesem Dilemma in Richtung standardisierte Therapieempfehlung koennte die Etablierung der vorgeschlagenen klinischen Klassifikation darstellen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Zusammenfassung . Desmoidtumore ( DTs ) sind seltene nicht-metastasierende Neoplasien , , die sowohl sporadisch als auch im Zusammenhang mit einer familiaeren adenomatoesen Polyposis ( FAP ) vorkommen . DTs weisen ein unvorhersehbares biologisches Verhalten auf , wobei etwa 10 % ein aeusserst aggressives Wachstumspotential demonstrieren und andere sich spontan zurueckbilden . Das chirurgische Trauma triggert das Desmoidwachstum und ist bei FAP-Patienten durch die indizierte prophylaktische Colektomie unvermeidbar . Therapeutische Strategien werden weiterhin kontrovers diskutiert . Die chirurgische Resektion eines Desmoidtumors sollte nur dann als Option diskutiert werden , wenn ein Sicherheitsabstand von mindestens 2 cm gewaehrleistet ist . Selbst bei R0-Resektionen sind die Rezidivraten sehr hoch . Debulking-Operationen fuehren unweigerlich zu einer Steigerung des aggressiven Wachstumspotentials . Die meisten Aspekte bei Desmoiden bleiben widerspruechlich und reflektieren das Fehlen einer systematischen Aufarbeitung der Erkrankung . Ein erster Loesungsschritt aus diesem Dilemma in Richtung standardisierte Therapieempfehlung koennte die Etablierung der vorgeschlagenen klinischen Klassifikation darstellen .	[ "Zusammenfassung", ".", "Desmoidtumore", "(", "DTs", ")", "sind", "seltene", "nicht", "-", "metastasierende", "Neoplasien", ",", ",", "die", "sowohl", "sporadisch", "als", "auch", "im", "Zusammenhang", "mit", "einer", "familiaeren", "adenomatoesen", "Polyposis", "(", "FAP", ")", "vorkommen", ".", "DTs", "weisen", "ein", "unvorhersehbares", "biologisches", "Verhalten", "auf", ",", "wobei", "etwa", "10", "%", "ein", "aeusserst", "aggressives", "Wachstumspotential", "demonstrieren", "und", "andere", "sich", "spontan", "zurueckbilden", ".", "Das", "chirurgische", "Trauma", "triggert", "das", "Desmoidwachstum", "und", "ist", "bei", "FAP", "-", "Patienten", "durch", "die", "indizierte", "prophylaktische", "Colektomie", "unvermeidbar", ".", "Therapeutische", "Strategien", "werden", "weiterhin", "kontrovers", "diskutiert", ".", "Die", "chirurgische", "Resektion", "eines", "Desmoidtumors", "sollte", "nur", "dann", "als", "Option", "diskutiert", "werden", ",", "wenn", "ein", "Sicherheitsabstand", "von", "mindestens", "2", "cm", "gewaehrleistet", "ist", ".", "Selbst", "bei", "R0-Resektionen", "sind", "die", "Rezidivraten", "sehr", "hoch", ".", "Debulking", "-", "Operationen", "fuehren", "unweigerlich", "zu", "einer", "Steigerung", "des", "aggressiven", "Wachstumspotentials", ".", "Die", "meisten", "Aspekte", "bei", "Desmoiden", "bleiben", "widerspruechlich", "und", "reflektieren", "das", "Fehlen", "einer", "systematischen", "Aufarbeitung", "der", "Erkrankung", ".", "Ein", "erster", "Loesungsschritt", "aus", "diesem", "Dilemma", "in", "Richtung", "standardisierte", "Therapieempfehlung", "koennte", "die", "Etablierung", "der", "vorgeschlagenen", "klinischen", "Klassifikation", "darstellen", "." ]	[ "umlsterm" ]
IkappaBalpha is a Protein, IkappaBalpha kinase is a Protein, p90(rsk ) is a Protein, p90(rsk ) is a Protein, IkappaBalpha is a Protein, IkappaBalpha is a Protein, IKKalpha is a Protein, -beta is a Protein, IKKbeta is a Protein	10438457_task0	Sentence: Protein kinase C and calcineurin synergize to activate IkappaB kinase and NF-kappaB in T lymphocytes. The nuclear factor of kappaB (NF-kappaB) is a ubiquitous transcription factor that is key in the regulation of the immune response and inflammation. T cell receptor (TCR) cross-linking is in part required for activation of NF-kappaB, which is dependent on the phosphorylation and degradation of IkappaBalpha. By using Jurkat and primary human T lymphocytes, we demonstrate that the simultaneous activation of two second messengers of the TCR-initiated signal transduction, protein kinase C (PKC) and calcineurin, results in the synergistic activation of the IkappaBalpha kinase (IKK) complex but not of another putative IkappaBalpha kinase, p90(rsk). We also demonstrate that the IKK complex, but not p90(rsk), is responsible for the in vivo phosphorylation of IkappaBalpha mediated by the co-activation of PKC and calcineurin. Each second messenger is necessary, as inhibition of either one reverses the activation of the IKK complex and IkappaBalpha phosphorylation in vivo. Overexpression of dominant negative forms of IKKalpha and -beta demonstrates that only IKKbeta is the target for PKC and calcineurin. These results indicate that within the TCR/CD3 signal transduction pathway both PKC and calcineurin are required for the effective activation of the IKK complex and NF-kappaB in T lymphocytes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Protein kinase C and calcineurin synergize to activate IkappaB kinase and NF-kappaB in T lymphocytes. The nuclear factor of kappaB (NF-kappaB) is a ubiquitous transcription factor that is key in the regulation of the immune response and inflammation. T cell receptor (TCR) cross-linking is in part required for activation of NF-kappaB, which is dependent on the phosphorylation and degradation of IkappaBalpha. By using Jurkat and primary human T lymphocytes, we demonstrate that the simultaneous activation of two second messengers of the TCR-initiated signal transduction, protein kinase C (PKC) and calcineurin, results in the synergistic activation of the IkappaBalpha kinase (IKK) complex but not of another putative IkappaBalpha kinase, p90(rsk). We also demonstrate that the IKK complex, but not p90(rsk), is responsible for the in vivo phosphorylation of IkappaBalpha mediated by the co-activation of PKC and calcineurin. Each second messenger is necessary, as inhibition of either one reverses the activation of the IKK complex and IkappaBalpha phosphorylation in vivo. Overexpression of dominant negative forms of IKKalpha and -beta demonstrates that only IKKbeta is the target for PKC and calcineurin. These results indicate that within the TCR/CD3 signal transduction pathway both PKC and calcineurin are required for the effective activation of the IKK complex and NF-kappaB in T lymphocytes.	[ "Protein", "kinase", "C", "and", "calcineurin", "synergize", "to", "activate", "IkappaB", "kinase", "and", "NF", "-", "kappaB", "in", "T", "lymphocytes", ".", "\n", "The", "nuclear", "factor", "of", "kappaB", "(", "NF", "-", "kappaB", ")", "is", "a", "ubiquitous", "transcription", "factor", "that", "is", "key", "in", "the", "regulation", "of", "the", "immune", "response", "and", "inflammation", ".", "T", "cell", "receptor", "(", "TCR", ")", "cross", "-", "linking", "is", "in", "part", "required", "for", "activation", "of", "NF", "-", "kappaB", ",", "which", "is", "dependent", "on", "the", "phosphorylation", "and", "degradation", "of", "IkappaBalpha", ".", "By", "using", "Jurkat", "and", "primary", "human", "T", "lymphocytes", ",", "we", "demonstrate", "that", "the", "simultaneous", "activation", "of", "two", "second", "messengers", "of", "the", "TCR", "-", "initiated", "signal", "transduction", ",", "protein", "kinase", "C", "(", "PKC", ")", "and", "calcineurin", ",", "results", "in", "the", "synergistic", "activation", "of", "the", "IkappaBalpha", "kinase", "(", "IKK", ")", "complex", "but", "not", "of", "another", "putative", "IkappaBalpha", "kinase", ",", "p90(rsk", ")", ".", "We", "also", "demonstrate", "that", "the", "IKK", "complex", ",", "but", "not", "p90(rsk", ")", ",", "is", "responsible", "for", "the", "in", "vivo", "phosphorylation", "of", "IkappaBalpha", "mediated", "by", "the", "co", "-", "activation", "of", "PKC", "and", "calcineurin", ".", "Each", "second", "messenger", "is", "necessary", ",", "as", "inhibition", "of", "either", "one", "reverses", "the", "activation", "of", "the", "IKK", "complex", "and", "IkappaBalpha", "phosphorylation", "in", "vivo", ".", "Overexpression", "of", "dominant", "negative", "forms", "of", "IKKalpha", "and", "-beta", "demonstrates", "that", "only", "IKKbeta", "is", "the", "target", "for", "PKC", "and", "calcineurin", ".", "These", "results", "indicate", "that", "within", "the", "TCR", "/", "CD3", "signal", "transduction", "pathway", "both", "PKC", "and", "calcineurin", "are", "required", "for", "the", "effective", "activation", "of", "the", "IKK", "complex", "and", "NF", "-", "kappaB", "in", "T", "lymphocytes", "." ]	[ "Protein" ]
IkappaBalpha is a Protein, IkappaBalpha kinase is a Protein, p90(rsk ) is a Protein, p90(rsk ) is a Protein, IkappaBalpha is a Protein, IkappaBalpha is a Protein, IKKalpha is a Protein, -beta is a Protein, IKKbeta is a Protein	10438457_task1	Sentence: Protein kinase C and calcineurin synergize to activate IkappaB kinase and NF-kappaB in T lymphocytes. The nuclear factor of kappaB (NF-kappaB) is a ubiquitous transcription factor that is key in the regulation of the immune response and inflammation. T cell receptor (TCR) cross-linking is in part required for activation of NF-kappaB, which is dependent on the phosphorylation and degradation of IkappaBalpha. By using Jurkat and primary human T lymphocytes, we demonstrate that the simultaneous activation of two second messengers of the TCR-initiated signal transduction, protein kinase C (PKC) and calcineurin, results in the synergistic activation of the IkappaBalpha kinase (IKK) complex but not of another putative IkappaBalpha kinase, p90(rsk). We also demonstrate that the IKK complex, but not p90(rsk), is responsible for the in vivo phosphorylation of IkappaBalpha mediated by the co-activation of PKC and calcineurin. Each second messenger is necessary, as inhibition of either one reverses the activation of the IKK complex and IkappaBalpha phosphorylation in vivo. Overexpression of dominant negative forms of IKKalpha and -beta demonstrates that only IKKbeta is the target for PKC and calcineurin. These results indicate that within the TCR/CD3 signal transduction pathway both PKC and calcineurin are required for the effective activation of the IKK complex and NF-kappaB in T lymphocytes. Instructions: please typing these entity words according to sentence: IkappaBalpha, IkappaBalpha kinase, p90(rsk ), p90(rsk ), IkappaBalpha, IkappaBalpha, IKKalpha, -beta, IKKbeta Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Protein kinase C and calcineurin synergize to activate IkappaB kinase and NF-kappaB in T lymphocytes. The nuclear factor of kappaB (NF-kappaB) is a ubiquitous transcription factor that is key in the regulation of the immune response and inflammation. T cell receptor (TCR) cross-linking is in part required for activation of NF-kappaB, which is dependent on the phosphorylation and degradation of IkappaBalpha. By using Jurkat and primary human T lymphocytes, we demonstrate that the simultaneous activation of two second messengers of the TCR-initiated signal transduction, protein kinase C (PKC) and calcineurin, results in the synergistic activation of the IkappaBalpha kinase (IKK) complex but not of another putative IkappaBalpha kinase, p90(rsk). We also demonstrate that the IKK complex, but not p90(rsk), is responsible for the in vivo phosphorylation of IkappaBalpha mediated by the co-activation of PKC and calcineurin. Each second messenger is necessary, as inhibition of either one reverses the activation of the IKK complex and IkappaBalpha phosphorylation in vivo. Overexpression of dominant negative forms of IKKalpha and -beta demonstrates that only IKKbeta is the target for PKC and calcineurin. These results indicate that within the TCR/CD3 signal transduction pathway both PKC and calcineurin are required for the effective activation of the IKK complex and NF-kappaB in T lymphocytes.	[ "Protein", "kinase", "C", "and", "calcineurin", "synergize", "to", "activate", "IkappaB", "kinase", "and", "NF", "-", "kappaB", "in", "T", "lymphocytes", ".", "\n", "The", "nuclear", "factor", "of", "kappaB", "(", "NF", "-", "kappaB", ")", "is", "a", "ubiquitous", "transcription", "factor", "that", "is", "key", "in", "the", "regulation", "of", "the", "immune", "response", "and", "inflammation", ".", "T", "cell", "receptor", "(", "TCR", ")", "cross", "-", "linking", "is", "in", "part", "required", "for", "activation", "of", "NF", "-", "kappaB", ",", "which", "is", "dependent", "on", "the", "phosphorylation", "and", "degradation", "of", "IkappaBalpha", ".", "By", "using", "Jurkat", "and", "primary", "human", "T", "lymphocytes", ",", "we", "demonstrate", "that", "the", "simultaneous", "activation", "of", "two", "second", "messengers", "of", "the", "TCR", "-", "initiated", "signal", "transduction", ",", "protein", "kinase", "C", "(", "PKC", ")", "and", "calcineurin", ",", "results", "in", "the", "synergistic", "activation", "of", "the", "IkappaBalpha", "kinase", "(", "IKK", ")", "complex", "but", "not", "of", "another", "putative", "IkappaBalpha", "kinase", ",", "p90(rsk", ")", ".", "We", "also", "demonstrate", "that", "the", "IKK", "complex", ",", "but", "not", "p90(rsk", ")", ",", "is", "responsible", "for", "the", "in", "vivo", "phosphorylation", "of", "IkappaBalpha", "mediated", "by", "the", "co", "-", "activation", "of", "PKC", "and", "calcineurin", ".", "Each", "second", "messenger", "is", "necessary", ",", "as", "inhibition", "of", "either", "one", "reverses", "the", "activation", "of", "the", "IKK", "complex", "and", "IkappaBalpha", "phosphorylation", "in", "vivo", ".", "Overexpression", "of", "dominant", "negative", "forms", "of", "IKKalpha", "and", "-beta", "demonstrates", "that", "only", "IKKbeta", "is", "the", "target", "for", "PKC", "and", "calcineurin", ".", "These", "results", "indicate", "that", "within", "the", "TCR", "/", "CD3", "signal", "transduction", "pathway", "both", "PKC", "and", "calcineurin", "are", "required", "for", "the", "effective", "activation", "of", "the", "IKK", "complex", "and", "NF", "-", "kappaB", "in", "T", "lymphocytes", "." ]	[ "Protein" ]
IkappaBalpha, IkappaBalpha kinase, p90(rsk ), p90(rsk ), IkappaBalpha, IkappaBalpha, IKKalpha, -beta, IKKbeta	10438457_task2	Sentence: Protein kinase C and calcineurin synergize to activate IkappaB kinase and NF-kappaB in T lymphocytes. The nuclear factor of kappaB (NF-kappaB) is a ubiquitous transcription factor that is key in the regulation of the immune response and inflammation. T cell receptor (TCR) cross-linking is in part required for activation of NF-kappaB, which is dependent on the phosphorylation and degradation of IkappaBalpha. By using Jurkat and primary human T lymphocytes, we demonstrate that the simultaneous activation of two second messengers of the TCR-initiated signal transduction, protein kinase C (PKC) and calcineurin, results in the synergistic activation of the IkappaBalpha kinase (IKK) complex but not of another putative IkappaBalpha kinase, p90(rsk). We also demonstrate that the IKK complex, but not p90(rsk), is responsible for the in vivo phosphorylation of IkappaBalpha mediated by the co-activation of PKC and calcineurin. Each second messenger is necessary, as inhibition of either one reverses the activation of the IKK complex and IkappaBalpha phosphorylation in vivo. Overexpression of dominant negative forms of IKKalpha and -beta demonstrates that only IKKbeta is the target for PKC and calcineurin. These results indicate that within the TCR/CD3 signal transduction pathway both PKC and calcineurin are required for the effective activation of the IKK complex and NF-kappaB in T lymphocytes. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Protein kinase C and calcineurin synergize to activate IkappaB kinase and NF-kappaB in T lymphocytes. The nuclear factor of kappaB (NF-kappaB) is a ubiquitous transcription factor that is key in the regulation of the immune response and inflammation. T cell receptor (TCR) cross-linking is in part required for activation of NF-kappaB, which is dependent on the phosphorylation and degradation of IkappaBalpha. By using Jurkat and primary human T lymphocytes, we demonstrate that the simultaneous activation of two second messengers of the TCR-initiated signal transduction, protein kinase C (PKC) and calcineurin, results in the synergistic activation of the IkappaBalpha kinase (IKK) complex but not of another putative IkappaBalpha kinase, p90(rsk). We also demonstrate that the IKK complex, but not p90(rsk), is responsible for the in vivo phosphorylation of IkappaBalpha mediated by the co-activation of PKC and calcineurin. Each second messenger is necessary, as inhibition of either one reverses the activation of the IKK complex and IkappaBalpha phosphorylation in vivo. Overexpression of dominant negative forms of IKKalpha and -beta demonstrates that only IKKbeta is the target for PKC and calcineurin. These results indicate that within the TCR/CD3 signal transduction pathway both PKC and calcineurin are required for the effective activation of the IKK complex and NF-kappaB in T lymphocytes.	[ "Protein", "kinase", "C", "and", "calcineurin", "synergize", "to", "activate", "IkappaB", "kinase", "and", "NF", "-", "kappaB", "in", "T", "lymphocytes", ".", "\n", "The", "nuclear", "factor", "of", "kappaB", "(", "NF", "-", "kappaB", ")", "is", "a", "ubiquitous", "transcription", "factor", "that", "is", "key", "in", "the", "regulation", "of", "the", "immune", "response", "and", "inflammation", ".", "T", "cell", "receptor", "(", "TCR", ")", "cross", "-", "linking", "is", "in", "part", "required", "for", "activation", "of", "NF", "-", "kappaB", ",", "which", "is", "dependent", "on", "the", "phosphorylation", "and", "degradation", "of", "IkappaBalpha", ".", "By", "using", "Jurkat", "and", "primary", "human", "T", "lymphocytes", ",", "we", "demonstrate", "that", "the", "simultaneous", "activation", "of", "two", "second", "messengers", "of", "the", "TCR", "-", "initiated", "signal", "transduction", ",", "protein", "kinase", "C", "(", "PKC", ")", "and", "calcineurin", ",", "results", "in", "the", "synergistic", "activation", "of", "the", "IkappaBalpha", "kinase", "(", "IKK", ")", "complex", "but", "not", "of", "another", "putative", "IkappaBalpha", "kinase", ",", "p90(rsk", ")", ".", "We", "also", "demonstrate", "that", "the", "IKK", "complex", ",", "but", "not", "p90(rsk", ")", ",", "is", "responsible", "for", "the", "in", "vivo", "phosphorylation", "of", "IkappaBalpha", "mediated", "by", "the", "co", "-", "activation", "of", "PKC", "and", "calcineurin", ".", "Each", "second", "messenger", "is", "necessary", ",", "as", "inhibition", "of", "either", "one", "reverses", "the", "activation", "of", "the", "IKK", "complex", "and", "IkappaBalpha", "phosphorylation", "in", "vivo", ".", "Overexpression", "of", "dominant", "negative", "forms", "of", "IKKalpha", "and", "-beta", "demonstrates", "that", "only", "IKKbeta", "is", "the", "target", "for", "PKC", "and", "calcineurin", ".", "These", "results", "indicate", "that", "within", "the", "TCR", "/", "CD3", "signal", "transduction", "pathway", "both", "PKC", "and", "calcineurin", "are", "required", "for", "the", "effective", "activation", "of", "the", "IKK", "complex", "and", "NF", "-", "kappaB", "in", "T", "lymphocytes", "." ]	[ "Protein" ]
nicotine is a Intervention_Pharmacological, tone is a Outcome_Physical, contractile activity is a Outcome_Physical, ulcerative colitis ( UC ) is a Participant_Condition, sustained resting pressure ( tone ) is a Outcome_Physical, placebo is a Intervention_Control, water - perfused manometry catheter is a Intervention_Physical, sigmoidoscopy is a Intervention_Physical, Baseline tone is a Outcome_Physical, Tone is a Outcome_Physical, rate of recovery is a Outcome_Physical	2007_task0	Sentence: Intra-luminal nicotine reduces smooth muscle tone and contractile activity in the distal large bowel . BACKGROUND Nicotine may be of therapeutic value in ulcerative colitis ( UC ) , although its mechanism of action has not been established . OBJECTIVE To examine the effect of a solution of nicotine on sustained resting pressure ( tone ) and contractile activity in the human colon . METHODS Ten healthy volunteers , and seven with UC in symptomatic remission took part ; all were non-smokers . All 17 subjects were given nicotine or placebo solution on two separate occasions in a randomized sequence . A water-perfused manometry catheter , with openings at 5 , 10 and 15 cm from the tip , was placed by rigid sigmoidoscopy in the recto-sigmoid region . Baseline tone and activity were measured for 15 min prior to instillation of 20 ml of saline alone or with nicotine , 1.2 mg , at pH 4.5 . Observations were made over the subsequent 15-20 min . RESULTS Baseline spontaneous activity in all subjects showed both high- and low-frequency components ; in three patients with UC , the low-frequency activity was of high amplitude . The nicotine reduced both tone and activity in all subjects , with reduction or abolition of the large contractions in UC . Tone in all 17 subjects was reduced significantly at 3 min after nicotine ( P = 0.000015 , sign test ) ; the rate of recovery varied in individuals . Results from normals and UC did not differ significantly from each other . No significant change in tone or activity was observed with the saline solution . CONCLUSION Intra-luminal nicotine significantly reduces both smooth muscle tone and contractile activity in the recto-sigmoid colon in both normal subjects and patients with UC . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Intervention_Control, Participant_Condition, Outcome_Physical	[ "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Intra-luminal nicotine reduces smooth muscle tone and contractile activity in the distal large bowel . BACKGROUND Nicotine may be of therapeutic value in ulcerative colitis ( UC ) , although its mechanism of action has not been established . OBJECTIVE To examine the effect of a solution of nicotine on sustained resting pressure ( tone ) and contractile activity in the human colon . METHODS Ten healthy volunteers , and seven with UC in symptomatic remission took part ; all were non-smokers . All 17 subjects were given nicotine or placebo solution on two separate occasions in a randomized sequence . A water-perfused manometry catheter , with openings at 5 , 10 and 15 cm from the tip , was placed by rigid sigmoidoscopy in the recto-sigmoid region . Baseline tone and activity were measured for 15 min prior to instillation of 20 ml of saline alone or with nicotine , 1.2 mg , at pH 4.5 . Observations were made over the subsequent 15-20 min . RESULTS Baseline spontaneous activity in all subjects showed both high- and low-frequency components ; in three patients with UC , the low-frequency activity was of high amplitude . The nicotine reduced both tone and activity in all subjects , with reduction or abolition of the large contractions in UC . Tone in all 17 subjects was reduced significantly at 3 min after nicotine ( P = 0.000015 , sign test ) ; the rate of recovery varied in individuals . Results from normals and UC did not differ significantly from each other . No significant change in tone or activity was observed with the saline solution . CONCLUSION Intra-luminal nicotine significantly reduces both smooth muscle tone and contractile activity in the recto-sigmoid colon in both normal subjects and patients with UC .	[ "Intra", "-", "luminal", "nicotine", "reduces", "smooth", "muscle", "tone", "and", "contractile", "activity", "in", "the", "distal", "large", "bowel", ".", "BACKGROUND", "Nicotine", "may", "be", "of", "therapeutic", "value", "in", "ulcerative", "colitis", "(", "UC", ")", ",", "although", "its", "mechanism", "of", "action", "has", "not", "been", "established", ".", "OBJECTIVE", "To", "examine", "the", "effect", "of", "a", "solution", "of", "nicotine", "on", "sustained", "resting", "pressure", "(", "tone", ")", "and", "contractile", "activity", "in", "the", "human", "colon", ".", "METHODS", "Ten", "healthy", "volunteers", ",", "and", "seven", "with", "UC", "in", "symptomatic", "remission", "took", "part", ";", "all", "were", "non", "-", "smokers", ".", "All", "17", "subjects", "were", "given", "nicotine", "or", "placebo", "solution", "on", "two", "separate", "occasions", "in", "a", "randomized", "sequence", ".", "A", "water", "-", "perfused", "manometry", "catheter", ",", "with", "openings", "at", "5", ",", "10", "and", "15", "cm", "from", "the", "tip", ",", "was", "placed", "by", "rigid", "sigmoidoscopy", "in", "the", "recto", "-", "sigmoid", "region", ".", "Baseline", "tone", "and", "activity", "were", "measured", "for", "15", "min", "prior", "to", "instillation", "of", "20", "ml", "of", "saline", "alone", "or", "with", "nicotine", ",", "1.2", "mg", ",", "at", "pH", "4.5", ".", "Observations", "were", "made", "over", "the", "subsequent", "15", "-", "20", "min", ".", "RESULTS", "Baseline", "spontaneous", "activity", "in", "all", "subjects", "showed", "both", "high-", "and", "low", "-", "frequency", "components", ";", "in", "three", "patients", "with", "UC", ",", "the", "low", "-", "frequency", "activity", "was", "of", "high", "amplitude", ".", "The", "nicotine", "reduced", "both", "tone", "and", "activity", "in", "all", "subjects", ",", "with", "reduction", "or", "abolition", "of", "the", "large", "contractions", "in", "UC", ".", "Tone", "in", "all", "17", "subjects", "was", "reduced", "significantly", "at", "3", "min", "after", "nicotine", "(", "P", "=", "0.000015", ",", "sign", "test", ")", ";", "the", "rate", "of", "recovery", "varied", "in", "individuals", ".", "Results", "from", "normals", "and", "UC", "did", "not", "differ", "significantly", "from", "each", "other", ".", "No", "significant", "change", "in", "tone", "or", "activity", "was", "observed", "with", "the", "saline", "solution", ".", "CONCLUSION", "Intra", "-", "luminal", "nicotine", "significantly", "reduces", "both", "smooth", "muscle", "tone", "and", "contractile", "activity", "in", "the", "recto", "-", "sigmoid", "colon", "in", "both", "normal", "subjects", "and", "patients", "with", "UC", "." ]	[ "Outcome_Physical", "Intervention_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control" ]
nicotine is a Intervention_Pharmacological, tone is a Outcome_Physical, contractile activity is a Outcome_Physical, ulcerative colitis ( UC ) is a Participant_Condition, sustained resting pressure ( tone ) is a Outcome_Physical, placebo is a Intervention_Control, water - perfused manometry catheter is a Intervention_Physical, sigmoidoscopy is a Intervention_Physical, Baseline tone is a Outcome_Physical, Tone is a Outcome_Physical, rate of recovery is a Outcome_Physical	2007_task1	Sentence: Intra-luminal nicotine reduces smooth muscle tone and contractile activity in the distal large bowel . BACKGROUND Nicotine may be of therapeutic value in ulcerative colitis ( UC ) , although its mechanism of action has not been established . OBJECTIVE To examine the effect of a solution of nicotine on sustained resting pressure ( tone ) and contractile activity in the human colon . METHODS Ten healthy volunteers , and seven with UC in symptomatic remission took part ; all were non-smokers . All 17 subjects were given nicotine or placebo solution on two separate occasions in a randomized sequence . A water-perfused manometry catheter , with openings at 5 , 10 and 15 cm from the tip , was placed by rigid sigmoidoscopy in the recto-sigmoid region . Baseline tone and activity were measured for 15 min prior to instillation of 20 ml of saline alone or with nicotine , 1.2 mg , at pH 4.5 . Observations were made over the subsequent 15-20 min . RESULTS Baseline spontaneous activity in all subjects showed both high- and low-frequency components ; in three patients with UC , the low-frequency activity was of high amplitude . The nicotine reduced both tone and activity in all subjects , with reduction or abolition of the large contractions in UC . Tone in all 17 subjects was reduced significantly at 3 min after nicotine ( P = 0.000015 , sign test ) ; the rate of recovery varied in individuals . Results from normals and UC did not differ significantly from each other . No significant change in tone or activity was observed with the saline solution . CONCLUSION Intra-luminal nicotine significantly reduces both smooth muscle tone and contractile activity in the recto-sigmoid colon in both normal subjects and patients with UC . Instructions: please typing these entity words according to sentence: nicotine, tone, contractile activity, ulcerative colitis ( UC ), sustained resting pressure ( tone ), placebo, water - perfused manometry catheter, sigmoidoscopy, Baseline tone, Tone, rate of recovery Options: Intervention_Pharmacological, Intervention_Physical, Intervention_Control, Participant_Condition, Outcome_Physical	[ "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Intra-luminal nicotine reduces smooth muscle tone and contractile activity in the distal large bowel . BACKGROUND Nicotine may be of therapeutic value in ulcerative colitis ( UC ) , although its mechanism of action has not been established . OBJECTIVE To examine the effect of a solution of nicotine on sustained resting pressure ( tone ) and contractile activity in the human colon . METHODS Ten healthy volunteers , and seven with UC in symptomatic remission took part ; all were non-smokers . All 17 subjects were given nicotine or placebo solution on two separate occasions in a randomized sequence . A water-perfused manometry catheter , with openings at 5 , 10 and 15 cm from the tip , was placed by rigid sigmoidoscopy in the recto-sigmoid region . Baseline tone and activity were measured for 15 min prior to instillation of 20 ml of saline alone or with nicotine , 1.2 mg , at pH 4.5 . Observations were made over the subsequent 15-20 min . RESULTS Baseline spontaneous activity in all subjects showed both high- and low-frequency components ; in three patients with UC , the low-frequency activity was of high amplitude . The nicotine reduced both tone and activity in all subjects , with reduction or abolition of the large contractions in UC . Tone in all 17 subjects was reduced significantly at 3 min after nicotine ( P = 0.000015 , sign test ) ; the rate of recovery varied in individuals . Results from normals and UC did not differ significantly from each other . No significant change in tone or activity was observed with the saline solution . CONCLUSION Intra-luminal nicotine significantly reduces both smooth muscle tone and contractile activity in the recto-sigmoid colon in both normal subjects and patients with UC .	[ "Intra", "-", "luminal", "nicotine", "reduces", "smooth", "muscle", "tone", "and", "contractile", "activity", "in", "the", "distal", "large", "bowel", ".", "BACKGROUND", "Nicotine", "may", "be", "of", "therapeutic", "value", "in", "ulcerative", "colitis", "(", "UC", ")", ",", "although", "its", "mechanism", "of", "action", "has", "not", "been", "established", ".", "OBJECTIVE", "To", "examine", "the", "effect", "of", "a", "solution", "of", "nicotine", "on", "sustained", "resting", "pressure", "(", "tone", ")", "and", "contractile", "activity", "in", "the", "human", "colon", ".", "METHODS", "Ten", "healthy", "volunteers", ",", "and", "seven", "with", "UC", "in", "symptomatic", "remission", "took", "part", ";", "all", "were", "non", "-", "smokers", ".", "All", "17", "subjects", "were", "given", "nicotine", "or", "placebo", "solution", "on", "two", "separate", "occasions", "in", "a", "randomized", "sequence", ".", "A", "water", "-", "perfused", "manometry", "catheter", ",", "with", "openings", "at", "5", ",", "10", "and", "15", "cm", "from", "the", "tip", ",", "was", "placed", "by", "rigid", "sigmoidoscopy", "in", "the", "recto", "-", "sigmoid", "region", ".", "Baseline", "tone", "and", "activity", "were", "measured", "for", "15", "min", "prior", "to", "instillation", "of", "20", "ml", "of", "saline", "alone", "or", "with", "nicotine", ",", "1.2", "mg", ",", "at", "pH", "4.5", ".", "Observations", "were", "made", "over", "the", "subsequent", "15", "-", "20", "min", ".", "RESULTS", "Baseline", "spontaneous", "activity", "in", "all", "subjects", "showed", "both", "high-", "and", "low", "-", "frequency", "components", ";", "in", "three", "patients", "with", "UC", ",", "the", "low", "-", "frequency", "activity", "was", "of", "high", "amplitude", ".", "The", "nicotine", "reduced", "both", "tone", "and", "activity", "in", "all", "subjects", ",", "with", "reduction", "or", "abolition", "of", "the", "large", "contractions", "in", "UC", ".", "Tone", "in", "all", "17", "subjects", "was", "reduced", "significantly", "at", "3", "min", "after", "nicotine", "(", "P", "=", "0.000015", ",", "sign", "test", ")", ";", "the", "rate", "of", "recovery", "varied", "in", "individuals", ".", "Results", "from", "normals", "and", "UC", "did", "not", "differ", "significantly", "from", "each", "other", ".", "No", "significant", "change", "in", "tone", "or", "activity", "was", "observed", "with", "the", "saline", "solution", ".", "CONCLUSION", "Intra", "-", "luminal", "nicotine", "significantly", "reduces", "both", "smooth", "muscle", "tone", "and", "contractile", "activity", "in", "the", "recto", "-", "sigmoid", "colon", "in", "both", "normal", "subjects", "and", "patients", "with", "UC", "." ]	[ "Outcome_Physical", "Intervention_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control" ]
nicotine, tone, contractile activity, ulcerative colitis ( UC ), sustained resting pressure ( tone ), placebo, water - perfused manometry catheter, sigmoidoscopy, Baseline tone, Tone, rate of recovery	2007_task2	Sentence: Intra-luminal nicotine reduces smooth muscle tone and contractile activity in the distal large bowel . BACKGROUND Nicotine may be of therapeutic value in ulcerative colitis ( UC ) , although its mechanism of action has not been established . OBJECTIVE To examine the effect of a solution of nicotine on sustained resting pressure ( tone ) and contractile activity in the human colon . METHODS Ten healthy volunteers , and seven with UC in symptomatic remission took part ; all were non-smokers . All 17 subjects were given nicotine or placebo solution on two separate occasions in a randomized sequence . A water-perfused manometry catheter , with openings at 5 , 10 and 15 cm from the tip , was placed by rigid sigmoidoscopy in the recto-sigmoid region . Baseline tone and activity were measured for 15 min prior to instillation of 20 ml of saline alone or with nicotine , 1.2 mg , at pH 4.5 . Observations were made over the subsequent 15-20 min . RESULTS Baseline spontaneous activity in all subjects showed both high- and low-frequency components ; in three patients with UC , the low-frequency activity was of high amplitude . The nicotine reduced both tone and activity in all subjects , with reduction or abolition of the large contractions in UC . Tone in all 17 subjects was reduced significantly at 3 min after nicotine ( P = 0.000015 , sign test ) ; the rate of recovery varied in individuals . Results from normals and UC did not differ significantly from each other . No significant change in tone or activity was observed with the saline solution . CONCLUSION Intra-luminal nicotine significantly reduces both smooth muscle tone and contractile activity in the recto-sigmoid colon in both normal subjects and patients with UC . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Intra-luminal nicotine reduces smooth muscle tone and contractile activity in the distal large bowel . BACKGROUND Nicotine may be of therapeutic value in ulcerative colitis ( UC ) , although its mechanism of action has not been established . OBJECTIVE To examine the effect of a solution of nicotine on sustained resting pressure ( tone ) and contractile activity in the human colon . METHODS Ten healthy volunteers , and seven with UC in symptomatic remission took part ; all were non-smokers . All 17 subjects were given nicotine or placebo solution on two separate occasions in a randomized sequence . A water-perfused manometry catheter , with openings at 5 , 10 and 15 cm from the tip , was placed by rigid sigmoidoscopy in the recto-sigmoid region . Baseline tone and activity were measured for 15 min prior to instillation of 20 ml of saline alone or with nicotine , 1.2 mg , at pH 4.5 . Observations were made over the subsequent 15-20 min . RESULTS Baseline spontaneous activity in all subjects showed both high- and low-frequency components ; in three patients with UC , the low-frequency activity was of high amplitude . The nicotine reduced both tone and activity in all subjects , with reduction or abolition of the large contractions in UC . Tone in all 17 subjects was reduced significantly at 3 min after nicotine ( P = 0.000015 , sign test ) ; the rate of recovery varied in individuals . Results from normals and UC did not differ significantly from each other . No significant change in tone or activity was observed with the saline solution . CONCLUSION Intra-luminal nicotine significantly reduces both smooth muscle tone and contractile activity in the recto-sigmoid colon in both normal subjects and patients with UC .	[ "Intra", "-", "luminal", "nicotine", "reduces", "smooth", "muscle", "tone", "and", "contractile", "activity", "in", "the", "distal", "large", "bowel", ".", "BACKGROUND", "Nicotine", "may", "be", "of", "therapeutic", "value", "in", "ulcerative", "colitis", "(", "UC", ")", ",", "although", "its", "mechanism", "of", "action", "has", "not", "been", "established", ".", "OBJECTIVE", "To", "examine", "the", "effect", "of", "a", "solution", "of", "nicotine", "on", "sustained", "resting", "pressure", "(", "tone", ")", "and", "contractile", "activity", "in", "the", "human", "colon", ".", "METHODS", "Ten", "healthy", "volunteers", ",", "and", "seven", "with", "UC", "in", "symptomatic", "remission", "took", "part", ";", "all", "were", "non", "-", "smokers", ".", "All", "17", "subjects", "were", "given", "nicotine", "or", "placebo", "solution", "on", "two", "separate", "occasions", "in", "a", "randomized", "sequence", ".", "A", "water", "-", "perfused", "manometry", "catheter", ",", "with", "openings", "at", "5", ",", "10", "and", "15", "cm", "from", "the", "tip", ",", "was", "placed", "by", "rigid", "sigmoidoscopy", "in", "the", "recto", "-", "sigmoid", "region", ".", "Baseline", "tone", "and", "activity", "were", "measured", "for", "15", "min", "prior", "to", "instillation", "of", "20", "ml", "of", "saline", "alone", "or", "with", "nicotine", ",", "1.2", "mg", ",", "at", "pH", "4.5", ".", "Observations", "were", "made", "over", "the", "subsequent", "15", "-", "20", "min", ".", "RESULTS", "Baseline", "spontaneous", "activity", "in", "all", "subjects", "showed", "both", "high-", "and", "low", "-", "frequency", "components", ";", "in", "three", "patients", "with", "UC", ",", "the", "low", "-", "frequency", "activity", "was", "of", "high", "amplitude", ".", "The", "nicotine", "reduced", "both", "tone", "and", "activity", "in", "all", "subjects", ",", "with", "reduction", "or", "abolition", "of", "the", "large", "contractions", "in", "UC", ".", "Tone", "in", "all", "17", "subjects", "was", "reduced", "significantly", "at", "3", "min", "after", "nicotine", "(", "P", "=", "0.000015", ",", "sign", "test", ")", ";", "the", "rate", "of", "recovery", "varied", "in", "individuals", ".", "Results", "from", "normals", "and", "UC", "did", "not", "differ", "significantly", "from", "each", "other", ".", "No", "significant", "change", "in", "tone", "or", "activity", "was", "observed", "with", "the", "saline", "solution", ".", "CONCLUSION", "Intra", "-", "luminal", "nicotine", "significantly", "reduces", "both", "smooth", "muscle", "tone", "and", "contractile", "activity", "in", "the", "recto", "-", "sigmoid", "colon", "in", "both", "normal", "subjects", "and", "patients", "with", "UC", "." ]	[ "Outcome_Physical", "Intervention_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control" ]
severe is a Qualifier, coronary artery disease , heart failure , kidney failure is a Scope, insulin - dependent DM is a Condition, diabetes mellitus is a Condition, poorly controlled is a Qualifier, type II DM is a Condition, duodenal ulcer is a Condition, allergy / contra - indication is a Scope, drug used in the study is a Drug, corticosteroid is a Drug, during last 3 months is a Temporal, preoperative is a Temporal, opioid drugs is a Drug, excl . is a Negation, codeine , tramadol is a Scope, neuropathy / sensory impairment is a Scope, lower limbs is a Qualifier, lack of co - operation is a Observation, inability to use is a Condition	NCT03034733_exc_task0	Sentence: severe coronary artery disease, heart failure, kidney failure insulin-dependent DM (diabetes mellitus), poorly controlled type II DM gastric/duodenal ulcer allergy/contra-indication for any drug used in the study corticosteroid use during last 3 months preoperative use of opioid drugs (excl. codeine, tramadol) neuropathy/sensory impairment of lower limbs lack of co-operation, e.g. inability to use a PCA (patient controlled analgesia)-device Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Observation, Negation, Scope, Drug	[ "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "O", "O", "B-Drug", "I-Drug", "O", "B-Negation", "I-Negation", "B-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Qualifier", "I-Qualifier", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O" ]	severe coronary artery disease, heart failure, kidney failure insulin-dependent DM (diabetes mellitus), poorly controlled type II DM gastric/duodenal ulcer allergy/contra-indication for any drug used in the study corticosteroid use during last 3 months preoperative use of opioid drugs (excl. codeine, tramadol) neuropathy/sensory impairment of lower limbs lack of co-operation, e.g. inability to use a PCA (patient controlled analgesia)-device	[ "severe", "coronary", "artery", "disease", ",", "heart", "failure", ",", "kidney", "failure", "\n", "insulin", "-", "dependent", "DM", "(", "diabetes", "mellitus", ")", ",", "poorly", "controlled", "type", "II", "DM", "\n", "gastric", "/", "duodenal", "ulcer", "\n", "allergy", "/", "contra", "-", "indication", "for", "any", "drug", "used", "in", "the", "study", "\n", "corticosteroid", "use", "during", "last", "3", "months", "\n", "preoperative", "use", "of", "opioid", "drugs", "(", "excl", ".", "codeine", ",", "tramadol", ")", "\n", "neuropathy", "/", "sensory", "impairment", "of", "lower", "limbs", "\n", "lack", "of", "co", "-", "operation", ",", "e.g", ".", "inability", "to", "use", "a", "PCA", "(", "patient", "controlled", "analgesia)-device", "\n" ]	[ "Scope", "Condition", "Drug", "Temporal", "Observation", "Qualifier", "Negation", "Device" ]
severe is a Qualifier, coronary artery disease , heart failure , kidney failure is a Scope, insulin - dependent DM is a Condition, diabetes mellitus is a Condition, poorly controlled is a Qualifier, type II DM is a Condition, duodenal ulcer is a Condition, allergy / contra - indication is a Scope, drug used in the study is a Drug, corticosteroid is a Drug, during last 3 months is a Temporal, preoperative is a Temporal, opioid drugs is a Drug, excl . is a Negation, codeine , tramadol is a Scope, neuropathy / sensory impairment is a Scope, lower limbs is a Qualifier, lack of co - operation is a Observation, inability to use is a Condition	NCT03034733_exc_task1	Sentence: severe coronary artery disease, heart failure, kidney failure insulin-dependent DM (diabetes mellitus), poorly controlled type II DM gastric/duodenal ulcer allergy/contra-indication for any drug used in the study corticosteroid use during last 3 months preoperative use of opioid drugs (excl. codeine, tramadol) neuropathy/sensory impairment of lower limbs lack of co-operation, e.g. inability to use a PCA (patient controlled analgesia)-device Instructions: please typing these entity words according to sentence: severe, coronary artery disease , heart failure , kidney failure, insulin - dependent DM, diabetes mellitus, poorly controlled, type II DM, duodenal ulcer, allergy / contra - indication, drug used in the study, corticosteroid, during last 3 months, preoperative, opioid drugs, excl ., codeine , tramadol, neuropathy / sensory impairment, lower limbs, lack of co - operation, inability to use Options: Temporal, Condition, Qualifier, Observation, Negation, Scope, Drug	[ "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "O", "O", "B-Drug", "I-Drug", "O", "B-Negation", "I-Negation", "B-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Qualifier", "I-Qualifier", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O" ]	severe coronary artery disease, heart failure, kidney failure insulin-dependent DM (diabetes mellitus), poorly controlled type II DM gastric/duodenal ulcer allergy/contra-indication for any drug used in the study corticosteroid use during last 3 months preoperative use of opioid drugs (excl. codeine, tramadol) neuropathy/sensory impairment of lower limbs lack of co-operation, e.g. inability to use a PCA (patient controlled analgesia)-device	[ "severe", "coronary", "artery", "disease", ",", "heart", "failure", ",", "kidney", "failure", "\n", "insulin", "-", "dependent", "DM", "(", "diabetes", "mellitus", ")", ",", "poorly", "controlled", "type", "II", "DM", "\n", "gastric", "/", "duodenal", "ulcer", "\n", "allergy", "/", "contra", "-", "indication", "for", "any", "drug", "used", "in", "the", "study", "\n", "corticosteroid", "use", "during", "last", "3", "months", "\n", "preoperative", "use", "of", "opioid", "drugs", "(", "excl", ".", "codeine", ",", "tramadol", ")", "\n", "neuropathy", "/", "sensory", "impairment", "of", "lower", "limbs", "\n", "lack", "of", "co", "-", "operation", ",", "e.g", ".", "inability", "to", "use", "a", "PCA", "(", "patient", "controlled", "analgesia)-device", "\n" ]	[ "Scope", "Condition", "Drug", "Temporal", "Observation", "Qualifier", "Negation", "Device" ]
severe, coronary artery disease , heart failure , kidney failure, insulin - dependent DM, diabetes mellitus, poorly controlled, type II DM, duodenal ulcer, allergy / contra - indication, drug used in the study, corticosteroid, during last 3 months, preoperative, opioid drugs, excl ., codeine , tramadol, neuropathy / sensory impairment, lower limbs, lack of co - operation, inability to use	NCT03034733_exc_task2	Sentence: severe coronary artery disease, heart failure, kidney failure insulin-dependent DM (diabetes mellitus), poorly controlled type II DM gastric/duodenal ulcer allergy/contra-indication for any drug used in the study corticosteroid use during last 3 months preoperative use of opioid drugs (excl. codeine, tramadol) neuropathy/sensory impairment of lower limbs lack of co-operation, e.g. inability to use a PCA (patient controlled analgesia)-device Instructions: please extract entity words from the input sentence	[ "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "O", "O", "B-Drug", "I-Drug", "O", "B-Negation", "I-Negation", "B-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Qualifier", "I-Qualifier", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O" ]	severe coronary artery disease, heart failure, kidney failure insulin-dependent DM (diabetes mellitus), poorly controlled type II DM gastric/duodenal ulcer allergy/contra-indication for any drug used in the study corticosteroid use during last 3 months preoperative use of opioid drugs (excl. codeine, tramadol) neuropathy/sensory impairment of lower limbs lack of co-operation, e.g. inability to use a PCA (patient controlled analgesia)-device	[ "severe", "coronary", "artery", "disease", ",", "heart", "failure", ",", "kidney", "failure", "\n", "insulin", "-", "dependent", "DM", "(", "diabetes", "mellitus", ")", ",", "poorly", "controlled", "type", "II", "DM", "\n", "gastric", "/", "duodenal", "ulcer", "\n", "allergy", "/", "contra", "-", "indication", "for", "any", "drug", "used", "in", "the", "study", "\n", "corticosteroid", "use", "during", "last", "3", "months", "\n", "preoperative", "use", "of", "opioid", "drugs", "(", "excl", ".", "codeine", ",", "tramadol", ")", "\n", "neuropathy", "/", "sensory", "impairment", "of", "lower", "limbs", "\n", "lack", "of", "co", "-", "operation", ",", "e.g", ".", "inability", "to", "use", "a", "PCA", "(", "patient", "controlled", "analgesia)-device", "\n" ]	[ "Scope", "Condition", "Drug", "Temporal", "Observation", "Qualifier", "Negation", "Device" ]
c - maf is a Protein, ubiquitin is a Protein, c - maf is a Protein, cyclin D2 is a Protein, c - maf is a Protein, c - maf is a Protein, cyclin D2 is a Protein, luciferase is a Protein, c - maf is a Protein, cyclin D2 is a Protein, c - maf is a Protein, c - maf is a Protein, ubiquitin C is a Protein, ubiquitin C is a Protein, c - maf is a Protein, ubiquitin is a Protein, c - maf is a Protein, ubiquitin is a Protein	262_task0	Sentence: A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. The oncogene c-maf is frequently overexpressed in multiple myeloma cell lines and patient samples and contributes to increased cellular proliferation in part by inducing cyclin D2 expression. To identify regulators of c-maf, we developed a chemical screen in NIH3T3 cells stably overexpressing c-maf and the cyclin D2 promoter driving luciferase. From a screen of 2400 off-patent drugs and chemicals, we identified glucocorticoids as c-maf-dependent inhibitors of cyclin D2 transactivation. In multiple myeloma cell lines, glucocorticoids reduced levels of c-maf protein without influencing corresponding mRNA levels. Subsequent studies demonstrated that glucocorticoids increased ubiquitination-dependent degradation of c-maf and up-regulated ubiquitin C mRNA. Moreover, ectopic expression of ubiquitin C recapitulated the effects of glucocorticoids, demonstrating regulation of c-maf protein through the abundance of the ubiquitin substrate. Thus, using a chemical biology approach, we identified a novel mechanism of action of glucocorticoids and a novel mechanism by which levels of c-maf protein are regulated by the abundance of the ubiquitin substrate. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O" ]	A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. The oncogene c-maf is frequently overexpressed in multiple myeloma cell lines and patient samples and contributes to increased cellular proliferation in part by inducing cyclin D2 expression. To identify regulators of c-maf, we developed a chemical screen in NIH3T3 cells stably overexpressing c-maf and the cyclin D2 promoter driving luciferase. From a screen of 2400 off-patent drugs and chemicals, we identified glucocorticoids as c-maf-dependent inhibitors of cyclin D2 transactivation. In multiple myeloma cell lines, glucocorticoids reduced levels of c-maf protein without influencing corresponding mRNA levels. Subsequent studies demonstrated that glucocorticoids increased ubiquitination-dependent degradation of c-maf and up-regulated ubiquitin C mRNA. Moreover, ectopic expression of ubiquitin C recapitulated the effects of glucocorticoids, demonstrating regulation of c-maf protein through the abundance of the ubiquitin substrate. Thus, using a chemical biology approach, we identified a novel mechanism of action of glucocorticoids and a novel mechanism by which levels of c-maf protein are regulated by the abundance of the ubiquitin substrate.	[ "A", "chemical", "biology", "screen", "identifies", "glucocorticoids", "that", "regulate", "c", "-", "maf", "expression", "by", "increasing", "its", "proteasomal", "degradation", "through", "up", "-", "regulation", "of", "ubiquitin", ".", "\n", "The", "oncogene", "c", "-", "maf", "is", "frequently", "overexpressed", "in", "multiple", "myeloma", "cell", "lines", "and", "patient", "samples", "and", "contributes", "to", "increased", "cellular", "proliferation", "in", "part", "by", "inducing", "cyclin", "D2", "expression", ".", "To", "identify", "regulators", "of", "c", "-", "maf", ",", "we", "developed", "a", "chemical", "screen", "in", "NIH3T3", "cells", "stably", "overexpressing", "c", "-", "maf", "and", "the", "cyclin", "D2", "promoter", "driving", "luciferase", ".", "From", "a", "screen", "of", "2400", "off", "-", "patent", "drugs", "and", "chemicals", ",", "we", "identified", "glucocorticoids", "as", "c", "-", "maf", "-", "dependent", "inhibitors", "of", "cyclin", "D2", "transactivation", ".", "In", "multiple", "myeloma", "cell", "lines", ",", "glucocorticoids", "reduced", "levels", "of", "c", "-", "maf", "protein", "without", "influencing", "corresponding", "mRNA", "levels", ".", "Subsequent", "studies", "demonstrated", "that", "glucocorticoids", "increased", "ubiquitination", "-", "dependent", "degradation", "of", "c", "-", "maf", "and", "up", "-", "regulated", "ubiquitin", "C", "mRNA", ".", "Moreover", ",", "ectopic", "expression", "of", "ubiquitin", "C", "recapitulated", "the", "effects", "of", "glucocorticoids", ",", "demonstrating", "regulation", "of", "c", "-", "maf", "protein", "through", "the", "abundance", "of", "the", "ubiquitin", "substrate", ".", "Thus", ",", "using", "a", "chemical", "biology", "approach", ",", "we", "identified", "a", "novel", "mechanism", "of", "action", "of", "glucocorticoids", "and", "a", "novel", "mechanism", "by", "which", "levels", "of", "c", "-", "maf", "protein", "are", "regulated", "by", "the", "abundance", "of", "the", "ubiquitin", "substrate", ".", "\n" ]	[ "Protein" ]
c - maf is a Protein, ubiquitin is a Protein, c - maf is a Protein, cyclin D2 is a Protein, c - maf is a Protein, c - maf is a Protein, cyclin D2 is a Protein, luciferase is a Protein, c - maf is a Protein, cyclin D2 is a Protein, c - maf is a Protein, c - maf is a Protein, ubiquitin C is a Protein, ubiquitin C is a Protein, c - maf is a Protein, ubiquitin is a Protein, c - maf is a Protein, ubiquitin is a Protein	262_task1	Sentence: A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. The oncogene c-maf is frequently overexpressed in multiple myeloma cell lines and patient samples and contributes to increased cellular proliferation in part by inducing cyclin D2 expression. To identify regulators of c-maf, we developed a chemical screen in NIH3T3 cells stably overexpressing c-maf and the cyclin D2 promoter driving luciferase. From a screen of 2400 off-patent drugs and chemicals, we identified glucocorticoids as c-maf-dependent inhibitors of cyclin D2 transactivation. In multiple myeloma cell lines, glucocorticoids reduced levels of c-maf protein without influencing corresponding mRNA levels. Subsequent studies demonstrated that glucocorticoids increased ubiquitination-dependent degradation of c-maf and up-regulated ubiquitin C mRNA. Moreover, ectopic expression of ubiquitin C recapitulated the effects of glucocorticoids, demonstrating regulation of c-maf protein through the abundance of the ubiquitin substrate. Thus, using a chemical biology approach, we identified a novel mechanism of action of glucocorticoids and a novel mechanism by which levels of c-maf protein are regulated by the abundance of the ubiquitin substrate. Instructions: please typing these entity words according to sentence: c - maf, ubiquitin, c - maf, cyclin D2, c - maf, c - maf, cyclin D2, luciferase, c - maf, cyclin D2, c - maf, c - maf, ubiquitin C, ubiquitin C, c - maf, ubiquitin, c - maf, ubiquitin Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O" ]	A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. The oncogene c-maf is frequently overexpressed in multiple myeloma cell lines and patient samples and contributes to increased cellular proliferation in part by inducing cyclin D2 expression. To identify regulators of c-maf, we developed a chemical screen in NIH3T3 cells stably overexpressing c-maf and the cyclin D2 promoter driving luciferase. From a screen of 2400 off-patent drugs and chemicals, we identified glucocorticoids as c-maf-dependent inhibitors of cyclin D2 transactivation. In multiple myeloma cell lines, glucocorticoids reduced levels of c-maf protein without influencing corresponding mRNA levels. Subsequent studies demonstrated that glucocorticoids increased ubiquitination-dependent degradation of c-maf and up-regulated ubiquitin C mRNA. Moreover, ectopic expression of ubiquitin C recapitulated the effects of glucocorticoids, demonstrating regulation of c-maf protein through the abundance of the ubiquitin substrate. Thus, using a chemical biology approach, we identified a novel mechanism of action of glucocorticoids and a novel mechanism by which levels of c-maf protein are regulated by the abundance of the ubiquitin substrate.	[ "A", "chemical", "biology", "screen", "identifies", "glucocorticoids", "that", "regulate", "c", "-", "maf", "expression", "by", "increasing", "its", "proteasomal", "degradation", "through", "up", "-", "regulation", "of", "ubiquitin", ".", "\n", "The", "oncogene", "c", "-", "maf", "is", "frequently", "overexpressed", "in", "multiple", "myeloma", "cell", "lines", "and", "patient", "samples", "and", "contributes", "to", "increased", "cellular", "proliferation", "in", "part", "by", "inducing", "cyclin", "D2", "expression", ".", "To", "identify", "regulators", "of", "c", "-", "maf", ",", "we", "developed", "a", "chemical", "screen", "in", "NIH3T3", "cells", "stably", "overexpressing", "c", "-", "maf", "and", "the", "cyclin", "D2", "promoter", "driving", "luciferase", ".", "From", "a", "screen", "of", "2400", "off", "-", "patent", "drugs", "and", "chemicals", ",", "we", "identified", "glucocorticoids", "as", "c", "-", "maf", "-", "dependent", "inhibitors", "of", "cyclin", "D2", "transactivation", ".", "In", "multiple", "myeloma", "cell", "lines", ",", "glucocorticoids", "reduced", "levels", "of", "c", "-", "maf", "protein", "without", "influencing", "corresponding", "mRNA", "levels", ".", "Subsequent", "studies", "demonstrated", "that", "glucocorticoids", "increased", "ubiquitination", "-", "dependent", "degradation", "of", "c", "-", "maf", "and", "up", "-", "regulated", "ubiquitin", "C", "mRNA", ".", "Moreover", ",", "ectopic", "expression", "of", "ubiquitin", "C", "recapitulated", "the", "effects", "of", "glucocorticoids", ",", "demonstrating", "regulation", "of", "c", "-", "maf", "protein", "through", "the", "abundance", "of", "the", "ubiquitin", "substrate", ".", "Thus", ",", "using", "a", "chemical", "biology", "approach", ",", "we", "identified", "a", "novel", "mechanism", "of", "action", "of", "glucocorticoids", "and", "a", "novel", "mechanism", "by", "which", "levels", "of", "c", "-", "maf", "protein", "are", "regulated", "by", "the", "abundance", "of", "the", "ubiquitin", "substrate", ".", "\n" ]	[ "Protein" ]
c - maf, ubiquitin, c - maf, cyclin D2, c - maf, c - maf, cyclin D2, luciferase, c - maf, cyclin D2, c - maf, c - maf, ubiquitin C, ubiquitin C, c - maf, ubiquitin, c - maf, ubiquitin	262_task2	Sentence: A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. The oncogene c-maf is frequently overexpressed in multiple myeloma cell lines and patient samples and contributes to increased cellular proliferation in part by inducing cyclin D2 expression. To identify regulators of c-maf, we developed a chemical screen in NIH3T3 cells stably overexpressing c-maf and the cyclin D2 promoter driving luciferase. From a screen of 2400 off-patent drugs and chemicals, we identified glucocorticoids as c-maf-dependent inhibitors of cyclin D2 transactivation. In multiple myeloma cell lines, glucocorticoids reduced levels of c-maf protein without influencing corresponding mRNA levels. Subsequent studies demonstrated that glucocorticoids increased ubiquitination-dependent degradation of c-maf and up-regulated ubiquitin C mRNA. Moreover, ectopic expression of ubiquitin C recapitulated the effects of glucocorticoids, demonstrating regulation of c-maf protein through the abundance of the ubiquitin substrate. Thus, using a chemical biology approach, we identified a novel mechanism of action of glucocorticoids and a novel mechanism by which levels of c-maf protein are regulated by the abundance of the ubiquitin substrate. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O" ]	A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. The oncogene c-maf is frequently overexpressed in multiple myeloma cell lines and patient samples and contributes to increased cellular proliferation in part by inducing cyclin D2 expression. To identify regulators of c-maf, we developed a chemical screen in NIH3T3 cells stably overexpressing c-maf and the cyclin D2 promoter driving luciferase. From a screen of 2400 off-patent drugs and chemicals, we identified glucocorticoids as c-maf-dependent inhibitors of cyclin D2 transactivation. In multiple myeloma cell lines, glucocorticoids reduced levels of c-maf protein without influencing corresponding mRNA levels. Subsequent studies demonstrated that glucocorticoids increased ubiquitination-dependent degradation of c-maf and up-regulated ubiquitin C mRNA. Moreover, ectopic expression of ubiquitin C recapitulated the effects of glucocorticoids, demonstrating regulation of c-maf protein through the abundance of the ubiquitin substrate. Thus, using a chemical biology approach, we identified a novel mechanism of action of glucocorticoids and a novel mechanism by which levels of c-maf protein are regulated by the abundance of the ubiquitin substrate.	[ "A", "chemical", "biology", "screen", "identifies", "glucocorticoids", "that", "regulate", "c", "-", "maf", "expression", "by", "increasing", "its", "proteasomal", "degradation", "through", "up", "-", "regulation", "of", "ubiquitin", ".", "\n", "The", "oncogene", "c", "-", "maf", "is", "frequently", "overexpressed", "in", "multiple", "myeloma", "cell", "lines", "and", "patient", "samples", "and", "contributes", "to", "increased", "cellular", "proliferation", "in", "part", "by", "inducing", "cyclin", "D2", "expression", ".", "To", "identify", "regulators", "of", "c", "-", "maf", ",", "we", "developed", "a", "chemical", "screen", "in", "NIH3T3", "cells", "stably", "overexpressing", "c", "-", "maf", "and", "the", "cyclin", "D2", "promoter", "driving", "luciferase", ".", "From", "a", "screen", "of", "2400", "off", "-", "patent", "drugs", "and", "chemicals", ",", "we", "identified", "glucocorticoids", "as", "c", "-", "maf", "-", "dependent", "inhibitors", "of", "cyclin", "D2", "transactivation", ".", "In", "multiple", "myeloma", "cell", "lines", ",", "glucocorticoids", "reduced", "levels", "of", "c", "-", "maf", "protein", "without", "influencing", "corresponding", "mRNA", "levels", ".", "Subsequent", "studies", "demonstrated", "that", "glucocorticoids", "increased", "ubiquitination", "-", "dependent", "degradation", "of", "c", "-", "maf", "and", "up", "-", "regulated", "ubiquitin", "C", "mRNA", ".", "Moreover", ",", "ectopic", "expression", "of", "ubiquitin", "C", "recapitulated", "the", "effects", "of", "glucocorticoids", ",", "demonstrating", "regulation", "of", "c", "-", "maf", "protein", "through", "the", "abundance", "of", "the", "ubiquitin", "substrate", ".", "Thus", ",", "using", "a", "chemical", "biology", "approach", ",", "we", "identified", "a", "novel", "mechanism", "of", "action", "of", "glucocorticoids", "and", "a", "novel", "mechanism", "by", "which", "levels", "of", "c", "-", "maf", "protein", "are", "regulated", "by", "the", "abundance", "of", "the", "ubiquitin", "substrate", ".", "\n" ]	[ "Protein" ]
GSK-3β is a protein, β - catenin is a protein, Axin is a protein	1.0alpha7.train.277_task0	Sentence: In this study, we identified binding domains of GSK-3β and β-catenin in Axin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "I-protein", "I-protein", "O", "B-protein", "O" ]	In this study, we identified binding domains of GSK-3β and β-catenin in Axin.	[ "In", "this", "study", ",", "we", "identified", "binding", "domains", "of", "GSK-3β", "and", "β", "-", "catenin", "in", "Axin", "." ]	[ "protein" ]
GSK-3β is a protein, β - catenin is a protein, Axin is a protein	1.0alpha7.train.277_task1	Sentence: In this study, we identified binding domains of GSK-3β and β-catenin in Axin. Instructions: please typing these entity words according to sentence: GSK-3β, β - catenin, Axin Options: protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "I-protein", "I-protein", "O", "B-protein", "O" ]	In this study, we identified binding domains of GSK-3β and β-catenin in Axin.	[ "In", "this", "study", ",", "we", "identified", "binding", "domains", "of", "GSK-3β", "and", "β", "-", "catenin", "in", "Axin", "." ]	[ "protein" ]
GSK-3β, β - catenin, Axin	1.0alpha7.train.277_task2	Sentence: In this study, we identified binding domains of GSK-3β and β-catenin in Axin. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "I-protein", "I-protein", "O", "B-protein", "O" ]	In this study, we identified binding domains of GSK-3β and β-catenin in Axin.	[ "In", "this", "study", ",", "we", "identified", "binding", "domains", "of", "GSK-3β", "and", "β", "-", "catenin", "in", "Axin", "." ]	[ "protein" ]
haemagglutinin - neuraminidase is a Protein, haemagglutinin - neuraminidase is a Protein, HN is a Protein, HN is a Protein, HN is a Protein, HN is a Protein, N - linked glycosylation sites is a Entity, HN is a Protein	107_task0	Sentence: Inhibition of fusion by neutralizing monoclonal antibodies to the haemagglutinin-neuraminidase glycoprotein of Newcastle disease virus. The majority of neutralizing monoclonal antibodies (MAbs) to the haemagglutinin-neuraminidase (HN) glycoprotein of Newcastle disease virus prevent attachment of the virus to cellular receptors and inhibits virion-induced fusion from without (FFWO) and fusion from within (FFWI) mediated by the virus glycoprotein-laden infected cell surface. For these antibodies, the inhibition of fusion is presumed to be the result of the prevention of HN-mediated bridging of potential fusion partners. MAbs against antigenic sites 3 and 4 neutralize virus infectivity, but by a mechanism other than the prevention of attachment, the exact nature of which remains to be established. Antibodies to both of these sites effectively inhibit virion-induced FFWO, even when the inducing virus is not infectious. This is consistent with the mechanism of neutralization of these MAbs involving the inhibition of an early, post-attachment step in infection. MAbs to site 3 also inhibit FFWI, but those to site 4 do not, even when added at high concentrations. This suggests that the requirement for HN may be different in the two modes of fusion. The epitopes recognized by MAbs to sites 3 and 4 have been delineated by the identification of individual nucleotide substitutions in the HN genes of neutralization escape variants. Some of the deduced amino acid substitutions result in additional N-linked glycosylation sites in HN, which are utilized and presumably account for the escape from neutralization. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Inhibition of fusion by neutralizing monoclonal antibodies to the haemagglutinin-neuraminidase glycoprotein of Newcastle disease virus. The majority of neutralizing monoclonal antibodies (MAbs) to the haemagglutinin-neuraminidase (HN) glycoprotein of Newcastle disease virus prevent attachment of the virus to cellular receptors and inhibits virion-induced fusion from without (FFWO) and fusion from within (FFWI) mediated by the virus glycoprotein-laden infected cell surface. For these antibodies, the inhibition of fusion is presumed to be the result of the prevention of HN-mediated bridging of potential fusion partners. MAbs against antigenic sites 3 and 4 neutralize virus infectivity, but by a mechanism other than the prevention of attachment, the exact nature of which remains to be established. Antibodies to both of these sites effectively inhibit virion-induced FFWO, even when the inducing virus is not infectious. This is consistent with the mechanism of neutralization of these MAbs involving the inhibition of an early, post-attachment step in infection. MAbs to site 3 also inhibit FFWI, but those to site 4 do not, even when added at high concentrations. This suggests that the requirement for HN may be different in the two modes of fusion. The epitopes recognized by MAbs to sites 3 and 4 have been delineated by the identification of individual nucleotide substitutions in the HN genes of neutralization escape variants. Some of the deduced amino acid substitutions result in additional N-linked glycosylation sites in HN, which are utilized and presumably account for the escape from neutralization.	[ "Inhibition", "of", "fusion", "by", "neutralizing", "monoclonal", "antibodies", "to", "the", "haemagglutinin", "-", "neuraminidase", "glycoprotein", "of", "Newcastle", "disease", "virus", ".", "\n", "The", "majority", "of", "neutralizing", "monoclonal", "antibodies", "(", "MAbs", ")", "to", "the", "haemagglutinin", "-", "neuraminidase", "(", "HN", ")", "glycoprotein", "of", "Newcastle", "disease", "virus", "prevent", "attachment", "of", "the", "virus", "to", "cellular", "receptors", "and", "inhibits", "virion", "-", "induced", "fusion", "from", "without", "(", "FFWO", ")", "and", "fusion", "from", "within", "(", "FFWI", ")", "mediated", "by", "the", "virus", "glycoprotein", "-", "laden", "infected", "cell", "surface", ".", "For", "these", "antibodies", ",", "the", "inhibition", "of", "fusion", "is", "presumed", "to", "be", "the", "result", "of", "the", "prevention", "of", "HN", "-", "mediated", "bridging", "of", "potential", "fusion", "partners", ".", "MAbs", "against", "antigenic", "sites", "3", "and", "4", "neutralize", "virus", "infectivity", ",", "but", "by", "a", "mechanism", "other", "than", "the", "prevention", "of", "attachment", ",", "the", "exact", "nature", "of", "which", "remains", "to", "be", "established", ".", "Antibodies", "to", "both", "of", "these", "sites", "effectively", "inhibit", "virion", "-", "induced", "FFWO", ",", "even", "when", "the", "inducing", "virus", "is", "not", "infectious", ".", "This", "is", "consistent", "with", "the", "mechanism", "of", "neutralization", "of", "these", "MAbs", "involving", "the", "inhibition", "of", "an", "early", ",", "post", "-", "attachment", "step", "in", "infection", ".", "MAbs", "to", "site", "3", "also", "inhibit", "FFWI", ",", "but", "those", "to", "site", "4", "do", "not", ",", "even", "when", "added", "at", "high", "concentrations", ".", "This", "suggests", "that", "the", "requirement", "for", "HN", "may", "be", "different", "in", "the", "two", "modes", "of", "fusion", ".", "The", "epitopes", "recognized", "by", "MAbs", "to", "sites", "3", "and", "4", "have", "been", "delineated", "by", "the", "identification", "of", "individual", "nucleotide", "substitutions", "in", "the", "HN", "genes", "of", "neutralization", "escape", "variants", ".", "Some", "of", "the", "deduced", "amino", "acid", "substitutions", "result", "in", "additional", "N", "-", "linked", "glycosylation", "sites", "in", "HN", ",", "which", "are", "utilized", "and", "presumably", "account", "for", "the", "escape", "from", "neutralization", ".", "\n" ]	[ "Protein", "Entity" ]
haemagglutinin - neuraminidase is a Protein, haemagglutinin - neuraminidase is a Protein, HN is a Protein, HN is a Protein, HN is a Protein, HN is a Protein, N - linked glycosylation sites is a Entity, HN is a Protein	107_task1	Sentence: Inhibition of fusion by neutralizing monoclonal antibodies to the haemagglutinin-neuraminidase glycoprotein of Newcastle disease virus. The majority of neutralizing monoclonal antibodies (MAbs) to the haemagglutinin-neuraminidase (HN) glycoprotein of Newcastle disease virus prevent attachment of the virus to cellular receptors and inhibits virion-induced fusion from without (FFWO) and fusion from within (FFWI) mediated by the virus glycoprotein-laden infected cell surface. For these antibodies, the inhibition of fusion is presumed to be the result of the prevention of HN-mediated bridging of potential fusion partners. MAbs against antigenic sites 3 and 4 neutralize virus infectivity, but by a mechanism other than the prevention of attachment, the exact nature of which remains to be established. Antibodies to both of these sites effectively inhibit virion-induced FFWO, even when the inducing virus is not infectious. This is consistent with the mechanism of neutralization of these MAbs involving the inhibition of an early, post-attachment step in infection. MAbs to site 3 also inhibit FFWI, but those to site 4 do not, even when added at high concentrations. This suggests that the requirement for HN may be different in the two modes of fusion. The epitopes recognized by MAbs to sites 3 and 4 have been delineated by the identification of individual nucleotide substitutions in the HN genes of neutralization escape variants. Some of the deduced amino acid substitutions result in additional N-linked glycosylation sites in HN, which are utilized and presumably account for the escape from neutralization. Instructions: please typing these entity words according to sentence: haemagglutinin - neuraminidase, haemagglutinin - neuraminidase, HN, HN, HN, HN, N - linked glycosylation sites, HN Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Inhibition of fusion by neutralizing monoclonal antibodies to the haemagglutinin-neuraminidase glycoprotein of Newcastle disease virus. The majority of neutralizing monoclonal antibodies (MAbs) to the haemagglutinin-neuraminidase (HN) glycoprotein of Newcastle disease virus prevent attachment of the virus to cellular receptors and inhibits virion-induced fusion from without (FFWO) and fusion from within (FFWI) mediated by the virus glycoprotein-laden infected cell surface. For these antibodies, the inhibition of fusion is presumed to be the result of the prevention of HN-mediated bridging of potential fusion partners. MAbs against antigenic sites 3 and 4 neutralize virus infectivity, but by a mechanism other than the prevention of attachment, the exact nature of which remains to be established. Antibodies to both of these sites effectively inhibit virion-induced FFWO, even when the inducing virus is not infectious. This is consistent with the mechanism of neutralization of these MAbs involving the inhibition of an early, post-attachment step in infection. MAbs to site 3 also inhibit FFWI, but those to site 4 do not, even when added at high concentrations. This suggests that the requirement for HN may be different in the two modes of fusion. The epitopes recognized by MAbs to sites 3 and 4 have been delineated by the identification of individual nucleotide substitutions in the HN genes of neutralization escape variants. Some of the deduced amino acid substitutions result in additional N-linked glycosylation sites in HN, which are utilized and presumably account for the escape from neutralization.	[ "Inhibition", "of", "fusion", "by", "neutralizing", "monoclonal", "antibodies", "to", "the", "haemagglutinin", "-", "neuraminidase", "glycoprotein", "of", "Newcastle", "disease", "virus", ".", "\n", "The", "majority", "of", "neutralizing", "monoclonal", "antibodies", "(", "MAbs", ")", "to", "the", "haemagglutinin", "-", "neuraminidase", "(", "HN", ")", "glycoprotein", "of", "Newcastle", "disease", "virus", "prevent", "attachment", "of", "the", "virus", "to", "cellular", "receptors", "and", "inhibits", "virion", "-", "induced", "fusion", "from", "without", "(", "FFWO", ")", "and", "fusion", "from", "within", "(", "FFWI", ")", "mediated", "by", "the", "virus", "glycoprotein", "-", "laden", "infected", "cell", "surface", ".", "For", "these", "antibodies", ",", "the", "inhibition", "of", "fusion", "is", "presumed", "to", "be", "the", "result", "of", "the", "prevention", "of", "HN", "-", "mediated", "bridging", "of", "potential", "fusion", "partners", ".", "MAbs", "against", "antigenic", "sites", "3", "and", "4", "neutralize", "virus", "infectivity", ",", "but", "by", "a", "mechanism", "other", "than", "the", "prevention", "of", "attachment", ",", "the", "exact", "nature", "of", "which", "remains", "to", "be", "established", ".", "Antibodies", "to", "both", "of", "these", "sites", "effectively", "inhibit", "virion", "-", "induced", "FFWO", ",", "even", "when", "the", "inducing", "virus", "is", "not", "infectious", ".", "This", "is", "consistent", "with", "the", "mechanism", "of", "neutralization", "of", "these", "MAbs", "involving", "the", "inhibition", "of", "an", "early", ",", "post", "-", "attachment", "step", "in", "infection", ".", "MAbs", "to", "site", "3", "also", "inhibit", "FFWI", ",", "but", "those", "to", "site", "4", "do", "not", ",", "even", "when", "added", "at", "high", "concentrations", ".", "This", "suggests", "that", "the", "requirement", "for", "HN", "may", "be", "different", "in", "the", "two", "modes", "of", "fusion", ".", "The", "epitopes", "recognized", "by", "MAbs", "to", "sites", "3", "and", "4", "have", "been", "delineated", "by", "the", "identification", "of", "individual", "nucleotide", "substitutions", "in", "the", "HN", "genes", "of", "neutralization", "escape", "variants", ".", "Some", "of", "the", "deduced", "amino", "acid", "substitutions", "result", "in", "additional", "N", "-", "linked", "glycosylation", "sites", "in", "HN", ",", "which", "are", "utilized", "and", "presumably", "account", "for", "the", "escape", "from", "neutralization", ".", "\n" ]	[ "Protein", "Entity" ]
haemagglutinin - neuraminidase, haemagglutinin - neuraminidase, HN, HN, HN, HN, N - linked glycosylation sites, HN	107_task2	Sentence: Inhibition of fusion by neutralizing monoclonal antibodies to the haemagglutinin-neuraminidase glycoprotein of Newcastle disease virus. The majority of neutralizing monoclonal antibodies (MAbs) to the haemagglutinin-neuraminidase (HN) glycoprotein of Newcastle disease virus prevent attachment of the virus to cellular receptors and inhibits virion-induced fusion from without (FFWO) and fusion from within (FFWI) mediated by the virus glycoprotein-laden infected cell surface. For these antibodies, the inhibition of fusion is presumed to be the result of the prevention of HN-mediated bridging of potential fusion partners. MAbs against antigenic sites 3 and 4 neutralize virus infectivity, but by a mechanism other than the prevention of attachment, the exact nature of which remains to be established. Antibodies to both of these sites effectively inhibit virion-induced FFWO, even when the inducing virus is not infectious. This is consistent with the mechanism of neutralization of these MAbs involving the inhibition of an early, post-attachment step in infection. MAbs to site 3 also inhibit FFWI, but those to site 4 do not, even when added at high concentrations. This suggests that the requirement for HN may be different in the two modes of fusion. The epitopes recognized by MAbs to sites 3 and 4 have been delineated by the identification of individual nucleotide substitutions in the HN genes of neutralization escape variants. Some of the deduced amino acid substitutions result in additional N-linked glycosylation sites in HN, which are utilized and presumably account for the escape from neutralization. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Inhibition of fusion by neutralizing monoclonal antibodies to the haemagglutinin-neuraminidase glycoprotein of Newcastle disease virus. The majority of neutralizing monoclonal antibodies (MAbs) to the haemagglutinin-neuraminidase (HN) glycoprotein of Newcastle disease virus prevent attachment of the virus to cellular receptors and inhibits virion-induced fusion from without (FFWO) and fusion from within (FFWI) mediated by the virus glycoprotein-laden infected cell surface. For these antibodies, the inhibition of fusion is presumed to be the result of the prevention of HN-mediated bridging of potential fusion partners. MAbs against antigenic sites 3 and 4 neutralize virus infectivity, but by a mechanism other than the prevention of attachment, the exact nature of which remains to be established. Antibodies to both of these sites effectively inhibit virion-induced FFWO, even when the inducing virus is not infectious. This is consistent with the mechanism of neutralization of these MAbs involving the inhibition of an early, post-attachment step in infection. MAbs to site 3 also inhibit FFWI, but those to site 4 do not, even when added at high concentrations. This suggests that the requirement for HN may be different in the two modes of fusion. The epitopes recognized by MAbs to sites 3 and 4 have been delineated by the identification of individual nucleotide substitutions in the HN genes of neutralization escape variants. Some of the deduced amino acid substitutions result in additional N-linked glycosylation sites in HN, which are utilized and presumably account for the escape from neutralization.	[ "Inhibition", "of", "fusion", "by", "neutralizing", "monoclonal", "antibodies", "to", "the", "haemagglutinin", "-", "neuraminidase", "glycoprotein", "of", "Newcastle", "disease", "virus", ".", "\n", "The", "majority", "of", "neutralizing", "monoclonal", "antibodies", "(", "MAbs", ")", "to", "the", "haemagglutinin", "-", "neuraminidase", "(", "HN", ")", "glycoprotein", "of", "Newcastle", "disease", "virus", "prevent", "attachment", "of", "the", "virus", "to", "cellular", "receptors", "and", "inhibits", "virion", "-", "induced", "fusion", "from", "without", "(", "FFWO", ")", "and", "fusion", "from", "within", "(", "FFWI", ")", "mediated", "by", "the", "virus", "glycoprotein", "-", "laden", "infected", "cell", "surface", ".", "For", "these", "antibodies", ",", "the", "inhibition", "of", "fusion", "is", "presumed", "to", "be", "the", "result", "of", "the", "prevention", "of", "HN", "-", "mediated", "bridging", "of", "potential", "fusion", "partners", ".", "MAbs", "against", "antigenic", "sites", "3", "and", "4", "neutralize", "virus", "infectivity", ",", "but", "by", "a", "mechanism", "other", "than", "the", "prevention", "of", "attachment", ",", "the", "exact", "nature", "of", "which", "remains", "to", "be", "established", ".", "Antibodies", "to", "both", "of", "these", "sites", "effectively", "inhibit", "virion", "-", "induced", "FFWO", ",", "even", "when", "the", "inducing", "virus", "is", "not", "infectious", ".", "This", "is", "consistent", "with", "the", "mechanism", "of", "neutralization", "of", "these", "MAbs", "involving", "the", "inhibition", "of", "an", "early", ",", "post", "-", "attachment", "step", "in", "infection", ".", "MAbs", "to", "site", "3", "also", "inhibit", "FFWI", ",", "but", "those", "to", "site", "4", "do", "not", ",", "even", "when", "added", "at", "high", "concentrations", ".", "This", "suggests", "that", "the", "requirement", "for", "HN", "may", "be", "different", "in", "the", "two", "modes", "of", "fusion", ".", "The", "epitopes", "recognized", "by", "MAbs", "to", "sites", "3", "and", "4", "have", "been", "delineated", "by", "the", "identification", "of", "individual", "nucleotide", "substitutions", "in", "the", "HN", "genes", "of", "neutralization", "escape", "variants", ".", "Some", "of", "the", "deduced", "amino", "acid", "substitutions", "result", "in", "additional", "N", "-", "linked", "glycosylation", "sites", "in", "HN", ",", "which", "are", "utilized", "and", "presumably", "account", "for", "the", "escape", "from", "neutralization", ".", "\n" ]	[ "Protein", "Entity" ]
FKBP52 is a protein, dynein is a protein-family, dynein is a protein-family, FKBP52 is a protein, PPIase is a protein-domain, TPR is a protein-domain, FKBP52 is a protein, hsp90 is a protein	1.0alpha7.train.642_task0	Sentence: Immunoadsorption of FKBP52 from reticulocyte lysate also yields co-immunoadsorption of cytoplasmic dynein, and we show that co-immunoadsorption of dynein is competed by a fragment of FKBP52 containing its PPIase domain, but not by a TPR domain fragment that blocks FKBP52 binding to hsp90. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-domain, protein-family, protein	[ "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein-domain", "O", "O", "O", "O", "O", "O", "B-protein-domain", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O" ]	Immunoadsorption of FKBP52 from reticulocyte lysate also yields co-immunoadsorption of cytoplasmic dynein, and we show that co-immunoadsorption of dynein is competed by a fragment of FKBP52 containing its PPIase domain, but not by a TPR domain fragment that blocks FKBP52 binding to hsp90.	[ "Immunoadsorption", "of", "FKBP52", "from", "reticulocyte", "lysate", "also", "yields", "co", "-", "immunoadsorption", "of", "cytoplasmic", "dynein", ",", "and", "we", "show", "that", "co", "-", "immunoadsorption", "of", "dynein", "is", "competed", "by", "a", "fragment", "of", "FKBP52", "containing", "its", "PPIase", "domain", ",", "but", "not", "by", "a", "TPR", "domain", "fragment", "that", "blocks", "FKBP52", "binding", "to", "hsp90", "." ]	[ "protein", "protein-family", "protein-domain" ]
FKBP52 is a protein, dynein is a protein-family, dynein is a protein-family, FKBP52 is a protein, PPIase is a protein-domain, TPR is a protein-domain, FKBP52 is a protein, hsp90 is a protein	1.0alpha7.train.642_task1	Sentence: Immunoadsorption of FKBP52 from reticulocyte lysate also yields co-immunoadsorption of cytoplasmic dynein, and we show that co-immunoadsorption of dynein is competed by a fragment of FKBP52 containing its PPIase domain, but not by a TPR domain fragment that blocks FKBP52 binding to hsp90. Instructions: please typing these entity words according to sentence: FKBP52, dynein, dynein, FKBP52, PPIase, TPR, FKBP52, hsp90 Options: protein-domain, protein-family, protein	[ "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein-domain", "O", "O", "O", "O", "O", "O", "B-protein-domain", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O" ]	Immunoadsorption of FKBP52 from reticulocyte lysate also yields co-immunoadsorption of cytoplasmic dynein, and we show that co-immunoadsorption of dynein is competed by a fragment of FKBP52 containing its PPIase domain, but not by a TPR domain fragment that blocks FKBP52 binding to hsp90.	[ "Immunoadsorption", "of", "FKBP52", "from", "reticulocyte", "lysate", "also", "yields", "co", "-", "immunoadsorption", "of", "cytoplasmic", "dynein", ",", "and", "we", "show", "that", "co", "-", "immunoadsorption", "of", "dynein", "is", "competed", "by", "a", "fragment", "of", "FKBP52", "containing", "its", "PPIase", "domain", ",", "but", "not", "by", "a", "TPR", "domain", "fragment", "that", "blocks", "FKBP52", "binding", "to", "hsp90", "." ]	[ "protein", "protein-family", "protein-domain" ]
FKBP52, dynein, dynein, FKBP52, PPIase, TPR, FKBP52, hsp90	1.0alpha7.train.642_task2	Sentence: Immunoadsorption of FKBP52 from reticulocyte lysate also yields co-immunoadsorption of cytoplasmic dynein, and we show that co-immunoadsorption of dynein is competed by a fragment of FKBP52 containing its PPIase domain, but not by a TPR domain fragment that blocks FKBP52 binding to hsp90. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein-domain", "O", "O", "O", "O", "O", "O", "B-protein-domain", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O" ]	Immunoadsorption of FKBP52 from reticulocyte lysate also yields co-immunoadsorption of cytoplasmic dynein, and we show that co-immunoadsorption of dynein is competed by a fragment of FKBP52 containing its PPIase domain, but not by a TPR domain fragment that blocks FKBP52 binding to hsp90.	[ "Immunoadsorption", "of", "FKBP52", "from", "reticulocyte", "lysate", "also", "yields", "co", "-", "immunoadsorption", "of", "cytoplasmic", "dynein", ",", "and", "we", "show", "that", "co", "-", "immunoadsorption", "of", "dynein", "is", "competed", "by", "a", "fragment", "of", "FKBP52", "containing", "its", "PPIase", "domain", ",", "but", "not", "by", "a", "TPR", "domain", "fragment", "that", "blocks", "FKBP52", "binding", "to", "hsp90", "." ]	[ "protein", "protein-family", "protein-domain" ]
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone is a CHEMICAL, nitric oxide is a CHEMICAL, NF - κB is a GENE-N, heme oxygenase-1 is a GENE-Y, 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone is a CHEMICAL, 5HHMF is a CHEMICAL, NO is a CHEMICAL, inducible NO synthase is a GENE-Y, iNOS is a GENE-Y, 5HHMF is a CHEMICAL, IκB is a GENE-N, nuclear factor - κB is a GENE-N, NF - κB is a GENE-N, p65 is a GENE-Y, p50 is a GENE-Y, iNOS is a GENE-Y, Pyrrolidine dithiocarbamate is a CHEMICAL, PDTC is a CHEMICAL, NF - κB is a GENE-N, 20S proteasome is a GENE-N, iNOS is a GENE-Y, 5HHMF is a CHEMICAL, iNOS is a GENE-Y, NF - κB is a GENE-N, 5HHMF is a CHEMICAL, heme oxygenase-1 is a GENE-Y, HO-1 is a GENE-Y, nuclear factor - erythroid 2-related factor 2 is a GENE-Y, Nrf2 is a GENE-Y, cobalt protoporphyrin is a CHEMICAL, CoPP is a CHEMICAL, HO-1 is a GENE-Y, NO is a CHEMICAL, zinc protoporphyrin is a CHEMICAL, ZnPP is a CHEMICAL, HO-1 is a GENE-Y, 5HHMF is a CHEMICAL, NO is a CHEMICAL, 5HHMF is a CHEMICAL, Nrf2 is a GENE-Y, Nrf2 is a GENE-Y, 5HHMF is a CHEMICAL, NO is a CHEMICAL, HO-1 is a GENE-Y, 5HHMF is a CHEMICAL, NO is a CHEMICAL, iNOS is a GENE-Y, NF - κB is a GENE-N, HO-1 is a GENE-Y	17897_task0	Sentence: 5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and Nrf-2-dependent heme oxygenase-1 induction. In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (iNOS) in BV2 microglia. In addition, 5HHMF blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of nuclear factor-κB (NF-κB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression. Pyrrolidine dithiocarbamate (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity. Thus, we found that 5HHMF enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation. In addition, cobalt protoporphyrin (CoPP), a specific HO-1 inducer, predominantly suppressed LPS-induced NO production. In contrast, zinc protoporphyrin (ZnPP), a specific HO-1 inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production. Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity. Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-κB activity and induction of Nrf2-dependent HO-1 activity. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL	[ "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O" ]	5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and Nrf-2-dependent heme oxygenase-1 induction. In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (iNOS) in BV2 microglia. In addition, 5HHMF blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of nuclear factor-κB (NF-κB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression. Pyrrolidine dithiocarbamate (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity. Thus, we found that 5HHMF enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation. In addition, cobalt protoporphyrin (CoPP), a specific HO-1 inducer, predominantly suppressed LPS-induced NO production. In contrast, zinc protoporphyrin (ZnPP), a specific HO-1 inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production. Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity. Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-κB activity and induction of Nrf2-dependent HO-1 activity.	[ "5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone", "inhibits", "nitric", "oxide", "production", "in", "lipopolysaccharide", "-", "stimulated", "BV2", "microglia", "via", "NF", "-", "κB", "suppression", "and", "Nrf-2-dependent", "heme", "oxygenase-1", "induction", ".", "\n", "In", "this", "study", ",", "we", "found", "that", "5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone", "(", "5HHMF", ")", "from", "Hizikia", "fusiforme", "considerably", "inhibits", "lipopolysaccharide", "(", "LPS)-stimulated", "NO", "production", "by", "suppressing", "the", "expression", "of", "inducible", "NO", "synthase", "(", "iNOS", ")", "in", "BV2", "microglia", ".", "In", "addition", ",", "5HHMF", "blocked", "LPS", "-", "induced", "phosphorylation", "of", "IκB", ",", "resulting", "in", "suppression", "of", "the", "nuclear", "translocation", "of", "nuclear", "factor", "-", "κB", "(", "NF", "-", "κB", ")", "subunits", ",", "namely", "p65", "and", "p50", ",", "which", "are", "important", "molecules", "involved", "in", "the", "regulation", "of", "iNOS", "expression", ".", "Pyrrolidine", "dithiocarbamate", "(", "PDTC", ")", ",", "a", "specific", "NF", "-", "κB", "inhibitor", ",", "along", "with", "20S", "proteasome", "inhibitor", "(", "PSI", ")", "significantly", "inhibited", "LPS", "-", "induced", "iNOS", "expression", ",", "which", "indirectly", "suggested", "that", "5HHMF", "downregulated", "iNOS", "expression", "by", "suppressing", "NF", "-", "κB", "activity", ".", "Thus", ",", "we", "found", "that", "5HHMF", "enhances", "heme", "oxygenase-1", "(", "HO-1", ")", "expression", "via", "nuclear", "factor", "-", "erythroid", "2-related", "factor", "2", "(", "Nrf2", ")", "activation", ".", "In", "addition", ",", "cobalt", "protoporphyrin", "(", "CoPP", ")", ",", "a", "specific", "HO-1", "inducer", ",", "predominantly", "suppressed", "LPS", "-", "induced", "NO", "production", ".", "In", "contrast", ",", "zinc", "protoporphyrin", "(", "ZnPP", ")", ",", "a", "specific", "HO-1", "inhibitor", ",", "showed", "a", "partial", "suppressive", "effect", "of", "5HHMF", "on", "LPS", "-", "induced", "NO", "production", ".", "Further", ",", "5HHMF", "increased", "specific", "DNA", "-", "binding", "activity", "of", "Nrf2", ",", "and", "transient", "knockdown", "with", "Nrf2", "siRNA", "subsequently", "reversed", "5HHMF", "-", "induced", "NO", "inhibition", ",", "which", "was", "followed", "by", "suppression", "of", "HO-1", "activity", ".", "Taken", "together", ",", "our", "findings", "indicate", "that", "5HHMF", "suppresses", "NO", "production", "through", "modulation", "of", "iNOS", ",", "consequently", "suppressing", "NF", "-", "κB", "activity", "and", "induction", "of", "Nrf2-dependent", "HO-1", "activity", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone is a CHEMICAL, nitric oxide is a CHEMICAL, NF - κB is a GENE-N, heme oxygenase-1 is a GENE-Y, 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone is a CHEMICAL, 5HHMF is a CHEMICAL, NO is a CHEMICAL, inducible NO synthase is a GENE-Y, iNOS is a GENE-Y, 5HHMF is a CHEMICAL, IκB is a GENE-N, nuclear factor - κB is a GENE-N, NF - κB is a GENE-N, p65 is a GENE-Y, p50 is a GENE-Y, iNOS is a GENE-Y, Pyrrolidine dithiocarbamate is a CHEMICAL, PDTC is a CHEMICAL, NF - κB is a GENE-N, 20S proteasome is a GENE-N, iNOS is a GENE-Y, 5HHMF is a CHEMICAL, iNOS is a GENE-Y, NF - κB is a GENE-N, 5HHMF is a CHEMICAL, heme oxygenase-1 is a GENE-Y, HO-1 is a GENE-Y, nuclear factor - erythroid 2-related factor 2 is a GENE-Y, Nrf2 is a GENE-Y, cobalt protoporphyrin is a CHEMICAL, CoPP is a CHEMICAL, HO-1 is a GENE-Y, NO is a CHEMICAL, zinc protoporphyrin is a CHEMICAL, ZnPP is a CHEMICAL, HO-1 is a GENE-Y, 5HHMF is a CHEMICAL, NO is a CHEMICAL, 5HHMF is a CHEMICAL, Nrf2 is a GENE-Y, Nrf2 is a GENE-Y, 5HHMF is a CHEMICAL, NO is a CHEMICAL, HO-1 is a GENE-Y, 5HHMF is a CHEMICAL, NO is a CHEMICAL, iNOS is a GENE-Y, NF - κB is a GENE-N, HO-1 is a GENE-Y	17897_task1	Sentence: 5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and Nrf-2-dependent heme oxygenase-1 induction. In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (iNOS) in BV2 microglia. In addition, 5HHMF blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of nuclear factor-κB (NF-κB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression. Pyrrolidine dithiocarbamate (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity. Thus, we found that 5HHMF enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation. In addition, cobalt protoporphyrin (CoPP), a specific HO-1 inducer, predominantly suppressed LPS-induced NO production. In contrast, zinc protoporphyrin (ZnPP), a specific HO-1 inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production. Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity. Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-κB activity and induction of Nrf2-dependent HO-1 activity. Instructions: please typing these entity words according to sentence: 5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone, nitric oxide, NF - κB, heme oxygenase-1, 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone, 5HHMF, NO, inducible NO synthase, iNOS, 5HHMF, IκB, nuclear factor - κB, NF - κB, p65, p50, iNOS, Pyrrolidine dithiocarbamate, PDTC, NF - κB, 20S proteasome, iNOS, 5HHMF, iNOS, NF - κB, 5HHMF, heme oxygenase-1, HO-1, nuclear factor - erythroid 2-related factor 2, Nrf2, cobalt protoporphyrin, CoPP, HO-1, NO, zinc protoporphyrin, ZnPP, HO-1, 5HHMF, NO, 5HHMF, Nrf2, Nrf2, 5HHMF, NO, HO-1, 5HHMF, NO, iNOS, NF - κB, HO-1 Options: GENE-Y, GENE-N, CHEMICAL	[ "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O" ]	5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and Nrf-2-dependent heme oxygenase-1 induction. In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (iNOS) in BV2 microglia. In addition, 5HHMF blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of nuclear factor-κB (NF-κB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression. Pyrrolidine dithiocarbamate (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity. Thus, we found that 5HHMF enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation. In addition, cobalt protoporphyrin (CoPP), a specific HO-1 inducer, predominantly suppressed LPS-induced NO production. In contrast, zinc protoporphyrin (ZnPP), a specific HO-1 inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production. Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity. Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-κB activity and induction of Nrf2-dependent HO-1 activity.	[ "5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone", "inhibits", "nitric", "oxide", "production", "in", "lipopolysaccharide", "-", "stimulated", "BV2", "microglia", "via", "NF", "-", "κB", "suppression", "and", "Nrf-2-dependent", "heme", "oxygenase-1", "induction", ".", "\n", "In", "this", "study", ",", "we", "found", "that", "5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone", "(", "5HHMF", ")", "from", "Hizikia", "fusiforme", "considerably", "inhibits", "lipopolysaccharide", "(", "LPS)-stimulated", "NO", "production", "by", "suppressing", "the", "expression", "of", "inducible", "NO", "synthase", "(", "iNOS", ")", "in", "BV2", "microglia", ".", "In", "addition", ",", "5HHMF", "blocked", "LPS", "-", "induced", "phosphorylation", "of", "IκB", ",", "resulting", "in", "suppression", "of", "the", "nuclear", "translocation", "of", "nuclear", "factor", "-", "κB", "(", "NF", "-", "κB", ")", "subunits", ",", "namely", "p65", "and", "p50", ",", "which", "are", "important", "molecules", "involved", "in", "the", "regulation", "of", "iNOS", "expression", ".", "Pyrrolidine", "dithiocarbamate", "(", "PDTC", ")", ",", "a", "specific", "NF", "-", "κB", "inhibitor", ",", "along", "with", "20S", "proteasome", "inhibitor", "(", "PSI", ")", "significantly", "inhibited", "LPS", "-", "induced", "iNOS", "expression", ",", "which", "indirectly", "suggested", "that", "5HHMF", "downregulated", "iNOS", "expression", "by", "suppressing", "NF", "-", "κB", "activity", ".", "Thus", ",", "we", "found", "that", "5HHMF", "enhances", "heme", "oxygenase-1", "(", "HO-1", ")", "expression", "via", "nuclear", "factor", "-", "erythroid", "2-related", "factor", "2", "(", "Nrf2", ")", "activation", ".", "In", "addition", ",", "cobalt", "protoporphyrin", "(", "CoPP", ")", ",", "a", "specific", "HO-1", "inducer", ",", "predominantly", "suppressed", "LPS", "-", "induced", "NO", "production", ".", "In", "contrast", ",", "zinc", "protoporphyrin", "(", "ZnPP", ")", ",", "a", "specific", "HO-1", "inhibitor", ",", "showed", "a", "partial", "suppressive", "effect", "of", "5HHMF", "on", "LPS", "-", "induced", "NO", "production", ".", "Further", ",", "5HHMF", "increased", "specific", "DNA", "-", "binding", "activity", "of", "Nrf2", ",", "and", "transient", "knockdown", "with", "Nrf2", "siRNA", "subsequently", "reversed", "5HHMF", "-", "induced", "NO", "inhibition", ",", "which", "was", "followed", "by", "suppression", "of", "HO-1", "activity", ".", "Taken", "together", ",", "our", "findings", "indicate", "that", "5HHMF", "suppresses", "NO", "production", "through", "modulation", "of", "iNOS", ",", "consequently", "suppressing", "NF", "-", "κB", "activity", "and", "induction", "of", "Nrf2-dependent", "HO-1", "activity", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone, nitric oxide, NF - κB, heme oxygenase-1, 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone, 5HHMF, NO, inducible NO synthase, iNOS, 5HHMF, IκB, nuclear factor - κB, NF - κB, p65, p50, iNOS, Pyrrolidine dithiocarbamate, PDTC, NF - κB, 20S proteasome, iNOS, 5HHMF, iNOS, NF - κB, 5HHMF, heme oxygenase-1, HO-1, nuclear factor - erythroid 2-related factor 2, Nrf2, cobalt protoporphyrin, CoPP, HO-1, NO, zinc protoporphyrin, ZnPP, HO-1, 5HHMF, NO, 5HHMF, Nrf2, Nrf2, 5HHMF, NO, HO-1, 5HHMF, NO, iNOS, NF - κB, HO-1	17897_task2	Sentence: 5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and Nrf-2-dependent heme oxygenase-1 induction. In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (iNOS) in BV2 microglia. In addition, 5HHMF blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of nuclear factor-κB (NF-κB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression. Pyrrolidine dithiocarbamate (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity. Thus, we found that 5HHMF enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation. In addition, cobalt protoporphyrin (CoPP), a specific HO-1 inducer, predominantly suppressed LPS-induced NO production. In contrast, zinc protoporphyrin (ZnPP), a specific HO-1 inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production. Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity. Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-κB activity and induction of Nrf2-dependent HO-1 activity. Instructions: please extract entity words from the input sentence	[ "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O" ]	5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and Nrf-2-dependent heme oxygenase-1 induction. In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (iNOS) in BV2 microglia. In addition, 5HHMF blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of nuclear factor-κB (NF-κB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression. Pyrrolidine dithiocarbamate (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity. Thus, we found that 5HHMF enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation. In addition, cobalt protoporphyrin (CoPP), a specific HO-1 inducer, predominantly suppressed LPS-induced NO production. In contrast, zinc protoporphyrin (ZnPP), a specific HO-1 inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production. Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity. Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-κB activity and induction of Nrf2-dependent HO-1 activity.	[ "5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone", "inhibits", "nitric", "oxide", "production", "in", "lipopolysaccharide", "-", "stimulated", "BV2", "microglia", "via", "NF", "-", "κB", "suppression", "and", "Nrf-2-dependent", "heme", "oxygenase-1", "induction", ".", "\n", "In", "this", "study", ",", "we", "found", "that", "5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone", "(", "5HHMF", ")", "from", "Hizikia", "fusiforme", "considerably", "inhibits", "lipopolysaccharide", "(", "LPS)-stimulated", "NO", "production", "by", "suppressing", "the", "expression", "of", "inducible", "NO", "synthase", "(", "iNOS", ")", "in", "BV2", "microglia", ".", "In", "addition", ",", "5HHMF", "blocked", "LPS", "-", "induced", "phosphorylation", "of", "IκB", ",", "resulting", "in", "suppression", "of", "the", "nuclear", "translocation", "of", "nuclear", "factor", "-", "κB", "(", "NF", "-", "κB", ")", "subunits", ",", "namely", "p65", "and", "p50", ",", "which", "are", "important", "molecules", "involved", "in", "the", "regulation", "of", "iNOS", "expression", ".", "Pyrrolidine", "dithiocarbamate", "(", "PDTC", ")", ",", "a", "specific", "NF", "-", "κB", "inhibitor", ",", "along", "with", "20S", "proteasome", "inhibitor", "(", "PSI", ")", "significantly", "inhibited", "LPS", "-", "induced", "iNOS", "expression", ",", "which", "indirectly", "suggested", "that", "5HHMF", "downregulated", "iNOS", "expression", "by", "suppressing", "NF", "-", "κB", "activity", ".", "Thus", ",", "we", "found", "that", "5HHMF", "enhances", "heme", "oxygenase-1", "(", "HO-1", ")", "expression", "via", "nuclear", "factor", "-", "erythroid", "2-related", "factor", "2", "(", "Nrf2", ")", "activation", ".", "In", "addition", ",", "cobalt", "protoporphyrin", "(", "CoPP", ")", ",", "a", "specific", "HO-1", "inducer", ",", "predominantly", "suppressed", "LPS", "-", "induced", "NO", "production", ".", "In", "contrast", ",", "zinc", "protoporphyrin", "(", "ZnPP", ")", ",", "a", "specific", "HO-1", "inhibitor", ",", "showed", "a", "partial", "suppressive", "effect", "of", "5HHMF", "on", "LPS", "-", "induced", "NO", "production", ".", "Further", ",", "5HHMF", "increased", "specific", "DNA", "-", "binding", "activity", "of", "Nrf2", ",", "and", "transient", "knockdown", "with", "Nrf2", "siRNA", "subsequently", "reversed", "5HHMF", "-", "induced", "NO", "inhibition", ",", "which", "was", "followed", "by", "suppression", "of", "HO-1", "activity", ".", "Taken", "together", ",", "our", "findings", "indicate", "that", "5HHMF", "suppresses", "NO", "production", "through", "modulation", "of", "iNOS", ",", "consequently", "suppressing", "NF", "-", "κB", "activity", "and", "induction", "of", "Nrf2-dependent", "HO-1", "activity", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
benzo[e]pyridoindolones is a CHEMICAL, aurora kinases is a GENE-N	23281044_task0	Sentence: Hydrosoluble benzo[e]pyridoindolones as potent inhibitors of aurora kinases. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL	[ "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O" ]	Hydrosoluble benzo[e]pyridoindolones as potent inhibitors of aurora kinases.	[ "Hydrosoluble", "benzo[e]pyridoindolones", "as", "potent", "inhibitors", "of", "aurora", "kinases", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
benzo[e]pyridoindolones is a CHEMICAL, aurora kinases is a GENE-N	23281044_task1	Sentence: Hydrosoluble benzo[e]pyridoindolones as potent inhibitors of aurora kinases. Instructions: please typing these entity words according to sentence: benzo[e]pyridoindolones, aurora kinases Options: GENE-N, CHEMICAL	[ "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O" ]	Hydrosoluble benzo[e]pyridoindolones as potent inhibitors of aurora kinases.	[ "Hydrosoluble", "benzo[e]pyridoindolones", "as", "potent", "inhibitors", "of", "aurora", "kinases", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
benzo[e]pyridoindolones, aurora kinases	23281044_task2	Sentence: Hydrosoluble benzo[e]pyridoindolones as potent inhibitors of aurora kinases. Instructions: please extract entity words from the input sentence	[ "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O" ]	Hydrosoluble benzo[e]pyridoindolones as potent inhibitors of aurora kinases.	[ "Hydrosoluble", "benzo[e]pyridoindolones", "as", "potent", "inhibitors", "of", "aurora", "kinases", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
RIPc is a Individual_protein, TRADD is a Individual_protein, FADD is a Individual_protein, MORT1 is a Individual_protein, TNF is a Individual_protein	625_task0	Sentence: RIPc, one of the cleavage products, enhanced interaction between TRADD and FADD/MORT1 and increased cells' sensitivity to TNF. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein	[ "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O" ]	RIPc, one of the cleavage products, enhanced interaction between TRADD and FADD/MORT1 and increased cells' sensitivity to TNF.	[ "RIPc", ",", "one", "of", "the", "cleavage", "products", ",", "enhanced", "interaction", "between", "TRADD", "and", "FADD", "/", "MORT1", "and", "increased", "cells", "'", "sensitivity", "to", "TNF", "." ]	[ "Individual_protein" ]
RIPc is a Individual_protein, TRADD is a Individual_protein, FADD is a Individual_protein, MORT1 is a Individual_protein, TNF is a Individual_protein	625_task1	Sentence: RIPc, one of the cleavage products, enhanced interaction between TRADD and FADD/MORT1 and increased cells' sensitivity to TNF. Instructions: please typing these entity words according to sentence: RIPc, TRADD, FADD, MORT1, TNF Options: Individual_protein	[ "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O" ]	RIPc, one of the cleavage products, enhanced interaction between TRADD and FADD/MORT1 and increased cells' sensitivity to TNF.	[ "RIPc", ",", "one", "of", "the", "cleavage", "products", ",", "enhanced", "interaction", "between", "TRADD", "and", "FADD", "/", "MORT1", "and", "increased", "cells", "'", "sensitivity", "to", "TNF", "." ]	[ "Individual_protein" ]
RIPc, TRADD, FADD, MORT1, TNF	625_task2	Sentence: RIPc, one of the cleavage products, enhanced interaction between TRADD and FADD/MORT1 and increased cells' sensitivity to TNF. Instructions: please extract entity words from the input sentence	[ "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O" ]	RIPc, one of the cleavage products, enhanced interaction between TRADD and FADD/MORT1 and increased cells' sensitivity to TNF.	[ "RIPc", ",", "one", "of", "the", "cleavage", "products", ",", "enhanced", "interaction", "between", "TRADD", "and", "FADD", "/", "MORT1", "and", "increased", "cells", "'", "sensitivity", "to", "TNF", "." ]	[ "Individual_protein" ]
Literatur is an umlsterm, Relevanzbeurteilung is an umlsterm, Dentallegierungen is an umlsterm, Allergiepraevalenz is an umlsterm, Quecksilberverbindungen is an umlsterm, Nickelallergien is an umlsterm, Nickel is an umlsterm, Allergen is an umlsterm, Goldsalze is an umlsterm, Vorhersage is an umlsterm, Goldunvertraeglichkeit is an umlsterm, Kunstharzen is an umlsterm, Methylmethacrylat is an umlsterm, Allergen is an umlsterm, Methacrylaten is an umlsterm, Gruppenallergien is an umlsterm, Benzoylperoxidtests is an umlsterm, Allergenkomplex is an umlsterm, aetherische Oele is an umlsterm, zahnmedizinischen is an umlsterm	DerHautarzt.60470844.ger.abstr_task0	Sentence: Anhand der IVDK-Daten , des eigenen Materials und der Literatur werden fuer die wichtigsten Dentalwerkstoffe ( DWS ) die Probleme beim Epikutantest und dessen Relevanzbeurteilung sowie die praktischen Konsequenzen besprochen . Im Vordergrund stehen bei den Dentallegierungen folgende Komplexe : Amalgam , mit niedriger Allergiepraevalenz und sicherer Korrelation nur zu Patchtestreaktionen auf anorganische Quecksilberverbindungen ; Palladiumsalze mit hoher Quote simultaner Nickelallergien , aber nur sehr geringer Korrelation zu Reaktionen auf metallisches Pd bzw. Pd-Legierungen ; Nickel als sehr haeufiges Allergen mit hoher Relevanz bei nicht absolut korrosionsfesten , nickelhaltigen DWS ; Goldsalze mit ihren stark differierenden Testergebnissen und deren begrenztem Wert fuer die Vorhersage einer Goldunvertraeglichkeit . Bei den Kunstharzen ist Methylmethacrylat allein wegen der Expositionshaeufigkeit noch immer das wichtigste Allergen . Bei Compositematerialien und anderen Methacrylaten ist auf die Problematik von Gruppenallergien und aktiver Sensibilisierung zu achten . Klinisch relevante Additivaallergien sind selten , positive Benzoylperoxidtests allein dafuer kein Beweis . Weit verbreitet im DWS ist der Allergenkomplex aetherische Oele - Perubalsam - Kolophonium . Bei DWS sollte die Testung unter standardisierten Bedingungen und die Bewertung besonders kritisch erfolgen , da die zahnmedizinischen Konsequenzen kostenaufwendig und belastend sein koennen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Anhand der IVDK-Daten , des eigenen Materials und der Literatur werden fuer die wichtigsten Dentalwerkstoffe ( DWS ) die Probleme beim Epikutantest und dessen Relevanzbeurteilung sowie die praktischen Konsequenzen besprochen . Im Vordergrund stehen bei den Dentallegierungen folgende Komplexe : Amalgam , mit niedriger Allergiepraevalenz und sicherer Korrelation nur zu Patchtestreaktionen auf anorganische Quecksilberverbindungen ; Palladiumsalze mit hoher Quote simultaner Nickelallergien , aber nur sehr geringer Korrelation zu Reaktionen auf metallisches Pd bzw. Pd-Legierungen ; Nickel als sehr haeufiges Allergen mit hoher Relevanz bei nicht absolut korrosionsfesten , nickelhaltigen DWS ; Goldsalze mit ihren stark differierenden Testergebnissen und deren begrenztem Wert fuer die Vorhersage einer Goldunvertraeglichkeit . Bei den Kunstharzen ist Methylmethacrylat allein wegen der Expositionshaeufigkeit noch immer das wichtigste Allergen . Bei Compositematerialien und anderen Methacrylaten ist auf die Problematik von Gruppenallergien und aktiver Sensibilisierung zu achten . Klinisch relevante Additivaallergien sind selten , positive Benzoylperoxidtests allein dafuer kein Beweis . Weit verbreitet im DWS ist der Allergenkomplex aetherische Oele - Perubalsam - Kolophonium . Bei DWS sollte die Testung unter standardisierten Bedingungen und die Bewertung besonders kritisch erfolgen , da die zahnmedizinischen Konsequenzen kostenaufwendig und belastend sein koennen .	[ "Anhand", "der", "IVDK", "-", "Daten", ",", "des", "eigenen", "Materials", "und", "der", "Literatur", "werden", "fuer", "die", "wichtigsten", "Dentalwerkstoffe", "(", "DWS", ")", "die", "Probleme", "beim", "Epikutantest", "und", "dessen", "Relevanzbeurteilung", "sowie", "die", "praktischen", "Konsequenzen", "besprochen", ".", "Im", "Vordergrund", "stehen", "bei", "den", "Dentallegierungen", "folgende", "Komplexe", ":", "Amalgam", ",", "mit", "niedriger", "Allergiepraevalenz", "und", "sicherer", "Korrelation", "nur", "zu", "Patchtestreaktionen", "auf", "anorganische", "Quecksilberverbindungen", ";", "Palladiumsalze", "mit", "hoher", "Quote", "simultaner", "Nickelallergien", ",", "aber", "nur", "sehr", "geringer", "Korrelation", "zu", "Reaktionen", "auf", "metallisches", "Pd", "bzw", ".", "Pd", "-", "Legierungen", ";", "Nickel", "als", "sehr", "haeufiges", "Allergen", "mit", "hoher", "Relevanz", "bei", "nicht", "absolut", "korrosionsfesten", ",", "nickelhaltigen", "DWS", ";", "Goldsalze", "mit", "ihren", "stark", "differierenden", "Testergebnissen", "und", "deren", "begrenztem", "Wert", "fuer", "die", "Vorhersage", "einer", "Goldunvertraeglichkeit", ".", "Bei", "den", "Kunstharzen", "ist", "Methylmethacrylat", "allein", "wegen", "der", "Expositionshaeufigkeit", "noch", "immer", "das", "wichtigste", "Allergen", ".", "Bei", "Compositematerialien", "und", "anderen", "Methacrylaten", "ist", "auf", "die", "Problematik", "von", "Gruppenallergien", "und", "aktiver", "Sensibilisierung", "zu", "achten", ".", "Klinisch", "relevante", "Additivaallergien", "sind", "selten", ",", "positive", "Benzoylperoxidtests", "allein", "dafuer", "kein", "Beweis", ".", "Weit", "verbreitet", "im", "DWS", "ist", "der", "Allergenkomplex", "aetherische", "Oele", "-", "Perubalsam", "-", "Kolophonium", ".", "Bei", "DWS", "sollte", "die", "Testung", "unter", "standardisierten", "Bedingungen", "und", "die", "Bewertung", "besonders", "kritisch", "erfolgen", ",", "da", "die", "zahnmedizinischen", "Konsequenzen", "kostenaufwendig", "und", "belastend", "sein", "koennen", "." ]	[ "umlsterm" ]
Literatur is an umlsterm, Relevanzbeurteilung is an umlsterm, Dentallegierungen is an umlsterm, Allergiepraevalenz is an umlsterm, Quecksilberverbindungen is an umlsterm, Nickelallergien is an umlsterm, Nickel is an umlsterm, Allergen is an umlsterm, Goldsalze is an umlsterm, Vorhersage is an umlsterm, Goldunvertraeglichkeit is an umlsterm, Kunstharzen is an umlsterm, Methylmethacrylat is an umlsterm, Allergen is an umlsterm, Methacrylaten is an umlsterm, Gruppenallergien is an umlsterm, Benzoylperoxidtests is an umlsterm, Allergenkomplex is an umlsterm, aetherische Oele is an umlsterm, zahnmedizinischen is an umlsterm	DerHautarzt.60470844.ger.abstr_task1	Sentence: Anhand der IVDK-Daten , des eigenen Materials und der Literatur werden fuer die wichtigsten Dentalwerkstoffe ( DWS ) die Probleme beim Epikutantest und dessen Relevanzbeurteilung sowie die praktischen Konsequenzen besprochen . Im Vordergrund stehen bei den Dentallegierungen folgende Komplexe : Amalgam , mit niedriger Allergiepraevalenz und sicherer Korrelation nur zu Patchtestreaktionen auf anorganische Quecksilberverbindungen ; Palladiumsalze mit hoher Quote simultaner Nickelallergien , aber nur sehr geringer Korrelation zu Reaktionen auf metallisches Pd bzw. Pd-Legierungen ; Nickel als sehr haeufiges Allergen mit hoher Relevanz bei nicht absolut korrosionsfesten , nickelhaltigen DWS ; Goldsalze mit ihren stark differierenden Testergebnissen und deren begrenztem Wert fuer die Vorhersage einer Goldunvertraeglichkeit . Bei den Kunstharzen ist Methylmethacrylat allein wegen der Expositionshaeufigkeit noch immer das wichtigste Allergen . Bei Compositematerialien und anderen Methacrylaten ist auf die Problematik von Gruppenallergien und aktiver Sensibilisierung zu achten . Klinisch relevante Additivaallergien sind selten , positive Benzoylperoxidtests allein dafuer kein Beweis . Weit verbreitet im DWS ist der Allergenkomplex aetherische Oele - Perubalsam - Kolophonium . Bei DWS sollte die Testung unter standardisierten Bedingungen und die Bewertung besonders kritisch erfolgen , da die zahnmedizinischen Konsequenzen kostenaufwendig und belastend sein koennen . Instructions: please typing these entity words according to sentence: Literatur, Relevanzbeurteilung, Dentallegierungen, Allergiepraevalenz, Quecksilberverbindungen, Nickelallergien, Nickel, Allergen, Goldsalze, Vorhersage, Goldunvertraeglichkeit, Kunstharzen, Methylmethacrylat, Allergen, Methacrylaten, Gruppenallergien, Benzoylperoxidtests, Allergenkomplex, aetherische Oele, zahnmedizinischen Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Anhand der IVDK-Daten , des eigenen Materials und der Literatur werden fuer die wichtigsten Dentalwerkstoffe ( DWS ) die Probleme beim Epikutantest und dessen Relevanzbeurteilung sowie die praktischen Konsequenzen besprochen . Im Vordergrund stehen bei den Dentallegierungen folgende Komplexe : Amalgam , mit niedriger Allergiepraevalenz und sicherer Korrelation nur zu Patchtestreaktionen auf anorganische Quecksilberverbindungen ; Palladiumsalze mit hoher Quote simultaner Nickelallergien , aber nur sehr geringer Korrelation zu Reaktionen auf metallisches Pd bzw. Pd-Legierungen ; Nickel als sehr haeufiges Allergen mit hoher Relevanz bei nicht absolut korrosionsfesten , nickelhaltigen DWS ; Goldsalze mit ihren stark differierenden Testergebnissen und deren begrenztem Wert fuer die Vorhersage einer Goldunvertraeglichkeit . Bei den Kunstharzen ist Methylmethacrylat allein wegen der Expositionshaeufigkeit noch immer das wichtigste Allergen . Bei Compositematerialien und anderen Methacrylaten ist auf die Problematik von Gruppenallergien und aktiver Sensibilisierung zu achten . Klinisch relevante Additivaallergien sind selten , positive Benzoylperoxidtests allein dafuer kein Beweis . Weit verbreitet im DWS ist der Allergenkomplex aetherische Oele - Perubalsam - Kolophonium . Bei DWS sollte die Testung unter standardisierten Bedingungen und die Bewertung besonders kritisch erfolgen , da die zahnmedizinischen Konsequenzen kostenaufwendig und belastend sein koennen .	[ "Anhand", "der", "IVDK", "-", "Daten", ",", "des", "eigenen", "Materials", "und", "der", "Literatur", "werden", "fuer", "die", "wichtigsten", "Dentalwerkstoffe", "(", "DWS", ")", "die", "Probleme", "beim", "Epikutantest", "und", "dessen", "Relevanzbeurteilung", "sowie", "die", "praktischen", "Konsequenzen", "besprochen", ".", "Im", "Vordergrund", "stehen", "bei", "den", "Dentallegierungen", "folgende", "Komplexe", ":", "Amalgam", ",", "mit", "niedriger", "Allergiepraevalenz", "und", "sicherer", "Korrelation", "nur", "zu", "Patchtestreaktionen", "auf", "anorganische", "Quecksilberverbindungen", ";", "Palladiumsalze", "mit", "hoher", "Quote", "simultaner", "Nickelallergien", ",", "aber", "nur", "sehr", "geringer", "Korrelation", "zu", "Reaktionen", "auf", "metallisches", "Pd", "bzw", ".", "Pd", "-", "Legierungen", ";", "Nickel", "als", "sehr", "haeufiges", "Allergen", "mit", "hoher", "Relevanz", "bei", "nicht", "absolut", "korrosionsfesten", ",", "nickelhaltigen", "DWS", ";", "Goldsalze", "mit", "ihren", "stark", "differierenden", "Testergebnissen", "und", "deren", "begrenztem", "Wert", "fuer", "die", "Vorhersage", "einer", "Goldunvertraeglichkeit", ".", "Bei", "den", "Kunstharzen", "ist", "Methylmethacrylat", "allein", "wegen", "der", "Expositionshaeufigkeit", "noch", "immer", "das", "wichtigste", "Allergen", ".", "Bei", "Compositematerialien", "und", "anderen", "Methacrylaten", "ist", "auf", "die", "Problematik", "von", "Gruppenallergien", "und", "aktiver", "Sensibilisierung", "zu", "achten", ".", "Klinisch", "relevante", "Additivaallergien", "sind", "selten", ",", "positive", "Benzoylperoxidtests", "allein", "dafuer", "kein", "Beweis", ".", "Weit", "verbreitet", "im", "DWS", "ist", "der", "Allergenkomplex", "aetherische", "Oele", "-", "Perubalsam", "-", "Kolophonium", ".", "Bei", "DWS", "sollte", "die", "Testung", "unter", "standardisierten", "Bedingungen", "und", "die", "Bewertung", "besonders", "kritisch", "erfolgen", ",", "da", "die", "zahnmedizinischen", "Konsequenzen", "kostenaufwendig", "und", "belastend", "sein", "koennen", "." ]	[ "umlsterm" ]
Literatur, Relevanzbeurteilung, Dentallegierungen, Allergiepraevalenz, Quecksilberverbindungen, Nickelallergien, Nickel, Allergen, Goldsalze, Vorhersage, Goldunvertraeglichkeit, Kunstharzen, Methylmethacrylat, Allergen, Methacrylaten, Gruppenallergien, Benzoylperoxidtests, Allergenkomplex, aetherische Oele, zahnmedizinischen	DerHautarzt.60470844.ger.abstr_task2	Sentence: Anhand der IVDK-Daten , des eigenen Materials und der Literatur werden fuer die wichtigsten Dentalwerkstoffe ( DWS ) die Probleme beim Epikutantest und dessen Relevanzbeurteilung sowie die praktischen Konsequenzen besprochen . Im Vordergrund stehen bei den Dentallegierungen folgende Komplexe : Amalgam , mit niedriger Allergiepraevalenz und sicherer Korrelation nur zu Patchtestreaktionen auf anorganische Quecksilberverbindungen ; Palladiumsalze mit hoher Quote simultaner Nickelallergien , aber nur sehr geringer Korrelation zu Reaktionen auf metallisches Pd bzw. Pd-Legierungen ; Nickel als sehr haeufiges Allergen mit hoher Relevanz bei nicht absolut korrosionsfesten , nickelhaltigen DWS ; Goldsalze mit ihren stark differierenden Testergebnissen und deren begrenztem Wert fuer die Vorhersage einer Goldunvertraeglichkeit . Bei den Kunstharzen ist Methylmethacrylat allein wegen der Expositionshaeufigkeit noch immer das wichtigste Allergen . Bei Compositematerialien und anderen Methacrylaten ist auf die Problematik von Gruppenallergien und aktiver Sensibilisierung zu achten . Klinisch relevante Additivaallergien sind selten , positive Benzoylperoxidtests allein dafuer kein Beweis . Weit verbreitet im DWS ist der Allergenkomplex aetherische Oele - Perubalsam - Kolophonium . Bei DWS sollte die Testung unter standardisierten Bedingungen und die Bewertung besonders kritisch erfolgen , da die zahnmedizinischen Konsequenzen kostenaufwendig und belastend sein koennen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Anhand der IVDK-Daten , des eigenen Materials und der Literatur werden fuer die wichtigsten Dentalwerkstoffe ( DWS ) die Probleme beim Epikutantest und dessen Relevanzbeurteilung sowie die praktischen Konsequenzen besprochen . Im Vordergrund stehen bei den Dentallegierungen folgende Komplexe : Amalgam , mit niedriger Allergiepraevalenz und sicherer Korrelation nur zu Patchtestreaktionen auf anorganische Quecksilberverbindungen ; Palladiumsalze mit hoher Quote simultaner Nickelallergien , aber nur sehr geringer Korrelation zu Reaktionen auf metallisches Pd bzw. Pd-Legierungen ; Nickel als sehr haeufiges Allergen mit hoher Relevanz bei nicht absolut korrosionsfesten , nickelhaltigen DWS ; Goldsalze mit ihren stark differierenden Testergebnissen und deren begrenztem Wert fuer die Vorhersage einer Goldunvertraeglichkeit . Bei den Kunstharzen ist Methylmethacrylat allein wegen der Expositionshaeufigkeit noch immer das wichtigste Allergen . Bei Compositematerialien und anderen Methacrylaten ist auf die Problematik von Gruppenallergien und aktiver Sensibilisierung zu achten . Klinisch relevante Additivaallergien sind selten , positive Benzoylperoxidtests allein dafuer kein Beweis . Weit verbreitet im DWS ist der Allergenkomplex aetherische Oele - Perubalsam - Kolophonium . Bei DWS sollte die Testung unter standardisierten Bedingungen und die Bewertung besonders kritisch erfolgen , da die zahnmedizinischen Konsequenzen kostenaufwendig und belastend sein koennen .	[ "Anhand", "der", "IVDK", "-", "Daten", ",", "des", "eigenen", "Materials", "und", "der", "Literatur", "werden", "fuer", "die", "wichtigsten", "Dentalwerkstoffe", "(", "DWS", ")", "die", "Probleme", "beim", "Epikutantest", "und", "dessen", "Relevanzbeurteilung", "sowie", "die", "praktischen", "Konsequenzen", "besprochen", ".", "Im", "Vordergrund", "stehen", "bei", "den", "Dentallegierungen", "folgende", "Komplexe", ":", "Amalgam", ",", "mit", "niedriger", "Allergiepraevalenz", "und", "sicherer", "Korrelation", "nur", "zu", "Patchtestreaktionen", "auf", "anorganische", "Quecksilberverbindungen", ";", "Palladiumsalze", "mit", "hoher", "Quote", "simultaner", "Nickelallergien", ",", "aber", "nur", "sehr", "geringer", "Korrelation", "zu", "Reaktionen", "auf", "metallisches", "Pd", "bzw", ".", "Pd", "-", "Legierungen", ";", "Nickel", "als", "sehr", "haeufiges", "Allergen", "mit", "hoher", "Relevanz", "bei", "nicht", "absolut", "korrosionsfesten", ",", "nickelhaltigen", "DWS", ";", "Goldsalze", "mit", "ihren", "stark", "differierenden", "Testergebnissen", "und", "deren", "begrenztem", "Wert", "fuer", "die", "Vorhersage", "einer", "Goldunvertraeglichkeit", ".", "Bei", "den", "Kunstharzen", "ist", "Methylmethacrylat", "allein", "wegen", "der", "Expositionshaeufigkeit", "noch", "immer", "das", "wichtigste", "Allergen", ".", "Bei", "Compositematerialien", "und", "anderen", "Methacrylaten", "ist", "auf", "die", "Problematik", "von", "Gruppenallergien", "und", "aktiver", "Sensibilisierung", "zu", "achten", ".", "Klinisch", "relevante", "Additivaallergien", "sind", "selten", ",", "positive", "Benzoylperoxidtests", "allein", "dafuer", "kein", "Beweis", ".", "Weit", "verbreitet", "im", "DWS", "ist", "der", "Allergenkomplex", "aetherische", "Oele", "-", "Perubalsam", "-", "Kolophonium", ".", "Bei", "DWS", "sollte", "die", "Testung", "unter", "standardisierten", "Bedingungen", "und", "die", "Bewertung", "besonders", "kritisch", "erfolgen", ",", "da", "die", "zahnmedizinischen", "Konsequenzen", "kostenaufwendig", "und", "belastend", "sein", "koennen", "." ]	[ "umlsterm" ]
laser is an umlsterm, therapy is an umlsterm, physics is an umlsterm, biophysics is an umlsterm, laser is an umlsterm, therapy is an umlsterm, laser is an umlsterm, dermatology is an umlsterm, laser is an umlsterm, side effects is an umlsterm, methods is an umlsterm	DerHautarzt.80490690.eng.abstr_task0	Sentence: Indications for dermatological laser therapy have been enlarged during the last few years . In this article the physics and biophysics of laser therapy and the common laser systems in dermatology are described . Modern pulsed laser systems are combined with little side effects . Nevertheless , suc-cessfully used alternative methods should not be neglected . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]	Indications for dermatological laser therapy have been enlarged during the last few years . In this article the physics and biophysics of laser therapy and the common laser systems in dermatology are described . Modern pulsed laser systems are combined with little side effects . Nevertheless , suc-cessfully used alternative methods should not be neglected .	[ "Indications", "for", "dermatological", "laser", "therapy", "have", "been", "enlarged", "during", "the", "last", "few", "years", ".", "In", "this", "article", "the", "physics", "and", "biophysics", "of", "laser", "therapy", "and", "the", "common", "laser", "systems", "in", "dermatology", "are", "described", ".", "Modern", "pulsed", "laser", "systems", "are", "combined", "with", "little", "side", "effects", ".", "Nevertheless", ",", "suc", "-", "cessfully", "used", "alternative", "methods", "should", "not", "be", "neglected", "." ]	[ "umlsterm" ]
laser is an umlsterm, therapy is an umlsterm, physics is an umlsterm, biophysics is an umlsterm, laser is an umlsterm, therapy is an umlsterm, laser is an umlsterm, dermatology is an umlsterm, laser is an umlsterm, side effects is an umlsterm, methods is an umlsterm	DerHautarzt.80490690.eng.abstr_task1	Sentence: Indications for dermatological laser therapy have been enlarged during the last few years . In this article the physics and biophysics of laser therapy and the common laser systems in dermatology are described . Modern pulsed laser systems are combined with little side effects . Nevertheless , suc-cessfully used alternative methods should not be neglected . Instructions: please typing these entity words according to sentence: laser, therapy, physics, biophysics, laser, therapy, laser, dermatology, laser, side effects, methods Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]	Indications for dermatological laser therapy have been enlarged during the last few years . In this article the physics and biophysics of laser therapy and the common laser systems in dermatology are described . Modern pulsed laser systems are combined with little side effects . Nevertheless , suc-cessfully used alternative methods should not be neglected .	[ "Indications", "for", "dermatological", "laser", "therapy", "have", "been", "enlarged", "during", "the", "last", "few", "years", ".", "In", "this", "article", "the", "physics", "and", "biophysics", "of", "laser", "therapy", "and", "the", "common", "laser", "systems", "in", "dermatology", "are", "described", ".", "Modern", "pulsed", "laser", "systems", "are", "combined", "with", "little", "side", "effects", ".", "Nevertheless", ",", "suc", "-", "cessfully", "used", "alternative", "methods", "should", "not", "be", "neglected", "." ]	[ "umlsterm" ]
laser, therapy, physics, biophysics, laser, therapy, laser, dermatology, laser, side effects, methods	DerHautarzt.80490690.eng.abstr_task2	Sentence: Indications for dermatological laser therapy have been enlarged during the last few years . In this article the physics and biophysics of laser therapy and the common laser systems in dermatology are described . Modern pulsed laser systems are combined with little side effects . Nevertheless , suc-cessfully used alternative methods should not be neglected . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]	Indications for dermatological laser therapy have been enlarged during the last few years . In this article the physics and biophysics of laser therapy and the common laser systems in dermatology are described . Modern pulsed laser systems are combined with little side effects . Nevertheless , suc-cessfully used alternative methods should not be neglected .	[ "Indications", "for", "dermatological", "laser", "therapy", "have", "been", "enlarged", "during", "the", "last", "few", "years", ".", "In", "this", "article", "the", "physics", "and", "biophysics", "of", "laser", "therapy", "and", "the", "common", "laser", "systems", "in", "dermatology", "are", "described", ".", "Modern", "pulsed", "laser", "systems", "are", "combined", "with", "little", "side", "effects", ".", "Nevertheless", ",", "suc", "-", "cessfully", "used", "alternative", "methods", "should", "not", "be", "neglected", "." ]	[ "umlsterm" ]
IRF-1-dependent pathway is an other_name, DNA damage - induced apoptosis is an other_name, mitogen - activated T lymphocytes is a cell_line	99505_task0	Sentence: An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_line, other_name	[ "O", "B-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]	An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes.	[ "An", "IRF-1-dependent", "pathway", "of", "DNA", "damage", "-", "induced", "apoptosis", "in", "mitogen", "-", "activated", "T", "lymphocytes", "." ]	[ "protein_molecule", "DNA_domain_or_region", "cell_line", "protein_family_or_group", "other_name", "mono_cell", "DNA_family_or_group", "cell_type" ]
IRF-1-dependent pathway is an other_name, DNA damage - induced apoptosis is an other_name, mitogen - activated T lymphocytes is a cell_line	99505_task1	Sentence: An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Instructions: please typing these entity words according to sentence: IRF-1-dependent pathway, DNA damage - induced apoptosis, mitogen - activated T lymphocytes Options: cell_line, other_name	[ "O", "B-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]	An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes.	[ "An", "IRF-1-dependent", "pathway", "of", "DNA", "damage", "-", "induced", "apoptosis", "in", "mitogen", "-", "activated", "T", "lymphocytes", "." ]	[ "protein_molecule", "DNA_domain_or_region", "cell_line", "protein_family_or_group", "other_name", "mono_cell", "DNA_family_or_group", "cell_type" ]
IRF-1-dependent pathway, DNA damage - induced apoptosis, mitogen - activated T lymphocytes	99505_task2	Sentence: An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Instructions: please extract entity words from the input sentence	[ "O", "B-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]	An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes.	[ "An", "IRF-1-dependent", "pathway", "of", "DNA", "damage", "-", "induced", "apoptosis", "in", "mitogen", "-", "activated", "T", "lymphocytes", "." ]	[ "protein_molecule", "DNA_domain_or_region", "cell_line", "protein_family_or_group", "other_name", "mono_cell", "DNA_family_or_group", "cell_type" ]
telemedicine is an umlsterm, goals is an umlsterm, teleradiology is an umlsterm, user 's is an umlsterm, teleradiology is an umlsterm, data security is an umlsterm, maintenance is an umlsterm, rights is an umlsterm, standardization is an umlsterm, functions is an umlsterm, needs is an umlsterm, functions is an umlsterm, selection is an umlsterm, electronic is an umlsterm, documentation is an umlsterm, teleradiology is an umlsterm, guidelines is an umlsterm	DerRadiologe.70370260.eng.abstr_task0	Sentence: Specific radiological requirements have to be considered for the realization of telemedicine . In this article the goals and requirements for an extensive introduction of teleradiology will be defined from the radiological user's point of view . Necessary medical , legal and professional prerequisites for teleradiology are presented . Essential requirements , such as data security , maintenance of personal rights and standardization , must be realized . Application-specific requirements , e . g . quality and extent of teleradiological functions , as well as technological alternatives , are discussed . Each project must be carefully planned in relation to one's own needs , extent of functions and system selection . Topics , such as acknowledgement of electronic documentation , reimbursement of teleradiology and liability , must be clarified . Legal advice and the observance of quality guidelines are recommended . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Specific radiological requirements have to be considered for the realization of telemedicine . In this article the goals and requirements for an extensive introduction of teleradiology will be defined from the radiological user's point of view . Necessary medical , legal and professional prerequisites for teleradiology are presented . Essential requirements , such as data security , maintenance of personal rights and standardization , must be realized . Application-specific requirements , e . g . quality and extent of teleradiological functions , as well as technological alternatives , are discussed . Each project must be carefully planned in relation to one's own needs , extent of functions and system selection . Topics , such as acknowledgement of electronic documentation , reimbursement of teleradiology and liability , must be clarified . Legal advice and the observance of quality guidelines are recommended .	[ "Specific", "radiological", "requirements", "have", "to", "be", "considered", "for", "the", "realization", "of", "telemedicine", ".", "In", "this", "article", "the", "goals", "and", "requirements", "for", "an", "extensive", "introduction", "of", "teleradiology", "will", "be", "defined", "from", "the", "radiological", "user", "'s", "point", "of", "view", ".", "Necessary", "medical", ",", "legal", "and", "professional", "prerequisites", "for", "teleradiology", "are", "presented", ".", "Essential", "requirements", ",", "such", "as", "data", "security", ",", "maintenance", "of", "personal", "rights", "and", "standardization", ",", "must", "be", "realized", ".", "Application", "-", "specific", "requirements", ",", "e", ".", "g", ".", "quality", "and", "extent", "of", "teleradiological", "functions", ",", "as", "well", "as", "technological", "alternatives", ",", "are", "discussed", ".", "Each", "project", "must", "be", "carefully", "planned", "in", "relation", "to", "one", "'s", "own", "needs", ",", "extent", "of", "functions", "and", "system", "selection", ".", "Topics", ",", "such", "as", "acknowledgement", "of", "electronic", "documentation", ",", "reimbursement", "of", "teleradiology", "and", "liability", ",", "must", "be", "clarified", ".", "Legal", "advice", "and", "the", "observance", "of", "quality", "guidelines", "are", "recommended", "." ]	[ "umlsterm" ]
telemedicine is an umlsterm, goals is an umlsterm, teleradiology is an umlsterm, user 's is an umlsterm, teleradiology is an umlsterm, data security is an umlsterm, maintenance is an umlsterm, rights is an umlsterm, standardization is an umlsterm, functions is an umlsterm, needs is an umlsterm, functions is an umlsterm, selection is an umlsterm, electronic is an umlsterm, documentation is an umlsterm, teleradiology is an umlsterm, guidelines is an umlsterm	DerRadiologe.70370260.eng.abstr_task1	Sentence: Specific radiological requirements have to be considered for the realization of telemedicine . In this article the goals and requirements for an extensive introduction of teleradiology will be defined from the radiological user's point of view . Necessary medical , legal and professional prerequisites for teleradiology are presented . Essential requirements , such as data security , maintenance of personal rights and standardization , must be realized . Application-specific requirements , e . g . quality and extent of teleradiological functions , as well as technological alternatives , are discussed . Each project must be carefully planned in relation to one's own needs , extent of functions and system selection . Topics , such as acknowledgement of electronic documentation , reimbursement of teleradiology and liability , must be clarified . Legal advice and the observance of quality guidelines are recommended . Instructions: please typing these entity words according to sentence: telemedicine, goals, teleradiology, user 's, teleradiology, data security, maintenance, rights, standardization, functions, needs, functions, selection, electronic, documentation, teleradiology, guidelines Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Specific radiological requirements have to be considered for the realization of telemedicine . In this article the goals and requirements for an extensive introduction of teleradiology will be defined from the radiological user's point of view . Necessary medical , legal and professional prerequisites for teleradiology are presented . Essential requirements , such as data security , maintenance of personal rights and standardization , must be realized . Application-specific requirements , e . g . quality and extent of teleradiological functions , as well as technological alternatives , are discussed . Each project must be carefully planned in relation to one's own needs , extent of functions and system selection . Topics , such as acknowledgement of electronic documentation , reimbursement of teleradiology and liability , must be clarified . Legal advice and the observance of quality guidelines are recommended .	[ "Specific", "radiological", "requirements", "have", "to", "be", "considered", "for", "the", "realization", "of", "telemedicine", ".", "In", "this", "article", "the", "goals", "and", "requirements", "for", "an", "extensive", "introduction", "of", "teleradiology", "will", "be", "defined", "from", "the", "radiological", "user", "'s", "point", "of", "view", ".", "Necessary", "medical", ",", "legal", "and", "professional", "prerequisites", "for", "teleradiology", "are", "presented", ".", "Essential", "requirements", ",", "such", "as", "data", "security", ",", "maintenance", "of", "personal", "rights", "and", "standardization", ",", "must", "be", "realized", ".", "Application", "-", "specific", "requirements", ",", "e", ".", "g", ".", "quality", "and", "extent", "of", "teleradiological", "functions", ",", "as", "well", "as", "technological", "alternatives", ",", "are", "discussed", ".", "Each", "project", "must", "be", "carefully", "planned", "in", "relation", "to", "one", "'s", "own", "needs", ",", "extent", "of", "functions", "and", "system", "selection", ".", "Topics", ",", "such", "as", "acknowledgement", "of", "electronic", "documentation", ",", "reimbursement", "of", "teleradiology", "and", "liability", ",", "must", "be", "clarified", ".", "Legal", "advice", "and", "the", "observance", "of", "quality", "guidelines", "are", "recommended", "." ]	[ "umlsterm" ]
telemedicine, goals, teleradiology, user 's, teleradiology, data security, maintenance, rights, standardization, functions, needs, functions, selection, electronic, documentation, teleradiology, guidelines	DerRadiologe.70370260.eng.abstr_task2	Sentence: Specific radiological requirements have to be considered for the realization of telemedicine . In this article the goals and requirements for an extensive introduction of teleradiology will be defined from the radiological user's point of view . Necessary medical , legal and professional prerequisites for teleradiology are presented . Essential requirements , such as data security , maintenance of personal rights and standardization , must be realized . Application-specific requirements , e . g . quality and extent of teleradiological functions , as well as technological alternatives , are discussed . Each project must be carefully planned in relation to one's own needs , extent of functions and system selection . Topics , such as acknowledgement of electronic documentation , reimbursement of teleradiology and liability , must be clarified . Legal advice and the observance of quality guidelines are recommended . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Specific radiological requirements have to be considered for the realization of telemedicine . In this article the goals and requirements for an extensive introduction of teleradiology will be defined from the radiological user's point of view . Necessary medical , legal and professional prerequisites for teleradiology are presented . Essential requirements , such as data security , maintenance of personal rights and standardization , must be realized . Application-specific requirements , e . g . quality and extent of teleradiological functions , as well as technological alternatives , are discussed . Each project must be carefully planned in relation to one's own needs , extent of functions and system selection . Topics , such as acknowledgement of electronic documentation , reimbursement of teleradiology and liability , must be clarified . Legal advice and the observance of quality guidelines are recommended .	[ "Specific", "radiological", "requirements", "have", "to", "be", "considered", "for", "the", "realization", "of", "telemedicine", ".", "In", "this", "article", "the", "goals", "and", "requirements", "for", "an", "extensive", "introduction", "of", "teleradiology", "will", "be", "defined", "from", "the", "radiological", "user", "'s", "point", "of", "view", ".", "Necessary", "medical", ",", "legal", "and", "professional", "prerequisites", "for", "teleradiology", "are", "presented", ".", "Essential", "requirements", ",", "such", "as", "data", "security", ",", "maintenance", "of", "personal", "rights", "and", "standardization", ",", "must", "be", "realized", ".", "Application", "-", "specific", "requirements", ",", "e", ".", "g", ".", "quality", "and", "extent", "of", "teleradiological", "functions", ",", "as", "well", "as", "technological", "alternatives", ",", "are", "discussed", ".", "Each", "project", "must", "be", "carefully", "planned", "in", "relation", "to", "one", "'s", "own", "needs", ",", "extent", "of", "functions", "and", "system", "selection", ".", "Topics", ",", "such", "as", "acknowledgement", "of", "electronic", "documentation", ",", "reimbursement", "of", "teleradiology", "and", "liability", ",", "must", "be", "clarified", ".", "Legal", "advice", "and", "the", "observance", "of", "quality", "guidelines", "are", "recommended", "." ]	[ "umlsterm" ]
assessment is an umlsterm, interviews is an umlsterm, patients is an umlsterm, neurotic depressions is an umlsterm, patients is an umlsterm, phobia is an umlsterm, panic disorders is an umlsterm, patients is an umlsterm, personality disorders is an umlsterm, patients is an umlsterm, bulimia is an umlsterm, interviews is an umlsterm, analysis is an umlsterm, biography is an umlsterm, personality is an umlsterm, self - description is an umlsterm, diagnostic is an umlsterm, patients is an umlsterm, diagnostic is an umlsterm, neurosis is an umlsterm, personality disorders is an umlsterm, needs is an umlsterm, psychotherapy is an umlsterm, psychotherapy is an umlsterm, research is an umlsterm	Psychotherapeut.70420163.eng.abstr_task0	Sentence: A study of verbatim transcripts of 47 psychotherapeutical assessment interviews . Four groups were examined : patients with neurotic depressions ( n=11), patients with phobia and panic disorders ( n=12), patients suffering from severe personality disorders ( n=12), and patients with bulimia ( n=12). The interviews were systematically evaluated by means of qualitative content analysis focussing on the following categories : subjective theories of illness , biography , and characterization of their own personality . As a result ideal types of self-description were found which also serve to reconstruct the determinants of the diagnostic process . Based on the patients ' self-descriptions arguments could be developed for reducing the present confusing multiplicity of nosological concepts . One could arrive at a simpler system of broader diagnostic concepts in the field of neurosis and personality disorders which is more appropriate to the needs of clinical psychotherapy and psychotherapy research . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O" ]	A study of verbatim transcripts of 47 psychotherapeutical assessment interviews . Four groups were examined : patients with neurotic depressions ( n=11), patients with phobia and panic disorders ( n=12), patients suffering from severe personality disorders ( n=12), and patients with bulimia ( n=12). The interviews were systematically evaluated by means of qualitative content analysis focussing on the following categories : subjective theories of illness , biography , and characterization of their own personality . As a result ideal types of self-description were found which also serve to reconstruct the determinants of the diagnostic process . Based on the patients ' self-descriptions arguments could be developed for reducing the present confusing multiplicity of nosological concepts . One could arrive at a simpler system of broader diagnostic concepts in the field of neurosis and personality disorders which is more appropriate to the needs of clinical psychotherapy and psychotherapy research .	[ "A", "study", "of", "verbatim", "transcripts", "of", "47", "psychotherapeutical", "assessment", "interviews", ".", "Four", "groups", "were", "examined", ":", "patients", "with", "neurotic", "depressions", "(", "n=11", ")", ",", "patients", "with", "phobia", "and", "panic", "disorders", "(", "n=12", ")", ",", "patients", "suffering", "from", "severe", "personality", "disorders", "(", "n=12", ")", ",", "and", "patients", "with", "bulimia", "(", "n=12", ")", ".", "The", "interviews", "were", "systematically", "evaluated", "by", "means", "of", "qualitative", "content", "analysis", "focussing", "on", "the", "following", "categories", ":", "subjective", "theories", "of", "illness", ",", "biography", ",", "and", "characterization", "of", "their", "own", "personality", ".", "As", "a", "result", "ideal", "types", "of", "self", "-", "description", "were", "found", "which", "also", "serve", "to", "reconstruct", "the", "determinants", "of", "the", "diagnostic", "process", ".", "Based", "on", "the", "patients", "'", "self", "-", "descriptions", "arguments", "could", "be", "developed", "for", "reducing", "the", "present", "confusing", "multiplicity", "of", "nosological", "concepts", ".", "One", "could", "arrive", "at", "a", "simpler", "system", "of", "broader", "diagnostic", "concepts", "in", "the", "field", "of", "neurosis", "and", "personality", "disorders", "which", "is", "more", "appropriate", "to", "the", "needs", "of", "clinical", "psychotherapy", "and", "psychotherapy", "research", "." ]	[ "umlsterm" ]
assessment is an umlsterm, interviews is an umlsterm, patients is an umlsterm, neurotic depressions is an umlsterm, patients is an umlsterm, phobia is an umlsterm, panic disorders is an umlsterm, patients is an umlsterm, personality disorders is an umlsterm, patients is an umlsterm, bulimia is an umlsterm, interviews is an umlsterm, analysis is an umlsterm, biography is an umlsterm, personality is an umlsterm, self - description is an umlsterm, diagnostic is an umlsterm, patients is an umlsterm, diagnostic is an umlsterm, neurosis is an umlsterm, personality disorders is an umlsterm, needs is an umlsterm, psychotherapy is an umlsterm, psychotherapy is an umlsterm, research is an umlsterm	Psychotherapeut.70420163.eng.abstr_task1	Sentence: A study of verbatim transcripts of 47 psychotherapeutical assessment interviews . Four groups were examined : patients with neurotic depressions ( n=11), patients with phobia and panic disorders ( n=12), patients suffering from severe personality disorders ( n=12), and patients with bulimia ( n=12). The interviews were systematically evaluated by means of qualitative content analysis focussing on the following categories : subjective theories of illness , biography , and characterization of their own personality . As a result ideal types of self-description were found which also serve to reconstruct the determinants of the diagnostic process . Based on the patients ' self-descriptions arguments could be developed for reducing the present confusing multiplicity of nosological concepts . One could arrive at a simpler system of broader diagnostic concepts in the field of neurosis and personality disorders which is more appropriate to the needs of clinical psychotherapy and psychotherapy research . Instructions: please typing these entity words according to sentence: assessment, interviews, patients, neurotic depressions, patients, phobia, panic disorders, patients, personality disorders, patients, bulimia, interviews, analysis, biography, personality, self - description, diagnostic, patients, diagnostic, neurosis, personality disorders, needs, psychotherapy, psychotherapy, research Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O" ]	A study of verbatim transcripts of 47 psychotherapeutical assessment interviews . Four groups were examined : patients with neurotic depressions ( n=11), patients with phobia and panic disorders ( n=12), patients suffering from severe personality disorders ( n=12), and patients with bulimia ( n=12). The interviews were systematically evaluated by means of qualitative content analysis focussing on the following categories : subjective theories of illness , biography , and characterization of their own personality . As a result ideal types of self-description were found which also serve to reconstruct the determinants of the diagnostic process . Based on the patients ' self-descriptions arguments could be developed for reducing the present confusing multiplicity of nosological concepts . One could arrive at a simpler system of broader diagnostic concepts in the field of neurosis and personality disorders which is more appropriate to the needs of clinical psychotherapy and psychotherapy research .	[ "A", "study", "of", "verbatim", "transcripts", "of", "47", "psychotherapeutical", "assessment", "interviews", ".", "Four", "groups", "were", "examined", ":", "patients", "with", "neurotic", "depressions", "(", "n=11", ")", ",", "patients", "with", "phobia", "and", "panic", "disorders", "(", "n=12", ")", ",", "patients", "suffering", "from", "severe", "personality", "disorders", "(", "n=12", ")", ",", "and", "patients", "with", "bulimia", "(", "n=12", ")", ".", "The", "interviews", "were", "systematically", "evaluated", "by", "means", "of", "qualitative", "content", "analysis", "focussing", "on", "the", "following", "categories", ":", "subjective", "theories", "of", "illness", ",", "biography", ",", "and", "characterization", "of", "their", "own", "personality", ".", "As", "a", "result", "ideal", "types", "of", "self", "-", "description", "were", "found", "which", "also", "serve", "to", "reconstruct", "the", "determinants", "of", "the", "diagnostic", "process", ".", "Based", "on", "the", "patients", "'", "self", "-", "descriptions", "arguments", "could", "be", "developed", "for", "reducing", "the", "present", "confusing", "multiplicity", "of", "nosological", "concepts", ".", "One", "could", "arrive", "at", "a", "simpler", "system", "of", "broader", "diagnostic", "concepts", "in", "the", "field", "of", "neurosis", "and", "personality", "disorders", "which", "is", "more", "appropriate", "to", "the", "needs", "of", "clinical", "psychotherapy", "and", "psychotherapy", "research", "." ]	[ "umlsterm" ]
assessment, interviews, patients, neurotic depressions, patients, phobia, panic disorders, patients, personality disorders, patients, bulimia, interviews, analysis, biography, personality, self - description, diagnostic, patients, diagnostic, neurosis, personality disorders, needs, psychotherapy, psychotherapy, research	Psychotherapeut.70420163.eng.abstr_task2	Sentence: A study of verbatim transcripts of 47 psychotherapeutical assessment interviews . Four groups were examined : patients with neurotic depressions ( n=11), patients with phobia and panic disorders ( n=12), patients suffering from severe personality disorders ( n=12), and patients with bulimia ( n=12). The interviews were systematically evaluated by means of qualitative content analysis focussing on the following categories : subjective theories of illness , biography , and characterization of their own personality . As a result ideal types of self-description were found which also serve to reconstruct the determinants of the diagnostic process . Based on the patients ' self-descriptions arguments could be developed for reducing the present confusing multiplicity of nosological concepts . One could arrive at a simpler system of broader diagnostic concepts in the field of neurosis and personality disorders which is more appropriate to the needs of clinical psychotherapy and psychotherapy research . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O" ]	A study of verbatim transcripts of 47 psychotherapeutical assessment interviews . Four groups were examined : patients with neurotic depressions ( n=11), patients with phobia and panic disorders ( n=12), patients suffering from severe personality disorders ( n=12), and patients with bulimia ( n=12). The interviews were systematically evaluated by means of qualitative content analysis focussing on the following categories : subjective theories of illness , biography , and characterization of their own personality . As a result ideal types of self-description were found which also serve to reconstruct the determinants of the diagnostic process . Based on the patients ' self-descriptions arguments could be developed for reducing the present confusing multiplicity of nosological concepts . One could arrive at a simpler system of broader diagnostic concepts in the field of neurosis and personality disorders which is more appropriate to the needs of clinical psychotherapy and psychotherapy research .	[ "A", "study", "of", "verbatim", "transcripts", "of", "47", "psychotherapeutical", "assessment", "interviews", ".", "Four", "groups", "were", "examined", ":", "patients", "with", "neurotic", "depressions", "(", "n=11", ")", ",", "patients", "with", "phobia", "and", "panic", "disorders", "(", "n=12", ")", ",", "patients", "suffering", "from", "severe", "personality", "disorders", "(", "n=12", ")", ",", "and", "patients", "with", "bulimia", "(", "n=12", ")", ".", "The", "interviews", "were", "systematically", "evaluated", "by", "means", "of", "qualitative", "content", "analysis", "focussing", "on", "the", "following", "categories", ":", "subjective", "theories", "of", "illness", ",", "biography", ",", "and", "characterization", "of", "their", "own", "personality", ".", "As", "a", "result", "ideal", "types", "of", "self", "-", "description", "were", "found", "which", "also", "serve", "to", "reconstruct", "the", "determinants", "of", "the", "diagnostic", "process", ".", "Based", "on", "the", "patients", "'", "self", "-", "descriptions", "arguments", "could", "be", "developed", "for", "reducing", "the", "present", "confusing", "multiplicity", "of", "nosological", "concepts", ".", "One", "could", "arrive", "at", "a", "simpler", "system", "of", "broader", "diagnostic", "concepts", "in", "the", "field", "of", "neurosis", "and", "personality", "disorders", "which", "is", "more", "appropriate", "to", "the", "needs", "of", "clinical", "psychotherapy", "and", "psychotherapy", "research", "." ]	[ "umlsterm" ]
Bipolar transurethral resection of the prostate is a Intervention_Surgical, monopolar technique : is a Intervention_Surgical, 202 is a Participant_Sample-size, bipolar is a Intervention_Surgical, conventional monopolar transurethral resection of the prostate ( TURP ) is a Intervention_Surgical, blood loss is a Outcome_Physical, resection speed is a Outcome_Other, operative duration is a Outcome_Other, resection weight is a Outcome_Other, radicality of resection is a Outcome_Other, blood haemoglobin concentration is a Outcome_Physical	42783_task0	Sentence: Bipolar transurethral resection of the prostate causes less bleeding than the monopolar technique : a single-centre randomized trial of 202 patients . OBJECTIVE To compare bipolar with the conventional monopolar transurethral resection of the prostate ( TURP ) for blood loss and speed of resection . PATIENTS AND METHODS In all , 202 consecutive patients from the hospital waiting list were randomized to undergo TURP using either a bipolar system ( Surgmaster TURis , Olympus , Tokyo , Japan ) or a monopolar system ( 24 F , Storz , Tübingen , Germany ) . The blood loss during and after surgery was measured using a photometer . Other variables compared included indices of resection speed and transfusion rate . RESULTS There were no statistically significant differences in operative duration , resection weight , resection speed or radicality of resection . However , the median blood loss was 235 mL for the bipolar and 350 mL for monopolar TURP ( P < 0.001 ) . The decrease in blood haemoglobin concentration during the day of surgery was smaller in the bipolar group ( 5.5 % vs 9.6 % P < 0.001 ) . Fewer patients were transfused with erythrocytes ( 4 % vs 11 % , P < 0.01 ) , which can be explained by the much lower 75th percentile for blood loss in the bipolar group ( at 472 vs 855 mL , respectively ) . CONCLUSIONS Bipolar TURP using the TURis system was performed with the same speed as monopolar TURP but caused 34 % less bleeding , the difference being greatest ( 81 % ) for the largest blood losses . Bipolar TURP also required fewer erythrocyte transfusions than the conventional monopolar technique . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Outcome_Physical, Intervention_Surgical, Participant_Sample-size	[ "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Bipolar transurethral resection of the prostate causes less bleeding than the monopolar technique : a single-centre randomized trial of 202 patients . OBJECTIVE To compare bipolar with the conventional monopolar transurethral resection of the prostate ( TURP ) for blood loss and speed of resection . PATIENTS AND METHODS In all , 202 consecutive patients from the hospital waiting list were randomized to undergo TURP using either a bipolar system ( Surgmaster TURis , Olympus , Tokyo , Japan ) or a monopolar system ( 24 F , Storz , Tübingen , Germany ) . The blood loss during and after surgery was measured using a photometer . Other variables compared included indices of resection speed and transfusion rate . RESULTS There were no statistically significant differences in operative duration , resection weight , resection speed or radicality of resection . However , the median blood loss was 235 mL for the bipolar and 350 mL for monopolar TURP ( P < 0.001 ) . The decrease in blood haemoglobin concentration during the day of surgery was smaller in the bipolar group ( 5.5 % vs 9.6 % P < 0.001 ) . Fewer patients were transfused with erythrocytes ( 4 % vs 11 % , P < 0.01 ) , which can be explained by the much lower 75th percentile for blood loss in the bipolar group ( at 472 vs 855 mL , respectively ) . CONCLUSIONS Bipolar TURP using the TURis system was performed with the same speed as monopolar TURP but caused 34 % less bleeding , the difference being greatest ( 81 % ) for the largest blood losses . Bipolar TURP also required fewer erythrocyte transfusions than the conventional monopolar technique .	[ "Bipolar", "transurethral", "resection", "of", "the", "prostate", "causes", "less", "bleeding", "than", "the", "monopolar", "technique", ":", "a", "single", "-", "centre", "randomized", "trial", "of", "202", "patients", ".", "OBJECTIVE", "To", "compare", "bipolar", "with", "the", "conventional", "monopolar", "transurethral", "resection", "of", "the", "prostate", "(", "TURP", ")", "for", "blood", "loss", "and", "speed", "of", "resection", ".", "PATIENTS", "AND", "METHODS", "In", "all", ",", "202", "consecutive", "patients", "from", "the", "hospital", "waiting", "list", "were", "randomized", "to", "undergo", "TURP", "using", "either", "a", "bipolar", "system", "(", "Surgmaster", "TURis", ",", "Olympus", ",", "Tokyo", ",", "Japan", ")", "or", "a", "monopolar", "system", "(", "24", "F", ",", "Storz", ",", "Tübingen", ",", "Germany", ")", ".", "The", "blood", "loss", "during", "and", "after", "surgery", "was", "measured", "using", "a", "photometer", ".", "Other", "variables", "compared", "included", "indices", "of", "resection", "speed", "and", "transfusion", "rate", ".", "RESULTS", "There", "were", "no", "statistically", "significant", "differences", "in", "operative", "duration", ",", "resection", "weight", ",", "resection", "speed", "or", "radicality", "of", "resection", ".", "However", ",", "the", "median", "blood", "loss", "was", "235", "mL", "for", "the", "bipolar", "and", "350", "mL", "for", "monopolar", "TURP", "(", "P", "<", "0.001", ")", ".", "The", "decrease", "in", "blood", "haemoglobin", "concentration", "during", "the", "day", "of", "surgery", "was", "smaller", "in", "the", "bipolar", "group", "(", "5.5", "%", "vs", "9.6", "%", "P", "<", "0.001", ")", ".", "Fewer", "patients", "were", "transfused", "with", "erythrocytes", "(", "4", "%", "vs", "11", "%", ",", "P", "<", "0.01", ")", ",", "which", "can", "be", "explained", "by", "the", "much", "lower", "75th", "percentile", "for", "blood", "loss", "in", "the", "bipolar", "group", "(", "at", "472", "vs", "855", "mL", ",", "respectively", ")", ".", "CONCLUSIONS", "Bipolar", "TURP", "using", "the", "TURis", "system", "was", "performed", "with", "the", "same", "speed", "as", "monopolar", "TURP", "but", "caused", "34", "%", "less", "bleeding", ",", "the", "difference", "being", "greatest", "(", "81", "%", ")", "for", "the", "largest", "blood", "losses", ".", "Bipolar", "TURP", "also", "required", "fewer", "erythrocyte", "transfusions", "than", "the", "conventional", "monopolar", "technique", "." ]	[ "Intervention_Surgical", "Participant_Condition", "Outcome_Physical", "Outcome_Other", "Participant_Sample-size" ]
Bipolar transurethral resection of the prostate is a Intervention_Surgical, monopolar technique : is a Intervention_Surgical, 202 is a Participant_Sample-size, bipolar is a Intervention_Surgical, conventional monopolar transurethral resection of the prostate ( TURP ) is a Intervention_Surgical, blood loss is a Outcome_Physical, resection speed is a Outcome_Other, operative duration is a Outcome_Other, resection weight is a Outcome_Other, radicality of resection is a Outcome_Other, blood haemoglobin concentration is a Outcome_Physical	42783_task1	Sentence: Bipolar transurethral resection of the prostate causes less bleeding than the monopolar technique : a single-centre randomized trial of 202 patients . OBJECTIVE To compare bipolar with the conventional monopolar transurethral resection of the prostate ( TURP ) for blood loss and speed of resection . PATIENTS AND METHODS In all , 202 consecutive patients from the hospital waiting list were randomized to undergo TURP using either a bipolar system ( Surgmaster TURis , Olympus , Tokyo , Japan ) or a monopolar system ( 24 F , Storz , Tübingen , Germany ) . The blood loss during and after surgery was measured using a photometer . Other variables compared included indices of resection speed and transfusion rate . RESULTS There were no statistically significant differences in operative duration , resection weight , resection speed or radicality of resection . However , the median blood loss was 235 mL for the bipolar and 350 mL for monopolar TURP ( P < 0.001 ) . The decrease in blood haemoglobin concentration during the day of surgery was smaller in the bipolar group ( 5.5 % vs 9.6 % P < 0.001 ) . Fewer patients were transfused with erythrocytes ( 4 % vs 11 % , P < 0.01 ) , which can be explained by the much lower 75th percentile for blood loss in the bipolar group ( at 472 vs 855 mL , respectively ) . CONCLUSIONS Bipolar TURP using the TURis system was performed with the same speed as monopolar TURP but caused 34 % less bleeding , the difference being greatest ( 81 % ) for the largest blood losses . Bipolar TURP also required fewer erythrocyte transfusions than the conventional monopolar technique . Instructions: please typing these entity words according to sentence: Bipolar transurethral resection of the prostate, monopolar technique :, 202, bipolar, conventional monopolar transurethral resection of the prostate ( TURP ), blood loss, resection speed, operative duration, resection weight, radicality of resection, blood haemoglobin concentration Options: Outcome_Other, Outcome_Physical, Intervention_Surgical, Participant_Sample-size	[ "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Bipolar transurethral resection of the prostate causes less bleeding than the monopolar technique : a single-centre randomized trial of 202 patients . OBJECTIVE To compare bipolar with the conventional monopolar transurethral resection of the prostate ( TURP ) for blood loss and speed of resection . PATIENTS AND METHODS In all , 202 consecutive patients from the hospital waiting list were randomized to undergo TURP using either a bipolar system ( Surgmaster TURis , Olympus , Tokyo , Japan ) or a monopolar system ( 24 F , Storz , Tübingen , Germany ) . The blood loss during and after surgery was measured using a photometer . Other variables compared included indices of resection speed and transfusion rate . RESULTS There were no statistically significant differences in operative duration , resection weight , resection speed or radicality of resection . However , the median blood loss was 235 mL for the bipolar and 350 mL for monopolar TURP ( P < 0.001 ) . The decrease in blood haemoglobin concentration during the day of surgery was smaller in the bipolar group ( 5.5 % vs 9.6 % P < 0.001 ) . Fewer patients were transfused with erythrocytes ( 4 % vs 11 % , P < 0.01 ) , which can be explained by the much lower 75th percentile for blood loss in the bipolar group ( at 472 vs 855 mL , respectively ) . CONCLUSIONS Bipolar TURP using the TURis system was performed with the same speed as monopolar TURP but caused 34 % less bleeding , the difference being greatest ( 81 % ) for the largest blood losses . Bipolar TURP also required fewer erythrocyte transfusions than the conventional monopolar technique .	[ "Bipolar", "transurethral", "resection", "of", "the", "prostate", "causes", "less", "bleeding", "than", "the", "monopolar", "technique", ":", "a", "single", "-", "centre", "randomized", "trial", "of", "202", "patients", ".", "OBJECTIVE", "To", "compare", "bipolar", "with", "the", "conventional", "monopolar", "transurethral", "resection", "of", "the", "prostate", "(", "TURP", ")", "for", "blood", "loss", "and", "speed", "of", "resection", ".", "PATIENTS", "AND", "METHODS", "In", "all", ",", "202", "consecutive", "patients", "from", "the", "hospital", "waiting", "list", "were", "randomized", "to", "undergo", "TURP", "using", "either", "a", "bipolar", "system", "(", "Surgmaster", "TURis", ",", "Olympus", ",", "Tokyo", ",", "Japan", ")", "or", "a", "monopolar", "system", "(", "24", "F", ",", "Storz", ",", "Tübingen", ",", "Germany", ")", ".", "The", "blood", "loss", "during", "and", "after", "surgery", "was", "measured", "using", "a", "photometer", ".", "Other", "variables", "compared", "included", "indices", "of", "resection", "speed", "and", "transfusion", "rate", ".", "RESULTS", "There", "were", "no", "statistically", "significant", "differences", "in", "operative", "duration", ",", "resection", "weight", ",", "resection", "speed", "or", "radicality", "of", "resection", ".", "However", ",", "the", "median", "blood", "loss", "was", "235", "mL", "for", "the", "bipolar", "and", "350", "mL", "for", "monopolar", "TURP", "(", "P", "<", "0.001", ")", ".", "The", "decrease", "in", "blood", "haemoglobin", "concentration", "during", "the", "day", "of", "surgery", "was", "smaller", "in", "the", "bipolar", "group", "(", "5.5", "%", "vs", "9.6", "%", "P", "<", "0.001", ")", ".", "Fewer", "patients", "were", "transfused", "with", "erythrocytes", "(", "4", "%", "vs", "11", "%", ",", "P", "<", "0.01", ")", ",", "which", "can", "be", "explained", "by", "the", "much", "lower", "75th", "percentile", "for", "blood", "loss", "in", "the", "bipolar", "group", "(", "at", "472", "vs", "855", "mL", ",", "respectively", ")", ".", "CONCLUSIONS", "Bipolar", "TURP", "using", "the", "TURis", "system", "was", "performed", "with", "the", "same", "speed", "as", "monopolar", "TURP", "but", "caused", "34", "%", "less", "bleeding", ",", "the", "difference", "being", "greatest", "(", "81", "%", ")", "for", "the", "largest", "blood", "losses", ".", "Bipolar", "TURP", "also", "required", "fewer", "erythrocyte", "transfusions", "than", "the", "conventional", "monopolar", "technique", "." ]	[ "Intervention_Surgical", "Participant_Condition", "Outcome_Physical", "Outcome_Other", "Participant_Sample-size" ]
Bipolar transurethral resection of the prostate, monopolar technique :, 202, bipolar, conventional monopolar transurethral resection of the prostate ( TURP ), blood loss, resection speed, operative duration, resection weight, radicality of resection, blood haemoglobin concentration	42783_task2	Sentence: Bipolar transurethral resection of the prostate causes less bleeding than the monopolar technique : a single-centre randomized trial of 202 patients . OBJECTIVE To compare bipolar with the conventional monopolar transurethral resection of the prostate ( TURP ) for blood loss and speed of resection . PATIENTS AND METHODS In all , 202 consecutive patients from the hospital waiting list were randomized to undergo TURP using either a bipolar system ( Surgmaster TURis , Olympus , Tokyo , Japan ) or a monopolar system ( 24 F , Storz , Tübingen , Germany ) . The blood loss during and after surgery was measured using a photometer . Other variables compared included indices of resection speed and transfusion rate . RESULTS There were no statistically significant differences in operative duration , resection weight , resection speed or radicality of resection . However , the median blood loss was 235 mL for the bipolar and 350 mL for monopolar TURP ( P < 0.001 ) . The decrease in blood haemoglobin concentration during the day of surgery was smaller in the bipolar group ( 5.5 % vs 9.6 % P < 0.001 ) . Fewer patients were transfused with erythrocytes ( 4 % vs 11 % , P < 0.01 ) , which can be explained by the much lower 75th percentile for blood loss in the bipolar group ( at 472 vs 855 mL , respectively ) . CONCLUSIONS Bipolar TURP using the TURis system was performed with the same speed as monopolar TURP but caused 34 % less bleeding , the difference being greatest ( 81 % ) for the largest blood losses . Bipolar TURP also required fewer erythrocyte transfusions than the conventional monopolar technique . Instructions: please extract entity words from the input sentence	[ "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Bipolar transurethral resection of the prostate causes less bleeding than the monopolar technique : a single-centre randomized trial of 202 patients . OBJECTIVE To compare bipolar with the conventional monopolar transurethral resection of the prostate ( TURP ) for blood loss and speed of resection . PATIENTS AND METHODS In all , 202 consecutive patients from the hospital waiting list were randomized to undergo TURP using either a bipolar system ( Surgmaster TURis , Olympus , Tokyo , Japan ) or a monopolar system ( 24 F , Storz , Tübingen , Germany ) . The blood loss during and after surgery was measured using a photometer . Other variables compared included indices of resection speed and transfusion rate . RESULTS There were no statistically significant differences in operative duration , resection weight , resection speed or radicality of resection . However , the median blood loss was 235 mL for the bipolar and 350 mL for monopolar TURP ( P < 0.001 ) . The decrease in blood haemoglobin concentration during the day of surgery was smaller in the bipolar group ( 5.5 % vs 9.6 % P < 0.001 ) . Fewer patients were transfused with erythrocytes ( 4 % vs 11 % , P < 0.01 ) , which can be explained by the much lower 75th percentile for blood loss in the bipolar group ( at 472 vs 855 mL , respectively ) . CONCLUSIONS Bipolar TURP using the TURis system was performed with the same speed as monopolar TURP but caused 34 % less bleeding , the difference being greatest ( 81 % ) for the largest blood losses . Bipolar TURP also required fewer erythrocyte transfusions than the conventional monopolar technique .	[ "Bipolar", "transurethral", "resection", "of", "the", "prostate", "causes", "less", "bleeding", "than", "the", "monopolar", "technique", ":", "a", "single", "-", "centre", "randomized", "trial", "of", "202", "patients", ".", "OBJECTIVE", "To", "compare", "bipolar", "with", "the", "conventional", "monopolar", "transurethral", "resection", "of", "the", "prostate", "(", "TURP", ")", "for", "blood", "loss", "and", "speed", "of", "resection", ".", "PATIENTS", "AND", "METHODS", "In", "all", ",", "202", "consecutive", "patients", "from", "the", "hospital", "waiting", "list", "were", "randomized", "to", "undergo", "TURP", "using", "either", "a", "bipolar", "system", "(", "Surgmaster", "TURis", ",", "Olympus", ",", "Tokyo", ",", "Japan", ")", "or", "a", "monopolar", "system", "(", "24", "F", ",", "Storz", ",", "Tübingen", ",", "Germany", ")", ".", "The", "blood", "loss", "during", "and", "after", "surgery", "was", "measured", "using", "a", "photometer", ".", "Other", "variables", "compared", "included", "indices", "of", "resection", "speed", "and", "transfusion", "rate", ".", "RESULTS", "There", "were", "no", "statistically", "significant", "differences", "in", "operative", "duration", ",", "resection", "weight", ",", "resection", "speed", "or", "radicality", "of", "resection", ".", "However", ",", "the", "median", "blood", "loss", "was", "235", "mL", "for", "the", "bipolar", "and", "350", "mL", "for", "monopolar", "TURP", "(", "P", "<", "0.001", ")", ".", "The", "decrease", "in", "blood", "haemoglobin", "concentration", "during", "the", "day", "of", "surgery", "was", "smaller", "in", "the", "bipolar", "group", "(", "5.5", "%", "vs", "9.6", "%", "P", "<", "0.001", ")", ".", "Fewer", "patients", "were", "transfused", "with", "erythrocytes", "(", "4", "%", "vs", "11", "%", ",", "P", "<", "0.01", ")", ",", "which", "can", "be", "explained", "by", "the", "much", "lower", "75th", "percentile", "for", "blood", "loss", "in", "the", "bipolar", "group", "(", "at", "472", "vs", "855", "mL", ",", "respectively", ")", ".", "CONCLUSIONS", "Bipolar", "TURP", "using", "the", "TURis", "system", "was", "performed", "with", "the", "same", "speed", "as", "monopolar", "TURP", "but", "caused", "34", "%", "less", "bleeding", ",", "the", "difference", "being", "greatest", "(", "81", "%", ")", "for", "the", "largest", "blood", "losses", ".", "Bipolar", "TURP", "also", "required", "fewer", "erythrocyte", "transfusions", "than", "the", "conventional", "monopolar", "technique", "." ]	[ "Intervention_Surgical", "Participant_Condition", "Outcome_Physical", "Outcome_Other", "Participant_Sample-size" ]
ritodrine is a CHEMICAL, ritodrine is a CHEMICAL, RU 486 is a CHEMICAL, mifepristone is a CHEMICAL, ritodrine is a CHEMICAL, beta 2-Adrenergic receptor is a GENE-Y, cyclic adenosine monophosphate is a CHEMICAL, Ritodrine is a CHEMICAL, ritodrine is a CHEMICAL, cyclic adenosine monophosphate is a CHEMICAL, beta 2-adrenergic receptor is a GENE-Y, ritodrine is a CHEMICAL, beta 2-adrenergic receptors is a GENE-Y	20354_task0	Sentence: Failure of ritodrine to prevent preterm labor in the sheep. OBJECTIVES: The purpose of this study was to determine whether continuous infusion of ritodrine could prevent preterm delivery in sheep. STUDY DESIGN: Sheep in preterm labor induced by RU 486 (mifepristone) received infusions of either ritodrine (n = 5) or saline solution (n = 5), and the progress of labor was monitored. beta 2-Adrenergic receptor density and function (agonist-induced cyclic adenosine monophosphate production) was measured in myometrial samples from both groups. RESULTS: Ritodrine initially inhibited labor contractions. This inhibition was only maintained for 16 hours, after which both the amplitude and frequency of electromyographic bursts and contractions returned. The failure of the myometrium to respond to ritodrine (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and beta 2-adrenergic receptor concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls. CONCLUSIONS: Continuous infusion of ritodrine to sheep in preterm labor produces only a transient inhibition of contractions. This desensitization is caused by a down-regulation of myometrial beta 2-adrenergic receptors. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]	Failure of ritodrine to prevent preterm labor in the sheep. OBJECTIVES: The purpose of this study was to determine whether continuous infusion of ritodrine could prevent preterm delivery in sheep. STUDY DESIGN: Sheep in preterm labor induced by RU 486 (mifepristone) received infusions of either ritodrine (n = 5) or saline solution (n = 5), and the progress of labor was monitored. beta 2-Adrenergic receptor density and function (agonist-induced cyclic adenosine monophosphate production) was measured in myometrial samples from both groups. RESULTS: Ritodrine initially inhibited labor contractions. This inhibition was only maintained for 16 hours, after which both the amplitude and frequency of electromyographic bursts and contractions returned. The failure of the myometrium to respond to ritodrine (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and beta 2-adrenergic receptor concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls. CONCLUSIONS: Continuous infusion of ritodrine to sheep in preterm labor produces only a transient inhibition of contractions. This desensitization is caused by a down-regulation of myometrial beta 2-adrenergic receptors.	[ "Failure", "of", "ritodrine", "to", "prevent", "preterm", "labor", "in", "the", "sheep", ".", "\n", "OBJECTIVES", ":", "The", "purpose", "of", "this", "study", "was", "to", "determine", "whether", "continuous", "infusion", "of", "ritodrine", "could", "prevent", "preterm", "delivery", "in", "sheep", ".", "STUDY", "DESIGN", ":", "Sheep", "in", "preterm", "labor", "induced", "by", "RU", "486", "(", "mifepristone", ")", "received", "infusions", "of", "either", "ritodrine", "(", "n", "=", "5", ")", "or", "saline", "solution", "(", "n", "=", "5", ")", ",", "and", "the", "progress", "of", "labor", "was", "monitored", ".", "beta", "2-Adrenergic", "receptor", "density", "and", "function", "(", "agonist", "-", "induced", "cyclic", "adenosine", "monophosphate", "production", ")", "was", "measured", "in", "myometrial", "samples", "from", "both", "groups", ".", "RESULTS", ":", "Ritodrine", "initially", "inhibited", "labor", "contractions", ".", "This", "inhibition", "was", "only", "maintained", "for", "16", "hours", ",", "after", "which", "both", "the", "amplitude", "and", "frequency", "of", "electromyographic", "bursts", "and", "contractions", "returned", ".", "The", "failure", "of", "the", "myometrium", "to", "respond", "to", "ritodrine", "(", "desensitization", ")", "was", "associated", "with", "significant", "reductions", "in", "agonist", "-", "induced", "cyclic", "adenosine", "monophosphate", "production", "and", "beta", "2-adrenergic", "receptor", "concentration", "in", "myometrial", "tissue", "collected", "from", "these", "animals", "compared", "with", "the", "saline", "solution", "-", "treated", "controls", ".", "CONCLUSIONS", ":", "Continuous", "infusion", "of", "ritodrine", "to", "sheep", "in", "preterm", "labor", "produces", "only", "a", "transient", "inhibition", "of", "contractions", ".", "This", "desensitization", "is", "caused", "by", "a", "down", "-", "regulation", "of", "myometrial", "beta", "2-adrenergic", "receptors", "." ]	[ "CHEMICAL", "GENE-Y" ]
ritodrine is a CHEMICAL, ritodrine is a CHEMICAL, RU 486 is a CHEMICAL, mifepristone is a CHEMICAL, ritodrine is a CHEMICAL, beta 2-Adrenergic receptor is a GENE-Y, cyclic adenosine monophosphate is a CHEMICAL, Ritodrine is a CHEMICAL, ritodrine is a CHEMICAL, cyclic adenosine monophosphate is a CHEMICAL, beta 2-adrenergic receptor is a GENE-Y, ritodrine is a CHEMICAL, beta 2-adrenergic receptors is a GENE-Y	20354_task1	Sentence: Failure of ritodrine to prevent preterm labor in the sheep. OBJECTIVES: The purpose of this study was to determine whether continuous infusion of ritodrine could prevent preterm delivery in sheep. STUDY DESIGN: Sheep in preterm labor induced by RU 486 (mifepristone) received infusions of either ritodrine (n = 5) or saline solution (n = 5), and the progress of labor was monitored. beta 2-Adrenergic receptor density and function (agonist-induced cyclic adenosine monophosphate production) was measured in myometrial samples from both groups. RESULTS: Ritodrine initially inhibited labor contractions. This inhibition was only maintained for 16 hours, after which both the amplitude and frequency of electromyographic bursts and contractions returned. The failure of the myometrium to respond to ritodrine (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and beta 2-adrenergic receptor concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls. CONCLUSIONS: Continuous infusion of ritodrine to sheep in preterm labor produces only a transient inhibition of contractions. This desensitization is caused by a down-regulation of myometrial beta 2-adrenergic receptors. Instructions: please typing these entity words according to sentence: ritodrine, ritodrine, RU 486, mifepristone, ritodrine, beta 2-Adrenergic receptor, cyclic adenosine monophosphate, Ritodrine, ritodrine, cyclic adenosine monophosphate, beta 2-adrenergic receptor, ritodrine, beta 2-adrenergic receptors Options: GENE-Y, CHEMICAL	[ "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]	Failure of ritodrine to prevent preterm labor in the sheep. OBJECTIVES: The purpose of this study was to determine whether continuous infusion of ritodrine could prevent preterm delivery in sheep. STUDY DESIGN: Sheep in preterm labor induced by RU 486 (mifepristone) received infusions of either ritodrine (n = 5) or saline solution (n = 5), and the progress of labor was monitored. beta 2-Adrenergic receptor density and function (agonist-induced cyclic adenosine monophosphate production) was measured in myometrial samples from both groups. RESULTS: Ritodrine initially inhibited labor contractions. This inhibition was only maintained for 16 hours, after which both the amplitude and frequency of electromyographic bursts and contractions returned. The failure of the myometrium to respond to ritodrine (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and beta 2-adrenergic receptor concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls. CONCLUSIONS: Continuous infusion of ritodrine to sheep in preterm labor produces only a transient inhibition of contractions. This desensitization is caused by a down-regulation of myometrial beta 2-adrenergic receptors.	[ "Failure", "of", "ritodrine", "to", "prevent", "preterm", "labor", "in", "the", "sheep", ".", "\n", "OBJECTIVES", ":", "The", "purpose", "of", "this", "study", "was", "to", "determine", "whether", "continuous", "infusion", "of", "ritodrine", "could", "prevent", "preterm", "delivery", "in", "sheep", ".", "STUDY", "DESIGN", ":", "Sheep", "in", "preterm", "labor", "induced", "by", "RU", "486", "(", "mifepristone", ")", "received", "infusions", "of", "either", "ritodrine", "(", "n", "=", "5", ")", "or", "saline", "solution", "(", "n", "=", "5", ")", ",", "and", "the", "progress", "of", "labor", "was", "monitored", ".", "beta", "2-Adrenergic", "receptor", "density", "and", "function", "(", "agonist", "-", "induced", "cyclic", "adenosine", "monophosphate", "production", ")", "was", "measured", "in", "myometrial", "samples", "from", "both", "groups", ".", "RESULTS", ":", "Ritodrine", "initially", "inhibited", "labor", "contractions", ".", "This", "inhibition", "was", "only", "maintained", "for", "16", "hours", ",", "after", "which", "both", "the", "amplitude", "and", "frequency", "of", "electromyographic", "bursts", "and", "contractions", "returned", ".", "The", "failure", "of", "the", "myometrium", "to", "respond", "to", "ritodrine", "(", "desensitization", ")", "was", "associated", "with", "significant", "reductions", "in", "agonist", "-", "induced", "cyclic", "adenosine", "monophosphate", "production", "and", "beta", "2-adrenergic", "receptor", "concentration", "in", "myometrial", "tissue", "collected", "from", "these", "animals", "compared", "with", "the", "saline", "solution", "-", "treated", "controls", ".", "CONCLUSIONS", ":", "Continuous", "infusion", "of", "ritodrine", "to", "sheep", "in", "preterm", "labor", "produces", "only", "a", "transient", "inhibition", "of", "contractions", ".", "This", "desensitization", "is", "caused", "by", "a", "down", "-", "regulation", "of", "myometrial", "beta", "2-adrenergic", "receptors", "." ]	[ "CHEMICAL", "GENE-Y" ]
ritodrine, ritodrine, RU 486, mifepristone, ritodrine, beta 2-Adrenergic receptor, cyclic adenosine monophosphate, Ritodrine, ritodrine, cyclic adenosine monophosphate, beta 2-adrenergic receptor, ritodrine, beta 2-adrenergic receptors	20354_task2	Sentence: Failure of ritodrine to prevent preterm labor in the sheep. OBJECTIVES: The purpose of this study was to determine whether continuous infusion of ritodrine could prevent preterm delivery in sheep. STUDY DESIGN: Sheep in preterm labor induced by RU 486 (mifepristone) received infusions of either ritodrine (n = 5) or saline solution (n = 5), and the progress of labor was monitored. beta 2-Adrenergic receptor density and function (agonist-induced cyclic adenosine monophosphate production) was measured in myometrial samples from both groups. RESULTS: Ritodrine initially inhibited labor contractions. This inhibition was only maintained for 16 hours, after which both the amplitude and frequency of electromyographic bursts and contractions returned. The failure of the myometrium to respond to ritodrine (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and beta 2-adrenergic receptor concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls. CONCLUSIONS: Continuous infusion of ritodrine to sheep in preterm labor produces only a transient inhibition of contractions. This desensitization is caused by a down-regulation of myometrial beta 2-adrenergic receptors. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]	Failure of ritodrine to prevent preterm labor in the sheep. OBJECTIVES: The purpose of this study was to determine whether continuous infusion of ritodrine could prevent preterm delivery in sheep. STUDY DESIGN: Sheep in preterm labor induced by RU 486 (mifepristone) received infusions of either ritodrine (n = 5) or saline solution (n = 5), and the progress of labor was monitored. beta 2-Adrenergic receptor density and function (agonist-induced cyclic adenosine monophosphate production) was measured in myometrial samples from both groups. RESULTS: Ritodrine initially inhibited labor contractions. This inhibition was only maintained for 16 hours, after which both the amplitude and frequency of electromyographic bursts and contractions returned. The failure of the myometrium to respond to ritodrine (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and beta 2-adrenergic receptor concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls. CONCLUSIONS: Continuous infusion of ritodrine to sheep in preterm labor produces only a transient inhibition of contractions. This desensitization is caused by a down-regulation of myometrial beta 2-adrenergic receptors.	[ "Failure", "of", "ritodrine", "to", "prevent", "preterm", "labor", "in", "the", "sheep", ".", "\n", "OBJECTIVES", ":", "The", "purpose", "of", "this", "study", "was", "to", "determine", "whether", "continuous", "infusion", "of", "ritodrine", "could", "prevent", "preterm", "delivery", "in", "sheep", ".", "STUDY", "DESIGN", ":", "Sheep", "in", "preterm", "labor", "induced", "by", "RU", "486", "(", "mifepristone", ")", "received", "infusions", "of", "either", "ritodrine", "(", "n", "=", "5", ")", "or", "saline", "solution", "(", "n", "=", "5", ")", ",", "and", "the", "progress", "of", "labor", "was", "monitored", ".", "beta", "2-Adrenergic", "receptor", "density", "and", "function", "(", "agonist", "-", "induced", "cyclic", "adenosine", "monophosphate", "production", ")", "was", "measured", "in", "myometrial", "samples", "from", "both", "groups", ".", "RESULTS", ":", "Ritodrine", "initially", "inhibited", "labor", "contractions", ".", "This", "inhibition", "was", "only", "maintained", "for", "16", "hours", ",", "after", "which", "both", "the", "amplitude", "and", "frequency", "of", "electromyographic", "bursts", "and", "contractions", "returned", ".", "The", "failure", "of", "the", "myometrium", "to", "respond", "to", "ritodrine", "(", "desensitization", ")", "was", "associated", "with", "significant", "reductions", "in", "agonist", "-", "induced", "cyclic", "adenosine", "monophosphate", "production", "and", "beta", "2-adrenergic", "receptor", "concentration", "in", "myometrial", "tissue", "collected", "from", "these", "animals", "compared", "with", "the", "saline", "solution", "-", "treated", "controls", ".", "CONCLUSIONS", ":", "Continuous", "infusion", "of", "ritodrine", "to", "sheep", "in", "preterm", "labor", "produces", "only", "a", "transient", "inhibition", "of", "contractions", ".", "This", "desensitization", "is", "caused", "by", "a", "down", "-", "regulation", "of", "myometrial", "beta", "2-adrenergic", "receptors", "." ]	[ "CHEMICAL", "GENE-Y" ]
arrhythmias is an umlsterm, diagnosis is an umlsterm, selection is an umlsterm, therapy is an umlsterm, Signs is an umlsterm, standard is an umlsterm, ECG is an umlsterm, analysis is an umlsterm, evaluation is an umlsterm, EPS is an umlsterm, myocardium is an umlsterm, EPS is an umlsterm, pacing is an umlsterm, pacing is an umlsterm, standard is an umlsterm, EPS is an umlsterm, pacing is an umlsterm, diagnostic is an umlsterm, leads is an umlsterm, pacing is an umlsterm, telemetry is an umlsterm, time is an umlsterm, analysis is an umlsterm, pacing is an umlsterm, arrhythmias is an umlsterm, pacing is an umlsterm, pacing is an umlsterm, sinus is an umlsterm, pacing is an umlsterm, pacing is an umlsterm, times is an umlsterm, pacing is an umlsterm, sinus is an umlsterm, pacing is an umlsterm, EPS is an umlsterm, pacing is an umlsterm, patients is an umlsterm, need is an umlsterm, pacing is an umlsterm, Time is an umlsterm, analysis is an umlsterm, diagnostic is an umlsterm, evaluation is an umlsterm, EPS is an umlsterm, pacing is an umlsterm	Herzschrittmachertherapie.00110117.eng.abstr_task0	Sentence: Intraartial conduction disturbances ( IACD ) are the known substrate of re-entrant atrial arrhythmias and their diagnosis is important for the selection of proper therapy . Signs of IACD can be missed on the standard ECG , and signal averaged ( SA ) P wave analysis has proved valuable for the evaluation of electrophysiological ( EPS ) properties of atrial myocardium . Unfavourable EPS effects of RAA pacing are known to electrophysiologists , but this aspect is rarely considered in normal practice , and RAA based pacing modes remain standard even for pts . with IACD . We examined and compared EPS effects of different atrial pacing modes using two diagnostic tools : IEGM obtained from two atrial leads of biatrial pacing system ( via telemetry ) and time domain analysis of SA P wave in 22 pts . with BiA pacing system ( implanted due to atrial arrhythmias and IACD ) . The results showed that different atrial pacing modes influence atrial activation timing parameters differently : RAA pacing aggravates IACD in comparison to sinus rhythm ; the effects of CS pacing is less visible . BiA pacing normalises all atrial activation times . The normalisation of SA P wave duration , reduction of SA P wave dispersion , increasing of RMS 20 and decreasing of LAS 5 and finally abolition of presence of late atrial potentials in most of pts . indicates beneficial effects of BiA pacing ( in pts . with IACD ) in comparison to sinus rhythm and RAA pacing . Unfavourable EPS effects of RAA pacing in patients with IACD indicates suitability the need for alternative ( resynchronising ) atrial pacing modes . Time domain analysis of SA P wave is a valuable and sensitive diagnostic tool for non-invasive evaluation of EPS effects of different modes of atrial pacing . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Intraartial conduction disturbances ( IACD ) are the known substrate of re-entrant atrial arrhythmias and their diagnosis is important for the selection of proper therapy . Signs of IACD can be missed on the standard ECG , and signal averaged ( SA ) P wave analysis has proved valuable for the evaluation of electrophysiological ( EPS ) properties of atrial myocardium . Unfavourable EPS effects of RAA pacing are known to electrophysiologists , but this aspect is rarely considered in normal practice , and RAA based pacing modes remain standard even for pts . with IACD . We examined and compared EPS effects of different atrial pacing modes using two diagnostic tools : IEGM obtained from two atrial leads of biatrial pacing system ( via telemetry ) and time domain analysis of SA P wave in 22 pts . with BiA pacing system ( implanted due to atrial arrhythmias and IACD ) . The results showed that different atrial pacing modes influence atrial activation timing parameters differently : RAA pacing aggravates IACD in comparison to sinus rhythm ; the effects of CS pacing is less visible . BiA pacing normalises all atrial activation times . The normalisation of SA P wave duration , reduction of SA P wave dispersion , increasing of RMS 20 and decreasing of LAS 5 and finally abolition of presence of late atrial potentials in most of pts . indicates beneficial effects of BiA pacing ( in pts . with IACD ) in comparison to sinus rhythm and RAA pacing . Unfavourable EPS effects of RAA pacing in patients with IACD indicates suitability the need for alternative ( resynchronising ) atrial pacing modes . Time domain analysis of SA P wave is a valuable and sensitive diagnostic tool for non-invasive evaluation of EPS effects of different modes of atrial pacing .	[ "Intraartial", "conduction", "disturbances", "(", "IACD", ")", "are", "the", "known", "substrate", "of", "re", "-", "entrant", "atrial", "arrhythmias", "and", "their", "diagnosis", "is", "important", "for", "the", "selection", "of", "proper", "therapy", ".", "Signs", "of", "IACD", "can", "be", "missed", "on", "the", "standard", "ECG", ",", "and", "signal", "averaged", "(", "SA", ")", "P", "wave", "analysis", "has", "proved", "valuable", "for", "the", "evaluation", "of", "electrophysiological", "(", "EPS", ")", "properties", "of", "atrial", "myocardium", ".", "Unfavourable", "EPS", "effects", "of", "RAA", "pacing", "are", "known", "to", "electrophysiologists", ",", "but", "this", "aspect", "is", "rarely", "considered", "in", "normal", "practice", ",", "and", "RAA", "based", "pacing", "modes", "remain", "standard", "even", "for", "pts", ".", "with", "IACD", ".", "We", "examined", "and", "compared", "EPS", "effects", "of", "different", "atrial", "pacing", "modes", "using", "two", "diagnostic", "tools", ":", "IEGM", "obtained", "from", "two", "atrial", "leads", "of", "biatrial", "pacing", "system", "(", "via", "telemetry", ")", "and", "time", "domain", "analysis", "of", "SA", "P", "wave", "in", "22", "pts", ".", "with", "BiA", "pacing", "system", "(", "implanted", "due", "to", "atrial", "arrhythmias", "and", "IACD", ")", ".", "The", "results", "showed", "that", "different", "atrial", "pacing", "modes", "influence", "atrial", "activation", "timing", "parameters", "differently", ":", "RAA", "pacing", "aggravates", "IACD", "in", "comparison", "to", "sinus", "rhythm", ";", "the", "effects", "of", "CS", "pacing", "is", "less", "visible", ".", "BiA", "pacing", "normalises", "all", "atrial", "activation", "times", ".", "The", "normalisation", "of", "SA", "P", "wave", "duration", ",", "reduction", "of", "SA", "P", "wave", "dispersion", ",", "increasing", "of", "RMS", "20", "and", "decreasing", "of", "LAS", "5", "and", "finally", "abolition", "of", "presence", "of", "late", "atrial", "potentials", "in", "most", "of", "pts", ".", "indicates", "beneficial", "effects", "of", "BiA", "pacing", "(", "in", "pts", ".", "with", "IACD", ")", "in", "comparison", "to", "sinus", "rhythm", "and", "RAA", "pacing", ".", "Unfavourable", "EPS", "effects", "of", "RAA", "pacing", "in", "patients", "with", "IACD", "indicates", "suitability", "the", "need", "for", "alternative", "(", "resynchronising", ")", "atrial", "pacing", "modes", ".", "Time", "domain", "analysis", "of", "SA", "P", "wave", "is", "a", "valuable", "and", "sensitive", "diagnostic", "tool", "for", "non", "-", "invasive", "evaluation", "of", "EPS", "effects", "of", "different", "modes", "of", "atrial", "pacing", "." ]	[ "umlsterm" ]
arrhythmias is an umlsterm, diagnosis is an umlsterm, selection is an umlsterm, therapy is an umlsterm, Signs is an umlsterm, standard is an umlsterm, ECG is an umlsterm, analysis is an umlsterm, evaluation is an umlsterm, EPS is an umlsterm, myocardium is an umlsterm, EPS is an umlsterm, pacing is an umlsterm, pacing is an umlsterm, standard is an umlsterm, EPS is an umlsterm, pacing is an umlsterm, diagnostic is an umlsterm, leads is an umlsterm, pacing is an umlsterm, telemetry is an umlsterm, time is an umlsterm, analysis is an umlsterm, pacing is an umlsterm, arrhythmias is an umlsterm, pacing is an umlsterm, pacing is an umlsterm, sinus is an umlsterm, pacing is an umlsterm, pacing is an umlsterm, times is an umlsterm, pacing is an umlsterm, sinus is an umlsterm, pacing is an umlsterm, EPS is an umlsterm, pacing is an umlsterm, patients is an umlsterm, need is an umlsterm, pacing is an umlsterm, Time is an umlsterm, analysis is an umlsterm, diagnostic is an umlsterm, evaluation is an umlsterm, EPS is an umlsterm, pacing is an umlsterm	Herzschrittmachertherapie.00110117.eng.abstr_task1	Sentence: Intraartial conduction disturbances ( IACD ) are the known substrate of re-entrant atrial arrhythmias and their diagnosis is important for the selection of proper therapy . Signs of IACD can be missed on the standard ECG , and signal averaged ( SA ) P wave analysis has proved valuable for the evaluation of electrophysiological ( EPS ) properties of atrial myocardium . Unfavourable EPS effects of RAA pacing are known to electrophysiologists , but this aspect is rarely considered in normal practice , and RAA based pacing modes remain standard even for pts . with IACD . We examined and compared EPS effects of different atrial pacing modes using two diagnostic tools : IEGM obtained from two atrial leads of biatrial pacing system ( via telemetry ) and time domain analysis of SA P wave in 22 pts . with BiA pacing system ( implanted due to atrial arrhythmias and IACD ) . The results showed that different atrial pacing modes influence atrial activation timing parameters differently : RAA pacing aggravates IACD in comparison to sinus rhythm ; the effects of CS pacing is less visible . BiA pacing normalises all atrial activation times . The normalisation of SA P wave duration , reduction of SA P wave dispersion , increasing of RMS 20 and decreasing of LAS 5 and finally abolition of presence of late atrial potentials in most of pts . indicates beneficial effects of BiA pacing ( in pts . with IACD ) in comparison to sinus rhythm and RAA pacing . Unfavourable EPS effects of RAA pacing in patients with IACD indicates suitability the need for alternative ( resynchronising ) atrial pacing modes . Time domain analysis of SA P wave is a valuable and sensitive diagnostic tool for non-invasive evaluation of EPS effects of different modes of atrial pacing . Instructions: please typing these entity words according to sentence: arrhythmias, diagnosis, selection, therapy, Signs, standard, ECG, analysis, evaluation, EPS, myocardium, EPS, pacing, pacing, standard, EPS, pacing, diagnostic, leads, pacing, telemetry, time, analysis, pacing, arrhythmias, pacing, pacing, sinus, pacing, pacing, times, pacing, sinus, pacing, EPS, pacing, patients, need, pacing, Time, analysis, diagnostic, evaluation, EPS, pacing Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Intraartial conduction disturbances ( IACD ) are the known substrate of re-entrant atrial arrhythmias and their diagnosis is important for the selection of proper therapy . Signs of IACD can be missed on the standard ECG , and signal averaged ( SA ) P wave analysis has proved valuable for the evaluation of electrophysiological ( EPS ) properties of atrial myocardium . Unfavourable EPS effects of RAA pacing are known to electrophysiologists , but this aspect is rarely considered in normal practice , and RAA based pacing modes remain standard even for pts . with IACD . We examined and compared EPS effects of different atrial pacing modes using two diagnostic tools : IEGM obtained from two atrial leads of biatrial pacing system ( via telemetry ) and time domain analysis of SA P wave in 22 pts . with BiA pacing system ( implanted due to atrial arrhythmias and IACD ) . The results showed that different atrial pacing modes influence atrial activation timing parameters differently : RAA pacing aggravates IACD in comparison to sinus rhythm ; the effects of CS pacing is less visible . BiA pacing normalises all atrial activation times . The normalisation of SA P wave duration , reduction of SA P wave dispersion , increasing of RMS 20 and decreasing of LAS 5 and finally abolition of presence of late atrial potentials in most of pts . indicates beneficial effects of BiA pacing ( in pts . with IACD ) in comparison to sinus rhythm and RAA pacing . Unfavourable EPS effects of RAA pacing in patients with IACD indicates suitability the need for alternative ( resynchronising ) atrial pacing modes . Time domain analysis of SA P wave is a valuable and sensitive diagnostic tool for non-invasive evaluation of EPS effects of different modes of atrial pacing .	[ "Intraartial", "conduction", "disturbances", "(", "IACD", ")", "are", "the", "known", "substrate", "of", "re", "-", "entrant", "atrial", "arrhythmias", "and", "their", "diagnosis", "is", "important", "for", "the", "selection", "of", "proper", "therapy", ".", "Signs", "of", "IACD", "can", "be", "missed", "on", "the", "standard", "ECG", ",", "and", "signal", "averaged", "(", "SA", ")", "P", "wave", "analysis", "has", "proved", "valuable", "for", "the", "evaluation", "of", "electrophysiological", "(", "EPS", ")", "properties", "of", "atrial", "myocardium", ".", "Unfavourable", "EPS", "effects", "of", "RAA", "pacing", "are", "known", "to", "electrophysiologists", ",", "but", "this", "aspect", "is", "rarely", "considered", "in", "normal", "practice", ",", "and", "RAA", "based", "pacing", "modes", "remain", "standard", "even", "for", "pts", ".", "with", "IACD", ".", "We", "examined", "and", "compared", "EPS", "effects", "of", "different", "atrial", "pacing", "modes", "using", "two", "diagnostic", "tools", ":", "IEGM", "obtained", "from", "two", "atrial", "leads", "of", "biatrial", "pacing", "system", "(", "via", "telemetry", ")", "and", "time", "domain", "analysis", "of", "SA", "P", "wave", "in", "22", "pts", ".", "with", "BiA", "pacing", "system", "(", "implanted", "due", "to", "atrial", "arrhythmias", "and", "IACD", ")", ".", "The", "results", "showed", "that", "different", "atrial", "pacing", "modes", "influence", "atrial", "activation", "timing", "parameters", "differently", ":", "RAA", "pacing", "aggravates", "IACD", "in", "comparison", "to", "sinus", "rhythm", ";", "the", "effects", "of", "CS", "pacing", "is", "less", "visible", ".", "BiA", "pacing", "normalises", "all", "atrial", "activation", "times", ".", "The", "normalisation", "of", "SA", "P", "wave", "duration", ",", "reduction", "of", "SA", "P", "wave", "dispersion", ",", "increasing", "of", "RMS", "20", "and", "decreasing", "of", "LAS", "5", "and", "finally", "abolition", "of", "presence", "of", "late", "atrial", "potentials", "in", "most", "of", "pts", ".", "indicates", "beneficial", "effects", "of", "BiA", "pacing", "(", "in", "pts", ".", "with", "IACD", ")", "in", "comparison", "to", "sinus", "rhythm", "and", "RAA", "pacing", ".", "Unfavourable", "EPS", "effects", "of", "RAA", "pacing", "in", "patients", "with", "IACD", "indicates", "suitability", "the", "need", "for", "alternative", "(", "resynchronising", ")", "atrial", "pacing", "modes", ".", "Time", "domain", "analysis", "of", "SA", "P", "wave", "is", "a", "valuable", "and", "sensitive", "diagnostic", "tool", "for", "non", "-", "invasive", "evaluation", "of", "EPS", "effects", "of", "different", "modes", "of", "atrial", "pacing", "." ]	[ "umlsterm" ]
arrhythmias, diagnosis, selection, therapy, Signs, standard, ECG, analysis, evaluation, EPS, myocardium, EPS, pacing, pacing, standard, EPS, pacing, diagnostic, leads, pacing, telemetry, time, analysis, pacing, arrhythmias, pacing, pacing, sinus, pacing, pacing, times, pacing, sinus, pacing, EPS, pacing, patients, need, pacing, Time, analysis, diagnostic, evaluation, EPS, pacing	Herzschrittmachertherapie.00110117.eng.abstr_task2	Sentence: Intraartial conduction disturbances ( IACD ) are the known substrate of re-entrant atrial arrhythmias and their diagnosis is important for the selection of proper therapy . Signs of IACD can be missed on the standard ECG , and signal averaged ( SA ) P wave analysis has proved valuable for the evaluation of electrophysiological ( EPS ) properties of atrial myocardium . Unfavourable EPS effects of RAA pacing are known to electrophysiologists , but this aspect is rarely considered in normal practice , and RAA based pacing modes remain standard even for pts . with IACD . We examined and compared EPS effects of different atrial pacing modes using two diagnostic tools : IEGM obtained from two atrial leads of biatrial pacing system ( via telemetry ) and time domain analysis of SA P wave in 22 pts . with BiA pacing system ( implanted due to atrial arrhythmias and IACD ) . The results showed that different atrial pacing modes influence atrial activation timing parameters differently : RAA pacing aggravates IACD in comparison to sinus rhythm ; the effects of CS pacing is less visible . BiA pacing normalises all atrial activation times . The normalisation of SA P wave duration , reduction of SA P wave dispersion , increasing of RMS 20 and decreasing of LAS 5 and finally abolition of presence of late atrial potentials in most of pts . indicates beneficial effects of BiA pacing ( in pts . with IACD ) in comparison to sinus rhythm and RAA pacing . Unfavourable EPS effects of RAA pacing in patients with IACD indicates suitability the need for alternative ( resynchronising ) atrial pacing modes . Time domain analysis of SA P wave is a valuable and sensitive diagnostic tool for non-invasive evaluation of EPS effects of different modes of atrial pacing . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Intraartial conduction disturbances ( IACD ) are the known substrate of re-entrant atrial arrhythmias and their diagnosis is important for the selection of proper therapy . Signs of IACD can be missed on the standard ECG , and signal averaged ( SA ) P wave analysis has proved valuable for the evaluation of electrophysiological ( EPS ) properties of atrial myocardium . Unfavourable EPS effects of RAA pacing are known to electrophysiologists , but this aspect is rarely considered in normal practice , and RAA based pacing modes remain standard even for pts . with IACD . We examined and compared EPS effects of different atrial pacing modes using two diagnostic tools : IEGM obtained from two atrial leads of biatrial pacing system ( via telemetry ) and time domain analysis of SA P wave in 22 pts . with BiA pacing system ( implanted due to atrial arrhythmias and IACD ) . The results showed that different atrial pacing modes influence atrial activation timing parameters differently : RAA pacing aggravates IACD in comparison to sinus rhythm ; the effects of CS pacing is less visible . BiA pacing normalises all atrial activation times . The normalisation of SA P wave duration , reduction of SA P wave dispersion , increasing of RMS 20 and decreasing of LAS 5 and finally abolition of presence of late atrial potentials in most of pts . indicates beneficial effects of BiA pacing ( in pts . with IACD ) in comparison to sinus rhythm and RAA pacing . Unfavourable EPS effects of RAA pacing in patients with IACD indicates suitability the need for alternative ( resynchronising ) atrial pacing modes . Time domain analysis of SA P wave is a valuable and sensitive diagnostic tool for non-invasive evaluation of EPS effects of different modes of atrial pacing .	[ "Intraartial", "conduction", "disturbances", "(", "IACD", ")", "are", "the", "known", "substrate", "of", "re", "-", "entrant", "atrial", "arrhythmias", "and", "their", "diagnosis", "is", "important", "for", "the", "selection", "of", "proper", "therapy", ".", "Signs", "of", "IACD", "can", "be", "missed", "on", "the", "standard", "ECG", ",", "and", "signal", "averaged", "(", "SA", ")", "P", "wave", "analysis", "has", "proved", "valuable", "for", "the", "evaluation", "of", "electrophysiological", "(", "EPS", ")", "properties", "of", "atrial", "myocardium", ".", "Unfavourable", "EPS", "effects", "of", "RAA", "pacing", "are", "known", "to", "electrophysiologists", ",", "but", "this", "aspect", "is", "rarely", "considered", "in", "normal", "practice", ",", "and", "RAA", "based", "pacing", "modes", "remain", "standard", "even", "for", "pts", ".", "with", "IACD", ".", "We", "examined", "and", "compared", "EPS", "effects", "of", "different", "atrial", "pacing", "modes", "using", "two", "diagnostic", "tools", ":", "IEGM", "obtained", "from", "two", "atrial", "leads", "of", "biatrial", "pacing", "system", "(", "via", "telemetry", ")", "and", "time", "domain", "analysis", "of", "SA", "P", "wave", "in", "22", "pts", ".", "with", "BiA", "pacing", "system", "(", "implanted", "due", "to", "atrial", "arrhythmias", "and", "IACD", ")", ".", "The", "results", "showed", "that", "different", "atrial", "pacing", "modes", "influence", "atrial", "activation", "timing", "parameters", "differently", ":", "RAA", "pacing", "aggravates", "IACD", "in", "comparison", "to", "sinus", "rhythm", ";", "the", "effects", "of", "CS", "pacing", "is", "less", "visible", ".", "BiA", "pacing", "normalises", "all", "atrial", "activation", "times", ".", "The", "normalisation", "of", "SA", "P", "wave", "duration", ",", "reduction", "of", "SA", "P", "wave", "dispersion", ",", "increasing", "of", "RMS", "20", "and", "decreasing", "of", "LAS", "5", "and", "finally", "abolition", "of", "presence", "of", "late", "atrial", "potentials", "in", "most", "of", "pts", ".", "indicates", "beneficial", "effects", "of", "BiA", "pacing", "(", "in", "pts", ".", "with", "IACD", ")", "in", "comparison", "to", "sinus", "rhythm", "and", "RAA", "pacing", ".", "Unfavourable", "EPS", "effects", "of", "RAA", "pacing", "in", "patients", "with", "IACD", "indicates", "suitability", "the", "need", "for", "alternative", "(", "resynchronising", ")", "atrial", "pacing", "modes", ".", "Time", "domain", "analysis", "of", "SA", "P", "wave", "is", "a", "valuable", "and", "sensitive", "diagnostic", "tool", "for", "non", "-", "invasive", "evaluation", "of", "EPS", "effects", "of", "different", "modes", "of", "atrial", "pacing", "." ]	[ "umlsterm" ]
aminoglycosides is a GROUP, gentamicin is a DRUG, amikacin is a DRUG, amphotericin B is a DRUG, cyclosporine is a DRUG, non - steroidal anti - inflammatory is a GROUP, ibuprofen is a DRUG, tacrolimus is a DRUG, vancomycin is a DRUG	Adefovir Dipivoxil_ddi_task0	Sentence: Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin. Do not start or stop any medicine without doctor or pharmacist approval. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, DRUG	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "I-DRUG", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin. Do not start or stop any medicine without doctor or pharmacist approval.	[ "Before", "using", "this", "medication", ",", "tell", "your", "doctor", "or", "pharmacist", "of", "all", "prescription", "and", "nonprescription", "products", "you", "may", "use", ",", "especially", "of", ":", "aminoglycosides", "(", "e.g", ".", ",", "gentamicin", ",", "amikacin", ")", ",", "amphotericin", "B", ",", "cyclosporine", ",", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "(", "e.g", ".", ",", "ibuprofen", ")", ",", "tacrolimus", ",", "vancomycin", ".", "Do", "not", "start", "or", "stop", "any", "medicine", "without", "doctor", "or", "pharmacist", "approval", "." ]	[ "GROUP", "DRUG" ]
aminoglycosides is a GROUP, gentamicin is a DRUG, amikacin is a DRUG, amphotericin B is a DRUG, cyclosporine is a DRUG, non - steroidal anti - inflammatory is a GROUP, ibuprofen is a DRUG, tacrolimus is a DRUG, vancomycin is a DRUG	Adefovir Dipivoxil_ddi_task1	Sentence: Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin. Do not start or stop any medicine without doctor or pharmacist approval. Instructions: please typing these entity words according to sentence: aminoglycosides, gentamicin, amikacin, amphotericin B, cyclosporine, non - steroidal anti - inflammatory, ibuprofen, tacrolimus, vancomycin Options: GROUP, DRUG	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "I-DRUG", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin. Do not start or stop any medicine without doctor or pharmacist approval.	[ "Before", "using", "this", "medication", ",", "tell", "your", "doctor", "or", "pharmacist", "of", "all", "prescription", "and", "nonprescription", "products", "you", "may", "use", ",", "especially", "of", ":", "aminoglycosides", "(", "e.g", ".", ",", "gentamicin", ",", "amikacin", ")", ",", "amphotericin", "B", ",", "cyclosporine", ",", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "(", "e.g", ".", ",", "ibuprofen", ")", ",", "tacrolimus", ",", "vancomycin", ".", "Do", "not", "start", "or", "stop", "any", "medicine", "without", "doctor", "or", "pharmacist", "approval", "." ]	[ "GROUP", "DRUG" ]
aminoglycosides, gentamicin, amikacin, amphotericin B, cyclosporine, non - steroidal anti - inflammatory, ibuprofen, tacrolimus, vancomycin	Adefovir Dipivoxil_ddi_task2	Sentence: Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin. Do not start or stop any medicine without doctor or pharmacist approval. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "I-DRUG", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin. Do not start or stop any medicine without doctor or pharmacist approval.	[ "Before", "using", "this", "medication", ",", "tell", "your", "doctor", "or", "pharmacist", "of", "all", "prescription", "and", "nonprescription", "products", "you", "may", "use", ",", "especially", "of", ":", "aminoglycosides", "(", "e.g", ".", ",", "gentamicin", ",", "amikacin", ")", ",", "amphotericin", "B", ",", "cyclosporine", ",", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "(", "e.g", ".", ",", "ibuprofen", ")", ",", "tacrolimus", ",", "vancomycin", ".", "Do", "not", "start", "or", "stop", "any", "medicine", "without", "doctor", "or", "pharmacist", "approval", "." ]	[ "GROUP", "DRUG" ]
Behandlung is an umlsterm, Patienten is an umlsterm, kutanem T - Zell - Lymphom is an umlsterm, Therapieverfahren is an umlsterm, photodynamischen Therapie is an umlsterm, Therapieverfahren is an umlsterm, Ohr is an umlsterm, Augenbraue is an umlsterm, Fusskante is an umlsterm, Patient is an umlsterm, Ohr is an umlsterm, Therapie is an umlsterm, Interferon- is an umlsterm, Tumorwachstum is an umlsterm, Patient is an umlsterm, Ohr is an umlsterm, Radiotherapie is an umlsterm, Patient is an umlsterm, Mycosis fungoides is an umlsterm, Tumorstadium is an umlsterm, Patient is an umlsterm, PUVA - Therapie is an umlsterm, Interferon- is an umlsterm, photodynamische Therapie is an umlsterm, Augenbraue is an umlsterm, Fusskante is an umlsterm, Behandlung is an umlsterm	DerHautarzt.90500109.ger.abstr_task0	Sentence: Die Behandlung der heterogenen Gruppe primaer kutaner B- und T-Zell-Lymphome erfolgt stadienadaptiert , aber insbesondere bei den seltenen Formen bisher nicht standardisiert . Wir berichten ueber 2 Patienten mit primaer kutanem T-Zell-Lymphom ( CTCL ) , die neben etablierten Therapieverfahren einer topischen photodynamischen Therapie ( PDT ) in besonderer und fuer die klassischen Therapieverfahren nur schwer zugaenglicher Lokalisation ( Ohr Augenbraue , Fusskante ) , zugefuehrt wurden . Bei Patient 1 handelte es sich um die seltene Variante eines mittelgrosszellig pleomorphen CD8-positiven, CD30-negativen, primaer kutanen CTCL , dessen Primaermanifestation am Ohr darueber hinaus eine Raritaet darstellt . Nachdem es unter Therapie mit PUVA , Interferon- und Retinoid zum lokalen progredienten Tumorwachstum gekommen war , erhielt der Patient eine topische PDT am Ohr . Hierunter histologisch gesicherte partielle Remission ( PR ) . Bei erneuter lokaler Krankheitsprogredienz ( PD ) wurde eine Radiotherapie angeschlossen , seitdem 22 Monate komplette Remission ( CR ) . Bei Patient 2 handelte es sich um das klassische Bild einer Mycosis fungoides im initialen Tumorstadium . Dieser Patient erhielt ergaenzend zu PUVA-Therapie und Interferon- eine topische photodynamische Therapie an den Lokalisationen Augenbraue und Fusskante . Histologisch kontrolliert wurde hier eine komplette Remission ( CR ) erzielt . Die PDT stellt in der palliativen Behandlung kutaner T-Zell-Lymphome insbesondere in Problemlokalisationen ein neues experimentelles Verfahren dar , das gewebsschonend und nebenwirkungsarm ist , beliebig oft wiederholt werden kann und zu einem guten kosmetischen Ergebnis fuehrt . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die Behandlung der heterogenen Gruppe primaer kutaner B- und T-Zell-Lymphome erfolgt stadienadaptiert , aber insbesondere bei den seltenen Formen bisher nicht standardisiert . Wir berichten ueber 2 Patienten mit primaer kutanem T-Zell-Lymphom ( CTCL ) , die neben etablierten Therapieverfahren einer topischen photodynamischen Therapie ( PDT ) in besonderer und fuer die klassischen Therapieverfahren nur schwer zugaenglicher Lokalisation ( Ohr Augenbraue , Fusskante ) , zugefuehrt wurden . Bei Patient 1 handelte es sich um die seltene Variante eines mittelgrosszellig pleomorphen CD8-positiven, CD30-negativen, primaer kutanen CTCL , dessen Primaermanifestation am Ohr darueber hinaus eine Raritaet darstellt . Nachdem es unter Therapie mit PUVA , Interferon- und Retinoid zum lokalen progredienten Tumorwachstum gekommen war , erhielt der Patient eine topische PDT am Ohr . Hierunter histologisch gesicherte partielle Remission ( PR ) . Bei erneuter lokaler Krankheitsprogredienz ( PD ) wurde eine Radiotherapie angeschlossen , seitdem 22 Monate komplette Remission ( CR ) . Bei Patient 2 handelte es sich um das klassische Bild einer Mycosis fungoides im initialen Tumorstadium . Dieser Patient erhielt ergaenzend zu PUVA-Therapie und Interferon- eine topische photodynamische Therapie an den Lokalisationen Augenbraue und Fusskante . Histologisch kontrolliert wurde hier eine komplette Remission ( CR ) erzielt . Die PDT stellt in der palliativen Behandlung kutaner T-Zell-Lymphome insbesondere in Problemlokalisationen ein neues experimentelles Verfahren dar , das gewebsschonend und nebenwirkungsarm ist , beliebig oft wiederholt werden kann und zu einem guten kosmetischen Ergebnis fuehrt .	[ "Die", "Behandlung", "der", "heterogenen", "Gruppe", "primaer", "kutaner", "B-", "und", "T", "-", "Zell", "-", "Lymphome", "erfolgt", "stadienadaptiert", ",", "aber", "insbesondere", "bei", "den", "seltenen", "Formen", "bisher", "nicht", "standardisiert", ".", "Wir", "berichten", "ueber", "2", "Patienten", "mit", "primaer", "kutanem", "T", "-", "Zell", "-", "Lymphom", "(", "CTCL", ")", ",", "die", "neben", "etablierten", "Therapieverfahren", "einer", "topischen", "photodynamischen", "Therapie", "(", "PDT", ")", "in", "besonderer", "und", "fuer", "die", "klassischen", "Therapieverfahren", "nur", "schwer", "zugaenglicher", "Lokalisation", "(", "Ohr", "Augenbraue", ",", "Fusskante", ")", ",", "zugefuehrt", "wurden", ".", "Bei", "Patient", "1", "handelte", "es", "sich", "um", "die", "seltene", "Variante", "eines", "mittelgrosszellig", "pleomorphen", "CD8-positiven", ",", "CD30-negativen", ",", "primaer", "kutanen", "CTCL", ",", "dessen", "Primaermanifestation", "am", "Ohr", "darueber", "hinaus", "eine", "Raritaet", "darstellt", ".", "Nachdem", "es", "unter", "Therapie", "mit", "PUVA", ",", "Interferon-", "und", "Retinoid", "zum", "lokalen", "progredienten", "Tumorwachstum", "gekommen", "war", ",", "erhielt", "der", "Patient", "eine", "topische", "PDT", "am", "Ohr", ".", "Hierunter", "histologisch", "gesicherte", "partielle", "Remission", "(", "PR", ")", ".", "Bei", "erneuter", "lokaler", "Krankheitsprogredienz", "(", "PD", ")", "wurde", "eine", "Radiotherapie", "angeschlossen", ",", "seitdem", "22", "Monate", "komplette", "Remission", "(", "CR", ")", ".", "Bei", "Patient", "2", "handelte", "es", "sich", "um", "das", "klassische", "Bild", "einer", "Mycosis", "fungoides", "im", "initialen", "Tumorstadium", ".", "Dieser", "Patient", "erhielt", "ergaenzend", "zu", "PUVA", "-", "Therapie", "und", "Interferon-", "eine", "topische", "photodynamische", "Therapie", "an", "den", "Lokalisationen", "Augenbraue", "und", "Fusskante", ".", "Histologisch", "kontrolliert", "wurde", "hier", "eine", "komplette", "Remission", "(", "CR", ")", "erzielt", ".", "Die", "PDT", "stellt", "in", "der", "palliativen", "Behandlung", "kutaner", "T", "-", "Zell", "-", "Lymphome", "insbesondere", "in", "Problemlokalisationen", "ein", "neues", "experimentelles", "Verfahren", "dar", ",", "das", "gewebsschonend", "und", "nebenwirkungsarm", "ist", ",", "beliebig", "oft", "wiederholt", "werden", "kann", "und", "zu", "einem", "guten", "kosmetischen", "Ergebnis", "fuehrt", "." ]	[ "umlsterm" ]
Behandlung is an umlsterm, Patienten is an umlsterm, kutanem T - Zell - Lymphom is an umlsterm, Therapieverfahren is an umlsterm, photodynamischen Therapie is an umlsterm, Therapieverfahren is an umlsterm, Ohr is an umlsterm, Augenbraue is an umlsterm, Fusskante is an umlsterm, Patient is an umlsterm, Ohr is an umlsterm, Therapie is an umlsterm, Interferon- is an umlsterm, Tumorwachstum is an umlsterm, Patient is an umlsterm, Ohr is an umlsterm, Radiotherapie is an umlsterm, Patient is an umlsterm, Mycosis fungoides is an umlsterm, Tumorstadium is an umlsterm, Patient is an umlsterm, PUVA - Therapie is an umlsterm, Interferon- is an umlsterm, photodynamische Therapie is an umlsterm, Augenbraue is an umlsterm, Fusskante is an umlsterm, Behandlung is an umlsterm	DerHautarzt.90500109.ger.abstr_task1	Sentence: Die Behandlung der heterogenen Gruppe primaer kutaner B- und T-Zell-Lymphome erfolgt stadienadaptiert , aber insbesondere bei den seltenen Formen bisher nicht standardisiert . Wir berichten ueber 2 Patienten mit primaer kutanem T-Zell-Lymphom ( CTCL ) , die neben etablierten Therapieverfahren einer topischen photodynamischen Therapie ( PDT ) in besonderer und fuer die klassischen Therapieverfahren nur schwer zugaenglicher Lokalisation ( Ohr Augenbraue , Fusskante ) , zugefuehrt wurden . Bei Patient 1 handelte es sich um die seltene Variante eines mittelgrosszellig pleomorphen CD8-positiven, CD30-negativen, primaer kutanen CTCL , dessen Primaermanifestation am Ohr darueber hinaus eine Raritaet darstellt . Nachdem es unter Therapie mit PUVA , Interferon- und Retinoid zum lokalen progredienten Tumorwachstum gekommen war , erhielt der Patient eine topische PDT am Ohr . Hierunter histologisch gesicherte partielle Remission ( PR ) . Bei erneuter lokaler Krankheitsprogredienz ( PD ) wurde eine Radiotherapie angeschlossen , seitdem 22 Monate komplette Remission ( CR ) . Bei Patient 2 handelte es sich um das klassische Bild einer Mycosis fungoides im initialen Tumorstadium . Dieser Patient erhielt ergaenzend zu PUVA-Therapie und Interferon- eine topische photodynamische Therapie an den Lokalisationen Augenbraue und Fusskante . Histologisch kontrolliert wurde hier eine komplette Remission ( CR ) erzielt . Die PDT stellt in der palliativen Behandlung kutaner T-Zell-Lymphome insbesondere in Problemlokalisationen ein neues experimentelles Verfahren dar , das gewebsschonend und nebenwirkungsarm ist , beliebig oft wiederholt werden kann und zu einem guten kosmetischen Ergebnis fuehrt . Instructions: please typing these entity words according to sentence: Behandlung, Patienten, kutanem T - Zell - Lymphom, Therapieverfahren, photodynamischen Therapie, Therapieverfahren, Ohr, Augenbraue, Fusskante, Patient, Ohr, Therapie, Interferon-, Tumorwachstum, Patient, Ohr, Radiotherapie, Patient, Mycosis fungoides, Tumorstadium, Patient, PUVA - Therapie, Interferon-, photodynamische Therapie, Augenbraue, Fusskante, Behandlung Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die Behandlung der heterogenen Gruppe primaer kutaner B- und T-Zell-Lymphome erfolgt stadienadaptiert , aber insbesondere bei den seltenen Formen bisher nicht standardisiert . Wir berichten ueber 2 Patienten mit primaer kutanem T-Zell-Lymphom ( CTCL ) , die neben etablierten Therapieverfahren einer topischen photodynamischen Therapie ( PDT ) in besonderer und fuer die klassischen Therapieverfahren nur schwer zugaenglicher Lokalisation ( Ohr Augenbraue , Fusskante ) , zugefuehrt wurden . Bei Patient 1 handelte es sich um die seltene Variante eines mittelgrosszellig pleomorphen CD8-positiven, CD30-negativen, primaer kutanen CTCL , dessen Primaermanifestation am Ohr darueber hinaus eine Raritaet darstellt . Nachdem es unter Therapie mit PUVA , Interferon- und Retinoid zum lokalen progredienten Tumorwachstum gekommen war , erhielt der Patient eine topische PDT am Ohr . Hierunter histologisch gesicherte partielle Remission ( PR ) . Bei erneuter lokaler Krankheitsprogredienz ( PD ) wurde eine Radiotherapie angeschlossen , seitdem 22 Monate komplette Remission ( CR ) . Bei Patient 2 handelte es sich um das klassische Bild einer Mycosis fungoides im initialen Tumorstadium . Dieser Patient erhielt ergaenzend zu PUVA-Therapie und Interferon- eine topische photodynamische Therapie an den Lokalisationen Augenbraue und Fusskante . Histologisch kontrolliert wurde hier eine komplette Remission ( CR ) erzielt . Die PDT stellt in der palliativen Behandlung kutaner T-Zell-Lymphome insbesondere in Problemlokalisationen ein neues experimentelles Verfahren dar , das gewebsschonend und nebenwirkungsarm ist , beliebig oft wiederholt werden kann und zu einem guten kosmetischen Ergebnis fuehrt .	[ "Die", "Behandlung", "der", "heterogenen", "Gruppe", "primaer", "kutaner", "B-", "und", "T", "-", "Zell", "-", "Lymphome", "erfolgt", "stadienadaptiert", ",", "aber", "insbesondere", "bei", "den", "seltenen", "Formen", "bisher", "nicht", "standardisiert", ".", "Wir", "berichten", "ueber", "2", "Patienten", "mit", "primaer", "kutanem", "T", "-", "Zell", "-", "Lymphom", "(", "CTCL", ")", ",", "die", "neben", "etablierten", "Therapieverfahren", "einer", "topischen", "photodynamischen", "Therapie", "(", "PDT", ")", "in", "besonderer", "und", "fuer", "die", "klassischen", "Therapieverfahren", "nur", "schwer", "zugaenglicher", "Lokalisation", "(", "Ohr", "Augenbraue", ",", "Fusskante", ")", ",", "zugefuehrt", "wurden", ".", "Bei", "Patient", "1", "handelte", "es", "sich", "um", "die", "seltene", "Variante", "eines", "mittelgrosszellig", "pleomorphen", "CD8-positiven", ",", "CD30-negativen", ",", "primaer", "kutanen", "CTCL", ",", "dessen", "Primaermanifestation", "am", "Ohr", "darueber", "hinaus", "eine", "Raritaet", "darstellt", ".", "Nachdem", "es", "unter", "Therapie", "mit", "PUVA", ",", "Interferon-", "und", "Retinoid", "zum", "lokalen", "progredienten", "Tumorwachstum", "gekommen", "war", ",", "erhielt", "der", "Patient", "eine", "topische", "PDT", "am", "Ohr", ".", "Hierunter", "histologisch", "gesicherte", "partielle", "Remission", "(", "PR", ")", ".", "Bei", "erneuter", "lokaler", "Krankheitsprogredienz", "(", "PD", ")", "wurde", "eine", "Radiotherapie", "angeschlossen", ",", "seitdem", "22", "Monate", "komplette", "Remission", "(", "CR", ")", ".", "Bei", "Patient", "2", "handelte", "es", "sich", "um", "das", "klassische", "Bild", "einer", "Mycosis", "fungoides", "im", "initialen", "Tumorstadium", ".", "Dieser", "Patient", "erhielt", "ergaenzend", "zu", "PUVA", "-", "Therapie", "und", "Interferon-", "eine", "topische", "photodynamische", "Therapie", "an", "den", "Lokalisationen", "Augenbraue", "und", "Fusskante", ".", "Histologisch", "kontrolliert", "wurde", "hier", "eine", "komplette", "Remission", "(", "CR", ")", "erzielt", ".", "Die", "PDT", "stellt", "in", "der", "palliativen", "Behandlung", "kutaner", "T", "-", "Zell", "-", "Lymphome", "insbesondere", "in", "Problemlokalisationen", "ein", "neues", "experimentelles", "Verfahren", "dar", ",", "das", "gewebsschonend", "und", "nebenwirkungsarm", "ist", ",", "beliebig", "oft", "wiederholt", "werden", "kann", "und", "zu", "einem", "guten", "kosmetischen", "Ergebnis", "fuehrt", "." ]	[ "umlsterm" ]
Behandlung, Patienten, kutanem T - Zell - Lymphom, Therapieverfahren, photodynamischen Therapie, Therapieverfahren, Ohr, Augenbraue, Fusskante, Patient, Ohr, Therapie, Interferon-, Tumorwachstum, Patient, Ohr, Radiotherapie, Patient, Mycosis fungoides, Tumorstadium, Patient, PUVA - Therapie, Interferon-, photodynamische Therapie, Augenbraue, Fusskante, Behandlung	DerHautarzt.90500109.ger.abstr_task2	Sentence: Die Behandlung der heterogenen Gruppe primaer kutaner B- und T-Zell-Lymphome erfolgt stadienadaptiert , aber insbesondere bei den seltenen Formen bisher nicht standardisiert . Wir berichten ueber 2 Patienten mit primaer kutanem T-Zell-Lymphom ( CTCL ) , die neben etablierten Therapieverfahren einer topischen photodynamischen Therapie ( PDT ) in besonderer und fuer die klassischen Therapieverfahren nur schwer zugaenglicher Lokalisation ( Ohr Augenbraue , Fusskante ) , zugefuehrt wurden . Bei Patient 1 handelte es sich um die seltene Variante eines mittelgrosszellig pleomorphen CD8-positiven, CD30-negativen, primaer kutanen CTCL , dessen Primaermanifestation am Ohr darueber hinaus eine Raritaet darstellt . Nachdem es unter Therapie mit PUVA , Interferon- und Retinoid zum lokalen progredienten Tumorwachstum gekommen war , erhielt der Patient eine topische PDT am Ohr . Hierunter histologisch gesicherte partielle Remission ( PR ) . Bei erneuter lokaler Krankheitsprogredienz ( PD ) wurde eine Radiotherapie angeschlossen , seitdem 22 Monate komplette Remission ( CR ) . Bei Patient 2 handelte es sich um das klassische Bild einer Mycosis fungoides im initialen Tumorstadium . Dieser Patient erhielt ergaenzend zu PUVA-Therapie und Interferon- eine topische photodynamische Therapie an den Lokalisationen Augenbraue und Fusskante . Histologisch kontrolliert wurde hier eine komplette Remission ( CR ) erzielt . Die PDT stellt in der palliativen Behandlung kutaner T-Zell-Lymphome insbesondere in Problemlokalisationen ein neues experimentelles Verfahren dar , das gewebsschonend und nebenwirkungsarm ist , beliebig oft wiederholt werden kann und zu einem guten kosmetischen Ergebnis fuehrt . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die Behandlung der heterogenen Gruppe primaer kutaner B- und T-Zell-Lymphome erfolgt stadienadaptiert , aber insbesondere bei den seltenen Formen bisher nicht standardisiert . Wir berichten ueber 2 Patienten mit primaer kutanem T-Zell-Lymphom ( CTCL ) , die neben etablierten Therapieverfahren einer topischen photodynamischen Therapie ( PDT ) in besonderer und fuer die klassischen Therapieverfahren nur schwer zugaenglicher Lokalisation ( Ohr Augenbraue , Fusskante ) , zugefuehrt wurden . Bei Patient 1 handelte es sich um die seltene Variante eines mittelgrosszellig pleomorphen CD8-positiven, CD30-negativen, primaer kutanen CTCL , dessen Primaermanifestation am Ohr darueber hinaus eine Raritaet darstellt . Nachdem es unter Therapie mit PUVA , Interferon- und Retinoid zum lokalen progredienten Tumorwachstum gekommen war , erhielt der Patient eine topische PDT am Ohr . Hierunter histologisch gesicherte partielle Remission ( PR ) . Bei erneuter lokaler Krankheitsprogredienz ( PD ) wurde eine Radiotherapie angeschlossen , seitdem 22 Monate komplette Remission ( CR ) . Bei Patient 2 handelte es sich um das klassische Bild einer Mycosis fungoides im initialen Tumorstadium . Dieser Patient erhielt ergaenzend zu PUVA-Therapie und Interferon- eine topische photodynamische Therapie an den Lokalisationen Augenbraue und Fusskante . Histologisch kontrolliert wurde hier eine komplette Remission ( CR ) erzielt . Die PDT stellt in der palliativen Behandlung kutaner T-Zell-Lymphome insbesondere in Problemlokalisationen ein neues experimentelles Verfahren dar , das gewebsschonend und nebenwirkungsarm ist , beliebig oft wiederholt werden kann und zu einem guten kosmetischen Ergebnis fuehrt .	[ "Die", "Behandlung", "der", "heterogenen", "Gruppe", "primaer", "kutaner", "B-", "und", "T", "-", "Zell", "-", "Lymphome", "erfolgt", "stadienadaptiert", ",", "aber", "insbesondere", "bei", "den", "seltenen", "Formen", "bisher", "nicht", "standardisiert", ".", "Wir", "berichten", "ueber", "2", "Patienten", "mit", "primaer", "kutanem", "T", "-", "Zell", "-", "Lymphom", "(", "CTCL", ")", ",", "die", "neben", "etablierten", "Therapieverfahren", "einer", "topischen", "photodynamischen", "Therapie", "(", "PDT", ")", "in", "besonderer", "und", "fuer", "die", "klassischen", "Therapieverfahren", "nur", "schwer", "zugaenglicher", "Lokalisation", "(", "Ohr", "Augenbraue", ",", "Fusskante", ")", ",", "zugefuehrt", "wurden", ".", "Bei", "Patient", "1", "handelte", "es", "sich", "um", "die", "seltene", "Variante", "eines", "mittelgrosszellig", "pleomorphen", "CD8-positiven", ",", "CD30-negativen", ",", "primaer", "kutanen", "CTCL", ",", "dessen", "Primaermanifestation", "am", "Ohr", "darueber", "hinaus", "eine", "Raritaet", "darstellt", ".", "Nachdem", "es", "unter", "Therapie", "mit", "PUVA", ",", "Interferon-", "und", "Retinoid", "zum", "lokalen", "progredienten", "Tumorwachstum", "gekommen", "war", ",", "erhielt", "der", "Patient", "eine", "topische", "PDT", "am", "Ohr", ".", "Hierunter", "histologisch", "gesicherte", "partielle", "Remission", "(", "PR", ")", ".", "Bei", "erneuter", "lokaler", "Krankheitsprogredienz", "(", "PD", ")", "wurde", "eine", "Radiotherapie", "angeschlossen", ",", "seitdem", "22", "Monate", "komplette", "Remission", "(", "CR", ")", ".", "Bei", "Patient", "2", "handelte", "es", "sich", "um", "das", "klassische", "Bild", "einer", "Mycosis", "fungoides", "im", "initialen", "Tumorstadium", ".", "Dieser", "Patient", "erhielt", "ergaenzend", "zu", "PUVA", "-", "Therapie", "und", "Interferon-", "eine", "topische", "photodynamische", "Therapie", "an", "den", "Lokalisationen", "Augenbraue", "und", "Fusskante", ".", "Histologisch", "kontrolliert", "wurde", "hier", "eine", "komplette", "Remission", "(", "CR", ")", "erzielt", ".", "Die", "PDT", "stellt", "in", "der", "palliativen", "Behandlung", "kutaner", "T", "-", "Zell", "-", "Lymphome", "insbesondere", "in", "Problemlokalisationen", "ein", "neues", "experimentelles", "Verfahren", "dar", ",", "das", "gewebsschonend", "und", "nebenwirkungsarm", "ist", ",", "beliebig", "oft", "wiederholt", "werden", "kann", "und", "zu", "einem", "guten", "kosmetischen", "Ergebnis", "fuehrt", "." ]	[ "umlsterm" ]
ErbB2 is a GENE-Y, FoxM1 is a GENE-Y, 14 - 3 - 3ζ is a GENE-Y	23318431_task0	Sentence: ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y	[ "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation.	[ "ErbB2", ",", "FoxM1", "and", "14", "-", "3", "-", "3ζ", "prime", "breast", "cancer", "cells", "for", "invasion", "in", "response", "to", "ionizing", "radiation", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
ErbB2 is a GENE-Y, FoxM1 is a GENE-Y, 14 - 3 - 3ζ is a GENE-Y	23318431_task1	Sentence: ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation. Instructions: please typing these entity words according to sentence: ErbB2, FoxM1, 14 - 3 - 3ζ Options: GENE-Y	[ "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation.	[ "ErbB2", ",", "FoxM1", "and", "14", "-", "3", "-", "3ζ", "prime", "breast", "cancer", "cells", "for", "invasion", "in", "response", "to", "ionizing", "radiation", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
ErbB2, FoxM1, 14 - 3 - 3ζ	23318431_task2	Sentence: ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation. Instructions: please extract entity words from the input sentence	[ "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation.	[ "ErbB2", ",", "FoxM1", "and", "14", "-", "3", "-", "3ζ", "prime", "breast", "cancer", "cells", "for", "invasion", "in", "response", "to", "ionizing", "radiation", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
prostate cancer is a Cancer, Prostate cancer is a Cancer, tumor is a Cancer, prostate cancer xenograft is a Cancer, LAPC-4 is a Cell, LAPC-9 is a Cell, PC3 is a Cell, CWR22Rv-1 is a Cell, cells is a Cell, tumor is a Cancer, metastases is a Cancer, Metastatic lesions is a Cancer, tumors is a Cancer, low - metastatic LAPC-9 tumor cells is a Cell, metastases is a Cancer, CWR22Rv-1 is a Cell, PC3 tumor cell lines is a Cell, LAPC-4 is a Cell, LAPC-9 is a Cell, tumor lymphatics is a Multi-tissue_structure, LAPC-9 is a Cell, tumor is a Cancer, metastatic lesions is a Cancer, tumor lymphatics is a Multi-tissue_structure, prostate cancer is a Cancer, prostate cancer is a Cancer	PMID-17583576_task0	Sentence: Modulating metastasis by a lymphangiogenic switch in prostate cancer. Prostate cancer dissemination is difficult to detect in the clinic, and few treatment options exist for patients with advanced-stage disease. Our aim was to investigate the role of tumor lymphangiogenesis during metastasis. Further, we implemented a noninvasive molecular imaging technique to facilitate the assessment of the metastatic process. The metastatic potentials of several human prostate cancer xenograft models, LAPC-4, LAPC-9, PC3 and CWR22Rv-1 were compared. The cells were labeled with luciferase, a bioluminescence imaging reporter gene, to enable optical imaging. After tumor implantation the animals were examined weekly during several months for the appearance of metastases. Metastatic lesions were confirmed by immunohistochemistry. Additionally, the angiogenic and lymphangiogenic profiles of the tumors were characterized. To confirm the role of lymphangiogenesis in mediating metastasis, the low-metastatic LAPC-9 tumor cells were engineered to overexpress VEGF-C, and the development of metastases was evaluated. Our results show CWR22Rv-1 and PC3 tumor cell lines to be more metastatic than LAPC-4, which in turn disseminates more readily than LAPC-9. The difference in metastatic potential correlated with the endogenous production levels of lymphangiogenic growth factor VEGF-C and the presence of tumor lymphatics. In agreement, induced overexpression of VEGF-C in LAPC-9 enhanced tumor lymphangiogenesis leading to the development of metastatic lesions. Taken together, our studies, based on a molecular imaging approach for semiquantitative detection of micrometastases, point to an important role of tumor lymphatics in the metastatic process of human prostate cancer. In particular, VEGF-C seems to play a key role in prostate cancer metastasis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cancer, Multi-tissue_structure, Cell	[ "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O" ]	Modulating metastasis by a lymphangiogenic switch in prostate cancer. Prostate cancer dissemination is difficult to detect in the clinic, and few treatment options exist for patients with advanced-stage disease. Our aim was to investigate the role of tumor lymphangiogenesis during metastasis. Further, we implemented a noninvasive molecular imaging technique to facilitate the assessment of the metastatic process. The metastatic potentials of several human prostate cancer xenograft models, LAPC-4, LAPC-9, PC3 and CWR22Rv-1 were compared. The cells were labeled with luciferase, a bioluminescence imaging reporter gene, to enable optical imaging. After tumor implantation the animals were examined weekly during several months for the appearance of metastases. Metastatic lesions were confirmed by immunohistochemistry. Additionally, the angiogenic and lymphangiogenic profiles of the tumors were characterized. To confirm the role of lymphangiogenesis in mediating metastasis, the low-metastatic LAPC-9 tumor cells were engineered to overexpress VEGF-C, and the development of metastases was evaluated. Our results show CWR22Rv-1 and PC3 tumor cell lines to be more metastatic than LAPC-4, which in turn disseminates more readily than LAPC-9. The difference in metastatic potential correlated with the endogenous production levels of lymphangiogenic growth factor VEGF-C and the presence of tumor lymphatics. In agreement, induced overexpression of VEGF-C in LAPC-9 enhanced tumor lymphangiogenesis leading to the development of metastatic lesions. Taken together, our studies, based on a molecular imaging approach for semiquantitative detection of micrometastases, point to an important role of tumor lymphatics in the metastatic process of human prostate cancer. In particular, VEGF-C seems to play a key role in prostate cancer metastasis.	[ "Modulating", "metastasis", "by", "a", "lymphangiogenic", "switch", "in", "prostate", "cancer", ".", "\n", "Prostate", "cancer", "dissemination", "is", "difficult", "to", "detect", "in", "the", "clinic", ",", "and", "few", "treatment", "options", "exist", "for", "patients", "with", "advanced", "-", "stage", "disease", ".", "Our", "aim", "was", "to", "investigate", "the", "role", "of", "tumor", "lymphangiogenesis", "during", "metastasis", ".", "Further", ",", "we", "implemented", "a", "noninvasive", "molecular", "imaging", "technique", "to", "facilitate", "the", "assessment", "of", "the", "metastatic", "process", ".", "The", "metastatic", "potentials", "of", "several", "human", "prostate", "cancer", "xenograft", "models", ",", "LAPC-4", ",", "LAPC-9", ",", "PC3", "and", "CWR22Rv-1", "were", "compared", ".", "The", "cells", "were", "labeled", "with", "luciferase", ",", "a", "bioluminescence", "imaging", "reporter", "gene", ",", "to", "enable", "optical", "imaging", ".", "After", "tumor", "implantation", "the", "animals", "were", "examined", "weekly", "during", "several", "months", "for", "the", "appearance", "of", "metastases", ".", "Metastatic", "lesions", "were", "confirmed", "by", "immunohistochemistry", ".", "Additionally", ",", "the", "angiogenic", "and", "lymphangiogenic", "profiles", "of", "the", "tumors", "were", "characterized", ".", "To", "confirm", "the", "role", "of", "lymphangiogenesis", "in", "mediating", "metastasis", ",", "the", "low", "-", "metastatic", "LAPC-9", "tumor", "cells", "were", "engineered", "to", "overexpress", "VEGF", "-", "C", ",", "and", "the", "development", "of", "metastases", "was", "evaluated", ".", "Our", "results", "show", "CWR22Rv-1", "and", "PC3", "tumor", "cell", "lines", "to", "be", "more", "metastatic", "than", "LAPC-4", ",", "which", "in", "turn", "disseminates", "more", "readily", "than", "LAPC-9", ".", "The", "difference", "in", "metastatic", "potential", "correlated", "with", "the", "endogenous", "production", "levels", "of", "lymphangiogenic", "growth", "factor", "VEGF", "-", "C", "and", "the", "presence", "of", "tumor", "lymphatics", ".", "In", "agreement", ",", "induced", "overexpression", "of", "VEGF", "-", "C", "in", "LAPC-9", "enhanced", "tumor", "lymphangiogenesis", "leading", "to", "the", "development", "of", "metastatic", "lesions", ".", "Taken", "together", ",", "our", "studies", ",", "based", "on", "a", "molecular", "imaging", "approach", "for", "semiquantitative", "detection", "of", "micrometastases", ",", "point", "to", "an", "important", "role", "of", "tumor", "lymphatics", "in", "the", "metastatic", "process", "of", "human", "prostate", "cancer", ".", "In", "particular", ",", "VEGF", "-", "C", "seems", "to", "play", "a", "key", "role", "in", "prostate", "cancer", "metastasis", ".", "\n" ]	[ "Cell", "Cancer", "Multi-tissue_structure" ]
prostate cancer is a Cancer, Prostate cancer is a Cancer, tumor is a Cancer, prostate cancer xenograft is a Cancer, LAPC-4 is a Cell, LAPC-9 is a Cell, PC3 is a Cell, CWR22Rv-1 is a Cell, cells is a Cell, tumor is a Cancer, metastases is a Cancer, Metastatic lesions is a Cancer, tumors is a Cancer, low - metastatic LAPC-9 tumor cells is a Cell, metastases is a Cancer, CWR22Rv-1 is a Cell, PC3 tumor cell lines is a Cell, LAPC-4 is a Cell, LAPC-9 is a Cell, tumor lymphatics is a Multi-tissue_structure, LAPC-9 is a Cell, tumor is a Cancer, metastatic lesions is a Cancer, tumor lymphatics is a Multi-tissue_structure, prostate cancer is a Cancer, prostate cancer is a Cancer	PMID-17583576_task1	Sentence: Modulating metastasis by a lymphangiogenic switch in prostate cancer. Prostate cancer dissemination is difficult to detect in the clinic, and few treatment options exist for patients with advanced-stage disease. Our aim was to investigate the role of tumor lymphangiogenesis during metastasis. Further, we implemented a noninvasive molecular imaging technique to facilitate the assessment of the metastatic process. The metastatic potentials of several human prostate cancer xenograft models, LAPC-4, LAPC-9, PC3 and CWR22Rv-1 were compared. The cells were labeled with luciferase, a bioluminescence imaging reporter gene, to enable optical imaging. After tumor implantation the animals were examined weekly during several months for the appearance of metastases. Metastatic lesions were confirmed by immunohistochemistry. Additionally, the angiogenic and lymphangiogenic profiles of the tumors were characterized. To confirm the role of lymphangiogenesis in mediating metastasis, the low-metastatic LAPC-9 tumor cells were engineered to overexpress VEGF-C, and the development of metastases was evaluated. Our results show CWR22Rv-1 and PC3 tumor cell lines to be more metastatic than LAPC-4, which in turn disseminates more readily than LAPC-9. The difference in metastatic potential correlated with the endogenous production levels of lymphangiogenic growth factor VEGF-C and the presence of tumor lymphatics. In agreement, induced overexpression of VEGF-C in LAPC-9 enhanced tumor lymphangiogenesis leading to the development of metastatic lesions. Taken together, our studies, based on a molecular imaging approach for semiquantitative detection of micrometastases, point to an important role of tumor lymphatics in the metastatic process of human prostate cancer. In particular, VEGF-C seems to play a key role in prostate cancer metastasis. Instructions: please typing these entity words according to sentence: prostate cancer, Prostate cancer, tumor, prostate cancer xenograft, LAPC-4, LAPC-9, PC3, CWR22Rv-1, cells, tumor, metastases, Metastatic lesions, tumors, low - metastatic LAPC-9 tumor cells, metastases, CWR22Rv-1, PC3 tumor cell lines, LAPC-4, LAPC-9, tumor lymphatics, LAPC-9, tumor, metastatic lesions, tumor lymphatics, prostate cancer, prostate cancer Options: Cancer, Multi-tissue_structure, Cell	[ "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O" ]	Modulating metastasis by a lymphangiogenic switch in prostate cancer. Prostate cancer dissemination is difficult to detect in the clinic, and few treatment options exist for patients with advanced-stage disease. Our aim was to investigate the role of tumor lymphangiogenesis during metastasis. Further, we implemented a noninvasive molecular imaging technique to facilitate the assessment of the metastatic process. The metastatic potentials of several human prostate cancer xenograft models, LAPC-4, LAPC-9, PC3 and CWR22Rv-1 were compared. The cells were labeled with luciferase, a bioluminescence imaging reporter gene, to enable optical imaging. After tumor implantation the animals were examined weekly during several months for the appearance of metastases. Metastatic lesions were confirmed by immunohistochemistry. Additionally, the angiogenic and lymphangiogenic profiles of the tumors were characterized. To confirm the role of lymphangiogenesis in mediating metastasis, the low-metastatic LAPC-9 tumor cells were engineered to overexpress VEGF-C, and the development of metastases was evaluated. Our results show CWR22Rv-1 and PC3 tumor cell lines to be more metastatic than LAPC-4, which in turn disseminates more readily than LAPC-9. The difference in metastatic potential correlated with the endogenous production levels of lymphangiogenic growth factor VEGF-C and the presence of tumor lymphatics. In agreement, induced overexpression of VEGF-C in LAPC-9 enhanced tumor lymphangiogenesis leading to the development of metastatic lesions. Taken together, our studies, based on a molecular imaging approach for semiquantitative detection of micrometastases, point to an important role of tumor lymphatics in the metastatic process of human prostate cancer. In particular, VEGF-C seems to play a key role in prostate cancer metastasis.	[ "Modulating", "metastasis", "by", "a", "lymphangiogenic", "switch", "in", "prostate", "cancer", ".", "\n", "Prostate", "cancer", "dissemination", "is", "difficult", "to", "detect", "in", "the", "clinic", ",", "and", "few", "treatment", "options", "exist", "for", "patients", "with", "advanced", "-", "stage", "disease", ".", "Our", "aim", "was", "to", "investigate", "the", "role", "of", "tumor", "lymphangiogenesis", "during", "metastasis", ".", "Further", ",", "we", "implemented", "a", "noninvasive", "molecular", "imaging", "technique", "to", "facilitate", "the", "assessment", "of", "the", "metastatic", "process", ".", "The", "metastatic", "potentials", "of", "several", "human", "prostate", "cancer", "xenograft", "models", ",", "LAPC-4", ",", "LAPC-9", ",", "PC3", "and", "CWR22Rv-1", "were", "compared", ".", "The", "cells", "were", "labeled", "with", "luciferase", ",", "a", "bioluminescence", "imaging", "reporter", "gene", ",", "to", "enable", "optical", "imaging", ".", "After", "tumor", "implantation", "the", "animals", "were", "examined", "weekly", "during", "several", "months", "for", "the", "appearance", "of", "metastases", ".", "Metastatic", "lesions", "were", "confirmed", "by", "immunohistochemistry", ".", "Additionally", ",", "the", "angiogenic", "and", "lymphangiogenic", "profiles", "of", "the", "tumors", "were", "characterized", ".", "To", "confirm", "the", "role", "of", "lymphangiogenesis", "in", "mediating", "metastasis", ",", "the", "low", "-", "metastatic", "LAPC-9", "tumor", "cells", "were", "engineered", "to", "overexpress", "VEGF", "-", "C", ",", "and", "the", "development", "of", "metastases", "was", "evaluated", ".", "Our", "results", "show", "CWR22Rv-1", "and", "PC3", "tumor", "cell", "lines", "to", "be", "more", "metastatic", "than", "LAPC-4", ",", "which", "in", "turn", "disseminates", "more", "readily", "than", "LAPC-9", ".", "The", "difference", "in", "metastatic", "potential", "correlated", "with", "the", "endogenous", "production", "levels", "of", "lymphangiogenic", "growth", "factor", "VEGF", "-", "C", "and", "the", "presence", "of", "tumor", "lymphatics", ".", "In", "agreement", ",", "induced", "overexpression", "of", "VEGF", "-", "C", "in", "LAPC-9", "enhanced", "tumor", "lymphangiogenesis", "leading", "to", "the", "development", "of", "metastatic", "lesions", ".", "Taken", "together", ",", "our", "studies", ",", "based", "on", "a", "molecular", "imaging", "approach", "for", "semiquantitative", "detection", "of", "micrometastases", ",", "point", "to", "an", "important", "role", "of", "tumor", "lymphatics", "in", "the", "metastatic", "process", "of", "human", "prostate", "cancer", ".", "In", "particular", ",", "VEGF", "-", "C", "seems", "to", "play", "a", "key", "role", "in", "prostate", "cancer", "metastasis", ".", "\n" ]	[ "Cell", "Cancer", "Multi-tissue_structure" ]
prostate cancer, Prostate cancer, tumor, prostate cancer xenograft, LAPC-4, LAPC-9, PC3, CWR22Rv-1, cells, tumor, metastases, Metastatic lesions, tumors, low - metastatic LAPC-9 tumor cells, metastases, CWR22Rv-1, PC3 tumor cell lines, LAPC-4, LAPC-9, tumor lymphatics, LAPC-9, tumor, metastatic lesions, tumor lymphatics, prostate cancer, prostate cancer	PMID-17583576_task2	Sentence: Modulating metastasis by a lymphangiogenic switch in prostate cancer. Prostate cancer dissemination is difficult to detect in the clinic, and few treatment options exist for patients with advanced-stage disease. Our aim was to investigate the role of tumor lymphangiogenesis during metastasis. Further, we implemented a noninvasive molecular imaging technique to facilitate the assessment of the metastatic process. The metastatic potentials of several human prostate cancer xenograft models, LAPC-4, LAPC-9, PC3 and CWR22Rv-1 were compared. The cells were labeled with luciferase, a bioluminescence imaging reporter gene, to enable optical imaging. After tumor implantation the animals were examined weekly during several months for the appearance of metastases. Metastatic lesions were confirmed by immunohistochemistry. Additionally, the angiogenic and lymphangiogenic profiles of the tumors were characterized. To confirm the role of lymphangiogenesis in mediating metastasis, the low-metastatic LAPC-9 tumor cells were engineered to overexpress VEGF-C, and the development of metastases was evaluated. Our results show CWR22Rv-1 and PC3 tumor cell lines to be more metastatic than LAPC-4, which in turn disseminates more readily than LAPC-9. The difference in metastatic potential correlated with the endogenous production levels of lymphangiogenic growth factor VEGF-C and the presence of tumor lymphatics. In agreement, induced overexpression of VEGF-C in LAPC-9 enhanced tumor lymphangiogenesis leading to the development of metastatic lesions. Taken together, our studies, based on a molecular imaging approach for semiquantitative detection of micrometastases, point to an important role of tumor lymphatics in the metastatic process of human prostate cancer. In particular, VEGF-C seems to play a key role in prostate cancer metastasis. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O" ]	Modulating metastasis by a lymphangiogenic switch in prostate cancer. Prostate cancer dissemination is difficult to detect in the clinic, and few treatment options exist for patients with advanced-stage disease. Our aim was to investigate the role of tumor lymphangiogenesis during metastasis. Further, we implemented a noninvasive molecular imaging technique to facilitate the assessment of the metastatic process. The metastatic potentials of several human prostate cancer xenograft models, LAPC-4, LAPC-9, PC3 and CWR22Rv-1 were compared. The cells were labeled with luciferase, a bioluminescence imaging reporter gene, to enable optical imaging. After tumor implantation the animals were examined weekly during several months for the appearance of metastases. Metastatic lesions were confirmed by immunohistochemistry. Additionally, the angiogenic and lymphangiogenic profiles of the tumors were characterized. To confirm the role of lymphangiogenesis in mediating metastasis, the low-metastatic LAPC-9 tumor cells were engineered to overexpress VEGF-C, and the development of metastases was evaluated. Our results show CWR22Rv-1 and PC3 tumor cell lines to be more metastatic than LAPC-4, which in turn disseminates more readily than LAPC-9. The difference in metastatic potential correlated with the endogenous production levels of lymphangiogenic growth factor VEGF-C and the presence of tumor lymphatics. In agreement, induced overexpression of VEGF-C in LAPC-9 enhanced tumor lymphangiogenesis leading to the development of metastatic lesions. Taken together, our studies, based on a molecular imaging approach for semiquantitative detection of micrometastases, point to an important role of tumor lymphatics in the metastatic process of human prostate cancer. In particular, VEGF-C seems to play a key role in prostate cancer metastasis.	[ "Modulating", "metastasis", "by", "a", "lymphangiogenic", "switch", "in", "prostate", "cancer", ".", "\n", "Prostate", "cancer", "dissemination", "is", "difficult", "to", "detect", "in", "the", "clinic", ",", "and", "few", "treatment", "options", "exist", "for", "patients", "with", "advanced", "-", "stage", "disease", ".", "Our", "aim", "was", "to", "investigate", "the", "role", "of", "tumor", "lymphangiogenesis", "during", "metastasis", ".", "Further", ",", "we", "implemented", "a", "noninvasive", "molecular", "imaging", "technique", "to", "facilitate", "the", "assessment", "of", "the", "metastatic", "process", ".", "The", "metastatic", "potentials", "of", "several", "human", "prostate", "cancer", "xenograft", "models", ",", "LAPC-4", ",", "LAPC-9", ",", "PC3", "and", "CWR22Rv-1", "were", "compared", ".", "The", "cells", "were", "labeled", "with", "luciferase", ",", "a", "bioluminescence", "imaging", "reporter", "gene", ",", "to", "enable", "optical", "imaging", ".", "After", "tumor", "implantation", "the", "animals", "were", "examined", "weekly", "during", "several", "months", "for", "the", "appearance", "of", "metastases", ".", "Metastatic", "lesions", "were", "confirmed", "by", "immunohistochemistry", ".", "Additionally", ",", "the", "angiogenic", "and", "lymphangiogenic", "profiles", "of", "the", "tumors", "were", "characterized", ".", "To", "confirm", "the", "role", "of", "lymphangiogenesis", "in", "mediating", "metastasis", ",", "the", "low", "-", "metastatic", "LAPC-9", "tumor", "cells", "were", "engineered", "to", "overexpress", "VEGF", "-", "C", ",", "and", "the", "development", "of", "metastases", "was", "evaluated", ".", "Our", "results", "show", "CWR22Rv-1", "and", "PC3", "tumor", "cell", "lines", "to", "be", "more", "metastatic", "than", "LAPC-4", ",", "which", "in", "turn", "disseminates", "more", "readily", "than", "LAPC-9", ".", "The", "difference", "in", "metastatic", "potential", "correlated", "with", "the", "endogenous", "production", "levels", "of", "lymphangiogenic", "growth", "factor", "VEGF", "-", "C", "and", "the", "presence", "of", "tumor", "lymphatics", ".", "In", "agreement", ",", "induced", "overexpression", "of", "VEGF", "-", "C", "in", "LAPC-9", "enhanced", "tumor", "lymphangiogenesis", "leading", "to", "the", "development", "of", "metastatic", "lesions", ".", "Taken", "together", ",", "our", "studies", ",", "based", "on", "a", "molecular", "imaging", "approach", "for", "semiquantitative", "detection", "of", "micrometastases", ",", "point", "to", "an", "important", "role", "of", "tumor", "lymphatics", "in", "the", "metastatic", "process", "of", "human", "prostate", "cancer", ".", "In", "particular", ",", "VEGF", "-", "C", "seems", "to", "play", "a", "key", "role", "in", "prostate", "cancer", "metastasis", ".", "\n" ]	[ "Cell", "Cancer", "Multi-tissue_structure" ]
triiodothyronine ( T3 ) mononuclear leukocyte receptor kinetics is an other_name, T3 administration is an other_name, cold - air exposures is an other_name	18768_task0	Sentence: Changes in triiodothyronine (T3) mononuclear leukocyte receptor kinetics after T3 administration and multiple cold-air exposures. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_name	[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]	Changes in triiodothyronine (T3) mononuclear leukocyte receptor kinetics after T3 administration and multiple cold-air exposures.	[ "Changes", "in", "triiodothyronine", "(", "T3", ")", "mononuclear", "leukocyte", "receptor", "kinetics", "after", "T3", "administration", "and", "multiple", "cold", "-", "air", "exposures", "." ]	[ "other_name", "(AND other_name other_name)", "cell_type", "multi_cell", "amino_acid_monomer", "protein_molecule", "", "tissue", "peptide" ]
triiodothyronine ( T3 ) mononuclear leukocyte receptor kinetics is an other_name, T3 administration is an other_name, cold - air exposures is an other_name	18768_task1	Sentence: Changes in triiodothyronine (T3) mononuclear leukocyte receptor kinetics after T3 administration and multiple cold-air exposures. Instructions: please typing these entity words according to sentence: triiodothyronine ( T3 ) mononuclear leukocyte receptor kinetics, T3 administration, cold - air exposures Options: other_name	[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]	Changes in triiodothyronine (T3) mononuclear leukocyte receptor kinetics after T3 administration and multiple cold-air exposures.	[ "Changes", "in", "triiodothyronine", "(", "T3", ")", "mononuclear", "leukocyte", "receptor", "kinetics", "after", "T3", "administration", "and", "multiple", "cold", "-", "air", "exposures", "." ]	[ "other_name", "(AND other_name other_name)", "cell_type", "multi_cell", "amino_acid_monomer", "protein_molecule", "", "tissue", "peptide" ]
triiodothyronine ( T3 ) mononuclear leukocyte receptor kinetics, T3 administration, cold - air exposures	18768_task2	Sentence: Changes in triiodothyronine (T3) mononuclear leukocyte receptor kinetics after T3 administration and multiple cold-air exposures. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]	Changes in triiodothyronine (T3) mononuclear leukocyte receptor kinetics after T3 administration and multiple cold-air exposures.	[ "Changes", "in", "triiodothyronine", "(", "T3", ")", "mononuclear", "leukocyte", "receptor", "kinetics", "after", "T3", "administration", "and", "multiple", "cold", "-", "air", "exposures", "." ]	[ "other_name", "(AND other_name other_name)", "cell_type", "multi_cell", "amino_acid_monomer", "protein_molecule", "", "tissue", "peptide" ]
gestational age is a Measurement, > = 28 weeks is a Value, Systolic blood pressure is a Measurement, > = 160 mm Hg is a Value, diastolic blood pressure is a Measurement, > = 110 mm Hg is a Value, > = 18 is a Value, years is a Person	NCT01912677_inc_task0	Sentence: Pregnant gestational age >= 28 weeks Systolic blood pressure >=160 mm Hg OR a diastolic blood pressure of >=110 mm Hg measured twice more than 15 minutes apart Able to swallow pills >= 18 years Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Person, Measurement, Value	[ "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Value", "I-Value", "I-Value", "B-Person", "O" ]	Pregnant gestational age >= 28 weeks Systolic blood pressure >=160 mm Hg OR a diastolic blood pressure of >=110 mm Hg measured twice more than 15 minutes apart Able to swallow pills >= 18 years	[ "Pregnant", "gestational", "age", ">", "=", "28", "weeks", "\n", "Systolic", "blood", "pressure", ">", "=", "160", "mm", "Hg", "OR", "a", "diastolic", "blood", "pressure", "of", ">", "=", "110", "mm", "Hg", "measured", "twice", "more", "than", "15", "minutes", "apart", "\n", "Able", "to", "swallow", "pills", "\n", ">", "=", "18", "years", "\n" ]	[ "Measurement", "Value", "Person" ]
gestational age is a Measurement, > = 28 weeks is a Value, Systolic blood pressure is a Measurement, > = 160 mm Hg is a Value, diastolic blood pressure is a Measurement, > = 110 mm Hg is a Value, > = 18 is a Value, years is a Person	NCT01912677_inc_task1	Sentence: Pregnant gestational age >= 28 weeks Systolic blood pressure >=160 mm Hg OR a diastolic blood pressure of >=110 mm Hg measured twice more than 15 minutes apart Able to swallow pills >= 18 years Instructions: please typing these entity words according to sentence: gestational age, > = 28 weeks, Systolic blood pressure, > = 160 mm Hg, diastolic blood pressure, > = 110 mm Hg, > = 18, years Options: Person, Measurement, Value	[ "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Value", "I-Value", "I-Value", "B-Person", "O" ]	Pregnant gestational age >= 28 weeks Systolic blood pressure >=160 mm Hg OR a diastolic blood pressure of >=110 mm Hg measured twice more than 15 minutes apart Able to swallow pills >= 18 years	[ "Pregnant", "gestational", "age", ">", "=", "28", "weeks", "\n", "Systolic", "blood", "pressure", ">", "=", "160", "mm", "Hg", "OR", "a", "diastolic", "blood", "pressure", "of", ">", "=", "110", "mm", "Hg", "measured", "twice", "more", "than", "15", "minutes", "apart", "\n", "Able", "to", "swallow", "pills", "\n", ">", "=", "18", "years", "\n" ]	[ "Measurement", "Value", "Person" ]

Retinoblastoma is a Protein, Oct-1 is a Protein, interleukin-8 is a Protein, retinoblastoma is a Protein, IFN - gamma is a Protein, Rb is a Protein, IFN - gamma is a Protein, Rb is a Protein, Rb is a Protein, Oct-1 is a Protein, Rb is a Protein, Rb is a Protein, Oct-1 is a Protein, Oct-1 is a Protein, interleukin 8 is a Protein, promoter is a Entity, Oct-1 is a Protein, Rb is a Protein, interleukin 8 is a Protein

215_task1

Sentence: Retinoblastoma protein expression leads to reduced Oct-1 DNA binding activity and enhances interleukin-8 expression. Tumor cell lines with a defective retinoblastoma gene are unable to transcribe the HLA class II genes in response to IFN-gamma treatment, and reconstitution of functional Rb rescues IFN-gamma-induced class II gene expression. However, the molecular mechanism of Rb rescue of the class II genes is unknown. We have examined the effect of Rb expression on the activation of the promoter for HLA-DRA, the prototype class II gene. Oct-1, a POU domain transcription factor, was identified as a repressor of HLA-DRA promoter activity in the Rb-defective cells. Rb expression led to phosphorylation of Oct-1, thus relieving its repressive effect. Oct-1 has also been shown to repress interleukin 8 promoter activity. Consistent with reduced levels of Oct-1 DNA binding activity in the Rb-transformed cell lines, interleukin 8 expression is higher in these cell lines. Instructions: please typing these entity words according to sentence: Retinoblastoma, Oct-1, interleukin-8, retinoblastoma, IFN - gamma, Rb, IFN - gamma, Rb, Rb, Oct-1, Rb, Rb, Oct-1, Oct-1, interleukin 8, promoter, Oct-1, Rb, interleukin 8 Options: Entity, Protein

[ "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

Retinoblastoma protein expression leads to reduced Oct-1 DNA binding activity and enhances interleukin-8 expression. Tumor cell lines with a defective retinoblastoma gene are unable to transcribe the HLA class II genes in response to IFN-gamma treatment, and reconstitution of functional Rb rescues IFN-gamma-induced class II gene expression. However, the molecular mechanism of Rb rescue of the class II genes is unknown. We have examined the effect of Rb expression on the activation of the promoter for HLA-DRA, the prototype class II gene. Oct-1, a POU domain transcription factor, was identified as a repressor of HLA-DRA promoter activity in the Rb-defective cells. Rb expression led to phosphorylation of Oct-1, thus relieving its repressive effect. Oct-1 has also been shown to repress interleukin 8 promoter activity. Consistent with reduced levels of Oct-1 DNA binding activity in the Rb-transformed cell lines, interleukin 8 expression is higher in these cell lines.

[ "Retinoblastoma", "protein", "expression", "leads", "to", "reduced", "Oct-1", "DNA", "binding", "activity", "and", "enhances", "interleukin-8", "expression", ".", "\n", "Tumor", "cell", "lines", "with", "a", "defective", "retinoblastoma", "gene", "are", "unable", "to", "transcribe", "the", "HLA", "class", "II", "genes", "in", "response", "to", "IFN", "-", "gamma", "treatment", ",", "and", "reconstitution", "of", "functional", "Rb", "rescues", "IFN", "-", "gamma", "-", "induced", "class", "II", "gene", "expression", ".", "However", ",", "the", "molecular", "mechanism", "of", "Rb", "rescue", "of", "the", "class", "II", "genes", "is", "unknown", ".", "We", "have", "examined", "the", "effect", "of", "Rb", "expression", "on", "the", "activation", "of", "the", "promoter", "for", "HLA", "-", "DRA", ",", "the", "prototype", "class", "II", "gene", ".", "Oct-1", ",", "a", "POU", "domain", "transcription", "factor", ",", "was", "identified", "as", "a", "repressor", "of", "HLA", "-", "DRA", "promoter", "activity", "in", "the", "Rb", "-", "defective", "cells", ".", "Rb", "expression", "led", "to", "phosphorylation", "of", "Oct-1", ",", "thus", "relieving", "its", "repressive", "effect", ".", "Oct-1", "has", "also", "been", "shown", "to", "repress", "interleukin", "8", "promoter", "activity", ".", "Consistent", "with", "reduced", "levels", "of", "Oct-1", "DNA", "binding", "activity", "in", "the", "Rb", "-", "transformed", "cell", "lines", ",", "interleukin", "8", "expression", "is", "higher", "in", "these", "cell", "lines", "." ]

[ "Protein", "Entity" ]

Retinoblastoma, Oct-1, interleukin-8, retinoblastoma, IFN - gamma, Rb, IFN - gamma, Rb, Rb, Oct-1, Rb, Rb, Oct-1, Oct-1, interleukin 8, promoter, Oct-1, Rb, interleukin 8

215_task2

Sentence: Retinoblastoma protein expression leads to reduced Oct-1 DNA binding activity and enhances interleukin-8 expression. Tumor cell lines with a defective retinoblastoma gene are unable to transcribe the HLA class II genes in response to IFN-gamma treatment, and reconstitution of functional Rb rescues IFN-gamma-induced class II gene expression. However, the molecular mechanism of Rb rescue of the class II genes is unknown. We have examined the effect of Rb expression on the activation of the promoter for HLA-DRA, the prototype class II gene. Oct-1, a POU domain transcription factor, was identified as a repressor of HLA-DRA promoter activity in the Rb-defective cells. Rb expression led to phosphorylation of Oct-1, thus relieving its repressive effect. Oct-1 has also been shown to repress interleukin 8 promoter activity. Consistent with reduced levels of Oct-1 DNA binding activity in the Rb-transformed cell lines, interleukin 8 expression is higher in these cell lines. Instructions: please extract entity words from the input sentence

[ "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

Retinoblastoma protein expression leads to reduced Oct-1 DNA binding activity and enhances interleukin-8 expression. Tumor cell lines with a defective retinoblastoma gene are unable to transcribe the HLA class II genes in response to IFN-gamma treatment, and reconstitution of functional Rb rescues IFN-gamma-induced class II gene expression. However, the molecular mechanism of Rb rescue of the class II genes is unknown. We have examined the effect of Rb expression on the activation of the promoter for HLA-DRA, the prototype class II gene. Oct-1, a POU domain transcription factor, was identified as a repressor of HLA-DRA promoter activity in the Rb-defective cells. Rb expression led to phosphorylation of Oct-1, thus relieving its repressive effect. Oct-1 has also been shown to repress interleukin 8 promoter activity. Consistent with reduced levels of Oct-1 DNA binding activity in the Rb-transformed cell lines, interleukin 8 expression is higher in these cell lines.

[ "Retinoblastoma", "protein", "expression", "leads", "to", "reduced", "Oct-1", "DNA", "binding", "activity", "and", "enhances", "interleukin-8", "expression", ".", "\n", "Tumor", "cell", "lines", "with", "a", "defective", "retinoblastoma", "gene", "are", "unable", "to", "transcribe", "the", "HLA", "class", "II", "genes", "in", "response", "to", "IFN", "-", "gamma", "treatment", ",", "and", "reconstitution", "of", "functional", "Rb", "rescues", "IFN", "-", "gamma", "-", "induced", "class", "II", "gene", "expression", ".", "However", ",", "the", "molecular", "mechanism", "of", "Rb", "rescue", "of", "the", "class", "II", "genes", "is", "unknown", ".", "We", "have", "examined", "the", "effect", "of", "Rb", "expression", "on", "the", "activation", "of", "the", "promoter", "for", "HLA", "-", "DRA", ",", "the", "prototype", "class", "II", "gene", ".", "Oct-1", ",", "a", "POU", "domain", "transcription", "factor", ",", "was", "identified", "as", "a", "repressor", "of", "HLA", "-", "DRA", "promoter", "activity", "in", "the", "Rb", "-", "defective", "cells", ".", "Rb", "expression", "led", "to", "phosphorylation", "of", "Oct-1", ",", "thus", "relieving", "its", "repressive", "effect", ".", "Oct-1", "has", "also", "been", "shown", "to", "repress", "interleukin", "8", "promoter", "activity", ".", "Consistent", "with", "reduced", "levels", "of", "Oct-1", "DNA", "binding", "activity", "in", "the", "Rb", "-", "transformed", "cell", "lines", ",", "interleukin", "8", "expression", "is", "higher", "in", "these", "cell", "lines", "." ]

[ "Protein", "Entity" ]

Serumkinetik is an umlsterm, hirnspezifischen is an umlsterm, Markers is an umlsterm, Protein is an umlsterm, angeborener is an umlsterm, Methodik is an umlsterm, Haemoglobin - Saettigung is an umlsterm, USA is an umlsterm, Protein is an umlsterm, Radioimmunassays is an umlsterm, Schweden is an umlsterm, Protein is an umlsterm, Kindern is an umlsterm, Komplikationen is an umlsterm, Standardabweichungen is an umlsterm, Kinder is an umlsterm, Bypasszeit is an umlsterm, Temperatur is an umlsterm, Protein is an umlsterm, Haemoglobin - Saettigung is an umlsterm, Reperfusion is an umlsterm, Protein is an umlsterm, Membranschaedigung is an umlsterm, Blut - Hirnschranke is an umlsterm, Proteins is an umlsterm, Hypothermie is an umlsterm

IntensiveMedizin.00370617.ger.abstr_task0

Sentence: Fragestellung : Das Ziel diese prospektiven Studie war , die Serumkinetik des hirnspezifischen Markers Protein S-100, eines Gliazell- und Astrozytenproteins , in Beziehung zur kontinuierlich registrierten zerebralen Oxygenierung vor und nach Korrekturoperationen angeborener Herzfehler zu evaluieren . Methodik : Die regionale zerebrale Haemoglobin-Saettigung wurde mit Hilfe der Nahinfrarotspektroskopie ( INVOS 3100A , Somanetics , USA ) bestimmt und das Protein S-100 mittels eines doppelseitigen Radioimmunassays analysiert ( Sangtec 100 IRMA , Bromma , Schweden ) . Ergebnisse : Das Protein S-100 war bei allen Kindern ohne nachweisbare neurologische Komplikationen nach Ende der extrakorporalen Zirkulation um 2 Standardabweichungen des praeoperativen Ausgangswertes erhoeht gefunden ( p 0,0001 ) . Die maximalen Serum-S-100-Konzentrationen korrelierten signifikant mit dem Alter ( r=-0,75, p 0,0001 ) und Gewicht ( r=-0,72, p=0,005) der Kinder , der Bypasszeit ( r=0,44, p=0,005) und der minimalen rektalen Temperatur ( r=-0,67, p=0,004) waehrend der extrakorporalen Zirkulation . Ein statistischer Zusammenhang fand sich zwischen dem postoperativen Serumspiegel des Protein S-100 und dem Abfall der regionalen zerebralen Haemoglobin-Saettigung waehrend der Reperfusion ( r=-0,37, p=0,02) und am Ende der extrakorporalen Zirkulation ( r=-0,42, p=0,008). Schlussfolgerung : Die Astrogliazellen scheinen auf die extrakorporale Zirkulation mit einer Expression des Protein S-100 zu reagieren . Eine Membranschaedigung im endothelialastrozytaeren Zellkomplex der Blut-Hirnschranke koennte die Freisetzung des Proteins in die Blutstrombahn erklaeren . Beeinflussende Faktoren scheinen geringes Alter , Laenge der extrakorporalen Zirkulation , Grad der Hypothermie und moegliche Reduktion der postoperativen zerebralen Oxygenierung zu sein . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fragestellung : Das Ziel diese prospektiven Studie war , die Serumkinetik des hirnspezifischen Markers Protein S-100, eines Gliazell- und Astrozytenproteins , in Beziehung zur kontinuierlich registrierten zerebralen Oxygenierung vor und nach Korrekturoperationen angeborener Herzfehler zu evaluieren . Methodik : Die regionale zerebrale Haemoglobin-Saettigung wurde mit Hilfe der Nahinfrarotspektroskopie ( INVOS 3100A , Somanetics , USA ) bestimmt und das Protein S-100 mittels eines doppelseitigen Radioimmunassays analysiert ( Sangtec 100 IRMA , Bromma , Schweden ) . Ergebnisse : Das Protein S-100 war bei allen Kindern ohne nachweisbare neurologische Komplikationen nach Ende der extrakorporalen Zirkulation um 2 Standardabweichungen des praeoperativen Ausgangswertes erhoeht gefunden ( p 0,0001 ) . Die maximalen Serum-S-100-Konzentrationen korrelierten signifikant mit dem Alter ( r=-0,75, p 0,0001 ) und Gewicht ( r=-0,72, p=0,005) der Kinder , der Bypasszeit ( r=0,44, p=0,005) und der minimalen rektalen Temperatur ( r=-0,67, p=0,004) waehrend der extrakorporalen Zirkulation . Ein statistischer Zusammenhang fand sich zwischen dem postoperativen Serumspiegel des Protein S-100 und dem Abfall der regionalen zerebralen Haemoglobin-Saettigung waehrend der Reperfusion ( r=-0,37, p=0,02) und am Ende der extrakorporalen Zirkulation ( r=-0,42, p=0,008). Schlussfolgerung : Die Astrogliazellen scheinen auf die extrakorporale Zirkulation mit einer Expression des Protein S-100 zu reagieren . Eine Membranschaedigung im endothelialastrozytaeren Zellkomplex der Blut-Hirnschranke koennte die Freisetzung des Proteins in die Blutstrombahn erklaeren . Beeinflussende Faktoren scheinen geringes Alter , Laenge der extrakorporalen Zirkulation , Grad der Hypothermie und moegliche Reduktion der postoperativen zerebralen Oxygenierung zu sein .

[ "Fragestellung", ":", "Das", "Ziel", "diese", "prospektiven", "Studie", "war", ",", "die", "Serumkinetik", "des", "hirnspezifischen", "Markers", "Protein", "S-100", ",", "eines", "Gliazell-", "und", "Astrozytenproteins", ",", "in", "Beziehung", "zur", "kontinuierlich", "registrierten", "zerebralen", "Oxygenierung", "vor", "und", "nach", "Korrekturoperationen", "angeborener", "Herzfehler", "zu", "evaluieren", ".", "Methodik", ":", "Die", "regionale", "zerebrale", "Haemoglobin", "-", "Saettigung", "wurde", "mit", "Hilfe", "der", "Nahinfrarotspektroskopie", "(", "INVOS", "3100A", ",", "Somanetics", ",", "USA", ")", "bestimmt", "und", "das", "Protein", "S-100", "mittels", "eines", "doppelseitigen", "Radioimmunassays", "analysiert", "(", "Sangtec", "100", "IRMA", ",", "Bromma", ",", "Schweden", ")", ".", "Ergebnisse", ":", "Das", "Protein", "S-100", "war", "bei", "allen", "Kindern", "ohne", "nachweisbare", "neurologische", "Komplikationen", "nach", "Ende", "der", "extrakorporalen", "Zirkulation", "um", "2", "Standardabweichungen", "des", "praeoperativen", "Ausgangswertes", "erhoeht", "gefunden", "(", "p", "0,0001", ")", ".", "Die", "maximalen", "Serum", "-", "S-100-Konzentrationen", "korrelierten", "signifikant", "mit", "dem", "Alter", "(", "r=-0,75", ",", "p", "0,0001", ")", "und", "Gewicht", "(", "r=-0,72", ",", "p=0,005", ")", "der", "Kinder", ",", "der", "Bypasszeit", "(", "r=0,44", ",", "p=0,005", ")", "und", "der", "minimalen", "rektalen", "Temperatur", "(", "r=-0,67", ",", "p=0,004", ")", "waehrend", "der", "extrakorporalen", "Zirkulation", ".", "Ein", "statistischer", "Zusammenhang", "fand", "sich", "zwischen", "dem", "postoperativen", "Serumspiegel", "des", "Protein", "S-100", "und", "dem", "Abfall", "der", "regionalen", "zerebralen", "Haemoglobin", "-", "Saettigung", "waehrend", "der", "Reperfusion", "(", "r=-0,37", ",", "p=0,02", ")", "und", "am", "Ende", "der", "extrakorporalen", "Zirkulation", "(", "r=-0,42", ",", "p=0,008", ")", ".", "Schlussfolgerung", ":", "Die", "Astrogliazellen", "scheinen", "auf", "die", "extrakorporale", "Zirkulation", "mit", "einer", "Expression", "des", "Protein", "S-100", "zu", "reagieren", ".", "Eine", "Membranschaedigung", "im", "endothelialastrozytaeren", "Zellkomplex", "der", "Blut", "-", "Hirnschranke", "koennte", "die", "Freisetzung", "des", "Proteins", "in", "die", "Blutstrombahn", "erklaeren", ".", "Beeinflussende", "Faktoren", "scheinen", "geringes", "Alter", ",", "Laenge", "der", "extrakorporalen", "Zirkulation", ",", "Grad", "der", "Hypothermie", "und", "moegliche", "Reduktion", "der", "postoperativen", "zerebralen", "Oxygenierung", "zu", "sein", "." ]

[ "umlsterm" ]

Serumkinetik is an umlsterm, hirnspezifischen is an umlsterm, Markers is an umlsterm, Protein is an umlsterm, angeborener is an umlsterm, Methodik is an umlsterm, Haemoglobin - Saettigung is an umlsterm, USA is an umlsterm, Protein is an umlsterm, Radioimmunassays is an umlsterm, Schweden is an umlsterm, Protein is an umlsterm, Kindern is an umlsterm, Komplikationen is an umlsterm, Standardabweichungen is an umlsterm, Kinder is an umlsterm, Bypasszeit is an umlsterm, Temperatur is an umlsterm, Protein is an umlsterm, Haemoglobin - Saettigung is an umlsterm, Reperfusion is an umlsterm, Protein is an umlsterm, Membranschaedigung is an umlsterm, Blut - Hirnschranke is an umlsterm, Proteins is an umlsterm, Hypothermie is an umlsterm

IntensiveMedizin.00370617.ger.abstr_task1

Sentence: Fragestellung : Das Ziel diese prospektiven Studie war , die Serumkinetik des hirnspezifischen Markers Protein S-100, eines Gliazell- und Astrozytenproteins , in Beziehung zur kontinuierlich registrierten zerebralen Oxygenierung vor und nach Korrekturoperationen angeborener Herzfehler zu evaluieren . Methodik : Die regionale zerebrale Haemoglobin-Saettigung wurde mit Hilfe der Nahinfrarotspektroskopie ( INVOS 3100A , Somanetics , USA ) bestimmt und das Protein S-100 mittels eines doppelseitigen Radioimmunassays analysiert ( Sangtec 100 IRMA , Bromma , Schweden ) . Ergebnisse : Das Protein S-100 war bei allen Kindern ohne nachweisbare neurologische Komplikationen nach Ende der extrakorporalen Zirkulation um 2 Standardabweichungen des praeoperativen Ausgangswertes erhoeht gefunden ( p 0,0001 ) . Die maximalen Serum-S-100-Konzentrationen korrelierten signifikant mit dem Alter ( r=-0,75, p 0,0001 ) und Gewicht ( r=-0,72, p=0,005) der Kinder , der Bypasszeit ( r=0,44, p=0,005) und der minimalen rektalen Temperatur ( r=-0,67, p=0,004) waehrend der extrakorporalen Zirkulation . Ein statistischer Zusammenhang fand sich zwischen dem postoperativen Serumspiegel des Protein S-100 und dem Abfall der regionalen zerebralen Haemoglobin-Saettigung waehrend der Reperfusion ( r=-0,37, p=0,02) und am Ende der extrakorporalen Zirkulation ( r=-0,42, p=0,008). Schlussfolgerung : Die Astrogliazellen scheinen auf die extrakorporale Zirkulation mit einer Expression des Protein S-100 zu reagieren . Eine Membranschaedigung im endothelialastrozytaeren Zellkomplex der Blut-Hirnschranke koennte die Freisetzung des Proteins in die Blutstrombahn erklaeren . Beeinflussende Faktoren scheinen geringes Alter , Laenge der extrakorporalen Zirkulation , Grad der Hypothermie und moegliche Reduktion der postoperativen zerebralen Oxygenierung zu sein . Instructions: please typing these entity words according to sentence: Serumkinetik, hirnspezifischen, Markers, Protein, angeborener, Methodik, Haemoglobin - Saettigung, USA, Protein, Radioimmunassays, Schweden, Protein, Kindern, Komplikationen, Standardabweichungen, Kinder, Bypasszeit, Temperatur, Protein, Haemoglobin - Saettigung, Reperfusion, Protein, Membranschaedigung, Blut - Hirnschranke, Proteins, Hypothermie Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fragestellung : Das Ziel diese prospektiven Studie war , die Serumkinetik des hirnspezifischen Markers Protein S-100, eines Gliazell- und Astrozytenproteins , in Beziehung zur kontinuierlich registrierten zerebralen Oxygenierung vor und nach Korrekturoperationen angeborener Herzfehler zu evaluieren . Methodik : Die regionale zerebrale Haemoglobin-Saettigung wurde mit Hilfe der Nahinfrarotspektroskopie ( INVOS 3100A , Somanetics , USA ) bestimmt und das Protein S-100 mittels eines doppelseitigen Radioimmunassays analysiert ( Sangtec 100 IRMA , Bromma , Schweden ) . Ergebnisse : Das Protein S-100 war bei allen Kindern ohne nachweisbare neurologische Komplikationen nach Ende der extrakorporalen Zirkulation um 2 Standardabweichungen des praeoperativen Ausgangswertes erhoeht gefunden ( p 0,0001 ) . Die maximalen Serum-S-100-Konzentrationen korrelierten signifikant mit dem Alter ( r=-0,75, p 0,0001 ) und Gewicht ( r=-0,72, p=0,005) der Kinder , der Bypasszeit ( r=0,44, p=0,005) und der minimalen rektalen Temperatur ( r=-0,67, p=0,004) waehrend der extrakorporalen Zirkulation . Ein statistischer Zusammenhang fand sich zwischen dem postoperativen Serumspiegel des Protein S-100 und dem Abfall der regionalen zerebralen Haemoglobin-Saettigung waehrend der Reperfusion ( r=-0,37, p=0,02) und am Ende der extrakorporalen Zirkulation ( r=-0,42, p=0,008). Schlussfolgerung : Die Astrogliazellen scheinen auf die extrakorporale Zirkulation mit einer Expression des Protein S-100 zu reagieren . Eine Membranschaedigung im endothelialastrozytaeren Zellkomplex der Blut-Hirnschranke koennte die Freisetzung des Proteins in die Blutstrombahn erklaeren . Beeinflussende Faktoren scheinen geringes Alter , Laenge der extrakorporalen Zirkulation , Grad der Hypothermie und moegliche Reduktion der postoperativen zerebralen Oxygenierung zu sein .

[ "Fragestellung", ":", "Das", "Ziel", "diese", "prospektiven", "Studie", "war", ",", "die", "Serumkinetik", "des", "hirnspezifischen", "Markers", "Protein", "S-100", ",", "eines", "Gliazell-", "und", "Astrozytenproteins", ",", "in", "Beziehung", "zur", "kontinuierlich", "registrierten", "zerebralen", "Oxygenierung", "vor", "und", "nach", "Korrekturoperationen", "angeborener", "Herzfehler", "zu", "evaluieren", ".", "Methodik", ":", "Die", "regionale", "zerebrale", "Haemoglobin", "-", "Saettigung", "wurde", "mit", "Hilfe", "der", "Nahinfrarotspektroskopie", "(", "INVOS", "3100A", ",", "Somanetics", ",", "USA", ")", "bestimmt", "und", "das", "Protein", "S-100", "mittels", "eines", "doppelseitigen", "Radioimmunassays", "analysiert", "(", "Sangtec", "100", "IRMA", ",", "Bromma", ",", "Schweden", ")", ".", "Ergebnisse", ":", "Das", "Protein", "S-100", "war", "bei", "allen", "Kindern", "ohne", "nachweisbare", "neurologische", "Komplikationen", "nach", "Ende", "der", "extrakorporalen", "Zirkulation", "um", "2", "Standardabweichungen", "des", "praeoperativen", "Ausgangswertes", "erhoeht", "gefunden", "(", "p", "0,0001", ")", ".", "Die", "maximalen", "Serum", "-", "S-100-Konzentrationen", "korrelierten", "signifikant", "mit", "dem", "Alter", "(", "r=-0,75", ",", "p", "0,0001", ")", "und", "Gewicht", "(", "r=-0,72", ",", "p=0,005", ")", "der", "Kinder", ",", "der", "Bypasszeit", "(", "r=0,44", ",", "p=0,005", ")", "und", "der", "minimalen", "rektalen", "Temperatur", "(", "r=-0,67", ",", "p=0,004", ")", "waehrend", "der", "extrakorporalen", "Zirkulation", ".", "Ein", "statistischer", "Zusammenhang", "fand", "sich", "zwischen", "dem", "postoperativen", "Serumspiegel", "des", "Protein", "S-100", "und", "dem", "Abfall", "der", "regionalen", "zerebralen", "Haemoglobin", "-", "Saettigung", "waehrend", "der", "Reperfusion", "(", "r=-0,37", ",", "p=0,02", ")", "und", "am", "Ende", "der", "extrakorporalen", "Zirkulation", "(", "r=-0,42", ",", "p=0,008", ")", ".", "Schlussfolgerung", ":", "Die", "Astrogliazellen", "scheinen", "auf", "die", "extrakorporale", "Zirkulation", "mit", "einer", "Expression", "des", "Protein", "S-100", "zu", "reagieren", ".", "Eine", "Membranschaedigung", "im", "endothelialastrozytaeren", "Zellkomplex", "der", "Blut", "-", "Hirnschranke", "koennte", "die", "Freisetzung", "des", "Proteins", "in", "die", "Blutstrombahn", "erklaeren", ".", "Beeinflussende", "Faktoren", "scheinen", "geringes", "Alter", ",", "Laenge", "der", "extrakorporalen", "Zirkulation", ",", "Grad", "der", "Hypothermie", "und", "moegliche", "Reduktion", "der", "postoperativen", "zerebralen", "Oxygenierung", "zu", "sein", "." ]

[ "umlsterm" ]

Serumkinetik, hirnspezifischen, Markers, Protein, angeborener, Methodik, Haemoglobin - Saettigung, USA, Protein, Radioimmunassays, Schweden, Protein, Kindern, Komplikationen, Standardabweichungen, Kinder, Bypasszeit, Temperatur, Protein, Haemoglobin - Saettigung, Reperfusion, Protein, Membranschaedigung, Blut - Hirnschranke, Proteins, Hypothermie

IntensiveMedizin.00370617.ger.abstr_task2

Sentence: Fragestellung : Das Ziel diese prospektiven Studie war , die Serumkinetik des hirnspezifischen Markers Protein S-100, eines Gliazell- und Astrozytenproteins , in Beziehung zur kontinuierlich registrierten zerebralen Oxygenierung vor und nach Korrekturoperationen angeborener Herzfehler zu evaluieren . Methodik : Die regionale zerebrale Haemoglobin-Saettigung wurde mit Hilfe der Nahinfrarotspektroskopie ( INVOS 3100A , Somanetics , USA ) bestimmt und das Protein S-100 mittels eines doppelseitigen Radioimmunassays analysiert ( Sangtec 100 IRMA , Bromma , Schweden ) . Ergebnisse : Das Protein S-100 war bei allen Kindern ohne nachweisbare neurologische Komplikationen nach Ende der extrakorporalen Zirkulation um 2 Standardabweichungen des praeoperativen Ausgangswertes erhoeht gefunden ( p 0,0001 ) . Die maximalen Serum-S-100-Konzentrationen korrelierten signifikant mit dem Alter ( r=-0,75, p 0,0001 ) und Gewicht ( r=-0,72, p=0,005) der Kinder , der Bypasszeit ( r=0,44, p=0,005) und der minimalen rektalen Temperatur ( r=-0,67, p=0,004) waehrend der extrakorporalen Zirkulation . Ein statistischer Zusammenhang fand sich zwischen dem postoperativen Serumspiegel des Protein S-100 und dem Abfall der regionalen zerebralen Haemoglobin-Saettigung waehrend der Reperfusion ( r=-0,37, p=0,02) und am Ende der extrakorporalen Zirkulation ( r=-0,42, p=0,008). Schlussfolgerung : Die Astrogliazellen scheinen auf die extrakorporale Zirkulation mit einer Expression des Protein S-100 zu reagieren . Eine Membranschaedigung im endothelialastrozytaeren Zellkomplex der Blut-Hirnschranke koennte die Freisetzung des Proteins in die Blutstrombahn erklaeren . Beeinflussende Faktoren scheinen geringes Alter , Laenge der extrakorporalen Zirkulation , Grad der Hypothermie und moegliche Reduktion der postoperativen zerebralen Oxygenierung zu sein . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fragestellung : Das Ziel diese prospektiven Studie war , die Serumkinetik des hirnspezifischen Markers Protein S-100, eines Gliazell- und Astrozytenproteins , in Beziehung zur kontinuierlich registrierten zerebralen Oxygenierung vor und nach Korrekturoperationen angeborener Herzfehler zu evaluieren . Methodik : Die regionale zerebrale Haemoglobin-Saettigung wurde mit Hilfe der Nahinfrarotspektroskopie ( INVOS 3100A , Somanetics , USA ) bestimmt und das Protein S-100 mittels eines doppelseitigen Radioimmunassays analysiert ( Sangtec 100 IRMA , Bromma , Schweden ) . Ergebnisse : Das Protein S-100 war bei allen Kindern ohne nachweisbare neurologische Komplikationen nach Ende der extrakorporalen Zirkulation um 2 Standardabweichungen des praeoperativen Ausgangswertes erhoeht gefunden ( p 0,0001 ) . Die maximalen Serum-S-100-Konzentrationen korrelierten signifikant mit dem Alter ( r=-0,75, p 0,0001 ) und Gewicht ( r=-0,72, p=0,005) der Kinder , der Bypasszeit ( r=0,44, p=0,005) und der minimalen rektalen Temperatur ( r=-0,67, p=0,004) waehrend der extrakorporalen Zirkulation . Ein statistischer Zusammenhang fand sich zwischen dem postoperativen Serumspiegel des Protein S-100 und dem Abfall der regionalen zerebralen Haemoglobin-Saettigung waehrend der Reperfusion ( r=-0,37, p=0,02) und am Ende der extrakorporalen Zirkulation ( r=-0,42, p=0,008). Schlussfolgerung : Die Astrogliazellen scheinen auf die extrakorporale Zirkulation mit einer Expression des Protein S-100 zu reagieren . Eine Membranschaedigung im endothelialastrozytaeren Zellkomplex der Blut-Hirnschranke koennte die Freisetzung des Proteins in die Blutstrombahn erklaeren . Beeinflussende Faktoren scheinen geringes Alter , Laenge der extrakorporalen Zirkulation , Grad der Hypothermie und moegliche Reduktion der postoperativen zerebralen Oxygenierung zu sein .

[ "Fragestellung", ":", "Das", "Ziel", "diese", "prospektiven", "Studie", "war", ",", "die", "Serumkinetik", "des", "hirnspezifischen", "Markers", "Protein", "S-100", ",", "eines", "Gliazell-", "und", "Astrozytenproteins", ",", "in", "Beziehung", "zur", "kontinuierlich", "registrierten", "zerebralen", "Oxygenierung", "vor", "und", "nach", "Korrekturoperationen", "angeborener", "Herzfehler", "zu", "evaluieren", ".", "Methodik", ":", "Die", "regionale", "zerebrale", "Haemoglobin", "-", "Saettigung", "wurde", "mit", "Hilfe", "der", "Nahinfrarotspektroskopie", "(", "INVOS", "3100A", ",", "Somanetics", ",", "USA", ")", "bestimmt", "und", "das", "Protein", "S-100", "mittels", "eines", "doppelseitigen", "Radioimmunassays", "analysiert", "(", "Sangtec", "100", "IRMA", ",", "Bromma", ",", "Schweden", ")", ".", "Ergebnisse", ":", "Das", "Protein", "S-100", "war", "bei", "allen", "Kindern", "ohne", "nachweisbare", "neurologische", "Komplikationen", "nach", "Ende", "der", "extrakorporalen", "Zirkulation", "um", "2", "Standardabweichungen", "des", "praeoperativen", "Ausgangswertes", "erhoeht", "gefunden", "(", "p", "0,0001", ")", ".", "Die", "maximalen", "Serum", "-", "S-100-Konzentrationen", "korrelierten", "signifikant", "mit", "dem", "Alter", "(", "r=-0,75", ",", "p", "0,0001", ")", "und", "Gewicht", "(", "r=-0,72", ",", "p=0,005", ")", "der", "Kinder", ",", "der", "Bypasszeit", "(", "r=0,44", ",", "p=0,005", ")", "und", "der", "minimalen", "rektalen", "Temperatur", "(", "r=-0,67", ",", "p=0,004", ")", "waehrend", "der", "extrakorporalen", "Zirkulation", ".", "Ein", "statistischer", "Zusammenhang", "fand", "sich", "zwischen", "dem", "postoperativen", "Serumspiegel", "des", "Protein", "S-100", "und", "dem", "Abfall", "der", "regionalen", "zerebralen", "Haemoglobin", "-", "Saettigung", "waehrend", "der", "Reperfusion", "(", "r=-0,37", ",", "p=0,02", ")", "und", "am", "Ende", "der", "extrakorporalen", "Zirkulation", "(", "r=-0,42", ",", "p=0,008", ")", ".", "Schlussfolgerung", ":", "Die", "Astrogliazellen", "scheinen", "auf", "die", "extrakorporale", "Zirkulation", "mit", "einer", "Expression", "des", "Protein", "S-100", "zu", "reagieren", ".", "Eine", "Membranschaedigung", "im", "endothelialastrozytaeren", "Zellkomplex", "der", "Blut", "-", "Hirnschranke", "koennte", "die", "Freisetzung", "des", "Proteins", "in", "die", "Blutstrombahn", "erklaeren", ".", "Beeinflussende", "Faktoren", "scheinen", "geringes", "Alter", ",", "Laenge", "der", "extrakorporalen", "Zirkulation", ",", "Grad", "der", "Hypothermie", "und", "moegliche", "Reduktion", "der", "postoperativen", "zerebralen", "Oxygenierung", "zu", "sein", "." ]

[ "umlsterm" ]

GSK-3 is a protein, Axin is a protein-family, GSK-3 is a protein, beta - catenin is a protein-family, APC is a protein

1.0alpha7.train.1041_task0

Sentence: GSK-3 functions as part of a multiprotein complex in which Axin directly binds GSK-3, beta-catenin, and APC ( Hart et al. 1998 ; Ikeda et al. 1998 Itoh ; et al. 1998 ; Nakamura et al. 1998 ; Sakanaka et al. 1998 ; Yamamoto et al. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-family, protein

[ "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "B-protein", "O", "O", "B-protein-family", "I-protein-family", "I-protein-family", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

GSK-3 functions as part of a multiprotein complex in which Axin directly binds GSK-3, beta-catenin, and APC ( Hart et al. 1998 ; Ikeda et al. 1998 Itoh ; et al. 1998 ; Nakamura et al. 1998 ; Sakanaka et al. 1998 ; Yamamoto et al.

[ "GSK-3", "functions", "as", "part", "of", "a", "multiprotein", "complex", "in", "which", " ", "Axin", "directly", "binds", " ", "GSK-3", ",", " ", "beta", "-", "catenin", ",", "and", " ", "APC", "(", "Hart", "et", "al", ".", "1998", " ", ";", " ", "Ikeda", " ", "et", "al", ".", "1998", "Itoh", " ", ";", " ", "et", "al", ".", "1998", " ", ";", " ", "Nakamura", "et", "al", ".", "1998", " ", ";", " ", "Sakanaka", "et", "al", ".", "1998", " ", ";", " ", "Yamamoto", "et", "al", "." ]

[ "protein-family", "protein" ]

GSK-3 is a protein, Axin is a protein-family, GSK-3 is a protein, beta - catenin is a protein-family, APC is a protein

1.0alpha7.train.1041_task1

Sentence: GSK-3 functions as part of a multiprotein complex in which Axin directly binds GSK-3, beta-catenin, and APC ( Hart et al. 1998 ; Ikeda et al. 1998 Itoh ; et al. 1998 ; Nakamura et al. 1998 ; Sakanaka et al. 1998 ; Yamamoto et al. Instructions: please typing these entity words according to sentence: GSK-3, Axin, GSK-3, beta - catenin, APC Options: protein-family, protein

[ "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "B-protein", "O", "O", "B-protein-family", "I-protein-family", "I-protein-family", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

GSK-3 functions as part of a multiprotein complex in which Axin directly binds GSK-3, beta-catenin, and APC ( Hart et al. 1998 ; Ikeda et al. 1998 Itoh ; et al. 1998 ; Nakamura et al. 1998 ; Sakanaka et al. 1998 ; Yamamoto et al.

[ "GSK-3", "functions", "as", "part", "of", "a", "multiprotein", "complex", "in", "which", " ", "Axin", "directly", "binds", " ", "GSK-3", ",", " ", "beta", "-", "catenin", ",", "and", " ", "APC", "(", "Hart", "et", "al", ".", "1998", " ", ";", " ", "Ikeda", " ", "et", "al", ".", "1998", "Itoh", " ", ";", " ", "et", "al", ".", "1998", " ", ";", " ", "Nakamura", "et", "al", ".", "1998", " ", ";", " ", "Sakanaka", "et", "al", ".", "1998", " ", ";", " ", "Yamamoto", "et", "al", "." ]

[ "protein-family", "protein" ]

GSK-3, Axin, GSK-3, beta - catenin, APC

1.0alpha7.train.1041_task2

Sentence: GSK-3 functions as part of a multiprotein complex in which Axin directly binds GSK-3, beta-catenin, and APC ( Hart et al. 1998 ; Ikeda et al. 1998 Itoh ; et al. 1998 ; Nakamura et al. 1998 ; Sakanaka et al. 1998 ; Yamamoto et al. Instructions: please extract entity words from the input sentence

[ "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "B-protein", "O", "O", "B-protein-family", "I-protein-family", "I-protein-family", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

GSK-3 functions as part of a multiprotein complex in which Axin directly binds GSK-3, beta-catenin, and APC ( Hart et al. 1998 ; Ikeda et al. 1998 Itoh ; et al. 1998 ; Nakamura et al. 1998 ; Sakanaka et al. 1998 ; Yamamoto et al.

[ "GSK-3", "functions", "as", "part", "of", "a", "multiprotein", "complex", "in", "which", " ", "Axin", "directly", "binds", " ", "GSK-3", ",", " ", "beta", "-", "catenin", ",", "and", " ", "APC", "(", "Hart", "et", "al", ".", "1998", " ", ";", " ", "Ikeda", " ", "et", "al", ".", "1998", "Itoh", " ", ";", " ", "et", "al", ".", "1998", " ", ";", " ", "Nakamura", "et", "al", ".", "1998", " ", ";", " ", "Sakanaka", "et", "al", ".", "1998", " ", ";", " ", "Yamamoto", "et", "al", "." ]

[ "protein-family", "protein" ]

Pentraxin-3 is a Intervention_Pharmacological, chronic heart failure : is a Participant_Condition, Pentraxin-3 ( PTX3 ) is a Intervention_Pharmacological, statin is a Intervention_Pharmacological, 1457 patients is a Participant_Sample-size, Controlled Rosuvastatin Multinational Trial in HF ( CORONA is a Participant_Condition, 1233 patients is a Participant_Sample-size, baseline PTX3 levels is a Intervention_Pharmacological, PTX3 concentration is a Outcome_Physical, Baseline elevated PTX3 is a Intervention_Pharmacological, risk of all - cause mortality is a Outcome_Mortality, cardiovascular mortality is a Outcome_Mortality, hospitalization for worsening HF is a Outcome_Physical, fatal events is a Outcome_Mortality, hsCRP levels is a Outcome_Physical, PTX3 . is a Outcome_Physical, patients with chronic HF is a Participant_Condition

55694_task0

Sentence: Pentraxin-3 in chronic heart failure : the CORONA and GISSI-HF trials . AIMS Pentraxin-3 ( PTX3 ) is a component of the humoral arm of innate immunity which can regulate inflammatory processes . Since the role of inflammation in the progression of chronic heart failure ( HF ) is debated , we investigated the prognostic value of PTX3 and the effect of a statin in two large populations of patients with HF . METHODS AND RESULTS Plasma levels of PTX3 were measured at randomization and after 3 months in 1457 patients enrolled in the Controlled Rosuvastatin Multinational Trial in HF ( CORONA ) and 1233 patients enrolled in the GISSI-Heart Failure trial ( GISSI-HF ) . The relationships between baseline PTX3 levels or their changes over time and mortality were evaluated with multivariable Cox proportional hazard models including clinical factors , high sensitivity C-reactive protein ( hsCRP ) , and N-terminal pro brain natriuretic peptide ( NT-proBNP ) . PTX3 concentration [ median ( Q1-Q3 ) = 5.34 ( 3.55-7.64 ) ng/mL , n = 2690 ] was higher in females , in older patients , and those with lower body mass index . Baseline elevated PTX3 was associated with a higher risk of all-cause mortality [ 759 events , hazard ratio ( HR ) for 1 SD increase 1.20 , 95 % confidence interval ( CI ) 1.12-1.30 , P < 0.0001 ] , cardiovascular mortality ( 587 events , HR 1.27 , 95 % CI 1.17-1.38 , P < 0.0001 ) , or hospitalization for worsening HF ( 720 events , HR 1.21 , 95 % CI 1.12-1.30 , P < 0.0001 ) , and marginally improved discrimination . Three-month changes in PTX3 were associated with fatal events after adjustment for hsCRP or NT-proBNP . Rosuvastatin lowered hsCRP levels but significantly raised PTX3 . CONCLUSION In two independent clinical trials that enrolled patients with chronic HF , PTX3 was consistently associated with outcomes . The opposite effects of a statin on hsCRP and PTX3 call for further investigation . TRIAL REGISTRATION NCT00336336 ( GISSI-HF ) , NCT00206310 ( CORONA ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size

[ "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Pentraxin-3 in chronic heart failure : the CORONA and GISSI-HF trials . AIMS Pentraxin-3 ( PTX3 ) is a component of the humoral arm of innate immunity which can regulate inflammatory processes . Since the role of inflammation in the progression of chronic heart failure ( HF ) is debated , we investigated the prognostic value of PTX3 and the effect of a statin in two large populations of patients with HF . METHODS AND RESULTS Plasma levels of PTX3 were measured at randomization and after 3 months in 1457 patients enrolled in the Controlled Rosuvastatin Multinational Trial in HF ( CORONA ) and 1233 patients enrolled in the GISSI-Heart Failure trial ( GISSI-HF ) . The relationships between baseline PTX3 levels or their changes over time and mortality were evaluated with multivariable Cox proportional hazard models including clinical factors , high sensitivity C-reactive protein ( hsCRP ) , and N-terminal pro brain natriuretic peptide ( NT-proBNP ) . PTX3 concentration [ median ( Q1-Q3 ) = 5.34 ( 3.55-7.64 ) ng/mL , n = 2690 ] was higher in females , in older patients , and those with lower body mass index . Baseline elevated PTX3 was associated with a higher risk of all-cause mortality [ 759 events , hazard ratio ( HR ) for 1 SD increase 1.20 , 95 % confidence interval ( CI ) 1.12-1.30 , P < 0.0001 ] , cardiovascular mortality ( 587 events , HR 1.27 , 95 % CI 1.17-1.38 , P < 0.0001 ) , or hospitalization for worsening HF ( 720 events , HR 1.21 , 95 % CI 1.12-1.30 , P < 0.0001 ) , and marginally improved discrimination . Three-month changes in PTX3 were associated with fatal events after adjustment for hsCRP or NT-proBNP . Rosuvastatin lowered hsCRP levels but significantly raised PTX3 . CONCLUSION In two independent clinical trials that enrolled patients with chronic HF , PTX3 was consistently associated with outcomes . The opposite effects of a statin on hsCRP and PTX3 call for further investigation . TRIAL REGISTRATION NCT00336336 ( GISSI-HF ) , NCT00206310 ( CORONA ) .

[ "Pentraxin-3", "in", "chronic", "heart", "failure", ":", "the", "CORONA", "and", "GISSI", "-", "HF", "trials", ".", "AIMS", "Pentraxin-3", "(", "PTX3", ")", "is", "a", "component", "of", "the", "humoral", "arm", "of", "innate", "immunity", "which", "can", "regulate", "inflammatory", "processes", ".", "Since", "the", "role", "of", "inflammation", "in", "the", "progression", "of", "chronic", "heart", "failure", "(", "HF", ")", "is", "debated", ",", "we", "investigated", "the", "prognostic", "value", "of", "PTX3", "and", "the", "effect", "of", "a", "statin", "in", "two", "large", "populations", "of", "patients", "with", "HF", ".", "METHODS", "AND", "RESULTS", "Plasma", "levels", "of", "PTX3", "were", "measured", "at", "randomization", "and", "after", "3", "months", "in", "1457", "patients", "enrolled", "in", "the", "Controlled", "Rosuvastatin", "Multinational", "Trial", "in", "HF", "(", "CORONA", ")", "and", "1233", "patients", "enrolled", "in", "the", "GISSI", "-", "Heart", "Failure", "trial", "(", "GISSI", "-", "HF", ")", ".", "The", "relationships", "between", "baseline", "PTX3", "levels", "or", "their", "changes", "over", "time", "and", "mortality", "were", "evaluated", "with", "multivariable", "Cox", "proportional", "hazard", "models", "including", "clinical", "factors", ",", "high", "sensitivity", "C", "-", "reactive", "protein", "(", "hsCRP", ")", ",", "and", "N", "-", "terminal", "pro", "brain", "natriuretic", "peptide", "(", "NT", "-", "proBNP", ")", ".", "PTX3", "concentration", "[", "median", "(", "Q1-Q3", ")", "=", "5.34", "(", "3.55", "-", "7.64", ")", "ng", "/", "mL", ",", "n", "=", "2690", "]", "was", "higher", "in", "females", ",", "in", "older", "patients", ",", "and", "those", "with", "lower", "body", "mass", "index", ".", "Baseline", "elevated", "PTX3", "was", "associated", "with", "a", "higher", "risk", "of", "all", "-", "cause", "mortality", "[", "759", "events", ",", "hazard", "ratio", "(", "HR", ")", "for", "1", "SD", "increase", "1.20", ",", "95", "%", "confidence", "interval", "(", "CI", ")", "1.12", "-", "1.30", ",", "P", "<", "0.0001", "]", ",", "cardiovascular", "mortality", "(", "587", "events", ",", "HR", "1.27", ",", "95", "%", "CI", "1.17", "-", "1.38", ",", "P", "<", "0.0001", ")", ",", "or", "hospitalization", "for", "worsening", "HF", "(", "720", "events", ",", "HR", "1.21", ",", "95", "%", "CI", "1.12", "-", "1.30", ",", "P", "<", "0.0001", ")", ",", "and", "marginally", "improved", "discrimination", ".", "Three", "-", "month", "changes", "in", "PTX3", "were", "associated", "with", "fatal", "events", "after", "adjustment", "for", "hsCRP", "or", "NT", "-", "proBNP", ".", "Rosuvastatin", "lowered", "hsCRP", "levels", "but", "significantly", "raised", "PTX3", ".", "CONCLUSION", "In", "two", "independent", "clinical", "trials", "that", "enrolled", "patients", "with", "chronic", "HF", ",", "PTX3", "was", "consistently", "associated", "with", "outcomes", ".", "The", "opposite", "effects", "of", "a", "statin", "on", "hsCRP", "and", "PTX3", "call", "for", "further", "investigation", ".", "TRIAL", "REGISTRATION", "NCT00336336", "(", "GISSI", "-", "HF", ")", ",", "NCT00206310", "(", "CORONA", ")", "." ]

[ "Participant_Condition", "Outcome_Physical", "Outcome_Mortality", "Intervention_Pharmacological", "Participant_Sample-size" ]

Pentraxin-3 is a Intervention_Pharmacological, chronic heart failure : is a Participant_Condition, Pentraxin-3 ( PTX3 ) is a Intervention_Pharmacological, statin is a Intervention_Pharmacological, 1457 patients is a Participant_Sample-size, Controlled Rosuvastatin Multinational Trial in HF ( CORONA is a Participant_Condition, 1233 patients is a Participant_Sample-size, baseline PTX3 levels is a Intervention_Pharmacological, PTX3 concentration is a Outcome_Physical, Baseline elevated PTX3 is a Intervention_Pharmacological, risk of all - cause mortality is a Outcome_Mortality, cardiovascular mortality is a Outcome_Mortality, hospitalization for worsening HF is a Outcome_Physical, fatal events is a Outcome_Mortality, hsCRP levels is a Outcome_Physical, PTX3 . is a Outcome_Physical, patients with chronic HF is a Participant_Condition

55694_task1

Sentence: Pentraxin-3 in chronic heart failure : the CORONA and GISSI-HF trials . AIMS Pentraxin-3 ( PTX3 ) is a component of the humoral arm of innate immunity which can regulate inflammatory processes . Since the role of inflammation in the progression of chronic heart failure ( HF ) is debated , we investigated the prognostic value of PTX3 and the effect of a statin in two large populations of patients with HF . METHODS AND RESULTS Plasma levels of PTX3 were measured at randomization and after 3 months in 1457 patients enrolled in the Controlled Rosuvastatin Multinational Trial in HF ( CORONA ) and 1233 patients enrolled in the GISSI-Heart Failure trial ( GISSI-HF ) . The relationships between baseline PTX3 levels or their changes over time and mortality were evaluated with multivariable Cox proportional hazard models including clinical factors , high sensitivity C-reactive protein ( hsCRP ) , and N-terminal pro brain natriuretic peptide ( NT-proBNP ) . PTX3 concentration [ median ( Q1-Q3 ) = 5.34 ( 3.55-7.64 ) ng/mL , n = 2690 ] was higher in females , in older patients , and those with lower body mass index . Baseline elevated PTX3 was associated with a higher risk of all-cause mortality [ 759 events , hazard ratio ( HR ) for 1 SD increase 1.20 , 95 % confidence interval ( CI ) 1.12-1.30 , P < 0.0001 ] , cardiovascular mortality ( 587 events , HR 1.27 , 95 % CI 1.17-1.38 , P < 0.0001 ) , or hospitalization for worsening HF ( 720 events , HR 1.21 , 95 % CI 1.12-1.30 , P < 0.0001 ) , and marginally improved discrimination . Three-month changes in PTX3 were associated with fatal events after adjustment for hsCRP or NT-proBNP . Rosuvastatin lowered hsCRP levels but significantly raised PTX3 . CONCLUSION In two independent clinical trials that enrolled patients with chronic HF , PTX3 was consistently associated with outcomes . The opposite effects of a statin on hsCRP and PTX3 call for further investigation . TRIAL REGISTRATION NCT00336336 ( GISSI-HF ) , NCT00206310 ( CORONA ) . Instructions: please typing these entity words according to sentence: Pentraxin-3, chronic heart failure :, Pentraxin-3 ( PTX3 ), statin, 1457 patients, Controlled Rosuvastatin Multinational Trial in HF ( CORONA, 1233 patients, baseline PTX3 levels, PTX3 concentration, Baseline elevated PTX3, risk of all - cause mortality, cardiovascular mortality, hospitalization for worsening HF, fatal events, hsCRP levels, PTX3 ., patients with chronic HF Options: Intervention_Pharmacological, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size

[ "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Pentraxin-3 in chronic heart failure : the CORONA and GISSI-HF trials . AIMS Pentraxin-3 ( PTX3 ) is a component of the humoral arm of innate immunity which can regulate inflammatory processes . Since the role of inflammation in the progression of chronic heart failure ( HF ) is debated , we investigated the prognostic value of PTX3 and the effect of a statin in two large populations of patients with HF . METHODS AND RESULTS Plasma levels of PTX3 were measured at randomization and after 3 months in 1457 patients enrolled in the Controlled Rosuvastatin Multinational Trial in HF ( CORONA ) and 1233 patients enrolled in the GISSI-Heart Failure trial ( GISSI-HF ) . The relationships between baseline PTX3 levels or their changes over time and mortality were evaluated with multivariable Cox proportional hazard models including clinical factors , high sensitivity C-reactive protein ( hsCRP ) , and N-terminal pro brain natriuretic peptide ( NT-proBNP ) . PTX3 concentration [ median ( Q1-Q3 ) = 5.34 ( 3.55-7.64 ) ng/mL , n = 2690 ] was higher in females , in older patients , and those with lower body mass index . Baseline elevated PTX3 was associated with a higher risk of all-cause mortality [ 759 events , hazard ratio ( HR ) for 1 SD increase 1.20 , 95 % confidence interval ( CI ) 1.12-1.30 , P < 0.0001 ] , cardiovascular mortality ( 587 events , HR 1.27 , 95 % CI 1.17-1.38 , P < 0.0001 ) , or hospitalization for worsening HF ( 720 events , HR 1.21 , 95 % CI 1.12-1.30 , P < 0.0001 ) , and marginally improved discrimination . Three-month changes in PTX3 were associated with fatal events after adjustment for hsCRP or NT-proBNP . Rosuvastatin lowered hsCRP levels but significantly raised PTX3 . CONCLUSION In two independent clinical trials that enrolled patients with chronic HF , PTX3 was consistently associated with outcomes . The opposite effects of a statin on hsCRP and PTX3 call for further investigation . TRIAL REGISTRATION NCT00336336 ( GISSI-HF ) , NCT00206310 ( CORONA ) .

[ "Pentraxin-3", "in", "chronic", "heart", "failure", ":", "the", "CORONA", "and", "GISSI", "-", "HF", "trials", ".", "AIMS", "Pentraxin-3", "(", "PTX3", ")", "is", "a", "component", "of", "the", "humoral", "arm", "of", "innate", "immunity", "which", "can", "regulate", "inflammatory", "processes", ".", "Since", "the", "role", "of", "inflammation", "in", "the", "progression", "of", "chronic", "heart", "failure", "(", "HF", ")", "is", "debated", ",", "we", "investigated", "the", "prognostic", "value", "of", "PTX3", "and", "the", "effect", "of", "a", "statin", "in", "two", "large", "populations", "of", "patients", "with", "HF", ".", "METHODS", "AND", "RESULTS", "Plasma", "levels", "of", "PTX3", "were", "measured", "at", "randomization", "and", "after", "3", "months", "in", "1457", "patients", "enrolled", "in", "the", "Controlled", "Rosuvastatin", "Multinational", "Trial", "in", "HF", "(", "CORONA", ")", "and", "1233", "patients", "enrolled", "in", "the", "GISSI", "-", "Heart", "Failure", "trial", "(", "GISSI", "-", "HF", ")", ".", "The", "relationships", "between", "baseline", "PTX3", "levels", "or", "their", "changes", "over", "time", "and", "mortality", "were", "evaluated", "with", "multivariable", "Cox", "proportional", "hazard", "models", "including", "clinical", "factors", ",", "high", "sensitivity", "C", "-", "reactive", "protein", "(", "hsCRP", ")", ",", "and", "N", "-", "terminal", "pro", "brain", "natriuretic", "peptide", "(", "NT", "-", "proBNP", ")", ".", "PTX3", "concentration", "[", "median", "(", "Q1-Q3", ")", "=", "5.34", "(", "3.55", "-", "7.64", ")", "ng", "/", "mL", ",", "n", "=", "2690", "]", "was", "higher", "in", "females", ",", "in", "older", "patients", ",", "and", "those", "with", "lower", "body", "mass", "index", ".", "Baseline", "elevated", "PTX3", "was", "associated", "with", "a", "higher", "risk", "of", "all", "-", "cause", "mortality", "[", "759", "events", ",", "hazard", "ratio", "(", "HR", ")", "for", "1", "SD", "increase", "1.20", ",", "95", "%", "confidence", "interval", "(", "CI", ")", "1.12", "-", "1.30", ",", "P", "<", "0.0001", "]", ",", "cardiovascular", "mortality", "(", "587", "events", ",", "HR", "1.27", ",", "95", "%", "CI", "1.17", "-", "1.38", ",", "P", "<", "0.0001", ")", ",", "or", "hospitalization", "for", "worsening", "HF", "(", "720", "events", ",", "HR", "1.21", ",", "95", "%", "CI", "1.12", "-", "1.30", ",", "P", "<", "0.0001", ")", ",", "and", "marginally", "improved", "discrimination", ".", "Three", "-", "month", "changes", "in", "PTX3", "were", "associated", "with", "fatal", "events", "after", "adjustment", "for", "hsCRP", "or", "NT", "-", "proBNP", ".", "Rosuvastatin", "lowered", "hsCRP", "levels", "but", "significantly", "raised", "PTX3", ".", "CONCLUSION", "In", "two", "independent", "clinical", "trials", "that", "enrolled", "patients", "with", "chronic", "HF", ",", "PTX3", "was", "consistently", "associated", "with", "outcomes", ".", "The", "opposite", "effects", "of", "a", "statin", "on", "hsCRP", "and", "PTX3", "call", "for", "further", "investigation", ".", "TRIAL", "REGISTRATION", "NCT00336336", "(", "GISSI", "-", "HF", ")", ",", "NCT00206310", "(", "CORONA", ")", "." ]

[ "Participant_Condition", "Outcome_Physical", "Outcome_Mortality", "Intervention_Pharmacological", "Participant_Sample-size" ]

Pentraxin-3, chronic heart failure :, Pentraxin-3 ( PTX3 ), statin, 1457 patients, Controlled Rosuvastatin Multinational Trial in HF ( CORONA, 1233 patients, baseline PTX3 levels, PTX3 concentration, Baseline elevated PTX3, risk of all - cause mortality, cardiovascular mortality, hospitalization for worsening HF, fatal events, hsCRP levels, PTX3 ., patients with chronic HF

55694_task2

Sentence: Pentraxin-3 in chronic heart failure : the CORONA and GISSI-HF trials . AIMS Pentraxin-3 ( PTX3 ) is a component of the humoral arm of innate immunity which can regulate inflammatory processes . Since the role of inflammation in the progression of chronic heart failure ( HF ) is debated , we investigated the prognostic value of PTX3 and the effect of a statin in two large populations of patients with HF . METHODS AND RESULTS Plasma levels of PTX3 were measured at randomization and after 3 months in 1457 patients enrolled in the Controlled Rosuvastatin Multinational Trial in HF ( CORONA ) and 1233 patients enrolled in the GISSI-Heart Failure trial ( GISSI-HF ) . The relationships between baseline PTX3 levels or their changes over time and mortality were evaluated with multivariable Cox proportional hazard models including clinical factors , high sensitivity C-reactive protein ( hsCRP ) , and N-terminal pro brain natriuretic peptide ( NT-proBNP ) . PTX3 concentration [ median ( Q1-Q3 ) = 5.34 ( 3.55-7.64 ) ng/mL , n = 2690 ] was higher in females , in older patients , and those with lower body mass index . Baseline elevated PTX3 was associated with a higher risk of all-cause mortality [ 759 events , hazard ratio ( HR ) for 1 SD increase 1.20 , 95 % confidence interval ( CI ) 1.12-1.30 , P < 0.0001 ] , cardiovascular mortality ( 587 events , HR 1.27 , 95 % CI 1.17-1.38 , P < 0.0001 ) , or hospitalization for worsening HF ( 720 events , HR 1.21 , 95 % CI 1.12-1.30 , P < 0.0001 ) , and marginally improved discrimination . Three-month changes in PTX3 were associated with fatal events after adjustment for hsCRP or NT-proBNP . Rosuvastatin lowered hsCRP levels but significantly raised PTX3 . CONCLUSION In two independent clinical trials that enrolled patients with chronic HF , PTX3 was consistently associated with outcomes . The opposite effects of a statin on hsCRP and PTX3 call for further investigation . TRIAL REGISTRATION NCT00336336 ( GISSI-HF ) , NCT00206310 ( CORONA ) . Instructions: please extract entity words from the input sentence

[ "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Pentraxin-3 in chronic heart failure : the CORONA and GISSI-HF trials . AIMS Pentraxin-3 ( PTX3 ) is a component of the humoral arm of innate immunity which can regulate inflammatory processes . Since the role of inflammation in the progression of chronic heart failure ( HF ) is debated , we investigated the prognostic value of PTX3 and the effect of a statin in two large populations of patients with HF . METHODS AND RESULTS Plasma levels of PTX3 were measured at randomization and after 3 months in 1457 patients enrolled in the Controlled Rosuvastatin Multinational Trial in HF ( CORONA ) and 1233 patients enrolled in the GISSI-Heart Failure trial ( GISSI-HF ) . The relationships between baseline PTX3 levels or their changes over time and mortality were evaluated with multivariable Cox proportional hazard models including clinical factors , high sensitivity C-reactive protein ( hsCRP ) , and N-terminal pro brain natriuretic peptide ( NT-proBNP ) . PTX3 concentration [ median ( Q1-Q3 ) = 5.34 ( 3.55-7.64 ) ng/mL , n = 2690 ] was higher in females , in older patients , and those with lower body mass index . Baseline elevated PTX3 was associated with a higher risk of all-cause mortality [ 759 events , hazard ratio ( HR ) for 1 SD increase 1.20 , 95 % confidence interval ( CI ) 1.12-1.30 , P < 0.0001 ] , cardiovascular mortality ( 587 events , HR 1.27 , 95 % CI 1.17-1.38 , P < 0.0001 ) , or hospitalization for worsening HF ( 720 events , HR 1.21 , 95 % CI 1.12-1.30 , P < 0.0001 ) , and marginally improved discrimination . Three-month changes in PTX3 were associated with fatal events after adjustment for hsCRP or NT-proBNP . Rosuvastatin lowered hsCRP levels but significantly raised PTX3 . CONCLUSION In two independent clinical trials that enrolled patients with chronic HF , PTX3 was consistently associated with outcomes . The opposite effects of a statin on hsCRP and PTX3 call for further investigation . TRIAL REGISTRATION NCT00336336 ( GISSI-HF ) , NCT00206310 ( CORONA ) .

[ "Pentraxin-3", "in", "chronic", "heart", "failure", ":", "the", "CORONA", "and", "GISSI", "-", "HF", "trials", ".", "AIMS", "Pentraxin-3", "(", "PTX3", ")", "is", "a", "component", "of", "the", "humoral", "arm", "of", "innate", "immunity", "which", "can", "regulate", "inflammatory", "processes", ".", "Since", "the", "role", "of", "inflammation", "in", "the", "progression", "of", "chronic", "heart", "failure", "(", "HF", ")", "is", "debated", ",", "we", "investigated", "the", "prognostic", "value", "of", "PTX3", "and", "the", "effect", "of", "a", "statin", "in", "two", "large", "populations", "of", "patients", "with", "HF", ".", "METHODS", "AND", "RESULTS", "Plasma", "levels", "of", "PTX3", "were", "measured", "at", "randomization", "and", "after", "3", "months", "in", "1457", "patients", "enrolled", "in", "the", "Controlled", "Rosuvastatin", "Multinational", "Trial", "in", "HF", "(", "CORONA", ")", "and", "1233", "patients", "enrolled", "in", "the", "GISSI", "-", "Heart", "Failure", "trial", "(", "GISSI", "-", "HF", ")", ".", "The", "relationships", "between", "baseline", "PTX3", "levels", "or", "their", "changes", "over", "time", "and", "mortality", "were", "evaluated", "with", "multivariable", "Cox", "proportional", "hazard", "models", "including", "clinical", "factors", ",", "high", "sensitivity", "C", "-", "reactive", "protein", "(", "hsCRP", ")", ",", "and", "N", "-", "terminal", "pro", "brain", "natriuretic", "peptide", "(", "NT", "-", "proBNP", ")", ".", "PTX3", "concentration", "[", "median", "(", "Q1-Q3", ")", "=", "5.34", "(", "3.55", "-", "7.64", ")", "ng", "/", "mL", ",", "n", "=", "2690", "]", "was", "higher", "in", "females", ",", "in", "older", "patients", ",", "and", "those", "with", "lower", "body", "mass", "index", ".", "Baseline", "elevated", "PTX3", "was", "associated", "with", "a", "higher", "risk", "of", "all", "-", "cause", "mortality", "[", "759", "events", ",", "hazard", "ratio", "(", "HR", ")", "for", "1", "SD", "increase", "1.20", ",", "95", "%", "confidence", "interval", "(", "CI", ")", "1.12", "-", "1.30", ",", "P", "<", "0.0001", "]", ",", "cardiovascular", "mortality", "(", "587", "events", ",", "HR", "1.27", ",", "95", "%", "CI", "1.17", "-", "1.38", ",", "P", "<", "0.0001", ")", ",", "or", "hospitalization", "for", "worsening", "HF", "(", "720", "events", ",", "HR", "1.21", ",", "95", "%", "CI", "1.12", "-", "1.30", ",", "P", "<", "0.0001", ")", ",", "and", "marginally", "improved", "discrimination", ".", "Three", "-", "month", "changes", "in", "PTX3", "were", "associated", "with", "fatal", "events", "after", "adjustment", "for", "hsCRP", "or", "NT", "-", "proBNP", ".", "Rosuvastatin", "lowered", "hsCRP", "levels", "but", "significantly", "raised", "PTX3", ".", "CONCLUSION", "In", "two", "independent", "clinical", "trials", "that", "enrolled", "patients", "with", "chronic", "HF", ",", "PTX3", "was", "consistently", "associated", "with", "outcomes", ".", "The", "opposite", "effects", "of", "a", "statin", "on", "hsCRP", "and", "PTX3", "call", "for", "further", "investigation", ".", "TRIAL", "REGISTRATION", "NCT00336336", "(", "GISSI", "-", "HF", ")", ",", "NCT00206310", "(", "CORONA", ")", "." ]

[ "Participant_Condition", "Outcome_Physical", "Outcome_Mortality", "Intervention_Pharmacological", "Participant_Sample-size" ]

Entzugsbehandlung is an umlsterm, Alkoholkranker is an umlsterm, Therapie is an umlsterm, Suchtberater is an umlsterm, Therapie- is an umlsterm, Alkoholpatienten is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Therapieziel is an umlsterm, Patienten is an umlsterm, alkoholrueckfaellig is an umlsterm, Patienten is an umlsterm, Zeit is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, alkoholrueckfaellig is an umlsterm, Alkoholkranke is an umlsterm, Therapieschritten is an umlsterm, Leben is an umlsterm

DerNervenarzt.70680574.ger.abstr_task0

Sentence: Die stationaere psychiatrische Entzugsbehandlung Alkoholkranker ist - neben der Therapie durch niedergelassene Nervenaerzte und Suchtberater - ein Bindeglied zwischen medizinisch ausgerichteter Entgiftung und psychosozial orientierter Entwoehnung . Ein wesentliches Ziel der integrierten Entgiftungs- und Motivationsbehandlung ist die Foerderung von Therapie- und Abstinenzbereitschaft . Von 529 Alkoholpatienten , die sich einer solchen 2- bis 3-woechigen stationaeren Behandlung unterzogen , wurden 469 89% ) ( nach 8 Monaten katamnestisch erfasst . 242 Patienten ( 52% der Katamnese- bzw. 46% der Ausgangsstichprobe ) hatten das primaere Therapieziel erreicht und eine Entwoehnungsbehandlung angetreten . Hiervon wurden 54 Patienten nur in der Wartezeit zwischen Entgiftung und Entwoehnung nach ihren Angaben alkoholrueckfaellig , lebten aber danach ( waehrend und nach der Entwoehnung ) abstinent . 60 dieser 242 Patienten ( 25% ) wurden indes in der Zeit nach der Entwoehnung bis zur Katamnese ( im Mittel 4 Monate ) rueckfaellig . 227 Patienten begannen nach der Entgiftungs- und Motivationstherapie keine weitere Entwoehnungsbehandlung . Von diesen Patienten wurden 113 50% ) ( innerhalb des achtmonatigen Katamnesezeitraumes alkoholrueckfaellig . Obwohl es sich bei dieser Untersuchung nicht um eine kontrollierte Studie handelt , weisen die Ergebnisse und die klinischen Erfahrungen daraufhin , dass sich im Rahmen eines integrierten stationaeren Entgiftungs- und Motivationskonzeptes auf spezialisierten Stationen zahlreiche akut aufgenommene Alkoholkranke zu weiteren suchtspezifischen Therapieschritten motivieren lassen , die die Chance auf ein dauerhaftes abstinentes Leben deutlich erhoehen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Die stationaere psychiatrische Entzugsbehandlung Alkoholkranker ist - neben der Therapie durch niedergelassene Nervenaerzte und Suchtberater - ein Bindeglied zwischen medizinisch ausgerichteter Entgiftung und psychosozial orientierter Entwoehnung . Ein wesentliches Ziel der integrierten Entgiftungs- und Motivationsbehandlung ist die Foerderung von Therapie- und Abstinenzbereitschaft . Von 529 Alkoholpatienten , die sich einer solchen 2- bis 3-woechigen stationaeren Behandlung unterzogen , wurden 469 89% ) ( nach 8 Monaten katamnestisch erfasst . 242 Patienten ( 52% der Katamnese- bzw. 46% der Ausgangsstichprobe ) hatten das primaere Therapieziel erreicht und eine Entwoehnungsbehandlung angetreten . Hiervon wurden 54 Patienten nur in der Wartezeit zwischen Entgiftung und Entwoehnung nach ihren Angaben alkoholrueckfaellig , lebten aber danach ( waehrend und nach der Entwoehnung ) abstinent . 60 dieser 242 Patienten ( 25% ) wurden indes in der Zeit nach der Entwoehnung bis zur Katamnese ( im Mittel 4 Monate ) rueckfaellig . 227 Patienten begannen nach der Entgiftungs- und Motivationstherapie keine weitere Entwoehnungsbehandlung . Von diesen Patienten wurden 113 50% ) ( innerhalb des achtmonatigen Katamnesezeitraumes alkoholrueckfaellig . Obwohl es sich bei dieser Untersuchung nicht um eine kontrollierte Studie handelt , weisen die Ergebnisse und die klinischen Erfahrungen daraufhin , dass sich im Rahmen eines integrierten stationaeren Entgiftungs- und Motivationskonzeptes auf spezialisierten Stationen zahlreiche akut aufgenommene Alkoholkranke zu weiteren suchtspezifischen Therapieschritten motivieren lassen , die die Chance auf ein dauerhaftes abstinentes Leben deutlich erhoehen .

[ "Die", "stationaere", "psychiatrische", "Entzugsbehandlung", "Alkoholkranker", "ist", "-", "neben", "der", "Therapie", "durch", "niedergelassene", "Nervenaerzte", "und", "Suchtberater", "-", "ein", "Bindeglied", "zwischen", "medizinisch", "ausgerichteter", "Entgiftung", "und", "psychosozial", "orientierter", "Entwoehnung", ".", "Ein", "wesentliches", "Ziel", "der", "integrierten", "Entgiftungs-", "und", "Motivationsbehandlung", "ist", "die", "Foerderung", "von", "Therapie-", "und", "Abstinenzbereitschaft", ".", "Von", "529", "Alkoholpatienten", ",", "die", "sich", "einer", "solchen", "2-", "bis", "3-woechigen", "stationaeren", "Behandlung", "unterzogen", ",", "wurden", "469", "89", "%", ")", "(", "nach", "8", "Monaten", "katamnestisch", "erfasst", ".", "242", "Patienten", "(", "52", "%", "der", "Katamnese-", "bzw", ".", "46", "%", "der", "Ausgangsstichprobe", ")", "hatten", "das", "primaere", "Therapieziel", "erreicht", "und", "eine", "Entwoehnungsbehandlung", "angetreten", ".", "Hiervon", "wurden", "54", "Patienten", "nur", "in", "der", "Wartezeit", "zwischen", "Entgiftung", "und", "Entwoehnung", "nach", "ihren", "Angaben", "alkoholrueckfaellig", ",", "lebten", "aber", "danach", "(", "waehrend", "und", "nach", "der", "Entwoehnung", ")", "abstinent", ".", "60", "dieser", "242", "Patienten", "(", "25", "%", ")", "wurden", "indes", "in", "der", "Zeit", "nach", "der", "Entwoehnung", "bis", "zur", "Katamnese", "(", "im", "Mittel", "4", "Monate", ")", "rueckfaellig", ".", "227", "Patienten", "begannen", "nach", "der", "Entgiftungs-", "und", "Motivationstherapie", "keine", "weitere", "Entwoehnungsbehandlung", ".", "Von", "diesen", "Patienten", "wurden", "113", "50", "%", ")", "(", "innerhalb", "des", "achtmonatigen", "Katamnesezeitraumes", "alkoholrueckfaellig", ".", "Obwohl", "es", "sich", "bei", "dieser", "Untersuchung", "nicht", "um", "eine", "kontrollierte", "Studie", "handelt", ",", "weisen", "die", "Ergebnisse", "und", "die", "klinischen", "Erfahrungen", "daraufhin", ",", "dass", "sich", "im", "Rahmen", "eines", "integrierten", "stationaeren", "Entgiftungs-", "und", "Motivationskonzeptes", "auf", "spezialisierten", "Stationen", "zahlreiche", "akut", "aufgenommene", "Alkoholkranke", "zu", "weiteren", "suchtspezifischen", "Therapieschritten", "motivieren", "lassen", ",", "die", "die", "Chance", "auf", "ein", "dauerhaftes", "abstinentes", "Leben", "deutlich", "erhoehen", "." ]

[ "umlsterm" ]

Entzugsbehandlung is an umlsterm, Alkoholkranker is an umlsterm, Therapie is an umlsterm, Suchtberater is an umlsterm, Therapie- is an umlsterm, Alkoholpatienten is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Therapieziel is an umlsterm, Patienten is an umlsterm, alkoholrueckfaellig is an umlsterm, Patienten is an umlsterm, Zeit is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, alkoholrueckfaellig is an umlsterm, Alkoholkranke is an umlsterm, Therapieschritten is an umlsterm, Leben is an umlsterm

DerNervenarzt.70680574.ger.abstr_task1

Sentence: Die stationaere psychiatrische Entzugsbehandlung Alkoholkranker ist - neben der Therapie durch niedergelassene Nervenaerzte und Suchtberater - ein Bindeglied zwischen medizinisch ausgerichteter Entgiftung und psychosozial orientierter Entwoehnung . Ein wesentliches Ziel der integrierten Entgiftungs- und Motivationsbehandlung ist die Foerderung von Therapie- und Abstinenzbereitschaft . Von 529 Alkoholpatienten , die sich einer solchen 2- bis 3-woechigen stationaeren Behandlung unterzogen , wurden 469 89% ) ( nach 8 Monaten katamnestisch erfasst . 242 Patienten ( 52% der Katamnese- bzw. 46% der Ausgangsstichprobe ) hatten das primaere Therapieziel erreicht und eine Entwoehnungsbehandlung angetreten . Hiervon wurden 54 Patienten nur in der Wartezeit zwischen Entgiftung und Entwoehnung nach ihren Angaben alkoholrueckfaellig , lebten aber danach ( waehrend und nach der Entwoehnung ) abstinent . 60 dieser 242 Patienten ( 25% ) wurden indes in der Zeit nach der Entwoehnung bis zur Katamnese ( im Mittel 4 Monate ) rueckfaellig . 227 Patienten begannen nach der Entgiftungs- und Motivationstherapie keine weitere Entwoehnungsbehandlung . Von diesen Patienten wurden 113 50% ) ( innerhalb des achtmonatigen Katamnesezeitraumes alkoholrueckfaellig . Obwohl es sich bei dieser Untersuchung nicht um eine kontrollierte Studie handelt , weisen die Ergebnisse und die klinischen Erfahrungen daraufhin , dass sich im Rahmen eines integrierten stationaeren Entgiftungs- und Motivationskonzeptes auf spezialisierten Stationen zahlreiche akut aufgenommene Alkoholkranke zu weiteren suchtspezifischen Therapieschritten motivieren lassen , die die Chance auf ein dauerhaftes abstinentes Leben deutlich erhoehen . Instructions: please typing these entity words according to sentence: Entzugsbehandlung, Alkoholkranker, Therapie, Suchtberater, Therapie-, Alkoholpatienten, Behandlung, Patienten, Therapieziel, Patienten, alkoholrueckfaellig, Patienten, Zeit, Patienten, Patienten, alkoholrueckfaellig, Alkoholkranke, Therapieschritten, Leben Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Die stationaere psychiatrische Entzugsbehandlung Alkoholkranker ist - neben der Therapie durch niedergelassene Nervenaerzte und Suchtberater - ein Bindeglied zwischen medizinisch ausgerichteter Entgiftung und psychosozial orientierter Entwoehnung . Ein wesentliches Ziel der integrierten Entgiftungs- und Motivationsbehandlung ist die Foerderung von Therapie- und Abstinenzbereitschaft . Von 529 Alkoholpatienten , die sich einer solchen 2- bis 3-woechigen stationaeren Behandlung unterzogen , wurden 469 89% ) ( nach 8 Monaten katamnestisch erfasst . 242 Patienten ( 52% der Katamnese- bzw. 46% der Ausgangsstichprobe ) hatten das primaere Therapieziel erreicht und eine Entwoehnungsbehandlung angetreten . Hiervon wurden 54 Patienten nur in der Wartezeit zwischen Entgiftung und Entwoehnung nach ihren Angaben alkoholrueckfaellig , lebten aber danach ( waehrend und nach der Entwoehnung ) abstinent . 60 dieser 242 Patienten ( 25% ) wurden indes in der Zeit nach der Entwoehnung bis zur Katamnese ( im Mittel 4 Monate ) rueckfaellig . 227 Patienten begannen nach der Entgiftungs- und Motivationstherapie keine weitere Entwoehnungsbehandlung . Von diesen Patienten wurden 113 50% ) ( innerhalb des achtmonatigen Katamnesezeitraumes alkoholrueckfaellig . Obwohl es sich bei dieser Untersuchung nicht um eine kontrollierte Studie handelt , weisen die Ergebnisse und die klinischen Erfahrungen daraufhin , dass sich im Rahmen eines integrierten stationaeren Entgiftungs- und Motivationskonzeptes auf spezialisierten Stationen zahlreiche akut aufgenommene Alkoholkranke zu weiteren suchtspezifischen Therapieschritten motivieren lassen , die die Chance auf ein dauerhaftes abstinentes Leben deutlich erhoehen .

[ "Die", "stationaere", "psychiatrische", "Entzugsbehandlung", "Alkoholkranker", "ist", "-", "neben", "der", "Therapie", "durch", "niedergelassene", "Nervenaerzte", "und", "Suchtberater", "-", "ein", "Bindeglied", "zwischen", "medizinisch", "ausgerichteter", "Entgiftung", "und", "psychosozial", "orientierter", "Entwoehnung", ".", "Ein", "wesentliches", "Ziel", "der", "integrierten", "Entgiftungs-", "und", "Motivationsbehandlung", "ist", "die", "Foerderung", "von", "Therapie-", "und", "Abstinenzbereitschaft", ".", "Von", "529", "Alkoholpatienten", ",", "die", "sich", "einer", "solchen", "2-", "bis", "3-woechigen", "stationaeren", "Behandlung", "unterzogen", ",", "wurden", "469", "89", "%", ")", "(", "nach", "8", "Monaten", "katamnestisch", "erfasst", ".", "242", "Patienten", "(", "52", "%", "der", "Katamnese-", "bzw", ".", "46", "%", "der", "Ausgangsstichprobe", ")", "hatten", "das", "primaere", "Therapieziel", "erreicht", "und", "eine", "Entwoehnungsbehandlung", "angetreten", ".", "Hiervon", "wurden", "54", "Patienten", "nur", "in", "der", "Wartezeit", "zwischen", "Entgiftung", "und", "Entwoehnung", "nach", "ihren", "Angaben", "alkoholrueckfaellig", ",", "lebten", "aber", "danach", "(", "waehrend", "und", "nach", "der", "Entwoehnung", ")", "abstinent", ".", "60", "dieser", "242", "Patienten", "(", "25", "%", ")", "wurden", "indes", "in", "der", "Zeit", "nach", "der", "Entwoehnung", "bis", "zur", "Katamnese", "(", "im", "Mittel", "4", "Monate", ")", "rueckfaellig", ".", "227", "Patienten", "begannen", "nach", "der", "Entgiftungs-", "und", "Motivationstherapie", "keine", "weitere", "Entwoehnungsbehandlung", ".", "Von", "diesen", "Patienten", "wurden", "113", "50", "%", ")", "(", "innerhalb", "des", "achtmonatigen", "Katamnesezeitraumes", "alkoholrueckfaellig", ".", "Obwohl", "es", "sich", "bei", "dieser", "Untersuchung", "nicht", "um", "eine", "kontrollierte", "Studie", "handelt", ",", "weisen", "die", "Ergebnisse", "und", "die", "klinischen", "Erfahrungen", "daraufhin", ",", "dass", "sich", "im", "Rahmen", "eines", "integrierten", "stationaeren", "Entgiftungs-", "und", "Motivationskonzeptes", "auf", "spezialisierten", "Stationen", "zahlreiche", "akut", "aufgenommene", "Alkoholkranke", "zu", "weiteren", "suchtspezifischen", "Therapieschritten", "motivieren", "lassen", ",", "die", "die", "Chance", "auf", "ein", "dauerhaftes", "abstinentes", "Leben", "deutlich", "erhoehen", "." ]

[ "umlsterm" ]

Entzugsbehandlung, Alkoholkranker, Therapie, Suchtberater, Therapie-, Alkoholpatienten, Behandlung, Patienten, Therapieziel, Patienten, alkoholrueckfaellig, Patienten, Zeit, Patienten, Patienten, alkoholrueckfaellig, Alkoholkranke, Therapieschritten, Leben

DerNervenarzt.70680574.ger.abstr_task2

Sentence: Die stationaere psychiatrische Entzugsbehandlung Alkoholkranker ist - neben der Therapie durch niedergelassene Nervenaerzte und Suchtberater - ein Bindeglied zwischen medizinisch ausgerichteter Entgiftung und psychosozial orientierter Entwoehnung . Ein wesentliches Ziel der integrierten Entgiftungs- und Motivationsbehandlung ist die Foerderung von Therapie- und Abstinenzbereitschaft . Von 529 Alkoholpatienten , die sich einer solchen 2- bis 3-woechigen stationaeren Behandlung unterzogen , wurden 469 89% ) ( nach 8 Monaten katamnestisch erfasst . 242 Patienten ( 52% der Katamnese- bzw. 46% der Ausgangsstichprobe ) hatten das primaere Therapieziel erreicht und eine Entwoehnungsbehandlung angetreten . Hiervon wurden 54 Patienten nur in der Wartezeit zwischen Entgiftung und Entwoehnung nach ihren Angaben alkoholrueckfaellig , lebten aber danach ( waehrend und nach der Entwoehnung ) abstinent . 60 dieser 242 Patienten ( 25% ) wurden indes in der Zeit nach der Entwoehnung bis zur Katamnese ( im Mittel 4 Monate ) rueckfaellig . 227 Patienten begannen nach der Entgiftungs- und Motivationstherapie keine weitere Entwoehnungsbehandlung . Von diesen Patienten wurden 113 50% ) ( innerhalb des achtmonatigen Katamnesezeitraumes alkoholrueckfaellig . Obwohl es sich bei dieser Untersuchung nicht um eine kontrollierte Studie handelt , weisen die Ergebnisse und die klinischen Erfahrungen daraufhin , dass sich im Rahmen eines integrierten stationaeren Entgiftungs- und Motivationskonzeptes auf spezialisierten Stationen zahlreiche akut aufgenommene Alkoholkranke zu weiteren suchtspezifischen Therapieschritten motivieren lassen , die die Chance auf ein dauerhaftes abstinentes Leben deutlich erhoehen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Die stationaere psychiatrische Entzugsbehandlung Alkoholkranker ist - neben der Therapie durch niedergelassene Nervenaerzte und Suchtberater - ein Bindeglied zwischen medizinisch ausgerichteter Entgiftung und psychosozial orientierter Entwoehnung . Ein wesentliches Ziel der integrierten Entgiftungs- und Motivationsbehandlung ist die Foerderung von Therapie- und Abstinenzbereitschaft . Von 529 Alkoholpatienten , die sich einer solchen 2- bis 3-woechigen stationaeren Behandlung unterzogen , wurden 469 89% ) ( nach 8 Monaten katamnestisch erfasst . 242 Patienten ( 52% der Katamnese- bzw. 46% der Ausgangsstichprobe ) hatten das primaere Therapieziel erreicht und eine Entwoehnungsbehandlung angetreten . Hiervon wurden 54 Patienten nur in der Wartezeit zwischen Entgiftung und Entwoehnung nach ihren Angaben alkoholrueckfaellig , lebten aber danach ( waehrend und nach der Entwoehnung ) abstinent . 60 dieser 242 Patienten ( 25% ) wurden indes in der Zeit nach der Entwoehnung bis zur Katamnese ( im Mittel 4 Monate ) rueckfaellig . 227 Patienten begannen nach der Entgiftungs- und Motivationstherapie keine weitere Entwoehnungsbehandlung . Von diesen Patienten wurden 113 50% ) ( innerhalb des achtmonatigen Katamnesezeitraumes alkoholrueckfaellig . Obwohl es sich bei dieser Untersuchung nicht um eine kontrollierte Studie handelt , weisen die Ergebnisse und die klinischen Erfahrungen daraufhin , dass sich im Rahmen eines integrierten stationaeren Entgiftungs- und Motivationskonzeptes auf spezialisierten Stationen zahlreiche akut aufgenommene Alkoholkranke zu weiteren suchtspezifischen Therapieschritten motivieren lassen , die die Chance auf ein dauerhaftes abstinentes Leben deutlich erhoehen .

[ "Die", "stationaere", "psychiatrische", "Entzugsbehandlung", "Alkoholkranker", "ist", "-", "neben", "der", "Therapie", "durch", "niedergelassene", "Nervenaerzte", "und", "Suchtberater", "-", "ein", "Bindeglied", "zwischen", "medizinisch", "ausgerichteter", "Entgiftung", "und", "psychosozial", "orientierter", "Entwoehnung", ".", "Ein", "wesentliches", "Ziel", "der", "integrierten", "Entgiftungs-", "und", "Motivationsbehandlung", "ist", "die", "Foerderung", "von", "Therapie-", "und", "Abstinenzbereitschaft", ".", "Von", "529", "Alkoholpatienten", ",", "die", "sich", "einer", "solchen", "2-", "bis", "3-woechigen", "stationaeren", "Behandlung", "unterzogen", ",", "wurden", "469", "89", "%", ")", "(", "nach", "8", "Monaten", "katamnestisch", "erfasst", ".", "242", "Patienten", "(", "52", "%", "der", "Katamnese-", "bzw", ".", "46", "%", "der", "Ausgangsstichprobe", ")", "hatten", "das", "primaere", "Therapieziel", "erreicht", "und", "eine", "Entwoehnungsbehandlung", "angetreten", ".", "Hiervon", "wurden", "54", "Patienten", "nur", "in", "der", "Wartezeit", "zwischen", "Entgiftung", "und", "Entwoehnung", "nach", "ihren", "Angaben", "alkoholrueckfaellig", ",", "lebten", "aber", "danach", "(", "waehrend", "und", "nach", "der", "Entwoehnung", ")", "abstinent", ".", "60", "dieser", "242", "Patienten", "(", "25", "%", ")", "wurden", "indes", "in", "der", "Zeit", "nach", "der", "Entwoehnung", "bis", "zur", "Katamnese", "(", "im", "Mittel", "4", "Monate", ")", "rueckfaellig", ".", "227", "Patienten", "begannen", "nach", "der", "Entgiftungs-", "und", "Motivationstherapie", "keine", "weitere", "Entwoehnungsbehandlung", ".", "Von", "diesen", "Patienten", "wurden", "113", "50", "%", ")", "(", "innerhalb", "des", "achtmonatigen", "Katamnesezeitraumes", "alkoholrueckfaellig", ".", "Obwohl", "es", "sich", "bei", "dieser", "Untersuchung", "nicht", "um", "eine", "kontrollierte", "Studie", "handelt", ",", "weisen", "die", "Ergebnisse", "und", "die", "klinischen", "Erfahrungen", "daraufhin", ",", "dass", "sich", "im", "Rahmen", "eines", "integrierten", "stationaeren", "Entgiftungs-", "und", "Motivationskonzeptes", "auf", "spezialisierten", "Stationen", "zahlreiche", "akut", "aufgenommene", "Alkoholkranke", "zu", "weiteren", "suchtspezifischen", "Therapieschritten", "motivieren", "lassen", ",", "die", "die", "Chance", "auf", "ein", "dauerhaftes", "abstinentes", "Leben", "deutlich", "erhoehen", "." ]

[ "umlsterm" ]

erythromycin is a Intervention_Pharmacological, gentamicin is a Intervention_Pharmacological, abomasal emptying rate is a Outcome_Other, gastric emptying is a Outcome_Physical, rate of abomasal emptying is a Outcome_Physical, control is a Intervention_Control, low - dose gentamicin is a Intervention_Pharmacological, high - dose gentamicin is a Intervention_Pharmacological, Abomasal emptying rate is a Outcome_Physical, acetaminophen and glucose absorption is a Outcome_Physical, plasma acetaminophen concentration is a Outcome_Physical, time of actual C ( max ) ( actual T ( max ) ) is a Outcome_Physical, model T ( max ) is a Outcome_Physical, time to actual T ( max ) is a Outcome_Physical

34609_task0

Sentence: Effect of erythromycin and gentamicin on abomasal emptying rate in suckling calves . BACKGROUND Commonly used dosage protocols for antimicrobial agents may alter the rate of gastric emptying . HYPOTHESIS Parenteral administration of erythromycin increases and gentamicin decreases the rate of abomasal emptying . ANIMALS Five male Holstein-Friesian calves ( 8-15 days of age ) . METHODS Calves received each of the following 4 IM treatments in random order : control , 2 mL of 0.9 % NaCl ; erythromycin , 8.8 mg/kg ; low-dose gentamicin , 4.4 mg/kg ; high-dose gentamicin , 6.6 mg/kg . Abomasal emptying rate was assessed by acetaminophen and glucose absorption . Calves were fed 2 L of cow 's milk containing acetaminophen ( 50 mg/kg body weight ) 30 minutes after each treatment was administered , and jugular venous blood samples were obtained periodically after suckling . The maximum observed plasma acetaminophen concentration ( actual C ( max ) ) and time of actual C ( max ) ( actual T ( max ) ) were determined , and pharmacokinetic modeling was used to calculate model C ( max ) and model T ( max ) . RESULTS Erythromycin increased abomasal emptying rate , as indicated by a shorter time to actual T ( max ) and model T ( max ) ( P < .05 ) . Abomasal emptying rate after injection of low-dose gentamicin was similar to that of control . Administration of high-dose gentamicin resulted in a longer time to actual T ( max ) ( P= .021 ) but did not change model T ( max ) ( P= .62 ) . CONCLUSIONS AND CLINICAL RELEVANCE IM injection of erythromycin increased abomasal emptying rate in dairy calves , whereas low-dose and high-dose gentamicin did not alter the rate of abomasal emptying as measured by acetaminophen kinetics and glucose absorption . The clinical relevance of these findings remains to be determined . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Intervention_Control

[ "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effect of erythromycin and gentamicin on abomasal emptying rate in suckling calves . BACKGROUND Commonly used dosage protocols for antimicrobial agents may alter the rate of gastric emptying . HYPOTHESIS Parenteral administration of erythromycin increases and gentamicin decreases the rate of abomasal emptying . ANIMALS Five male Holstein-Friesian calves ( 8-15 days of age ) . METHODS Calves received each of the following 4 IM treatments in random order : control , 2 mL of 0.9 % NaCl ; erythromycin , 8.8 mg/kg ; low-dose gentamicin , 4.4 mg/kg ; high-dose gentamicin , 6.6 mg/kg . Abomasal emptying rate was assessed by acetaminophen and glucose absorption . Calves were fed 2 L of cow 's milk containing acetaminophen ( 50 mg/kg body weight ) 30 minutes after each treatment was administered , and jugular venous blood samples were obtained periodically after suckling . The maximum observed plasma acetaminophen concentration ( actual C ( max ) ) and time of actual C ( max ) ( actual T ( max ) ) were determined , and pharmacokinetic modeling was used to calculate model C ( max ) and model T ( max ) . RESULTS Erythromycin increased abomasal emptying rate , as indicated by a shorter time to actual T ( max ) and model T ( max ) ( P < .05 ) . Abomasal emptying rate after injection of low-dose gentamicin was similar to that of control . Administration of high-dose gentamicin resulted in a longer time to actual T ( max ) ( P= .021 ) but did not change model T ( max ) ( P= .62 ) . CONCLUSIONS AND CLINICAL RELEVANCE IM injection of erythromycin increased abomasal emptying rate in dairy calves , whereas low-dose and high-dose gentamicin did not alter the rate of abomasal emptying as measured by acetaminophen kinetics and glucose absorption . The clinical relevance of these findings remains to be determined .

[ "Effect", "of", "erythromycin", "and", "gentamicin", "on", "abomasal", "emptying", "rate", "in", "suckling", "calves", ".", "BACKGROUND", "Commonly", "used", "dosage", "protocols", "for", "antimicrobial", "agents", "may", "alter", "the", "rate", "of", "gastric", "emptying", ".", "HYPOTHESIS", "Parenteral", "administration", "of", "erythromycin", "increases", "and", "gentamicin", "decreases", "the", "rate", "of", "abomasal", "emptying", ".", "ANIMALS", "Five", "male", "Holstein", "-", "Friesian", "calves", "(", "8", "-", "15", "days", "of", "age", ")", ".", "METHODS", "Calves", "received", "each", "of", "the", "following", "4", "IM", "treatments", "in", "random", "order", ":", "control", ",", "2", "mL", "of", "0.9", "%", "NaCl", ";", "erythromycin", ",", "8.8", "mg", "/", "kg", ";", "low", "-", "dose", "gentamicin", ",", "4.4", "mg", "/", "kg", ";", "high", "-", "dose", "gentamicin", ",", "6.6", "mg", "/", "kg", ".", "Abomasal", "emptying", "rate", "was", "assessed", "by", "acetaminophen", "and", "glucose", "absorption", ".", "Calves", "were", "fed", "2", "L", "of", "cow", "'", "s", "milk", "containing", "acetaminophen", "(", "50", "mg", "/", "kg", "body", "weight", ")", "30", "minutes", "after", "each", "treatment", "was", "administered", ",", "and", "jugular", "venous", "blood", "samples", "were", "obtained", "periodically", "after", "suckling", ".", "The", "maximum", "observed", "plasma", "acetaminophen", "concentration", "(", "actual", "C", "(", "max", ")", ")", "and", "time", "of", "actual", "C", "(", "max", ")", "(", "actual", "T", "(", "max", ")", ")", "were", "determined", ",", "and", "pharmacokinetic", "modeling", "was", "used", "to", "calculate", "model", "C", "(", "max", ")", "and", "model", "T", "(", "max", ")", ".", "RESULTS", "Erythromycin", "increased", "abomasal", "emptying", "rate", ",", "as", "indicated", "by", "a", "shorter", "time", "to", "actual", "T", "(", "max", ")", "and", "model", "T", "(", "max", ")", "(", "P", "<", ".05", ")", ".", "Abomasal", "emptying", "rate", "after", "injection", "of", "low", "-", "dose", "gentamicin", "was", "similar", "to", "that", "of", "control", ".", "Administration", "of", "high", "-", "dose", "gentamicin", "resulted", "in", "a", "longer", "time", "to", "actual", "T", "(", "max", ")", "(", "P=", ".021", ")", "but", "did", "not", "change", "model", "T", "(", "max", ")", "(", "P=", ".62", ")", ".", "CONCLUSIONS", "AND", "CLINICAL", "RELEVANCE", "IM", "injection", "of", "erythromycin", "increased", "abomasal", "emptying", "rate", "in", "dairy", "calves", ",", "whereas", "low", "-", "dose", "and", "high", "-", "dose", "gentamicin", "did", "not", "alter", "the", "rate", "of", "abomasal", "emptying", "as", "measured", "by", "acetaminophen", "kinetics", "and", "glucose", "absorption", ".", "The", "clinical", "relevance", "of", "these", "findings", "remains", "to", "be", "determined", "." ]

[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control" ]

erythromycin is a Intervention_Pharmacological, gentamicin is a Intervention_Pharmacological, abomasal emptying rate is a Outcome_Other, gastric emptying is a Outcome_Physical, rate of abomasal emptying is a Outcome_Physical, control is a Intervention_Control, low - dose gentamicin is a Intervention_Pharmacological, high - dose gentamicin is a Intervention_Pharmacological, Abomasal emptying rate is a Outcome_Physical, acetaminophen and glucose absorption is a Outcome_Physical, plasma acetaminophen concentration is a Outcome_Physical, time of actual C ( max ) ( actual T ( max ) ) is a Outcome_Physical, model T ( max ) is a Outcome_Physical, time to actual T ( max ) is a Outcome_Physical

34609_task1

Sentence: Effect of erythromycin and gentamicin on abomasal emptying rate in suckling calves . BACKGROUND Commonly used dosage protocols for antimicrobial agents may alter the rate of gastric emptying . HYPOTHESIS Parenteral administration of erythromycin increases and gentamicin decreases the rate of abomasal emptying . ANIMALS Five male Holstein-Friesian calves ( 8-15 days of age ) . METHODS Calves received each of the following 4 IM treatments in random order : control , 2 mL of 0.9 % NaCl ; erythromycin , 8.8 mg/kg ; low-dose gentamicin , 4.4 mg/kg ; high-dose gentamicin , 6.6 mg/kg . Abomasal emptying rate was assessed by acetaminophen and glucose absorption . Calves were fed 2 L of cow 's milk containing acetaminophen ( 50 mg/kg body weight ) 30 minutes after each treatment was administered , and jugular venous blood samples were obtained periodically after suckling . The maximum observed plasma acetaminophen concentration ( actual C ( max ) ) and time of actual C ( max ) ( actual T ( max ) ) were determined , and pharmacokinetic modeling was used to calculate model C ( max ) and model T ( max ) . RESULTS Erythromycin increased abomasal emptying rate , as indicated by a shorter time to actual T ( max ) and model T ( max ) ( P < .05 ) . Abomasal emptying rate after injection of low-dose gentamicin was similar to that of control . Administration of high-dose gentamicin resulted in a longer time to actual T ( max ) ( P= .021 ) but did not change model T ( max ) ( P= .62 ) . CONCLUSIONS AND CLINICAL RELEVANCE IM injection of erythromycin increased abomasal emptying rate in dairy calves , whereas low-dose and high-dose gentamicin did not alter the rate of abomasal emptying as measured by acetaminophen kinetics and glucose absorption . The clinical relevance of these findings remains to be determined . Instructions: please typing these entity words according to sentence: erythromycin, gentamicin, abomasal emptying rate, gastric emptying, rate of abomasal emptying, control, low - dose gentamicin, high - dose gentamicin, Abomasal emptying rate, acetaminophen and glucose absorption, plasma acetaminophen concentration, time of actual C ( max ) ( actual T ( max ) ), model T ( max ), time to actual T ( max ) Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Intervention_Control

[ "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effect of erythromycin and gentamicin on abomasal emptying rate in suckling calves . BACKGROUND Commonly used dosage protocols for antimicrobial agents may alter the rate of gastric emptying . HYPOTHESIS Parenteral administration of erythromycin increases and gentamicin decreases the rate of abomasal emptying . ANIMALS Five male Holstein-Friesian calves ( 8-15 days of age ) . METHODS Calves received each of the following 4 IM treatments in random order : control , 2 mL of 0.9 % NaCl ; erythromycin , 8.8 mg/kg ; low-dose gentamicin , 4.4 mg/kg ; high-dose gentamicin , 6.6 mg/kg . Abomasal emptying rate was assessed by acetaminophen and glucose absorption . Calves were fed 2 L of cow 's milk containing acetaminophen ( 50 mg/kg body weight ) 30 minutes after each treatment was administered , and jugular venous blood samples were obtained periodically after suckling . The maximum observed plasma acetaminophen concentration ( actual C ( max ) ) and time of actual C ( max ) ( actual T ( max ) ) were determined , and pharmacokinetic modeling was used to calculate model C ( max ) and model T ( max ) . RESULTS Erythromycin increased abomasal emptying rate , as indicated by a shorter time to actual T ( max ) and model T ( max ) ( P < .05 ) . Abomasal emptying rate after injection of low-dose gentamicin was similar to that of control . Administration of high-dose gentamicin resulted in a longer time to actual T ( max ) ( P= .021 ) but did not change model T ( max ) ( P= .62 ) . CONCLUSIONS AND CLINICAL RELEVANCE IM injection of erythromycin increased abomasal emptying rate in dairy calves , whereas low-dose and high-dose gentamicin did not alter the rate of abomasal emptying as measured by acetaminophen kinetics and glucose absorption . The clinical relevance of these findings remains to be determined .

[ "Effect", "of", "erythromycin", "and", "gentamicin", "on", "abomasal", "emptying", "rate", "in", "suckling", "calves", ".", "BACKGROUND", "Commonly", "used", "dosage", "protocols", "for", "antimicrobial", "agents", "may", "alter", "the", "rate", "of", "gastric", "emptying", ".", "HYPOTHESIS", "Parenteral", "administration", "of", "erythromycin", "increases", "and", "gentamicin", "decreases", "the", "rate", "of", "abomasal", "emptying", ".", "ANIMALS", "Five", "male", "Holstein", "-", "Friesian", "calves", "(", "8", "-", "15", "days", "of", "age", ")", ".", "METHODS", "Calves", "received", "each", "of", "the", "following", "4", "IM", "treatments", "in", "random", "order", ":", "control", ",", "2", "mL", "of", "0.9", "%", "NaCl", ";", "erythromycin", ",", "8.8", "mg", "/", "kg", ";", "low", "-", "dose", "gentamicin", ",", "4.4", "mg", "/", "kg", ";", "high", "-", "dose", "gentamicin", ",", "6.6", "mg", "/", "kg", ".", "Abomasal", "emptying", "rate", "was", "assessed", "by", "acetaminophen", "and", "glucose", "absorption", ".", "Calves", "were", "fed", "2", "L", "of", "cow", "'", "s", "milk", "containing", "acetaminophen", "(", "50", "mg", "/", "kg", "body", "weight", ")", "30", "minutes", "after", "each", "treatment", "was", "administered", ",", "and", "jugular", "venous", "blood", "samples", "were", "obtained", "periodically", "after", "suckling", ".", "The", "maximum", "observed", "plasma", "acetaminophen", "concentration", "(", "actual", "C", "(", "max", ")", ")", "and", "time", "of", "actual", "C", "(", "max", ")", "(", "actual", "T", "(", "max", ")", ")", "were", "determined", ",", "and", "pharmacokinetic", "modeling", "was", "used", "to", "calculate", "model", "C", "(", "max", ")", "and", "model", "T", "(", "max", ")", ".", "RESULTS", "Erythromycin", "increased", "abomasal", "emptying", "rate", ",", "as", "indicated", "by", "a", "shorter", "time", "to", "actual", "T", "(", "max", ")", "and", "model", "T", "(", "max", ")", "(", "P", "<", ".05", ")", ".", "Abomasal", "emptying", "rate", "after", "injection", "of", "low", "-", "dose", "gentamicin", "was", "similar", "to", "that", "of", "control", ".", "Administration", "of", "high", "-", "dose", "gentamicin", "resulted", "in", "a", "longer", "time", "to", "actual", "T", "(", "max", ")", "(", "P=", ".021", ")", "but", "did", "not", "change", "model", "T", "(", "max", ")", "(", "P=", ".62", ")", ".", "CONCLUSIONS", "AND", "CLINICAL", "RELEVANCE", "IM", "injection", "of", "erythromycin", "increased", "abomasal", "emptying", "rate", "in", "dairy", "calves", ",", "whereas", "low", "-", "dose", "and", "high", "-", "dose", "gentamicin", "did", "not", "alter", "the", "rate", "of", "abomasal", "emptying", "as", "measured", "by", "acetaminophen", "kinetics", "and", "glucose", "absorption", ".", "The", "clinical", "relevance", "of", "these", "findings", "remains", "to", "be", "determined", "." ]

[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control" ]

erythromycin, gentamicin, abomasal emptying rate, gastric emptying, rate of abomasal emptying, control, low - dose gentamicin, high - dose gentamicin, Abomasal emptying rate, acetaminophen and glucose absorption, plasma acetaminophen concentration, time of actual C ( max ) ( actual T ( max ) ), model T ( max ), time to actual T ( max )

34609_task2

Sentence: Effect of erythromycin and gentamicin on abomasal emptying rate in suckling calves . BACKGROUND Commonly used dosage protocols for antimicrobial agents may alter the rate of gastric emptying . HYPOTHESIS Parenteral administration of erythromycin increases and gentamicin decreases the rate of abomasal emptying . ANIMALS Five male Holstein-Friesian calves ( 8-15 days of age ) . METHODS Calves received each of the following 4 IM treatments in random order : control , 2 mL of 0.9 % NaCl ; erythromycin , 8.8 mg/kg ; low-dose gentamicin , 4.4 mg/kg ; high-dose gentamicin , 6.6 mg/kg . Abomasal emptying rate was assessed by acetaminophen and glucose absorption . Calves were fed 2 L of cow 's milk containing acetaminophen ( 50 mg/kg body weight ) 30 minutes after each treatment was administered , and jugular venous blood samples were obtained periodically after suckling . The maximum observed plasma acetaminophen concentration ( actual C ( max ) ) and time of actual C ( max ) ( actual T ( max ) ) were determined , and pharmacokinetic modeling was used to calculate model C ( max ) and model T ( max ) . RESULTS Erythromycin increased abomasal emptying rate , as indicated by a shorter time to actual T ( max ) and model T ( max ) ( P < .05 ) . Abomasal emptying rate after injection of low-dose gentamicin was similar to that of control . Administration of high-dose gentamicin resulted in a longer time to actual T ( max ) ( P= .021 ) but did not change model T ( max ) ( P= .62 ) . CONCLUSIONS AND CLINICAL RELEVANCE IM injection of erythromycin increased abomasal emptying rate in dairy calves , whereas low-dose and high-dose gentamicin did not alter the rate of abomasal emptying as measured by acetaminophen kinetics and glucose absorption . The clinical relevance of these findings remains to be determined . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effect of erythromycin and gentamicin on abomasal emptying rate in suckling calves . BACKGROUND Commonly used dosage protocols for antimicrobial agents may alter the rate of gastric emptying . HYPOTHESIS Parenteral administration of erythromycin increases and gentamicin decreases the rate of abomasal emptying . ANIMALS Five male Holstein-Friesian calves ( 8-15 days of age ) . METHODS Calves received each of the following 4 IM treatments in random order : control , 2 mL of 0.9 % NaCl ; erythromycin , 8.8 mg/kg ; low-dose gentamicin , 4.4 mg/kg ; high-dose gentamicin , 6.6 mg/kg . Abomasal emptying rate was assessed by acetaminophen and glucose absorption . Calves were fed 2 L of cow 's milk containing acetaminophen ( 50 mg/kg body weight ) 30 minutes after each treatment was administered , and jugular venous blood samples were obtained periodically after suckling . The maximum observed plasma acetaminophen concentration ( actual C ( max ) ) and time of actual C ( max ) ( actual T ( max ) ) were determined , and pharmacokinetic modeling was used to calculate model C ( max ) and model T ( max ) . RESULTS Erythromycin increased abomasal emptying rate , as indicated by a shorter time to actual T ( max ) and model T ( max ) ( P < .05 ) . Abomasal emptying rate after injection of low-dose gentamicin was similar to that of control . Administration of high-dose gentamicin resulted in a longer time to actual T ( max ) ( P= .021 ) but did not change model T ( max ) ( P= .62 ) . CONCLUSIONS AND CLINICAL RELEVANCE IM injection of erythromycin increased abomasal emptying rate in dairy calves , whereas low-dose and high-dose gentamicin did not alter the rate of abomasal emptying as measured by acetaminophen kinetics and glucose absorption . The clinical relevance of these findings remains to be determined .

[ "Effect", "of", "erythromycin", "and", "gentamicin", "on", "abomasal", "emptying", "rate", "in", "suckling", "calves", ".", "BACKGROUND", "Commonly", "used", "dosage", "protocols", "for", "antimicrobial", "agents", "may", "alter", "the", "rate", "of", "gastric", "emptying", ".", "HYPOTHESIS", "Parenteral", "administration", "of", "erythromycin", "increases", "and", "gentamicin", "decreases", "the", "rate", "of", "abomasal", "emptying", ".", "ANIMALS", "Five", "male", "Holstein", "-", "Friesian", "calves", "(", "8", "-", "15", "days", "of", "age", ")", ".", "METHODS", "Calves", "received", "each", "of", "the", "following", "4", "IM", "treatments", "in", "random", "order", ":", "control", ",", "2", "mL", "of", "0.9", "%", "NaCl", ";", "erythromycin", ",", "8.8", "mg", "/", "kg", ";", "low", "-", "dose", "gentamicin", ",", "4.4", "mg", "/", "kg", ";", "high", "-", "dose", "gentamicin", ",", "6.6", "mg", "/", "kg", ".", "Abomasal", "emptying", "rate", "was", "assessed", "by", "acetaminophen", "and", "glucose", "absorption", ".", "Calves", "were", "fed", "2", "L", "of", "cow", "'", "s", "milk", "containing", "acetaminophen", "(", "50", "mg", "/", "kg", "body", "weight", ")", "30", "minutes", "after", "each", "treatment", "was", "administered", ",", "and", "jugular", "venous", "blood", "samples", "were", "obtained", "periodically", "after", "suckling", ".", "The", "maximum", "observed", "plasma", "acetaminophen", "concentration", "(", "actual", "C", "(", "max", ")", ")", "and", "time", "of", "actual", "C", "(", "max", ")", "(", "actual", "T", "(", "max", ")", ")", "were", "determined", ",", "and", "pharmacokinetic", "modeling", "was", "used", "to", "calculate", "model", "C", "(", "max", ")", "and", "model", "T", "(", "max", ")", ".", "RESULTS", "Erythromycin", "increased", "abomasal", "emptying", "rate", ",", "as", "indicated", "by", "a", "shorter", "time", "to", "actual", "T", "(", "max", ")", "and", "model", "T", "(", "max", ")", "(", "P", "<", ".05", ")", ".", "Abomasal", "emptying", "rate", "after", "injection", "of", "low", "-", "dose", "gentamicin", "was", "similar", "to", "that", "of", "control", ".", "Administration", "of", "high", "-", "dose", "gentamicin", "resulted", "in", "a", "longer", "time", "to", "actual", "T", "(", "max", ")", "(", "P=", ".021", ")", "but", "did", "not", "change", "model", "T", "(", "max", ")", "(", "P=", ".62", ")", ".", "CONCLUSIONS", "AND", "CLINICAL", "RELEVANCE", "IM", "injection", "of", "erythromycin", "increased", "abomasal", "emptying", "rate", "in", "dairy", "calves", ",", "whereas", "low", "-", "dose", "and", "high", "-", "dose", "gentamicin", "did", "not", "alter", "the", "rate", "of", "abomasal", "emptying", "as", "measured", "by", "acetaminophen", "kinetics", "and", "glucose", "absorption", ".", "The", "clinical", "relevance", "of", "these", "findings", "remains", "to", "be", "determined", "." ]

[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control" ]

cell is a Cell

PMC-2959883-sec-06_task0

Sentence: Data collection: CrystalClear (Rigaku/MSC, 2005 >); cell refinement: CrystalClear; data reduction: CrystalClear; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 >); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 >); molecular graphics: ORTEPII (Johnson, 1976 >); software used to prepare material for publication: SHELXL97. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cell

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Data collection: CrystalClear (Rigaku/MSC, 2005 >); cell refinement: CrystalClear; data reduction: CrystalClear; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 >); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 >); molecular graphics: ORTEPII (Johnson, 1976 >); software used to prepare material for publication: SHELXL97.

[ "Data", "collection", ":", "CrystalClear", "(", "Rigaku", "/", "MSC", ",", "2005", ">", ")", ";", "cell", "refinement", ":", "CrystalClear", ";", "data", "reduction", ":", "CrystalClear", ";", "program(s", ")", "used", "to", "solve", "structure", ":", "SHELXS97", "(", "Sheldrick", ",", "2008", ">", ")", ";", "program(s", ")", "used", "to", "refine", "structure", ":", "SHELXL97", "(", "Sheldrick", ",", "2008", ">", ")", ";", "molecular", "graphics", ":", "ORTEPII", "(", "Johnson", ",", "1976", ">", ")", ";", "software", "used", "to", "prepare", "material", "for", "publication", ":", "SHELXL97", ".", "\n" ]

[ "Cell" ]

cell is a Cell

PMC-2959883-sec-06_task1

Sentence: Data collection: CrystalClear (Rigaku/MSC, 2005 >); cell refinement: CrystalClear; data reduction: CrystalClear; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 >); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 >); molecular graphics: ORTEPII (Johnson, 1976 >); software used to prepare material for publication: SHELXL97. Instructions: please typing these entity words according to sentence: cell Options: Cell

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Data collection: CrystalClear (Rigaku/MSC, 2005 >); cell refinement: CrystalClear; data reduction: CrystalClear; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 >); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 >); molecular graphics: ORTEPII (Johnson, 1976 >); software used to prepare material for publication: SHELXL97.

[ "Data", "collection", ":", "CrystalClear", "(", "Rigaku", "/", "MSC", ",", "2005", ">", ")", ";", "cell", "refinement", ":", "CrystalClear", ";", "data", "reduction", ":", "CrystalClear", ";", "program(s", ")", "used", "to", "solve", "structure", ":", "SHELXS97", "(", "Sheldrick", ",", "2008", ">", ")", ";", "program(s", ")", "used", "to", "refine", "structure", ":", "SHELXL97", "(", "Sheldrick", ",", "2008", ">", ")", ";", "molecular", "graphics", ":", "ORTEPII", "(", "Johnson", ",", "1976", ">", ")", ";", "software", "used", "to", "prepare", "material", "for", "publication", ":", "SHELXL97", ".", "\n" ]

[ "Cell" ]

cell

PMC-2959883-sec-06_task2

Sentence: Data collection: CrystalClear (Rigaku/MSC, 2005 >); cell refinement: CrystalClear; data reduction: CrystalClear; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 >); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 >); molecular graphics: ORTEPII (Johnson, 1976 >); software used to prepare material for publication: SHELXL97. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Data collection: CrystalClear (Rigaku/MSC, 2005 >); cell refinement: CrystalClear; data reduction: CrystalClear; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 >); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 >); molecular graphics: ORTEPII (Johnson, 1976 >); software used to prepare material for publication: SHELXL97.

[ "Data", "collection", ":", "CrystalClear", "(", "Rigaku", "/", "MSC", ",", "2005", ">", ")", ";", "cell", "refinement", ":", "CrystalClear", ";", "data", "reduction", ":", "CrystalClear", ";", "program(s", ")", "used", "to", "solve", "structure", ":", "SHELXS97", "(", "Sheldrick", ",", "2008", ">", ")", ";", "program(s", ")", "used", "to", "refine", "structure", ":", "SHELXL97", "(", "Sheldrick", ",", "2008", ">", ")", ";", "molecular", "graphics", ":", "ORTEPII", "(", "Johnson", ",", "1976", ">", ")", ";", "software", "used", "to", "prepare", "material", "for", "publication", ":", "SHELXL97", ".", "\n" ]

[ "Cell" ]

Lidocain is an umlsterm, Tocainid is an umlsterm, Tinnitus aurium is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Lidocain is an umlsterm, medikamentoese Therapie is an umlsterm, Tocainid is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Therapie is an umlsterm, Tocainid is an umlsterm, Patienten is an umlsterm, Therapie is an umlsterm, Tocainid is an umlsterm, Patienten is an umlsterm, Medikament is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Tinnitus aurium is an umlsterm, Lidocain is an umlsterm, Tocainid is an umlsterm

HNO.70450069.ger.abstr_task0

Sentence: Um die Wirksamkeit von Lidocain und Tocainid auf Tinnitus aurium zu ueberpruefen , untersuchten wir retrospektiv von 1993 bis Mai 1995 77 Patienten . Waehrend des stationaeren Aufenthalts erhielten die Patienten eine Testdosis Lidocain i.v. und bei positivem Ansprechen auf die Testdosis eine sich anschliessende medikamentoese Therapie mit Tocainid , einem oral verabreichbaren Strukturanalogon des Lidocains . Die tinnitussupprimierende Wirkung wurde entsprechend den subjektiven Angaben und anhand einer visuellen Analogskala klassifiziert . Unsere Ergebnisse zeigen , dass von 77 Patienten nur 19 Patienten eine Tinnitussuppression unterschiedlicher Auspraegung angaben . Von ihnen waehlten 14 Patienten eine weiterfuehrende Therapie mit Tocainid ( 3x400 mg/Tag ) ; 5 Patienten lehnten die Therapie wegen moeglicher Nebenwirkungen ab ; 3 Monate nach der Verordnung von Tocainid hatten 10 Patienten das Medikament wegen Nebenwirkungen und 3 Patienten wegen mangelnder Wirkung abgesetzt . Wir schaetzen die therapeutische Erfolgsquote fuer die Behandlung des Tinnitus aurium mit Lidocain bedeutend geringer ein als dies im Schrifttum der Fall ist . Das oral anwendbare Stukturanalogon Tocainid kommt wegen der hohen Rate an Nebenwirkungen und nicht ausreichender Tinnitussuppression allenfalls in besonderen Einzelfaellen als Behandlungsmoeglichkeit in Frage . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Um die Wirksamkeit von Lidocain und Tocainid auf Tinnitus aurium zu ueberpruefen , untersuchten wir retrospektiv von 1993 bis Mai 1995 77 Patienten . Waehrend des stationaeren Aufenthalts erhielten die Patienten eine Testdosis Lidocain i.v. und bei positivem Ansprechen auf die Testdosis eine sich anschliessende medikamentoese Therapie mit Tocainid , einem oral verabreichbaren Strukturanalogon des Lidocains . Die tinnitussupprimierende Wirkung wurde entsprechend den subjektiven Angaben und anhand einer visuellen Analogskala klassifiziert . Unsere Ergebnisse zeigen , dass von 77 Patienten nur 19 Patienten eine Tinnitussuppression unterschiedlicher Auspraegung angaben . Von ihnen waehlten 14 Patienten eine weiterfuehrende Therapie mit Tocainid ( 3x400 mg/Tag ) ; 5 Patienten lehnten die Therapie wegen moeglicher Nebenwirkungen ab ; 3 Monate nach der Verordnung von Tocainid hatten 10 Patienten das Medikament wegen Nebenwirkungen und 3 Patienten wegen mangelnder Wirkung abgesetzt . Wir schaetzen die therapeutische Erfolgsquote fuer die Behandlung des Tinnitus aurium mit Lidocain bedeutend geringer ein als dies im Schrifttum der Fall ist . Das oral anwendbare Stukturanalogon Tocainid kommt wegen der hohen Rate an Nebenwirkungen und nicht ausreichender Tinnitussuppression allenfalls in besonderen Einzelfaellen als Behandlungsmoeglichkeit in Frage .

[ "Um", "die", "Wirksamkeit", "von", "Lidocain", "und", "Tocainid", "auf", "Tinnitus", "aurium", "zu", "ueberpruefen", ",", "untersuchten", "wir", "retrospektiv", "von", "1993", "bis", "Mai", "1995", "77", "Patienten", ".", "Waehrend", "des", "stationaeren", "Aufenthalts", "erhielten", "die", "Patienten", "eine", "Testdosis", "Lidocain", "i.v", ".", "und", "bei", "positivem", "Ansprechen", "auf", "die", "Testdosis", "eine", "sich", "anschliessende", "medikamentoese", "Therapie", "mit", "Tocainid", ",", "einem", "oral", "verabreichbaren", "Strukturanalogon", "des", "Lidocains", ".", "Die", "tinnitussupprimierende", "Wirkung", "wurde", "entsprechend", "den", "subjektiven", "Angaben", "und", "anhand", "einer", "visuellen", "Analogskala", "klassifiziert", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "von", "77", "Patienten", "nur", "19", "Patienten", "eine", "Tinnitussuppression", "unterschiedlicher", "Auspraegung", "angaben", ".", "Von", "ihnen", "waehlten", "14", "Patienten", "eine", "weiterfuehrende", "Therapie", "mit", "Tocainid", "(", "3x400", "mg", "/", "Tag", ")", ";", "5", "Patienten", "lehnten", "die", "Therapie", "wegen", "moeglicher", "Nebenwirkungen", "ab", ";", "3", "Monate", "nach", "der", "Verordnung", "von", "Tocainid", "hatten", "10", "Patienten", "das", "Medikament", "wegen", "Nebenwirkungen", "und", "3", "Patienten", "wegen", "mangelnder", "Wirkung", "abgesetzt", ".", "Wir", "schaetzen", "die", "therapeutische", "Erfolgsquote", "fuer", "die", "Behandlung", "des", "Tinnitus", "aurium", "mit", "Lidocain", "bedeutend", "geringer", "ein", "als", "dies", "im", "Schrifttum", "der", "Fall", "ist", ".", "Das", "oral", "anwendbare", "Stukturanalogon", "Tocainid", "kommt", "wegen", "der", "hohen", "Rate", "an", "Nebenwirkungen", "und", "nicht", "ausreichender", "Tinnitussuppression", "allenfalls", "in", "besonderen", "Einzelfaellen", "als", "Behandlungsmoeglichkeit", "in", "Frage", "." ]

[ "umlsterm" ]

Lidocain is an umlsterm, Tocainid is an umlsterm, Tinnitus aurium is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Lidocain is an umlsterm, medikamentoese Therapie is an umlsterm, Tocainid is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Therapie is an umlsterm, Tocainid is an umlsterm, Patienten is an umlsterm, Therapie is an umlsterm, Tocainid is an umlsterm, Patienten is an umlsterm, Medikament is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Tinnitus aurium is an umlsterm, Lidocain is an umlsterm, Tocainid is an umlsterm

HNO.70450069.ger.abstr_task1

Sentence: Um die Wirksamkeit von Lidocain und Tocainid auf Tinnitus aurium zu ueberpruefen , untersuchten wir retrospektiv von 1993 bis Mai 1995 77 Patienten . Waehrend des stationaeren Aufenthalts erhielten die Patienten eine Testdosis Lidocain i.v. und bei positivem Ansprechen auf die Testdosis eine sich anschliessende medikamentoese Therapie mit Tocainid , einem oral verabreichbaren Strukturanalogon des Lidocains . Die tinnitussupprimierende Wirkung wurde entsprechend den subjektiven Angaben und anhand einer visuellen Analogskala klassifiziert . Unsere Ergebnisse zeigen , dass von 77 Patienten nur 19 Patienten eine Tinnitussuppression unterschiedlicher Auspraegung angaben . Von ihnen waehlten 14 Patienten eine weiterfuehrende Therapie mit Tocainid ( 3x400 mg/Tag ) ; 5 Patienten lehnten die Therapie wegen moeglicher Nebenwirkungen ab ; 3 Monate nach der Verordnung von Tocainid hatten 10 Patienten das Medikament wegen Nebenwirkungen und 3 Patienten wegen mangelnder Wirkung abgesetzt . Wir schaetzen die therapeutische Erfolgsquote fuer die Behandlung des Tinnitus aurium mit Lidocain bedeutend geringer ein als dies im Schrifttum der Fall ist . Das oral anwendbare Stukturanalogon Tocainid kommt wegen der hohen Rate an Nebenwirkungen und nicht ausreichender Tinnitussuppression allenfalls in besonderen Einzelfaellen als Behandlungsmoeglichkeit in Frage . Instructions: please typing these entity words according to sentence: Lidocain, Tocainid, Tinnitus aurium, Patienten, Patienten, Lidocain, medikamentoese Therapie, Tocainid, Patienten, Patienten, Patienten, Therapie, Tocainid, Patienten, Therapie, Tocainid, Patienten, Medikament, Patienten, Behandlung, Tinnitus aurium, Lidocain, Tocainid Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Um die Wirksamkeit von Lidocain und Tocainid auf Tinnitus aurium zu ueberpruefen , untersuchten wir retrospektiv von 1993 bis Mai 1995 77 Patienten . Waehrend des stationaeren Aufenthalts erhielten die Patienten eine Testdosis Lidocain i.v. und bei positivem Ansprechen auf die Testdosis eine sich anschliessende medikamentoese Therapie mit Tocainid , einem oral verabreichbaren Strukturanalogon des Lidocains . Die tinnitussupprimierende Wirkung wurde entsprechend den subjektiven Angaben und anhand einer visuellen Analogskala klassifiziert . Unsere Ergebnisse zeigen , dass von 77 Patienten nur 19 Patienten eine Tinnitussuppression unterschiedlicher Auspraegung angaben . Von ihnen waehlten 14 Patienten eine weiterfuehrende Therapie mit Tocainid ( 3x400 mg/Tag ) ; 5 Patienten lehnten die Therapie wegen moeglicher Nebenwirkungen ab ; 3 Monate nach der Verordnung von Tocainid hatten 10 Patienten das Medikament wegen Nebenwirkungen und 3 Patienten wegen mangelnder Wirkung abgesetzt . Wir schaetzen die therapeutische Erfolgsquote fuer die Behandlung des Tinnitus aurium mit Lidocain bedeutend geringer ein als dies im Schrifttum der Fall ist . Das oral anwendbare Stukturanalogon Tocainid kommt wegen der hohen Rate an Nebenwirkungen und nicht ausreichender Tinnitussuppression allenfalls in besonderen Einzelfaellen als Behandlungsmoeglichkeit in Frage .

[ "Um", "die", "Wirksamkeit", "von", "Lidocain", "und", "Tocainid", "auf", "Tinnitus", "aurium", "zu", "ueberpruefen", ",", "untersuchten", "wir", "retrospektiv", "von", "1993", "bis", "Mai", "1995", "77", "Patienten", ".", "Waehrend", "des", "stationaeren", "Aufenthalts", "erhielten", "die", "Patienten", "eine", "Testdosis", "Lidocain", "i.v", ".", "und", "bei", "positivem", "Ansprechen", "auf", "die", "Testdosis", "eine", "sich", "anschliessende", "medikamentoese", "Therapie", "mit", "Tocainid", ",", "einem", "oral", "verabreichbaren", "Strukturanalogon", "des", "Lidocains", ".", "Die", "tinnitussupprimierende", "Wirkung", "wurde", "entsprechend", "den", "subjektiven", "Angaben", "und", "anhand", "einer", "visuellen", "Analogskala", "klassifiziert", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "von", "77", "Patienten", "nur", "19", "Patienten", "eine", "Tinnitussuppression", "unterschiedlicher", "Auspraegung", "angaben", ".", "Von", "ihnen", "waehlten", "14", "Patienten", "eine", "weiterfuehrende", "Therapie", "mit", "Tocainid", "(", "3x400", "mg", "/", "Tag", ")", ";", "5", "Patienten", "lehnten", "die", "Therapie", "wegen", "moeglicher", "Nebenwirkungen", "ab", ";", "3", "Monate", "nach", "der", "Verordnung", "von", "Tocainid", "hatten", "10", "Patienten", "das", "Medikament", "wegen", "Nebenwirkungen", "und", "3", "Patienten", "wegen", "mangelnder", "Wirkung", "abgesetzt", ".", "Wir", "schaetzen", "die", "therapeutische", "Erfolgsquote", "fuer", "die", "Behandlung", "des", "Tinnitus", "aurium", "mit", "Lidocain", "bedeutend", "geringer", "ein", "als", "dies", "im", "Schrifttum", "der", "Fall", "ist", ".", "Das", "oral", "anwendbare", "Stukturanalogon", "Tocainid", "kommt", "wegen", "der", "hohen", "Rate", "an", "Nebenwirkungen", "und", "nicht", "ausreichender", "Tinnitussuppression", "allenfalls", "in", "besonderen", "Einzelfaellen", "als", "Behandlungsmoeglichkeit", "in", "Frage", "." ]

[ "umlsterm" ]

Lidocain, Tocainid, Tinnitus aurium, Patienten, Patienten, Lidocain, medikamentoese Therapie, Tocainid, Patienten, Patienten, Patienten, Therapie, Tocainid, Patienten, Therapie, Tocainid, Patienten, Medikament, Patienten, Behandlung, Tinnitus aurium, Lidocain, Tocainid

HNO.70450069.ger.abstr_task2

Sentence: Um die Wirksamkeit von Lidocain und Tocainid auf Tinnitus aurium zu ueberpruefen , untersuchten wir retrospektiv von 1993 bis Mai 1995 77 Patienten . Waehrend des stationaeren Aufenthalts erhielten die Patienten eine Testdosis Lidocain i.v. und bei positivem Ansprechen auf die Testdosis eine sich anschliessende medikamentoese Therapie mit Tocainid , einem oral verabreichbaren Strukturanalogon des Lidocains . Die tinnitussupprimierende Wirkung wurde entsprechend den subjektiven Angaben und anhand einer visuellen Analogskala klassifiziert . Unsere Ergebnisse zeigen , dass von 77 Patienten nur 19 Patienten eine Tinnitussuppression unterschiedlicher Auspraegung angaben . Von ihnen waehlten 14 Patienten eine weiterfuehrende Therapie mit Tocainid ( 3x400 mg/Tag ) ; 5 Patienten lehnten die Therapie wegen moeglicher Nebenwirkungen ab ; 3 Monate nach der Verordnung von Tocainid hatten 10 Patienten das Medikament wegen Nebenwirkungen und 3 Patienten wegen mangelnder Wirkung abgesetzt . Wir schaetzen die therapeutische Erfolgsquote fuer die Behandlung des Tinnitus aurium mit Lidocain bedeutend geringer ein als dies im Schrifttum der Fall ist . Das oral anwendbare Stukturanalogon Tocainid kommt wegen der hohen Rate an Nebenwirkungen und nicht ausreichender Tinnitussuppression allenfalls in besonderen Einzelfaellen als Behandlungsmoeglichkeit in Frage . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Um die Wirksamkeit von Lidocain und Tocainid auf Tinnitus aurium zu ueberpruefen , untersuchten wir retrospektiv von 1993 bis Mai 1995 77 Patienten . Waehrend des stationaeren Aufenthalts erhielten die Patienten eine Testdosis Lidocain i.v. und bei positivem Ansprechen auf die Testdosis eine sich anschliessende medikamentoese Therapie mit Tocainid , einem oral verabreichbaren Strukturanalogon des Lidocains . Die tinnitussupprimierende Wirkung wurde entsprechend den subjektiven Angaben und anhand einer visuellen Analogskala klassifiziert . Unsere Ergebnisse zeigen , dass von 77 Patienten nur 19 Patienten eine Tinnitussuppression unterschiedlicher Auspraegung angaben . Von ihnen waehlten 14 Patienten eine weiterfuehrende Therapie mit Tocainid ( 3x400 mg/Tag ) ; 5 Patienten lehnten die Therapie wegen moeglicher Nebenwirkungen ab ; 3 Monate nach der Verordnung von Tocainid hatten 10 Patienten das Medikament wegen Nebenwirkungen und 3 Patienten wegen mangelnder Wirkung abgesetzt . Wir schaetzen die therapeutische Erfolgsquote fuer die Behandlung des Tinnitus aurium mit Lidocain bedeutend geringer ein als dies im Schrifttum der Fall ist . Das oral anwendbare Stukturanalogon Tocainid kommt wegen der hohen Rate an Nebenwirkungen und nicht ausreichender Tinnitussuppression allenfalls in besonderen Einzelfaellen als Behandlungsmoeglichkeit in Frage .

[ "Um", "die", "Wirksamkeit", "von", "Lidocain", "und", "Tocainid", "auf", "Tinnitus", "aurium", "zu", "ueberpruefen", ",", "untersuchten", "wir", "retrospektiv", "von", "1993", "bis", "Mai", "1995", "77", "Patienten", ".", "Waehrend", "des", "stationaeren", "Aufenthalts", "erhielten", "die", "Patienten", "eine", "Testdosis", "Lidocain", "i.v", ".", "und", "bei", "positivem", "Ansprechen", "auf", "die", "Testdosis", "eine", "sich", "anschliessende", "medikamentoese", "Therapie", "mit", "Tocainid", ",", "einem", "oral", "verabreichbaren", "Strukturanalogon", "des", "Lidocains", ".", "Die", "tinnitussupprimierende", "Wirkung", "wurde", "entsprechend", "den", "subjektiven", "Angaben", "und", "anhand", "einer", "visuellen", "Analogskala", "klassifiziert", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "von", "77", "Patienten", "nur", "19", "Patienten", "eine", "Tinnitussuppression", "unterschiedlicher", "Auspraegung", "angaben", ".", "Von", "ihnen", "waehlten", "14", "Patienten", "eine", "weiterfuehrende", "Therapie", "mit", "Tocainid", "(", "3x400", "mg", "/", "Tag", ")", ";", "5", "Patienten", "lehnten", "die", "Therapie", "wegen", "moeglicher", "Nebenwirkungen", "ab", ";", "3", "Monate", "nach", "der", "Verordnung", "von", "Tocainid", "hatten", "10", "Patienten", "das", "Medikament", "wegen", "Nebenwirkungen", "und", "3", "Patienten", "wegen", "mangelnder", "Wirkung", "abgesetzt", ".", "Wir", "schaetzen", "die", "therapeutische", "Erfolgsquote", "fuer", "die", "Behandlung", "des", "Tinnitus", "aurium", "mit", "Lidocain", "bedeutend", "geringer", "ein", "als", "dies", "im", "Schrifttum", "der", "Fall", "ist", ".", "Das", "oral", "anwendbare", "Stukturanalogon", "Tocainid", "kommt", "wegen", "der", "hohen", "Rate", "an", "Nebenwirkungen", "und", "nicht", "ausreichender", "Tinnitussuppression", "allenfalls", "in", "besonderen", "Einzelfaellen", "als", "Behandlungsmoeglichkeit", "in", "Frage", "." ]

[ "umlsterm" ]

Three hundred forty - one Tanzanian preschool children is a participant, levamisole is an intervention, placebo is an intervention

1157_task0

Sentence: Three hundred forty-one Tanzanian preschool children were randomly assigned to levamisole or placebo treatment given at three-month intervals . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: intervention, participant

[ "B-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "O", "O", "O", "O", "B-intervention", "O", "B-intervention", "O", "O", "O", "O", "O", "O", "O", "O" ]

Three hundred forty-one Tanzanian preschool children were randomly assigned to levamisole or placebo treatment given at three-month intervals .

[ "Three", "hundred", "forty", "-", "one", "Tanzanian", "preschool", "children", "were", "randomly", "assigned", "to", "levamisole", "or", "placebo", "treatment", "given", "at", "three", "-", "month", "intervals", "." ]

[ "participant", "intervention" ]

Three hundred forty - one Tanzanian preschool children is a participant, levamisole is an intervention, placebo is an intervention

1157_task1

Sentence: Three hundred forty-one Tanzanian preschool children were randomly assigned to levamisole or placebo treatment given at three-month intervals . Instructions: please typing these entity words according to sentence: Three hundred forty - one Tanzanian preschool children, levamisole, placebo Options: intervention, participant

[ "B-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "O", "O", "O", "O", "B-intervention", "O", "B-intervention", "O", "O", "O", "O", "O", "O", "O", "O" ]

Three hundred forty-one Tanzanian preschool children were randomly assigned to levamisole or placebo treatment given at three-month intervals .

[ "Three", "hundred", "forty", "-", "one", "Tanzanian", "preschool", "children", "were", "randomly", "assigned", "to", "levamisole", "or", "placebo", "treatment", "given", "at", "three", "-", "month", "intervals", "." ]

[ "participant", "intervention" ]

Three hundred forty - one Tanzanian preschool children, levamisole, placebo

1157_task2

Sentence: Three hundred forty-one Tanzanian preschool children were randomly assigned to levamisole or placebo treatment given at three-month intervals . Instructions: please extract entity words from the input sentence

[ "B-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "O", "O", "O", "O", "B-intervention", "O", "B-intervention", "O", "O", "O", "O", "O", "O", "O", "O" ]

Three hundred forty-one Tanzanian preschool children were randomly assigned to levamisole or placebo treatment given at three-month intervals .

[ "Three", "hundred", "forty", "-", "one", "Tanzanian", "preschool", "children", "were", "randomly", "assigned", "to", "levamisole", "or", "placebo", "treatment", "given", "at", "three", "-", "month", "intervals", "." ]

[ "participant", "intervention" ]

Neoplasien is an umlsterm, Verhalten is an umlsterm, Wachstumspotential is an umlsterm, Trauma is an umlsterm, Selbst is an umlsterm, Rezidivraten is an umlsterm, Wachstumspotentials is an umlsterm, Therapieempfehlung is an umlsterm, Klassifikation is an umlsterm

DerChirurg.00710894.ger.abstr_task0

Sentence: Zusammenfassung . Desmoidtumore ( DTs ) sind seltene nicht-metastasierende Neoplasien , , die sowohl sporadisch als auch im Zusammenhang mit einer familiaeren adenomatoesen Polyposis ( FAP ) vorkommen . DTs weisen ein unvorhersehbares biologisches Verhalten auf , wobei etwa 10 % ein aeusserst aggressives Wachstumspotential demonstrieren und andere sich spontan zurueckbilden . Das chirurgische Trauma triggert das Desmoidwachstum und ist bei FAP-Patienten durch die indizierte prophylaktische Colektomie unvermeidbar . Therapeutische Strategien werden weiterhin kontrovers diskutiert . Die chirurgische Resektion eines Desmoidtumors sollte nur dann als Option diskutiert werden , wenn ein Sicherheitsabstand von mindestens 2 cm gewaehrleistet ist . Selbst bei R0-Resektionen sind die Rezidivraten sehr hoch . Debulking-Operationen fuehren unweigerlich zu einer Steigerung des aggressiven Wachstumspotentials . Die meisten Aspekte bei Desmoiden bleiben widerspruechlich und reflektieren das Fehlen einer systematischen Aufarbeitung der Erkrankung . Ein erster Loesungsschritt aus diesem Dilemma in Richtung standardisierte Therapieempfehlung koennte die Etablierung der vorgeschlagenen klinischen Klassifikation darstellen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Zusammenfassung . Desmoidtumore ( DTs ) sind seltene nicht-metastasierende Neoplasien , , die sowohl sporadisch als auch im Zusammenhang mit einer familiaeren adenomatoesen Polyposis ( FAP ) vorkommen . DTs weisen ein unvorhersehbares biologisches Verhalten auf , wobei etwa 10 % ein aeusserst aggressives Wachstumspotential demonstrieren und andere sich spontan zurueckbilden . Das chirurgische Trauma triggert das Desmoidwachstum und ist bei FAP-Patienten durch die indizierte prophylaktische Colektomie unvermeidbar . Therapeutische Strategien werden weiterhin kontrovers diskutiert . Die chirurgische Resektion eines Desmoidtumors sollte nur dann als Option diskutiert werden , wenn ein Sicherheitsabstand von mindestens 2 cm gewaehrleistet ist . Selbst bei R0-Resektionen sind die Rezidivraten sehr hoch . Debulking-Operationen fuehren unweigerlich zu einer Steigerung des aggressiven Wachstumspotentials . Die meisten Aspekte bei Desmoiden bleiben widerspruechlich und reflektieren das Fehlen einer systematischen Aufarbeitung der Erkrankung . Ein erster Loesungsschritt aus diesem Dilemma in Richtung standardisierte Therapieempfehlung koennte die Etablierung der vorgeschlagenen klinischen Klassifikation darstellen .

[ "Zusammenfassung", ".", "Desmoidtumore", "(", "DTs", ")", "sind", "seltene", "nicht", "-", "metastasierende", "Neoplasien", ",", ",", "die", "sowohl", "sporadisch", "als", "auch", "im", "Zusammenhang", "mit", "einer", "familiaeren", "adenomatoesen", "Polyposis", "(", "FAP", ")", "vorkommen", ".", "DTs", "weisen", "ein", "unvorhersehbares", "biologisches", "Verhalten", "auf", ",", "wobei", "etwa", "10", "%", "ein", "aeusserst", "aggressives", "Wachstumspotential", "demonstrieren", "und", "andere", "sich", "spontan", "zurueckbilden", ".", "Das", "chirurgische", "Trauma", "triggert", "das", "Desmoidwachstum", "und", "ist", "bei", "FAP", "-", "Patienten", "durch", "die", "indizierte", "prophylaktische", "Colektomie", "unvermeidbar", ".", "Therapeutische", "Strategien", "werden", "weiterhin", "kontrovers", "diskutiert", ".", "Die", "chirurgische", "Resektion", "eines", "Desmoidtumors", "sollte", "nur", "dann", "als", "Option", "diskutiert", "werden", ",", "wenn", "ein", "Sicherheitsabstand", "von", "mindestens", "2", "cm", "gewaehrleistet", "ist", ".", "Selbst", "bei", "R0-Resektionen", "sind", "die", "Rezidivraten", "sehr", "hoch", ".", "Debulking", "-", "Operationen", "fuehren", "unweigerlich", "zu", "einer", "Steigerung", "des", "aggressiven", "Wachstumspotentials", ".", "Die", "meisten", "Aspekte", "bei", "Desmoiden", "bleiben", "widerspruechlich", "und", "reflektieren", "das", "Fehlen", "einer", "systematischen", "Aufarbeitung", "der", "Erkrankung", ".", "Ein", "erster", "Loesungsschritt", "aus", "diesem", "Dilemma", "in", "Richtung", "standardisierte", "Therapieempfehlung", "koennte", "die", "Etablierung", "der", "vorgeschlagenen", "klinischen", "Klassifikation", "darstellen", "." ]

[ "umlsterm" ]

Neoplasien is an umlsterm, Verhalten is an umlsterm, Wachstumspotential is an umlsterm, Trauma is an umlsterm, Selbst is an umlsterm, Rezidivraten is an umlsterm, Wachstumspotentials is an umlsterm, Therapieempfehlung is an umlsterm, Klassifikation is an umlsterm

DerChirurg.00710894.ger.abstr_task1

Sentence: Zusammenfassung . Desmoidtumore ( DTs ) sind seltene nicht-metastasierende Neoplasien , , die sowohl sporadisch als auch im Zusammenhang mit einer familiaeren adenomatoesen Polyposis ( FAP ) vorkommen . DTs weisen ein unvorhersehbares biologisches Verhalten auf , wobei etwa 10 % ein aeusserst aggressives Wachstumspotential demonstrieren und andere sich spontan zurueckbilden . Das chirurgische Trauma triggert das Desmoidwachstum und ist bei FAP-Patienten durch die indizierte prophylaktische Colektomie unvermeidbar . Therapeutische Strategien werden weiterhin kontrovers diskutiert . Die chirurgische Resektion eines Desmoidtumors sollte nur dann als Option diskutiert werden , wenn ein Sicherheitsabstand von mindestens 2 cm gewaehrleistet ist . Selbst bei R0-Resektionen sind die Rezidivraten sehr hoch . Debulking-Operationen fuehren unweigerlich zu einer Steigerung des aggressiven Wachstumspotentials . Die meisten Aspekte bei Desmoiden bleiben widerspruechlich und reflektieren das Fehlen einer systematischen Aufarbeitung der Erkrankung . Ein erster Loesungsschritt aus diesem Dilemma in Richtung standardisierte Therapieempfehlung koennte die Etablierung der vorgeschlagenen klinischen Klassifikation darstellen . Instructions: please typing these entity words according to sentence: Neoplasien, Verhalten, Wachstumspotential, Trauma, Selbst, Rezidivraten, Wachstumspotentials, Therapieempfehlung, Klassifikation Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Zusammenfassung . Desmoidtumore ( DTs ) sind seltene nicht-metastasierende Neoplasien , , die sowohl sporadisch als auch im Zusammenhang mit einer familiaeren adenomatoesen Polyposis ( FAP ) vorkommen . DTs weisen ein unvorhersehbares biologisches Verhalten auf , wobei etwa 10 % ein aeusserst aggressives Wachstumspotential demonstrieren und andere sich spontan zurueckbilden . Das chirurgische Trauma triggert das Desmoidwachstum und ist bei FAP-Patienten durch die indizierte prophylaktische Colektomie unvermeidbar . Therapeutische Strategien werden weiterhin kontrovers diskutiert . Die chirurgische Resektion eines Desmoidtumors sollte nur dann als Option diskutiert werden , wenn ein Sicherheitsabstand von mindestens 2 cm gewaehrleistet ist . Selbst bei R0-Resektionen sind die Rezidivraten sehr hoch . Debulking-Operationen fuehren unweigerlich zu einer Steigerung des aggressiven Wachstumspotentials . Die meisten Aspekte bei Desmoiden bleiben widerspruechlich und reflektieren das Fehlen einer systematischen Aufarbeitung der Erkrankung . Ein erster Loesungsschritt aus diesem Dilemma in Richtung standardisierte Therapieempfehlung koennte die Etablierung der vorgeschlagenen klinischen Klassifikation darstellen .

[ "Zusammenfassung", ".", "Desmoidtumore", "(", "DTs", ")", "sind", "seltene", "nicht", "-", "metastasierende", "Neoplasien", ",", ",", "die", "sowohl", "sporadisch", "als", "auch", "im", "Zusammenhang", "mit", "einer", "familiaeren", "adenomatoesen", "Polyposis", "(", "FAP", ")", "vorkommen", ".", "DTs", "weisen", "ein", "unvorhersehbares", "biologisches", "Verhalten", "auf", ",", "wobei", "etwa", "10", "%", "ein", "aeusserst", "aggressives", "Wachstumspotential", "demonstrieren", "und", "andere", "sich", "spontan", "zurueckbilden", ".", "Das", "chirurgische", "Trauma", "triggert", "das", "Desmoidwachstum", "und", "ist", "bei", "FAP", "-", "Patienten", "durch", "die", "indizierte", "prophylaktische", "Colektomie", "unvermeidbar", ".", "Therapeutische", "Strategien", "werden", "weiterhin", "kontrovers", "diskutiert", ".", "Die", "chirurgische", "Resektion", "eines", "Desmoidtumors", "sollte", "nur", "dann", "als", "Option", "diskutiert", "werden", ",", "wenn", "ein", "Sicherheitsabstand", "von", "mindestens", "2", "cm", "gewaehrleistet", "ist", ".", "Selbst", "bei", "R0-Resektionen", "sind", "die", "Rezidivraten", "sehr", "hoch", ".", "Debulking", "-", "Operationen", "fuehren", "unweigerlich", "zu", "einer", "Steigerung", "des", "aggressiven", "Wachstumspotentials", ".", "Die", "meisten", "Aspekte", "bei", "Desmoiden", "bleiben", "widerspruechlich", "und", "reflektieren", "das", "Fehlen", "einer", "systematischen", "Aufarbeitung", "der", "Erkrankung", ".", "Ein", "erster", "Loesungsschritt", "aus", "diesem", "Dilemma", "in", "Richtung", "standardisierte", "Therapieempfehlung", "koennte", "die", "Etablierung", "der", "vorgeschlagenen", "klinischen", "Klassifikation", "darstellen", "." ]

[ "umlsterm" ]

Neoplasien, Verhalten, Wachstumspotential, Trauma, Selbst, Rezidivraten, Wachstumspotentials, Therapieempfehlung, Klassifikation

DerChirurg.00710894.ger.abstr_task2

Sentence: Zusammenfassung . Desmoidtumore ( DTs ) sind seltene nicht-metastasierende Neoplasien , , die sowohl sporadisch als auch im Zusammenhang mit einer familiaeren adenomatoesen Polyposis ( FAP ) vorkommen . DTs weisen ein unvorhersehbares biologisches Verhalten auf , wobei etwa 10 % ein aeusserst aggressives Wachstumspotential demonstrieren und andere sich spontan zurueckbilden . Das chirurgische Trauma triggert das Desmoidwachstum und ist bei FAP-Patienten durch die indizierte prophylaktische Colektomie unvermeidbar . Therapeutische Strategien werden weiterhin kontrovers diskutiert . Die chirurgische Resektion eines Desmoidtumors sollte nur dann als Option diskutiert werden , wenn ein Sicherheitsabstand von mindestens 2 cm gewaehrleistet ist . Selbst bei R0-Resektionen sind die Rezidivraten sehr hoch . Debulking-Operationen fuehren unweigerlich zu einer Steigerung des aggressiven Wachstumspotentials . Die meisten Aspekte bei Desmoiden bleiben widerspruechlich und reflektieren das Fehlen einer systematischen Aufarbeitung der Erkrankung . Ein erster Loesungsschritt aus diesem Dilemma in Richtung standardisierte Therapieempfehlung koennte die Etablierung der vorgeschlagenen klinischen Klassifikation darstellen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Zusammenfassung . Desmoidtumore ( DTs ) sind seltene nicht-metastasierende Neoplasien , , die sowohl sporadisch als auch im Zusammenhang mit einer familiaeren adenomatoesen Polyposis ( FAP ) vorkommen . DTs weisen ein unvorhersehbares biologisches Verhalten auf , wobei etwa 10 % ein aeusserst aggressives Wachstumspotential demonstrieren und andere sich spontan zurueckbilden . Das chirurgische Trauma triggert das Desmoidwachstum und ist bei FAP-Patienten durch die indizierte prophylaktische Colektomie unvermeidbar . Therapeutische Strategien werden weiterhin kontrovers diskutiert . Die chirurgische Resektion eines Desmoidtumors sollte nur dann als Option diskutiert werden , wenn ein Sicherheitsabstand von mindestens 2 cm gewaehrleistet ist . Selbst bei R0-Resektionen sind die Rezidivraten sehr hoch . Debulking-Operationen fuehren unweigerlich zu einer Steigerung des aggressiven Wachstumspotentials . Die meisten Aspekte bei Desmoiden bleiben widerspruechlich und reflektieren das Fehlen einer systematischen Aufarbeitung der Erkrankung . Ein erster Loesungsschritt aus diesem Dilemma in Richtung standardisierte Therapieempfehlung koennte die Etablierung der vorgeschlagenen klinischen Klassifikation darstellen .

[ "Zusammenfassung", ".", "Desmoidtumore", "(", "DTs", ")", "sind", "seltene", "nicht", "-", "metastasierende", "Neoplasien", ",", ",", "die", "sowohl", "sporadisch", "als", "auch", "im", "Zusammenhang", "mit", "einer", "familiaeren", "adenomatoesen", "Polyposis", "(", "FAP", ")", "vorkommen", ".", "DTs", "weisen", "ein", "unvorhersehbares", "biologisches", "Verhalten", "auf", ",", "wobei", "etwa", "10", "%", "ein", "aeusserst", "aggressives", "Wachstumspotential", "demonstrieren", "und", "andere", "sich", "spontan", "zurueckbilden", ".", "Das", "chirurgische", "Trauma", "triggert", "das", "Desmoidwachstum", "und", "ist", "bei", "FAP", "-", "Patienten", "durch", "die", "indizierte", "prophylaktische", "Colektomie", "unvermeidbar", ".", "Therapeutische", "Strategien", "werden", "weiterhin", "kontrovers", "diskutiert", ".", "Die", "chirurgische", "Resektion", "eines", "Desmoidtumors", "sollte", "nur", "dann", "als", "Option", "diskutiert", "werden", ",", "wenn", "ein", "Sicherheitsabstand", "von", "mindestens", "2", "cm", "gewaehrleistet", "ist", ".", "Selbst", "bei", "R0-Resektionen", "sind", "die", "Rezidivraten", "sehr", "hoch", ".", "Debulking", "-", "Operationen", "fuehren", "unweigerlich", "zu", "einer", "Steigerung", "des", "aggressiven", "Wachstumspotentials", ".", "Die", "meisten", "Aspekte", "bei", "Desmoiden", "bleiben", "widerspruechlich", "und", "reflektieren", "das", "Fehlen", "einer", "systematischen", "Aufarbeitung", "der", "Erkrankung", ".", "Ein", "erster", "Loesungsschritt", "aus", "diesem", "Dilemma", "in", "Richtung", "standardisierte", "Therapieempfehlung", "koennte", "die", "Etablierung", "der", "vorgeschlagenen", "klinischen", "Klassifikation", "darstellen", "." ]

[ "umlsterm" ]

IkappaBalpha is a Protein, IkappaBalpha kinase is a Protein, p90(rsk ) is a Protein, p90(rsk ) is a Protein, IkappaBalpha is a Protein, IkappaBalpha is a Protein, IKKalpha is a Protein, -beta is a Protein, IKKbeta is a Protein

10438457_task0

Sentence: Protein kinase C and calcineurin synergize to activate IkappaB kinase and NF-kappaB in T lymphocytes. The nuclear factor of kappaB (NF-kappaB) is a ubiquitous transcription factor that is key in the regulation of the immune response and inflammation. T cell receptor (TCR) cross-linking is in part required for activation of NF-kappaB, which is dependent on the phosphorylation and degradation of IkappaBalpha. By using Jurkat and primary human T lymphocytes, we demonstrate that the simultaneous activation of two second messengers of the TCR-initiated signal transduction, protein kinase C (PKC) and calcineurin, results in the synergistic activation of the IkappaBalpha kinase (IKK) complex but not of another putative IkappaBalpha kinase, p90(rsk). We also demonstrate that the IKK complex, but not p90(rsk), is responsible for the in vivo phosphorylation of IkappaBalpha mediated by the co-activation of PKC and calcineurin. Each second messenger is necessary, as inhibition of either one reverses the activation of the IKK complex and IkappaBalpha phosphorylation in vivo. Overexpression of dominant negative forms of IKKalpha and -beta demonstrates that only IKKbeta is the target for PKC and calcineurin. These results indicate that within the TCR/CD3 signal transduction pathway both PKC and calcineurin are required for the effective activation of the IKK complex and NF-kappaB in T lymphocytes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Protein kinase C and calcineurin synergize to activate IkappaB kinase and NF-kappaB in T lymphocytes. The nuclear factor of kappaB (NF-kappaB) is a ubiquitous transcription factor that is key in the regulation of the immune response and inflammation. T cell receptor (TCR) cross-linking is in part required for activation of NF-kappaB, which is dependent on the phosphorylation and degradation of IkappaBalpha. By using Jurkat and primary human T lymphocytes, we demonstrate that the simultaneous activation of two second messengers of the TCR-initiated signal transduction, protein kinase C (PKC) and calcineurin, results in the synergistic activation of the IkappaBalpha kinase (IKK) complex but not of another putative IkappaBalpha kinase, p90(rsk). We also demonstrate that the IKK complex, but not p90(rsk), is responsible for the in vivo phosphorylation of IkappaBalpha mediated by the co-activation of PKC and calcineurin. Each second messenger is necessary, as inhibition of either one reverses the activation of the IKK complex and IkappaBalpha phosphorylation in vivo. Overexpression of dominant negative forms of IKKalpha and -beta demonstrates that only IKKbeta is the target for PKC and calcineurin. These results indicate that within the TCR/CD3 signal transduction pathway both PKC and calcineurin are required for the effective activation of the IKK complex and NF-kappaB in T lymphocytes.

[ "Protein", "kinase", "C", "and", "calcineurin", "synergize", "to", "activate", "IkappaB", "kinase", "and", "NF", "-", "kappaB", "in", "T", "lymphocytes", ".", "\n", "The", "nuclear", "factor", "of", "kappaB", "(", "NF", "-", "kappaB", ")", "is", "a", "ubiquitous", "transcription", "factor", "that", "is", "key", "in", "the", "regulation", "of", "the", "immune", "response", "and", "inflammation", ".", "T", "cell", "receptor", "(", "TCR", ")", "cross", "-", "linking", "is", "in", "part", "required", "for", "activation", "of", "NF", "-", "kappaB", ",", "which", "is", "dependent", "on", "the", "phosphorylation", "and", "degradation", "of", "IkappaBalpha", ".", "By", "using", "Jurkat", "and", "primary", "human", "T", "lymphocytes", ",", "we", "demonstrate", "that", "the", "simultaneous", "activation", "of", "two", "second", "messengers", "of", "the", "TCR", "-", "initiated", "signal", "transduction", ",", "protein", "kinase", "C", "(", "PKC", ")", "and", "calcineurin", ",", "results", "in", "the", "synergistic", "activation", "of", "the", "IkappaBalpha", "kinase", "(", "IKK", ")", "complex", "but", "not", "of", "another", "putative", "IkappaBalpha", "kinase", ",", "p90(rsk", ")", ".", "We", "also", "demonstrate", "that", "the", "IKK", "complex", ",", "but", "not", "p90(rsk", ")", ",", "is", "responsible", "for", "the", "in", "vivo", "phosphorylation", "of", "IkappaBalpha", "mediated", "by", "the", "co", "-", "activation", "of", "PKC", "and", "calcineurin", ".", "Each", "second", "messenger", "is", "necessary", ",", "as", "inhibition", "of", "either", "one", "reverses", "the", "activation", "of", "the", "IKK", "complex", "and", "IkappaBalpha", "phosphorylation", "in", "vivo", ".", "Overexpression", "of", "dominant", "negative", "forms", "of", "IKKalpha", "and", "-beta", "demonstrates", "that", "only", "IKKbeta", "is", "the", "target", "for", "PKC", "and", "calcineurin", ".", "These", "results", "indicate", "that", "within", "the", "TCR", "/", "CD3", "signal", "transduction", "pathway", "both", "PKC", "and", "calcineurin", "are", "required", "for", "the", "effective", "activation", "of", "the", "IKK", "complex", "and", "NF", "-", "kappaB", "in", "T", "lymphocytes", "." ]

[ "Protein" ]

IkappaBalpha is a Protein, IkappaBalpha kinase is a Protein, p90(rsk ) is a Protein, p90(rsk ) is a Protein, IkappaBalpha is a Protein, IkappaBalpha is a Protein, IKKalpha is a Protein, -beta is a Protein, IKKbeta is a Protein

10438457_task1

Sentence: Protein kinase C and calcineurin synergize to activate IkappaB kinase and NF-kappaB in T lymphocytes. The nuclear factor of kappaB (NF-kappaB) is a ubiquitous transcription factor that is key in the regulation of the immune response and inflammation. T cell receptor (TCR) cross-linking is in part required for activation of NF-kappaB, which is dependent on the phosphorylation and degradation of IkappaBalpha. By using Jurkat and primary human T lymphocytes, we demonstrate that the simultaneous activation of two second messengers of the TCR-initiated signal transduction, protein kinase C (PKC) and calcineurin, results in the synergistic activation of the IkappaBalpha kinase (IKK) complex but not of another putative IkappaBalpha kinase, p90(rsk). We also demonstrate that the IKK complex, but not p90(rsk), is responsible for the in vivo phosphorylation of IkappaBalpha mediated by the co-activation of PKC and calcineurin. Each second messenger is necessary, as inhibition of either one reverses the activation of the IKK complex and IkappaBalpha phosphorylation in vivo. Overexpression of dominant negative forms of IKKalpha and -beta demonstrates that only IKKbeta is the target for PKC and calcineurin. These results indicate that within the TCR/CD3 signal transduction pathway both PKC and calcineurin are required for the effective activation of the IKK complex and NF-kappaB in T lymphocytes. Instructions: please typing these entity words according to sentence: IkappaBalpha, IkappaBalpha kinase, p90(rsk ), p90(rsk ), IkappaBalpha, IkappaBalpha, IKKalpha, -beta, IKKbeta Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Protein kinase C and calcineurin synergize to activate IkappaB kinase and NF-kappaB in T lymphocytes. The nuclear factor of kappaB (NF-kappaB) is a ubiquitous transcription factor that is key in the regulation of the immune response and inflammation. T cell receptor (TCR) cross-linking is in part required for activation of NF-kappaB, which is dependent on the phosphorylation and degradation of IkappaBalpha. By using Jurkat and primary human T lymphocytes, we demonstrate that the simultaneous activation of two second messengers of the TCR-initiated signal transduction, protein kinase C (PKC) and calcineurin, results in the synergistic activation of the IkappaBalpha kinase (IKK) complex but not of another putative IkappaBalpha kinase, p90(rsk). We also demonstrate that the IKK complex, but not p90(rsk), is responsible for the in vivo phosphorylation of IkappaBalpha mediated by the co-activation of PKC and calcineurin. Each second messenger is necessary, as inhibition of either one reverses the activation of the IKK complex and IkappaBalpha phosphorylation in vivo. Overexpression of dominant negative forms of IKKalpha and -beta demonstrates that only IKKbeta is the target for PKC and calcineurin. These results indicate that within the TCR/CD3 signal transduction pathway both PKC and calcineurin are required for the effective activation of the IKK complex and NF-kappaB in T lymphocytes.

[ "Protein", "kinase", "C", "and", "calcineurin", "synergize", "to", "activate", "IkappaB", "kinase", "and", "NF", "-", "kappaB", "in", "T", "lymphocytes", ".", "\n", "The", "nuclear", "factor", "of", "kappaB", "(", "NF", "-", "kappaB", ")", "is", "a", "ubiquitous", "transcription", "factor", "that", "is", "key", "in", "the", "regulation", "of", "the", "immune", "response", "and", "inflammation", ".", "T", "cell", "receptor", "(", "TCR", ")", "cross", "-", "linking", "is", "in", "part", "required", "for", "activation", "of", "NF", "-", "kappaB", ",", "which", "is", "dependent", "on", "the", "phosphorylation", "and", "degradation", "of", "IkappaBalpha", ".", "By", "using", "Jurkat", "and", "primary", "human", "T", "lymphocytes", ",", "we", "demonstrate", "that", "the", "simultaneous", "activation", "of", "two", "second", "messengers", "of", "the", "TCR", "-", "initiated", "signal", "transduction", ",", "protein", "kinase", "C", "(", "PKC", ")", "and", "calcineurin", ",", "results", "in", "the", "synergistic", "activation", "of", "the", "IkappaBalpha", "kinase", "(", "IKK", ")", "complex", "but", "not", "of", "another", "putative", "IkappaBalpha", "kinase", ",", "p90(rsk", ")", ".", "We", "also", "demonstrate", "that", "the", "IKK", "complex", ",", "but", "not", "p90(rsk", ")", ",", "is", "responsible", "for", "the", "in", "vivo", "phosphorylation", "of", "IkappaBalpha", "mediated", "by", "the", "co", "-", "activation", "of", "PKC", "and", "calcineurin", ".", "Each", "second", "messenger", "is", "necessary", ",", "as", "inhibition", "of", "either", "one", "reverses", "the", "activation", "of", "the", "IKK", "complex", "and", "IkappaBalpha", "phosphorylation", "in", "vivo", ".", "Overexpression", "of", "dominant", "negative", "forms", "of", "IKKalpha", "and", "-beta", "demonstrates", "that", "only", "IKKbeta", "is", "the", "target", "for", "PKC", "and", "calcineurin", ".", "These", "results", "indicate", "that", "within", "the", "TCR", "/", "CD3", "signal", "transduction", "pathway", "both", "PKC", "and", "calcineurin", "are", "required", "for", "the", "effective", "activation", "of", "the", "IKK", "complex", "and", "NF", "-", "kappaB", "in", "T", "lymphocytes", "." ]

[ "Protein" ]

IkappaBalpha, IkappaBalpha kinase, p90(rsk ), p90(rsk ), IkappaBalpha, IkappaBalpha, IKKalpha, -beta, IKKbeta

10438457_task2

Sentence: Protein kinase C and calcineurin synergize to activate IkappaB kinase and NF-kappaB in T lymphocytes. The nuclear factor of kappaB (NF-kappaB) is a ubiquitous transcription factor that is key in the regulation of the immune response and inflammation. T cell receptor (TCR) cross-linking is in part required for activation of NF-kappaB, which is dependent on the phosphorylation and degradation of IkappaBalpha. By using Jurkat and primary human T lymphocytes, we demonstrate that the simultaneous activation of two second messengers of the TCR-initiated signal transduction, protein kinase C (PKC) and calcineurin, results in the synergistic activation of the IkappaBalpha kinase (IKK) complex but not of another putative IkappaBalpha kinase, p90(rsk). We also demonstrate that the IKK complex, but not p90(rsk), is responsible for the in vivo phosphorylation of IkappaBalpha mediated by the co-activation of PKC and calcineurin. Each second messenger is necessary, as inhibition of either one reverses the activation of the IKK complex and IkappaBalpha phosphorylation in vivo. Overexpression of dominant negative forms of IKKalpha and -beta demonstrates that only IKKbeta is the target for PKC and calcineurin. These results indicate that within the TCR/CD3 signal transduction pathway both PKC and calcineurin are required for the effective activation of the IKK complex and NF-kappaB in T lymphocytes. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Protein kinase C and calcineurin synergize to activate IkappaB kinase and NF-kappaB in T lymphocytes. The nuclear factor of kappaB (NF-kappaB) is a ubiquitous transcription factor that is key in the regulation of the immune response and inflammation. T cell receptor (TCR) cross-linking is in part required for activation of NF-kappaB, which is dependent on the phosphorylation and degradation of IkappaBalpha. By using Jurkat and primary human T lymphocytes, we demonstrate that the simultaneous activation of two second messengers of the TCR-initiated signal transduction, protein kinase C (PKC) and calcineurin, results in the synergistic activation of the IkappaBalpha kinase (IKK) complex but not of another putative IkappaBalpha kinase, p90(rsk). We also demonstrate that the IKK complex, but not p90(rsk), is responsible for the in vivo phosphorylation of IkappaBalpha mediated by the co-activation of PKC and calcineurin. Each second messenger is necessary, as inhibition of either one reverses the activation of the IKK complex and IkappaBalpha phosphorylation in vivo. Overexpression of dominant negative forms of IKKalpha and -beta demonstrates that only IKKbeta is the target for PKC and calcineurin. These results indicate that within the TCR/CD3 signal transduction pathway both PKC and calcineurin are required for the effective activation of the IKK complex and NF-kappaB in T lymphocytes.

[ "Protein", "kinase", "C", "and", "calcineurin", "synergize", "to", "activate", "IkappaB", "kinase", "and", "NF", "-", "kappaB", "in", "T", "lymphocytes", ".", "\n", "The", "nuclear", "factor", "of", "kappaB", "(", "NF", "-", "kappaB", ")", "is", "a", "ubiquitous", "transcription", "factor", "that", "is", "key", "in", "the", "regulation", "of", "the", "immune", "response", "and", "inflammation", ".", "T", "cell", "receptor", "(", "TCR", ")", "cross", "-", "linking", "is", "in", "part", "required", "for", "activation", "of", "NF", "-", "kappaB", ",", "which", "is", "dependent", "on", "the", "phosphorylation", "and", "degradation", "of", "IkappaBalpha", ".", "By", "using", "Jurkat", "and", "primary", "human", "T", "lymphocytes", ",", "we", "demonstrate", "that", "the", "simultaneous", "activation", "of", "two", "second", "messengers", "of", "the", "TCR", "-", "initiated", "signal", "transduction", ",", "protein", "kinase", "C", "(", "PKC", ")", "and", "calcineurin", ",", "results", "in", "the", "synergistic", "activation", "of", "the", "IkappaBalpha", "kinase", "(", "IKK", ")", "complex", "but", "not", "of", "another", "putative", "IkappaBalpha", "kinase", ",", "p90(rsk", ")", ".", "We", "also", "demonstrate", "that", "the", "IKK", "complex", ",", "but", "not", "p90(rsk", ")", ",", "is", "responsible", "for", "the", "in", "vivo", "phosphorylation", "of", "IkappaBalpha", "mediated", "by", "the", "co", "-", "activation", "of", "PKC", "and", "calcineurin", ".", "Each", "second", "messenger", "is", "necessary", ",", "as", "inhibition", "of", "either", "one", "reverses", "the", "activation", "of", "the", "IKK", "complex", "and", "IkappaBalpha", "phosphorylation", "in", "vivo", ".", "Overexpression", "of", "dominant", "negative", "forms", "of", "IKKalpha", "and", "-beta", "demonstrates", "that", "only", "IKKbeta", "is", "the", "target", "for", "PKC", "and", "calcineurin", ".", "These", "results", "indicate", "that", "within", "the", "TCR", "/", "CD3", "signal", "transduction", "pathway", "both", "PKC", "and", "calcineurin", "are", "required", "for", "the", "effective", "activation", "of", "the", "IKK", "complex", "and", "NF", "-", "kappaB", "in", "T", "lymphocytes", "." ]

[ "Protein" ]

nicotine is a Intervention_Pharmacological, tone is a Outcome_Physical, contractile activity is a Outcome_Physical, ulcerative colitis ( UC ) is a Participant_Condition, sustained resting pressure ( tone ) is a Outcome_Physical, placebo is a Intervention_Control, water - perfused manometry catheter is a Intervention_Physical, sigmoidoscopy is a Intervention_Physical, Baseline tone is a Outcome_Physical, Tone is a Outcome_Physical, rate of recovery is a Outcome_Physical

2007_task0

Sentence: Intra-luminal nicotine reduces smooth muscle tone and contractile activity in the distal large bowel . BACKGROUND Nicotine may be of therapeutic value in ulcerative colitis ( UC ) , although its mechanism of action has not been established . OBJECTIVE To examine the effect of a solution of nicotine on sustained resting pressure ( tone ) and contractile activity in the human colon . METHODS Ten healthy volunteers , and seven with UC in symptomatic remission took part ; all were non-smokers . All 17 subjects were given nicotine or placebo solution on two separate occasions in a randomized sequence . A water-perfused manometry catheter , with openings at 5 , 10 and 15 cm from the tip , was placed by rigid sigmoidoscopy in the recto-sigmoid region . Baseline tone and activity were measured for 15 min prior to instillation of 20 ml of saline alone or with nicotine , 1.2 mg , at pH 4.5 . Observations were made over the subsequent 15-20 min . RESULTS Baseline spontaneous activity in all subjects showed both high- and low-frequency components ; in three patients with UC , the low-frequency activity was of high amplitude . The nicotine reduced both tone and activity in all subjects , with reduction or abolition of the large contractions in UC . Tone in all 17 subjects was reduced significantly at 3 min after nicotine ( P = 0.000015 , sign test ) ; the rate of recovery varied in individuals . Results from normals and UC did not differ significantly from each other . No significant change in tone or activity was observed with the saline solution . CONCLUSION Intra-luminal nicotine significantly reduces both smooth muscle tone and contractile activity in the recto-sigmoid colon in both normal subjects and patients with UC . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Intervention_Control, Participant_Condition, Outcome_Physical

[ "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Intra-luminal nicotine reduces smooth muscle tone and contractile activity in the distal large bowel . BACKGROUND Nicotine may be of therapeutic value in ulcerative colitis ( UC ) , although its mechanism of action has not been established . OBJECTIVE To examine the effect of a solution of nicotine on sustained resting pressure ( tone ) and contractile activity in the human colon . METHODS Ten healthy volunteers , and seven with UC in symptomatic remission took part ; all were non-smokers . All 17 subjects were given nicotine or placebo solution on two separate occasions in a randomized sequence . A water-perfused manometry catheter , with openings at 5 , 10 and 15 cm from the tip , was placed by rigid sigmoidoscopy in the recto-sigmoid region . Baseline tone and activity were measured for 15 min prior to instillation of 20 ml of saline alone or with nicotine , 1.2 mg , at pH 4.5 . Observations were made over the subsequent 15-20 min . RESULTS Baseline spontaneous activity in all subjects showed both high- and low-frequency components ; in three patients with UC , the low-frequency activity was of high amplitude . The nicotine reduced both tone and activity in all subjects , with reduction or abolition of the large contractions in UC . Tone in all 17 subjects was reduced significantly at 3 min after nicotine ( P = 0.000015 , sign test ) ; the rate of recovery varied in individuals . Results from normals and UC did not differ significantly from each other . No significant change in tone or activity was observed with the saline solution . CONCLUSION Intra-luminal nicotine significantly reduces both smooth muscle tone and contractile activity in the recto-sigmoid colon in both normal subjects and patients with UC .

[ "Intra", "-", "luminal", "nicotine", "reduces", "smooth", "muscle", "tone", "and", "contractile", "activity", "in", "the", "distal", "large", "bowel", ".", "BACKGROUND", "Nicotine", "may", "be", "of", "therapeutic", "value", "in", "ulcerative", "colitis", "(", "UC", ")", ",", "although", "its", "mechanism", "of", "action", "has", "not", "been", "established", ".", "OBJECTIVE", "To", "examine", "the", "effect", "of", "a", "solution", "of", "nicotine", "on", "sustained", "resting", "pressure", "(", "tone", ")", "and", "contractile", "activity", "in", "the", "human", "colon", ".", "METHODS", "Ten", "healthy", "volunteers", ",", "and", "seven", "with", "UC", "in", "symptomatic", "remission", "took", "part", ";", "all", "were", "non", "-", "smokers", ".", "All", "17", "subjects", "were", "given", "nicotine", "or", "placebo", "solution", "on", "two", "separate", "occasions", "in", "a", "randomized", "sequence", ".", "A", "water", "-", "perfused", "manometry", "catheter", ",", "with", "openings", "at", "5", ",", "10", "and", "15", "cm", "from", "the", "tip", ",", "was", "placed", "by", "rigid", "sigmoidoscopy", "in", "the", "recto", "-", "sigmoid", "region", ".", "Baseline", "tone", "and", "activity", "were", "measured", "for", "15", "min", "prior", "to", "instillation", "of", "20", "ml", "of", "saline", "alone", "or", "with", "nicotine", ",", "1.2", "mg", ",", "at", "pH", "4.5", ".", "Observations", "were", "made", "over", "the", "subsequent", "15", "-", "20", "min", ".", "RESULTS", "Baseline", "spontaneous", "activity", "in", "all", "subjects", "showed", "both", "high-", "and", "low", "-", "frequency", "components", ";", "in", "three", "patients", "with", "UC", ",", "the", "low", "-", "frequency", "activity", "was", "of", "high", "amplitude", ".", "The", "nicotine", "reduced", "both", "tone", "and", "activity", "in", "all", "subjects", ",", "with", "reduction", "or", "abolition", "of", "the", "large", "contractions", "in", "UC", ".", "Tone", "in", "all", "17", "subjects", "was", "reduced", "significantly", "at", "3", "min", "after", "nicotine", "(", "P", "=", "0.000015", ",", "sign", "test", ")", ";", "the", "rate", "of", "recovery", "varied", "in", "individuals", ".", "Results", "from", "normals", "and", "UC", "did", "not", "differ", "significantly", "from", "each", "other", ".", "No", "significant", "change", "in", "tone", "or", "activity", "was", "observed", "with", "the", "saline", "solution", ".", "CONCLUSION", "Intra", "-", "luminal", "nicotine", "significantly", "reduces", "both", "smooth", "muscle", "tone", "and", "contractile", "activity", "in", "the", "recto", "-", "sigmoid", "colon", "in", "both", "normal", "subjects", "and", "patients", "with", "UC", "." ]

[ "Outcome_Physical", "Intervention_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control" ]

nicotine is a Intervention_Pharmacological, tone is a Outcome_Physical, contractile activity is a Outcome_Physical, ulcerative colitis ( UC ) is a Participant_Condition, sustained resting pressure ( tone ) is a Outcome_Physical, placebo is a Intervention_Control, water - perfused manometry catheter is a Intervention_Physical, sigmoidoscopy is a Intervention_Physical, Baseline tone is a Outcome_Physical, Tone is a Outcome_Physical, rate of recovery is a Outcome_Physical

2007_task1

Sentence: Intra-luminal nicotine reduces smooth muscle tone and contractile activity in the distal large bowel . BACKGROUND Nicotine may be of therapeutic value in ulcerative colitis ( UC ) , although its mechanism of action has not been established . OBJECTIVE To examine the effect of a solution of nicotine on sustained resting pressure ( tone ) and contractile activity in the human colon . METHODS Ten healthy volunteers , and seven with UC in symptomatic remission took part ; all were non-smokers . All 17 subjects were given nicotine or placebo solution on two separate occasions in a randomized sequence . A water-perfused manometry catheter , with openings at 5 , 10 and 15 cm from the tip , was placed by rigid sigmoidoscopy in the recto-sigmoid region . Baseline tone and activity were measured for 15 min prior to instillation of 20 ml of saline alone or with nicotine , 1.2 mg , at pH 4.5 . Observations were made over the subsequent 15-20 min . RESULTS Baseline spontaneous activity in all subjects showed both high- and low-frequency components ; in three patients with UC , the low-frequency activity was of high amplitude . The nicotine reduced both tone and activity in all subjects , with reduction or abolition of the large contractions in UC . Tone in all 17 subjects was reduced significantly at 3 min after nicotine ( P = 0.000015 , sign test ) ; the rate of recovery varied in individuals . Results from normals and UC did not differ significantly from each other . No significant change in tone or activity was observed with the saline solution . CONCLUSION Intra-luminal nicotine significantly reduces both smooth muscle tone and contractile activity in the recto-sigmoid colon in both normal subjects and patients with UC . Instructions: please typing these entity words according to sentence: nicotine, tone, contractile activity, ulcerative colitis ( UC ), sustained resting pressure ( tone ), placebo, water - perfused manometry catheter, sigmoidoscopy, Baseline tone, Tone, rate of recovery Options: Intervention_Pharmacological, Intervention_Physical, Intervention_Control, Participant_Condition, Outcome_Physical

[ "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Intra-luminal nicotine reduces smooth muscle tone and contractile activity in the distal large bowel . BACKGROUND Nicotine may be of therapeutic value in ulcerative colitis ( UC ) , although its mechanism of action has not been established . OBJECTIVE To examine the effect of a solution of nicotine on sustained resting pressure ( tone ) and contractile activity in the human colon . METHODS Ten healthy volunteers , and seven with UC in symptomatic remission took part ; all were non-smokers . All 17 subjects were given nicotine or placebo solution on two separate occasions in a randomized sequence . A water-perfused manometry catheter , with openings at 5 , 10 and 15 cm from the tip , was placed by rigid sigmoidoscopy in the recto-sigmoid region . Baseline tone and activity were measured for 15 min prior to instillation of 20 ml of saline alone or with nicotine , 1.2 mg , at pH 4.5 . Observations were made over the subsequent 15-20 min . RESULTS Baseline spontaneous activity in all subjects showed both high- and low-frequency components ; in three patients with UC , the low-frequency activity was of high amplitude . The nicotine reduced both tone and activity in all subjects , with reduction or abolition of the large contractions in UC . Tone in all 17 subjects was reduced significantly at 3 min after nicotine ( P = 0.000015 , sign test ) ; the rate of recovery varied in individuals . Results from normals and UC did not differ significantly from each other . No significant change in tone or activity was observed with the saline solution . CONCLUSION Intra-luminal nicotine significantly reduces both smooth muscle tone and contractile activity in the recto-sigmoid colon in both normal subjects and patients with UC .

[ "Intra", "-", "luminal", "nicotine", "reduces", "smooth", "muscle", "tone", "and", "contractile", "activity", "in", "the", "distal", "large", "bowel", ".", "BACKGROUND", "Nicotine", "may", "be", "of", "therapeutic", "value", "in", "ulcerative", "colitis", "(", "UC", ")", ",", "although", "its", "mechanism", "of", "action", "has", "not", "been", "established", ".", "OBJECTIVE", "To", "examine", "the", "effect", "of", "a", "solution", "of", "nicotine", "on", "sustained", "resting", "pressure", "(", "tone", ")", "and", "contractile", "activity", "in", "the", "human", "colon", ".", "METHODS", "Ten", "healthy", "volunteers", ",", "and", "seven", "with", "UC", "in", "symptomatic", "remission", "took", "part", ";", "all", "were", "non", "-", "smokers", ".", "All", "17", "subjects", "were", "given", "nicotine", "or", "placebo", "solution", "on", "two", "separate", "occasions", "in", "a", "randomized", "sequence", ".", "A", "water", "-", "perfused", "manometry", "catheter", ",", "with", "openings", "at", "5", ",", "10", "and", "15", "cm", "from", "the", "tip", ",", "was", "placed", "by", "rigid", "sigmoidoscopy", "in", "the", "recto", "-", "sigmoid", "region", ".", "Baseline", "tone", "and", "activity", "were", "measured", "for", "15", "min", "prior", "to", "instillation", "of", "20", "ml", "of", "saline", "alone", "or", "with", "nicotine", ",", "1.2", "mg", ",", "at", "pH", "4.5", ".", "Observations", "were", "made", "over", "the", "subsequent", "15", "-", "20", "min", ".", "RESULTS", "Baseline", "spontaneous", "activity", "in", "all", "subjects", "showed", "both", "high-", "and", "low", "-", "frequency", "components", ";", "in", "three", "patients", "with", "UC", ",", "the", "low", "-", "frequency", "activity", "was", "of", "high", "amplitude", ".", "The", "nicotine", "reduced", "both", "tone", "and", "activity", "in", "all", "subjects", ",", "with", "reduction", "or", "abolition", "of", "the", "large", "contractions", "in", "UC", ".", "Tone", "in", "all", "17", "subjects", "was", "reduced", "significantly", "at", "3", "min", "after", "nicotine", "(", "P", "=", "0.000015", ",", "sign", "test", ")", ";", "the", "rate", "of", "recovery", "varied", "in", "individuals", ".", "Results", "from", "normals", "and", "UC", "did", "not", "differ", "significantly", "from", "each", "other", ".", "No", "significant", "change", "in", "tone", "or", "activity", "was", "observed", "with", "the", "saline", "solution", ".", "CONCLUSION", "Intra", "-", "luminal", "nicotine", "significantly", "reduces", "both", "smooth", "muscle", "tone", "and", "contractile", "activity", "in", "the", "recto", "-", "sigmoid", "colon", "in", "both", "normal", "subjects", "and", "patients", "with", "UC", "." ]

[ "Outcome_Physical", "Intervention_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control" ]

nicotine, tone, contractile activity, ulcerative colitis ( UC ), sustained resting pressure ( tone ), placebo, water - perfused manometry catheter, sigmoidoscopy, Baseline tone, Tone, rate of recovery

2007_task2

Sentence: Intra-luminal nicotine reduces smooth muscle tone and contractile activity in the distal large bowel . BACKGROUND Nicotine may be of therapeutic value in ulcerative colitis ( UC ) , although its mechanism of action has not been established . OBJECTIVE To examine the effect of a solution of nicotine on sustained resting pressure ( tone ) and contractile activity in the human colon . METHODS Ten healthy volunteers , and seven with UC in symptomatic remission took part ; all were non-smokers . All 17 subjects were given nicotine or placebo solution on two separate occasions in a randomized sequence . A water-perfused manometry catheter , with openings at 5 , 10 and 15 cm from the tip , was placed by rigid sigmoidoscopy in the recto-sigmoid region . Baseline tone and activity were measured for 15 min prior to instillation of 20 ml of saline alone or with nicotine , 1.2 mg , at pH 4.5 . Observations were made over the subsequent 15-20 min . RESULTS Baseline spontaneous activity in all subjects showed both high- and low-frequency components ; in three patients with UC , the low-frequency activity was of high amplitude . The nicotine reduced both tone and activity in all subjects , with reduction or abolition of the large contractions in UC . Tone in all 17 subjects was reduced significantly at 3 min after nicotine ( P = 0.000015 , sign test ) ; the rate of recovery varied in individuals . Results from normals and UC did not differ significantly from each other . No significant change in tone or activity was observed with the saline solution . CONCLUSION Intra-luminal nicotine significantly reduces both smooth muscle tone and contractile activity in the recto-sigmoid colon in both normal subjects and patients with UC . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Intra-luminal nicotine reduces smooth muscle tone and contractile activity in the distal large bowel . BACKGROUND Nicotine may be of therapeutic value in ulcerative colitis ( UC ) , although its mechanism of action has not been established . OBJECTIVE To examine the effect of a solution of nicotine on sustained resting pressure ( tone ) and contractile activity in the human colon . METHODS Ten healthy volunteers , and seven with UC in symptomatic remission took part ; all were non-smokers . All 17 subjects were given nicotine or placebo solution on two separate occasions in a randomized sequence . A water-perfused manometry catheter , with openings at 5 , 10 and 15 cm from the tip , was placed by rigid sigmoidoscopy in the recto-sigmoid region . Baseline tone and activity were measured for 15 min prior to instillation of 20 ml of saline alone or with nicotine , 1.2 mg , at pH 4.5 . Observations were made over the subsequent 15-20 min . RESULTS Baseline spontaneous activity in all subjects showed both high- and low-frequency components ; in three patients with UC , the low-frequency activity was of high amplitude . The nicotine reduced both tone and activity in all subjects , with reduction or abolition of the large contractions in UC . Tone in all 17 subjects was reduced significantly at 3 min after nicotine ( P = 0.000015 , sign test ) ; the rate of recovery varied in individuals . Results from normals and UC did not differ significantly from each other . No significant change in tone or activity was observed with the saline solution . CONCLUSION Intra-luminal nicotine significantly reduces both smooth muscle tone and contractile activity in the recto-sigmoid colon in both normal subjects and patients with UC .

[ "Intra", "-", "luminal", "nicotine", "reduces", "smooth", "muscle", "tone", "and", "contractile", "activity", "in", "the", "distal", "large", "bowel", ".", "BACKGROUND", "Nicotine", "may", "be", "of", "therapeutic", "value", "in", "ulcerative", "colitis", "(", "UC", ")", ",", "although", "its", "mechanism", "of", "action", "has", "not", "been", "established", ".", "OBJECTIVE", "To", "examine", "the", "effect", "of", "a", "solution", "of", "nicotine", "on", "sustained", "resting", "pressure", "(", "tone", ")", "and", "contractile", "activity", "in", "the", "human", "colon", ".", "METHODS", "Ten", "healthy", "volunteers", ",", "and", "seven", "with", "UC", "in", "symptomatic", "remission", "took", "part", ";", "all", "were", "non", "-", "smokers", ".", "All", "17", "subjects", "were", "given", "nicotine", "or", "placebo", "solution", "on", "two", "separate", "occasions", "in", "a", "randomized", "sequence", ".", "A", "water", "-", "perfused", "manometry", "catheter", ",", "with", "openings", "at", "5", ",", "10", "and", "15", "cm", "from", "the", "tip", ",", "was", "placed", "by", "rigid", "sigmoidoscopy", "in", "the", "recto", "-", "sigmoid", "region", ".", "Baseline", "tone", "and", "activity", "were", "measured", "for", "15", "min", "prior", "to", "instillation", "of", "20", "ml", "of", "saline", "alone", "or", "with", "nicotine", ",", "1.2", "mg", ",", "at", "pH", "4.5", ".", "Observations", "were", "made", "over", "the", "subsequent", "15", "-", "20", "min", ".", "RESULTS", "Baseline", "spontaneous", "activity", "in", "all", "subjects", "showed", "both", "high-", "and", "low", "-", "frequency", "components", ";", "in", "three", "patients", "with", "UC", ",", "the", "low", "-", "frequency", "activity", "was", "of", "high", "amplitude", ".", "The", "nicotine", "reduced", "both", "tone", "and", "activity", "in", "all", "subjects", ",", "with", "reduction", "or", "abolition", "of", "the", "large", "contractions", "in", "UC", ".", "Tone", "in", "all", "17", "subjects", "was", "reduced", "significantly", "at", "3", "min", "after", "nicotine", "(", "P", "=", "0.000015", ",", "sign", "test", ")", ";", "the", "rate", "of", "recovery", "varied", "in", "individuals", ".", "Results", "from", "normals", "and", "UC", "did", "not", "differ", "significantly", "from", "each", "other", ".", "No", "significant", "change", "in", "tone", "or", "activity", "was", "observed", "with", "the", "saline", "solution", ".", "CONCLUSION", "Intra", "-", "luminal", "nicotine", "significantly", "reduces", "both", "smooth", "muscle", "tone", "and", "contractile", "activity", "in", "the", "recto", "-", "sigmoid", "colon", "in", "both", "normal", "subjects", "and", "patients", "with", "UC", "." ]

[ "Outcome_Physical", "Intervention_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control" ]

severe is a Qualifier, coronary artery disease , heart failure , kidney failure is a Scope, insulin - dependent DM is a Condition, diabetes mellitus is a Condition, poorly controlled is a Qualifier, type II DM is a Condition, duodenal ulcer is a Condition, allergy / contra - indication is a Scope, drug used in the study is a Drug, corticosteroid is a Drug, during last 3 months is a Temporal, preoperative is a Temporal, opioid drugs is a Drug, excl . is a Negation, codeine , tramadol is a Scope, neuropathy / sensory impairment is a Scope, lower limbs is a Qualifier, lack of co - operation is a Observation, inability to use is a Condition

NCT03034733_exc_task0

Sentence: severe coronary artery disease, heart failure, kidney failure insulin-dependent DM (diabetes mellitus), poorly controlled type II DM gastric/duodenal ulcer allergy/contra-indication for any drug used in the study corticosteroid use during last 3 months preoperative use of opioid drugs (excl. codeine, tramadol) neuropathy/sensory impairment of lower limbs lack of co-operation, e.g. inability to use a PCA (patient controlled analgesia)-device Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Observation, Negation, Scope, Drug

[ "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "O", "O", "B-Drug", "I-Drug", "O", "B-Negation", "I-Negation", "B-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Qualifier", "I-Qualifier", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O" ]

severe coronary artery disease, heart failure, kidney failure insulin-dependent DM (diabetes mellitus), poorly controlled type II DM gastric/duodenal ulcer allergy/contra-indication for any drug used in the study corticosteroid use during last 3 months preoperative use of opioid drugs (excl. codeine, tramadol) neuropathy/sensory impairment of lower limbs lack of co-operation, e.g. inability to use a PCA (patient controlled analgesia)-device

[ "severe", "coronary", "artery", "disease", ",", "heart", "failure", ",", "kidney", "failure", "\n", "insulin", "-", "dependent", "DM", "(", "diabetes", "mellitus", ")", ",", "poorly", "controlled", "type", "II", "DM", "\n", "gastric", "/", "duodenal", "ulcer", "\n", "allergy", "/", "contra", "-", "indication", "for", "any", "drug", "used", "in", "the", "study", "\n", "corticosteroid", "use", "during", "last", "3", "months", "\n", "preoperative", "use", "of", "opioid", "drugs", "(", "excl", ".", "codeine", ",", "tramadol", ")", "\n", "neuropathy", "/", "sensory", "impairment", "of", "lower", "limbs", "\n", "lack", "of", "co", "-", "operation", ",", "e.g", ".", "inability", "to", "use", "a", "PCA", "(", "patient", "controlled", "analgesia)-device", "\n" ]

[ "Scope", "Condition", "Drug", "Temporal", "Observation", "Qualifier", "Negation", "Device" ]

severe is a Qualifier, coronary artery disease , heart failure , kidney failure is a Scope, insulin - dependent DM is a Condition, diabetes mellitus is a Condition, poorly controlled is a Qualifier, type II DM is a Condition, duodenal ulcer is a Condition, allergy / contra - indication is a Scope, drug used in the study is a Drug, corticosteroid is a Drug, during last 3 months is a Temporal, preoperative is a Temporal, opioid drugs is a Drug, excl . is a Negation, codeine , tramadol is a Scope, neuropathy / sensory impairment is a Scope, lower limbs is a Qualifier, lack of co - operation is a Observation, inability to use is a Condition

NCT03034733_exc_task1

Sentence: severe coronary artery disease, heart failure, kidney failure insulin-dependent DM (diabetes mellitus), poorly controlled type II DM gastric/duodenal ulcer allergy/contra-indication for any drug used in the study corticosteroid use during last 3 months preoperative use of opioid drugs (excl. codeine, tramadol) neuropathy/sensory impairment of lower limbs lack of co-operation, e.g. inability to use a PCA (patient controlled analgesia)-device Instructions: please typing these entity words according to sentence: severe, coronary artery disease , heart failure , kidney failure, insulin - dependent DM, diabetes mellitus, poorly controlled, type II DM, duodenal ulcer, allergy / contra - indication, drug used in the study, corticosteroid, during last 3 months, preoperative, opioid drugs, excl ., codeine , tramadol, neuropathy / sensory impairment, lower limbs, lack of co - operation, inability to use Options: Temporal, Condition, Qualifier, Observation, Negation, Scope, Drug

[ "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "O", "O", "B-Drug", "I-Drug", "O", "B-Negation", "I-Negation", "B-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Qualifier", "I-Qualifier", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O" ]

severe coronary artery disease, heart failure, kidney failure insulin-dependent DM (diabetes mellitus), poorly controlled type II DM gastric/duodenal ulcer allergy/contra-indication for any drug used in the study corticosteroid use during last 3 months preoperative use of opioid drugs (excl. codeine, tramadol) neuropathy/sensory impairment of lower limbs lack of co-operation, e.g. inability to use a PCA (patient controlled analgesia)-device

[ "severe", "coronary", "artery", "disease", ",", "heart", "failure", ",", "kidney", "failure", "\n", "insulin", "-", "dependent", "DM", "(", "diabetes", "mellitus", ")", ",", "poorly", "controlled", "type", "II", "DM", "\n", "gastric", "/", "duodenal", "ulcer", "\n", "allergy", "/", "contra", "-", "indication", "for", "any", "drug", "used", "in", "the", "study", "\n", "corticosteroid", "use", "during", "last", "3", "months", "\n", "preoperative", "use", "of", "opioid", "drugs", "(", "excl", ".", "codeine", ",", "tramadol", ")", "\n", "neuropathy", "/", "sensory", "impairment", "of", "lower", "limbs", "\n", "lack", "of", "co", "-", "operation", ",", "e.g", ".", "inability", "to", "use", "a", "PCA", "(", "patient", "controlled", "analgesia)-device", "\n" ]

[ "Scope", "Condition", "Drug", "Temporal", "Observation", "Qualifier", "Negation", "Device" ]

severe, coronary artery disease , heart failure , kidney failure, insulin - dependent DM, diabetes mellitus, poorly controlled, type II DM, duodenal ulcer, allergy / contra - indication, drug used in the study, corticosteroid, during last 3 months, preoperative, opioid drugs, excl ., codeine , tramadol, neuropathy / sensory impairment, lower limbs, lack of co - operation, inability to use

NCT03034733_exc_task2

Sentence: severe coronary artery disease, heart failure, kidney failure insulin-dependent DM (diabetes mellitus), poorly controlled type II DM gastric/duodenal ulcer allergy/contra-indication for any drug used in the study corticosteroid use during last 3 months preoperative use of opioid drugs (excl. codeine, tramadol) neuropathy/sensory impairment of lower limbs lack of co-operation, e.g. inability to use a PCA (patient controlled analgesia)-device Instructions: please extract entity words from the input sentence

[ "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "I-Drug", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "O", "O", "B-Drug", "I-Drug", "O", "B-Negation", "I-Negation", "B-Scope", "I-Scope", "I-Scope", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Qualifier", "I-Qualifier", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O" ]

severe coronary artery disease, heart failure, kidney failure insulin-dependent DM (diabetes mellitus), poorly controlled type II DM gastric/duodenal ulcer allergy/contra-indication for any drug used in the study corticosteroid use during last 3 months preoperative use of opioid drugs (excl. codeine, tramadol) neuropathy/sensory impairment of lower limbs lack of co-operation, e.g. inability to use a PCA (patient controlled analgesia)-device

[ "severe", "coronary", "artery", "disease", ",", "heart", "failure", ",", "kidney", "failure", "\n", "insulin", "-", "dependent", "DM", "(", "diabetes", "mellitus", ")", ",", "poorly", "controlled", "type", "II", "DM", "\n", "gastric", "/", "duodenal", "ulcer", "\n", "allergy", "/", "contra", "-", "indication", "for", "any", "drug", "used", "in", "the", "study", "\n", "corticosteroid", "use", "during", "last", "3", "months", "\n", "preoperative", "use", "of", "opioid", "drugs", "(", "excl", ".", "codeine", ",", "tramadol", ")", "\n", "neuropathy", "/", "sensory", "impairment", "of", "lower", "limbs", "\n", "lack", "of", "co", "-", "operation", ",", "e.g", ".", "inability", "to", "use", "a", "PCA", "(", "patient", "controlled", "analgesia)-device", "\n" ]

[ "Scope", "Condition", "Drug", "Temporal", "Observation", "Qualifier", "Negation", "Device" ]

c - maf is a Protein, ubiquitin is a Protein, c - maf is a Protein, cyclin D2 is a Protein, c - maf is a Protein, c - maf is a Protein, cyclin D2 is a Protein, luciferase is a Protein, c - maf is a Protein, cyclin D2 is a Protein, c - maf is a Protein, c - maf is a Protein, ubiquitin C is a Protein, ubiquitin C is a Protein, c - maf is a Protein, ubiquitin is a Protein, c - maf is a Protein, ubiquitin is a Protein

262_task0

Sentence: A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. The oncogene c-maf is frequently overexpressed in multiple myeloma cell lines and patient samples and contributes to increased cellular proliferation in part by inducing cyclin D2 expression. To identify regulators of c-maf, we developed a chemical screen in NIH3T3 cells stably overexpressing c-maf and the cyclin D2 promoter driving luciferase. From a screen of 2400 off-patent drugs and chemicals, we identified glucocorticoids as c-maf-dependent inhibitors of cyclin D2 transactivation. In multiple myeloma cell lines, glucocorticoids reduced levels of c-maf protein without influencing corresponding mRNA levels. Subsequent studies demonstrated that glucocorticoids increased ubiquitination-dependent degradation of c-maf and up-regulated ubiquitin C mRNA. Moreover, ectopic expression of ubiquitin C recapitulated the effects of glucocorticoids, demonstrating regulation of c-maf protein through the abundance of the ubiquitin substrate. Thus, using a chemical biology approach, we identified a novel mechanism of action of glucocorticoids and a novel mechanism by which levels of c-maf protein are regulated by the abundance of the ubiquitin substrate. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O" ]

A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. The oncogene c-maf is frequently overexpressed in multiple myeloma cell lines and patient samples and contributes to increased cellular proliferation in part by inducing cyclin D2 expression. To identify regulators of c-maf, we developed a chemical screen in NIH3T3 cells stably overexpressing c-maf and the cyclin D2 promoter driving luciferase. From a screen of 2400 off-patent drugs and chemicals, we identified glucocorticoids as c-maf-dependent inhibitors of cyclin D2 transactivation. In multiple myeloma cell lines, glucocorticoids reduced levels of c-maf protein without influencing corresponding mRNA levels. Subsequent studies demonstrated that glucocorticoids increased ubiquitination-dependent degradation of c-maf and up-regulated ubiquitin C mRNA. Moreover, ectopic expression of ubiquitin C recapitulated the effects of glucocorticoids, demonstrating regulation of c-maf protein through the abundance of the ubiquitin substrate. Thus, using a chemical biology approach, we identified a novel mechanism of action of glucocorticoids and a novel mechanism by which levels of c-maf protein are regulated by the abundance of the ubiquitin substrate.

[ "A", "chemical", "biology", "screen", "identifies", "glucocorticoids", "that", "regulate", "c", "-", "maf", "expression", "by", "increasing", "its", "proteasomal", "degradation", "through", "up", "-", "regulation", "of", "ubiquitin", ".", "\n", "The", "oncogene", "c", "-", "maf", "is", "frequently", "overexpressed", "in", "multiple", "myeloma", "cell", "lines", "and", "patient", "samples", "and", "contributes", "to", "increased", "cellular", "proliferation", "in", "part", "by", "inducing", "cyclin", "D2", "expression", ".", "To", "identify", "regulators", "of", "c", "-", "maf", ",", "we", "developed", "a", "chemical", "screen", "in", "NIH3T3", "cells", "stably", "overexpressing", "c", "-", "maf", "and", "the", "cyclin", "D2", "promoter", "driving", "luciferase", ".", "From", "a", "screen", "of", "2400", "off", "-", "patent", "drugs", "and", "chemicals", ",", "we", "identified", "glucocorticoids", "as", "c", "-", "maf", "-", "dependent", "inhibitors", "of", "cyclin", "D2", "transactivation", ".", "In", "multiple", "myeloma", "cell", "lines", ",", "glucocorticoids", "reduced", "levels", "of", "c", "-", "maf", "protein", "without", "influencing", "corresponding", "mRNA", "levels", ".", "Subsequent", "studies", "demonstrated", "that", "glucocorticoids", "increased", "ubiquitination", "-", "dependent", "degradation", "of", "c", "-", "maf", "and", "up", "-", "regulated", "ubiquitin", "C", "mRNA", ".", "Moreover", ",", "ectopic", "expression", "of", "ubiquitin", "C", "recapitulated", "the", "effects", "of", "glucocorticoids", ",", "demonstrating", "regulation", "of", "c", "-", "maf", "protein", "through", "the", "abundance", "of", "the", "ubiquitin", "substrate", ".", "Thus", ",", "using", "a", "chemical", "biology", "approach", ",", "we", "identified", "a", "novel", "mechanism", "of", "action", "of", "glucocorticoids", "and", "a", "novel", "mechanism", "by", "which", "levels", "of", "c", "-", "maf", "protein", "are", "regulated", "by", "the", "abundance", "of", "the", "ubiquitin", "substrate", ".", "\n" ]

[ "Protein" ]

c - maf is a Protein, ubiquitin is a Protein, c - maf is a Protein, cyclin D2 is a Protein, c - maf is a Protein, c - maf is a Protein, cyclin D2 is a Protein, luciferase is a Protein, c - maf is a Protein, cyclin D2 is a Protein, c - maf is a Protein, c - maf is a Protein, ubiquitin C is a Protein, ubiquitin C is a Protein, c - maf is a Protein, ubiquitin is a Protein, c - maf is a Protein, ubiquitin is a Protein

262_task1

Sentence: A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. The oncogene c-maf is frequently overexpressed in multiple myeloma cell lines and patient samples and contributes to increased cellular proliferation in part by inducing cyclin D2 expression. To identify regulators of c-maf, we developed a chemical screen in NIH3T3 cells stably overexpressing c-maf and the cyclin D2 promoter driving luciferase. From a screen of 2400 off-patent drugs and chemicals, we identified glucocorticoids as c-maf-dependent inhibitors of cyclin D2 transactivation. In multiple myeloma cell lines, glucocorticoids reduced levels of c-maf protein without influencing corresponding mRNA levels. Subsequent studies demonstrated that glucocorticoids increased ubiquitination-dependent degradation of c-maf and up-regulated ubiquitin C mRNA. Moreover, ectopic expression of ubiquitin C recapitulated the effects of glucocorticoids, demonstrating regulation of c-maf protein through the abundance of the ubiquitin substrate. Thus, using a chemical biology approach, we identified a novel mechanism of action of glucocorticoids and a novel mechanism by which levels of c-maf protein are regulated by the abundance of the ubiquitin substrate. Instructions: please typing these entity words according to sentence: c - maf, ubiquitin, c - maf, cyclin D2, c - maf, c - maf, cyclin D2, luciferase, c - maf, cyclin D2, c - maf, c - maf, ubiquitin C, ubiquitin C, c - maf, ubiquitin, c - maf, ubiquitin Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O" ]

A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. The oncogene c-maf is frequently overexpressed in multiple myeloma cell lines and patient samples and contributes to increased cellular proliferation in part by inducing cyclin D2 expression. To identify regulators of c-maf, we developed a chemical screen in NIH3T3 cells stably overexpressing c-maf and the cyclin D2 promoter driving luciferase. From a screen of 2400 off-patent drugs and chemicals, we identified glucocorticoids as c-maf-dependent inhibitors of cyclin D2 transactivation. In multiple myeloma cell lines, glucocorticoids reduced levels of c-maf protein without influencing corresponding mRNA levels. Subsequent studies demonstrated that glucocorticoids increased ubiquitination-dependent degradation of c-maf and up-regulated ubiquitin C mRNA. Moreover, ectopic expression of ubiquitin C recapitulated the effects of glucocorticoids, demonstrating regulation of c-maf protein through the abundance of the ubiquitin substrate. Thus, using a chemical biology approach, we identified a novel mechanism of action of glucocorticoids and a novel mechanism by which levels of c-maf protein are regulated by the abundance of the ubiquitin substrate.

[ "A", "chemical", "biology", "screen", "identifies", "glucocorticoids", "that", "regulate", "c", "-", "maf", "expression", "by", "increasing", "its", "proteasomal", "degradation", "through", "up", "-", "regulation", "of", "ubiquitin", ".", "\n", "The", "oncogene", "c", "-", "maf", "is", "frequently", "overexpressed", "in", "multiple", "myeloma", "cell", "lines", "and", "patient", "samples", "and", "contributes", "to", "increased", "cellular", "proliferation", "in", "part", "by", "inducing", "cyclin", "D2", "expression", ".", "To", "identify", "regulators", "of", "c", "-", "maf", ",", "we", "developed", "a", "chemical", "screen", "in", "NIH3T3", "cells", "stably", "overexpressing", "c", "-", "maf", "and", "the", "cyclin", "D2", "promoter", "driving", "luciferase", ".", "From", "a", "screen", "of", "2400", "off", "-", "patent", "drugs", "and", "chemicals", ",", "we", "identified", "glucocorticoids", "as", "c", "-", "maf", "-", "dependent", "inhibitors", "of", "cyclin", "D2", "transactivation", ".", "In", "multiple", "myeloma", "cell", "lines", ",", "glucocorticoids", "reduced", "levels", "of", "c", "-", "maf", "protein", "without", "influencing", "corresponding", "mRNA", "levels", ".", "Subsequent", "studies", "demonstrated", "that", "glucocorticoids", "increased", "ubiquitination", "-", "dependent", "degradation", "of", "c", "-", "maf", "and", "up", "-", "regulated", "ubiquitin", "C", "mRNA", ".", "Moreover", ",", "ectopic", "expression", "of", "ubiquitin", "C", "recapitulated", "the", "effects", "of", "glucocorticoids", ",", "demonstrating", "regulation", "of", "c", "-", "maf", "protein", "through", "the", "abundance", "of", "the", "ubiquitin", "substrate", ".", "Thus", ",", "using", "a", "chemical", "biology", "approach", ",", "we", "identified", "a", "novel", "mechanism", "of", "action", "of", "glucocorticoids", "and", "a", "novel", "mechanism", "by", "which", "levels", "of", "c", "-", "maf", "protein", "are", "regulated", "by", "the", "abundance", "of", "the", "ubiquitin", "substrate", ".", "\n" ]

[ "Protein" ]

c - maf, ubiquitin, c - maf, cyclin D2, c - maf, c - maf, cyclin D2, luciferase, c - maf, cyclin D2, c - maf, c - maf, ubiquitin C, ubiquitin C, c - maf, ubiquitin, c - maf, ubiquitin

262_task2

Sentence: A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. The oncogene c-maf is frequently overexpressed in multiple myeloma cell lines and patient samples and contributes to increased cellular proliferation in part by inducing cyclin D2 expression. To identify regulators of c-maf, we developed a chemical screen in NIH3T3 cells stably overexpressing c-maf and the cyclin D2 promoter driving luciferase. From a screen of 2400 off-patent drugs and chemicals, we identified glucocorticoids as c-maf-dependent inhibitors of cyclin D2 transactivation. In multiple myeloma cell lines, glucocorticoids reduced levels of c-maf protein without influencing corresponding mRNA levels. Subsequent studies demonstrated that glucocorticoids increased ubiquitination-dependent degradation of c-maf and up-regulated ubiquitin C mRNA. Moreover, ectopic expression of ubiquitin C recapitulated the effects of glucocorticoids, demonstrating regulation of c-maf protein through the abundance of the ubiquitin substrate. Thus, using a chemical biology approach, we identified a novel mechanism of action of glucocorticoids and a novel mechanism by which levels of c-maf protein are regulated by the abundance of the ubiquitin substrate. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O" ]

A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. The oncogene c-maf is frequently overexpressed in multiple myeloma cell lines and patient samples and contributes to increased cellular proliferation in part by inducing cyclin D2 expression. To identify regulators of c-maf, we developed a chemical screen in NIH3T3 cells stably overexpressing c-maf and the cyclin D2 promoter driving luciferase. From a screen of 2400 off-patent drugs and chemicals, we identified glucocorticoids as c-maf-dependent inhibitors of cyclin D2 transactivation. In multiple myeloma cell lines, glucocorticoids reduced levels of c-maf protein without influencing corresponding mRNA levels. Subsequent studies demonstrated that glucocorticoids increased ubiquitination-dependent degradation of c-maf and up-regulated ubiquitin C mRNA. Moreover, ectopic expression of ubiquitin C recapitulated the effects of glucocorticoids, demonstrating regulation of c-maf protein through the abundance of the ubiquitin substrate. Thus, using a chemical biology approach, we identified a novel mechanism of action of glucocorticoids and a novel mechanism by which levels of c-maf protein are regulated by the abundance of the ubiquitin substrate.

[ "A", "chemical", "biology", "screen", "identifies", "glucocorticoids", "that", "regulate", "c", "-", "maf", "expression", "by", "increasing", "its", "proteasomal", "degradation", "through", "up", "-", "regulation", "of", "ubiquitin", ".", "\n", "The", "oncogene", "c", "-", "maf", "is", "frequently", "overexpressed", "in", "multiple", "myeloma", "cell", "lines", "and", "patient", "samples", "and", "contributes", "to", "increased", "cellular", "proliferation", "in", "part", "by", "inducing", "cyclin", "D2", "expression", ".", "To", "identify", "regulators", "of", "c", "-", "maf", ",", "we", "developed", "a", "chemical", "screen", "in", "NIH3T3", "cells", "stably", "overexpressing", "c", "-", "maf", "and", "the", "cyclin", "D2", "promoter", "driving", "luciferase", ".", "From", "a", "screen", "of", "2400", "off", "-", "patent", "drugs", "and", "chemicals", ",", "we", "identified", "glucocorticoids", "as", "c", "-", "maf", "-", "dependent", "inhibitors", "of", "cyclin", "D2", "transactivation", ".", "In", "multiple", "myeloma", "cell", "lines", ",", "glucocorticoids", "reduced", "levels", "of", "c", "-", "maf", "protein", "without", "influencing", "corresponding", "mRNA", "levels", ".", "Subsequent", "studies", "demonstrated", "that", "glucocorticoids", "increased", "ubiquitination", "-", "dependent", "degradation", "of", "c", "-", "maf", "and", "up", "-", "regulated", "ubiquitin", "C", "mRNA", ".", "Moreover", ",", "ectopic", "expression", "of", "ubiquitin", "C", "recapitulated", "the", "effects", "of", "glucocorticoids", ",", "demonstrating", "regulation", "of", "c", "-", "maf", "protein", "through", "the", "abundance", "of", "the", "ubiquitin", "substrate", ".", "Thus", ",", "using", "a", "chemical", "biology", "approach", ",", "we", "identified", "a", "novel", "mechanism", "of", "action", "of", "glucocorticoids", "and", "a", "novel", "mechanism", "by", "which", "levels", "of", "c", "-", "maf", "protein", "are", "regulated", "by", "the", "abundance", "of", "the", "ubiquitin", "substrate", ".", "\n" ]

[ "Protein" ]

GSK-3β is a protein, β - catenin is a protein, Axin is a protein

1.0alpha7.train.277_task0

Sentence: In this study, we identified binding domains of GSK-3β and β-catenin in Axin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "I-protein", "I-protein", "O", "B-protein", "O" ]

In this study, we identified binding domains of GSK-3β and β-catenin in Axin.

[ "In", "this", "study", ",", "we", "identified", "binding", "domains", "of", "GSK-3β", "and", "β", "-", "catenin", "in", "Axin", "." ]

[ "protein" ]

GSK-3β is a protein, β - catenin is a protein, Axin is a protein

1.0alpha7.train.277_task1

Sentence: In this study, we identified binding domains of GSK-3β and β-catenin in Axin. Instructions: please typing these entity words according to sentence: GSK-3β, β - catenin, Axin Options: protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "I-protein", "I-protein", "O", "B-protein", "O" ]

In this study, we identified binding domains of GSK-3β and β-catenin in Axin.

[ "In", "this", "study", ",", "we", "identified", "binding", "domains", "of", "GSK-3β", "and", "β", "-", "catenin", "in", "Axin", "." ]

[ "protein" ]

GSK-3β, β - catenin, Axin

1.0alpha7.train.277_task2

Sentence: In this study, we identified binding domains of GSK-3β and β-catenin in Axin. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "I-protein", "I-protein", "O", "B-protein", "O" ]

In this study, we identified binding domains of GSK-3β and β-catenin in Axin.

[ "In", "this", "study", ",", "we", "identified", "binding", "domains", "of", "GSK-3β", "and", "β", "-", "catenin", "in", "Axin", "." ]

[ "protein" ]

haemagglutinin - neuraminidase is a Protein, haemagglutinin - neuraminidase is a Protein, HN is a Protein, HN is a Protein, HN is a Protein, HN is a Protein, N - linked glycosylation sites is a Entity, HN is a Protein

107_task0

Sentence: Inhibition of fusion by neutralizing monoclonal antibodies to the haemagglutinin-neuraminidase glycoprotein of Newcastle disease virus. The majority of neutralizing monoclonal antibodies (MAbs) to the haemagglutinin-neuraminidase (HN) glycoprotein of Newcastle disease virus prevent attachment of the virus to cellular receptors and inhibits virion-induced fusion from without (FFWO) and fusion from within (FFWI) mediated by the virus glycoprotein-laden infected cell surface. For these antibodies, the inhibition of fusion is presumed to be the result of the prevention of HN-mediated bridging of potential fusion partners. MAbs against antigenic sites 3 and 4 neutralize virus infectivity, but by a mechanism other than the prevention of attachment, the exact nature of which remains to be established. Antibodies to both of these sites effectively inhibit virion-induced FFWO, even when the inducing virus is not infectious. This is consistent with the mechanism of neutralization of these MAbs involving the inhibition of an early, post-attachment step in infection. MAbs to site 3 also inhibit FFWI, but those to site 4 do not, even when added at high concentrations. This suggests that the requirement for HN may be different in the two modes of fusion. The epitopes recognized by MAbs to sites 3 and 4 have been delineated by the identification of individual nucleotide substitutions in the HN genes of neutralization escape variants. Some of the deduced amino acid substitutions result in additional N-linked glycosylation sites in HN, which are utilized and presumably account for the escape from neutralization. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Inhibition of fusion by neutralizing monoclonal antibodies to the haemagglutinin-neuraminidase glycoprotein of Newcastle disease virus. The majority of neutralizing monoclonal antibodies (MAbs) to the haemagglutinin-neuraminidase (HN) glycoprotein of Newcastle disease virus prevent attachment of the virus to cellular receptors and inhibits virion-induced fusion from without (FFWO) and fusion from within (FFWI) mediated by the virus glycoprotein-laden infected cell surface. For these antibodies, the inhibition of fusion is presumed to be the result of the prevention of HN-mediated bridging of potential fusion partners. MAbs against antigenic sites 3 and 4 neutralize virus infectivity, but by a mechanism other than the prevention of attachment, the exact nature of which remains to be established. Antibodies to both of these sites effectively inhibit virion-induced FFWO, even when the inducing virus is not infectious. This is consistent with the mechanism of neutralization of these MAbs involving the inhibition of an early, post-attachment step in infection. MAbs to site 3 also inhibit FFWI, but those to site 4 do not, even when added at high concentrations. This suggests that the requirement for HN may be different in the two modes of fusion. The epitopes recognized by MAbs to sites 3 and 4 have been delineated by the identification of individual nucleotide substitutions in the HN genes of neutralization escape variants. Some of the deduced amino acid substitutions result in additional N-linked glycosylation sites in HN, which are utilized and presumably account for the escape from neutralization.

[ "Inhibition", "of", "fusion", "by", "neutralizing", "monoclonal", "antibodies", "to", "the", "haemagglutinin", "-", "neuraminidase", "glycoprotein", "of", "Newcastle", "disease", "virus", ".", "\n", "The", "majority", "of", "neutralizing", "monoclonal", "antibodies", "(", "MAbs", ")", "to", "the", "haemagglutinin", "-", "neuraminidase", "(", "HN", ")", "glycoprotein", "of", "Newcastle", "disease", "virus", "prevent", "attachment", "of", "the", "virus", "to", "cellular", "receptors", "and", "inhibits", "virion", "-", "induced", "fusion", "from", "without", "(", "FFWO", ")", "and", "fusion", "from", "within", "(", "FFWI", ")", "mediated", "by", "the", "virus", "glycoprotein", "-", "laden", "infected", "cell", "surface", ".", "For", "these", "antibodies", ",", "the", "inhibition", "of", "fusion", "is", "presumed", "to", "be", "the", "result", "of", "the", "prevention", "of", "HN", "-", "mediated", "bridging", "of", "potential", "fusion", "partners", ".", "MAbs", "against", "antigenic", "sites", "3", "and", "4", "neutralize", "virus", "infectivity", ",", "but", "by", "a", "mechanism", "other", "than", "the", "prevention", "of", "attachment", ",", "the", "exact", "nature", "of", "which", "remains", "to", "be", "established", ".", "Antibodies", "to", "both", "of", "these", "sites", "effectively", "inhibit", "virion", "-", "induced", "FFWO", ",", "even", "when", "the", "inducing", "virus", "is", "not", "infectious", ".", "This", "is", "consistent", "with", "the", "mechanism", "of", "neutralization", "of", "these", "MAbs", "involving", "the", "inhibition", "of", "an", "early", ",", "post", "-", "attachment", "step", "in", "infection", ".", "MAbs", "to", "site", "3", "also", "inhibit", "FFWI", ",", "but", "those", "to", "site", "4", "do", "not", ",", "even", "when", "added", "at", "high", "concentrations", ".", "This", "suggests", "that", "the", "requirement", "for", "HN", "may", "be", "different", "in", "the", "two", "modes", "of", "fusion", ".", "The", "epitopes", "recognized", "by", "MAbs", "to", "sites", "3", "and", "4", "have", "been", "delineated", "by", "the", "identification", "of", "individual", "nucleotide", "substitutions", "in", "the", "HN", "genes", "of", "neutralization", "escape", "variants", ".", "Some", "of", "the", "deduced", "amino", "acid", "substitutions", "result", "in", "additional", "N", "-", "linked", "glycosylation", "sites", "in", "HN", ",", "which", "are", "utilized", "and", "presumably", "account", "for", "the", "escape", "from", "neutralization", ".", "\n" ]

[ "Protein", "Entity" ]

haemagglutinin - neuraminidase is a Protein, haemagglutinin - neuraminidase is a Protein, HN is a Protein, HN is a Protein, HN is a Protein, HN is a Protein, N - linked glycosylation sites is a Entity, HN is a Protein

107_task1

Sentence: Inhibition of fusion by neutralizing monoclonal antibodies to the haemagglutinin-neuraminidase glycoprotein of Newcastle disease virus. The majority of neutralizing monoclonal antibodies (MAbs) to the haemagglutinin-neuraminidase (HN) glycoprotein of Newcastle disease virus prevent attachment of the virus to cellular receptors and inhibits virion-induced fusion from without (FFWO) and fusion from within (FFWI) mediated by the virus glycoprotein-laden infected cell surface. For these antibodies, the inhibition of fusion is presumed to be the result of the prevention of HN-mediated bridging of potential fusion partners. MAbs against antigenic sites 3 and 4 neutralize virus infectivity, but by a mechanism other than the prevention of attachment, the exact nature of which remains to be established. Antibodies to both of these sites effectively inhibit virion-induced FFWO, even when the inducing virus is not infectious. This is consistent with the mechanism of neutralization of these MAbs involving the inhibition of an early, post-attachment step in infection. MAbs to site 3 also inhibit FFWI, but those to site 4 do not, even when added at high concentrations. This suggests that the requirement for HN may be different in the two modes of fusion. The epitopes recognized by MAbs to sites 3 and 4 have been delineated by the identification of individual nucleotide substitutions in the HN genes of neutralization escape variants. Some of the deduced amino acid substitutions result in additional N-linked glycosylation sites in HN, which are utilized and presumably account for the escape from neutralization. Instructions: please typing these entity words according to sentence: haemagglutinin - neuraminidase, haemagglutinin - neuraminidase, HN, HN, HN, HN, N - linked glycosylation sites, HN Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Inhibition of fusion by neutralizing monoclonal antibodies to the haemagglutinin-neuraminidase glycoprotein of Newcastle disease virus. The majority of neutralizing monoclonal antibodies (MAbs) to the haemagglutinin-neuraminidase (HN) glycoprotein of Newcastle disease virus prevent attachment of the virus to cellular receptors and inhibits virion-induced fusion from without (FFWO) and fusion from within (FFWI) mediated by the virus glycoprotein-laden infected cell surface. For these antibodies, the inhibition of fusion is presumed to be the result of the prevention of HN-mediated bridging of potential fusion partners. MAbs against antigenic sites 3 and 4 neutralize virus infectivity, but by a mechanism other than the prevention of attachment, the exact nature of which remains to be established. Antibodies to both of these sites effectively inhibit virion-induced FFWO, even when the inducing virus is not infectious. This is consistent with the mechanism of neutralization of these MAbs involving the inhibition of an early, post-attachment step in infection. MAbs to site 3 also inhibit FFWI, but those to site 4 do not, even when added at high concentrations. This suggests that the requirement for HN may be different in the two modes of fusion. The epitopes recognized by MAbs to sites 3 and 4 have been delineated by the identification of individual nucleotide substitutions in the HN genes of neutralization escape variants. Some of the deduced amino acid substitutions result in additional N-linked glycosylation sites in HN, which are utilized and presumably account for the escape from neutralization.

[ "Inhibition", "of", "fusion", "by", "neutralizing", "monoclonal", "antibodies", "to", "the", "haemagglutinin", "-", "neuraminidase", "glycoprotein", "of", "Newcastle", "disease", "virus", ".", "\n", "The", "majority", "of", "neutralizing", "monoclonal", "antibodies", "(", "MAbs", ")", "to", "the", "haemagglutinin", "-", "neuraminidase", "(", "HN", ")", "glycoprotein", "of", "Newcastle", "disease", "virus", "prevent", "attachment", "of", "the", "virus", "to", "cellular", "receptors", "and", "inhibits", "virion", "-", "induced", "fusion", "from", "without", "(", "FFWO", ")", "and", "fusion", "from", "within", "(", "FFWI", ")", "mediated", "by", "the", "virus", "glycoprotein", "-", "laden", "infected", "cell", "surface", ".", "For", "these", "antibodies", ",", "the", "inhibition", "of", "fusion", "is", "presumed", "to", "be", "the", "result", "of", "the", "prevention", "of", "HN", "-", "mediated", "bridging", "of", "potential", "fusion", "partners", ".", "MAbs", "against", "antigenic", "sites", "3", "and", "4", "neutralize", "virus", "infectivity", ",", "but", "by", "a", "mechanism", "other", "than", "the", "prevention", "of", "attachment", ",", "the", "exact", "nature", "of", "which", "remains", "to", "be", "established", ".", "Antibodies", "to", "both", "of", "these", "sites", "effectively", "inhibit", "virion", "-", "induced", "FFWO", ",", "even", "when", "the", "inducing", "virus", "is", "not", "infectious", ".", "This", "is", "consistent", "with", "the", "mechanism", "of", "neutralization", "of", "these", "MAbs", "involving", "the", "inhibition", "of", "an", "early", ",", "post", "-", "attachment", "step", "in", "infection", ".", "MAbs", "to", "site", "3", "also", "inhibit", "FFWI", ",", "but", "those", "to", "site", "4", "do", "not", ",", "even", "when", "added", "at", "high", "concentrations", ".", "This", "suggests", "that", "the", "requirement", "for", "HN", "may", "be", "different", "in", "the", "two", "modes", "of", "fusion", ".", "The", "epitopes", "recognized", "by", "MAbs", "to", "sites", "3", "and", "4", "have", "been", "delineated", "by", "the", "identification", "of", "individual", "nucleotide", "substitutions", "in", "the", "HN", "genes", "of", "neutralization", "escape", "variants", ".", "Some", "of", "the", "deduced", "amino", "acid", "substitutions", "result", "in", "additional", "N", "-", "linked", "glycosylation", "sites", "in", "HN", ",", "which", "are", "utilized", "and", "presumably", "account", "for", "the", "escape", "from", "neutralization", ".", "\n" ]

[ "Protein", "Entity" ]

haemagglutinin - neuraminidase, haemagglutinin - neuraminidase, HN, HN, HN, HN, N - linked glycosylation sites, HN

107_task2

Sentence: Inhibition of fusion by neutralizing monoclonal antibodies to the haemagglutinin-neuraminidase glycoprotein of Newcastle disease virus. The majority of neutralizing monoclonal antibodies (MAbs) to the haemagglutinin-neuraminidase (HN) glycoprotein of Newcastle disease virus prevent attachment of the virus to cellular receptors and inhibits virion-induced fusion from without (FFWO) and fusion from within (FFWI) mediated by the virus glycoprotein-laden infected cell surface. For these antibodies, the inhibition of fusion is presumed to be the result of the prevention of HN-mediated bridging of potential fusion partners. MAbs against antigenic sites 3 and 4 neutralize virus infectivity, but by a mechanism other than the prevention of attachment, the exact nature of which remains to be established. Antibodies to both of these sites effectively inhibit virion-induced FFWO, even when the inducing virus is not infectious. This is consistent with the mechanism of neutralization of these MAbs involving the inhibition of an early, post-attachment step in infection. MAbs to site 3 also inhibit FFWI, but those to site 4 do not, even when added at high concentrations. This suggests that the requirement for HN may be different in the two modes of fusion. The epitopes recognized by MAbs to sites 3 and 4 have been delineated by the identification of individual nucleotide substitutions in the HN genes of neutralization escape variants. Some of the deduced amino acid substitutions result in additional N-linked glycosylation sites in HN, which are utilized and presumably account for the escape from neutralization. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Inhibition of fusion by neutralizing monoclonal antibodies to the haemagglutinin-neuraminidase glycoprotein of Newcastle disease virus. The majority of neutralizing monoclonal antibodies (MAbs) to the haemagglutinin-neuraminidase (HN) glycoprotein of Newcastle disease virus prevent attachment of the virus to cellular receptors and inhibits virion-induced fusion from without (FFWO) and fusion from within (FFWI) mediated by the virus glycoprotein-laden infected cell surface. For these antibodies, the inhibition of fusion is presumed to be the result of the prevention of HN-mediated bridging of potential fusion partners. MAbs against antigenic sites 3 and 4 neutralize virus infectivity, but by a mechanism other than the prevention of attachment, the exact nature of which remains to be established. Antibodies to both of these sites effectively inhibit virion-induced FFWO, even when the inducing virus is not infectious. This is consistent with the mechanism of neutralization of these MAbs involving the inhibition of an early, post-attachment step in infection. MAbs to site 3 also inhibit FFWI, but those to site 4 do not, even when added at high concentrations. This suggests that the requirement for HN may be different in the two modes of fusion. The epitopes recognized by MAbs to sites 3 and 4 have been delineated by the identification of individual nucleotide substitutions in the HN genes of neutralization escape variants. Some of the deduced amino acid substitutions result in additional N-linked glycosylation sites in HN, which are utilized and presumably account for the escape from neutralization.

[ "Inhibition", "of", "fusion", "by", "neutralizing", "monoclonal", "antibodies", "to", "the", "haemagglutinin", "-", "neuraminidase", "glycoprotein", "of", "Newcastle", "disease", "virus", ".", "\n", "The", "majority", "of", "neutralizing", "monoclonal", "antibodies", "(", "MAbs", ")", "to", "the", "haemagglutinin", "-", "neuraminidase", "(", "HN", ")", "glycoprotein", "of", "Newcastle", "disease", "virus", "prevent", "attachment", "of", "the", "virus", "to", "cellular", "receptors", "and", "inhibits", "virion", "-", "induced", "fusion", "from", "without", "(", "FFWO", ")", "and", "fusion", "from", "within", "(", "FFWI", ")", "mediated", "by", "the", "virus", "glycoprotein", "-", "laden", "infected", "cell", "surface", ".", "For", "these", "antibodies", ",", "the", "inhibition", "of", "fusion", "is", "presumed", "to", "be", "the", "result", "of", "the", "prevention", "of", "HN", "-", "mediated", "bridging", "of", "potential", "fusion", "partners", ".", "MAbs", "against", "antigenic", "sites", "3", "and", "4", "neutralize", "virus", "infectivity", ",", "but", "by", "a", "mechanism", "other", "than", "the", "prevention", "of", "attachment", ",", "the", "exact", "nature", "of", "which", "remains", "to", "be", "established", ".", "Antibodies", "to", "both", "of", "these", "sites", "effectively", "inhibit", "virion", "-", "induced", "FFWO", ",", "even", "when", "the", "inducing", "virus", "is", "not", "infectious", ".", "This", "is", "consistent", "with", "the", "mechanism", "of", "neutralization", "of", "these", "MAbs", "involving", "the", "inhibition", "of", "an", "early", ",", "post", "-", "attachment", "step", "in", "infection", ".", "MAbs", "to", "site", "3", "also", "inhibit", "FFWI", ",", "but", "those", "to", "site", "4", "do", "not", ",", "even", "when", "added", "at", "high", "concentrations", ".", "This", "suggests", "that", "the", "requirement", "for", "HN", "may", "be", "different", "in", "the", "two", "modes", "of", "fusion", ".", "The", "epitopes", "recognized", "by", "MAbs", "to", "sites", "3", "and", "4", "have", "been", "delineated", "by", "the", "identification", "of", "individual", "nucleotide", "substitutions", "in", "the", "HN", "genes", "of", "neutralization", "escape", "variants", ".", "Some", "of", "the", "deduced", "amino", "acid", "substitutions", "result", "in", "additional", "N", "-", "linked", "glycosylation", "sites", "in", "HN", ",", "which", "are", "utilized", "and", "presumably", "account", "for", "the", "escape", "from", "neutralization", ".", "\n" ]

[ "Protein", "Entity" ]

FKBP52 is a protein, dynein is a protein-family, dynein is a protein-family, FKBP52 is a protein, PPIase is a protein-domain, TPR is a protein-domain, FKBP52 is a protein, hsp90 is a protein

1.0alpha7.train.642_task0

Sentence: Immunoadsorption of FKBP52 from reticulocyte lysate also yields co-immunoadsorption of cytoplasmic dynein, and we show that co-immunoadsorption of dynein is competed by a fragment of FKBP52 containing its PPIase domain, but not by a TPR domain fragment that blocks FKBP52 binding to hsp90. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-domain, protein-family, protein

[ "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein-domain", "O", "O", "O", "O", "O", "O", "B-protein-domain", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O" ]

Immunoadsorption of FKBP52 from reticulocyte lysate also yields co-immunoadsorption of cytoplasmic dynein, and we show that co-immunoadsorption of dynein is competed by a fragment of FKBP52 containing its PPIase domain, but not by a TPR domain fragment that blocks FKBP52 binding to hsp90.

[ "Immunoadsorption", "of", "FKBP52", "from", "reticulocyte", "lysate", "also", "yields", "co", "-", "immunoadsorption", "of", "cytoplasmic", "dynein", ",", "and", "we", "show", "that", "co", "-", "immunoadsorption", "of", "dynein", "is", "competed", "by", "a", "fragment", "of", "FKBP52", "containing", "its", "PPIase", "domain", ",", "but", "not", "by", "a", "TPR", "domain", "fragment", "that", "blocks", "FKBP52", "binding", "to", "hsp90", "." ]

[ "protein", "protein-family", "protein-domain" ]

FKBP52 is a protein, dynein is a protein-family, dynein is a protein-family, FKBP52 is a protein, PPIase is a protein-domain, TPR is a protein-domain, FKBP52 is a protein, hsp90 is a protein

1.0alpha7.train.642_task1

Sentence: Immunoadsorption of FKBP52 from reticulocyte lysate also yields co-immunoadsorption of cytoplasmic dynein, and we show that co-immunoadsorption of dynein is competed by a fragment of FKBP52 containing its PPIase domain, but not by a TPR domain fragment that blocks FKBP52 binding to hsp90. Instructions: please typing these entity words according to sentence: FKBP52, dynein, dynein, FKBP52, PPIase, TPR, FKBP52, hsp90 Options: protein-domain, protein-family, protein

[ "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein-domain", "O", "O", "O", "O", "O", "O", "B-protein-domain", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O" ]

Immunoadsorption of FKBP52 from reticulocyte lysate also yields co-immunoadsorption of cytoplasmic dynein, and we show that co-immunoadsorption of dynein is competed by a fragment of FKBP52 containing its PPIase domain, but not by a TPR domain fragment that blocks FKBP52 binding to hsp90.

[ "Immunoadsorption", "of", "FKBP52", "from", "reticulocyte", "lysate", "also", "yields", "co", "-", "immunoadsorption", "of", "cytoplasmic", "dynein", ",", "and", "we", "show", "that", "co", "-", "immunoadsorption", "of", "dynein", "is", "competed", "by", "a", "fragment", "of", "FKBP52", "containing", "its", "PPIase", "domain", ",", "but", "not", "by", "a", "TPR", "domain", "fragment", "that", "blocks", "FKBP52", "binding", "to", "hsp90", "." ]

[ "protein", "protein-family", "protein-domain" ]

FKBP52, dynein, dynein, FKBP52, PPIase, TPR, FKBP52, hsp90

1.0alpha7.train.642_task2

Sentence: Immunoadsorption of FKBP52 from reticulocyte lysate also yields co-immunoadsorption of cytoplasmic dynein, and we show that co-immunoadsorption of dynein is competed by a fragment of FKBP52 containing its PPIase domain, but not by a TPR domain fragment that blocks FKBP52 binding to hsp90. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein-domain", "O", "O", "O", "O", "O", "O", "B-protein-domain", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O" ]

Immunoadsorption of FKBP52 from reticulocyte lysate also yields co-immunoadsorption of cytoplasmic dynein, and we show that co-immunoadsorption of dynein is competed by a fragment of FKBP52 containing its PPIase domain, but not by a TPR domain fragment that blocks FKBP52 binding to hsp90.

[ "Immunoadsorption", "of", "FKBP52", "from", "reticulocyte", "lysate", "also", "yields", "co", "-", "immunoadsorption", "of", "cytoplasmic", "dynein", ",", "and", "we", "show", "that", "co", "-", "immunoadsorption", "of", "dynein", "is", "competed", "by", "a", "fragment", "of", "FKBP52", "containing", "its", "PPIase", "domain", ",", "but", "not", "by", "a", "TPR", "domain", "fragment", "that", "blocks", "FKBP52", "binding", "to", "hsp90", "." ]

[ "protein", "protein-family", "protein-domain" ]

5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone is a CHEMICAL, nitric oxide is a CHEMICAL, NF - κB is a GENE-N, heme oxygenase-1 is a GENE-Y, 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone is a CHEMICAL, 5HHMF is a CHEMICAL, NO is a CHEMICAL, inducible NO synthase is a GENE-Y, iNOS is a GENE-Y, 5HHMF is a CHEMICAL, IκB is a GENE-N, nuclear factor - κB is a GENE-N, NF - κB is a GENE-N, p65 is a GENE-Y, p50 is a GENE-Y, iNOS is a GENE-Y, Pyrrolidine dithiocarbamate is a CHEMICAL, PDTC is a CHEMICAL, NF - κB is a GENE-N, 20S proteasome is a GENE-N, iNOS is a GENE-Y, 5HHMF is a CHEMICAL, iNOS is a GENE-Y, NF - κB is a GENE-N, 5HHMF is a CHEMICAL, heme oxygenase-1 is a GENE-Y, HO-1 is a GENE-Y, nuclear factor - erythroid 2-related factor 2 is a GENE-Y, Nrf2 is a GENE-Y, cobalt protoporphyrin is a CHEMICAL, CoPP is a CHEMICAL, HO-1 is a GENE-Y, NO is a CHEMICAL, zinc protoporphyrin is a CHEMICAL, ZnPP is a CHEMICAL, HO-1 is a GENE-Y, 5HHMF is a CHEMICAL, NO is a CHEMICAL, 5HHMF is a CHEMICAL, Nrf2 is a GENE-Y, Nrf2 is a GENE-Y, 5HHMF is a CHEMICAL, NO is a CHEMICAL, HO-1 is a GENE-Y, 5HHMF is a CHEMICAL, NO is a CHEMICAL, iNOS is a GENE-Y, NF - κB is a GENE-N, HO-1 is a GENE-Y

17897_task0

Sentence: 5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and Nrf-2-dependent heme oxygenase-1 induction. In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (iNOS) in BV2 microglia. In addition, 5HHMF blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of nuclear factor-κB (NF-κB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression. Pyrrolidine dithiocarbamate (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity. Thus, we found that 5HHMF enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation. In addition, cobalt protoporphyrin (CoPP), a specific HO-1 inducer, predominantly suppressed LPS-induced NO production. In contrast, zinc protoporphyrin (ZnPP), a specific HO-1 inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production. Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity. Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-κB activity and induction of Nrf2-dependent HO-1 activity. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL

[ "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O" ]

5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and Nrf-2-dependent heme oxygenase-1 induction. In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (iNOS) in BV2 microglia. In addition, 5HHMF blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of nuclear factor-κB (NF-κB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression. Pyrrolidine dithiocarbamate (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity. Thus, we found that 5HHMF enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation. In addition, cobalt protoporphyrin (CoPP), a specific HO-1 inducer, predominantly suppressed LPS-induced NO production. In contrast, zinc protoporphyrin (ZnPP), a specific HO-1 inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production. Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity. Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-κB activity and induction of Nrf2-dependent HO-1 activity.

[ "5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone", "inhibits", "nitric", "oxide", "production", "in", "lipopolysaccharide", "-", "stimulated", "BV2", "microglia", "via", "NF", "-", "κB", "suppression", "and", "Nrf-2-dependent", "heme", "oxygenase-1", "induction", ".", "\n", "In", "this", "study", ",", "we", "found", "that", "5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone", "(", "5HHMF", ")", "from", "Hizikia", "fusiforme", "considerably", "inhibits", "lipopolysaccharide", "(", "LPS)-stimulated", "NO", "production", "by", "suppressing", "the", "expression", "of", "inducible", "NO", "synthase", "(", "iNOS", ")", "in", "BV2", "microglia", ".", "In", "addition", ",", "5HHMF", "blocked", "LPS", "-", "induced", "phosphorylation", "of", "IκB", ",", "resulting", "in", "suppression", "of", "the", "nuclear", "translocation", "of", "nuclear", "factor", "-", "κB", "(", "NF", "-", "κB", ")", "subunits", ",", "namely", "p65", "and", "p50", ",", "which", "are", "important", "molecules", "involved", "in", "the", "regulation", "of", "iNOS", "expression", ".", "Pyrrolidine", "dithiocarbamate", "(", "PDTC", ")", ",", "a", "specific", "NF", "-", "κB", "inhibitor", ",", "along", "with", "20S", "proteasome", "inhibitor", "(", "PSI", ")", "significantly", "inhibited", "LPS", "-", "induced", "iNOS", "expression", ",", "which", "indirectly", "suggested", "that", "5HHMF", "downregulated", "iNOS", "expression", "by", "suppressing", "NF", "-", "κB", "activity", ".", "Thus", ",", "we", "found", "that", "5HHMF", "enhances", "heme", "oxygenase-1", "(", "HO-1", ")", "expression", "via", "nuclear", "factor", "-", "erythroid", "2-related", "factor", "2", "(", "Nrf2", ")", "activation", ".", "In", "addition", ",", "cobalt", "protoporphyrin", "(", "CoPP", ")", ",", "a", "specific", "HO-1", "inducer", ",", "predominantly", "suppressed", "LPS", "-", "induced", "NO", "production", ".", "In", "contrast", ",", "zinc", "protoporphyrin", "(", "ZnPP", ")", ",", "a", "specific", "HO-1", "inhibitor", ",", "showed", "a", "partial", "suppressive", "effect", "of", "5HHMF", "on", "LPS", "-", "induced", "NO", "production", ".", "Further", ",", "5HHMF", "increased", "specific", "DNA", "-", "binding", "activity", "of", "Nrf2", ",", "and", "transient", "knockdown", "with", "Nrf2", "siRNA", "subsequently", "reversed", "5HHMF", "-", "induced", "NO", "inhibition", ",", "which", "was", "followed", "by", "suppression", "of", "HO-1", "activity", ".", "Taken", "together", ",", "our", "findings", "indicate", "that", "5HHMF", "suppresses", "NO", "production", "through", "modulation", "of", "iNOS", ",", "consequently", "suppressing", "NF", "-", "κB", "activity", "and", "induction", "of", "Nrf2-dependent", "HO-1", "activity", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone is a CHEMICAL, nitric oxide is a CHEMICAL, NF - κB is a GENE-N, heme oxygenase-1 is a GENE-Y, 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone is a CHEMICAL, 5HHMF is a CHEMICAL, NO is a CHEMICAL, inducible NO synthase is a GENE-Y, iNOS is a GENE-Y, 5HHMF is a CHEMICAL, IκB is a GENE-N, nuclear factor - κB is a GENE-N, NF - κB is a GENE-N, p65 is a GENE-Y, p50 is a GENE-Y, iNOS is a GENE-Y, Pyrrolidine dithiocarbamate is a CHEMICAL, PDTC is a CHEMICAL, NF - κB is a GENE-N, 20S proteasome is a GENE-N, iNOS is a GENE-Y, 5HHMF is a CHEMICAL, iNOS is a GENE-Y, NF - κB is a GENE-N, 5HHMF is a CHEMICAL, heme oxygenase-1 is a GENE-Y, HO-1 is a GENE-Y, nuclear factor - erythroid 2-related factor 2 is a GENE-Y, Nrf2 is a GENE-Y, cobalt protoporphyrin is a CHEMICAL, CoPP is a CHEMICAL, HO-1 is a GENE-Y, NO is a CHEMICAL, zinc protoporphyrin is a CHEMICAL, ZnPP is a CHEMICAL, HO-1 is a GENE-Y, 5HHMF is a CHEMICAL, NO is a CHEMICAL, 5HHMF is a CHEMICAL, Nrf2 is a GENE-Y, Nrf2 is a GENE-Y, 5HHMF is a CHEMICAL, NO is a CHEMICAL, HO-1 is a GENE-Y, 5HHMF is a CHEMICAL, NO is a CHEMICAL, iNOS is a GENE-Y, NF - κB is a GENE-N, HO-1 is a GENE-Y

17897_task1

Sentence: 5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and Nrf-2-dependent heme oxygenase-1 induction. In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (iNOS) in BV2 microglia. In addition, 5HHMF blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of nuclear factor-κB (NF-κB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression. Pyrrolidine dithiocarbamate (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity. Thus, we found that 5HHMF enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation. In addition, cobalt protoporphyrin (CoPP), a specific HO-1 inducer, predominantly suppressed LPS-induced NO production. In contrast, zinc protoporphyrin (ZnPP), a specific HO-1 inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production. Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity. Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-κB activity and induction of Nrf2-dependent HO-1 activity. Instructions: please typing these entity words according to sentence: 5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone, nitric oxide, NF - κB, heme oxygenase-1, 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone, 5HHMF, NO, inducible NO synthase, iNOS, 5HHMF, IκB, nuclear factor - κB, NF - κB, p65, p50, iNOS, Pyrrolidine dithiocarbamate, PDTC, NF - κB, 20S proteasome, iNOS, 5HHMF, iNOS, NF - κB, 5HHMF, heme oxygenase-1, HO-1, nuclear factor - erythroid 2-related factor 2, Nrf2, cobalt protoporphyrin, CoPP, HO-1, NO, zinc protoporphyrin, ZnPP, HO-1, 5HHMF, NO, 5HHMF, Nrf2, Nrf2, 5HHMF, NO, HO-1, 5HHMF, NO, iNOS, NF - κB, HO-1 Options: GENE-Y, GENE-N, CHEMICAL

[ "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O" ]

5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and Nrf-2-dependent heme oxygenase-1 induction. In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (iNOS) in BV2 microglia. In addition, 5HHMF blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of nuclear factor-κB (NF-κB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression. Pyrrolidine dithiocarbamate (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity. Thus, we found that 5HHMF enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation. In addition, cobalt protoporphyrin (CoPP), a specific HO-1 inducer, predominantly suppressed LPS-induced NO production. In contrast, zinc protoporphyrin (ZnPP), a specific HO-1 inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production. Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity. Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-κB activity and induction of Nrf2-dependent HO-1 activity.

[ "5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone", "inhibits", "nitric", "oxide", "production", "in", "lipopolysaccharide", "-", "stimulated", "BV2", "microglia", "via", "NF", "-", "κB", "suppression", "and", "Nrf-2-dependent", "heme", "oxygenase-1", "induction", ".", "\n", "In", "this", "study", ",", "we", "found", "that", "5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone", "(", "5HHMF", ")", "from", "Hizikia", "fusiforme", "considerably", "inhibits", "lipopolysaccharide", "(", "LPS)-stimulated", "NO", "production", "by", "suppressing", "the", "expression", "of", "inducible", "NO", "synthase", "(", "iNOS", ")", "in", "BV2", "microglia", ".", "In", "addition", ",", "5HHMF", "blocked", "LPS", "-", "induced", "phosphorylation", "of", "IκB", ",", "resulting", "in", "suppression", "of", "the", "nuclear", "translocation", "of", "nuclear", "factor", "-", "κB", "(", "NF", "-", "κB", ")", "subunits", ",", "namely", "p65", "and", "p50", ",", "which", "are", "important", "molecules", "involved", "in", "the", "regulation", "of", "iNOS", "expression", ".", "Pyrrolidine", "dithiocarbamate", "(", "PDTC", ")", ",", "a", "specific", "NF", "-", "κB", "inhibitor", ",", "along", "with", "20S", "proteasome", "inhibitor", "(", "PSI", ")", "significantly", "inhibited", "LPS", "-", "induced", "iNOS", "expression", ",", "which", "indirectly", "suggested", "that", "5HHMF", "downregulated", "iNOS", "expression", "by", "suppressing", "NF", "-", "κB", "activity", ".", "Thus", ",", "we", "found", "that", "5HHMF", "enhances", "heme", "oxygenase-1", "(", "HO-1", ")", "expression", "via", "nuclear", "factor", "-", "erythroid", "2-related", "factor", "2", "(", "Nrf2", ")", "activation", ".", "In", "addition", ",", "cobalt", "protoporphyrin", "(", "CoPP", ")", ",", "a", "specific", "HO-1", "inducer", ",", "predominantly", "suppressed", "LPS", "-", "induced", "NO", "production", ".", "In", "contrast", ",", "zinc", "protoporphyrin", "(", "ZnPP", ")", ",", "a", "specific", "HO-1", "inhibitor", ",", "showed", "a", "partial", "suppressive", "effect", "of", "5HHMF", "on", "LPS", "-", "induced", "NO", "production", ".", "Further", ",", "5HHMF", "increased", "specific", "DNA", "-", "binding", "activity", "of", "Nrf2", ",", "and", "transient", "knockdown", "with", "Nrf2", "siRNA", "subsequently", "reversed", "5HHMF", "-", "induced", "NO", "inhibition", ",", "which", "was", "followed", "by", "suppression", "of", "HO-1", "activity", ".", "Taken", "together", ",", "our", "findings", "indicate", "that", "5HHMF", "suppresses", "NO", "production", "through", "modulation", "of", "iNOS", ",", "consequently", "suppressing", "NF", "-", "κB", "activity", "and", "induction", "of", "Nrf2-dependent", "HO-1", "activity", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone, nitric oxide, NF - κB, heme oxygenase-1, 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone, 5HHMF, NO, inducible NO synthase, iNOS, 5HHMF, IκB, nuclear factor - κB, NF - κB, p65, p50, iNOS, Pyrrolidine dithiocarbamate, PDTC, NF - κB, 20S proteasome, iNOS, 5HHMF, iNOS, NF - κB, 5HHMF, heme oxygenase-1, HO-1, nuclear factor - erythroid 2-related factor 2, Nrf2, cobalt protoporphyrin, CoPP, HO-1, NO, zinc protoporphyrin, ZnPP, HO-1, 5HHMF, NO, 5HHMF, Nrf2, Nrf2, 5HHMF, NO, HO-1, 5HHMF, NO, iNOS, NF - κB, HO-1

17897_task2

Sentence: 5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and Nrf-2-dependent heme oxygenase-1 induction. In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (iNOS) in BV2 microglia. In addition, 5HHMF blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of nuclear factor-κB (NF-κB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression. Pyrrolidine dithiocarbamate (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity. Thus, we found that 5HHMF enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation. In addition, cobalt protoporphyrin (CoPP), a specific HO-1 inducer, predominantly suppressed LPS-induced NO production. In contrast, zinc protoporphyrin (ZnPP), a specific HO-1 inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production. Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity. Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-κB activity and induction of Nrf2-dependent HO-1 activity. Instructions: please extract entity words from the input sentence

[ "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O" ]

5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and Nrf-2-dependent heme oxygenase-1 induction. In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (iNOS) in BV2 microglia. In addition, 5HHMF blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of nuclear factor-κB (NF-κB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression. Pyrrolidine dithiocarbamate (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity. Thus, we found that 5HHMF enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation. In addition, cobalt protoporphyrin (CoPP), a specific HO-1 inducer, predominantly suppressed LPS-induced NO production. In contrast, zinc protoporphyrin (ZnPP), a specific HO-1 inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production. Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity. Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-κB activity and induction of Nrf2-dependent HO-1 activity.

[ "5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone", "inhibits", "nitric", "oxide", "production", "in", "lipopolysaccharide", "-", "stimulated", "BV2", "microglia", "via", "NF", "-", "κB", "suppression", "and", "Nrf-2-dependent", "heme", "oxygenase-1", "induction", ".", "\n", "In", "this", "study", ",", "we", "found", "that", "5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone", "(", "5HHMF", ")", "from", "Hizikia", "fusiforme", "considerably", "inhibits", "lipopolysaccharide", "(", "LPS)-stimulated", "NO", "production", "by", "suppressing", "the", "expression", "of", "inducible", "NO", "synthase", "(", "iNOS", ")", "in", "BV2", "microglia", ".", "In", "addition", ",", "5HHMF", "blocked", "LPS", "-", "induced", "phosphorylation", "of", "IκB", ",", "resulting", "in", "suppression", "of", "the", "nuclear", "translocation", "of", "nuclear", "factor", "-", "κB", "(", "NF", "-", "κB", ")", "subunits", ",", "namely", "p65", "and", "p50", ",", "which", "are", "important", "molecules", "involved", "in", "the", "regulation", "of", "iNOS", "expression", ".", "Pyrrolidine", "dithiocarbamate", "(", "PDTC", ")", ",", "a", "specific", "NF", "-", "κB", "inhibitor", ",", "along", "with", "20S", "proteasome", "inhibitor", "(", "PSI", ")", "significantly", "inhibited", "LPS", "-", "induced", "iNOS", "expression", ",", "which", "indirectly", "suggested", "that", "5HHMF", "downregulated", "iNOS", "expression", "by", "suppressing", "NF", "-", "κB", "activity", ".", "Thus", ",", "we", "found", "that", "5HHMF", "enhances", "heme", "oxygenase-1", "(", "HO-1", ")", "expression", "via", "nuclear", "factor", "-", "erythroid", "2-related", "factor", "2", "(", "Nrf2", ")", "activation", ".", "In", "addition", ",", "cobalt", "protoporphyrin", "(", "CoPP", ")", ",", "a", "specific", "HO-1", "inducer", ",", "predominantly", "suppressed", "LPS", "-", "induced", "NO", "production", ".", "In", "contrast", ",", "zinc", "protoporphyrin", "(", "ZnPP", ")", ",", "a", "specific", "HO-1", "inhibitor", ",", "showed", "a", "partial", "suppressive", "effect", "of", "5HHMF", "on", "LPS", "-", "induced", "NO", "production", ".", "Further", ",", "5HHMF", "increased", "specific", "DNA", "-", "binding", "activity", "of", "Nrf2", ",", "and", "transient", "knockdown", "with", "Nrf2", "siRNA", "subsequently", "reversed", "5HHMF", "-", "induced", "NO", "inhibition", ",", "which", "was", "followed", "by", "suppression", "of", "HO-1", "activity", ".", "Taken", "together", ",", "our", "findings", "indicate", "that", "5HHMF", "suppresses", "NO", "production", "through", "modulation", "of", "iNOS", ",", "consequently", "suppressing", "NF", "-", "κB", "activity", "and", "induction", "of", "Nrf2-dependent", "HO-1", "activity", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

benzo[e]pyridoindolones is a CHEMICAL, aurora kinases is a GENE-N

23281044_task0

Sentence: Hydrosoluble benzo[e]pyridoindolones as potent inhibitors of aurora kinases. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL

[ "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O" ]

Hydrosoluble benzo[e]pyridoindolones as potent inhibitors of aurora kinases.

[ "Hydrosoluble", "benzo[e]pyridoindolones", "as", "potent", "inhibitors", "of", "aurora", "kinases", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

benzo[e]pyridoindolones is a CHEMICAL, aurora kinases is a GENE-N

23281044_task1

Sentence: Hydrosoluble benzo[e]pyridoindolones as potent inhibitors of aurora kinases. Instructions: please typing these entity words according to sentence: benzo[e]pyridoindolones, aurora kinases Options: GENE-N, CHEMICAL

[ "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O" ]

Hydrosoluble benzo[e]pyridoindolones as potent inhibitors of aurora kinases.

[ "Hydrosoluble", "benzo[e]pyridoindolones", "as", "potent", "inhibitors", "of", "aurora", "kinases", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

benzo[e]pyridoindolones, aurora kinases

23281044_task2

Sentence: Hydrosoluble benzo[e]pyridoindolones as potent inhibitors of aurora kinases. Instructions: please extract entity words from the input sentence

[ "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O" ]

Hydrosoluble benzo[e]pyridoindolones as potent inhibitors of aurora kinases.

[ "Hydrosoluble", "benzo[e]pyridoindolones", "as", "potent", "inhibitors", "of", "aurora", "kinases", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

RIPc is a Individual_protein, TRADD is a Individual_protein, FADD is a Individual_protein, MORT1 is a Individual_protein, TNF is a Individual_protein

625_task0

Sentence: RIPc, one of the cleavage products, enhanced interaction between TRADD and FADD/MORT1 and increased cells' sensitivity to TNF. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein

[ "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O" ]

RIPc, one of the cleavage products, enhanced interaction between TRADD and FADD/MORT1 and increased cells' sensitivity to TNF.

[ "RIPc", ",", "one", "of", "the", "cleavage", "products", ",", "enhanced", "interaction", "between", "TRADD", "and", "FADD", "/", "MORT1", "and", "increased", "cells", "'", "sensitivity", "to", "TNF", "." ]

[ "Individual_protein" ]

RIPc is a Individual_protein, TRADD is a Individual_protein, FADD is a Individual_protein, MORT1 is a Individual_protein, TNF is a Individual_protein

625_task1

Sentence: RIPc, one of the cleavage products, enhanced interaction between TRADD and FADD/MORT1 and increased cells' sensitivity to TNF. Instructions: please typing these entity words according to sentence: RIPc, TRADD, FADD, MORT1, TNF Options: Individual_protein

[ "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O" ]

RIPc, one of the cleavage products, enhanced interaction between TRADD and FADD/MORT1 and increased cells' sensitivity to TNF.

[ "RIPc", ",", "one", "of", "the", "cleavage", "products", ",", "enhanced", "interaction", "between", "TRADD", "and", "FADD", "/", "MORT1", "and", "increased", "cells", "'", "sensitivity", "to", "TNF", "." ]

[ "Individual_protein" ]

RIPc, TRADD, FADD, MORT1, TNF

625_task2

Sentence: RIPc, one of the cleavage products, enhanced interaction between TRADD and FADD/MORT1 and increased cells' sensitivity to TNF. Instructions: please extract entity words from the input sentence

[ "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O" ]

RIPc, one of the cleavage products, enhanced interaction between TRADD and FADD/MORT1 and increased cells' sensitivity to TNF.

[ "RIPc", ",", "one", "of", "the", "cleavage", "products", ",", "enhanced", "interaction", "between", "TRADD", "and", "FADD", "/", "MORT1", "and", "increased", "cells", "'", "sensitivity", "to", "TNF", "." ]

[ "Individual_protein" ]

Literatur is an umlsterm, Relevanzbeurteilung is an umlsterm, Dentallegierungen is an umlsterm, Allergiepraevalenz is an umlsterm, Quecksilberverbindungen is an umlsterm, Nickelallergien is an umlsterm, Nickel is an umlsterm, Allergen is an umlsterm, Goldsalze is an umlsterm, Vorhersage is an umlsterm, Goldunvertraeglichkeit is an umlsterm, Kunstharzen is an umlsterm, Methylmethacrylat is an umlsterm, Allergen is an umlsterm, Methacrylaten is an umlsterm, Gruppenallergien is an umlsterm, Benzoylperoxidtests is an umlsterm, Allergenkomplex is an umlsterm, aetherische Oele is an umlsterm, zahnmedizinischen is an umlsterm

DerHautarzt.60470844.ger.abstr_task0

Sentence: Anhand der IVDK-Daten , des eigenen Materials und der Literatur werden fuer die wichtigsten Dentalwerkstoffe ( DWS ) die Probleme beim Epikutantest und dessen Relevanzbeurteilung sowie die praktischen Konsequenzen besprochen . Im Vordergrund stehen bei den Dentallegierungen folgende Komplexe : Amalgam , mit niedriger Allergiepraevalenz und sicherer Korrelation nur zu Patchtestreaktionen auf anorganische Quecksilberverbindungen ; Palladiumsalze mit hoher Quote simultaner Nickelallergien , aber nur sehr geringer Korrelation zu Reaktionen auf metallisches Pd bzw. Pd-Legierungen ; Nickel als sehr haeufiges Allergen mit hoher Relevanz bei nicht absolut korrosionsfesten , nickelhaltigen DWS ; Goldsalze mit ihren stark differierenden Testergebnissen und deren begrenztem Wert fuer die Vorhersage einer Goldunvertraeglichkeit . Bei den Kunstharzen ist Methylmethacrylat allein wegen der Expositionshaeufigkeit noch immer das wichtigste Allergen . Bei Compositematerialien und anderen Methacrylaten ist auf die Problematik von Gruppenallergien und aktiver Sensibilisierung zu achten . Klinisch relevante Additivaallergien sind selten , positive Benzoylperoxidtests allein dafuer kein Beweis . Weit verbreitet im DWS ist der Allergenkomplex aetherische Oele - Perubalsam - Kolophonium . Bei DWS sollte die Testung unter standardisierten Bedingungen und die Bewertung besonders kritisch erfolgen , da die zahnmedizinischen Konsequenzen kostenaufwendig und belastend sein koennen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Anhand der IVDK-Daten , des eigenen Materials und der Literatur werden fuer die wichtigsten Dentalwerkstoffe ( DWS ) die Probleme beim Epikutantest und dessen Relevanzbeurteilung sowie die praktischen Konsequenzen besprochen . Im Vordergrund stehen bei den Dentallegierungen folgende Komplexe : Amalgam , mit niedriger Allergiepraevalenz und sicherer Korrelation nur zu Patchtestreaktionen auf anorganische Quecksilberverbindungen ; Palladiumsalze mit hoher Quote simultaner Nickelallergien , aber nur sehr geringer Korrelation zu Reaktionen auf metallisches Pd bzw. Pd-Legierungen ; Nickel als sehr haeufiges Allergen mit hoher Relevanz bei nicht absolut korrosionsfesten , nickelhaltigen DWS ; Goldsalze mit ihren stark differierenden Testergebnissen und deren begrenztem Wert fuer die Vorhersage einer Goldunvertraeglichkeit . Bei den Kunstharzen ist Methylmethacrylat allein wegen der Expositionshaeufigkeit noch immer das wichtigste Allergen . Bei Compositematerialien und anderen Methacrylaten ist auf die Problematik von Gruppenallergien und aktiver Sensibilisierung zu achten . Klinisch relevante Additivaallergien sind selten , positive Benzoylperoxidtests allein dafuer kein Beweis . Weit verbreitet im DWS ist der Allergenkomplex aetherische Oele - Perubalsam - Kolophonium . Bei DWS sollte die Testung unter standardisierten Bedingungen und die Bewertung besonders kritisch erfolgen , da die zahnmedizinischen Konsequenzen kostenaufwendig und belastend sein koennen .

[ "Anhand", "der", "IVDK", "-", "Daten", ",", "des", "eigenen", "Materials", "und", "der", "Literatur", "werden", "fuer", "die", "wichtigsten", "Dentalwerkstoffe", "(", "DWS", ")", "die", "Probleme", "beim", "Epikutantest", "und", "dessen", "Relevanzbeurteilung", "sowie", "die", "praktischen", "Konsequenzen", "besprochen", ".", "Im", "Vordergrund", "stehen", "bei", "den", "Dentallegierungen", "folgende", "Komplexe", ":", "Amalgam", ",", "mit", "niedriger", "Allergiepraevalenz", "und", "sicherer", "Korrelation", "nur", "zu", "Patchtestreaktionen", "auf", "anorganische", "Quecksilberverbindungen", ";", "Palladiumsalze", "mit", "hoher", "Quote", "simultaner", "Nickelallergien", ",", "aber", "nur", "sehr", "geringer", "Korrelation", "zu", "Reaktionen", "auf", "metallisches", "Pd", "bzw", ".", "Pd", "-", "Legierungen", ";", "Nickel", "als", "sehr", "haeufiges", "Allergen", "mit", "hoher", "Relevanz", "bei", "nicht", "absolut", "korrosionsfesten", ",", "nickelhaltigen", "DWS", ";", "Goldsalze", "mit", "ihren", "stark", "differierenden", "Testergebnissen", "und", "deren", "begrenztem", "Wert", "fuer", "die", "Vorhersage", "einer", "Goldunvertraeglichkeit", ".", "Bei", "den", "Kunstharzen", "ist", "Methylmethacrylat", "allein", "wegen", "der", "Expositionshaeufigkeit", "noch", "immer", "das", "wichtigste", "Allergen", ".", "Bei", "Compositematerialien", "und", "anderen", "Methacrylaten", "ist", "auf", "die", "Problematik", "von", "Gruppenallergien", "und", "aktiver", "Sensibilisierung", "zu", "achten", ".", "Klinisch", "relevante", "Additivaallergien", "sind", "selten", ",", "positive", "Benzoylperoxidtests", "allein", "dafuer", "kein", "Beweis", ".", "Weit", "verbreitet", "im", "DWS", "ist", "der", "Allergenkomplex", "aetherische", "Oele", "-", "Perubalsam", "-", "Kolophonium", ".", "Bei", "DWS", "sollte", "die", "Testung", "unter", "standardisierten", "Bedingungen", "und", "die", "Bewertung", "besonders", "kritisch", "erfolgen", ",", "da", "die", "zahnmedizinischen", "Konsequenzen", "kostenaufwendig", "und", "belastend", "sein", "koennen", "." ]

[ "umlsterm" ]

Literatur is an umlsterm, Relevanzbeurteilung is an umlsterm, Dentallegierungen is an umlsterm, Allergiepraevalenz is an umlsterm, Quecksilberverbindungen is an umlsterm, Nickelallergien is an umlsterm, Nickel is an umlsterm, Allergen is an umlsterm, Goldsalze is an umlsterm, Vorhersage is an umlsterm, Goldunvertraeglichkeit is an umlsterm, Kunstharzen is an umlsterm, Methylmethacrylat is an umlsterm, Allergen is an umlsterm, Methacrylaten is an umlsterm, Gruppenallergien is an umlsterm, Benzoylperoxidtests is an umlsterm, Allergenkomplex is an umlsterm, aetherische Oele is an umlsterm, zahnmedizinischen is an umlsterm

DerHautarzt.60470844.ger.abstr_task1

Sentence: Anhand der IVDK-Daten , des eigenen Materials und der Literatur werden fuer die wichtigsten Dentalwerkstoffe ( DWS ) die Probleme beim Epikutantest und dessen Relevanzbeurteilung sowie die praktischen Konsequenzen besprochen . Im Vordergrund stehen bei den Dentallegierungen folgende Komplexe : Amalgam , mit niedriger Allergiepraevalenz und sicherer Korrelation nur zu Patchtestreaktionen auf anorganische Quecksilberverbindungen ; Palladiumsalze mit hoher Quote simultaner Nickelallergien , aber nur sehr geringer Korrelation zu Reaktionen auf metallisches Pd bzw. Pd-Legierungen ; Nickel als sehr haeufiges Allergen mit hoher Relevanz bei nicht absolut korrosionsfesten , nickelhaltigen DWS ; Goldsalze mit ihren stark differierenden Testergebnissen und deren begrenztem Wert fuer die Vorhersage einer Goldunvertraeglichkeit . Bei den Kunstharzen ist Methylmethacrylat allein wegen der Expositionshaeufigkeit noch immer das wichtigste Allergen . Bei Compositematerialien und anderen Methacrylaten ist auf die Problematik von Gruppenallergien und aktiver Sensibilisierung zu achten . Klinisch relevante Additivaallergien sind selten , positive Benzoylperoxidtests allein dafuer kein Beweis . Weit verbreitet im DWS ist der Allergenkomplex aetherische Oele - Perubalsam - Kolophonium . Bei DWS sollte die Testung unter standardisierten Bedingungen und die Bewertung besonders kritisch erfolgen , da die zahnmedizinischen Konsequenzen kostenaufwendig und belastend sein koennen . Instructions: please typing these entity words according to sentence: Literatur, Relevanzbeurteilung, Dentallegierungen, Allergiepraevalenz, Quecksilberverbindungen, Nickelallergien, Nickel, Allergen, Goldsalze, Vorhersage, Goldunvertraeglichkeit, Kunstharzen, Methylmethacrylat, Allergen, Methacrylaten, Gruppenallergien, Benzoylperoxidtests, Allergenkomplex, aetherische Oele, zahnmedizinischen Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Anhand der IVDK-Daten , des eigenen Materials und der Literatur werden fuer die wichtigsten Dentalwerkstoffe ( DWS ) die Probleme beim Epikutantest und dessen Relevanzbeurteilung sowie die praktischen Konsequenzen besprochen . Im Vordergrund stehen bei den Dentallegierungen folgende Komplexe : Amalgam , mit niedriger Allergiepraevalenz und sicherer Korrelation nur zu Patchtestreaktionen auf anorganische Quecksilberverbindungen ; Palladiumsalze mit hoher Quote simultaner Nickelallergien , aber nur sehr geringer Korrelation zu Reaktionen auf metallisches Pd bzw. Pd-Legierungen ; Nickel als sehr haeufiges Allergen mit hoher Relevanz bei nicht absolut korrosionsfesten , nickelhaltigen DWS ; Goldsalze mit ihren stark differierenden Testergebnissen und deren begrenztem Wert fuer die Vorhersage einer Goldunvertraeglichkeit . Bei den Kunstharzen ist Methylmethacrylat allein wegen der Expositionshaeufigkeit noch immer das wichtigste Allergen . Bei Compositematerialien und anderen Methacrylaten ist auf die Problematik von Gruppenallergien und aktiver Sensibilisierung zu achten . Klinisch relevante Additivaallergien sind selten , positive Benzoylperoxidtests allein dafuer kein Beweis . Weit verbreitet im DWS ist der Allergenkomplex aetherische Oele - Perubalsam - Kolophonium . Bei DWS sollte die Testung unter standardisierten Bedingungen und die Bewertung besonders kritisch erfolgen , da die zahnmedizinischen Konsequenzen kostenaufwendig und belastend sein koennen .

[ "Anhand", "der", "IVDK", "-", "Daten", ",", "des", "eigenen", "Materials", "und", "der", "Literatur", "werden", "fuer", "die", "wichtigsten", "Dentalwerkstoffe", "(", "DWS", ")", "die", "Probleme", "beim", "Epikutantest", "und", "dessen", "Relevanzbeurteilung", "sowie", "die", "praktischen", "Konsequenzen", "besprochen", ".", "Im", "Vordergrund", "stehen", "bei", "den", "Dentallegierungen", "folgende", "Komplexe", ":", "Amalgam", ",", "mit", "niedriger", "Allergiepraevalenz", "und", "sicherer", "Korrelation", "nur", "zu", "Patchtestreaktionen", "auf", "anorganische", "Quecksilberverbindungen", ";", "Palladiumsalze", "mit", "hoher", "Quote", "simultaner", "Nickelallergien", ",", "aber", "nur", "sehr", "geringer", "Korrelation", "zu", "Reaktionen", "auf", "metallisches", "Pd", "bzw", ".", "Pd", "-", "Legierungen", ";", "Nickel", "als", "sehr", "haeufiges", "Allergen", "mit", "hoher", "Relevanz", "bei", "nicht", "absolut", "korrosionsfesten", ",", "nickelhaltigen", "DWS", ";", "Goldsalze", "mit", "ihren", "stark", "differierenden", "Testergebnissen", "und", "deren", "begrenztem", "Wert", "fuer", "die", "Vorhersage", "einer", "Goldunvertraeglichkeit", ".", "Bei", "den", "Kunstharzen", "ist", "Methylmethacrylat", "allein", "wegen", "der", "Expositionshaeufigkeit", "noch", "immer", "das", "wichtigste", "Allergen", ".", "Bei", "Compositematerialien", "und", "anderen", "Methacrylaten", "ist", "auf", "die", "Problematik", "von", "Gruppenallergien", "und", "aktiver", "Sensibilisierung", "zu", "achten", ".", "Klinisch", "relevante", "Additivaallergien", "sind", "selten", ",", "positive", "Benzoylperoxidtests", "allein", "dafuer", "kein", "Beweis", ".", "Weit", "verbreitet", "im", "DWS", "ist", "der", "Allergenkomplex", "aetherische", "Oele", "-", "Perubalsam", "-", "Kolophonium", ".", "Bei", "DWS", "sollte", "die", "Testung", "unter", "standardisierten", "Bedingungen", "und", "die", "Bewertung", "besonders", "kritisch", "erfolgen", ",", "da", "die", "zahnmedizinischen", "Konsequenzen", "kostenaufwendig", "und", "belastend", "sein", "koennen", "." ]

[ "umlsterm" ]

Literatur, Relevanzbeurteilung, Dentallegierungen, Allergiepraevalenz, Quecksilberverbindungen, Nickelallergien, Nickel, Allergen, Goldsalze, Vorhersage, Goldunvertraeglichkeit, Kunstharzen, Methylmethacrylat, Allergen, Methacrylaten, Gruppenallergien, Benzoylperoxidtests, Allergenkomplex, aetherische Oele, zahnmedizinischen

DerHautarzt.60470844.ger.abstr_task2

Sentence: Anhand der IVDK-Daten , des eigenen Materials und der Literatur werden fuer die wichtigsten Dentalwerkstoffe ( DWS ) die Probleme beim Epikutantest und dessen Relevanzbeurteilung sowie die praktischen Konsequenzen besprochen . Im Vordergrund stehen bei den Dentallegierungen folgende Komplexe : Amalgam , mit niedriger Allergiepraevalenz und sicherer Korrelation nur zu Patchtestreaktionen auf anorganische Quecksilberverbindungen ; Palladiumsalze mit hoher Quote simultaner Nickelallergien , aber nur sehr geringer Korrelation zu Reaktionen auf metallisches Pd bzw. Pd-Legierungen ; Nickel als sehr haeufiges Allergen mit hoher Relevanz bei nicht absolut korrosionsfesten , nickelhaltigen DWS ; Goldsalze mit ihren stark differierenden Testergebnissen und deren begrenztem Wert fuer die Vorhersage einer Goldunvertraeglichkeit . Bei den Kunstharzen ist Methylmethacrylat allein wegen der Expositionshaeufigkeit noch immer das wichtigste Allergen . Bei Compositematerialien und anderen Methacrylaten ist auf die Problematik von Gruppenallergien und aktiver Sensibilisierung zu achten . Klinisch relevante Additivaallergien sind selten , positive Benzoylperoxidtests allein dafuer kein Beweis . Weit verbreitet im DWS ist der Allergenkomplex aetherische Oele - Perubalsam - Kolophonium . Bei DWS sollte die Testung unter standardisierten Bedingungen und die Bewertung besonders kritisch erfolgen , da die zahnmedizinischen Konsequenzen kostenaufwendig und belastend sein koennen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Anhand der IVDK-Daten , des eigenen Materials und der Literatur werden fuer die wichtigsten Dentalwerkstoffe ( DWS ) die Probleme beim Epikutantest und dessen Relevanzbeurteilung sowie die praktischen Konsequenzen besprochen . Im Vordergrund stehen bei den Dentallegierungen folgende Komplexe : Amalgam , mit niedriger Allergiepraevalenz und sicherer Korrelation nur zu Patchtestreaktionen auf anorganische Quecksilberverbindungen ; Palladiumsalze mit hoher Quote simultaner Nickelallergien , aber nur sehr geringer Korrelation zu Reaktionen auf metallisches Pd bzw. Pd-Legierungen ; Nickel als sehr haeufiges Allergen mit hoher Relevanz bei nicht absolut korrosionsfesten , nickelhaltigen DWS ; Goldsalze mit ihren stark differierenden Testergebnissen und deren begrenztem Wert fuer die Vorhersage einer Goldunvertraeglichkeit . Bei den Kunstharzen ist Methylmethacrylat allein wegen der Expositionshaeufigkeit noch immer das wichtigste Allergen . Bei Compositematerialien und anderen Methacrylaten ist auf die Problematik von Gruppenallergien und aktiver Sensibilisierung zu achten . Klinisch relevante Additivaallergien sind selten , positive Benzoylperoxidtests allein dafuer kein Beweis . Weit verbreitet im DWS ist der Allergenkomplex aetherische Oele - Perubalsam - Kolophonium . Bei DWS sollte die Testung unter standardisierten Bedingungen und die Bewertung besonders kritisch erfolgen , da die zahnmedizinischen Konsequenzen kostenaufwendig und belastend sein koennen .

[ "Anhand", "der", "IVDK", "-", "Daten", ",", "des", "eigenen", "Materials", "und", "der", "Literatur", "werden", "fuer", "die", "wichtigsten", "Dentalwerkstoffe", "(", "DWS", ")", "die", "Probleme", "beim", "Epikutantest", "und", "dessen", "Relevanzbeurteilung", "sowie", "die", "praktischen", "Konsequenzen", "besprochen", ".", "Im", "Vordergrund", "stehen", "bei", "den", "Dentallegierungen", "folgende", "Komplexe", ":", "Amalgam", ",", "mit", "niedriger", "Allergiepraevalenz", "und", "sicherer", "Korrelation", "nur", "zu", "Patchtestreaktionen", "auf", "anorganische", "Quecksilberverbindungen", ";", "Palladiumsalze", "mit", "hoher", "Quote", "simultaner", "Nickelallergien", ",", "aber", "nur", "sehr", "geringer", "Korrelation", "zu", "Reaktionen", "auf", "metallisches", "Pd", "bzw", ".", "Pd", "-", "Legierungen", ";", "Nickel", "als", "sehr", "haeufiges", "Allergen", "mit", "hoher", "Relevanz", "bei", "nicht", "absolut", "korrosionsfesten", ",", "nickelhaltigen", "DWS", ";", "Goldsalze", "mit", "ihren", "stark", "differierenden", "Testergebnissen", "und", "deren", "begrenztem", "Wert", "fuer", "die", "Vorhersage", "einer", "Goldunvertraeglichkeit", ".", "Bei", "den", "Kunstharzen", "ist", "Methylmethacrylat", "allein", "wegen", "der", "Expositionshaeufigkeit", "noch", "immer", "das", "wichtigste", "Allergen", ".", "Bei", "Compositematerialien", "und", "anderen", "Methacrylaten", "ist", "auf", "die", "Problematik", "von", "Gruppenallergien", "und", "aktiver", "Sensibilisierung", "zu", "achten", ".", "Klinisch", "relevante", "Additivaallergien", "sind", "selten", ",", "positive", "Benzoylperoxidtests", "allein", "dafuer", "kein", "Beweis", ".", "Weit", "verbreitet", "im", "DWS", "ist", "der", "Allergenkomplex", "aetherische", "Oele", "-", "Perubalsam", "-", "Kolophonium", ".", "Bei", "DWS", "sollte", "die", "Testung", "unter", "standardisierten", "Bedingungen", "und", "die", "Bewertung", "besonders", "kritisch", "erfolgen", ",", "da", "die", "zahnmedizinischen", "Konsequenzen", "kostenaufwendig", "und", "belastend", "sein", "koennen", "." ]

[ "umlsterm" ]

laser is an umlsterm, therapy is an umlsterm, physics is an umlsterm, biophysics is an umlsterm, laser is an umlsterm, therapy is an umlsterm, laser is an umlsterm, dermatology is an umlsterm, laser is an umlsterm, side effects is an umlsterm, methods is an umlsterm

DerHautarzt.80490690.eng.abstr_task0

Sentence: Indications for dermatological laser therapy have been enlarged during the last few years . In this article the physics and biophysics of laser therapy and the common laser systems in dermatology are described . Modern pulsed laser systems are combined with little side effects . Nevertheless , suc-cessfully used alternative methods should not be neglected . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]

Indications for dermatological laser therapy have been enlarged during the last few years . In this article the physics and biophysics of laser therapy and the common laser systems in dermatology are described . Modern pulsed laser systems are combined with little side effects . Nevertheless , suc-cessfully used alternative methods should not be neglected .

[ "Indications", "for", "dermatological", "laser", "therapy", "have", "been", "enlarged", "during", "the", "last", "few", "years", ".", "In", "this", "article", "the", "physics", "and", "biophysics", "of", "laser", "therapy", "and", "the", "common", "laser", "systems", "in", "dermatology", "are", "described", ".", "Modern", "pulsed", "laser", "systems", "are", "combined", "with", "little", "side", "effects", ".", "Nevertheless", ",", "suc", "-", "cessfully", "used", "alternative", "methods", "should", "not", "be", "neglected", "." ]

[ "umlsterm" ]

laser is an umlsterm, therapy is an umlsterm, physics is an umlsterm, biophysics is an umlsterm, laser is an umlsterm, therapy is an umlsterm, laser is an umlsterm, dermatology is an umlsterm, laser is an umlsterm, side effects is an umlsterm, methods is an umlsterm

DerHautarzt.80490690.eng.abstr_task1

Sentence: Indications for dermatological laser therapy have been enlarged during the last few years . In this article the physics and biophysics of laser therapy and the common laser systems in dermatology are described . Modern pulsed laser systems are combined with little side effects . Nevertheless , suc-cessfully used alternative methods should not be neglected . Instructions: please typing these entity words according to sentence: laser, therapy, physics, biophysics, laser, therapy, laser, dermatology, laser, side effects, methods Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]

Indications for dermatological laser therapy have been enlarged during the last few years . In this article the physics and biophysics of laser therapy and the common laser systems in dermatology are described . Modern pulsed laser systems are combined with little side effects . Nevertheless , suc-cessfully used alternative methods should not be neglected .

[ "Indications", "for", "dermatological", "laser", "therapy", "have", "been", "enlarged", "during", "the", "last", "few", "years", ".", "In", "this", "article", "the", "physics", "and", "biophysics", "of", "laser", "therapy", "and", "the", "common", "laser", "systems", "in", "dermatology", "are", "described", ".", "Modern", "pulsed", "laser", "systems", "are", "combined", "with", "little", "side", "effects", ".", "Nevertheless", ",", "suc", "-", "cessfully", "used", "alternative", "methods", "should", "not", "be", "neglected", "." ]

[ "umlsterm" ]

laser, therapy, physics, biophysics, laser, therapy, laser, dermatology, laser, side effects, methods

DerHautarzt.80490690.eng.abstr_task2

Sentence: Indications for dermatological laser therapy have been enlarged during the last few years . In this article the physics and biophysics of laser therapy and the common laser systems in dermatology are described . Modern pulsed laser systems are combined with little side effects . Nevertheless , suc-cessfully used alternative methods should not be neglected . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]

Indications for dermatological laser therapy have been enlarged during the last few years . In this article the physics and biophysics of laser therapy and the common laser systems in dermatology are described . Modern pulsed laser systems are combined with little side effects . Nevertheless , suc-cessfully used alternative methods should not be neglected .

[ "Indications", "for", "dermatological", "laser", "therapy", "have", "been", "enlarged", "during", "the", "last", "few", "years", ".", "In", "this", "article", "the", "physics", "and", "biophysics", "of", "laser", "therapy", "and", "the", "common", "laser", "systems", "in", "dermatology", "are", "described", ".", "Modern", "pulsed", "laser", "systems", "are", "combined", "with", "little", "side", "effects", ".", "Nevertheless", ",", "suc", "-", "cessfully", "used", "alternative", "methods", "should", "not", "be", "neglected", "." ]

[ "umlsterm" ]

IRF-1-dependent pathway is an other_name, DNA damage - induced apoptosis is an other_name, mitogen - activated T lymphocytes is a cell_line

99505_task0

Sentence: An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_line, other_name

[ "O", "B-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]

An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes.

[ "An", "IRF-1-dependent", "pathway", "of", "DNA", "damage", "-", "induced", "apoptosis", "in", "mitogen", "-", "activated", "T", "lymphocytes", "." ]

[ "protein_molecule", "DNA_domain_or_region", "cell_line", "protein_family_or_group", "other_name", "mono_cell", "DNA_family_or_group", "cell_type" ]

IRF-1-dependent pathway is an other_name, DNA damage - induced apoptosis is an other_name, mitogen - activated T lymphocytes is a cell_line

99505_task1

Sentence: An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Instructions: please typing these entity words according to sentence: IRF-1-dependent pathway, DNA damage - induced apoptosis, mitogen - activated T lymphocytes Options: cell_line, other_name

[ "O", "B-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]

An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes.

[ "An", "IRF-1-dependent", "pathway", "of", "DNA", "damage", "-", "induced", "apoptosis", "in", "mitogen", "-", "activated", "T", "lymphocytes", "." ]

[ "protein_molecule", "DNA_domain_or_region", "cell_line", "protein_family_or_group", "other_name", "mono_cell", "DNA_family_or_group", "cell_type" ]

IRF-1-dependent pathway, DNA damage - induced apoptosis, mitogen - activated T lymphocytes

99505_task2

Sentence: An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Instructions: please extract entity words from the input sentence

[ "O", "B-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]

An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes.

[ "An", "IRF-1-dependent", "pathway", "of", "DNA", "damage", "-", "induced", "apoptosis", "in", "mitogen", "-", "activated", "T", "lymphocytes", "." ]

[ "protein_molecule", "DNA_domain_or_region", "cell_line", "protein_family_or_group", "other_name", "mono_cell", "DNA_family_or_group", "cell_type" ]

telemedicine is an umlsterm, goals is an umlsterm, teleradiology is an umlsterm, user 's is an umlsterm, teleradiology is an umlsterm, data security is an umlsterm, maintenance is an umlsterm, rights is an umlsterm, standardization is an umlsterm, functions is an umlsterm, needs is an umlsterm, functions is an umlsterm, selection is an umlsterm, electronic is an umlsterm, documentation is an umlsterm, teleradiology is an umlsterm, guidelines is an umlsterm

DerRadiologe.70370260.eng.abstr_task0

Sentence: Specific radiological requirements have to be considered for the realization of telemedicine . In this article the goals and requirements for an extensive introduction of teleradiology will be defined from the radiological user's point of view . Necessary medical , legal and professional prerequisites for teleradiology are presented . Essential requirements , such as data security , maintenance of personal rights and standardization , must be realized . Application-specific requirements , e . g . quality and extent of teleradiological functions , as well as technological alternatives , are discussed . Each project must be carefully planned in relation to one's own needs , extent of functions and system selection . Topics , such as acknowledgement of electronic documentation , reimbursement of teleradiology and liability , must be clarified . Legal advice and the observance of quality guidelines are recommended . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Specific radiological requirements have to be considered for the realization of telemedicine . In this article the goals and requirements for an extensive introduction of teleradiology will be defined from the radiological user's point of view . Necessary medical , legal and professional prerequisites for teleradiology are presented . Essential requirements , such as data security , maintenance of personal rights and standardization , must be realized . Application-specific requirements , e . g . quality and extent of teleradiological functions , as well as technological alternatives , are discussed . Each project must be carefully planned in relation to one's own needs , extent of functions and system selection . Topics , such as acknowledgement of electronic documentation , reimbursement of teleradiology and liability , must be clarified . Legal advice and the observance of quality guidelines are recommended .

[ "Specific", "radiological", "requirements", "have", "to", "be", "considered", "for", "the", "realization", "of", "telemedicine", ".", "In", "this", "article", "the", "goals", "and", "requirements", "for", "an", "extensive", "introduction", "of", "teleradiology", "will", "be", "defined", "from", "the", "radiological", "user", "'s", "point", "of", "view", ".", "Necessary", "medical", ",", "legal", "and", "professional", "prerequisites", "for", "teleradiology", "are", "presented", ".", "Essential", "requirements", ",", "such", "as", "data", "security", ",", "maintenance", "of", "personal", "rights", "and", "standardization", ",", "must", "be", "realized", ".", "Application", "-", "specific", "requirements", ",", "e", ".", "g", ".", "quality", "and", "extent", "of", "teleradiological", "functions", ",", "as", "well", "as", "technological", "alternatives", ",", "are", "discussed", ".", "Each", "project", "must", "be", "carefully", "planned", "in", "relation", "to", "one", "'s", "own", "needs", ",", "extent", "of", "functions", "and", "system", "selection", ".", "Topics", ",", "such", "as", "acknowledgement", "of", "electronic", "documentation", ",", "reimbursement", "of", "teleradiology", "and", "liability", ",", "must", "be", "clarified", ".", "Legal", "advice", "and", "the", "observance", "of", "quality", "guidelines", "are", "recommended", "." ]

[ "umlsterm" ]

telemedicine is an umlsterm, goals is an umlsterm, teleradiology is an umlsterm, user 's is an umlsterm, teleradiology is an umlsterm, data security is an umlsterm, maintenance is an umlsterm, rights is an umlsterm, standardization is an umlsterm, functions is an umlsterm, needs is an umlsterm, functions is an umlsterm, selection is an umlsterm, electronic is an umlsterm, documentation is an umlsterm, teleradiology is an umlsterm, guidelines is an umlsterm

DerRadiologe.70370260.eng.abstr_task1

Sentence: Specific radiological requirements have to be considered for the realization of telemedicine . In this article the goals and requirements for an extensive introduction of teleradiology will be defined from the radiological user's point of view . Necessary medical , legal and professional prerequisites for teleradiology are presented . Essential requirements , such as data security , maintenance of personal rights and standardization , must be realized . Application-specific requirements , e . g . quality and extent of teleradiological functions , as well as technological alternatives , are discussed . Each project must be carefully planned in relation to one's own needs , extent of functions and system selection . Topics , such as acknowledgement of electronic documentation , reimbursement of teleradiology and liability , must be clarified . Legal advice and the observance of quality guidelines are recommended . Instructions: please typing these entity words according to sentence: telemedicine, goals, teleradiology, user 's, teleradiology, data security, maintenance, rights, standardization, functions, needs, functions, selection, electronic, documentation, teleradiology, guidelines Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Specific radiological requirements have to be considered for the realization of telemedicine . In this article the goals and requirements for an extensive introduction of teleradiology will be defined from the radiological user's point of view . Necessary medical , legal and professional prerequisites for teleradiology are presented . Essential requirements , such as data security , maintenance of personal rights and standardization , must be realized . Application-specific requirements , e . g . quality and extent of teleradiological functions , as well as technological alternatives , are discussed . Each project must be carefully planned in relation to one's own needs , extent of functions and system selection . Topics , such as acknowledgement of electronic documentation , reimbursement of teleradiology and liability , must be clarified . Legal advice and the observance of quality guidelines are recommended .

[ "Specific", "radiological", "requirements", "have", "to", "be", "considered", "for", "the", "realization", "of", "telemedicine", ".", "In", "this", "article", "the", "goals", "and", "requirements", "for", "an", "extensive", "introduction", "of", "teleradiology", "will", "be", "defined", "from", "the", "radiological", "user", "'s", "point", "of", "view", ".", "Necessary", "medical", ",", "legal", "and", "professional", "prerequisites", "for", "teleradiology", "are", "presented", ".", "Essential", "requirements", ",", "such", "as", "data", "security", ",", "maintenance", "of", "personal", "rights", "and", "standardization", ",", "must", "be", "realized", ".", "Application", "-", "specific", "requirements", ",", "e", ".", "g", ".", "quality", "and", "extent", "of", "teleradiological", "functions", ",", "as", "well", "as", "technological", "alternatives", ",", "are", "discussed", ".", "Each", "project", "must", "be", "carefully", "planned", "in", "relation", "to", "one", "'s", "own", "needs", ",", "extent", "of", "functions", "and", "system", "selection", ".", "Topics", ",", "such", "as", "acknowledgement", "of", "electronic", "documentation", ",", "reimbursement", "of", "teleradiology", "and", "liability", ",", "must", "be", "clarified", ".", "Legal", "advice", "and", "the", "observance", "of", "quality", "guidelines", "are", "recommended", "." ]

[ "umlsterm" ]

telemedicine, goals, teleradiology, user 's, teleradiology, data security, maintenance, rights, standardization, functions, needs, functions, selection, electronic, documentation, teleradiology, guidelines

DerRadiologe.70370260.eng.abstr_task2

Sentence: Specific radiological requirements have to be considered for the realization of telemedicine . In this article the goals and requirements for an extensive introduction of teleradiology will be defined from the radiological user's point of view . Necessary medical , legal and professional prerequisites for teleradiology are presented . Essential requirements , such as data security , maintenance of personal rights and standardization , must be realized . Application-specific requirements , e . g . quality and extent of teleradiological functions , as well as technological alternatives , are discussed . Each project must be carefully planned in relation to one's own needs , extent of functions and system selection . Topics , such as acknowledgement of electronic documentation , reimbursement of teleradiology and liability , must be clarified . Legal advice and the observance of quality guidelines are recommended . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Specific radiological requirements have to be considered for the realization of telemedicine . In this article the goals and requirements for an extensive introduction of teleradiology will be defined from the radiological user's point of view . Necessary medical , legal and professional prerequisites for teleradiology are presented . Essential requirements , such as data security , maintenance of personal rights and standardization , must be realized . Application-specific requirements , e . g . quality and extent of teleradiological functions , as well as technological alternatives , are discussed . Each project must be carefully planned in relation to one's own needs , extent of functions and system selection . Topics , such as acknowledgement of electronic documentation , reimbursement of teleradiology and liability , must be clarified . Legal advice and the observance of quality guidelines are recommended .

[ "Specific", "radiological", "requirements", "have", "to", "be", "considered", "for", "the", "realization", "of", "telemedicine", ".", "In", "this", "article", "the", "goals", "and", "requirements", "for", "an", "extensive", "introduction", "of", "teleradiology", "will", "be", "defined", "from", "the", "radiological", "user", "'s", "point", "of", "view", ".", "Necessary", "medical", ",", "legal", "and", "professional", "prerequisites", "for", "teleradiology", "are", "presented", ".", "Essential", "requirements", ",", "such", "as", "data", "security", ",", "maintenance", "of", "personal", "rights", "and", "standardization", ",", "must", "be", "realized", ".", "Application", "-", "specific", "requirements", ",", "e", ".", "g", ".", "quality", "and", "extent", "of", "teleradiological", "functions", ",", "as", "well", "as", "technological", "alternatives", ",", "are", "discussed", ".", "Each", "project", "must", "be", "carefully", "planned", "in", "relation", "to", "one", "'s", "own", "needs", ",", "extent", "of", "functions", "and", "system", "selection", ".", "Topics", ",", "such", "as", "acknowledgement", "of", "electronic", "documentation", ",", "reimbursement", "of", "teleradiology", "and", "liability", ",", "must", "be", "clarified", ".", "Legal", "advice", "and", "the", "observance", "of", "quality", "guidelines", "are", "recommended", "." ]

[ "umlsterm" ]

assessment is an umlsterm, interviews is an umlsterm, patients is an umlsterm, neurotic depressions is an umlsterm, patients is an umlsterm, phobia is an umlsterm, panic disorders is an umlsterm, patients is an umlsterm, personality disorders is an umlsterm, patients is an umlsterm, bulimia is an umlsterm, interviews is an umlsterm, analysis is an umlsterm, biography is an umlsterm, personality is an umlsterm, self - description is an umlsterm, diagnostic is an umlsterm, patients is an umlsterm, diagnostic is an umlsterm, neurosis is an umlsterm, personality disorders is an umlsterm, needs is an umlsterm, psychotherapy is an umlsterm, psychotherapy is an umlsterm, research is an umlsterm

Psychotherapeut.70420163.eng.abstr_task0

Sentence: A study of verbatim transcripts of 47 psychotherapeutical assessment interviews . Four groups were examined : patients with neurotic depressions ( n=11), patients with phobia and panic disorders ( n=12), patients suffering from severe personality disorders ( n=12), and patients with bulimia ( n=12). The interviews were systematically evaluated by means of qualitative content analysis focussing on the following categories : subjective theories of illness , biography , and characterization of their own personality . As a result ideal types of self-description were found which also serve to reconstruct the determinants of the diagnostic process . Based on the patients ' self-descriptions arguments could be developed for reducing the present confusing multiplicity of nosological concepts . One could arrive at a simpler system of broader diagnostic concepts in the field of neurosis and personality disorders which is more appropriate to the needs of clinical psychotherapy and psychotherapy research . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O" ]

A study of verbatim transcripts of 47 psychotherapeutical assessment interviews . Four groups were examined : patients with neurotic depressions ( n=11), patients with phobia and panic disorders ( n=12), patients suffering from severe personality disorders ( n=12), and patients with bulimia ( n=12). The interviews were systematically evaluated by means of qualitative content analysis focussing on the following categories : subjective theories of illness , biography , and characterization of their own personality . As a result ideal types of self-description were found which also serve to reconstruct the determinants of the diagnostic process . Based on the patients ' self-descriptions arguments could be developed for reducing the present confusing multiplicity of nosological concepts . One could arrive at a simpler system of broader diagnostic concepts in the field of neurosis and personality disorders which is more appropriate to the needs of clinical psychotherapy and psychotherapy research .

[ "A", "study", "of", "verbatim", "transcripts", "of", "47", "psychotherapeutical", "assessment", "interviews", ".", "Four", "groups", "were", "examined", ":", "patients", "with", "neurotic", "depressions", "(", "n=11", ")", ",", "patients", "with", "phobia", "and", "panic", "disorders", "(", "n=12", ")", ",", "patients", "suffering", "from", "severe", "personality", "disorders", "(", "n=12", ")", ",", "and", "patients", "with", "bulimia", "(", "n=12", ")", ".", "The", "interviews", "were", "systematically", "evaluated", "by", "means", "of", "qualitative", "content", "analysis", "focussing", "on", "the", "following", "categories", ":", "subjective", "theories", "of", "illness", ",", "biography", ",", "and", "characterization", "of", "their", "own", "personality", ".", "As", "a", "result", "ideal", "types", "of", "self", "-", "description", "were", "found", "which", "also", "serve", "to", "reconstruct", "the", "determinants", "of", "the", "diagnostic", "process", ".", "Based", "on", "the", "patients", "'", "self", "-", "descriptions", "arguments", "could", "be", "developed", "for", "reducing", "the", "present", "confusing", "multiplicity", "of", "nosological", "concepts", ".", "One", "could", "arrive", "at", "a", "simpler", "system", "of", "broader", "diagnostic", "concepts", "in", "the", "field", "of", "neurosis", "and", "personality", "disorders", "which", "is", "more", "appropriate", "to", "the", "needs", "of", "clinical", "psychotherapy", "and", "psychotherapy", "research", "." ]

[ "umlsterm" ]

assessment is an umlsterm, interviews is an umlsterm, patients is an umlsterm, neurotic depressions is an umlsterm, patients is an umlsterm, phobia is an umlsterm, panic disorders is an umlsterm, patients is an umlsterm, personality disorders is an umlsterm, patients is an umlsterm, bulimia is an umlsterm, interviews is an umlsterm, analysis is an umlsterm, biography is an umlsterm, personality is an umlsterm, self - description is an umlsterm, diagnostic is an umlsterm, patients is an umlsterm, diagnostic is an umlsterm, neurosis is an umlsterm, personality disorders is an umlsterm, needs is an umlsterm, psychotherapy is an umlsterm, psychotherapy is an umlsterm, research is an umlsterm

Psychotherapeut.70420163.eng.abstr_task1

Sentence: A study of verbatim transcripts of 47 psychotherapeutical assessment interviews . Four groups were examined : patients with neurotic depressions ( n=11), patients with phobia and panic disorders ( n=12), patients suffering from severe personality disorders ( n=12), and patients with bulimia ( n=12). The interviews were systematically evaluated by means of qualitative content analysis focussing on the following categories : subjective theories of illness , biography , and characterization of their own personality . As a result ideal types of self-description were found which also serve to reconstruct the determinants of the diagnostic process . Based on the patients ' self-descriptions arguments could be developed for reducing the present confusing multiplicity of nosological concepts . One could arrive at a simpler system of broader diagnostic concepts in the field of neurosis and personality disorders which is more appropriate to the needs of clinical psychotherapy and psychotherapy research . Instructions: please typing these entity words according to sentence: assessment, interviews, patients, neurotic depressions, patients, phobia, panic disorders, patients, personality disorders, patients, bulimia, interviews, analysis, biography, personality, self - description, diagnostic, patients, diagnostic, neurosis, personality disorders, needs, psychotherapy, psychotherapy, research Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O" ]

A study of verbatim transcripts of 47 psychotherapeutical assessment interviews . Four groups were examined : patients with neurotic depressions ( n=11), patients with phobia and panic disorders ( n=12), patients suffering from severe personality disorders ( n=12), and patients with bulimia ( n=12). The interviews were systematically evaluated by means of qualitative content analysis focussing on the following categories : subjective theories of illness , biography , and characterization of their own personality . As a result ideal types of self-description were found which also serve to reconstruct the determinants of the diagnostic process . Based on the patients ' self-descriptions arguments could be developed for reducing the present confusing multiplicity of nosological concepts . One could arrive at a simpler system of broader diagnostic concepts in the field of neurosis and personality disorders which is more appropriate to the needs of clinical psychotherapy and psychotherapy research .

[ "A", "study", "of", "verbatim", "transcripts", "of", "47", "psychotherapeutical", "assessment", "interviews", ".", "Four", "groups", "were", "examined", ":", "patients", "with", "neurotic", "depressions", "(", "n=11", ")", ",", "patients", "with", "phobia", "and", "panic", "disorders", "(", "n=12", ")", ",", "patients", "suffering", "from", "severe", "personality", "disorders", "(", "n=12", ")", ",", "and", "patients", "with", "bulimia", "(", "n=12", ")", ".", "The", "interviews", "were", "systematically", "evaluated", "by", "means", "of", "qualitative", "content", "analysis", "focussing", "on", "the", "following", "categories", ":", "subjective", "theories", "of", "illness", ",", "biography", ",", "and", "characterization", "of", "their", "own", "personality", ".", "As", "a", "result", "ideal", "types", "of", "self", "-", "description", "were", "found", "which", "also", "serve", "to", "reconstruct", "the", "determinants", "of", "the", "diagnostic", "process", ".", "Based", "on", "the", "patients", "'", "self", "-", "descriptions", "arguments", "could", "be", "developed", "for", "reducing", "the", "present", "confusing", "multiplicity", "of", "nosological", "concepts", ".", "One", "could", "arrive", "at", "a", "simpler", "system", "of", "broader", "diagnostic", "concepts", "in", "the", "field", "of", "neurosis", "and", "personality", "disorders", "which", "is", "more", "appropriate", "to", "the", "needs", "of", "clinical", "psychotherapy", "and", "psychotherapy", "research", "." ]

[ "umlsterm" ]

assessment, interviews, patients, neurotic depressions, patients, phobia, panic disorders, patients, personality disorders, patients, bulimia, interviews, analysis, biography, personality, self - description, diagnostic, patients, diagnostic, neurosis, personality disorders, needs, psychotherapy, psychotherapy, research

Psychotherapeut.70420163.eng.abstr_task2

Sentence: A study of verbatim transcripts of 47 psychotherapeutical assessment interviews . Four groups were examined : patients with neurotic depressions ( n=11), patients with phobia and panic disorders ( n=12), patients suffering from severe personality disorders ( n=12), and patients with bulimia ( n=12). The interviews were systematically evaluated by means of qualitative content analysis focussing on the following categories : subjective theories of illness , biography , and characterization of their own personality . As a result ideal types of self-description were found which also serve to reconstruct the determinants of the diagnostic process . Based on the patients ' self-descriptions arguments could be developed for reducing the present confusing multiplicity of nosological concepts . One could arrive at a simpler system of broader diagnostic concepts in the field of neurosis and personality disorders which is more appropriate to the needs of clinical psychotherapy and psychotherapy research . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O" ]

A study of verbatim transcripts of 47 psychotherapeutical assessment interviews . Four groups were examined : patients with neurotic depressions ( n=11), patients with phobia and panic disorders ( n=12), patients suffering from severe personality disorders ( n=12), and patients with bulimia ( n=12). The interviews were systematically evaluated by means of qualitative content analysis focussing on the following categories : subjective theories of illness , biography , and characterization of their own personality . As a result ideal types of self-description were found which also serve to reconstruct the determinants of the diagnostic process . Based on the patients ' self-descriptions arguments could be developed for reducing the present confusing multiplicity of nosological concepts . One could arrive at a simpler system of broader diagnostic concepts in the field of neurosis and personality disorders which is more appropriate to the needs of clinical psychotherapy and psychotherapy research .

[ "A", "study", "of", "verbatim", "transcripts", "of", "47", "psychotherapeutical", "assessment", "interviews", ".", "Four", "groups", "were", "examined", ":", "patients", "with", "neurotic", "depressions", "(", "n=11", ")", ",", "patients", "with", "phobia", "and", "panic", "disorders", "(", "n=12", ")", ",", "patients", "suffering", "from", "severe", "personality", "disorders", "(", "n=12", ")", ",", "and", "patients", "with", "bulimia", "(", "n=12", ")", ".", "The", "interviews", "were", "systematically", "evaluated", "by", "means", "of", "qualitative", "content", "analysis", "focussing", "on", "the", "following", "categories", ":", "subjective", "theories", "of", "illness", ",", "biography", ",", "and", "characterization", "of", "their", "own", "personality", ".", "As", "a", "result", "ideal", "types", "of", "self", "-", "description", "were", "found", "which", "also", "serve", "to", "reconstruct", "the", "determinants", "of", "the", "diagnostic", "process", ".", "Based", "on", "the", "patients", "'", "self", "-", "descriptions", "arguments", "could", "be", "developed", "for", "reducing", "the", "present", "confusing", "multiplicity", "of", "nosological", "concepts", ".", "One", "could", "arrive", "at", "a", "simpler", "system", "of", "broader", "diagnostic", "concepts", "in", "the", "field", "of", "neurosis", "and", "personality", "disorders", "which", "is", "more", "appropriate", "to", "the", "needs", "of", "clinical", "psychotherapy", "and", "psychotherapy", "research", "." ]

[ "umlsterm" ]

Bipolar transurethral resection of the prostate is a Intervention_Surgical, monopolar technique : is a Intervention_Surgical, 202 is a Participant_Sample-size, bipolar is a Intervention_Surgical, conventional monopolar transurethral resection of the prostate ( TURP ) is a Intervention_Surgical, blood loss is a Outcome_Physical, resection speed is a Outcome_Other, operative duration is a Outcome_Other, resection weight is a Outcome_Other, radicality of resection is a Outcome_Other, blood haemoglobin concentration is a Outcome_Physical

42783_task0

Sentence: Bipolar transurethral resection of the prostate causes less bleeding than the monopolar technique : a single-centre randomized trial of 202 patients . OBJECTIVE To compare bipolar with the conventional monopolar transurethral resection of the prostate ( TURP ) for blood loss and speed of resection . PATIENTS AND METHODS In all , 202 consecutive patients from the hospital waiting list were randomized to undergo TURP using either a bipolar system ( Surgmaster TURis , Olympus , Tokyo , Japan ) or a monopolar system ( 24 F , Storz , Tübingen , Germany ) . The blood loss during and after surgery was measured using a photometer . Other variables compared included indices of resection speed and transfusion rate . RESULTS There were no statistically significant differences in operative duration , resection weight , resection speed or radicality of resection . However , the median blood loss was 235 mL for the bipolar and 350 mL for monopolar TURP ( P < 0.001 ) . The decrease in blood haemoglobin concentration during the day of surgery was smaller in the bipolar group ( 5.5 % vs 9.6 % P < 0.001 ) . Fewer patients were transfused with erythrocytes ( 4 % vs 11 % , P < 0.01 ) , which can be explained by the much lower 75th percentile for blood loss in the bipolar group ( at 472 vs 855 mL , respectively ) . CONCLUSIONS Bipolar TURP using the TURis system was performed with the same speed as monopolar TURP but caused 34 % less bleeding , the difference being greatest ( 81 % ) for the largest blood losses . Bipolar TURP also required fewer erythrocyte transfusions than the conventional monopolar technique . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Outcome_Physical, Intervention_Surgical, Participant_Sample-size

[ "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Bipolar transurethral resection of the prostate causes less bleeding than the monopolar technique : a single-centre randomized trial of 202 patients . OBJECTIVE To compare bipolar with the conventional monopolar transurethral resection of the prostate ( TURP ) for blood loss and speed of resection . PATIENTS AND METHODS In all , 202 consecutive patients from the hospital waiting list were randomized to undergo TURP using either a bipolar system ( Surgmaster TURis , Olympus , Tokyo , Japan ) or a monopolar system ( 24 F , Storz , Tübingen , Germany ) . The blood loss during and after surgery was measured using a photometer . Other variables compared included indices of resection speed and transfusion rate . RESULTS There were no statistically significant differences in operative duration , resection weight , resection speed or radicality of resection . However , the median blood loss was 235 mL for the bipolar and 350 mL for monopolar TURP ( P < 0.001 ) . The decrease in blood haemoglobin concentration during the day of surgery was smaller in the bipolar group ( 5.5 % vs 9.6 % P < 0.001 ) . Fewer patients were transfused with erythrocytes ( 4 % vs 11 % , P < 0.01 ) , which can be explained by the much lower 75th percentile for blood loss in the bipolar group ( at 472 vs 855 mL , respectively ) . CONCLUSIONS Bipolar TURP using the TURis system was performed with the same speed as monopolar TURP but caused 34 % less bleeding , the difference being greatest ( 81 % ) for the largest blood losses . Bipolar TURP also required fewer erythrocyte transfusions than the conventional monopolar technique .

[ "Bipolar", "transurethral", "resection", "of", "the", "prostate", "causes", "less", "bleeding", "than", "the", "monopolar", "technique", ":", "a", "single", "-", "centre", "randomized", "trial", "of", "202", "patients", ".", "OBJECTIVE", "To", "compare", "bipolar", "with", "the", "conventional", "monopolar", "transurethral", "resection", "of", "the", "prostate", "(", "TURP", ")", "for", "blood", "loss", "and", "speed", "of", "resection", ".", "PATIENTS", "AND", "METHODS", "In", "all", ",", "202", "consecutive", "patients", "from", "the", "hospital", "waiting", "list", "were", "randomized", "to", "undergo", "TURP", "using", "either", "a", "bipolar", "system", "(", "Surgmaster", "TURis", ",", "Olympus", ",", "Tokyo", ",", "Japan", ")", "or", "a", "monopolar", "system", "(", "24", "F", ",", "Storz", ",", "Tübingen", ",", "Germany", ")", ".", "The", "blood", "loss", "during", "and", "after", "surgery", "was", "measured", "using", "a", "photometer", ".", "Other", "variables", "compared", "included", "indices", "of", "resection", "speed", "and", "transfusion", "rate", ".", "RESULTS", "There", "were", "no", "statistically", "significant", "differences", "in", "operative", "duration", ",", "resection", "weight", ",", "resection", "speed", "or", "radicality", "of", "resection", ".", "However", ",", "the", "median", "blood", "loss", "was", "235", "mL", "for", "the", "bipolar", "and", "350", "mL", "for", "monopolar", "TURP", "(", "P", "<", "0.001", ")", ".", "The", "decrease", "in", "blood", "haemoglobin", "concentration", "during", "the", "day", "of", "surgery", "was", "smaller", "in", "the", "bipolar", "group", "(", "5.5", "%", "vs", "9.6", "%", "P", "<", "0.001", ")", ".", "Fewer", "patients", "were", "transfused", "with", "erythrocytes", "(", "4", "%", "vs", "11", "%", ",", "P", "<", "0.01", ")", ",", "which", "can", "be", "explained", "by", "the", "much", "lower", "75th", "percentile", "for", "blood", "loss", "in", "the", "bipolar", "group", "(", "at", "472", "vs", "855", "mL", ",", "respectively", ")", ".", "CONCLUSIONS", "Bipolar", "TURP", "using", "the", "TURis", "system", "was", "performed", "with", "the", "same", "speed", "as", "monopolar", "TURP", "but", "caused", "34", "%", "less", "bleeding", ",", "the", "difference", "being", "greatest", "(", "81", "%", ")", "for", "the", "largest", "blood", "losses", ".", "Bipolar", "TURP", "also", "required", "fewer", "erythrocyte", "transfusions", "than", "the", "conventional", "monopolar", "technique", "." ]

[ "Intervention_Surgical", "Participant_Condition", "Outcome_Physical", "Outcome_Other", "Participant_Sample-size" ]

Bipolar transurethral resection of the prostate is a Intervention_Surgical, monopolar technique : is a Intervention_Surgical, 202 is a Participant_Sample-size, bipolar is a Intervention_Surgical, conventional monopolar transurethral resection of the prostate ( TURP ) is a Intervention_Surgical, blood loss is a Outcome_Physical, resection speed is a Outcome_Other, operative duration is a Outcome_Other, resection weight is a Outcome_Other, radicality of resection is a Outcome_Other, blood haemoglobin concentration is a Outcome_Physical

42783_task1

Sentence: Bipolar transurethral resection of the prostate causes less bleeding than the monopolar technique : a single-centre randomized trial of 202 patients . OBJECTIVE To compare bipolar with the conventional monopolar transurethral resection of the prostate ( TURP ) for blood loss and speed of resection . PATIENTS AND METHODS In all , 202 consecutive patients from the hospital waiting list were randomized to undergo TURP using either a bipolar system ( Surgmaster TURis , Olympus , Tokyo , Japan ) or a monopolar system ( 24 F , Storz , Tübingen , Germany ) . The blood loss during and after surgery was measured using a photometer . Other variables compared included indices of resection speed and transfusion rate . RESULTS There were no statistically significant differences in operative duration , resection weight , resection speed or radicality of resection . However , the median blood loss was 235 mL for the bipolar and 350 mL for monopolar TURP ( P < 0.001 ) . The decrease in blood haemoglobin concentration during the day of surgery was smaller in the bipolar group ( 5.5 % vs 9.6 % P < 0.001 ) . Fewer patients were transfused with erythrocytes ( 4 % vs 11 % , P < 0.01 ) , which can be explained by the much lower 75th percentile for blood loss in the bipolar group ( at 472 vs 855 mL , respectively ) . CONCLUSIONS Bipolar TURP using the TURis system was performed with the same speed as monopolar TURP but caused 34 % less bleeding , the difference being greatest ( 81 % ) for the largest blood losses . Bipolar TURP also required fewer erythrocyte transfusions than the conventional monopolar technique . Instructions: please typing these entity words according to sentence: Bipolar transurethral resection of the prostate, monopolar technique :, 202, bipolar, conventional monopolar transurethral resection of the prostate ( TURP ), blood loss, resection speed, operative duration, resection weight, radicality of resection, blood haemoglobin concentration Options: Outcome_Other, Outcome_Physical, Intervention_Surgical, Participant_Sample-size

[ "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Bipolar transurethral resection of the prostate causes less bleeding than the monopolar technique : a single-centre randomized trial of 202 patients . OBJECTIVE To compare bipolar with the conventional monopolar transurethral resection of the prostate ( TURP ) for blood loss and speed of resection . PATIENTS AND METHODS In all , 202 consecutive patients from the hospital waiting list were randomized to undergo TURP using either a bipolar system ( Surgmaster TURis , Olympus , Tokyo , Japan ) or a monopolar system ( 24 F , Storz , Tübingen , Germany ) . The blood loss during and after surgery was measured using a photometer . Other variables compared included indices of resection speed and transfusion rate . RESULTS There were no statistically significant differences in operative duration , resection weight , resection speed or radicality of resection . However , the median blood loss was 235 mL for the bipolar and 350 mL for monopolar TURP ( P < 0.001 ) . The decrease in blood haemoglobin concentration during the day of surgery was smaller in the bipolar group ( 5.5 % vs 9.6 % P < 0.001 ) . Fewer patients were transfused with erythrocytes ( 4 % vs 11 % , P < 0.01 ) , which can be explained by the much lower 75th percentile for blood loss in the bipolar group ( at 472 vs 855 mL , respectively ) . CONCLUSIONS Bipolar TURP using the TURis system was performed with the same speed as monopolar TURP but caused 34 % less bleeding , the difference being greatest ( 81 % ) for the largest blood losses . Bipolar TURP also required fewer erythrocyte transfusions than the conventional monopolar technique .

[ "Bipolar", "transurethral", "resection", "of", "the", "prostate", "causes", "less", "bleeding", "than", "the", "monopolar", "technique", ":", "a", "single", "-", "centre", "randomized", "trial", "of", "202", "patients", ".", "OBJECTIVE", "To", "compare", "bipolar", "with", "the", "conventional", "monopolar", "transurethral", "resection", "of", "the", "prostate", "(", "TURP", ")", "for", "blood", "loss", "and", "speed", "of", "resection", ".", "PATIENTS", "AND", "METHODS", "In", "all", ",", "202", "consecutive", "patients", "from", "the", "hospital", "waiting", "list", "were", "randomized", "to", "undergo", "TURP", "using", "either", "a", "bipolar", "system", "(", "Surgmaster", "TURis", ",", "Olympus", ",", "Tokyo", ",", "Japan", ")", "or", "a", "monopolar", "system", "(", "24", "F", ",", "Storz", ",", "Tübingen", ",", "Germany", ")", ".", "The", "blood", "loss", "during", "and", "after", "surgery", "was", "measured", "using", "a", "photometer", ".", "Other", "variables", "compared", "included", "indices", "of", "resection", "speed", "and", "transfusion", "rate", ".", "RESULTS", "There", "were", "no", "statistically", "significant", "differences", "in", "operative", "duration", ",", "resection", "weight", ",", "resection", "speed", "or", "radicality", "of", "resection", ".", "However", ",", "the", "median", "blood", "loss", "was", "235", "mL", "for", "the", "bipolar", "and", "350", "mL", "for", "monopolar", "TURP", "(", "P", "<", "0.001", ")", ".", "The", "decrease", "in", "blood", "haemoglobin", "concentration", "during", "the", "day", "of", "surgery", "was", "smaller", "in", "the", "bipolar", "group", "(", "5.5", "%", "vs", "9.6", "%", "P", "<", "0.001", ")", ".", "Fewer", "patients", "were", "transfused", "with", "erythrocytes", "(", "4", "%", "vs", "11", "%", ",", "P", "<", "0.01", ")", ",", "which", "can", "be", "explained", "by", "the", "much", "lower", "75th", "percentile", "for", "blood", "loss", "in", "the", "bipolar", "group", "(", "at", "472", "vs", "855", "mL", ",", "respectively", ")", ".", "CONCLUSIONS", "Bipolar", "TURP", "using", "the", "TURis", "system", "was", "performed", "with", "the", "same", "speed", "as", "monopolar", "TURP", "but", "caused", "34", "%", "less", "bleeding", ",", "the", "difference", "being", "greatest", "(", "81", "%", ")", "for", "the", "largest", "blood", "losses", ".", "Bipolar", "TURP", "also", "required", "fewer", "erythrocyte", "transfusions", "than", "the", "conventional", "monopolar", "technique", "." ]

[ "Intervention_Surgical", "Participant_Condition", "Outcome_Physical", "Outcome_Other", "Participant_Sample-size" ]

Bipolar transurethral resection of the prostate, monopolar technique :, 202, bipolar, conventional monopolar transurethral resection of the prostate ( TURP ), blood loss, resection speed, operative duration, resection weight, radicality of resection, blood haemoglobin concentration

42783_task2

Sentence: Bipolar transurethral resection of the prostate causes less bleeding than the monopolar technique : a single-centre randomized trial of 202 patients . OBJECTIVE To compare bipolar with the conventional monopolar transurethral resection of the prostate ( TURP ) for blood loss and speed of resection . PATIENTS AND METHODS In all , 202 consecutive patients from the hospital waiting list were randomized to undergo TURP using either a bipolar system ( Surgmaster TURis , Olympus , Tokyo , Japan ) or a monopolar system ( 24 F , Storz , Tübingen , Germany ) . The blood loss during and after surgery was measured using a photometer . Other variables compared included indices of resection speed and transfusion rate . RESULTS There were no statistically significant differences in operative duration , resection weight , resection speed or radicality of resection . However , the median blood loss was 235 mL for the bipolar and 350 mL for monopolar TURP ( P < 0.001 ) . The decrease in blood haemoglobin concentration during the day of surgery was smaller in the bipolar group ( 5.5 % vs 9.6 % P < 0.001 ) . Fewer patients were transfused with erythrocytes ( 4 % vs 11 % , P < 0.01 ) , which can be explained by the much lower 75th percentile for blood loss in the bipolar group ( at 472 vs 855 mL , respectively ) . CONCLUSIONS Bipolar TURP using the TURis system was performed with the same speed as monopolar TURP but caused 34 % less bleeding , the difference being greatest ( 81 % ) for the largest blood losses . Bipolar TURP also required fewer erythrocyte transfusions than the conventional monopolar technique . Instructions: please extract entity words from the input sentence

[ "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Bipolar transurethral resection of the prostate causes less bleeding than the monopolar technique : a single-centre randomized trial of 202 patients . OBJECTIVE To compare bipolar with the conventional monopolar transurethral resection of the prostate ( TURP ) for blood loss and speed of resection . PATIENTS AND METHODS In all , 202 consecutive patients from the hospital waiting list were randomized to undergo TURP using either a bipolar system ( Surgmaster TURis , Olympus , Tokyo , Japan ) or a monopolar system ( 24 F , Storz , Tübingen , Germany ) . The blood loss during and after surgery was measured using a photometer . Other variables compared included indices of resection speed and transfusion rate . RESULTS There were no statistically significant differences in operative duration , resection weight , resection speed or radicality of resection . However , the median blood loss was 235 mL for the bipolar and 350 mL for monopolar TURP ( P < 0.001 ) . The decrease in blood haemoglobin concentration during the day of surgery was smaller in the bipolar group ( 5.5 % vs 9.6 % P < 0.001 ) . Fewer patients were transfused with erythrocytes ( 4 % vs 11 % , P < 0.01 ) , which can be explained by the much lower 75th percentile for blood loss in the bipolar group ( at 472 vs 855 mL , respectively ) . CONCLUSIONS Bipolar TURP using the TURis system was performed with the same speed as monopolar TURP but caused 34 % less bleeding , the difference being greatest ( 81 % ) for the largest blood losses . Bipolar TURP also required fewer erythrocyte transfusions than the conventional monopolar technique .

[ "Bipolar", "transurethral", "resection", "of", "the", "prostate", "causes", "less", "bleeding", "than", "the", "monopolar", "technique", ":", "a", "single", "-", "centre", "randomized", "trial", "of", "202", "patients", ".", "OBJECTIVE", "To", "compare", "bipolar", "with", "the", "conventional", "monopolar", "transurethral", "resection", "of", "the", "prostate", "(", "TURP", ")", "for", "blood", "loss", "and", "speed", "of", "resection", ".", "PATIENTS", "AND", "METHODS", "In", "all", ",", "202", "consecutive", "patients", "from", "the", "hospital", "waiting", "list", "were", "randomized", "to", "undergo", "TURP", "using", "either", "a", "bipolar", "system", "(", "Surgmaster", "TURis", ",", "Olympus", ",", "Tokyo", ",", "Japan", ")", "or", "a", "monopolar", "system", "(", "24", "F", ",", "Storz", ",", "Tübingen", ",", "Germany", ")", ".", "The", "blood", "loss", "during", "and", "after", "surgery", "was", "measured", "using", "a", "photometer", ".", "Other", "variables", "compared", "included", "indices", "of", "resection", "speed", "and", "transfusion", "rate", ".", "RESULTS", "There", "were", "no", "statistically", "significant", "differences", "in", "operative", "duration", ",", "resection", "weight", ",", "resection", "speed", "or", "radicality", "of", "resection", ".", "However", ",", "the", "median", "blood", "loss", "was", "235", "mL", "for", "the", "bipolar", "and", "350", "mL", "for", "monopolar", "TURP", "(", "P", "<", "0.001", ")", ".", "The", "decrease", "in", "blood", "haemoglobin", "concentration", "during", "the", "day", "of", "surgery", "was", "smaller", "in", "the", "bipolar", "group", "(", "5.5", "%", "vs", "9.6", "%", "P", "<", "0.001", ")", ".", "Fewer", "patients", "were", "transfused", "with", "erythrocytes", "(", "4", "%", "vs", "11", "%", ",", "P", "<", "0.01", ")", ",", "which", "can", "be", "explained", "by", "the", "much", "lower", "75th", "percentile", "for", "blood", "loss", "in", "the", "bipolar", "group", "(", "at", "472", "vs", "855", "mL", ",", "respectively", ")", ".", "CONCLUSIONS", "Bipolar", "TURP", "using", "the", "TURis", "system", "was", "performed", "with", "the", "same", "speed", "as", "monopolar", "TURP", "but", "caused", "34", "%", "less", "bleeding", ",", "the", "difference", "being", "greatest", "(", "81", "%", ")", "for", "the", "largest", "blood", "losses", ".", "Bipolar", "TURP", "also", "required", "fewer", "erythrocyte", "transfusions", "than", "the", "conventional", "monopolar", "technique", "." ]

[ "Intervention_Surgical", "Participant_Condition", "Outcome_Physical", "Outcome_Other", "Participant_Sample-size" ]

ritodrine is a CHEMICAL, ritodrine is a CHEMICAL, RU 486 is a CHEMICAL, mifepristone is a CHEMICAL, ritodrine is a CHEMICAL, beta 2-Adrenergic receptor is a GENE-Y, cyclic adenosine monophosphate is a CHEMICAL, Ritodrine is a CHEMICAL, ritodrine is a CHEMICAL, cyclic adenosine monophosphate is a CHEMICAL, beta 2-adrenergic receptor is a GENE-Y, ritodrine is a CHEMICAL, beta 2-adrenergic receptors is a GENE-Y

20354_task0

Sentence: Failure of ritodrine to prevent preterm labor in the sheep. OBJECTIVES: The purpose of this study was to determine whether continuous infusion of ritodrine could prevent preterm delivery in sheep. STUDY DESIGN: Sheep in preterm labor induced by RU 486 (mifepristone) received infusions of either ritodrine (n = 5) or saline solution (n = 5), and the progress of labor was monitored. beta 2-Adrenergic receptor density and function (agonist-induced cyclic adenosine monophosphate production) was measured in myometrial samples from both groups. RESULTS: Ritodrine initially inhibited labor contractions. This inhibition was only maintained for 16 hours, after which both the amplitude and frequency of electromyographic bursts and contractions returned. The failure of the myometrium to respond to ritodrine (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and beta 2-adrenergic receptor concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls. CONCLUSIONS: Continuous infusion of ritodrine to sheep in preterm labor produces only a transient inhibition of contractions. This desensitization is caused by a down-regulation of myometrial beta 2-adrenergic receptors. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]

Failure of ritodrine to prevent preterm labor in the sheep. OBJECTIVES: The purpose of this study was to determine whether continuous infusion of ritodrine could prevent preterm delivery in sheep. STUDY DESIGN: Sheep in preterm labor induced by RU 486 (mifepristone) received infusions of either ritodrine (n = 5) or saline solution (n = 5), and the progress of labor was monitored. beta 2-Adrenergic receptor density and function (agonist-induced cyclic adenosine monophosphate production) was measured in myometrial samples from both groups. RESULTS: Ritodrine initially inhibited labor contractions. This inhibition was only maintained for 16 hours, after which both the amplitude and frequency of electromyographic bursts and contractions returned. The failure of the myometrium to respond to ritodrine (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and beta 2-adrenergic receptor concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls. CONCLUSIONS: Continuous infusion of ritodrine to sheep in preterm labor produces only a transient inhibition of contractions. This desensitization is caused by a down-regulation of myometrial beta 2-adrenergic receptors.

[ "Failure", "of", "ritodrine", "to", "prevent", "preterm", "labor", "in", "the", "sheep", ".", "\n", "OBJECTIVES", ":", "The", "purpose", "of", "this", "study", "was", "to", "determine", "whether", "continuous", "infusion", "of", "ritodrine", "could", "prevent", "preterm", "delivery", "in", "sheep", ".", "STUDY", "DESIGN", ":", "Sheep", "in", "preterm", "labor", "induced", "by", "RU", "486", "(", "mifepristone", ")", "received", "infusions", "of", "either", "ritodrine", "(", "n", "=", "5", ")", "or", "saline", "solution", "(", "n", "=", "5", ")", ",", "and", "the", "progress", "of", "labor", "was", "monitored", ".", "beta", "2-Adrenergic", "receptor", "density", "and", "function", "(", "agonist", "-", "induced", "cyclic", "adenosine", "monophosphate", "production", ")", "was", "measured", "in", "myometrial", "samples", "from", "both", "groups", ".", "RESULTS", ":", "Ritodrine", "initially", "inhibited", "labor", "contractions", ".", "This", "inhibition", "was", "only", "maintained", "for", "16", "hours", ",", "after", "which", "both", "the", "amplitude", "and", "frequency", "of", "electromyographic", "bursts", "and", "contractions", "returned", ".", "The", "failure", "of", "the", "myometrium", "to", "respond", "to", "ritodrine", "(", "desensitization", ")", "was", "associated", "with", "significant", "reductions", "in", "agonist", "-", "induced", "cyclic", "adenosine", "monophosphate", "production", "and", "beta", "2-adrenergic", "receptor", "concentration", "in", "myometrial", "tissue", "collected", "from", "these", "animals", "compared", "with", "the", "saline", "solution", "-", "treated", "controls", ".", "CONCLUSIONS", ":", "Continuous", "infusion", "of", "ritodrine", "to", "sheep", "in", "preterm", "labor", "produces", "only", "a", "transient", "inhibition", "of", "contractions", ".", "This", "desensitization", "is", "caused", "by", "a", "down", "-", "regulation", "of", "myometrial", "beta", "2-adrenergic", "receptors", "." ]

[ "CHEMICAL", "GENE-Y" ]

ritodrine is a CHEMICAL, ritodrine is a CHEMICAL, RU 486 is a CHEMICAL, mifepristone is a CHEMICAL, ritodrine is a CHEMICAL, beta 2-Adrenergic receptor is a GENE-Y, cyclic adenosine monophosphate is a CHEMICAL, Ritodrine is a CHEMICAL, ritodrine is a CHEMICAL, cyclic adenosine monophosphate is a CHEMICAL, beta 2-adrenergic receptor is a GENE-Y, ritodrine is a CHEMICAL, beta 2-adrenergic receptors is a GENE-Y

20354_task1

Sentence: Failure of ritodrine to prevent preterm labor in the sheep. OBJECTIVES: The purpose of this study was to determine whether continuous infusion of ritodrine could prevent preterm delivery in sheep. STUDY DESIGN: Sheep in preterm labor induced by RU 486 (mifepristone) received infusions of either ritodrine (n = 5) or saline solution (n = 5), and the progress of labor was monitored. beta 2-Adrenergic receptor density and function (agonist-induced cyclic adenosine monophosphate production) was measured in myometrial samples from both groups. RESULTS: Ritodrine initially inhibited labor contractions. This inhibition was only maintained for 16 hours, after which both the amplitude and frequency of electromyographic bursts and contractions returned. The failure of the myometrium to respond to ritodrine (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and beta 2-adrenergic receptor concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls. CONCLUSIONS: Continuous infusion of ritodrine to sheep in preterm labor produces only a transient inhibition of contractions. This desensitization is caused by a down-regulation of myometrial beta 2-adrenergic receptors. Instructions: please typing these entity words according to sentence: ritodrine, ritodrine, RU 486, mifepristone, ritodrine, beta 2-Adrenergic receptor, cyclic adenosine monophosphate, Ritodrine, ritodrine, cyclic adenosine monophosphate, beta 2-adrenergic receptor, ritodrine, beta 2-adrenergic receptors Options: GENE-Y, CHEMICAL

[ "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]

Failure of ritodrine to prevent preterm labor in the sheep. OBJECTIVES: The purpose of this study was to determine whether continuous infusion of ritodrine could prevent preterm delivery in sheep. STUDY DESIGN: Sheep in preterm labor induced by RU 486 (mifepristone) received infusions of either ritodrine (n = 5) or saline solution (n = 5), and the progress of labor was monitored. beta 2-Adrenergic receptor density and function (agonist-induced cyclic adenosine monophosphate production) was measured in myometrial samples from both groups. RESULTS: Ritodrine initially inhibited labor contractions. This inhibition was only maintained for 16 hours, after which both the amplitude and frequency of electromyographic bursts and contractions returned. The failure of the myometrium to respond to ritodrine (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and beta 2-adrenergic receptor concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls. CONCLUSIONS: Continuous infusion of ritodrine to sheep in preterm labor produces only a transient inhibition of contractions. This desensitization is caused by a down-regulation of myometrial beta 2-adrenergic receptors.

[ "Failure", "of", "ritodrine", "to", "prevent", "preterm", "labor", "in", "the", "sheep", ".", "\n", "OBJECTIVES", ":", "The", "purpose", "of", "this", "study", "was", "to", "determine", "whether", "continuous", "infusion", "of", "ritodrine", "could", "prevent", "preterm", "delivery", "in", "sheep", ".", "STUDY", "DESIGN", ":", "Sheep", "in", "preterm", "labor", "induced", "by", "RU", "486", "(", "mifepristone", ")", "received", "infusions", "of", "either", "ritodrine", "(", "n", "=", "5", ")", "or", "saline", "solution", "(", "n", "=", "5", ")", ",", "and", "the", "progress", "of", "labor", "was", "monitored", ".", "beta", "2-Adrenergic", "receptor", "density", "and", "function", "(", "agonist", "-", "induced", "cyclic", "adenosine", "monophosphate", "production", ")", "was", "measured", "in", "myometrial", "samples", "from", "both", "groups", ".", "RESULTS", ":", "Ritodrine", "initially", "inhibited", "labor", "contractions", ".", "This", "inhibition", "was", "only", "maintained", "for", "16", "hours", ",", "after", "which", "both", "the", "amplitude", "and", "frequency", "of", "electromyographic", "bursts", "and", "contractions", "returned", ".", "The", "failure", "of", "the", "myometrium", "to", "respond", "to", "ritodrine", "(", "desensitization", ")", "was", "associated", "with", "significant", "reductions", "in", "agonist", "-", "induced", "cyclic", "adenosine", "monophosphate", "production", "and", "beta", "2-adrenergic", "receptor", "concentration", "in", "myometrial", "tissue", "collected", "from", "these", "animals", "compared", "with", "the", "saline", "solution", "-", "treated", "controls", ".", "CONCLUSIONS", ":", "Continuous", "infusion", "of", "ritodrine", "to", "sheep", "in", "preterm", "labor", "produces", "only", "a", "transient", "inhibition", "of", "contractions", ".", "This", "desensitization", "is", "caused", "by", "a", "down", "-", "regulation", "of", "myometrial", "beta", "2-adrenergic", "receptors", "." ]

[ "CHEMICAL", "GENE-Y" ]

ritodrine, ritodrine, RU 486, mifepristone, ritodrine, beta 2-Adrenergic receptor, cyclic adenosine monophosphate, Ritodrine, ritodrine, cyclic adenosine monophosphate, beta 2-adrenergic receptor, ritodrine, beta 2-adrenergic receptors

20354_task2

Sentence: Failure of ritodrine to prevent preterm labor in the sheep. OBJECTIVES: The purpose of this study was to determine whether continuous infusion of ritodrine could prevent preterm delivery in sheep. STUDY DESIGN: Sheep in preterm labor induced by RU 486 (mifepristone) received infusions of either ritodrine (n = 5) or saline solution (n = 5), and the progress of labor was monitored. beta 2-Adrenergic receptor density and function (agonist-induced cyclic adenosine monophosphate production) was measured in myometrial samples from both groups. RESULTS: Ritodrine initially inhibited labor contractions. This inhibition was only maintained for 16 hours, after which both the amplitude and frequency of electromyographic bursts and contractions returned. The failure of the myometrium to respond to ritodrine (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and beta 2-adrenergic receptor concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls. CONCLUSIONS: Continuous infusion of ritodrine to sheep in preterm labor produces only a transient inhibition of contractions. This desensitization is caused by a down-regulation of myometrial beta 2-adrenergic receptors. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]

Failure of ritodrine to prevent preterm labor in the sheep. OBJECTIVES: The purpose of this study was to determine whether continuous infusion of ritodrine could prevent preterm delivery in sheep. STUDY DESIGN: Sheep in preterm labor induced by RU 486 (mifepristone) received infusions of either ritodrine (n = 5) or saline solution (n = 5), and the progress of labor was monitored. beta 2-Adrenergic receptor density and function (agonist-induced cyclic adenosine monophosphate production) was measured in myometrial samples from both groups. RESULTS: Ritodrine initially inhibited labor contractions. This inhibition was only maintained for 16 hours, after which both the amplitude and frequency of electromyographic bursts and contractions returned. The failure of the myometrium to respond to ritodrine (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and beta 2-adrenergic receptor concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls. CONCLUSIONS: Continuous infusion of ritodrine to sheep in preterm labor produces only a transient inhibition of contractions. This desensitization is caused by a down-regulation of myometrial beta 2-adrenergic receptors.

[ "Failure", "of", "ritodrine", "to", "prevent", "preterm", "labor", "in", "the", "sheep", ".", "\n", "OBJECTIVES", ":", "The", "purpose", "of", "this", "study", "was", "to", "determine", "whether", "continuous", "infusion", "of", "ritodrine", "could", "prevent", "preterm", "delivery", "in", "sheep", ".", "STUDY", "DESIGN", ":", "Sheep", "in", "preterm", "labor", "induced", "by", "RU", "486", "(", "mifepristone", ")", "received", "infusions", "of", "either", "ritodrine", "(", "n", "=", "5", ")", "or", "saline", "solution", "(", "n", "=", "5", ")", ",", "and", "the", "progress", "of", "labor", "was", "monitored", ".", "beta", "2-Adrenergic", "receptor", "density", "and", "function", "(", "agonist", "-", "induced", "cyclic", "adenosine", "monophosphate", "production", ")", "was", "measured", "in", "myometrial", "samples", "from", "both", "groups", ".", "RESULTS", ":", "Ritodrine", "initially", "inhibited", "labor", "contractions", ".", "This", "inhibition", "was", "only", "maintained", "for", "16", "hours", ",", "after", "which", "both", "the", "amplitude", "and", "frequency", "of", "electromyographic", "bursts", "and", "contractions", "returned", ".", "The", "failure", "of", "the", "myometrium", "to", "respond", "to", "ritodrine", "(", "desensitization", ")", "was", "associated", "with", "significant", "reductions", "in", "agonist", "-", "induced", "cyclic", "adenosine", "monophosphate", "production", "and", "beta", "2-adrenergic", "receptor", "concentration", "in", "myometrial", "tissue", "collected", "from", "these", "animals", "compared", "with", "the", "saline", "solution", "-", "treated", "controls", ".", "CONCLUSIONS", ":", "Continuous", "infusion", "of", "ritodrine", "to", "sheep", "in", "preterm", "labor", "produces", "only", "a", "transient", "inhibition", "of", "contractions", ".", "This", "desensitization", "is", "caused", "by", "a", "down", "-", "regulation", "of", "myometrial", "beta", "2-adrenergic", "receptors", "." ]

[ "CHEMICAL", "GENE-Y" ]

arrhythmias is an umlsterm, diagnosis is an umlsterm, selection is an umlsterm, therapy is an umlsterm, Signs is an umlsterm, standard is an umlsterm, ECG is an umlsterm, analysis is an umlsterm, evaluation is an umlsterm, EPS is an umlsterm, myocardium is an umlsterm, EPS is an umlsterm, pacing is an umlsterm, pacing is an umlsterm, standard is an umlsterm, EPS is an umlsterm, pacing is an umlsterm, diagnostic is an umlsterm, leads is an umlsterm, pacing is an umlsterm, telemetry is an umlsterm, time is an umlsterm, analysis is an umlsterm, pacing is an umlsterm, arrhythmias is an umlsterm, pacing is an umlsterm, pacing is an umlsterm, sinus is an umlsterm, pacing is an umlsterm, pacing is an umlsterm, times is an umlsterm, pacing is an umlsterm, sinus is an umlsterm, pacing is an umlsterm, EPS is an umlsterm, pacing is an umlsterm, patients is an umlsterm, need is an umlsterm, pacing is an umlsterm, Time is an umlsterm, analysis is an umlsterm, diagnostic is an umlsterm, evaluation is an umlsterm, EPS is an umlsterm, pacing is an umlsterm

Herzschrittmachertherapie.00110117.eng.abstr_task0

Sentence: Intraartial conduction disturbances ( IACD ) are the known substrate of re-entrant atrial arrhythmias and their diagnosis is important for the selection of proper therapy . Signs of IACD can be missed on the standard ECG , and signal averaged ( SA ) P wave analysis has proved valuable for the evaluation of electrophysiological ( EPS ) properties of atrial myocardium . Unfavourable EPS effects of RAA pacing are known to electrophysiologists , but this aspect is rarely considered in normal practice , and RAA based pacing modes remain standard even for pts . with IACD . We examined and compared EPS effects of different atrial pacing modes using two diagnostic tools : IEGM obtained from two atrial leads of biatrial pacing system ( via telemetry ) and time domain analysis of SA P wave in 22 pts . with BiA pacing system ( implanted due to atrial arrhythmias and IACD ) . The results showed that different atrial pacing modes influence atrial activation timing parameters differently : RAA pacing aggravates IACD in comparison to sinus rhythm ; the effects of CS pacing is less visible . BiA pacing normalises all atrial activation times . The normalisation of SA P wave duration , reduction of SA P wave dispersion , increasing of RMS 20 and decreasing of LAS 5 and finally abolition of presence of late atrial potentials in most of pts . indicates beneficial effects of BiA pacing ( in pts . with IACD ) in comparison to sinus rhythm and RAA pacing . Unfavourable EPS effects of RAA pacing in patients with IACD indicates suitability the need for alternative ( resynchronising ) atrial pacing modes . Time domain analysis of SA P wave is a valuable and sensitive diagnostic tool for non-invasive evaluation of EPS effects of different modes of atrial pacing . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Intraartial conduction disturbances ( IACD ) are the known substrate of re-entrant atrial arrhythmias and their diagnosis is important for the selection of proper therapy . Signs of IACD can be missed on the standard ECG , and signal averaged ( SA ) P wave analysis has proved valuable for the evaluation of electrophysiological ( EPS ) properties of atrial myocardium . Unfavourable EPS effects of RAA pacing are known to electrophysiologists , but this aspect is rarely considered in normal practice , and RAA based pacing modes remain standard even for pts . with IACD . We examined and compared EPS effects of different atrial pacing modes using two diagnostic tools : IEGM obtained from two atrial leads of biatrial pacing system ( via telemetry ) and time domain analysis of SA P wave in 22 pts . with BiA pacing system ( implanted due to atrial arrhythmias and IACD ) . The results showed that different atrial pacing modes influence atrial activation timing parameters differently : RAA pacing aggravates IACD in comparison to sinus rhythm ; the effects of CS pacing is less visible . BiA pacing normalises all atrial activation times . The normalisation of SA P wave duration , reduction of SA P wave dispersion , increasing of RMS 20 and decreasing of LAS 5 and finally abolition of presence of late atrial potentials in most of pts . indicates beneficial effects of BiA pacing ( in pts . with IACD ) in comparison to sinus rhythm and RAA pacing . Unfavourable EPS effects of RAA pacing in patients with IACD indicates suitability the need for alternative ( resynchronising ) atrial pacing modes . Time domain analysis of SA P wave is a valuable and sensitive diagnostic tool for non-invasive evaluation of EPS effects of different modes of atrial pacing .

[ "Intraartial", "conduction", "disturbances", "(", "IACD", ")", "are", "the", "known", "substrate", "of", "re", "-", "entrant", "atrial", "arrhythmias", "and", "their", "diagnosis", "is", "important", "for", "the", "selection", "of", "proper", "therapy", ".", "Signs", "of", "IACD", "can", "be", "missed", "on", "the", "standard", "ECG", ",", "and", "signal", "averaged", "(", "SA", ")", "P", "wave", "analysis", "has", "proved", "valuable", "for", "the", "evaluation", "of", "electrophysiological", "(", "EPS", ")", "properties", "of", "atrial", "myocardium", ".", "Unfavourable", "EPS", "effects", "of", "RAA", "pacing", "are", "known", "to", "electrophysiologists", ",", "but", "this", "aspect", "is", "rarely", "considered", "in", "normal", "practice", ",", "and", "RAA", "based", "pacing", "modes", "remain", "standard", "even", "for", "pts", ".", "with", "IACD", ".", "We", "examined", "and", "compared", "EPS", "effects", "of", "different", "atrial", "pacing", "modes", "using", "two", "diagnostic", "tools", ":", "IEGM", "obtained", "from", "two", "atrial", "leads", "of", "biatrial", "pacing", "system", "(", "via", "telemetry", ")", "and", "time", "domain", "analysis", "of", "SA", "P", "wave", "in", "22", "pts", ".", "with", "BiA", "pacing", "system", "(", "implanted", "due", "to", "atrial", "arrhythmias", "and", "IACD", ")", ".", "The", "results", "showed", "that", "different", "atrial", "pacing", "modes", "influence", "atrial", "activation", "timing", "parameters", "differently", ":", "RAA", "pacing", "aggravates", "IACD", "in", "comparison", "to", "sinus", "rhythm", ";", "the", "effects", "of", "CS", "pacing", "is", "less", "visible", ".", "BiA", "pacing", "normalises", "all", "atrial", "activation", "times", ".", "The", "normalisation", "of", "SA", "P", "wave", "duration", ",", "reduction", "of", "SA", "P", "wave", "dispersion", ",", "increasing", "of", "RMS", "20", "and", "decreasing", "of", "LAS", "5", "and", "finally", "abolition", "of", "presence", "of", "late", "atrial", "potentials", "in", "most", "of", "pts", ".", "indicates", "beneficial", "effects", "of", "BiA", "pacing", "(", "in", "pts", ".", "with", "IACD", ")", "in", "comparison", "to", "sinus", "rhythm", "and", "RAA", "pacing", ".", "Unfavourable", "EPS", "effects", "of", "RAA", "pacing", "in", "patients", "with", "IACD", "indicates", "suitability", "the", "need", "for", "alternative", "(", "resynchronising", ")", "atrial", "pacing", "modes", ".", "Time", "domain", "analysis", "of", "SA", "P", "wave", "is", "a", "valuable", "and", "sensitive", "diagnostic", "tool", "for", "non", "-", "invasive", "evaluation", "of", "EPS", "effects", "of", "different", "modes", "of", "atrial", "pacing", "." ]

[ "umlsterm" ]

arrhythmias is an umlsterm, diagnosis is an umlsterm, selection is an umlsterm, therapy is an umlsterm, Signs is an umlsterm, standard is an umlsterm, ECG is an umlsterm, analysis is an umlsterm, evaluation is an umlsterm, EPS is an umlsterm, myocardium is an umlsterm, EPS is an umlsterm, pacing is an umlsterm, pacing is an umlsterm, standard is an umlsterm, EPS is an umlsterm, pacing is an umlsterm, diagnostic is an umlsterm, leads is an umlsterm, pacing is an umlsterm, telemetry is an umlsterm, time is an umlsterm, analysis is an umlsterm, pacing is an umlsterm, arrhythmias is an umlsterm, pacing is an umlsterm, pacing is an umlsterm, sinus is an umlsterm, pacing is an umlsterm, pacing is an umlsterm, times is an umlsterm, pacing is an umlsterm, sinus is an umlsterm, pacing is an umlsterm, EPS is an umlsterm, pacing is an umlsterm, patients is an umlsterm, need is an umlsterm, pacing is an umlsterm, Time is an umlsterm, analysis is an umlsterm, diagnostic is an umlsterm, evaluation is an umlsterm, EPS is an umlsterm, pacing is an umlsterm

Herzschrittmachertherapie.00110117.eng.abstr_task1

Sentence: Intraartial conduction disturbances ( IACD ) are the known substrate of re-entrant atrial arrhythmias and their diagnosis is important for the selection of proper therapy . Signs of IACD can be missed on the standard ECG , and signal averaged ( SA ) P wave analysis has proved valuable for the evaluation of electrophysiological ( EPS ) properties of atrial myocardium . Unfavourable EPS effects of RAA pacing are known to electrophysiologists , but this aspect is rarely considered in normal practice , and RAA based pacing modes remain standard even for pts . with IACD . We examined and compared EPS effects of different atrial pacing modes using two diagnostic tools : IEGM obtained from two atrial leads of biatrial pacing system ( via telemetry ) and time domain analysis of SA P wave in 22 pts . with BiA pacing system ( implanted due to atrial arrhythmias and IACD ) . The results showed that different atrial pacing modes influence atrial activation timing parameters differently : RAA pacing aggravates IACD in comparison to sinus rhythm ; the effects of CS pacing is less visible . BiA pacing normalises all atrial activation times . The normalisation of SA P wave duration , reduction of SA P wave dispersion , increasing of RMS 20 and decreasing of LAS 5 and finally abolition of presence of late atrial potentials in most of pts . indicates beneficial effects of BiA pacing ( in pts . with IACD ) in comparison to sinus rhythm and RAA pacing . Unfavourable EPS effects of RAA pacing in patients with IACD indicates suitability the need for alternative ( resynchronising ) atrial pacing modes . Time domain analysis of SA P wave is a valuable and sensitive diagnostic tool for non-invasive evaluation of EPS effects of different modes of atrial pacing . Instructions: please typing these entity words according to sentence: arrhythmias, diagnosis, selection, therapy, Signs, standard, ECG, analysis, evaluation, EPS, myocardium, EPS, pacing, pacing, standard, EPS, pacing, diagnostic, leads, pacing, telemetry, time, analysis, pacing, arrhythmias, pacing, pacing, sinus, pacing, pacing, times, pacing, sinus, pacing, EPS, pacing, patients, need, pacing, Time, analysis, diagnostic, evaluation, EPS, pacing Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Intraartial conduction disturbances ( IACD ) are the known substrate of re-entrant atrial arrhythmias and their diagnosis is important for the selection of proper therapy . Signs of IACD can be missed on the standard ECG , and signal averaged ( SA ) P wave analysis has proved valuable for the evaluation of electrophysiological ( EPS ) properties of atrial myocardium . Unfavourable EPS effects of RAA pacing are known to electrophysiologists , but this aspect is rarely considered in normal practice , and RAA based pacing modes remain standard even for pts . with IACD . We examined and compared EPS effects of different atrial pacing modes using two diagnostic tools : IEGM obtained from two atrial leads of biatrial pacing system ( via telemetry ) and time domain analysis of SA P wave in 22 pts . with BiA pacing system ( implanted due to atrial arrhythmias and IACD ) . The results showed that different atrial pacing modes influence atrial activation timing parameters differently : RAA pacing aggravates IACD in comparison to sinus rhythm ; the effects of CS pacing is less visible . BiA pacing normalises all atrial activation times . The normalisation of SA P wave duration , reduction of SA P wave dispersion , increasing of RMS 20 and decreasing of LAS 5 and finally abolition of presence of late atrial potentials in most of pts . indicates beneficial effects of BiA pacing ( in pts . with IACD ) in comparison to sinus rhythm and RAA pacing . Unfavourable EPS effects of RAA pacing in patients with IACD indicates suitability the need for alternative ( resynchronising ) atrial pacing modes . Time domain analysis of SA P wave is a valuable and sensitive diagnostic tool for non-invasive evaluation of EPS effects of different modes of atrial pacing .

[ "Intraartial", "conduction", "disturbances", "(", "IACD", ")", "are", "the", "known", "substrate", "of", "re", "-", "entrant", "atrial", "arrhythmias", "and", "their", "diagnosis", "is", "important", "for", "the", "selection", "of", "proper", "therapy", ".", "Signs", "of", "IACD", "can", "be", "missed", "on", "the", "standard", "ECG", ",", "and", "signal", "averaged", "(", "SA", ")", "P", "wave", "analysis", "has", "proved", "valuable", "for", "the", "evaluation", "of", "electrophysiological", "(", "EPS", ")", "properties", "of", "atrial", "myocardium", ".", "Unfavourable", "EPS", "effects", "of", "RAA", "pacing", "are", "known", "to", "electrophysiologists", ",", "but", "this", "aspect", "is", "rarely", "considered", "in", "normal", "practice", ",", "and", "RAA", "based", "pacing", "modes", "remain", "standard", "even", "for", "pts", ".", "with", "IACD", ".", "We", "examined", "and", "compared", "EPS", "effects", "of", "different", "atrial", "pacing", "modes", "using", "two", "diagnostic", "tools", ":", "IEGM", "obtained", "from", "two", "atrial", "leads", "of", "biatrial", "pacing", "system", "(", "via", "telemetry", ")", "and", "time", "domain", "analysis", "of", "SA", "P", "wave", "in", "22", "pts", ".", "with", "BiA", "pacing", "system", "(", "implanted", "due", "to", "atrial", "arrhythmias", "and", "IACD", ")", ".", "The", "results", "showed", "that", "different", "atrial", "pacing", "modes", "influence", "atrial", "activation", "timing", "parameters", "differently", ":", "RAA", "pacing", "aggravates", "IACD", "in", "comparison", "to", "sinus", "rhythm", ";", "the", "effects", "of", "CS", "pacing", "is", "less", "visible", ".", "BiA", "pacing", "normalises", "all", "atrial", "activation", "times", ".", "The", "normalisation", "of", "SA", "P", "wave", "duration", ",", "reduction", "of", "SA", "P", "wave", "dispersion", ",", "increasing", "of", "RMS", "20", "and", "decreasing", "of", "LAS", "5", "and", "finally", "abolition", "of", "presence", "of", "late", "atrial", "potentials", "in", "most", "of", "pts", ".", "indicates", "beneficial", "effects", "of", "BiA", "pacing", "(", "in", "pts", ".", "with", "IACD", ")", "in", "comparison", "to", "sinus", "rhythm", "and", "RAA", "pacing", ".", "Unfavourable", "EPS", "effects", "of", "RAA", "pacing", "in", "patients", "with", "IACD", "indicates", "suitability", "the", "need", "for", "alternative", "(", "resynchronising", ")", "atrial", "pacing", "modes", ".", "Time", "domain", "analysis", "of", "SA", "P", "wave", "is", "a", "valuable", "and", "sensitive", "diagnostic", "tool", "for", "non", "-", "invasive", "evaluation", "of", "EPS", "effects", "of", "different", "modes", "of", "atrial", "pacing", "." ]

[ "umlsterm" ]

arrhythmias, diagnosis, selection, therapy, Signs, standard, ECG, analysis, evaluation, EPS, myocardium, EPS, pacing, pacing, standard, EPS, pacing, diagnostic, leads, pacing, telemetry, time, analysis, pacing, arrhythmias, pacing, pacing, sinus, pacing, pacing, times, pacing, sinus, pacing, EPS, pacing, patients, need, pacing, Time, analysis, diagnostic, evaluation, EPS, pacing

Herzschrittmachertherapie.00110117.eng.abstr_task2

Sentence: Intraartial conduction disturbances ( IACD ) are the known substrate of re-entrant atrial arrhythmias and their diagnosis is important for the selection of proper therapy . Signs of IACD can be missed on the standard ECG , and signal averaged ( SA ) P wave analysis has proved valuable for the evaluation of electrophysiological ( EPS ) properties of atrial myocardium . Unfavourable EPS effects of RAA pacing are known to electrophysiologists , but this aspect is rarely considered in normal practice , and RAA based pacing modes remain standard even for pts . with IACD . We examined and compared EPS effects of different atrial pacing modes using two diagnostic tools : IEGM obtained from two atrial leads of biatrial pacing system ( via telemetry ) and time domain analysis of SA P wave in 22 pts . with BiA pacing system ( implanted due to atrial arrhythmias and IACD ) . The results showed that different atrial pacing modes influence atrial activation timing parameters differently : RAA pacing aggravates IACD in comparison to sinus rhythm ; the effects of CS pacing is less visible . BiA pacing normalises all atrial activation times . The normalisation of SA P wave duration , reduction of SA P wave dispersion , increasing of RMS 20 and decreasing of LAS 5 and finally abolition of presence of late atrial potentials in most of pts . indicates beneficial effects of BiA pacing ( in pts . with IACD ) in comparison to sinus rhythm and RAA pacing . Unfavourable EPS effects of RAA pacing in patients with IACD indicates suitability the need for alternative ( resynchronising ) atrial pacing modes . Time domain analysis of SA P wave is a valuable and sensitive diagnostic tool for non-invasive evaluation of EPS effects of different modes of atrial pacing . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Intraartial conduction disturbances ( IACD ) are the known substrate of re-entrant atrial arrhythmias and their diagnosis is important for the selection of proper therapy . Signs of IACD can be missed on the standard ECG , and signal averaged ( SA ) P wave analysis has proved valuable for the evaluation of electrophysiological ( EPS ) properties of atrial myocardium . Unfavourable EPS effects of RAA pacing are known to electrophysiologists , but this aspect is rarely considered in normal practice , and RAA based pacing modes remain standard even for pts . with IACD . We examined and compared EPS effects of different atrial pacing modes using two diagnostic tools : IEGM obtained from two atrial leads of biatrial pacing system ( via telemetry ) and time domain analysis of SA P wave in 22 pts . with BiA pacing system ( implanted due to atrial arrhythmias and IACD ) . The results showed that different atrial pacing modes influence atrial activation timing parameters differently : RAA pacing aggravates IACD in comparison to sinus rhythm ; the effects of CS pacing is less visible . BiA pacing normalises all atrial activation times . The normalisation of SA P wave duration , reduction of SA P wave dispersion , increasing of RMS 20 and decreasing of LAS 5 and finally abolition of presence of late atrial potentials in most of pts . indicates beneficial effects of BiA pacing ( in pts . with IACD ) in comparison to sinus rhythm and RAA pacing . Unfavourable EPS effects of RAA pacing in patients with IACD indicates suitability the need for alternative ( resynchronising ) atrial pacing modes . Time domain analysis of SA P wave is a valuable and sensitive diagnostic tool for non-invasive evaluation of EPS effects of different modes of atrial pacing .

[ "Intraartial", "conduction", "disturbances", "(", "IACD", ")", "are", "the", "known", "substrate", "of", "re", "-", "entrant", "atrial", "arrhythmias", "and", "their", "diagnosis", "is", "important", "for", "the", "selection", "of", "proper", "therapy", ".", "Signs", "of", "IACD", "can", "be", "missed", "on", "the", "standard", "ECG", ",", "and", "signal", "averaged", "(", "SA", ")", "P", "wave", "analysis", "has", "proved", "valuable", "for", "the", "evaluation", "of", "electrophysiological", "(", "EPS", ")", "properties", "of", "atrial", "myocardium", ".", "Unfavourable", "EPS", "effects", "of", "RAA", "pacing", "are", "known", "to", "electrophysiologists", ",", "but", "this", "aspect", "is", "rarely", "considered", "in", "normal", "practice", ",", "and", "RAA", "based", "pacing", "modes", "remain", "standard", "even", "for", "pts", ".", "with", "IACD", ".", "We", "examined", "and", "compared", "EPS", "effects", "of", "different", "atrial", "pacing", "modes", "using", "two", "diagnostic", "tools", ":", "IEGM", "obtained", "from", "two", "atrial", "leads", "of", "biatrial", "pacing", "system", "(", "via", "telemetry", ")", "and", "time", "domain", "analysis", "of", "SA", "P", "wave", "in", "22", "pts", ".", "with", "BiA", "pacing", "system", "(", "implanted", "due", "to", "atrial", "arrhythmias", "and", "IACD", ")", ".", "The", "results", "showed", "that", "different", "atrial", "pacing", "modes", "influence", "atrial", "activation", "timing", "parameters", "differently", ":", "RAA", "pacing", "aggravates", "IACD", "in", "comparison", "to", "sinus", "rhythm", ";", "the", "effects", "of", "CS", "pacing", "is", "less", "visible", ".", "BiA", "pacing", "normalises", "all", "atrial", "activation", "times", ".", "The", "normalisation", "of", "SA", "P", "wave", "duration", ",", "reduction", "of", "SA", "P", "wave", "dispersion", ",", "increasing", "of", "RMS", "20", "and", "decreasing", "of", "LAS", "5", "and", "finally", "abolition", "of", "presence", "of", "late", "atrial", "potentials", "in", "most", "of", "pts", ".", "indicates", "beneficial", "effects", "of", "BiA", "pacing", "(", "in", "pts", ".", "with", "IACD", ")", "in", "comparison", "to", "sinus", "rhythm", "and", "RAA", "pacing", ".", "Unfavourable", "EPS", "effects", "of", "RAA", "pacing", "in", "patients", "with", "IACD", "indicates", "suitability", "the", "need", "for", "alternative", "(", "resynchronising", ")", "atrial", "pacing", "modes", ".", "Time", "domain", "analysis", "of", "SA", "P", "wave", "is", "a", "valuable", "and", "sensitive", "diagnostic", "tool", "for", "non", "-", "invasive", "evaluation", "of", "EPS", "effects", "of", "different", "modes", "of", "atrial", "pacing", "." ]

[ "umlsterm" ]

aminoglycosides is a GROUP, gentamicin is a DRUG, amikacin is a DRUG, amphotericin B is a DRUG, cyclosporine is a DRUG, non - steroidal anti - inflammatory is a GROUP, ibuprofen is a DRUG, tacrolimus is a DRUG, vancomycin is a DRUG

Adefovir Dipivoxil_ddi_task0

Sentence: Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin. Do not start or stop any medicine without doctor or pharmacist approval. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, DRUG

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "I-DRUG", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin. Do not start or stop any medicine without doctor or pharmacist approval.

[ "Before", "using", "this", "medication", ",", "tell", "your", "doctor", "or", "pharmacist", "of", "all", "prescription", "and", "nonprescription", "products", "you", "may", "use", ",", "especially", "of", ":", "aminoglycosides", "(", "e.g", ".", ",", "gentamicin", ",", "amikacin", ")", ",", "amphotericin", "B", ",", "cyclosporine", ",", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "(", "e.g", ".", ",", "ibuprofen", ")", ",", "tacrolimus", ",", "vancomycin", ".", "Do", "not", "start", "or", "stop", "any", "medicine", "without", "doctor", "or", "pharmacist", "approval", "." ]

[ "GROUP", "DRUG" ]

aminoglycosides is a GROUP, gentamicin is a DRUG, amikacin is a DRUG, amphotericin B is a DRUG, cyclosporine is a DRUG, non - steroidal anti - inflammatory is a GROUP, ibuprofen is a DRUG, tacrolimus is a DRUG, vancomycin is a DRUG

Adefovir Dipivoxil_ddi_task1

Sentence: Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin. Do not start or stop any medicine without doctor or pharmacist approval. Instructions: please typing these entity words according to sentence: aminoglycosides, gentamicin, amikacin, amphotericin B, cyclosporine, non - steroidal anti - inflammatory, ibuprofen, tacrolimus, vancomycin Options: GROUP, DRUG

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "I-DRUG", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin. Do not start or stop any medicine without doctor or pharmacist approval.

[ "Before", "using", "this", "medication", ",", "tell", "your", "doctor", "or", "pharmacist", "of", "all", "prescription", "and", "nonprescription", "products", "you", "may", "use", ",", "especially", "of", ":", "aminoglycosides", "(", "e.g", ".", ",", "gentamicin", ",", "amikacin", ")", ",", "amphotericin", "B", ",", "cyclosporine", ",", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "(", "e.g", ".", ",", "ibuprofen", ")", ",", "tacrolimus", ",", "vancomycin", ".", "Do", "not", "start", "or", "stop", "any", "medicine", "without", "doctor", "or", "pharmacist", "approval", "." ]

[ "GROUP", "DRUG" ]

aminoglycosides, gentamicin, amikacin, amphotericin B, cyclosporine, non - steroidal anti - inflammatory, ibuprofen, tacrolimus, vancomycin

Adefovir Dipivoxil_ddi_task2

Sentence: Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin. Do not start or stop any medicine without doctor or pharmacist approval. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "I-DRUG", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin. Do not start or stop any medicine without doctor or pharmacist approval.

[ "Before", "using", "this", "medication", ",", "tell", "your", "doctor", "or", "pharmacist", "of", "all", "prescription", "and", "nonprescription", "products", "you", "may", "use", ",", "especially", "of", ":", "aminoglycosides", "(", "e.g", ".", ",", "gentamicin", ",", "amikacin", ")", ",", "amphotericin", "B", ",", "cyclosporine", ",", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "(", "e.g", ".", ",", "ibuprofen", ")", ",", "tacrolimus", ",", "vancomycin", ".", "Do", "not", "start", "or", "stop", "any", "medicine", "without", "doctor", "or", "pharmacist", "approval", "." ]

[ "GROUP", "DRUG" ]

Behandlung is an umlsterm, Patienten is an umlsterm, kutanem T - Zell - Lymphom is an umlsterm, Therapieverfahren is an umlsterm, photodynamischen Therapie is an umlsterm, Therapieverfahren is an umlsterm, Ohr is an umlsterm, Augenbraue is an umlsterm, Fusskante is an umlsterm, Patient is an umlsterm, Ohr is an umlsterm, Therapie is an umlsterm, Interferon- is an umlsterm, Tumorwachstum is an umlsterm, Patient is an umlsterm, Ohr is an umlsterm, Radiotherapie is an umlsterm, Patient is an umlsterm, Mycosis fungoides is an umlsterm, Tumorstadium is an umlsterm, Patient is an umlsterm, PUVA - Therapie is an umlsterm, Interferon- is an umlsterm, photodynamische Therapie is an umlsterm, Augenbraue is an umlsterm, Fusskante is an umlsterm, Behandlung is an umlsterm

DerHautarzt.90500109.ger.abstr_task0

Sentence: Die Behandlung der heterogenen Gruppe primaer kutaner B- und T-Zell-Lymphome erfolgt stadienadaptiert , aber insbesondere bei den seltenen Formen bisher nicht standardisiert . Wir berichten ueber 2 Patienten mit primaer kutanem T-Zell-Lymphom ( CTCL ) , die neben etablierten Therapieverfahren einer topischen photodynamischen Therapie ( PDT ) in besonderer und fuer die klassischen Therapieverfahren nur schwer zugaenglicher Lokalisation ( Ohr Augenbraue , Fusskante ) , zugefuehrt wurden . Bei Patient 1 handelte es sich um die seltene Variante eines mittelgrosszellig pleomorphen CD8-positiven, CD30-negativen, primaer kutanen CTCL , dessen Primaermanifestation am Ohr darueber hinaus eine Raritaet darstellt . Nachdem es unter Therapie mit PUVA , Interferon- und Retinoid zum lokalen progredienten Tumorwachstum gekommen war , erhielt der Patient eine topische PDT am Ohr . Hierunter histologisch gesicherte partielle Remission ( PR ) . Bei erneuter lokaler Krankheitsprogredienz ( PD ) wurde eine Radiotherapie angeschlossen , seitdem 22 Monate komplette Remission ( CR ) . Bei Patient 2 handelte es sich um das klassische Bild einer Mycosis fungoides im initialen Tumorstadium . Dieser Patient erhielt ergaenzend zu PUVA-Therapie und Interferon- eine topische photodynamische Therapie an den Lokalisationen Augenbraue und Fusskante . Histologisch kontrolliert wurde hier eine komplette Remission ( CR ) erzielt . Die PDT stellt in der palliativen Behandlung kutaner T-Zell-Lymphome insbesondere in Problemlokalisationen ein neues experimentelles Verfahren dar , das gewebsschonend und nebenwirkungsarm ist , beliebig oft wiederholt werden kann und zu einem guten kosmetischen Ergebnis fuehrt . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die Behandlung der heterogenen Gruppe primaer kutaner B- und T-Zell-Lymphome erfolgt stadienadaptiert , aber insbesondere bei den seltenen Formen bisher nicht standardisiert . Wir berichten ueber 2 Patienten mit primaer kutanem T-Zell-Lymphom ( CTCL ) , die neben etablierten Therapieverfahren einer topischen photodynamischen Therapie ( PDT ) in besonderer und fuer die klassischen Therapieverfahren nur schwer zugaenglicher Lokalisation ( Ohr Augenbraue , Fusskante ) , zugefuehrt wurden . Bei Patient 1 handelte es sich um die seltene Variante eines mittelgrosszellig pleomorphen CD8-positiven, CD30-negativen, primaer kutanen CTCL , dessen Primaermanifestation am Ohr darueber hinaus eine Raritaet darstellt . Nachdem es unter Therapie mit PUVA , Interferon- und Retinoid zum lokalen progredienten Tumorwachstum gekommen war , erhielt der Patient eine topische PDT am Ohr . Hierunter histologisch gesicherte partielle Remission ( PR ) . Bei erneuter lokaler Krankheitsprogredienz ( PD ) wurde eine Radiotherapie angeschlossen , seitdem 22 Monate komplette Remission ( CR ) . Bei Patient 2 handelte es sich um das klassische Bild einer Mycosis fungoides im initialen Tumorstadium . Dieser Patient erhielt ergaenzend zu PUVA-Therapie und Interferon- eine topische photodynamische Therapie an den Lokalisationen Augenbraue und Fusskante . Histologisch kontrolliert wurde hier eine komplette Remission ( CR ) erzielt . Die PDT stellt in der palliativen Behandlung kutaner T-Zell-Lymphome insbesondere in Problemlokalisationen ein neues experimentelles Verfahren dar , das gewebsschonend und nebenwirkungsarm ist , beliebig oft wiederholt werden kann und zu einem guten kosmetischen Ergebnis fuehrt .

[ "Die", "Behandlung", "der", "heterogenen", "Gruppe", "primaer", "kutaner", "B-", "und", "T", "-", "Zell", "-", "Lymphome", "erfolgt", "stadienadaptiert", ",", "aber", "insbesondere", "bei", "den", "seltenen", "Formen", "bisher", "nicht", "standardisiert", ".", "Wir", "berichten", "ueber", "2", "Patienten", "mit", "primaer", "kutanem", "T", "-", "Zell", "-", "Lymphom", "(", "CTCL", ")", ",", "die", "neben", "etablierten", "Therapieverfahren", "einer", "topischen", "photodynamischen", "Therapie", "(", "PDT", ")", "in", "besonderer", "und", "fuer", "die", "klassischen", "Therapieverfahren", "nur", "schwer", "zugaenglicher", "Lokalisation", "(", "Ohr", "Augenbraue", ",", "Fusskante", ")", ",", "zugefuehrt", "wurden", ".", "Bei", "Patient", "1", "handelte", "es", "sich", "um", "die", "seltene", "Variante", "eines", "mittelgrosszellig", "pleomorphen", "CD8-positiven", ",", "CD30-negativen", ",", "primaer", "kutanen", "CTCL", ",", "dessen", "Primaermanifestation", "am", "Ohr", "darueber", "hinaus", "eine", "Raritaet", "darstellt", ".", "Nachdem", "es", "unter", "Therapie", "mit", "PUVA", ",", "Interferon-", "und", "Retinoid", "zum", "lokalen", "progredienten", "Tumorwachstum", "gekommen", "war", ",", "erhielt", "der", "Patient", "eine", "topische", "PDT", "am", "Ohr", ".", "Hierunter", "histologisch", "gesicherte", "partielle", "Remission", "(", "PR", ")", ".", "Bei", "erneuter", "lokaler", "Krankheitsprogredienz", "(", "PD", ")", "wurde", "eine", "Radiotherapie", "angeschlossen", ",", "seitdem", "22", "Monate", "komplette", "Remission", "(", "CR", ")", ".", "Bei", "Patient", "2", "handelte", "es", "sich", "um", "das", "klassische", "Bild", "einer", "Mycosis", "fungoides", "im", "initialen", "Tumorstadium", ".", "Dieser", "Patient", "erhielt", "ergaenzend", "zu", "PUVA", "-", "Therapie", "und", "Interferon-", "eine", "topische", "photodynamische", "Therapie", "an", "den", "Lokalisationen", "Augenbraue", "und", "Fusskante", ".", "Histologisch", "kontrolliert", "wurde", "hier", "eine", "komplette", "Remission", "(", "CR", ")", "erzielt", ".", "Die", "PDT", "stellt", "in", "der", "palliativen", "Behandlung", "kutaner", "T", "-", "Zell", "-", "Lymphome", "insbesondere", "in", "Problemlokalisationen", "ein", "neues", "experimentelles", "Verfahren", "dar", ",", "das", "gewebsschonend", "und", "nebenwirkungsarm", "ist", ",", "beliebig", "oft", "wiederholt", "werden", "kann", "und", "zu", "einem", "guten", "kosmetischen", "Ergebnis", "fuehrt", "." ]

[ "umlsterm" ]

Behandlung is an umlsterm, Patienten is an umlsterm, kutanem T - Zell - Lymphom is an umlsterm, Therapieverfahren is an umlsterm, photodynamischen Therapie is an umlsterm, Therapieverfahren is an umlsterm, Ohr is an umlsterm, Augenbraue is an umlsterm, Fusskante is an umlsterm, Patient is an umlsterm, Ohr is an umlsterm, Therapie is an umlsterm, Interferon- is an umlsterm, Tumorwachstum is an umlsterm, Patient is an umlsterm, Ohr is an umlsterm, Radiotherapie is an umlsterm, Patient is an umlsterm, Mycosis fungoides is an umlsterm, Tumorstadium is an umlsterm, Patient is an umlsterm, PUVA - Therapie is an umlsterm, Interferon- is an umlsterm, photodynamische Therapie is an umlsterm, Augenbraue is an umlsterm, Fusskante is an umlsterm, Behandlung is an umlsterm

DerHautarzt.90500109.ger.abstr_task1

Sentence: Die Behandlung der heterogenen Gruppe primaer kutaner B- und T-Zell-Lymphome erfolgt stadienadaptiert , aber insbesondere bei den seltenen Formen bisher nicht standardisiert . Wir berichten ueber 2 Patienten mit primaer kutanem T-Zell-Lymphom ( CTCL ) , die neben etablierten Therapieverfahren einer topischen photodynamischen Therapie ( PDT ) in besonderer und fuer die klassischen Therapieverfahren nur schwer zugaenglicher Lokalisation ( Ohr Augenbraue , Fusskante ) , zugefuehrt wurden . Bei Patient 1 handelte es sich um die seltene Variante eines mittelgrosszellig pleomorphen CD8-positiven, CD30-negativen, primaer kutanen CTCL , dessen Primaermanifestation am Ohr darueber hinaus eine Raritaet darstellt . Nachdem es unter Therapie mit PUVA , Interferon- und Retinoid zum lokalen progredienten Tumorwachstum gekommen war , erhielt der Patient eine topische PDT am Ohr . Hierunter histologisch gesicherte partielle Remission ( PR ) . Bei erneuter lokaler Krankheitsprogredienz ( PD ) wurde eine Radiotherapie angeschlossen , seitdem 22 Monate komplette Remission ( CR ) . Bei Patient 2 handelte es sich um das klassische Bild einer Mycosis fungoides im initialen Tumorstadium . Dieser Patient erhielt ergaenzend zu PUVA-Therapie und Interferon- eine topische photodynamische Therapie an den Lokalisationen Augenbraue und Fusskante . Histologisch kontrolliert wurde hier eine komplette Remission ( CR ) erzielt . Die PDT stellt in der palliativen Behandlung kutaner T-Zell-Lymphome insbesondere in Problemlokalisationen ein neues experimentelles Verfahren dar , das gewebsschonend und nebenwirkungsarm ist , beliebig oft wiederholt werden kann und zu einem guten kosmetischen Ergebnis fuehrt . Instructions: please typing these entity words according to sentence: Behandlung, Patienten, kutanem T - Zell - Lymphom, Therapieverfahren, photodynamischen Therapie, Therapieverfahren, Ohr, Augenbraue, Fusskante, Patient, Ohr, Therapie, Interferon-, Tumorwachstum, Patient, Ohr, Radiotherapie, Patient, Mycosis fungoides, Tumorstadium, Patient, PUVA - Therapie, Interferon-, photodynamische Therapie, Augenbraue, Fusskante, Behandlung Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die Behandlung der heterogenen Gruppe primaer kutaner B- und T-Zell-Lymphome erfolgt stadienadaptiert , aber insbesondere bei den seltenen Formen bisher nicht standardisiert . Wir berichten ueber 2 Patienten mit primaer kutanem T-Zell-Lymphom ( CTCL ) , die neben etablierten Therapieverfahren einer topischen photodynamischen Therapie ( PDT ) in besonderer und fuer die klassischen Therapieverfahren nur schwer zugaenglicher Lokalisation ( Ohr Augenbraue , Fusskante ) , zugefuehrt wurden . Bei Patient 1 handelte es sich um die seltene Variante eines mittelgrosszellig pleomorphen CD8-positiven, CD30-negativen, primaer kutanen CTCL , dessen Primaermanifestation am Ohr darueber hinaus eine Raritaet darstellt . Nachdem es unter Therapie mit PUVA , Interferon- und Retinoid zum lokalen progredienten Tumorwachstum gekommen war , erhielt der Patient eine topische PDT am Ohr . Hierunter histologisch gesicherte partielle Remission ( PR ) . Bei erneuter lokaler Krankheitsprogredienz ( PD ) wurde eine Radiotherapie angeschlossen , seitdem 22 Monate komplette Remission ( CR ) . Bei Patient 2 handelte es sich um das klassische Bild einer Mycosis fungoides im initialen Tumorstadium . Dieser Patient erhielt ergaenzend zu PUVA-Therapie und Interferon- eine topische photodynamische Therapie an den Lokalisationen Augenbraue und Fusskante . Histologisch kontrolliert wurde hier eine komplette Remission ( CR ) erzielt . Die PDT stellt in der palliativen Behandlung kutaner T-Zell-Lymphome insbesondere in Problemlokalisationen ein neues experimentelles Verfahren dar , das gewebsschonend und nebenwirkungsarm ist , beliebig oft wiederholt werden kann und zu einem guten kosmetischen Ergebnis fuehrt .

[ "Die", "Behandlung", "der", "heterogenen", "Gruppe", "primaer", "kutaner", "B-", "und", "T", "-", "Zell", "-", "Lymphome", "erfolgt", "stadienadaptiert", ",", "aber", "insbesondere", "bei", "den", "seltenen", "Formen", "bisher", "nicht", "standardisiert", ".", "Wir", "berichten", "ueber", "2", "Patienten", "mit", "primaer", "kutanem", "T", "-", "Zell", "-", "Lymphom", "(", "CTCL", ")", ",", "die", "neben", "etablierten", "Therapieverfahren", "einer", "topischen", "photodynamischen", "Therapie", "(", "PDT", ")", "in", "besonderer", "und", "fuer", "die", "klassischen", "Therapieverfahren", "nur", "schwer", "zugaenglicher", "Lokalisation", "(", "Ohr", "Augenbraue", ",", "Fusskante", ")", ",", "zugefuehrt", "wurden", ".", "Bei", "Patient", "1", "handelte", "es", "sich", "um", "die", "seltene", "Variante", "eines", "mittelgrosszellig", "pleomorphen", "CD8-positiven", ",", "CD30-negativen", ",", "primaer", "kutanen", "CTCL", ",", "dessen", "Primaermanifestation", "am", "Ohr", "darueber", "hinaus", "eine", "Raritaet", "darstellt", ".", "Nachdem", "es", "unter", "Therapie", "mit", "PUVA", ",", "Interferon-", "und", "Retinoid", "zum", "lokalen", "progredienten", "Tumorwachstum", "gekommen", "war", ",", "erhielt", "der", "Patient", "eine", "topische", "PDT", "am", "Ohr", ".", "Hierunter", "histologisch", "gesicherte", "partielle", "Remission", "(", "PR", ")", ".", "Bei", "erneuter", "lokaler", "Krankheitsprogredienz", "(", "PD", ")", "wurde", "eine", "Radiotherapie", "angeschlossen", ",", "seitdem", "22", "Monate", "komplette", "Remission", "(", "CR", ")", ".", "Bei", "Patient", "2", "handelte", "es", "sich", "um", "das", "klassische", "Bild", "einer", "Mycosis", "fungoides", "im", "initialen", "Tumorstadium", ".", "Dieser", "Patient", "erhielt", "ergaenzend", "zu", "PUVA", "-", "Therapie", "und", "Interferon-", "eine", "topische", "photodynamische", "Therapie", "an", "den", "Lokalisationen", "Augenbraue", "und", "Fusskante", ".", "Histologisch", "kontrolliert", "wurde", "hier", "eine", "komplette", "Remission", "(", "CR", ")", "erzielt", ".", "Die", "PDT", "stellt", "in", "der", "palliativen", "Behandlung", "kutaner", "T", "-", "Zell", "-", "Lymphome", "insbesondere", "in", "Problemlokalisationen", "ein", "neues", "experimentelles", "Verfahren", "dar", ",", "das", "gewebsschonend", "und", "nebenwirkungsarm", "ist", ",", "beliebig", "oft", "wiederholt", "werden", "kann", "und", "zu", "einem", "guten", "kosmetischen", "Ergebnis", "fuehrt", "." ]

[ "umlsterm" ]

Behandlung, Patienten, kutanem T - Zell - Lymphom, Therapieverfahren, photodynamischen Therapie, Therapieverfahren, Ohr, Augenbraue, Fusskante, Patient, Ohr, Therapie, Interferon-, Tumorwachstum, Patient, Ohr, Radiotherapie, Patient, Mycosis fungoides, Tumorstadium, Patient, PUVA - Therapie, Interferon-, photodynamische Therapie, Augenbraue, Fusskante, Behandlung

DerHautarzt.90500109.ger.abstr_task2

Sentence: Die Behandlung der heterogenen Gruppe primaer kutaner B- und T-Zell-Lymphome erfolgt stadienadaptiert , aber insbesondere bei den seltenen Formen bisher nicht standardisiert . Wir berichten ueber 2 Patienten mit primaer kutanem T-Zell-Lymphom ( CTCL ) , die neben etablierten Therapieverfahren einer topischen photodynamischen Therapie ( PDT ) in besonderer und fuer die klassischen Therapieverfahren nur schwer zugaenglicher Lokalisation ( Ohr Augenbraue , Fusskante ) , zugefuehrt wurden . Bei Patient 1 handelte es sich um die seltene Variante eines mittelgrosszellig pleomorphen CD8-positiven, CD30-negativen, primaer kutanen CTCL , dessen Primaermanifestation am Ohr darueber hinaus eine Raritaet darstellt . Nachdem es unter Therapie mit PUVA , Interferon- und Retinoid zum lokalen progredienten Tumorwachstum gekommen war , erhielt der Patient eine topische PDT am Ohr . Hierunter histologisch gesicherte partielle Remission ( PR ) . Bei erneuter lokaler Krankheitsprogredienz ( PD ) wurde eine Radiotherapie angeschlossen , seitdem 22 Monate komplette Remission ( CR ) . Bei Patient 2 handelte es sich um das klassische Bild einer Mycosis fungoides im initialen Tumorstadium . Dieser Patient erhielt ergaenzend zu PUVA-Therapie und Interferon- eine topische photodynamische Therapie an den Lokalisationen Augenbraue und Fusskante . Histologisch kontrolliert wurde hier eine komplette Remission ( CR ) erzielt . Die PDT stellt in der palliativen Behandlung kutaner T-Zell-Lymphome insbesondere in Problemlokalisationen ein neues experimentelles Verfahren dar , das gewebsschonend und nebenwirkungsarm ist , beliebig oft wiederholt werden kann und zu einem guten kosmetischen Ergebnis fuehrt . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die Behandlung der heterogenen Gruppe primaer kutaner B- und T-Zell-Lymphome erfolgt stadienadaptiert , aber insbesondere bei den seltenen Formen bisher nicht standardisiert . Wir berichten ueber 2 Patienten mit primaer kutanem T-Zell-Lymphom ( CTCL ) , die neben etablierten Therapieverfahren einer topischen photodynamischen Therapie ( PDT ) in besonderer und fuer die klassischen Therapieverfahren nur schwer zugaenglicher Lokalisation ( Ohr Augenbraue , Fusskante ) , zugefuehrt wurden . Bei Patient 1 handelte es sich um die seltene Variante eines mittelgrosszellig pleomorphen CD8-positiven, CD30-negativen, primaer kutanen CTCL , dessen Primaermanifestation am Ohr darueber hinaus eine Raritaet darstellt . Nachdem es unter Therapie mit PUVA , Interferon- und Retinoid zum lokalen progredienten Tumorwachstum gekommen war , erhielt der Patient eine topische PDT am Ohr . Hierunter histologisch gesicherte partielle Remission ( PR ) . Bei erneuter lokaler Krankheitsprogredienz ( PD ) wurde eine Radiotherapie angeschlossen , seitdem 22 Monate komplette Remission ( CR ) . Bei Patient 2 handelte es sich um das klassische Bild einer Mycosis fungoides im initialen Tumorstadium . Dieser Patient erhielt ergaenzend zu PUVA-Therapie und Interferon- eine topische photodynamische Therapie an den Lokalisationen Augenbraue und Fusskante . Histologisch kontrolliert wurde hier eine komplette Remission ( CR ) erzielt . Die PDT stellt in der palliativen Behandlung kutaner T-Zell-Lymphome insbesondere in Problemlokalisationen ein neues experimentelles Verfahren dar , das gewebsschonend und nebenwirkungsarm ist , beliebig oft wiederholt werden kann und zu einem guten kosmetischen Ergebnis fuehrt .

[ "Die", "Behandlung", "der", "heterogenen", "Gruppe", "primaer", "kutaner", "B-", "und", "T", "-", "Zell", "-", "Lymphome", "erfolgt", "stadienadaptiert", ",", "aber", "insbesondere", "bei", "den", "seltenen", "Formen", "bisher", "nicht", "standardisiert", ".", "Wir", "berichten", "ueber", "2", "Patienten", "mit", "primaer", "kutanem", "T", "-", "Zell", "-", "Lymphom", "(", "CTCL", ")", ",", "die", "neben", "etablierten", "Therapieverfahren", "einer", "topischen", "photodynamischen", "Therapie", "(", "PDT", ")", "in", "besonderer", "und", "fuer", "die", "klassischen", "Therapieverfahren", "nur", "schwer", "zugaenglicher", "Lokalisation", "(", "Ohr", "Augenbraue", ",", "Fusskante", ")", ",", "zugefuehrt", "wurden", ".", "Bei", "Patient", "1", "handelte", "es", "sich", "um", "die", "seltene", "Variante", "eines", "mittelgrosszellig", "pleomorphen", "CD8-positiven", ",", "CD30-negativen", ",", "primaer", "kutanen", "CTCL", ",", "dessen", "Primaermanifestation", "am", "Ohr", "darueber", "hinaus", "eine", "Raritaet", "darstellt", ".", "Nachdem", "es", "unter", "Therapie", "mit", "PUVA", ",", "Interferon-", "und", "Retinoid", "zum", "lokalen", "progredienten", "Tumorwachstum", "gekommen", "war", ",", "erhielt", "der", "Patient", "eine", "topische", "PDT", "am", "Ohr", ".", "Hierunter", "histologisch", "gesicherte", "partielle", "Remission", "(", "PR", ")", ".", "Bei", "erneuter", "lokaler", "Krankheitsprogredienz", "(", "PD", ")", "wurde", "eine", "Radiotherapie", "angeschlossen", ",", "seitdem", "22", "Monate", "komplette", "Remission", "(", "CR", ")", ".", "Bei", "Patient", "2", "handelte", "es", "sich", "um", "das", "klassische", "Bild", "einer", "Mycosis", "fungoides", "im", "initialen", "Tumorstadium", ".", "Dieser", "Patient", "erhielt", "ergaenzend", "zu", "PUVA", "-", "Therapie", "und", "Interferon-", "eine", "topische", "photodynamische", "Therapie", "an", "den", "Lokalisationen", "Augenbraue", "und", "Fusskante", ".", "Histologisch", "kontrolliert", "wurde", "hier", "eine", "komplette", "Remission", "(", "CR", ")", "erzielt", ".", "Die", "PDT", "stellt", "in", "der", "palliativen", "Behandlung", "kutaner", "T", "-", "Zell", "-", "Lymphome", "insbesondere", "in", "Problemlokalisationen", "ein", "neues", "experimentelles", "Verfahren", "dar", ",", "das", "gewebsschonend", "und", "nebenwirkungsarm", "ist", ",", "beliebig", "oft", "wiederholt", "werden", "kann", "und", "zu", "einem", "guten", "kosmetischen", "Ergebnis", "fuehrt", "." ]

[ "umlsterm" ]

ErbB2 is a GENE-Y, FoxM1 is a GENE-Y, 14 - 3 - 3ζ is a GENE-Y

23318431_task0

Sentence: ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y

[ "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation.

[ "ErbB2", ",", "FoxM1", "and", "14", "-", "3", "-", "3ζ", "prime", "breast", "cancer", "cells", "for", "invasion", "in", "response", "to", "ionizing", "radiation", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

ErbB2 is a GENE-Y, FoxM1 is a GENE-Y, 14 - 3 - 3ζ is a GENE-Y

23318431_task1

Sentence: ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation. Instructions: please typing these entity words according to sentence: ErbB2, FoxM1, 14 - 3 - 3ζ Options: GENE-Y

[ "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation.

[ "ErbB2", ",", "FoxM1", "and", "14", "-", "3", "-", "3ζ", "prime", "breast", "cancer", "cells", "for", "invasion", "in", "response", "to", "ionizing", "radiation", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

ErbB2, FoxM1, 14 - 3 - 3ζ

23318431_task2

Sentence: ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation. Instructions: please extract entity words from the input sentence

[ "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation.

[ "ErbB2", ",", "FoxM1", "and", "14", "-", "3", "-", "3ζ", "prime", "breast", "cancer", "cells", "for", "invasion", "in", "response", "to", "ionizing", "radiation", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

prostate cancer is a Cancer, Prostate cancer is a Cancer, tumor is a Cancer, prostate cancer xenograft is a Cancer, LAPC-4 is a Cell, LAPC-9 is a Cell, PC3 is a Cell, CWR22Rv-1 is a Cell, cells is a Cell, tumor is a Cancer, metastases is a Cancer, Metastatic lesions is a Cancer, tumors is a Cancer, low - metastatic LAPC-9 tumor cells is a Cell, metastases is a Cancer, CWR22Rv-1 is a Cell, PC3 tumor cell lines is a Cell, LAPC-4 is a Cell, LAPC-9 is a Cell, tumor lymphatics is a Multi-tissue_structure, LAPC-9 is a Cell, tumor is a Cancer, metastatic lesions is a Cancer, tumor lymphatics is a Multi-tissue_structure, prostate cancer is a Cancer, prostate cancer is a Cancer

PMID-17583576_task0

Sentence: Modulating metastasis by a lymphangiogenic switch in prostate cancer. Prostate cancer dissemination is difficult to detect in the clinic, and few treatment options exist for patients with advanced-stage disease. Our aim was to investigate the role of tumor lymphangiogenesis during metastasis. Further, we implemented a noninvasive molecular imaging technique to facilitate the assessment of the metastatic process. The metastatic potentials of several human prostate cancer xenograft models, LAPC-4, LAPC-9, PC3 and CWR22Rv-1 were compared. The cells were labeled with luciferase, a bioluminescence imaging reporter gene, to enable optical imaging. After tumor implantation the animals were examined weekly during several months for the appearance of metastases. Metastatic lesions were confirmed by immunohistochemistry. Additionally, the angiogenic and lymphangiogenic profiles of the tumors were characterized. To confirm the role of lymphangiogenesis in mediating metastasis, the low-metastatic LAPC-9 tumor cells were engineered to overexpress VEGF-C, and the development of metastases was evaluated. Our results show CWR22Rv-1 and PC3 tumor cell lines to be more metastatic than LAPC-4, which in turn disseminates more readily than LAPC-9. The difference in metastatic potential correlated with the endogenous production levels of lymphangiogenic growth factor VEGF-C and the presence of tumor lymphatics. In agreement, induced overexpression of VEGF-C in LAPC-9 enhanced tumor lymphangiogenesis leading to the development of metastatic lesions. Taken together, our studies, based on a molecular imaging approach for semiquantitative detection of micrometastases, point to an important role of tumor lymphatics in the metastatic process of human prostate cancer. In particular, VEGF-C seems to play a key role in prostate cancer metastasis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cancer, Multi-tissue_structure, Cell

[ "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O" ]

Modulating metastasis by a lymphangiogenic switch in prostate cancer. Prostate cancer dissemination is difficult to detect in the clinic, and few treatment options exist for patients with advanced-stage disease. Our aim was to investigate the role of tumor lymphangiogenesis during metastasis. Further, we implemented a noninvasive molecular imaging technique to facilitate the assessment of the metastatic process. The metastatic potentials of several human prostate cancer xenograft models, LAPC-4, LAPC-9, PC3 and CWR22Rv-1 were compared. The cells were labeled with luciferase, a bioluminescence imaging reporter gene, to enable optical imaging. After tumor implantation the animals were examined weekly during several months for the appearance of metastases. Metastatic lesions were confirmed by immunohistochemistry. Additionally, the angiogenic and lymphangiogenic profiles of the tumors were characterized. To confirm the role of lymphangiogenesis in mediating metastasis, the low-metastatic LAPC-9 tumor cells were engineered to overexpress VEGF-C, and the development of metastases was evaluated. Our results show CWR22Rv-1 and PC3 tumor cell lines to be more metastatic than LAPC-4, which in turn disseminates more readily than LAPC-9. The difference in metastatic potential correlated with the endogenous production levels of lymphangiogenic growth factor VEGF-C and the presence of tumor lymphatics. In agreement, induced overexpression of VEGF-C in LAPC-9 enhanced tumor lymphangiogenesis leading to the development of metastatic lesions. Taken together, our studies, based on a molecular imaging approach for semiquantitative detection of micrometastases, point to an important role of tumor lymphatics in the metastatic process of human prostate cancer. In particular, VEGF-C seems to play a key role in prostate cancer metastasis.

[ "Modulating", "metastasis", "by", "a", "lymphangiogenic", "switch", "in", "prostate", "cancer", ".", "\n", "Prostate", "cancer", "dissemination", "is", "difficult", "to", "detect", "in", "the", "clinic", ",", "and", "few", "treatment", "options", "exist", "for", "patients", "with", "advanced", "-", "stage", "disease", ".", "Our", "aim", "was", "to", "investigate", "the", "role", "of", "tumor", "lymphangiogenesis", "during", "metastasis", ".", "Further", ",", "we", "implemented", "a", "noninvasive", "molecular", "imaging", "technique", "to", "facilitate", "the", "assessment", "of", "the", "metastatic", "process", ".", "The", "metastatic", "potentials", "of", "several", "human", "prostate", "cancer", "xenograft", "models", ",", "LAPC-4", ",", "LAPC-9", ",", "PC3", "and", "CWR22Rv-1", "were", "compared", ".", "The", "cells", "were", "labeled", "with", "luciferase", ",", "a", "bioluminescence", "imaging", "reporter", "gene", ",", "to", "enable", "optical", "imaging", ".", "After", "tumor", "implantation", "the", "animals", "were", "examined", "weekly", "during", "several", "months", "for", "the", "appearance", "of", "metastases", ".", "Metastatic", "lesions", "were", "confirmed", "by", "immunohistochemistry", ".", "Additionally", ",", "the", "angiogenic", "and", "lymphangiogenic", "profiles", "of", "the", "tumors", "were", "characterized", ".", "To", "confirm", "the", "role", "of", "lymphangiogenesis", "in", "mediating", "metastasis", ",", "the", "low", "-", "metastatic", "LAPC-9", "tumor", "cells", "were", "engineered", "to", "overexpress", "VEGF", "-", "C", ",", "and", "the", "development", "of", "metastases", "was", "evaluated", ".", "Our", "results", "show", "CWR22Rv-1", "and", "PC3", "tumor", "cell", "lines", "to", "be", "more", "metastatic", "than", "LAPC-4", ",", "which", "in", "turn", "disseminates", "more", "readily", "than", "LAPC-9", ".", "The", "difference", "in", "metastatic", "potential", "correlated", "with", "the", "endogenous", "production", "levels", "of", "lymphangiogenic", "growth", "factor", "VEGF", "-", "C", "and", "the", "presence", "of", "tumor", "lymphatics", ".", "In", "agreement", ",", "induced", "overexpression", "of", "VEGF", "-", "C", "in", "LAPC-9", "enhanced", "tumor", "lymphangiogenesis", "leading", "to", "the", "development", "of", "metastatic", "lesions", ".", "Taken", "together", ",", "our", "studies", ",", "based", "on", "a", "molecular", "imaging", "approach", "for", "semiquantitative", "detection", "of", "micrometastases", ",", "point", "to", "an", "important", "role", "of", "tumor", "lymphatics", "in", "the", "metastatic", "process", "of", "human", "prostate", "cancer", ".", "In", "particular", ",", "VEGF", "-", "C", "seems", "to", "play", "a", "key", "role", "in", "prostate", "cancer", "metastasis", ".", "\n" ]

[ "Cell", "Cancer", "Multi-tissue_structure" ]

prostate cancer is a Cancer, Prostate cancer is a Cancer, tumor is a Cancer, prostate cancer xenograft is a Cancer, LAPC-4 is a Cell, LAPC-9 is a Cell, PC3 is a Cell, CWR22Rv-1 is a Cell, cells is a Cell, tumor is a Cancer, metastases is a Cancer, Metastatic lesions is a Cancer, tumors is a Cancer, low - metastatic LAPC-9 tumor cells is a Cell, metastases is a Cancer, CWR22Rv-1 is a Cell, PC3 tumor cell lines is a Cell, LAPC-4 is a Cell, LAPC-9 is a Cell, tumor lymphatics is a Multi-tissue_structure, LAPC-9 is a Cell, tumor is a Cancer, metastatic lesions is a Cancer, tumor lymphatics is a Multi-tissue_structure, prostate cancer is a Cancer, prostate cancer is a Cancer

PMID-17583576_task1

Sentence: Modulating metastasis by a lymphangiogenic switch in prostate cancer. Prostate cancer dissemination is difficult to detect in the clinic, and few treatment options exist for patients with advanced-stage disease. Our aim was to investigate the role of tumor lymphangiogenesis during metastasis. Further, we implemented a noninvasive molecular imaging technique to facilitate the assessment of the metastatic process. The metastatic potentials of several human prostate cancer xenograft models, LAPC-4, LAPC-9, PC3 and CWR22Rv-1 were compared. The cells were labeled with luciferase, a bioluminescence imaging reporter gene, to enable optical imaging. After tumor implantation the animals were examined weekly during several months for the appearance of metastases. Metastatic lesions were confirmed by immunohistochemistry. Additionally, the angiogenic and lymphangiogenic profiles of the tumors were characterized. To confirm the role of lymphangiogenesis in mediating metastasis, the low-metastatic LAPC-9 tumor cells were engineered to overexpress VEGF-C, and the development of metastases was evaluated. Our results show CWR22Rv-1 and PC3 tumor cell lines to be more metastatic than LAPC-4, which in turn disseminates more readily than LAPC-9. The difference in metastatic potential correlated with the endogenous production levels of lymphangiogenic growth factor VEGF-C and the presence of tumor lymphatics. In agreement, induced overexpression of VEGF-C in LAPC-9 enhanced tumor lymphangiogenesis leading to the development of metastatic lesions. Taken together, our studies, based on a molecular imaging approach for semiquantitative detection of micrometastases, point to an important role of tumor lymphatics in the metastatic process of human prostate cancer. In particular, VEGF-C seems to play a key role in prostate cancer metastasis. Instructions: please typing these entity words according to sentence: prostate cancer, Prostate cancer, tumor, prostate cancer xenograft, LAPC-4, LAPC-9, PC3, CWR22Rv-1, cells, tumor, metastases, Metastatic lesions, tumors, low - metastatic LAPC-9 tumor cells, metastases, CWR22Rv-1, PC3 tumor cell lines, LAPC-4, LAPC-9, tumor lymphatics, LAPC-9, tumor, metastatic lesions, tumor lymphatics, prostate cancer, prostate cancer Options: Cancer, Multi-tissue_structure, Cell

[ "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O" ]

Modulating metastasis by a lymphangiogenic switch in prostate cancer. Prostate cancer dissemination is difficult to detect in the clinic, and few treatment options exist for patients with advanced-stage disease. Our aim was to investigate the role of tumor lymphangiogenesis during metastasis. Further, we implemented a noninvasive molecular imaging technique to facilitate the assessment of the metastatic process. The metastatic potentials of several human prostate cancer xenograft models, LAPC-4, LAPC-9, PC3 and CWR22Rv-1 were compared. The cells were labeled with luciferase, a bioluminescence imaging reporter gene, to enable optical imaging. After tumor implantation the animals were examined weekly during several months for the appearance of metastases. Metastatic lesions were confirmed by immunohistochemistry. Additionally, the angiogenic and lymphangiogenic profiles of the tumors were characterized. To confirm the role of lymphangiogenesis in mediating metastasis, the low-metastatic LAPC-9 tumor cells were engineered to overexpress VEGF-C, and the development of metastases was evaluated. Our results show CWR22Rv-1 and PC3 tumor cell lines to be more metastatic than LAPC-4, which in turn disseminates more readily than LAPC-9. The difference in metastatic potential correlated with the endogenous production levels of lymphangiogenic growth factor VEGF-C and the presence of tumor lymphatics. In agreement, induced overexpression of VEGF-C in LAPC-9 enhanced tumor lymphangiogenesis leading to the development of metastatic lesions. Taken together, our studies, based on a molecular imaging approach for semiquantitative detection of micrometastases, point to an important role of tumor lymphatics in the metastatic process of human prostate cancer. In particular, VEGF-C seems to play a key role in prostate cancer metastasis.

[ "Modulating", "metastasis", "by", "a", "lymphangiogenic", "switch", "in", "prostate", "cancer", ".", "\n", "Prostate", "cancer", "dissemination", "is", "difficult", "to", "detect", "in", "the", "clinic", ",", "and", "few", "treatment", "options", "exist", "for", "patients", "with", "advanced", "-", "stage", "disease", ".", "Our", "aim", "was", "to", "investigate", "the", "role", "of", "tumor", "lymphangiogenesis", "during", "metastasis", ".", "Further", ",", "we", "implemented", "a", "noninvasive", "molecular", "imaging", "technique", "to", "facilitate", "the", "assessment", "of", "the", "metastatic", "process", ".", "The", "metastatic", "potentials", "of", "several", "human", "prostate", "cancer", "xenograft", "models", ",", "LAPC-4", ",", "LAPC-9", ",", "PC3", "and", "CWR22Rv-1", "were", "compared", ".", "The", "cells", "were", "labeled", "with", "luciferase", ",", "a", "bioluminescence", "imaging", "reporter", "gene", ",", "to", "enable", "optical", "imaging", ".", "After", "tumor", "implantation", "the", "animals", "were", "examined", "weekly", "during", "several", "months", "for", "the", "appearance", "of", "metastases", ".", "Metastatic", "lesions", "were", "confirmed", "by", "immunohistochemistry", ".", "Additionally", ",", "the", "angiogenic", "and", "lymphangiogenic", "profiles", "of", "the", "tumors", "were", "characterized", ".", "To", "confirm", "the", "role", "of", "lymphangiogenesis", "in", "mediating", "metastasis", ",", "the", "low", "-", "metastatic", "LAPC-9", "tumor", "cells", "were", "engineered", "to", "overexpress", "VEGF", "-", "C", ",", "and", "the", "development", "of", "metastases", "was", "evaluated", ".", "Our", "results", "show", "CWR22Rv-1", "and", "PC3", "tumor", "cell", "lines", "to", "be", "more", "metastatic", "than", "LAPC-4", ",", "which", "in", "turn", "disseminates", "more", "readily", "than", "LAPC-9", ".", "The", "difference", "in", "metastatic", "potential", "correlated", "with", "the", "endogenous", "production", "levels", "of", "lymphangiogenic", "growth", "factor", "VEGF", "-", "C", "and", "the", "presence", "of", "tumor", "lymphatics", ".", "In", "agreement", ",", "induced", "overexpression", "of", "VEGF", "-", "C", "in", "LAPC-9", "enhanced", "tumor", "lymphangiogenesis", "leading", "to", "the", "development", "of", "metastatic", "lesions", ".", "Taken", "together", ",", "our", "studies", ",", "based", "on", "a", "molecular", "imaging", "approach", "for", "semiquantitative", "detection", "of", "micrometastases", ",", "point", "to", "an", "important", "role", "of", "tumor", "lymphatics", "in", "the", "metastatic", "process", "of", "human", "prostate", "cancer", ".", "In", "particular", ",", "VEGF", "-", "C", "seems", "to", "play", "a", "key", "role", "in", "prostate", "cancer", "metastasis", ".", "\n" ]

[ "Cell", "Cancer", "Multi-tissue_structure" ]

prostate cancer, Prostate cancer, tumor, prostate cancer xenograft, LAPC-4, LAPC-9, PC3, CWR22Rv-1, cells, tumor, metastases, Metastatic lesions, tumors, low - metastatic LAPC-9 tumor cells, metastases, CWR22Rv-1, PC3 tumor cell lines, LAPC-4, LAPC-9, tumor lymphatics, LAPC-9, tumor, metastatic lesions, tumor lymphatics, prostate cancer, prostate cancer

PMID-17583576_task2

Sentence: Modulating metastasis by a lymphangiogenic switch in prostate cancer. Prostate cancer dissemination is difficult to detect in the clinic, and few treatment options exist for patients with advanced-stage disease. Our aim was to investigate the role of tumor lymphangiogenesis during metastasis. Further, we implemented a noninvasive molecular imaging technique to facilitate the assessment of the metastatic process. The metastatic potentials of several human prostate cancer xenograft models, LAPC-4, LAPC-9, PC3 and CWR22Rv-1 were compared. The cells were labeled with luciferase, a bioluminescence imaging reporter gene, to enable optical imaging. After tumor implantation the animals were examined weekly during several months for the appearance of metastases. Metastatic lesions were confirmed by immunohistochemistry. Additionally, the angiogenic and lymphangiogenic profiles of the tumors were characterized. To confirm the role of lymphangiogenesis in mediating metastasis, the low-metastatic LAPC-9 tumor cells were engineered to overexpress VEGF-C, and the development of metastases was evaluated. Our results show CWR22Rv-1 and PC3 tumor cell lines to be more metastatic than LAPC-4, which in turn disseminates more readily than LAPC-9. The difference in metastatic potential correlated with the endogenous production levels of lymphangiogenic growth factor VEGF-C and the presence of tumor lymphatics. In agreement, induced overexpression of VEGF-C in LAPC-9 enhanced tumor lymphangiogenesis leading to the development of metastatic lesions. Taken together, our studies, based on a molecular imaging approach for semiquantitative detection of micrometastases, point to an important role of tumor lymphatics in the metastatic process of human prostate cancer. In particular, VEGF-C seems to play a key role in prostate cancer metastasis. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O" ]

Modulating metastasis by a lymphangiogenic switch in prostate cancer. Prostate cancer dissemination is difficult to detect in the clinic, and few treatment options exist for patients with advanced-stage disease. Our aim was to investigate the role of tumor lymphangiogenesis during metastasis. Further, we implemented a noninvasive molecular imaging technique to facilitate the assessment of the metastatic process. The metastatic potentials of several human prostate cancer xenograft models, LAPC-4, LAPC-9, PC3 and CWR22Rv-1 were compared. The cells were labeled with luciferase, a bioluminescence imaging reporter gene, to enable optical imaging. After tumor implantation the animals were examined weekly during several months for the appearance of metastases. Metastatic lesions were confirmed by immunohistochemistry. Additionally, the angiogenic and lymphangiogenic profiles of the tumors were characterized. To confirm the role of lymphangiogenesis in mediating metastasis, the low-metastatic LAPC-9 tumor cells were engineered to overexpress VEGF-C, and the development of metastases was evaluated. Our results show CWR22Rv-1 and PC3 tumor cell lines to be more metastatic than LAPC-4, which in turn disseminates more readily than LAPC-9. The difference in metastatic potential correlated with the endogenous production levels of lymphangiogenic growth factor VEGF-C and the presence of tumor lymphatics. In agreement, induced overexpression of VEGF-C in LAPC-9 enhanced tumor lymphangiogenesis leading to the development of metastatic lesions. Taken together, our studies, based on a molecular imaging approach for semiquantitative detection of micrometastases, point to an important role of tumor lymphatics in the metastatic process of human prostate cancer. In particular, VEGF-C seems to play a key role in prostate cancer metastasis.

[ "Modulating", "metastasis", "by", "a", "lymphangiogenic", "switch", "in", "prostate", "cancer", ".", "\n", "Prostate", "cancer", "dissemination", "is", "difficult", "to", "detect", "in", "the", "clinic", ",", "and", "few", "treatment", "options", "exist", "for", "patients", "with", "advanced", "-", "stage", "disease", ".", "Our", "aim", "was", "to", "investigate", "the", "role", "of", "tumor", "lymphangiogenesis", "during", "metastasis", ".", "Further", ",", "we", "implemented", "a", "noninvasive", "molecular", "imaging", "technique", "to", "facilitate", "the", "assessment", "of", "the", "metastatic", "process", ".", "The", "metastatic", "potentials", "of", "several", "human", "prostate", "cancer", "xenograft", "models", ",", "LAPC-4", ",", "LAPC-9", ",", "PC3", "and", "CWR22Rv-1", "were", "compared", ".", "The", "cells", "were", "labeled", "with", "luciferase", ",", "a", "bioluminescence", "imaging", "reporter", "gene", ",", "to", "enable", "optical", "imaging", ".", "After", "tumor", "implantation", "the", "animals", "were", "examined", "weekly", "during", "several", "months", "for", "the", "appearance", "of", "metastases", ".", "Metastatic", "lesions", "were", "confirmed", "by", "immunohistochemistry", ".", "Additionally", ",", "the", "angiogenic", "and", "lymphangiogenic", "profiles", "of", "the", "tumors", "were", "characterized", ".", "To", "confirm", "the", "role", "of", "lymphangiogenesis", "in", "mediating", "metastasis", ",", "the", "low", "-", "metastatic", "LAPC-9", "tumor", "cells", "were", "engineered", "to", "overexpress", "VEGF", "-", "C", ",", "and", "the", "development", "of", "metastases", "was", "evaluated", ".", "Our", "results", "show", "CWR22Rv-1", "and", "PC3", "tumor", "cell", "lines", "to", "be", "more", "metastatic", "than", "LAPC-4", ",", "which", "in", "turn", "disseminates", "more", "readily", "than", "LAPC-9", ".", "The", "difference", "in", "metastatic", "potential", "correlated", "with", "the", "endogenous", "production", "levels", "of", "lymphangiogenic", "growth", "factor", "VEGF", "-", "C", "and", "the", "presence", "of", "tumor", "lymphatics", ".", "In", "agreement", ",", "induced", "overexpression", "of", "VEGF", "-", "C", "in", "LAPC-9", "enhanced", "tumor", "lymphangiogenesis", "leading", "to", "the", "development", "of", "metastatic", "lesions", ".", "Taken", "together", ",", "our", "studies", ",", "based", "on", "a", "molecular", "imaging", "approach", "for", "semiquantitative", "detection", "of", "micrometastases", ",", "point", "to", "an", "important", "role", "of", "tumor", "lymphatics", "in", "the", "metastatic", "process", "of", "human", "prostate", "cancer", ".", "In", "particular", ",", "VEGF", "-", "C", "seems", "to", "play", "a", "key", "role", "in", "prostate", "cancer", "metastasis", ".", "\n" ]

[ "Cell", "Cancer", "Multi-tissue_structure" ]

triiodothyronine ( T3 ) mononuclear leukocyte receptor kinetics is an other_name, T3 administration is an other_name, cold - air exposures is an other_name

18768_task0

Sentence: Changes in triiodothyronine (T3) mononuclear leukocyte receptor kinetics after T3 administration and multiple cold-air exposures. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_name

[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]

Changes in triiodothyronine (T3) mononuclear leukocyte receptor kinetics after T3 administration and multiple cold-air exposures.

[ "Changes", "in", "triiodothyronine", "(", "T3", ")", "mononuclear", "leukocyte", "receptor", "kinetics", "after", "T3", "administration", "and", "multiple", "cold", "-", "air", "exposures", "." ]

[ "other_name", "(AND other_name other_name)", "cell_type", "multi_cell", "amino_acid_monomer", "protein_molecule", "", "tissue", "peptide" ]

triiodothyronine ( T3 ) mononuclear leukocyte receptor kinetics is an other_name, T3 administration is an other_name, cold - air exposures is an other_name

18768_task1

Sentence: Changes in triiodothyronine (T3) mononuclear leukocyte receptor kinetics after T3 administration and multiple cold-air exposures. Instructions: please typing these entity words according to sentence: triiodothyronine ( T3 ) mononuclear leukocyte receptor kinetics, T3 administration, cold - air exposures Options: other_name

[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]

Changes in triiodothyronine (T3) mononuclear leukocyte receptor kinetics after T3 administration and multiple cold-air exposures.

[ "Changes", "in", "triiodothyronine", "(", "T3", ")", "mononuclear", "leukocyte", "receptor", "kinetics", "after", "T3", "administration", "and", "multiple", "cold", "-", "air", "exposures", "." ]

[ "other_name", "(AND other_name other_name)", "cell_type", "multi_cell", "amino_acid_monomer", "protein_molecule", "", "tissue", "peptide" ]

triiodothyronine ( T3 ) mononuclear leukocyte receptor kinetics, T3 administration, cold - air exposures

18768_task2

Sentence: Changes in triiodothyronine (T3) mononuclear leukocyte receptor kinetics after T3 administration and multiple cold-air exposures. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]

Changes in triiodothyronine (T3) mononuclear leukocyte receptor kinetics after T3 administration and multiple cold-air exposures.

[ "Changes", "in", "triiodothyronine", "(", "T3", ")", "mononuclear", "leukocyte", "receptor", "kinetics", "after", "T3", "administration", "and", "multiple", "cold", "-", "air", "exposures", "." ]

[ "other_name", "(AND other_name other_name)", "cell_type", "multi_cell", "amino_acid_monomer", "protein_molecule", "", "tissue", "peptide" ]

gestational age is a Measurement, > = 28 weeks is a Value, Systolic blood pressure is a Measurement, > = 160 mm Hg is a Value, diastolic blood pressure is a Measurement, > = 110 mm Hg is a Value, > = 18 is a Value, years is a Person

NCT01912677_inc_task0

Sentence: Pregnant gestational age >= 28 weeks Systolic blood pressure >=160 mm Hg OR a diastolic blood pressure of >=110 mm Hg measured twice more than 15 minutes apart Able to swallow pills >= 18 years Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Person, Measurement, Value

[ "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Value", "I-Value", "I-Value", "B-Person", "O" ]

Pregnant gestational age >= 28 weeks Systolic blood pressure >=160 mm Hg OR a diastolic blood pressure of >=110 mm Hg measured twice more than 15 minutes apart Able to swallow pills >= 18 years

[ "Pregnant", "gestational", "age", ">", "=", "28", "weeks", "\n", "Systolic", "blood", "pressure", ">", "=", "160", "mm", "Hg", "OR", "a", "diastolic", "blood", "pressure", "of", ">", "=", "110", "mm", "Hg", "measured", "twice", "more", "than", "15", "minutes", "apart", "\n", "Able", "to", "swallow", "pills", "\n", ">", "=", "18", "years", "\n" ]

[ "Measurement", "Value", "Person" ]

gestational age is a Measurement, > = 28 weeks is a Value, Systolic blood pressure is a Measurement, > = 160 mm Hg is a Value, diastolic blood pressure is a Measurement, > = 110 mm Hg is a Value, > = 18 is a Value, years is a Person

NCT01912677_inc_task1

Sentence: Pregnant gestational age >= 28 weeks Systolic blood pressure >=160 mm Hg OR a diastolic blood pressure of >=110 mm Hg measured twice more than 15 minutes apart Able to swallow pills >= 18 years Instructions: please typing these entity words according to sentence: gestational age, > = 28 weeks, Systolic blood pressure, > = 160 mm Hg, diastolic blood pressure, > = 110 mm Hg, > = 18, years Options: Person, Measurement, Value

[ "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Value", "I-Value", "I-Value", "B-Person", "O" ]

Pregnant gestational age >= 28 weeks Systolic blood pressure >=160 mm Hg OR a diastolic blood pressure of >=110 mm Hg measured twice more than 15 minutes apart Able to swallow pills >= 18 years

[ "Pregnant", "gestational", "age", ">", "=", "28", "weeks", "\n", "Systolic", "blood", "pressure", ">", "=", "160", "mm", "Hg", "OR", "a", "diastolic", "blood", "pressure", "of", ">", "=", "110", "mm", "Hg", "measured", "twice", "more", "than", "15", "minutes", "apart", "\n", "Able", "to", "swallow", "pills", "\n", ">", "=", "18", "years", "\n" ]

[ "Measurement", "Value", "Person" ]